DRAMP_ID	Sequence	Sequence_Length	Name	Source	Activity	Patent_No	Patent_Type	Publication_Date	Also_Publication_As	Patent_Title	Abstract
DRAMP04719	VNPGVVVRISQKGLDYASQQGTAALQXXLKHIKIPDYL	38	Sequence 3 from Patent EP 0272489	Synthetic construct	Antimicrobial	EP 0272489 B1	Granted Patent	1996##3##13	DE3751741D1, DE3751741T2, EP0272489A2, EP0272489A3, US5126257	Antimicrobial proteins, compositions containing same and uses thereof.	Further provided are purified polypeptides useful as antimicrobial agents, and methods for producing these polypeptides.
DRAMP04720	IIGGRESRPHSRPYMAYLQIQXPA	24	Sequence 4 from Patent EP 0272489	Synthetic construct	Antimicrobial	EP 0272489 B1	Granted Patent	1996##3##13	DE3751741D1, DE3751741T2, EP0272489A2, EP0272489A3, US5126257	Antimicrobial proteins, compositions containing same and uses thereof.	Further provided are purified polypeptides useful as antimicrobial agents, and methods for producing these polypeptides.
DRAMP04721	KVFERXELARTLKRL	15	Sequence 5 from Patent EP 0272489	Synthetic construct	Antimicrobial	EP 0272489 B1	Granted Patent	1996##3##13	DE3751741D1, DE3751741T2, EP0272489A2, EP0272489A3, US5126257	Antimicrobial proteins, compositions containing same and uses thereof.	Further provided are purified polypeptides useful as antimicrobial agents, and methods for producing these polypeptides.
DRAMP04722	VNPGVVVRISQKGLDYASQQGTAALQXXLKNIKIPDYL	38	Sequence 6 from Patent EP 0272489	Synthetic construct	Antimicrobial	EP 0272489 B1	Granted Patent	1996##3##13	DE3751741D1, DE3751741T2, EP0272489A2, EP0272489A3, US5126257	Antimicrobial proteins, compositions containing same and uses thereof.	Further provided are purified polypeptides useful as antimicrobial agents, and methods for producing these polypeptides.
DRAMP04723	TCRYLLVRSLQTFSQAXFTXRRXYRGNLVSINNFNINYRI	40	Sequence 7 from Patent EP 0272489	Synthetic construct	Antimicrobial	EP 0272489 B1	Granted Patent	1996##3##13	DE3751741D1, DE3751741T2, EP0272489A2, EP0272489A3, US5126257	Antimicrobial proteins, compositions containing same and uses thereof.	Further provided are purified polypeptides useful as antimicrobial agents, and methods for producing these polypeptides.
DRAMP04724	KNLRRXXRKXXHIIKKYG	18	Sequence 1 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04725	KNLRRIIRKIIHIIKKYG	18	Sequence 2 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04726	KNLRRGIRKIIHIIKKYG	18	Sequence 3 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04727	KNLRRTIRKIIHIIKKYG	18	Sequence 4 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04728	KNLRRSIRKIIHIIKKYG	18	Sequence 5 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04729	KNLRREIRKIIHIIKKYG	18	Sequence 6 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04730	KNLRRDIRKIIHIIKKYG	18	Sequence 7 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04731	KNLRRAIRKIIHIIKKYG	18	Sequence 8 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04732	KNLRRIGRKIIHIIKKYG	18	Sequence 10 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04733	KNLRRITRKIIHIIKKYG	18	Sequence 11 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04734	KNLRRISRKIIHIIKKYG	18	Sequence 12 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04735	KNLRRIERKIIHIIKKYG	18	Sequence 13 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04736	KNLRRIDRKIIHIIKKYG	18	Sequence 14 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04737	KNLRRIARKIIHIIKKYG	18	Sequence 15 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04738	KNLRRIIRKGIHIIKKYG	18	Sequence 17 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04739	KNLRRIIRKTIHIIKKYG	18	Sequence 18 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04740	KNLRRIIRKSIHIIKKYG	18	Sequence 19 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04741	KNLRRIIRKEIHIIKKYG	18	Sequence 20 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04742	KNLRRIIRKDIHIIKKYG	18	Sequence 21 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04743	KNLRRIIRKAIHIIKKYG	18	Sequence 22 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04744	KNLRRIIRKIGHIIKKYG	18	Sequence 24 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04745	KNLRRIIRKITHIIKKYG	18	Sequence 25 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04746	KNLRRIIRKISHIIKKYG	18	Sequence 26 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04747	KNLRRIIRKIEHIIKKYG	18	Sequence 27 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04748	KNLRRIIRKIDHIIKKYG	18	Sequence 28 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04749	KNLRRIIRKIAHIIKKYG	18	Sequence 29 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04750	KNLRRIIRKGIRIIKKYG	18	Sequence 32 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04751	KRLRRIIRKGIHIIKKYG	18	Sequence 34 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04752	RRLRRIIRKGIRIIKKYG	18	Sequence 36 from Patent US 20020082195	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0082195 A1	Patent Application	2002##6##27	CN1735422A, US6492328	Novispirins: antimicrobial peptides.	Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.
DRAMP04753	MRIHYLLFALLFLFLVPVPGHGGIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK	67	Sequence 2 from Patent US 20020115602	Synthetic construct	Antimicrobial	US 2002/0115602 A1	Patent Application	2002##8##22	US6809181, WO2001092309A2, WO2001092309A3	Human beta-defensin-3 (HBD-3), a highly cationic beta-defensin antimicrobial peptide.	The present invention relates a novel antimicrobial peptide HBD-3 and derivatives thereof as well as the gene encoding the peptide. The invention further relates to methods of use of the HBD-3 peptide including a method of inhibiting microbial growth by administering an effective amount of the HBD-3 peptide alone or in combinination with other antimicrobial agents or antibiotics. In addition, the immunomodulatory properties of the HBD-3 peptide also facilitate the manipulation of the immune response, i.e., as a chemoattractant for immature dentritic cells or memory T cells.
DRAMP04754	TLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK	41	Sequence 3 from Patent US 20020115602	Synthetic construct	Antimicrobial	US 2002/0115602 A1	Patent Application	2002##8##22	US6809181, WO2001092309A2, WO2001092309A3	Human beta-defensin-3 (HBD-3), a highly cationic beta-defensin antimicrobial peptide.	The present invention relates a novel antimicrobial peptide HBD-3 and derivatives thereof as well as the gene encoding the peptide. The invention further relates to methods of use of the HBD-3 peptide including a method of inhibiting microbial growth by administering an effective amount of the HBD-3 peptide alone or in combinination with other antimicrobial agents or antibiotics. In addition, the immunomodulatory properties of the HBD-3 peptide also facilitate the manipulation of the immune response, i.e., as a chemoattractant for immature dentritic cells or memory T cells.
DRAMP04755	GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK	45	Sequence 4 from Patent US 20020115602	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2002/0115602 A1	Patent Application	2002##8##22	US6809181, WO2001092309A2, WO2001092309A3	Human beta-defensin-3 (HBD-3), a highly cationic beta-defensin antimicrobial peptide.	The present invention relates a novel antimicrobial peptide HBD-3 and derivatives thereof as well as the gene encoding the peptide. The invention further relates to methods of use of the HBD-3 peptide including a method of inhibiting microbial growth by administering an effective amount of the HBD-3 peptide alone or in combinination with other antimicrobial agents or antibiotics. In addition, the immunomodulatory properties of the HBD-3 peptide also facilitate the manipulation of the immune response, i.e., as a chemoattractant for immature dentritic cells or memory T cells.
DRAMP04756	WCFAVCRRGRCRYKCRR	17	Sequence 1 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04757	WCFAVCYRGRCRRKCRR	17	Sequence 2 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04758	FRWCFRVCYKGRCRYKCR	18	Sequence 3 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04759	RRWCFRVCYKGFCRYKCR	18	Sequence 4 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04760	RRWCFRVCYRGFCRYFCR	18	Sequence 5 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04761	RRWCFIVCRRGACYRRCR	18	Sequence 6 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04762	RRWCFIVCRRGRCYVACRR	19	Sequence 7 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04763	RVWCRRRCYRGFCRYFCR	18	Sequence 8 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04764	RVWCRYRCYRGFCRRFCR	18	Sequence 9 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04765	RRWCRRVCYAGFCYRKCR	18	Sequence 10 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04766	RRWCFRVCYRGRFCYRKCR	19	Sequence 11 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04767	KWCFRVCYRGICYRRCR	17	Sequence 12 from Patent US 20020156017	Tachypleus tridentatus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04768	RRWCFRVCYRGFCYRKCR	18	Sequence 13 from Patent US 20020156017	Limulus polyphemus	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04769	WCFXVCXRGXCRXKCRR	17	Sequence 14 from Patent US 20020156017	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04770	XRWCFRVCYXGXCXXXCR	18	Sequence 15 from Patent US 20020156017	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04771	RRWCFXVCXRGXCYXXCRX	19	Sequence 16 from Patent US 20020156017	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04772	RXWCXXXCYRGFCXXXCR	18	Sequence 17 from Patent US 20020156017	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04773	RRWCXRVCYXGFCYRKCR	18	Sequence 18 from Patent US 20020156017	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04774	RRWCFRVCYRGXFCYRKCR	19	Sequence 19 from Patent US 20020156017	Synthetic construct	Antimicrobial, Antibacterial, Antifungal	US 2002/0156017 A1	Patent Application	2002##10##24	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Antimicrobial peptides and methods of use thereof.	A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO: 3), RRWCFRVCYKGFCRYKCR (SEQ ID NO: 4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO: 11). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04775	GIGKFLKSAKKFGKAFVKILNS	22	Sequence 3 from Patent US 20020162135	Synthetic construct	Antimicrobial	US 2002/0162135 A1	Patent Application	2002##10##31	CA2412531A1, CA2412531C, EP1294745A2, US6337317, US6747007, WO2002000687A2, WO2002000687A3, WO2002000687A9	Expression of antimicrobial peptide via the plastid genome to control phytopathogenic bacteria.	This invention provides a novel method to confer disease resistance to plants. Plant plastids are transformed using a plastid vector which contains heterologous DNA sequences coding for a cytotoxic antimicrobial peptide. Transgenic plants are capable of fighting off phytopathogenic bacterial infection.
DRAMP04776	RQRDPQQQAEQAQKRAQRRETE	22	Sequence 9 from Patent US 20020168392	Synthetic construct	Antimicrobial	US 2002/0168392 A1	Patent Application	2002##11##14	CA2274730A1, CN1244769A, DE69736904D1, DE69736904T2, EP1006785A1, EP1006785A4, EP1006785B1, US7067624, US20030171274, WO1998027805A1	Antimicrobial proteins.	A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadaniia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to express the antimicrobial protein or to introduce the antimicrobial protein into a plant. Compositions comprising the antimicrobial proteins or the antimicrobial protein per se can be administered to plants or mammilian animals to combat microbial infestation.
DRAMP04777	PRHMQIAQQRAERRAEKEKRKQQKR	25	Sequence 10 from Patent US 20020168392	Synthetic construct	Antimicrobial	US 2002/0168392 A1	Patent Application	2002##11##14	CA2274730A1, CN1244769A, DE69736904D1, DE69736904T2, EP1006785A1, EP1006785A4, EP1006785B1, US7067624, US20030171274, WO1998027805A1	Antimicrobial proteins.	A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadaniia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to express the antimicrobial protein or to introduce the antimicrobial protein into a plant. Compositions comprising the antimicrobial proteins or the antimicrobial protein per se can be administered to plants or mammilian animals to combat microbial infestation.
DRAMP04778	SEQIDNMAWFHVSVCNAVFVVIIIIMLLMFVPVVRG	36	Sequence 11 from Patent US 20020168392	Synthetic construct	Antimicrobial	US 2002/0168392 A1	Patent Application	2002##11##14	CA2274730A1, CN1244769A, DE69736904D1, DE69736904T2, EP1006785A1, EP1006785A4, EP1006785B1, US7067624, US20030171274, WO1998027805A1	Antimicrobial proteins.	A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadaniia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to express the antimicrobial protein or to introduce the antimicrobial protein into a plant. Compositions comprising the antimicrobial proteins or the antimicrobial protein per se can be administered to plants or mammilian animals to combat microbial infestation.
DRAMP04779	MGHHHHHHHHHHSSGHIEGRHM	22	Sequence 16 from Patent US 20020168392	Synthetic construct	Antimicrobial	US 2002/0168392 A1	Patent Application	2002##11##14	CA2274730A1, CN1244769A, DE69736904D1, DE69736904T2, EP1006785A1, EP1006785A4, EP1006785B1, US7067624, US20030171274, WO1998027805A1	Antimicrobial proteins.	A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadaniia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to express the antimicrobial protein or to introduce the antimicrobial protein into a plant. Compositions comprising the antimicrobial proteins or the antimicrobial protein per se can be administered to plants or mammilian animals to combat microbial infestation.
DRAMP04780	RSGRGECRRQCLRRHEGQPWETQECMRRCRRRG	33	Sequence 23 from Patent US 20020168392	Maize	Antimicrobial	US 2002/0168392 A1	Patent Application	2002##11##14	CA2274730A1, CN1244769A, DE69736904D1, DE69736904T2, EP1006785A1, EP1006785A4, EP1006785B1, US7067624, US20030171274, WO1998027805A1	Antimicrobial proteins.	A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadaniia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to express the antimicrobial protein or to introduce the antimicrobial protein into a plant. Compositions comprising the antimicrobial proteins or the antimicrobial protein per se can be administered to plants or mammilian animals to combat microbial infestation.
DRAMP04781	VKEDHQFETRGEILECYRLCQQQ	23	Sequence 26 from Patent US 20020168392	Stenocarpus sinuatus	Antimicrobial	US 2002/0168392 A1	Patent Application	2002##11##14	CA2274730A1, CN1244769A, DE69736904D1, DE69736904T2, EP1006785A1, EP1006785A4, EP1006785B1, US7067624, US20030171274, WO1998027805A1	Antimicrobial proteins.	A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadaniia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to express the antimicrobial protein or to introduce the antimicrobial protein into a plant. Compositions comprising the antimicrobial proteins or the antimicrobial protein per se can be administered to plants or mammilian animals to combat microbial infestation.
DRAMP04782	QKHRSQILGCYLXCQQL	17	Sequence 27 from Patent US 20020168392	Stenocarpus sinuatus	Antimicrobial	US 2002/0168392 A1	Patent Application	2002##11##14	CA2274730A1, CN1244769A, DE69736904D1, DE69736904T2, EP1006785A1, EP1006785A4, EP1006785B1, US7067624, US20030171274, WO1998027805A1	Antimicrobial proteins.	A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadaniia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to express the antimicrobial protein or to introduce the antimicrobial protein into a plant. Compositions comprising the antimicrobial proteins or the antimicrobial protein per se can be administered to plants or mammilian animals to combat microbial infestation.
DRAMP04783	LDPIRQQQLCQMRCQQQEKDPRQQQQCK	28	Sequence 28 from Patent US 20020168392	Stenocarpus sinuatus	Antimicrobial	US 2002/0168392 A1	Patent Application	2002##11##14	CA2274730A1, CN1244769A, DE69736904D1, DE69736904T2, EP1006785A1, EP1006785A4, EP1006785B1, US7067624, US20030171274, WO1998027805A1	Antimicrobial proteins.	A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadaniia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to express the antimicrobial protein or to introduce the antimicrobial protein into a plant. Compositions comprising the antimicrobial proteins or the antimicrobial protein per se can be administered to plants or mammilian animals to combat microbial infestation.
DRAMP04784	MAWFHVSVCNAVFVVIIIIMLLMFVPVVRGRQRDPQQQYEQCQKRCQRRETEPRHMQICQQRCERRYEKEKRKQQKR	77	Sequence 30 from Patent US 20020168392	Synthetic construct	Antimicrobial	US 2002/0168392 A1	Patent Application	2002##11##14	CA2274730A1, CN1244769A, DE69736904D1, DE69736904T2, EP1006785A1, EP1006785A4, EP1006785B1, US7067624, US20030171274, WO1998027805A1	Antimicrobial proteins.	A new family of antimicrobial proteins is described. Prototype proteins can be isolated from Macadaniia integrifolia as well as other plant species. DNA encoding the protein is also described as well as DNA constructs which can be used to express the antimicrobial protein or to introduce the antimicrobial protein into a plant. Compositions comprising the antimicrobial proteins or the antimicrobial protein per se can be administered to plants or mammilian animals to combat microbial infestation.
DRAMP04785	RVIRVVQRACRAIRHIVRRIRQGLRRIL	28	Sequence 1 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04786	RVIRVVQRACRAIRHIVRRIRQGLRRILRVV	31	Sequence 2 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04787	RWIRVVQRWCRAIRHIWRRIRQGLRRWLRVV	31	Sequence 3 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04788	RVVRVVRRVVRR	12	Sequence 4 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04789	RRVVRRVRRVVRRVVRVVRRVVRR	24	Sequence 5 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04790	VRRVVRRVVRVVRRVVRRVRRVVRRVVRVVRRVVRR	36	Sequence 6 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04791	RRVVRRVRRVVRRVVRVVRRVVRRVRRVVRRVVRVVRRVVRR	42	Sequence 7 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04792	RVVRVVRRVVRRVRRVVRRVVRVVRRVVRRVRRVVRRVVRVVRRVVRR	48	Sequence 8 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04793	RVVRVVRRWVRR	12	Sequence 9 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04794	RRWVRRVRRVWRRVVRVVRRWVRR	24	Sequence 10 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04795	VRRVWRRVVRVVRRWVRRVRRVWRRVVRVVRRWVRR	36	Sequence 11 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04796	RVVRVVRRWVRRVRRVWRRVVRVVRRWVRRVRRVWRRVVRVVRRWRVV	48	Sequence 12 from Patent US 20020169279	Synthetic construct	Antimicrobial, Antibacterial	US 2002/0169279 A1	Patent Application	2002##11##14	US6835713	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04797	RVVRVVRRWVRRVRRVWRRVVRVVRRWVRRVRRVWRRVVRVVRRWVRR	48	Sequence 12 from Patent US 6835713	Synthetic construct	Antimicrobial, Antibacterial	US 6835713 B2	Granted Patent	2004##12##28	US20020169279	Virus derived antimicrobial peptides.	The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.
DRAMP04798	MAVMKSRTVIVAAVLLAVVILSSLCPCYEAGGCTIGKPPKTPAPKRPCFSPYSEDHCDRQNCRFVCMSHGYSDGGWCDEREVRKMCCCYH	90	Sequence 2 from Patent US 20030028921	Zea mays	Antimicrobial	US 2003/0028921 A1	Patent Application	2003##2##6	US20130052682	Maize basal layer antimicrobial protein polynucleotides and method of use.	Methods and compositions for modulating development and defense response are provided. Nucleotide sequences encoding maize BTL proteins are provided. The sequence can be used in expression cassettes for antimicrobial resistance, modulating development, developmental pathways, and defense response. Transformed plants, plant cells, tissues, and seed are also provided.
DRAMP04799	MAVMKSRTVIVAAVLLAVVILSSLCPCYEAGGCIGKPPKTPAPKRPCFSPYSEDHCDRQNCRFVCMSHGYSDGGWCDEREVRKMCCCYH	89	Sequence 6 from Patent US 20030028921	Zea mays	Antimicrobial	US 2003/0028921 A1	Patent Application	2003##2##6	US20130052682	Maize basal layer antimicrobial protein polynucleotides and method of use.	Methods and compositions for modulating development and defense response are provided. Nucleotide sequences encoding maize BTL proteins are provided. The sequence can be used in expression cassettes for antimicrobial resistance, modulating development, developmental pathways, and defense response. Transformed plants, plant cells, tissues, and seed are also provided.
DRAMP04800	MMALNGGWRKTFVSILTTCFLVVVVIVSLSCEAKGGVVPRLRPPFCFPYDREYCTPFHCGKVCQEYNFPAKNGGYCDKRGDPWKCCCPY	89	Sequence 10 from Patent US 20030028921	Zea mays	Antimicrobial	US 2003/0028921 A1	Patent Application	2003##2##6	US20130052682	Maize basal layer antimicrobial protein polynucleotides and method of use.	Methods and compositions for modulating development and defense response are provided. Nucleotide sequences encoding maize BTL proteins are provided. The sequence can be used in expression cassettes for antimicrobial resistance, modulating development, developmental pathways, and defense response. Transformed plants, plant cells, tissues, and seed are also provided.
DRAMP04801	MAKFFNYTIVQGLLMLSMVLLASCVIHAHIISGETEEVSNIGSPTVMVTMGANRKIIGDNKNLLCYLKALEYCCERTKQCYDDIKKCLEHCHG	93	Sequence 14 from Patent US 20030028921	Zea mays	Antimicrobial	US 2003/0028921 A1	Patent Application	2003##2##6	US20130052682	Maize basal layer antimicrobial protein polynucleotides and method of use.	Methods and compositions for modulating development and defense response are provided. Nucleotide sequences encoding maize BTL proteins are provided. The sequence can be used in expression cassettes for antimicrobial resistance, modulating development, developmental pathways, and defense response. Transformed plants, plant cells, tissues, and seed are also provided.
DRAMP04802	MMTKCQKRASIQGLWLLSMVLLASSSLVCASMAVDGQTKEDINATSVTSMNMTRSSSASYNMTGGGGELNRGPCVVRSGFYWCQNIGYPTMSECLKNCES	100	Sequence 18 from Patent US 20030028921	Zea mays	Antimicrobial	US 2003/0028921 A1	Patent Application	2003##2##6	US20130052682	Maize basal layer antimicrobial protein polynucleotides and method of use.	Methods and compositions for modulating development and defense response are provided. Nucleotide sequences encoding maize BTL proteins are provided. The sequence can be used in expression cassettes for antimicrobial resistance, modulating development, developmental pathways, and defense response. Transformed plants, plant cells, tissues, and seed are also provided.
DRAMP04803	MARCLKSCSVHGLWLLSMILLASCVVHAHIINGRQSNTGSLTMTTTGEASMIIGDEKDAICYIKAALYCCKRTIQCYQDIAQCLRNCRKNV	91	Sequence 22 from Patent US 20030028921	Zea mays	Antimicrobial	US 2003/0028921 A1	Patent Application	2003##2##6	US20130052682	Maize basal layer antimicrobial protein polynucleotides and method of use.	Methods and compositions for modulating development and defense response are provided. Nucleotide sequences encoding maize BTL proteins are provided. The sequence can be used in expression cassettes for antimicrobial resistance, modulating development, developmental pathways, and defense response. Transformed plants, plant cells, tissues, and seed are also provided.
DRAMP04804	MIVGHGIDI	9	Sequence 6 from Patent US 20030068802	Streptococcus pneumoniae	Antimicrobial	US 2003/0068802 A1	Patent Application	2003##4##10	Unknown	Use of streptococcus pneumoniae acyl carrier protein synthase crystal structure in diagnostics, antimicrobial drug design, and biosensors.	Provided are methods of purifying and crystallizing Streptococcus pneumoniae acyl carrier protein synthase (AcpS) enzyme, crystals of AcpS, the use of such crystals to determine the three-dimensional structure of AcpS enzymes, and the three-dimensional structure of AcpS. The three-dimensional crystal structure of AcpS can be used in medical diagnostics to produce antibodies that permit detection of Streptococcus pneumoniae both in vitro and in vivo. The three-dimensional crystal structure of AcpS can also be used in pharmaceutical discovery and development to identify and design compounds that inhibit the biochemical activity of AcpS enzyme in bacteria. Inhibitory compounds identified in this way can be optimized by structure/activity studies to develop antibacterial pharmaceutical compounds useful for the prevention or treatment of bacterial infections.
DRAMP04805	FIHHIFRGIVHAGRSIGRFLTG	22	Sequence 1 from Patent US 20030083247	Morone saxitilis x Morone	Antimicrobial	US 2003/0083247 A1	Patent Application	2003##5##1	US6753407	Antimicrobial peptides isolated from fish.	Antimicrobial peptides (endobiotic peptides), isolated from fish are described. Such endobiotic peptides may be isolated as 22 amino acid peptides having molecular weights of about 2500 Da from the gills of hybrid striped bass (Morone saxitilis×Morone chrysops). Antibodies that bind such peptides and methods of using such peptides are also described.
DRAMP04806	FFHHIFRGIVHVGKTIHRLVTG	22	Sequence 2 from Patent US 20030083247	Morone saxitilis x Morone	Antimicrobial	US 2003/0083247 A1	Patent Application	2003##5##1	US6753407	Antimicrobial peptides isolated from fish.	Antimicrobial peptides (endobiotic peptides), isolated from fish are described. Such endobiotic peptides may be isolated as 22 amino acid peptides having molecular weights of about 2500 Da from the gills of hybrid striped bass (Morone saxitilis×Morone chrysops). Antibodies that bind such peptides and methods of using such peptides are also described.
DRAMP04807	FFHHIFRGIVHVGKTIHKLVTG	22	Sequence 3 from Patent US 20030083247	Morone saxitilis x Morone	Antimicrobial	US 2003/0083247 A1	Patent Application	2003##5##1	US6753407	Antimicrobial peptides isolated from fish.	Antimicrobial peptides (endobiotic peptides), isolated from fish are described. Such endobiotic peptides may be isolated as 22 amino acid peptides having molecular weights of about 2500 Da from the gills of hybrid striped bass (Morone saxitilis×Morone chrysops). Antibodies that bind such peptides and methods of using such peptides are also described.
DRAMP04808	FFRHLFRGAKAIFRGARQGXRAHKVVSRYRNRDVPETDNNQEEP	44	Sequence 4 from Patent US 20030083247	Morone saxitilis x Morone	Antimicrobial	US 2003/0083247 A1	Patent Application	2003##5##1	US6753407	Antimicrobial peptides isolated from fish.	Antimicrobial peptides (endobiotic peptides), isolated from fish are described. Such endobiotic peptides may be isolated as 22 amino acid peptides having molecular weights of about 2500 Da from the gills of hybrid striped bass (Morone saxitilis×Morone chrysops). Antibodies that bind such peptides and methods of using such peptides are also described.
DRAMP04809	HIFR	4	Sequence 5 from Patent US 20030083247	Synthetic construct	Antimicrobial	US 2003/0083247 A1	Patent Application	2003##5##1	US6753407	Antimicrobial peptides isolated from fish.	Antimicrobial peptides (endobiotic peptides), isolated from fish are described. Such endobiotic peptides may be isolated as 22 amino acid peptides having molecular weights of about 2500 Da from the gills of hybrid striped bass (Morone saxitilis×Morone chrysops). Antibodies that bind such peptides and methods of using such peptides are also described.
DRAMP04810	GIGKFLHSAGKFGKAFVGEIMKS	23	Sequence 1 from Patent US 20030092612	Xenopus laevis	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04811	GIGKFLHSAKKFGKAFVGEIMNS	23	Sequence 2 from Patent US 20030092612	Xenopus laevis	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04812	GIGKFLKKAKKFGKAFVKILKX	22	Sequence 3 from Patent US 20030092612	Synthetic construct	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04813	GIGKFLKKAKKFGKAFVKILKK	22	Sequence 4 from Patent US 20030092612	Synthetic construct	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04814	KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK	37	Sequence 5 from Patent US 20030092612	Silk moth	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04815	KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKALG	36	Sequence 6 from Patent US 20030092612	Silk moth	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04816	MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG	38	Sequence 7 from Patent US 20030092612	Synthetic construct	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04817	ACYCRIPACIAGERRYGTCIYQGRLWAFCC	30	Sequence 8 from Patent US 20030092612	Human	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04818	CYCRIPACIAGERRYGTCIYQGRLWAFCC	29	Sequence 9 from Patent US 20030092612	Human	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04819	DCYCRIPACIAGERRYGTCIYQGRLWAFCC	30	Sequence 10 from Patent US 20030092612	Human	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04820	VVCACRRALCLPRERRAGFCRIRGRIHPLCCRR	33	Sequence 11 from Patent US 20030092612	Rabbit	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04821	RLCRVVIRVCR	11	Sequence 12 from Patent US 20030092612	Cow	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04822	KWKLFKKIGIGAVLKVLTTGLPALIX	26	Sequence 13 from Patent US 20030092612	Synthetic construct	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04823	KWKGIGAVLKVLTTGX	16	Sequence 14 from Patent US 20030092612	Synthetic construct	Antimicrobial	US 2003/0092612 A1	Patent Application	2003##5##15	CA2451469A1, EP1406647A1, EP1406647A4, US6872705, WO2003006046A1	Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.	Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
DRAMP04824	KWKLFKKIGIGAVLKVLTTGLPALKLTK	28	Sequence 1 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04825	KWKSFIKKLTTAVKKVLTTGLPALIS	26	Sequence 2 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04826	KWKSFIKKLTSAAKKVVTTAKPLALIS	27	Sequence 3 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04827	KWKSFIKKLTKAAKKVVTTAKKPLIV	26	Sequence 4 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04828	KWKKFIKSLTKSAAKTVVKTAKKPLIV	27	Sequence 5 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04829	KWKLFKKIGIGAVLKVLKVLTTGLPALKLTLK	32	Sequence 6 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04830	KLFKKIGIGAVLKVLKVLTTGLPALKLTLK	30	Sequence 7 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04831	KWKFKKIGIGAVLKVLKVLTTGLPALKLTLK	31	Sequence 8 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04832	KLWKLFKKIGIGAVLKVLKVLTTGLPALKLTLK	33	Sequence 9 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04833	KWKSFIKKLTSAAKKVTTAAKPLTK	25	Sequence 10 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04834	KWKKFIKKIGIGAVLKVLTTGLPALKLTKK	30	Sequence 11 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04835	KKWKKFIKKIGIGAVLTTPGAKK	23	Sequence 12 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04836	GWGSFFKKAAHVGKHVGKAALTHYL	25	Sequence 13 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04837	KGWGSFFKKAAHVGKHVGKAALTHYL	26	Sequence 15 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04838	ALWKTMLKKAAHVGKHVGKAALTHYL	26	Sequence 17 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04839	SIGSAFKKAAHVGKHVGKAALTHYL	25	Sequence 18 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04840	GWGSFFKKAAHVGKHVGKAALGAAARRRK	29	Sequence 19 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04841	ALWKTMLKKAAHVGKHVGKAALGAAARRRK	30	Sequence 20 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04842	SIGSAFKKAAHVGKHVGKAALGAAARRRK	29	Sequence 21 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04843	RQRVEELSKFSKKGAAARRRK	21	Sequence 22 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04844	ALWKTMLKKLGTMALHAGKAALGAAADTISQTQ	33	Sequence 23 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04845	SIGSAFKKALPVAKKIGKAALPIAKAALP	29	Sequence 24 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04846	KWKSFIKKLTSAAKKVVTTAKPLISS	26	Sequence 25 from Patent US 20030096949	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0096949 A1	Patent Application	2003##5##22	CA2341340A1, CA2341340C, EP1107976A1, EP1107976A4, US6288212, US6818407, WO2000012528A1	Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.	A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of respiratory infections, such as in cystic fibrosis patients. Such methods are further useful for accelerating wound healing.
DRAMP04847	HVIGRFIHHFFCCFFHHIFRGIVH	24	Sequence 6 from Patent US 20030105281	Synthetic construct	Antimicrobial	US 2003/0105281 A1	Patent Application	2003##6##5	WO2002014345A2, WO2002014345A3, WO2002014346A2, WO2002014346A8	Antimicrobial peptides isolated from mast cells.	"Antimicrobial peptides (endobiotic peptides) isolated from mast cells are described, along with compositions containing the same and methods of use thereof. Such peptides obtained from fish mast cells are referred to as ""piscidins"" herein."
DRAMP04848	KWKSFIKNLTKGGSKILTTGLPALIS	26	Sequence 3 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04849	KWKKFIKNLTKGGSKILTTGLPALIS	26	Sequence 4 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04850	KWKSFIKNLEKVLKPGGLLSNIVTSL	26	Sequence 5 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04851	KWKSFIKNLEKVLKKGPILANLVSIV	26	Sequence 6 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04852	KWKEFIKKLTTAVKKVLTTGLPALIS	26	Sequence 7 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04853	KWKKFIKELQKVLAPGGLLSNIVTSL	26	Sequence 8 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04854	KWKSFIKKLTSVLKKVVTTALPALIS	26	Sequence 9 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04855	KWKSFIKNLTKVLKKVVTTALPALIS	26	Sequence 10 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04856	KWKLFKKKGTGAVLTVLTTGLPALIS	26	Sequence 11 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04857	KWKSFIKKLTSVLKKVVTTAKPLISS	26	Sequence 12 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04858	KKKSFIKLLTSAKVSVLTTAKPLISS	26	Sequence 13 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04859	KWKKFIKELQKVLKPGGLLSNIVTSL	26	Sequence 14 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04860	KKWWRRVLSGLKTGPALSNV	20	Sequence 15 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04861	KKWWRRVLKGLSSGPALSNV	20	Sequence 16 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04862	KKWWRRALQALKNGPALSNV	20	Sequence 17 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04863	KKWWRRVLSGLKTAGPAIQSVLNK	24	Sequence 18 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04864	KKWWRRALQGLKTAGPAIQSVLNK	24	Sequence 19 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04865	KKWWKAQKAVNSGPNALQTLAQ	22	Sequence 20 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04866	KKWWKAKKFANSGPNALQTLAQ	22	Sequence 21 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04867	KKWWKFIKKAVNSGTTGLQTLAS	23	Sequence 22 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04868	KKSFFKKLTSVASSVLS	17	Sequence 23 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04869	WKVFKSFIKKASSFAQSVLD	20	Sequence 24 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04870	KWKSFIKK	8	Sequence 34 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04871	KKWWRRXXXGLKTAGPAIQSVLNK	24	Sequence 35 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04872	KWKLFKKIGIGAVLKVLTTGLPALIS	26	Sequence 36 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04873	KWKLFKKIGIGAVLKVLTTGLPALKKTK	28	Sequence 37 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04874	KKWWRRXLXXLXXXGPAXXSXVXXX	25	Sequence 38 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04875	KKWWKXXXKXXNSGXXXLQTLAX	23	Sequence 39 from Patent US 20030176337	Synthetic construct	Antimicrobial, Antibacterial	US 2003/0176337 A1	Patent Application	2003##9##18	US6057291, US6297215, US6465429, US6906035, WO1998025953A1	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2-KWKSFIKKLTTAVKKVLTTGLPALIS-COOH (SEQ ID NO: 1) and NH2-KWKSFIKKLTSAAKKVVTTAKPLISS-COOH (SEQ ID NO: 2). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP04876	YNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK	34	Sequence 1 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04877	YKCLQHGGFCLRSSCPSNTKLQGTCKPDKPNCCKS	35	Sequence 2 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04878	TRCYKFGGFCHYNICPGNSRFMSNCHPENLRCCKN	35	Sequence 3 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04879	ARCYKFGGFCYNSMCPPHTKFIGNCHPDHLHCCIN	35	Sequence 4 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04880	DHCHTNGGYCVRAICPPSARRPGSCFPEKNPCCKY	35	Sequence 5 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04881	ERCHKKGGYCYFYCFSSHKKIGSCFPEWPRCCKN	34	Sequence 6 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04882	YYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRR	35	Sequence 7 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04883	FFCRIRGGRCAVLNCLGKEEQIGRCSNSGRKCCRK	35	Sequence 8 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04884	VSCIRNGGICQYRCIGLRHKIGTCGSPFKCCK	32	Sequence 9 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04885	VSCLRKGGRCWNRCIGNTRQIGSCGVPFLKCCKR	34	Sequence 10 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04886	RACYREGGECLRCIGLFHKIGTCNFRFKCCKF	32	Sequence 11 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04887	ITCMTNGAICWGPCPTAFRQIGNCGHFKVRCCKI	34	Sequence 12 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04888	VTCMSYGGSCQRSCNGSFRLGGHCGHPKIRCCRR	34	Sequence 13 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04889	VSCCMIGGICRYLCKGNILQNGNCGVTSLNCCKR	34	Sequence 14 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04890	VTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKK	35	Sequence 15 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04891	GHCLNLSGVCRRDVCKVVEDQIGACRRRMKCCRA	34	Sequence 16 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04892	KQCIALKGVCRDKLCSTLDDTIGICNEGKKCCRR	34	Sequence 18 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04893	KQCISLKGICKDLACT	16	Sequence 19 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04894	KKCVQRKNACHYFECPWLYYSVGTCYKGKGKCCQK	35	Sequence 20 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04895	IKCLQGNNNCHIQKCPWFLLQVSTCYKGKGRCCQK	35	Sequence 21 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04896	IQCFQKNNTCHTNQCPYFQDEIGTCYDKRGKCCQK	35	Sequence 22 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04897	IACIENKDTCRLKNCPRLHNVVGTCYEGKGKCCHK	35	Sequence 23 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04898	TICRMQQGICRLFFCHSGEKKRDICSDPWNRCCVS	35	Sequence 24 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04899	TVCLMQQGHCRLFMCRSGERKGDICSDPWNRCCVP	35	Sequence 25 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04900	DECPSEYYHCRLKCNADEHAIRYCADFSICCKL	33	Sequence 26 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04901	QDCSKHRHCRMKCKANEYAVRYCEDWTICCRV	32	Sequence 27 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04902	KKCLNDVGICKKKCKPEEMHVKNGWAMCGKQRDCCVP	37	Sequence 28 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04903	KKCANTLGNCRKMCRDGEKQTEPATSKCPIGKLCCVL	37	Sequence 29 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04904	RRCLMGLGRCRDHCNVDEKEIQKCKMKKCCVG	32	Sequence 30 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04905	KRCLVGFGKCKDSCLADETQMQHCKAKKCCIG	32	Sequence 31 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04906	RRCYYGTGRCRKSCKEIERKKEKCGEKHICCVP	33	Sequence 32 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04907	RTCFYGLGKCRRICRANEKKKERCGERTFCCLR	33	Sequence 33 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04908	RICGYGTARCRKKCRSQEYRIGRCPNTYACCLR	33	Sequence 34 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04909	NPCELYQGMCRNACREYEIQYLTCPNDQKCCLK	33	Sequence 35 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04910	IACELYQGLCRNACQKYEIQYLSCPKTRKCCLK	33	Sequence 36 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04911	LRCMGNSGICRASCKKNEQPYLYCRNCQSCCLQ	33	Sequence 37 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04912	LQCMGNRGFCRSSCKKSEQAYFYCRTFQMCCLQ	33	Sequence 38 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04913	KKCFNKVTGYCRKKCKVGERYEIGCLSGKLCCAN	34	Sequence 39 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04914	KRCFSNVEGYCRKKCRLVEISEMGCLHGKYCC	32	Sequence 40 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04915	KKCWNNYVQGHCRKICRVNEVPEALCENGRYCCLN	35	Sequence 41 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04916	KSCWIIKGHCRKNCKPGEQVKKPCKNGDYCCIP	33	Sequence 42 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04917	KACWVLRGHCRKHCRSGERVRKPCSNGDYCC	31	Sequence 43 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04918	KKCWNRSGHCRKQCKDGEAVKDTCKNLRACCIP	33	Sequence 44 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04919	KRCLKILGHCRRHCKDGEMDHGSCKYYRVCCVP	33	Sequence 45 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04920	VECWMDGHCRLLCKDGEDSIIRCRNRKRCCVP	32	Sequence 46 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04921	QKCWKNNVGHCRRRCLDTERYILLCRNKLSCCIS	34	Sequence 47 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04922	KCWKNSLGYCRVRCQEEERYIYLCKNKVSCCIH	33	Sequence 48 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04923	KRCWKGQGACQTYCTRQETYMHLCPDASLCCLS	33	Sequence 49 from Patent US 20030176652	Homo sapiens	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04924	KRCWNGQGACRTFCTRQETFMHLCPDASLCCLS	33	Sequence 50 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04925	MKCWGKSGRCRTTCKESEVYYILCKTEAKCCVD	33	Sequence 55 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04926	DTCWKLKGICRNTCQKEEIYHIFCGIQSLCCLE	33	Sequence 56 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04927	RECRIGNGQCKNQCHENEIRIAYCIRPGTHCCLQ	34	Sequence 57 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04928	KECKMRRGHCKLQCSEKELRISFCIRPGTHCC	32	Sequence 58 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04929	KSCTAIGGRCKNQCDDSEFRISYCARPTTHCCVT	34	Sequence 59 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04930	DRCTKRYGRCKRDCLESEKQIDICSLPRKICCTE	34	Sequence 60 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04931	VDCRRSEGFCQEYCNYMETQVGYCSKKKDACCLH	34	Sequence 61 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04932	VNCKKSEGQCQEYCNFMETQVGYCSKKKEPCCLH	34	Sequence 62 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04933	ERCEKVRGICKTFCDDVEYDYGYCIKWRSQCCV	33	Sequence 63 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04934	ERCEKVRGMCKTVCDIDEYDYGYCIRWRNQCCI	33	Sequence 64 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04935	KRECQLVRGACKPECNSWEYVYYYCNVNPCCAV	33	Sequence 65 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04936	HKCSLVRGTCKSECNSWEYKYNYCHTEPCCVV	32	Sequence 66 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04937	ETCRLGRGKCRRTCIESEKIAGWCKLNFFCCRE	33	Sequence 67 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04938	ETCRLGRGKCRRACIESEKIVGWCKLNFFCCRE	33	Sequence 68 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04939	ESCKLGRGKCRKECLENEKPDGNCRLNFLCCRQ	33	Sequence 69 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04940	TNCFLYLARTAIHRALISKRMEGHCEAECLTFEVKIGGCRAELAPFCCKN	50	Sequence 70 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04941	FLCKKMNGQCEAECFTFEQKIGTCQANFLCCRK	33	Sequence 71 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04942	EKCSRVNGRCTASCLKNEELVALCQKNLKCCVT	33	Sequence 72 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04943	EKCSRINGRCTASCLKNEELVALCWKNLKCCVT	33	Sequence 73 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04944	EKCNKLKGTCKNNCGKNEELIALCQKSLKCCRT	33	Sequence 74 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04945	EICERPNGSCRDFCLETEIHVGRCLNSRPCCLP	33	Sequence 75 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04946	KLCLDQKDTCPDSRTCLEGTQPCHPHHPNCCES	33	Sequence 76 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04947	RPCEKMGGICKSQKTHGCSILPAECKSRYKHCCRL	35	Sequence 77 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04948	CRSWGTCSIAAICFDSLSRRGQCGPVKDPCCPL	33	Sequence 78 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04949	LTCIANRGFCWHSCIQGFQLAGHCGHPKVRLLH	33	Sequence 80 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04950	LVCRRKGGRCYIKCPDNTDZIGMCRLPFKCCKRQ	34	Sequence 81 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04951	LSCWMKZGICQYRCFGNTHKIGSCGAPFLKCCKR	34	Sequence 82 from Patent US 20030176652	Mus musculus	Antimicrobial	US 2003/0176652 A1	Patent Application	2003##9##18	US20050277176, WO2003024992A2, WO2003024992A3	Human and mouse beta-defensins, antimicrobial peptides.	The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.
DRAMP04952	XCRRLCYKQRCVTYCRGR	18	Sequence 1 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04953	XCRRLCYKQRCVTYCRGX	18	Sequence 2 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04954	XCKRLCYKQRCVTYCRGR	18	Sequence 3 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04955	XCHRLCYKQRCVTYCRGR	18	Sequence 4 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04956	XCRKLCYKQRCVTYCRGR	18	Sequence 5 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04957	XCRHLCYKQRCVTYCRGR	18	Sequence 6 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04958	XCRRYCYKQRCVTYCRGR	18	Sequence 7 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04959	XCRRVCYKQRCVTYCRGR	18	Sequence 8 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04960	XCRRICYKQRCVTYCRGR	18	Sequence 9 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04961	XCRRMCYKQRCVTYCRGR	18	Sequence 10 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04962	XCRRFCYKQRCVTYCRGR	18	Sequence 11 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04963	XCRRWCYKQRCVTYCRGR	18	Sequence 12 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04964	XCRRLCLKQRCVTYCRGR	18	Sequence 13 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04965	XCRRLCVKQRCVTYCRGR	18	Sequence 14 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04966	XCRRLCIKQRCVTYCRGR	18	Sequence 15 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04967	XCRRLCMKQRCVTYCRGR	18	Sequence 16 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04968	XCRRLCFKQRCVTYCRGR	18	Sequence 17 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04969	XCRRLCWKQRCVTYCRGR	18	Sequence 18 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04970	XCRRLCYRQRCVTYCRGR	18	Sequence 19 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04971	XCRRLCYHQRCVTYCRGR	18	Sequence 20 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04972	XCRRLCYKNRCVTYCRGR	18	Sequence 21 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04973	XCRRLCYKQKCVTYCRGR	18	Sequence 22 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04974	XCRRLCYKQHCVTYCRGR	18	Sequence 23 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04975	XCRRLCYKQRCLTYCRGR	18	Sequence 24 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04976	XCRRLCYKQRCYTYCRGR	18	Sequence 25 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04977	XCRRLCYKQRCITYCRGR	18	Sequence 26 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04978	XCRRLCYKQRCMTYCRGR	18	Sequence 27 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04979	XCRRLCYKQRCFTYCRGR	18	Sequence 28 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04980	XCRRLCYKQRCWTYCRGR	18	Sequence 29 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04981	XCRRLCYKQRCVGYCRGR	18	Sequence 30 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04982	XCRRLCYKQRCVSYCRGR	18	Sequence 31 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04983	XCRRLCYKQRCVAYCRGR	18	Sequence 32 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04984	XCRRLCYKQRCVTLCRGR	18	Sequence 33 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04985	XCRRLCYKQRCVTVCRGR	18	Sequence 34 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04986	XCRRLCYKQRCVTICRGR	18	Sequence 35 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04987	XCRRLCYKQRCVTMCRGR	18	Sequence 36 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04988	XCRRLCYKQRCVTFCRGR	18	Sequence 37 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04989	XCRRLCYKQRCVTWCRGR	18	Sequence 38 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04990	XCRRLCYKQRCVTYCKGR	18	Sequence 39 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04991	XCRRLCYKQRCVTYCHGR	18	Sequence 40 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04992	XCRRLCYKQRCVTYCRTR	18	Sequence 41 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04993	XCRRLCYKQRCVTYCRSR	18	Sequence 42 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04994	XCRRLCYKQRCVTYCRAR	18	Sequence 43 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04995	XCRRLCYKQRCVTYCRGK	18	Sequence 44 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04996	XCKHICFKNRCWSVCKGR	18	Sequence 45 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04997	XCRHLCYKNKCVTYCRGK	18	Sequence 46 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04998	XCRRVCYRQRCVGICHTR	18	Sequence 47 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP04999	XCHKMCLKQHCYAWCRGR	18	Sequence 48 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05000	XCHRLCIHQRCVTYCKAK	18	Sequence 49 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05001	XCRRYCMRQRCVTYCRGR	18	Sequence 50 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05002	XCHKFCLKNKCFSYCKTR	18	Sequence 51 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05003	XCKRLCYKQRCVTYCRGX	18	Sequence 52 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05004	XCHRLCYKQRCVTYCRGX	18	Sequence 53 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05005	XCRKLCYKQRCVTYCRGX	18	Sequence 54 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05006	XCRHLCYKQRCVTYCRGX	18	Sequence 55 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05007	XCRRYCYKQRCVTYCRGX	18	Sequence 56 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05008	XCRRVCYKQRCVTYCRGX	18	Sequence 57 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05009	XCRRICYKQRCVTYCRGX	18	Sequence 58 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05010	XCRRMCYKQRCVTYCRGX	18	Sequence 59 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05011	XCRRFCYKQRCVTYCRGX	18	Sequence 60 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05012	XCRRWCYKQRCVTYCRGX	18	Sequence 61 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05013	XCRRLCLKQRCVTYCRGX	18	Sequence 62 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05014	XCRRLCVKQRCVTYCRGX	18	Sequence 63 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05015	XCRRLCIKQRCVTYCRGX	18	Sequence 64 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05016	XCRRLCMKQRCVTYCRGX	18	Sequence 65 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05017	XCRRLCFKQRCVTYCRGX	18	Sequence 66 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05018	XCRRLCWKQRCVTYCRGX	18	Sequence 67 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05019	XCRRLCYRQRCVTYCRGX	18	Sequence 68 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05020	XCRRLCYHQRCVTYCRGX	18	Sequence 69 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05021	XCRRLCYKNRCVTYCRGX	18	Sequence 70 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05022	XCRRLCYKQKCVTYCRGX	18	Sequence 71 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05023	XCRRLCYKQHCVTYCRGX	18	Sequence 72 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05024	XCRRLCYKQRCLTYCRGX	18	Sequence 73 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05025	XCRRLCYKQRCYTYCRGX	18	Sequence 74 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05026	XCRRLCYKQRCITYCRGX	18	Sequence 75 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05027	XCRRLCYKQRCMTYCRGX	18	Sequence 76 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05028	XCRRLCYKQRCFTYCRGX	18	Sequence 77 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05029	XCRRLCYKQRCWTYCRGX	18	Sequence 78 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05030	XCRRLCYKQRCVGYCRGX	18	Sequence 79 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05031	XCRRLCYKQRCVSYCRGX	18	Sequence 80 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05032	XCRRLCYKQRCVAYCRGX	18	Sequence 81 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05033	XCRRLCYKQRCVTLCRGX	18	Sequence 82 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05034	XCRRLCYKQRCVTVCRGX	18	Sequence 83 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05035	XCRRLCYKQRCVTICRGX	18	Sequence 84 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05036	XCRRLCYKQRCVTMCRGX	18	Sequence 85 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05037	XCRRLCYKQRCVTFCRGX	18	Sequence 86 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05038	XCRRLCYKQRCVTWCRGX	18	Sequence 87 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05039	XCRRLCYKQRCVTYCKGX	18	Sequence 88 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05040	XCRRLCYKQRCVTYCHGX	18	Sequence 89 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05041	XCRRLCYKQRCVTYCRTX	18	Sequence 90 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05042	XCRRLCYKQRCVTYCRSX	18	Sequence 91 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05043	XCRRLCYKQRCVTYCRAX	18	Sequence 92 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05044	XCKHICFKNRCWSVCKGX	18	Sequence 94 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05045	XCRHLCYKNKCVTYCRGX	18	Sequence 95 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05046	XCRRVCYRQRCVGICHTX	18	Sequence 96 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05047	XCHKMCLKQHCYAWCRGX	18	Sequence 97 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05048	XCHRLCIHQRCVTYCKAX	18	Sequence 98 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05049	XCRRYCMRQRCVTYCRGX	18	Sequence 99 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05050	XCHKFCLKNKCFSYCKTX	18	Sequence 100 from Patent US 20030186854	Arachinid	Antimicrobial, Antiparasitic, Antifungal	US 2003/0186854 A1	Patent Application	2003##10##2	US7723468, US20060276380, WO2001092290A2, WO2001092290A3	Antimicrobial peptide, process to obtain a peptide and uses therefor.	The invention refers to small peptides with low hemolytic activity, presenting equal antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a clamp-like structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable residues of cystein forming two disulphide bridges, optionally configurable as a cyclic chain with closed edges.
DRAMP05051	PGPIPN	6	Sequence 1 from Patent US 20030195150	Bovine	Antimicrobial	US 2003/0195150 A1	Patent Application	2003##10##16	CA2311389A1, CA2311389C, DE69838143D1, DE69838143T2, EP1032592A1, EP1032592A4, EP1032592B1, US7588752, WO1999026971A1	Antimicrobial peptides.	The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEASigmaPEVIESPPE (SEQ ID NO:3), AVESTVATLEDSigmaPEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.
DRAMP05052	TTMPLW	6	Sequence 2 from Patent US 20030195150	Bovine	Antimicrobial	US 2003/0195150 A1	Patent Application	2003##10##16	CA2311389A1, CA2311389C, DE69838143D1, DE69838143T2, EP1032592A1, EP1032592A4, EP1032592B1, US7588752, WO1999026971A1	Antimicrobial peptides.	The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEASigmaPEVIESPPE (SEQ ID NO:3), AVESTVATLEDSigmaPEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.
DRAMP05053	AVESTVATLEASPEVIESPPE	21	Sequence 3 from Patent US 20030195150	Bovine	Antimicrobial	US 2003/0195150 A1	Patent Application	2003##10##16	CA2311389A1, CA2311389C, DE69838143D1, DE69838143T2, EP1032592A1, EP1032592A4, EP1032592B1, US7588752, WO1999026971A1	Antimicrobial peptides.	The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEASigmaPEVIESPPE (SEQ ID NO:3), AVESTVATLEDSigmaPEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.
DRAMP05054	AVESTVATLEDSPEVIESPPE	21	Sequence 4 from Patent US 20030195150	Bovine	Antimicrobial	US 2003/0195150 A1	Patent Application	2003##10##16	CA2311389A1, CA2311389C, DE69838143D1, DE69838143T2, EP1032592A1, EP1032592A4, EP1032592B1, US7588752, WO1999026971A1	Antimicrobial peptides.	The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEASigmaPEVIESPPE (SEQ ID NO:3), AVESTVATLEDSigmaPEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.
DRAMP05055	DMPIQAFLLYQQPVLGPVR	19	Sequence 7 from Patent US 20030195150	Bovine	Antimicrobial	US 2003/0195150 A1	Patent Application	2003##10##16	CA2311389A1, CA2311389C, DE69838143D1, DE69838143T2, EP1032592A1, EP1032592A4, EP1032592B1, US7588752, WO1999026971A1	Antimicrobial peptides.	The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEASigmaPEVIESPPE (SEQ ID NO:3), AVESTVATLEDSigmaPEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.
DRAMP05056	MAIPPKKNQDKTEIPTINTIASGEPTSTPTIEAVESTVATLEASPEVIESPPEINTVQVTSTAV	64	Sequence 8 from Patent US 20030195150	Bovine	Antimicrobial	US 2003/0195150 A1	Patent Application	2003##10##16	CA2311389A1, CA2311389C, DE69838143D1, DE69838143T2, EP1032592A1, EP1032592A4, EP1032592B1, US7588752, WO1999026971A1	Antimicrobial peptides.	The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEASigmaPEVIESPPE (SEQ ID NO:3), AVESTVATLEDSigmaPEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.
DRAMP05057	MAIPPKKNQDKTEIPTINTIASGEPTSTPTTEAVESTVATLEDSPEVIESPPEINTVQVTSTAV	64	Sequence 10 from Patent US 20030195150	Bovine	Antimicrobial	US 2003/0195150 A1	Patent Application	2003##10##16	CA2311389A1, CA2311389C, DE69838143D1, DE69838143T2, EP1032592A1, EP1032592A4, EP1032592B1, US7588752, WO1999026971A1	Antimicrobial peptides.	The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEASigmaPEVIESPPE (SEQ ID NO:3), AVESTVATLEDSigmaPEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.
DRAMP05058	TEIPTINTIASGEPTSTPTIEAVESTVATLEASPEVIESPPEINTVQVTSTAV	53	Sequence 12 from Patent US 20030195150	Bovine	Antimicrobial	US 2003/0195150 A1	Patent Application	2003##10##16	CA2311389A1, CA2311389C, DE69838143D1, DE69838143T2, EP1032592A1, EP1032592A4, EP1032592B1, US7588752, WO1999026971A1	Antimicrobial peptides.	The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEASigmaPEVIESPPE (SEQ ID NO:3), AVESTVATLEDSigmaPEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.
DRAMP05059	TEIPTINTIASGEPTSTPTTEAVESTVATLEDSPEVIESPPEINTVQVTSTAV	53	Sequence 14 from Patent US 20030195150	Bovine	Antimicrobial	US 2003/0195150 A1	Patent Application	2003##10##16	CA2311389A1, CA2311389C, DE69838143D1, DE69838143T2, EP1032592A1, EP1032592A4, EP1032592B1, US7588752, WO1999026971A1	Antimicrobial peptides.	The present invention provides antimicrobial peptides. The peptides are non-glycosylated, less than about 100 amino acids in length, and include an amino acid sequence selected from: AVESTVATLEASigmaPEVIESPPE (SEQ ID NO:3), AVESTVATLEDSigmaPEVIESPPE (SEQ ID NO:4), AVESTVATLEASPEVIESPPE (SEQ ID NO:5), AVESTVATLEDSPEVIESPPE (SEQ ID NO:6), DMPIQAFLLYQQPVLGPVR (SEQ ID NO:7), and conservative substitutions therein. These peptides can be produced synthetically; however, they can most conveniently be derived from casein.
DRAMP05060	DPAA	4	Sequence 3 from Patent US 20030228654	Hordeum vulgare	Antimicrobial	US 2003/0228654 A1	Patent Application	2003##12##11	Masana Hirai, Takao Imaeda, Katsunori Kohda, Nobuhiko Muramoto, Takashi Shimamura, Yukio Yamada	Method for producing antimicrobial protein and fusion protein.	A basic antimicrobial protein is activated by a partner protein having an isoelectric point below pH 7 and a chaperon function, by expressing an antimicrobially inactive fusion protein between the basic antimicrobial protein and the partner protein, recovering the fusion protein and separating the two proteins from each other. In such manner, an advantageous mass expression system of the basic antimicrobial protein having an appropriate disulfide bond as an active type is realized at lost cost.
DRAMP05061	DKHMIEGRMKSCCRSTLGRNCYNLCRVRGAQKLCAGVCRCKLTSSGKCPTGFPK	54	Sequence 8 from Patent US 20030228654	Hordeum vulgare	Antimicrobial	US 2003/0228654 A1	Patent Application	2003##12##11	Masana Hirai, Takao Imaeda, Katsunori Kohda, Nobuhiko Muramoto, Takashi Shimamura, Yukio Yamada	Method for producing antimicrobial protein and fusion protein.	A basic antimicrobial protein is activated by a partner protein having an isoelectric point below pH 7 and a chaperon function, by expressing an antimicrobially inactive fusion protein between the basic antimicrobial protein and the partner protein, recovering the fusion protein and separating the two proteins from each other. In such manner, an advantageous mass expression system of the basic antimicrobial protein having an appropriate disulfide bond as an active type is realized at lost cost.
DRAMP05062	DKHMIEGRKSCCRSTLGRNCYNLCRVRGAQKLCAGVCRCKLTSSGKCPTGFPKMIEGRETSSATETTTETATKSEEAAKETATEHDEL	88	Sequence 11 from Patent US 20030228654	Hordeum vulgare	Antimicrobial	US 2003/0228654 A1	Patent Application	2003##12##11	Masana Hirai, Takao Imaeda, Katsunori Kohda, Nobuhiko Muramoto, Takashi Shimamura, Yukio Yamada	Method for producing antimicrobial protein and fusion protein.	A basic antimicrobial protein is activated by a partner protein having an isoelectric point below pH 7 and a chaperon function, by expressing an antimicrobially inactive fusion protein between the basic antimicrobial protein and the partner protein, recovering the fusion protein and separating the two proteins from each other. In such manner, an advantageous mass expression system of the basic antimicrobial protein having an appropriate disulfide bond as an active type is realized at lost cost.
DRAMP05063	ILKKWPWWPWRRK	13	Sequence 1 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05064	ILKPWKWPWWPWRRKK	16	Sequence 2 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05065	ILKPWKWPWWPWRR	14	Sequence 3 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05066	ILPWKKWPWWRWRR	14	Sequence 4 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05067	ILKKWPWWPWRR	12	Sequence 5 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05068	ILPWKWPWWPWRKWR	15	Sequence 6 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05069	ILPWKWPWWPWRRWR	15	Sequence 7 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05070	ILPWKWPWWPWKKWK	15	Sequence 8 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05071	PWKWPWWPWRR	11	Sequence 9 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05072	ILPWKWPWRR	10	Sequence 10 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05073	ILPWKWPWWPWWPWRR	16	Sequence 11 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05074	ILPWKWPWWPWWKKPWRR	18	Sequence 12 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05075	ILPWICPWRPSKAN	14	Sequence 13 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05076	IVPWKWTLWPWRR	13	Sequence 14 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05077	TLPCLWPWWPWSI	13	Sequence 15 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05078	ILPWKWPWWPWRR	13	Sequence 16 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05079	ILKKWPWWPWKRR	13	Sequence 17 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05080	ILKKWPWWPWKWKK	14	Sequence 18 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05081	ILPWKWPWYVRR	12	Sequence 19 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05082	IKWPWYVWL	9	Sequence 20 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05083	ILPWKWFFPPWPWRR	15	Sequence 21 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05084	ILPWKWPPWPPWPWRR	16	Sequence 22 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05085	ILKKWPWWRWRR	12	Sequence 27 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05086	ILKKFPFFPFRRK	13	Sequence 28 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05087	ILKKFPFFPFKKK	13	Sequence 29 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05088	ILKKWAWWPWRRK	13	Sequence 30 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05089	ILKKWPWWAWRRK	13	Sequence 31 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05090	ILKKWPWWPWKKK	13	Sequence 32 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05091	ILRRWPWWPWRRR	13	Sequence 33 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05092	WWKKWPWWPWRRK	13	Sequence 34 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05093	FFKKWPWWPWRRK	13	Sequence 35 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05094	FFKKFPFFPFRRK	13	Sequence 36 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05095	FFKKFPFFPFKKK	13	Sequence 37 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05096	ILKKWPWWPWWPWRRK	16	Sequence 38 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05097	ILKKWPWWPWRWWRR	15	Sequence 39 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05098	ILKKWPWWPWRRWWK	15	Sequence 40 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05099	ILKKWPWWPWPPRRK	15	Sequence 41 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05100	ILKKWPWWPWPPFFRRK	17	Sequence 42 from Patent US 20040019181	Synthetic construct	Antimicrobial	US 2004/0019181 A1	Patent Application	2004##1##29	CA2230160A1, DE69637731D1, EP0846128A2, EP0846128B1, US6191254, US7390873, WO1997008199A2, WO1997008199A3	Antimicrobial cationic peptides.	A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X 1 X 1 PX 2 X 3 X 2 P(X 2 X 2 P) n X 2 X 3 (X 5) 0; (SEQ ID NO: 23) X 1 X 1 PX 2 X 3 X 4 (X 5) r PX 2 X 3 X 3; (SEQ ID NO: 24) X 1 X 1 X 3 (PW) u X 3 X 2 X 5 X 2 X 2 X 5 X 2 (X 5) 0; and (SEQ ID NO: 25) X 1 X 1 X 3 X 3 X 2 P(X 2 X 2 P) n X 2 (X 5) m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X 1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X 2 represents Tryptophan or Phenylalanine X 3 represents Arginine or Lysine; X 4 represents Tryptophan or Lysine; and X 5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.
DRAMP05101	MFLKAVVLTVALVAITGTQAEVTSDQVANV	30	Sequence 1 from Patent US 20040037781	Synthetic construct	Antimicrobial	US 2004/0037781 A1	Patent Application	2004##2##26	US7273847, US20080020983, WO2002006301A2, WO2002006301A3	Peptides with antioxidant and antimicrobial properties.	Methods of treating conditions associated with lipid oxidation or microbial proliferation include the step of administering a composition comprising a pharmacologically effective amount of an antioxidant or antimicrobial lung surfactant protein compound. Peptides derived from lung surfactant protein compounds possess lipid oxidation inhibiting and/or antimicrobial properties.
DRAMP05102	AYLDEELQTELYEIKHQILQTMGVLSLQGSMLSVGDKVSTNGQSVNFDTIKEMCTFRAGGNIAVPRTPEENEAIASIAKKYNNYVYLGMIEDQ	93	Sequence 3 from Patent US 20040037781	Rat	Antimicrobial	US 2004/0037781 A1	Patent Application	2004##2##26	US7273847, US20080020983, WO2002006301A2, WO2002006301A3	Peptides with antioxidant and antimicrobial properties.	Methods of treating conditions associated with lipid oxidation or microbial proliferation include the step of administering a composition comprising a pharmacologically effective amount of an antioxidant or antimicrobial lung surfactant protein compound. Peptides derived from lung surfactant protein compounds possess lipid oxidation inhibiting and/or antimicrobial properties.
DRAMP05103	AHLDEELQATLHDFRHQILQTRGALSLQGSIMTVGEKVFSSNGQSITFDAIQEACARAGGRIAVPRNPEENEAIASFVKKYNTYAYVGLTEGP	93	Sequence 6 from Patent US 20040037781	Homo sapiens	Antimicrobial	US 2004/0037781 A1	Patent Application	2004##2##26	US7273847, US20080020983, WO2002006301A2, WO2002006301A3	Peptides with antioxidant and antimicrobial properties.	Methods of treating conditions associated with lipid oxidation or microbial proliferation include the step of administering a composition comprising a pharmacologically effective amount of an antioxidant or antimicrobial lung surfactant protein compound. Peptides derived from lung surfactant protein compounds possess lipid oxidation inhibiting and/or antimicrobial properties.
DRAMP05104	DVASLRQQVEALQGQVQHLQAAFSQYKKVELFPNGQSVGEKIFKTAGFVKPFTEAQLLCTQAGGQLASPRSAAENAALQQLVVAKNEAAFLSMTDS	96	Sequence 11 from Patent US 20040037781	Homo sapiens	Antimicrobial	US 2004/0037781 A1	Patent Application	2004##2##26	US7273847, US20080020983, WO2002006301A2, WO2002006301A3	Peptides with antioxidant and antimicrobial properties.	Methods of treating conditions associated with lipid oxidation or microbial proliferation include the step of administering a composition comprising a pharmacologically effective amount of an antioxidant or antimicrobial lung surfactant protein compound. Peptides derived from lung surfactant protein compounds possess lipid oxidation inhibiting and/or antimicrobial properties.
DRAMP05105	AYLDEELQTELYEIKHQILQTMGVLSLQGSMLSVGDKVFSTNGQSVNFDTIKEMCTRAGGNIAVPRTPEENEAIASIAKKYNNYVYLGMIED	92	Sequence 15 from Patent US 20040037781	Synthetic construct	Antimicrobial	US 2004/0037781 A1	Patent Application	2004##2##26	US7273847, US20080020983, WO2002006301A2, WO2002006301A3	Peptides with antioxidant and antimicrobial properties.	Methods of treating conditions associated with lipid oxidation or microbial proliferation include the step of administering a composition comprising a pharmacologically effective amount of an antioxidant or antimicrobial lung surfactant protein compound. Peptides derived from lung surfactant protein compounds possess lipid oxidation inhibiting and/or antimicrobial properties.
DRAMP05106	TPGDFHYLDGASVNYTNWYPG	21	Sequence 16 from Patent US 20040037781	Synthetic construct	Antimicrobial	US 2004/0037781 A1	Patent Application	2004##2##26	US7273847, US20080020983, WO2002006301A2, WO2002006301A3	Peptides with antioxidant and antimicrobial properties.	Methods of treating conditions associated with lipid oxidation or microbial proliferation include the step of administering a composition comprising a pharmacologically effective amount of an antioxidant or antimicrobial lung surfactant protein compound. Peptides derived from lung surfactant protein compounds possess lipid oxidation inhibiting and/or antimicrobial properties.
DRAMP05107	SPGDFRYSDGTPVNYTNWYRG	21	Sequence 17 from Patent US 20040037781	Synthetic construct	Antimicrobial	US 2004/0037781 A1	Patent Application	2004##2##26	US7273847, US20080020983, WO2002006301A2, WO2002006301A3	Peptides with antioxidant and antimicrobial properties.	Methods of treating conditions associated with lipid oxidation or microbial proliferation include the step of administering a composition comprising a pharmacologically effective amount of an antioxidant or antimicrobial lung surfactant protein compound. Peptides derived from lung surfactant protein compounds possess lipid oxidation inhibiting and/or antimicrobial properties.
DRAMP05108	NQGRHFCGGALIHARFVMTAASCFQ	25	Sequence 1 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05109	RHFCGGALIHARFVMTAASC	20	Sequence 2 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05110	NQGRHFSGGALIHARFVMTAASCFQ	25	Sequence 3 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05111	RHFSGGALIHARFVMTAASC	20	Sequence 4 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05112	NQGRHFCGGALIHARFVMTAASSFQ	25	Sequence 5 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05113	RHFCGGALIHARFVMTAASS	20	Sequence 6 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05114	NQGRHFSGGALIHARFVMTAASSFQ	25	Sequence 7 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05115	RHFSGGALIHARFVMTAASS	20	Sequence 8 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05116	NQGRHFCGGALIHARFVMTAARCFQ	25	Sequence 10 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05117	NQGRHFCGGALIHARFVMTAAKCFQ	25	Sequence 11 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05118	RHFCGGALIHARFVMTAAHC	20	Sequence 12 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05119	RHFCGGALIHARFVMTAARC	20	Sequence 13 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05120	RHFCGGALIHARFVMTAAKC	20	Sequence 14 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05121	NQGRHFSGGALIHARFVMTAAHCFQ	25	Sequence 15 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05122	NQGRHFSGGALIHARFVMTAARCFQ	25	Sequence 16 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05123	NQGRHFSGGALIHARFVMTAAKCFQ	25	Sequence 17 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05124	NQGRHFCGGALIHARFVMTAAHSFQ	25	Sequence 18 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05125	NQGRHFCGGALIHARFVMTAARSFQ	25	Sequence 19 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05126	NQGRHFCGGALIHARFVMTAAKSFQ	25	Sequence 20 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05127	RHFSGGALIHARFVMTAAHC	20	Sequence 21 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05128	RHFSGGALIHARFVMTAARC	20	Sequence 22 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05129	RHFSGGALIHARFVMTAAKC	20	Sequence 23 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05130	RHFCGGALIHARFVMTAAHS	20	Sequence 24 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05131	RHFCGGALIHARFVMTAARS	20	Sequence 25 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05132	RHFCGGALIHARFVMTAAKS	20	Sequence 26 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05133	NQGRHFCAGALIHARFVMTAASCFQ	25	Sequence 27 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05134	NQGRHFCGAALIHARFVMTAASCFQ	25	Sequence 28 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05135	NQGRHFCAAALIHARFVMTAASCFQ	25	Sequence 29 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05136	NQGRHFSAGALIHARFVMTAASCFQ	25	Sequence 30 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05137	NQGRHFSGAALIHARFVMTAASCFQ	25	Sequence 31 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05138	NQGRHFSAAALIHARFVMTAASCFQ	25	Sequence 32 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05139	NQGRHFCAGALIHARFVMTAASSFQ	25	Sequence 33 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05140	NQGRHFCGAALIHARFVMTAASSFQ	25	Sequence 34 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05141	NQGRHFCAAALIHARFVMTAASSFQ	25	Sequence 35 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05142	NQGRHFCGGALIHARFVMTAATCFQ	25	Sequence 36 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05143	NQGRHFCGGALIHARFLMTAASCFQ	25	Sequence 37 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05144	NQGRHFCGGALIHARFIMTAASCFQ	25	Sequence 38 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05145	NQGRHFCGGALIHARFAMTAASCFQ	25	Sequence 39 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05146	NQGRHYCGGALIHARFVMTAASCFQ	25	Sequence 40 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05147	NQGRHFCGGALIHARYVMTAASCFQ	25	Sequence 41 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05148	NQGRHFCGGALIHARFVMTAASCYQ	25	Sequence 42 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05149	RHFSAGALIHARFVMTAASC	20	Sequence 43 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05150	RHFSGAALIHARFVMTAASC	20	Sequence 44 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05151	RHFSAAALIHARFVMTAASC	20	Sequence 45 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05152	RHFSGGALIHARFLMTAASC	20	Sequence 46 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05153	RHFSGGALIHARFIMTAASC	20	Sequence 47 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05154	RHFSGGALIHARFAMTAASC	20	Sequence 48 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05155	RHYSGGALIHARFVMTAASC	20	Sequence 49 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05156	RHFSGGALIHARYVMTAASC	20	Sequence 50 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05157	RHFCAGALIHARFVMTAASS	20	Sequence 51 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05158	RHFCGAALIHARFVMTAASS	20	Sequence 52 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05159	RHFCAAALIHARFVMTAASS	20	Sequence 53 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05160	RHFCGGALIHARFLMTAASS	20	Sequence 54 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05161	RHFCGGALIHARFIMTAASS	20	Sequence 55 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05162	RHFCGGALIHARFAMTAASS	20	Sequence 56 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05163	RHYCGGALIHARFVMTAASS	20	Sequence 57 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05164	RHFCGGALIHARYVMTAASS	20	Sequence 58 from Patent US 20040048792	Homo Sapiens	Antimicrobial	US 2004/0048792 A1	Patent Application	2004##3##11	US6107460, US6514701, US6730659	Antimicrobial peptides and methods of use thereof.	Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
DRAMP05165	MKVFFLFAVLFCLVQTNSVHISHQEARGPSFRICVDFLGPRWARGCSTGN	50	Sequence 3 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05166	MKVFFLFAVLFCLVQTNSVHISHQEARGPSFKICVGFLGPRWARGCSTGN	50	Sequence 4 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05167	MKVFFLFAVLFCLVQTNSGDVPPGIRNTICRMQQGICRLFFCHSGEKKRDICSDPWNRCCVSNTDEEGKEKPEMDGRSGI	80	Sequence 9 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05168	MKVFFLFAVLFCLVQTNSGDVPLGIRNTICRMQQGICRLFFCHSGEKKRDICSDPWNRCCVSNTDEEGKEKPEMDGRSGI	80	Sequence 10 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05169	MRQRLLPSVTSLLLVALLFPEPASDLKVVDCRRSEGFCQEYCNYMETQVGYCSKKKDACCLH	62	Sequence 11 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05170	MRQRLLPSVTSLLLVALLFPEPASDLKVVDFRRSEGFCQEYCNYMETQVGYCPKKKDACCLH	62	Sequence 12 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05171	ARHVNHSATEALGELRERAPGQGTNGFQLLRHAVKRDLLPPRTPPYQVHISHQEARGPSFRICVDFLGPRWARGCSTGN	79	Sequence 13 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05172	ARHVNHSATEALGELRERAPGQGTNGFQLLRHAVKRDLLPPRTPPYQVHISHQEARGPSFKICVGFLGPRWARGCSTGN	79	Sequence 14 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05173	NSVHISHQEARGPSFRICVDFLGPRWARGCSTGN	34	Sequence 15 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05174	NSVHISHQEARGPSFKICVGFLGPRWARGCSTGN	34	Sequence 16 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05175	ARHVNHSATEALGELRERAPGQGTNGFQLLRHAVKRDLLPPRTPPYQEPASDLKVVDCRRSEGFCQEYCNYMETQVGYCSKKKDACCLH	89	Sequence 17 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05176	ARHVNHSATEALGELRERAPGQGTNGFQLLRHAVKRDLLPPRTPPYQEPASDLKVVDFRRSEGFCQEYCNYMETQVGYCPKKKDACCLH	89	Sequence 18 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05177	NSGDVPPGIRNTICRMQQGICRLFFCHSGEKKRDICSDPWNRCCVSNTDEEGKEKPEMDGRSGI	64	Sequence 21 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05178	NSGDVPLGIRNTICRMQQGICRLFFCHSGEKKRDICSDPWNRCCVSNTDEEGKEKPEMDGRSGI	64	Sequence 22 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05179	PASDLKVVDCRRSEGFCQEYCNYMETQVGYCSKKKDACCLH	41	Sequence 23 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05180	PASDLKVVDFRRSEGFCQEYCNYMETQVGYCPKKKDACCLH	41	Sequence 24 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05181	ARHVNHSATEALGELRERAPGQGTNGFQLLRHAVKRDLLPPRTPPYQ	47	Sequence 25 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05182	VHISHQEARGPSFRICVDFLGPRWARGCSTGN	32	Sequence 26 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05183	VHISHQEARGPSFKICVGFLGPRWARGCSTGN	32	Sequence 27 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05184	EPASDLKVVDCRRSEGFCQEYCNYMETQVGYCSKKKDACCLH	42	Sequence 28 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05185	EPASDLKVVDFRRSEGFCQEYCNYMETQVGYCPKKKDACCLH	42	Sequence 29 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05186	GDVPPGIRNTICRMQQGICRLFFCHSGEKKRDICSDPWNRCCVSNTDEEGKEKPEMDGRSGI	62	Sequence 30 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05187	GDVPLGIRNTICRMQQGICRLFFCHSGEKKRDICSDPWNRCCVSNTDEEGKEKPEMDGRSGI	62	Sequence 31 from Patent US 20040072777	Pan troglodytes	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05188	GNFLTGLGHRSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK	47	Sequence 63 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05189	GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP	41	Sequence 64 from Patent US 20040072777	Homo sapiens	Antimicrobial	US 2004/0072777 A1	Patent Application	2004##4##15	CA2396364A1, EP1246834A1, EP1246834A4, WO2001049702A1	Epididymal antimicrobial peptides.	"The present invention provides novel antimicrobial peptides expressed in the primate epididyrnis (hereinafter, ""EP2 peptides"") and the nucleic acids encoding therefore. EP2 peptides and the nucleic acids encoding therefore can be administered to an individual having a microbial infection in an amount effective to treat the microbial infection or the endogenous production of EP2 peptides can be upregulated to an amount effective to treat the microbial infection. EP2 peptides are useful as antimicrobial agents in animals, including humans, and as antimicrobial agents in agricultural and industrial applications."
DRAMP05190	KWRRWI	6	Sequence 1 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05191	KWRRWV	6	Sequence 3 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05192	KWIKWR	6	Sequence 5 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05193	KWVKWI	6	Sequence 7 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05194	KWIKWI	6	Sequence 9 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05195	KWIKWIKWI	9	Sequence 11 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05196	KFIKFIKFI	9	Sequence 13 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05197	KWRRWVRWI	9	Sequence 15 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05198	IWRVWRRWK	9	Sequence 17 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05199	KFRRFVRFI	9	Sequence 19 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05200	KPRRPVRPI	9	Sequence 21 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05201	KWIRWVRWI	9	Sequence 23 from Patent US 20040072990	Synthetic construct	Antimicrobial	US 2004/0072990 A1	Patent Application	2004##4##15	CA2450540A1, DE10360435A1	Antimicrobial peptides with reduced hemolysis and methods of their use.	The invention is directed to antimicrobial peptides related to cyclic and short peptides (less than 10 amino acid residues) with unique patterns of aromatic and cationic residues that perform a wide range of antimicrobial activities but display low hemolysis.
DRAMP05202	ACNFQSCWATCQAQHSIYFRRAFCDRSQCKCVFVRG	36	Sequence 2 from Patent US 20040087771	Pseudacanthotermes spinig	Antimicrobial	US 2004/0087771 A1	Patent Application	2004##5##6	CA2410575A1, EP1294880A2, WO2002000706A2, WO2002000706A3	Antimicrobial peptides of the family of defensins, polynucleotides encoding said peptides, transformed vectors and organisms containing them.	The invention concerns novel antimicrobial peptides of the family of defensins, in particular antifungal, called termicines, polynucleotides encoding said peptides, vectors containing them for transforming a host organism and the method for transforming said organism. The invention also concerns transformed organisms, in particular yeast producing termicine, or plant cells and plants, the termicines produced by the transformed plats providing them with resistence to fungus-mediated diseases. The invention further concerns the use of termicines as medicine and pharmaceutical compositions containing them.
DRAMP05203	SLDKRACNFQSCWATCQAQHSIYFRRAFCDRSQCKCVFVRG	41	Sequence 4 from Patent US 20040087771	Synthetic construct	Antimicrobial	US 2004/0087771 A1	Patent Application	2004##5##6	CA2410575A1, EP1294880A2, WO2002000706A2, WO2002000706A3	Antimicrobial peptides of the family of defensins, polynucleotides encoding said peptides, transformed vectors and organisms containing them.	The invention concerns novel antimicrobial peptides of the family of defensins, in particular antifungal, called termicines, polynucleotides encoding said peptides, vectors containing them for transforming a host organism and the method for transforming said organism. The invention also concerns transformed organisms, in particular yeast producing termicine, or plant cells and plants, the termicines produced by the transformed plats providing them with resistence to fungus-mediated diseases. The invention further concerns the use of termicines as medicine and pharmaceutical compositions containing them.
DRAMP05204	SRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKL	32	Sequence 1 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05205	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	37	Sequence 2 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05206	RLCRIVVIRVCR	12	Sequence 4 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05207	QLRYREAVLRAVDRLNEQSSEANLYRLLELDQPPKADEDPGTPKPVSFTVKETVCPRPTRQPPELCDFKEKQCVGTVTLNPSIHSLDISCNEIQSV	96	Sequence 6 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05208	GLLSRLRDFLSDRGRRLGEKIERIGQKIKDLSEFFQS	37	Sequence 12 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05209	GRFKRFRKKFKKLFKKLSPVIPLLHLG	27	Sequence 14 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05210	GLRKRLRKFRNKIKEKLKKIGQKIQGFVPKLAPRTDY	37	Sequence 15 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05211	RFRPPIRRPPIRPPFYPPFRPPIRPPIFPPIRPPFRPPLGPFPGRR	46	Sequence 16 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05212	RRIRPRPPRLPRPRPRPLPFPRPGPRPIPRPLPFPRPGPRPIPRPLPFPRPGPRPIPRPL	60	Sequence 17 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05213	RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFPGKR	42	Sequence 18 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05214	RGGRLCYCRRRFCICVG	17	Sequence 19 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05215	LFEAIEGFIFL	11	Sequence 20 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05216	GILGFVFTLT	10	Sequence 21 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05217	QYIKANSKFIGITE	14	Sequence 22 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05218	VYDFFVWL	8	Sequence 23 from Patent US 20040170642	Synthetic construct	Antimicrobial	US 2004/0170642 A1	Patent Application	2004##9##2	CA2418854A1, EP1309345A2, US7658928, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05219	ILPWKWPWWPWRRG	14	Sequence 19 from Patent US 7658928	Synthetic construct	Antimicrobial	US 7658928 B2	Granted Patent	2010##2##9	CA2418854A1, EP1309345A2, US20040170642, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Method of vaccination comprising administering an antigen and a cathelicidin derived antimicrobial peptide.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05220	LFEAIEGFI	9	Sequence 22 from Patent US 7658928	Synthetic construct	Antimicrobial	US 7658928 B2	Granted Patent	2010##2##9	CA2418854A1, EP1309345A2, US20040170642, US20080166368, WO2002013857A2, WO2002013857A3, WO2002013857A8	Method of vaccination comprising administering an antigen and a cathelicidin derived antimicrobial peptide.	Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
DRAMP05221	SLRCGSCRRIIQHLMDKLGDQPDENTVIEEASKVCSKMRLLKGLCKSIMKKFLRTIAEDIVAGKTSRVICVDIKMCKSKPVGFI	84	Sequence 23 from Patent US 20040204575	Bos taurus	Antimicrobial	US 2004/0204575 A1	Patent Application	2004##10##14	US7160696	Bovine lymphocyte-derived antibacterial protein.	A nucleic acid sequence encoding a polypeptide having antibacterial activity, which nucleic acid sequence has the nucleotide sequence of Bases 198 to 452 of Seq. ID No. 13 or is a nucleic acid that hybridizes under highly stringent conditions to a complement of a nucleic acid having the nucleotide sequence of Bases 198 to 452 of Seq. ID No. 13, and the polypeptide encoded thereby.
DRAMP05222	GLICESCRKIIQKLEDMVGPQPNEDTVTQAASRVCDKMKILRGVCKKIMRTFLRRISKDILTGKKPQAICVDIKICKEKTGLI	83	Sequence 24 from Patent US 20040204575	Sus scrofa	Antimicrobial	US 2004/0204575 A1	Patent Application	2004##10##14	US7160696	Bovine lymphocyte-derived antibacterial protein.	A nucleic acid sequence encoding a polypeptide having antibacterial activity, which nucleic acid sequence has the nucleotide sequence of Bases 198 to 452 of Seq. ID No. 13 or is a nucleic acid that hybridizes under highly stringent conditions to a complement of a nucleic acid having the nucleotide sequence of Bases 198 to 452 of Seq. ID No. 13, and the polypeptide encoded thereby.
DRAMP05223	GRDYRTCLTIVQKLKKMVDKPTQRSVSNAATRVCRTGRSRWRDVCRNFMRRYQSRVTQGLVAGETAQQICEDLRLCIPSTGPL	83	Sequence 25 from Patent US 20040204575	Homo sapiens	Antimicrobial	US 2004/0204575 A1	Patent Application	2004##10##14	US7160696	Bovine lymphocyte-derived antibacterial protein.	A nucleic acid sequence encoding a polypeptide having antibacterial activity, which nucleic acid sequence has the nucleotide sequence of Bases 198 to 452 of Seq. ID No. 13 or is a nucleic acid that hybridizes under highly stringent conditions to a complement of a nucleic acid having the nucleotide sequence of Bases 198 to 452 of Seq. ID No. 13, and the polypeptide encoded thereby.
DRAMP05224	MTSWAVLLITSVLL	14	Sequence 28 from Patent US 20040204575	Bos taurus	Antimicrobial	US 2004/0204575 A1	Patent Application	2004##10##14	US7160696	Bovine lymphocyte-derived antibacterial protein.	A nucleic acid sequence encoding a polypeptide having antibacterial activity, which nucleic acid sequence has the nucleotide sequence of Bases 198 to 452 of Seq. ID No. 13 or is a nucleic acid that hybridizes under highly stringent conditions to a complement of a nucleic acid having the nucleotide sequence of Bases 198 to 452 of Seq. ID No. 13, and the polypeptide encoded thereby.
DRAMP05225	MRLVVCLVFLASFALVCQAQGYQGGYTRPFPRPPYGGGYHPVPVCTSCHRLSPLQARACCRQLGRCCDAKQTYG	74	Sequence 1 from Patent US 20040235738	Penaeus monodon	Antimicrobial	US 2004/0235738 A1	Patent Application	2004##11##25	US7670836, US20080032385	Novel antimicrobial peptide isolated from penaeus monodon.	"The present invention provides an antimicrobial peptide, monodoncin, which is isolated and purified from Penaeus monodon and is capable of being mass produced by molecular cloning techniques in a heterologous expression system, such as yeast. Monodoncin demonstrates a wide-range of bacteriostatic and bactericidal effects on G(-) and G(+) bacteria as well as fungicidal activities, and can be used in combination with conventional antibiotics as ""cocktail therapy"" to improve the therapeutic effects of the conventional antibiotics."
DRAMP05226	KKAAAXAAAAAXAAXAAXAAAKKKK	25	Sequence 1 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05227	KKAAAXAAAAAXAAWAAXAAAKKKK	25	Sequence 2 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05228	KKAAAFAAAAAFAAWAAFAAAKKKK	25	Sequence 3 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05229	KKAAAWAAAAAWAAWAAWAAAKKKK	25	Sequence 4 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05230	KKAAALAAAAALAAWAALAAAKKKK	25	Sequence 5 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05231	KKAAAIAAAAAIAAWAAIAAAKKKK	25	Sequence 6 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05232	KKAAAYAAAAAYAAWAAYAAAKKKK	25	Sequence 7 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05233	KKAAASAAAAASAAWAASAAAKKKK	25	Sequence 8 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05234	KKAFAAAAAFAAWAAFAKKKK	21	Sequence 9 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05235	KKKKKKAAFAAWAAFAA	17	Sequence 10 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05236	RRRAAFAAWAAFAARRR	17	Sequence 11 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05237	KKAAAAFAAFAAWFAAFAAAAKKKK	25	Sequence 12 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05238	KKAAAMAAAAAMAAWAAMAAAKKKK	25	Sequence 13 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05239	KKAAALAAAAACAAWAALAAAKKKK	25	Sequence 14 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05240	KKATALVGAASLTAWVGLASAKKKK	25	Sequence 15 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05241	KKAAAFAAAAAFAAXAAFAAAKKKK	25	Sequence 16 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05242	KKAAAWAAAAAWAAXAAWAAAKKKK	25	Sequence 17 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05243	KKAAALAAAAALAAXAALAAAKKKK	25	Sequence 18 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05244	KKAAAIAAAAAIAAXAAIAAAKKKK	25	Sequence 19 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05245	KKAAAYAAAAAYAAXAAYAAAKKKK	25	Sequence 20 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05246	KKAFAAAAAFAAXAAFAKKKK	21	Sequence 21 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05247	KKKKKAAAFAAXAAFA	16	Sequence 22 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05248	RRRAAAFAAXAAFARRR	17	Sequence 23 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05249	KKAAAAFAAFAAXFAAFAAAAKKKK	25	Sequence 24 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05250	KKAAAMAAAAAMAAXAAMAAAKKKK	25	Sequence 25 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05251	KKAAALAAAAACAAXAALAAAKKKK	25	Sequence 26 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05252	KKATALVGAASLTAXVGLASAKKKK	25	Sequence 27 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05253	KKAAAVAAAAAVAAWAAVAAAKKKK	25	Sequence 28 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05254	KKAAAAAAAAAAAAWAAAAAAKKKK	25	Sequence 29 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05255	KKAAATAAAAATAAWAATAAAKKKK	25	Sequence 30 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05256	KKAAAGAAAAAGAAWAAGAAAKKKK	25	Sequence 31 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05257	KKAAANAAAAANAAWAANAAAKKKK	25	Sequence 32 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05258	KKKKKKAAAFAAAAAFAAWAAFAAA	25	Sequence 33 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05259	KKKAAAFAAWAAFAKKK	17	Sequence 34 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05260	RRRRRRAAFAAWAAFAA	17	Sequence 36 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05261	KKKKKKAAAAFWAAAAF	17	Sequence 37 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05262	KKKKKKAAFAAFAAFAA	17	Sequence 38 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05263	KKKKKKAAWAAWAAWAA	17	Sequence 39 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05264	KKAAAVAAAAAVAAXAAVAAAKKKK	25	Sequence 40 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05265	KKAAAAAAAAAAAAXAAAAAAKKKK	25	Sequence 41 from Patent US 20040235745	Synthetic construct	Antimicrobial	US 2004/0235745 A1	Patent Application	2004##11##25	CA2451310A1, CN1516598A, EP1401478A2, WO2003000277A2, WO2003000277A3	Antimicrobial Peptides.	A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: (a) B n1 -Z; (b) B n1 -Z-B n2; and (c) Z-B n1 wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of about 11 to about 24 amino acid residues, the sequence having an average hydrophobicity value of at least 0.3, and preferably at least 0.4. These peptides show antimicrobial activity against microorganisms including both Gram-positive and Gram-negative bacteria.
DRAMP05266	GWFKKAWRKVKHAGRRVLDTAKGVGRHYLNNWLNRYRG	38	Sequence 5 from Patent US 20040249143	Myxine glutinosa	Antimicrobial	US 2004/0249143 A1	Patent Application	2004##12##9	CA2455918A1, EP1499633A2, EP1499633A4, WO2003012044A2, WO2003012044A3, WO2003012044A9	Hagfish cathelin-associated antimicrobial peptides and genes.	The present invention includes Myxine glutinosa cathelin-associated antimicrobial peptides and genes encoding these peptides. The invention also includes compositions an methods for producing these peptides as well as method of preventing and treating microbial infections using these peptides.
DRAMP05267	GWFKKAWRKVKNAGRVLKGVGIHYGVGLIG	30	Sequence 6 from Patent US 20040249143	Myxine glutinosa	Antimicrobial	US 2004/0249143 A1	Patent Application	2004##12##9	CA2455918A1, EP1499633A2, EP1499633A4, WO2003012044A2, WO2003012044A3, WO2003012044A9	Hagfish cathelin-associated antimicrobial peptides and genes.	The present invention includes Myxine glutinosa cathelin-associated antimicrobial peptides and genes encoding these peptides. The invention also includes compositions an methods for producing these peptides as well as method of preventing and treating microbial infections using these peptides.
DRAMP05268	GFFKKAXRKVKHAGRRVLDTAKGVGRHYVNNXLNRYRZ	38	Sequence 9 from Patent US 20040249143	Myxine glutinosa	Antimicrobial	US 2004/0249143 A1	Patent Application	2004##12##9	CA2455918A1, EP1499633A2, EP1499633A4, WO2003012044A2, WO2003012044A3, WO2003012044A9	Hagfish cathelin-associated antimicrobial peptides and genes.	The present invention includes Myxine glutinosa cathelin-associated antimicrobial peptides and genes encoding these peptides. The invention also includes compositions an methods for producing these peptides as well as method of preventing and treating microbial infections using these peptides.
DRAMP05269	GXFKKAXRKVKNAGRRVLKGVGIHYGVGLIZ	31	Sequence 10 from Patent US 20040249143	Myxine glutinosa	Antimicrobial	US 2004/0249143 A1	Patent Application	2004##12##9	CA2455918A1, EP1499633A2, EP1499633A4, WO2003012044A2, WO2003012044A3, WO2003012044A9	Hagfish cathelin-associated antimicrobial peptides and genes.	The present invention includes Myxine glutinosa cathelin-associated antimicrobial peptides and genes encoding these peptides. The invention also includes compositions an methods for producing these peptides as well as method of preventing and treating microbial infections using these peptides.
DRAMP05270	MRVLYLLFSFLFIFLMPLPGVFGGIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP	64	Sequence 2 from Patent US 20050004355	Synthetic construct	Antimicrobial	US 2005/0004355 A1	Patent Application	2005##1##6	CA2290781A1, CN1260834A, EP0980431A1, US6143498, US6420116, US7223840, WO1998051794A1	Antimicrobial peptide.	The present invention relates to a novel human antimicrobial peptide which is a member of the defensin superfamily. In particular, isolated nucleic acid molecules are provided encoding the human antimicrobial peptide. Antimicrobial peptide are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting disorders related to the immune system and therapeutic methods for such disorders.
DRAMP05271	MRLHHLLLALLFLVLSAWSGFTQGVGNPVSCVRNKGICVPIRCPGSMKQIGTCVGRAVKCCRK	63	Sequence 3 from Patent US 20050004355	Synthetic construct	Antimicrobial	US 2005/0004355 A1	Patent Application	2005##1##6	CA2290781A1, CN1260834A, EP0980431A1, US6143498, US6420116, US7223840, WO1998051794A1	Antimicrobial peptide.	The present invention relates to a novel human antimicrobial peptide which is a member of the defensin superfamily. In particular, isolated nucleic acid molecules are provided encoding the human antimicrobial peptide. Antimicrobial peptide are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting disorders related to the immune system and therapeutic methods for such disorders.
DRAMP05272	ITFTG	5	Sequence 1 from Patent US 20050037972	Synthetic construct	Antimicrobial	US 2005/0037972 A1	Patent Application	2005##2##17	US7238669	Phage-display peptides as novel antimicrobial agents against haemophilus influenzae.	Whole cell phage-display techniques were used to identify several peptides that bound preferentially to a non-typeable strain of Haemophilus influenzae. These peptides were able to inhibit growth of both H. influenzae and Staphylococcal aureus. Thus, methods for treating bacterial infections, alone or in combination with traditional antibiotics, are envisioned.
DRAMP05273	ACGGACAGATGCAGATTGG	19	Sequence 2 from Patent US 20050037972	Synthetic construct	Antimicrobial	US 2005/0037972 A1	Patent Application	2005##2##17	US7238669	Phage-display peptides as novel antimicrobial agents against haemophilus influenzae.	Whole cell phage-display techniques were used to identify several peptides that bound preferentially to a non-typeable strain of Haemophilus influenzae. These peptides were able to inhibit growth of both H. influenzae and Staphylococcal aureus. Thus, methods for treating bacterial infections, alone or in combination with traditional antibiotics, are envisioned.
DRAMP05274	CCGAGGCCAGTTGAGATCAGTC	22	Sequence 3 from Patent US 20050037972	Synthetic construct	Antimicrobial	US 2005/0037972 A1	Patent Application	2005##2##17	US7238669	Phage-display peptides as novel antimicrobial agents against haemophilus influenzae.	Whole cell phage-display techniques were used to identify several peptides that bound preferentially to a non-typeable strain of Haemophilus influenzae. These peptides were able to inhibit growth of both H. influenzae and Staphylococcal aureus. Thus, methods for treating bacterial infections, alone or in combination with traditional antibiotics, are envisioned.
DRAMP05275	ASPTYRLYSASPASPASPASPLYS	24	Sequence 5 from Patent US 20050037972	Synthetic construct	Antimicrobial	US 2005/0037972 A1	Patent Application	2005##2##17	US7238669	Phage-display peptides as novel antimicrobial agents against haemophilus influenzae.	Whole cell phage-display techniques were used to identify several peptides that bound preferentially to a non-typeable strain of Haemophilus influenzae. These peptides were able to inhibit growth of both H. influenzae and Staphylococcal aureus. Thus, methods for treating bacterial infections, alone or in combination with traditional antibiotics, are envisioned.
DRAMP05276	GSRGKHTFVRPTLVF	15	Sequence 6 from Patent US 20050037972	Synthetic construct	Antimicrobial	US 2005/0037972 A1	Patent Application	2005##2##17	US7238669	Phage-display peptides as novel antimicrobial agents against haemophilus influenzae.	Whole cell phage-display techniques were used to identify several peptides that bound preferentially to a non-typeable strain of Haemophilus influenzae. These peptides were able to inhibit growth of both H. influenzae and Staphylococcal aureus. Thus, methods for treating bacterial infections, alone or in combination with traditional antibiotics, are envisioned.
DRAMP05277	FISYSSPSHMGARMR	15	Sequence 7 from Patent US 20050037972	Synthetic construct	Antimicrobial	US 2005/0037972 A1	Patent Application	2005##2##17	US7238669	Phage-display peptides as novel antimicrobial agents against haemophilus influenzae.	Whole cell phage-display techniques were used to identify several peptides that bound preferentially to a non-typeable strain of Haemophilus influenzae. These peptides were able to inhibit growth of both H. influenzae and Staphylococcal aureus. Thus, methods for treating bacterial infections, alone or in combination with traditional antibiotics, are envisioned.
DRAMP05278	AATTTAATACGACTCACTATAGGCAAACGACTGTCCTGGCCGT	43	Sequence 8 from Patent US 20050037972	Synthetic construct	Antimicrobial	US 2005/0037972 A1	Patent Application	2005##2##17	US7238669	Phage-display peptides as novel antimicrobial agents against haemophilus influenzae.	Whole cell phage-display techniques were used to identify several peptides that bound preferentially to a non-typeable strain of Haemophilus influenzae. These peptides were able to inhibit growth of both H. influenzae and Staphylococcal aureus. Thus, methods for treating bacterial infections, alone or in combination with traditional antibiotics, are envisioned.
DRAMP05279	VAPIAKYLATALAKWALKQGFAKLKS	26	Sequence 1 from Patent US 20050043508	Synthetic construct	Antimicrobial	US 2005/0043508 A1	Patent Application	2005##2##24	US7041647	Synthetic peptide having an ionophoric and antimicrobial activity.	This invention provides a novel synthetic peptide (P1) of 26 amino acids, which inhibits the microbial growing. Peptide P1 also shows ionophoric activity in rat liver mitochondria. Furthermore, this invention provides pharmaceutical compositions and compositions for agricultural use, which contain the peptide of the invention.
DRAMP05280	GNNRPVYIPQPRPPHPRI	18	Sequence 1 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05281	KKAAAKAAAAAKAAWAAKAAAKKKK	25	Sequence 2 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05282	KRRWPWWPWKKLI	13	Sequence 7 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05283	ILKKIPIIPIRRK	13	Sequence 9 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05284	ILKKYPYYPYRRK	13	Sequence 10 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05285	ILKKWPWPWRRK	12	Sequence 11 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05286	ILKKYPWYPWRRK	13	Sequence 12 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05287	ILKKFPWFPWRRK	13	Sequence 13 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05288	ILKKFPFWPWRRK	13	Sequence 14 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05289	ILRYVYYVYRRK	12	Sequence 15 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05290	ILRWPWWPWWPWRRK	15	Sequence 16 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05291	WWRWPWWPWRRK	12	Sequence 17 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05292	ILRRWPWWPWRRK	13	Sequence 18 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05293	ILRRWPWWPWRK	12	Sequence 19 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05294	ILKWPWWPWRRK	12	Sequence 20 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05295	ILKKWPWWPWRK	12	Sequence 21 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05296	ILKWPWWPWRK	11	Sequence 22 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05297	ILRWPWWPWRRK	12	Sequence 23 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05298	KRRWPWWPWRLI	12	Sequence 24 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05299	ILWPWWPWRRK	11	Sequence 25 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05300	ILRWPWWPWRRKIMILKKAGS	21	Sequence 28 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05301	ILRWPWWPWRRKMILKKAGS	20	Sequence 29 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05302	ILRWPWWPWRRKDMILKKAGS	21	Sequence 30 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05303	ILRWPWRRWPWRRK	14	Sequence 31 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05304	ILRWPWWPWRRKILMRWPWWPWRRKMAA	28	Sequence 32 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05305	KRKWPWWPWRLI	12	Sequence 33 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05306	ILKWVWWVWRRK	12	Sequence 34 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05307	LKKWPWWPWRRK	12	Sequence 38 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05308	PWWPWRRK	8	Sequence 39 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05309	ILKKWPWWPWRRKMILKKAGS	21	Sequence 40 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05310	ILKKWPWWPWRRMILKKAGS	20	Sequence 41 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05311	ILKKWPWWPWRRIMILKKAGS	21	Sequence 42 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05312	WWPWRRK	7	Sequence 43 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05313	ILKKWPW	7	Sequence 44 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05314	ILKKWPWWPWRRKM	14	Sequence 45 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05315	ILKKWPWWPWRRM	13	Sequence 46 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05316	ILKKWPWWPWRRIM	14	Sequence 47 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05317	ILKKWWWPWRK	11	Sequence 48 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05318	ILKKWPWWWRK	11	Sequence 49 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05319	WRIWKPKWRLPKW	13	Sequence 50 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05320	CLRWPWWPWRRK	12	Sequence 51 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05321	ILKKWVWWVWRRK	13	Sequence 55 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05322	ILKKWPWWVWRRK	13	Sequence 56 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05323	ILKKWVWWPWRRK	13	Sequence 57 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05324	ILRWVWWVWRRK	12	Sequence 58 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05325	KRRWVWWVWRLI	12	Sequence 59 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05326	ILRRWVWWVWRRK	13	Sequence 60 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05327	ILRWWVWWVWWRRK	14	Sequence 61 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05328	RLWVWWVWRRK	11	Sequence 62 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05329	RLWVWWVWRR	10	Sequence 63 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05330	RLGGGWVWWVWRR	13	Sequence 64 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05331	RLWWVVWWRR	10	Sequence 65 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05332	RLVVWWVVRR	10	Sequence 66 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05333	RLFVWWVFRR	10	Sequence 67 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05334	RLVVWVVWRR	10	Sequence 68 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05335	WVRLWWRRVW	10	Sequence 71 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05336	IKKWPWWPWRRK	12	Sequence 72 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05337	ILKKPWWPWRRK	12	Sequence 73 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05338	ILKKWWWPWRRK	12	Sequence 74 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05339	ILKKWPWWWRRK	12	Sequence 75 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05340	ILKKWPWWPRRK	12	Sequence 76 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05341	ILKKWPWWPWK	11	Sequence 78 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05342	ILKKWPWWPWR	11	Sequence 79 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05343	LWPWWPWRRK	10	Sequence 80 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05344	LRWWWPWRRK	10	Sequence 81 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05345	LRWPWWPW	8	Sequence 82 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05346	WPWWPWRRK	9	Sequence 83 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05347	RWWWPWRRK	9	Sequence 84 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05348	ALRWPWWPWRRK	12	Sequence 85 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05349	IARWPWWPWRRK	12	Sequence 86 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05350	ILAWPWWPWRRK	12	Sequence 87 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05351	ILRAPWWPWRRK	12	Sequence 88 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05352	ILRWAWWPWRRK	12	Sequence 89 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05353	ILRWPAWPWRRK	12	Sequence 90 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05354	ILRWPWAPWRRK	12	Sequence 91 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05355	ILRWPWWAWRRK	12	Sequence 92 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05356	ILRWPWWPARRK	12	Sequence 93 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05357	ILRWPWWPWARK	12	Sequence 94 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05358	ILRWPWWPWRAK	12	Sequence 95 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05359	ILRWPWWPWRRA	12	Sequence 96 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05360	RRIWKPKWRLPKR	13	Sequence 97 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05361	WRWWKPKWRWPKW	13	Sequence 98 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05362	WRWWKVAWRWVKW	13	Sequence 100 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05363	WRWWKVWRWVKW	12	Sequence 101 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05364	WRWWKVVWRWVKW	13	Sequence 102 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05365	WXWWXVAWXWVXW	13	Sequence 103 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05366	WXWWXPXWXWPXW	13	Sequence 104 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05367	KKWWRRALQALKNGLPALIS	20	Sequence 109 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05368	KWKSFIKKLTSAAKKVLTTGLPALIS	26	Sequence 115 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05369	KWKLFIKKLTPAVKKVLLTGLPALIS	26	Sequence 116 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05370	GKPRPYSPIPTSPRPIRY	18	Sequence 117 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05371	RLARIVVIRVAR	12	Sequence 118 from Patent US 20050049182	Synthetic construct	Antimicrobial	US 2005/0049182 A1	Patent Application	2005##3##3	CA2456477A1, DE60239707D1, EP1469876A2, EP1469876B1, US6835536, US8138144, US20030171281, US20120202735, WO2003015809A2, WO2003015809A3, WO2003015809A	Antimicrobial cationic peptides and formulations thereof.	Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.
DRAMP05372	MSDVIIPFLTSAVTAFIVAYLLDRWYIKRRR	31	Sequence 1 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05373	MRKFVTTLTASPRNKKVGNHRLEISPFVSLRRYYYFNTAICIENPVTREFAIDDSYGSLSTNQNCAQYRQYFSLGGYKEVSLEEIHAV	88	Sequence 6 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05374	MIQLSERQQDLLQVAEKYEQCHIEFYTAQSRLFGTEIMGEVVKTSLGTLKIAHPEEDLFEVALAYLASKKDILTAQERKDVLFYIQNNLC	90	Sequence 7 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05375	MMMDKQVEEVKKHYPIVEDWSVIVARKEDDCMTVTDAVPFILAGYKNVSYEMDDIVVLCSEPIGLTWEDVRFLKNHEGSVSFEEIGYEDKAMVYHVDLG	99	Sequence 9 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05376	MMTEDQKFKYLTKIEELEAGCFSDWTKEDITGDLKYLKKGIIEESIELIRAVNGLTYSEELHDFTQEIIEELDISPL	77	Sequence 10 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05377	MDWTKMTFMGTVDEVKEIWNGLEEAGRLYAVWLSDDHVYGIVDVNEEGLFCLGWVSDISPESLQNMLGGGAELFESYEDVLSEHGGSIAIRVEV	94	Sequence 11 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05378	MDKLAAGGLYLLFLLLAGIIVTH	23	Sequence 14 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05379	MVIIKYTTKTQPTPVKEMFISPQHYAKWRSHMGSKLTSVKPIKGGR	46	Sequence 18 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05380	MFKLLTLFKRNKITSAEEYYTQAIHICEQFDRSTQKYTSM	40	Sequence 19 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05381	MFKYTDRSVRQYIERQQRSAMLEQEQAEKDKKERRKAGLLFFGTIVVLVAVVAVYIVPQSLDAMWHENYEKPAQEAARN	79	Sequence 20 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05382	MTLAGYRVDSCNGCGKAYLVGESHDRKKCAECASK	35	Sequence 22 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05383	MKKRYKVTALFEDGTSQCLVVGNFSSPTNAWCAAMRNLTPEGIARVQHYNVEEISK	56	Sequence 23 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05384	LNQVEVLREEYVEGYVVQMWRRNPSNAPVIEVFTEDNLEEGIIPEYVTANDDTFDRIVDAVEFGYLEELELV	72	Sequence 24 from Patent US 20050054571	SPO1 Bacteriophage	Antimicrobial	US 2005/0054571 A1	Patent Application	2005##3##10	US7157427	Antimicrobial proteins from the SPO1 bacteriophage.	Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.
DRAMP05385	KGLKKLLKGLKKLLKL	16	Sequence 1 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05386	KGLKKGLKLLKKLLKL	16	Sequence 2 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05387	KGLKKLLKLGKKLLKL	16	Sequence 3 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05388	KGLKKLGKLLKKLLKL	16	Sequence 4 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05389	KGLKKLLKLLKKGLKL	16	Sequence 5 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05390	KGLKKLLKLLKKLGKL	16	Sequence 6 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05391	KCLKKLLKLGKKLLKL	16	Sequence 7 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05392	KCLKKGLKLLKKLLKL	16	Sequence 8 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05393	KCLKKLLKGLKKLLKL	16	Sequence 9 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05394	KCLKKLGKLLKKLLKL	16	Sequence 10 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05395	KCLKKLGKLLKKLGKL	16	Sequence 11 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05396	KCLKKGLKLLKKLLKG	16	Sequence 12 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05397	KGLKKLLKLLKKLLKL	16	Sequence 13 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05398	KCLKKLLKLGKKLLKLC	17	Sequence 14 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05399	KCLKKGLKLLKKLLKLC	17	Sequence 15 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05400	KCLKKLLKLLKKLGKLC	17	Sequence 16 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05401	KCLKKLLKLLKKGLKLC	17	Sequence 17 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05402	KCLKKLLKGLKKLLKLC	17	Sequence 18 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05403	KCLKKLGKLLKKLLKLC	17	Sequence 19 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05404	KCLKKLGKLLKKLLKGC	17	Sequence 20 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05405	CLKKLLKLGKKLLKLC	16	Sequence 21 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05406	CLKKGLKLLKKLLKLC	16	Sequence 22 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05407	CLKKLLKLLKKLGKLC	16	Sequence 23 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05408	CLKKLLKLLKKGLKLC	16	Sequence 24 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05409	CLKKLLKGLKKLLKLC	16	Sequence 25 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05410	CLKKLGKLLKKLLKLC	16	Sequence 26 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05411	KGLKKGLKGLKKLLKL	16	Sequence 40 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05412	KGLKKLLKALKKLLKL	16	Sequence 41 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05413	KGGKKLLKGLKKLLKL	16	Sequence 43 from Patent US 20050065072	Synthetic construct	Antimicrobial	US 2005/0065072 A1	Patent Application	2005##3##24	US7550430, WO2005019241A2, WO2005019241A3	Cationic antimicrobial peptides and compositions.	The invention described herein relates to compositions of novel antimicrobial peptides. The peptides of the present invention exhibit high antibacterial activity and low hemolytic activity. The invention further provides compositions comprising these antimicrobial peptides and methods of use thereof for killing, reducing the growth of, or preventing the growth of microorganisms. The invention also provides antimicrobial substrates and articles comprising the peptides of the present invention.
DRAMP05414	MKTLTFYTLLLCAALYSNFFDCKAVADAELPKLPDDKVLIRSRSNCPKGKVWNGFDCKSPFAFSKK	66	Sequence 6 from Patent US 20050069977	Oryctes rhinoceros	Antimicrobial	US 2005/0069977 A1	Patent Application	2005##3##31	DE60219340D1, DE60219340T2, EP1443054A1, EP1443054A4, EP1443054B1, US7041808, WO2003033532A1	Antimicrobial proteins, genes encoding the proteins and method of using the same.	It is intended to provide thermotolerant and antimicrobial proteins having a broad antibacterial spectrum and being useful in the agricultural, medical and industrial field; and plants resistant to pathogenic microorganisms. Namely, DNAs comprising the base sequences represented by SEQ ID NOS: 1 to 5 respectively; antimicrobial proteins encoded by these DNAs; and fungicides, antibacterial agents and antibacterial/antifungal agents for industrial use comprising the antimicrobial proteins as the active ingredient.
DRAMP05415	ELPKLPDDKVLIRSRSNCPKGKVWNGFDCKSPFAFS	36	Sequence 7 from Patent US 20050069977	Oryctes rhinoceros	Antimicrobial	US 2005/0069977 A1	Patent Application	2005##3##31	DE60219340D1, DE60219340T2, EP1443054A1, EP1443054A4, EP1443054B1, US7041808, WO2003033532A1	Antimicrobial proteins, genes encoding the proteins and method of using the same.	It is intended to provide thermotolerant and antimicrobial proteins having a broad antibacterial spectrum and being useful in the agricultural, medical and industrial field; and plants resistant to pathogenic microorganisms. Namely, DNAs comprising the base sequences represented by SEQ ID NOS: 1 to 5 respectively; antimicrobial proteins encoded by these DNAs; and fungicides, antibacterial agents and antibacterial/antifungal agents for industrial use comprising the antimicrobial proteins as the active ingredient.
DRAMP05416	DAELPKLPDDKVLIRSRSNCPKGKVWNGFDCKSPFAFS	38	Sequence 8 from Patent US 20050069977	Oryctes rhinoceros	Antimicrobial	US 2005/0069977 A1	Patent Application	2005##3##31	DE60219340D1, DE60219340T2, EP1443054A1, EP1443054A4, EP1443054B1, US7041808, WO2003033532A1	Antimicrobial proteins, genes encoding the proteins and method of using the same.	It is intended to provide thermotolerant and antimicrobial proteins having a broad antibacterial spectrum and being useful in the agricultural, medical and industrial field; and plants resistant to pathogenic microorganisms. Namely, DNAs comprising the base sequences represented by SEQ ID NOS: 1 to 5 respectively; antimicrobial proteins encoded by these DNAs; and fungicides, antibacterial agents and antibacterial/antifungal agents for industrial use comprising the antimicrobial proteins as the active ingredient.
DRAMP05417	ELPKLPDDKVLIRSRSNCPKGKVWNGFDCKSPFAFSKK	38	Sequence 9 from Patent US 20050069977	Oryctes rhinoceros	Antimicrobial	US 2005/0069977 A1	Patent Application	2005##3##31	DE60219340D1, DE60219340T2, EP1443054A1, EP1443054A4, EP1443054B1, US7041808, WO2003033532A1	Antimicrobial proteins, genes encoding the proteins and method of using the same.	It is intended to provide thermotolerant and antimicrobial proteins having a broad antibacterial spectrum and being useful in the agricultural, medical and industrial field; and plants resistant to pathogenic microorganisms. Namely, DNAs comprising the base sequences represented by SEQ ID NOS: 1 to 5 respectively; antimicrobial proteins encoded by these DNAs; and fungicides, antibacterial agents and antibacterial/antifungal agents for industrial use comprising the antimicrobial proteins as the active ingredient.
DRAMP05418	DAELPKLPDDKVLIRSRSNCPKGKVWNGFDCKSPFAFSKK	40	Sequence 10 from Patent US 20050069977	Oryctes rhinoceros	Antimicrobial	US 2005/0069977 A1	Patent Application	2005##3##31	DE60219340D1, DE60219340T2, EP1443054A1, EP1443054A4, EP1443054B1, US7041808, WO2003033532A1	Antimicrobial proteins, genes encoding the proteins and method of using the same.	It is intended to provide thermotolerant and antimicrobial proteins having a broad antibacterial spectrum and being useful in the agricultural, medical and industrial field; and plants resistant to pathogenic microorganisms. Namely, DNAs comprising the base sequences represented by SEQ ID NOS: 1 to 5 respectively; antimicrobial proteins encoded by these DNAs; and fungicides, antibacterial agents and antibacterial/antifungal agents for industrial use comprising the antimicrobial proteins as the active ingredient.
DRAMP05419	RLLRKWWWKRLL	12	Sequence 1 from Patent US 20050171335	Synthetic construct	Antimicrobial	US 2005/0171335 A1	Patent Application	2005##8##4	US7176276	Novel antimicrobial peptide and use thereof.	An object of the invention is to provide an antimicrobial peptide having an amino acid sequence which is different from a peptide existing and functioning as an antimicrobial peptide in the natural world and is not based on the conventional developmental approach for an antimicrobial peptide-containing antimicrobial agent, and a polynucleotide coding for said peptide. Another object is to provide an antimicrobial agent which contains such an antimicrobial peptide. Namely, an antimicrobial peptide represented by a general formula (1) (Xa)n-S (1) wherein Xa of the formula (1) is a hydrophilic amino acid residue, n is an integer of from 1 to 6, two or more of the Xa may be the same or different from one another, S is a peptide represented by hydrophobic amino acid part-basic amino acid part-bridge part-basic amino acid part-hydrophobic amino acid part, and amino acid residue of the bridge part is selected from the group consisting of hydrophobic amino acids and neutral amino acids.
DRAMP05420	RRLLRKWWWKRLL	13	Sequence 2 from Patent US 20050171335	Synthetic construct	Antimicrobial	US 2005/0171335 A1	Patent Application	2005##8##4	US7176276	Novel antimicrobial peptide and use thereof.	An object of the invention is to provide an antimicrobial peptide having an amino acid sequence which is different from a peptide existing and functioning as an antimicrobial peptide in the natural world and is not based on the conventional developmental approach for an antimicrobial peptide-containing antimicrobial agent, and a polynucleotide coding for said peptide. Another object is to provide an antimicrobial agent which contains such an antimicrobial peptide. Namely, an antimicrobial peptide represented by a general formula (1) (Xa)n-S (1) wherein Xa of the formula (1) is a hydrophilic amino acid residue, n is an integer of from 1 to 6, two or more of the Xa may be the same or different from one another, S is a peptide represented by hydrophobic amino acid part-basic amino acid part-bridge part-basic amino acid part-hydrophobic amino acid part, and amino acid residue of the bridge part is selected from the group consisting of hydrophobic amino acids and neutral amino acids.
DRAMP05421	RRRLLRKWWWKRLL	14	Sequence 3 from Patent US 20050171335	Synthetic construct	Antimicrobial	US 2005/0171335 A1	Patent Application	2005##8##4	US7176276	Novel antimicrobial peptide and use thereof.	An object of the invention is to provide an antimicrobial peptide having an amino acid sequence which is different from a peptide existing and functioning as an antimicrobial peptide in the natural world and is not based on the conventional developmental approach for an antimicrobial peptide-containing antimicrobial agent, and a polynucleotide coding for said peptide. Another object is to provide an antimicrobial agent which contains such an antimicrobial peptide. Namely, an antimicrobial peptide represented by a general formula (1) (Xa)n-S (1) wherein Xa of the formula (1) is a hydrophilic amino acid residue, n is an integer of from 1 to 6, two or more of the Xa may be the same or different from one another, S is a peptide represented by hydrophobic amino acid part-basic amino acid part-bridge part-basic amino acid part-hydrophobic amino acid part, and amino acid residue of the bridge part is selected from the group consisting of hydrophobic amino acids and neutral amino acids.
DRAMP05422	LLRKWWWKRLL	11	Sequence 4 from Patent US 20050171335	Synthetic construct	Antimicrobial	US 2005/0171335 A1	Patent Application	2005##8##4	US7176276	Novel antimicrobial peptide and use thereof.	An object of the invention is to provide an antimicrobial peptide having an amino acid sequence which is different from a peptide existing and functioning as an antimicrobial peptide in the natural world and is not based on the conventional developmental approach for an antimicrobial peptide-containing antimicrobial agent, and a polynucleotide coding for said peptide. Another object is to provide an antimicrobial agent which contains such an antimicrobial peptide. Namely, an antimicrobial peptide represented by a general formula (1) (Xa)n-S (1) wherein Xa of the formula (1) is a hydrophilic amino acid residue, n is an integer of from 1 to 6, two or more of the Xa may be the same or different from one another, S is a peptide represented by hydrophobic amino acid part-basic amino acid part-bridge part-basic amino acid part-hydrophobic amino acid part, and amino acid residue of the bridge part is selected from the group consisting of hydrophobic amino acids and neutral amino acids.
DRAMP05423	KFAKKFAKKFAKKFAK	16	Sequence 1 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05424	KFAKKFAKKFAKKFAKKFAK	20	Sequence 2 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05425	KFAKKFAKKFAKKFAKKFAKKFAK	24	Sequence 3 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05426	KFAKKFAKKFAKKFAKKFAKKFAKKFAK	28	Sequence 4 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05427	KFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAK	32	Sequence 5 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05428	KFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAK	48	Sequence 6 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05429	KFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAK	68	Sequence 7 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05430	KFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAK	84	Sequence 8 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05431	RFARRFARRFARRFARRFARRFAR	24	Sequence 9 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05432	RFARRFARRFARRFARRFARRFARRFAR	28	Sequence 10 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05433	RFARRFARRFARRFARRFARRFARRFARRFAR	32	Sequence 11 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05434	FAKKFAKKFAKKFAKKFAKKFAKK	24	Sequence 12 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05435	AKKFAKKFAKKFAKKFAKKFAKKF	24	Sequence 13 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05436	KKFAKKFAKKFAKKFAKKFAKKFA	24	Sequence 14 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05437	LKKLLKKLLKKLLKKLLKKL	20	Sequence 15 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05438	LKKLLKKLLKKLLKKLLKKLLKKL	24	Sequence 16 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05439	LKKLLKKLLKKLLKKLLKKLLKKLLKKL	28	Sequence 17 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05440	LKKLLKKLLKKLLKKLLKKLLKKLLKKLLKKL	32	Sequence 18 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05441	KFAFKFAFKFAFKFAFKFAFKFAFKFAF	28	Sequence 19 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05442	KFFKKFFKKFFKKFFKKFFKKFFKKFFK	28	Sequence 20 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP18754	RCICRRGFC	9	Sequence 34 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP05444	KAAKKAAKKAAKKAAKKAAKKAAKKAAK	28	Sequence 22 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05445	KKAKKKAKKKAKKKAKKKAKKKAKKKAK	28	Sequence 23 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05446	KFKKFKKFKKFKKFK	15	Sequence 24 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05447	KFKKFKKFKKFKKFKKFK	18	Sequence 25 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05448	KFKKFKKFKKFKKFKKFKKFK	21	Sequence 26 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05449	KFKKFKKFKKFKKFKKFKKFKKFK	24	Sequence 27 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05450	KFKKFKKFKKFKKFKKFKKFKKFKKFK	27	Sequence 28 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05451	KFKKFKKFKKFKKFKKFKKFKKFKKFKKFK	30	Sequence 29 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05452	KFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFK	36	Sequence 30 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05453	KFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFK	48	Sequence 31 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05454	KFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFKKFK	63	Sequence 32 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05455	FKAFKA	6	Sequence 33 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05456	FKAFKAFKAFKA	12	Sequence 34 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05457	FKAFKAFKAFKAFKAFKA	18	Sequence 35 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05458	FKAFKAFKAFKAFKAFKAFKA	21	Sequence 36 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05459	FKAFKAFKAFKAFKAFKAFKAFKA	24	Sequence 37 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05460	FKAFKAFKAFKAFKAFKAFKAFKAFKA	27	Sequence 38 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05461	FKAFKAFKAFKAFKAFKAFKAFKAFKAFKA	30	Sequence 39 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05462	FKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKA	51	Sequence 40 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05463	FKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKAFKA	63	Sequence 41 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05464	LKLK	4	Sequence 42 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05465	LKLKLKLKLK	10	Sequence 43 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05466	LKLKLKLKLKLKLKLK	16	Sequence 44 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05467	LKLKLKLKLKLKLKLKLK	18	Sequence 45 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05468	LKLKLKLKLKLKLKLKLKLK	20	Sequence 46 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05469	LKLKLKLKLKLKLKLKLKLKLK	22	Sequence 47 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05470	LKLKLKLKLKLKLKLKLKLKLKLK	24	Sequence 48 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05471	LKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLK	36	Sequence 49 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05472	LKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLKLK	48	Sequence 50 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05473	LRLRLRLRLRLRLR	14	Sequence 51 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05474	LRLRLRLRLRLRLRLRLR	18	Sequence 52 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05475	LRLRLRLRLRLRLRLRLRLRLR	22	Sequence 53 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05476	KGKKGKKGKKGKKGKKGKKGKKGKKGKKGKKGK	33	Sequence 54 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05477	KGKKGKKGKKGKKGKKGKKGKKGKKGKKGKKGKKGKKGKKGKKGK	45	Sequence 55 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05478	KTKKTKKTKKTKKTKKTKKTK	21	Sequence 56 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05479	KFAK	4	Sequence 57 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05480	KFAKKFAK	8	Sequence 58 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05481	KFAKKFAKKFAK	12	Sequence 59 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05482	LKLKLKLKLKLKLK	14	Sequence 60 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05483	KFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAK	80	Sequence 61 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05484	KFKKFKKFK	9	Sequence 62 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05485	KFKKFKKFKKFK	12	Sequence 63 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05486	KGKKGKKGKKGKKGKKGKKGK	21	Sequence 64 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05487	FAKKFAKKFKKFAKKFAKFAFAF	23	Sequence 65 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05488	FKLRAKIKVRLRAKIKL	17	Sequence 66 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05489	KFAKKFAKKFAKKAAK	16	Sequence 67 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05490	KFAKKFAKKAAKKAAK	16	Sequence 68 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05491	KFAKKAAKKFAKKAAK	16	Sequence 69 from Patent US 7091185	Synthetic construct	Antimicrobial	US 7091185 B2	Granted Patent	2006##8##15	US20050187151	Periodic antimicrobial peptides.	One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%.
DRAMP05492	RVVRQWPIGRVVRRVVRRVVR	21	Sequence 1 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05493	KVVKQWPIGKVVKKVVKKVVK	21	Sequence 2 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05494	RLLRQWPIGRLLRRLLRRLLR	21	Sequence 3 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05495	KLLKQWPIGKLLKKLLKKLLK	21	Sequence 4 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05496	RVLRQWPIGRVLRRVLRRVLR	21	Sequence 5 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05497	KVLKQWPIGKVLKKVLKKVLK	21	Sequence 6 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05498	RLVRQWPIGRLVRRLVRRLVR	21	Sequence 7 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05499	KLVKQWPIGKLVKKLVKKLVK	21	Sequence 8 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05500	RVVKQWPIGRVVKRVVKRVVK	21	Sequence 9 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05501	KVVRQWPIGKVVRKVVRKVVR	21	Sequence 10 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05502	RLLKQWPIGRLLKRLLKRLLK	21	Sequence 11 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05503	KLLRQWPIGKLLRKLLRKLLR	21	Sequence 12 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05504	RVLKQWPIGRVLKRVLKRVLK	21	Sequence 13 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05505	KVLRQWPIGKVLRKVLRKVLR	21	Sequence 14 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05506	RLVKQWPIGRLVKRLVKRLVK	21	Sequence 15 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05507	KLVRQWPIGKLVRKLVRKLVR	21	Sequence 16 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05508	KLVRQFPVGKLVRKLVRKLVR	21	Sequence 17 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05509	RVVRNWPIGRVVRRVVRRVVR	21	Sequence 18 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP05510	KVVKNWPIGKVVKKVVKKVVK	21	Sequence 19 from Patent US 20050215481	Synthetic construct	Antimicrobial	US 2005/0215481 A1	Patent Application	2005##9##29	US7348402, WO2003080652A1	Antimicrobial peptide, its analogs and antimicrobial composition comprising them.	Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
DRAMP10738	KRWKHIRRI	9	Sequence 764 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10739	WIVWIRKRI	9	Sequence 765 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10740	RRWVIRIYK	9	Sequence 766 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10741	WFWRRKMIR	9	Sequence 767 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10742	RYRRWVRKR	9	Sequence 768 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10743	RKWWWKWRR	9	Sequence 769 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10744	RIWMFKIFR	9	Sequence 770 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10745	IVRVGIFRL	9	Sequence 771 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10746	IIRLIKWWR	9	Sequence 772 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10747	WVRRYQMRR	9	Sequence 773 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10748	WQVVMRYRR	9	Sequence 774 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10749	KKWKVWRFG	9	Sequence 775 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10750	WRYWWTRRI	9	Sequence 776 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10751	RIRKGWKWG	9	Sequence 777 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10752	KKRRGNRVR	9	Sequence 778 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10753	VMRKLRRRW	9	Sequence 779 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10754	RNRTHWWRK	9	Sequence 780 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10755	RFTWWWRKF	9	Sequence 781 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10756	KRIRYKRWH	9	Sequence 782 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10757	RWRRYGRVY	9	Sequence 783 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10758	TVVKKRVKK	9	Sequence 784 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10759	RKYRRRYRR	9	Sequence 785 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10760	YFRWWKRWI	9	Sequence 786 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10761	WWQWIVWRK	9	Sequence 787 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10762	RKRLYRWIK	9	Sequence 788 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10763	GWWKNWRWW	9	Sequence 789 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10764	KWWWYWYRR	9	Sequence 790 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10765	RFKWFIRRF	9	Sequence 791 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10766	RIRRLWNIV	9	Sequence 792 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10767	ARWMWRRWR	9	Sequence 793 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10768	LVRWVWGKR	9	Sequence 794 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10769	KRWLKWWRV	9	Sequence 795 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10770	FVYRGWRRK	9	Sequence 796 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10771	RRRWKIYKW	9	Sequence 797 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10772	KRWWQWRWF	9	Sequence 798 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10773	KRVKVRWVT	9	Sequence 799 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10774	RFKYWRWWQ	9	Sequence 800 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10775	KRQWWRVFK	9	Sequence 801 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10776	FKIVWWRRR	9	Sequence 802 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10777	QWWWKYRWK	9	Sequence 803 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10778	RWLRIRKVY	9	Sequence 804 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10779	RYKRVVYRH	9	Sequence 805 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10780	KVRWKWWGW	9	Sequence 806 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10781	IWKVRIFKR	9	Sequence 807 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10782	AIWHKTRRL	9	Sequence 808 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10783	IRQRVRWRW	9	Sequence 809 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10784	MKVWIRWRI	9	Sequence 810 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10785	QRRWWGRFK	9	Sequence 811 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10786	NKRVWFIYR	9	Sequence 812 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10787	RVVNWKGGL	9	Sequence 813 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10788	RYRRFRVRW	9	Sequence 814 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10789	KKVRRVIWW	9	Sequence 815 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10790	WFTRWKWRW	9	Sequence 816 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10791	KWVWFRWRK	9	Sequence 817 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10792	KYLRSVIFY	9	Sequence 818 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10793	FKRSWVQIV	9	Sequence 819 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10794	RWWFIRKWW	9	Sequence 820 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10795	IRRWKRVWW	9	Sequence 821 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10796	QKWYRQRRN	9	Sequence 822 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10797	VWRKWYRVK	9	Sequence 823 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10798	KKKLWRKFR	9	Sequence 824 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10799	RRWWWWRFN	9	Sequence 825 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10800	WFFKSKVYW	9	Sequence 826 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10801	RVVNLNWRW	9	Sequence 827 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10802	RWRRNWMTK	9	Sequence 828 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10803	WKIWKIRWF	9	Sequence 829 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10804	WWFWVIRKY	9	Sequence 830 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10805	RYVKIRWVR	9	Sequence 831 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10806	RIWILSWRW	9	Sequence 832 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10807	KSWRKLFIW	9	Sequence 833 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10808	VWVRWKIWY	9	Sequence 834 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10809	KKRRFKRRY	9	Sequence 835 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10810	RFWKKIRRH	9	Sequence 836 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10811	RKVWWRVFY	9	Sequence 837 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10812	YWRRKWRRK	9	Sequence 838 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10813	KRIRRWKWW	9	Sequence 839 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10814	YWRYLWIRF	9	Sequence 840 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10815	IIYKWRWYW	9	Sequence 841 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10816	QTVYLIFRR	9	Sequence 842 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10817	AKKIKWLVW	9	Sequence 843 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10818	YRFVRRWIV	9	Sequence 844 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10819	VWRRYWWYR	9	Sequence 845 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10820	ARKWKYWRF	9	Sequence 846 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10821	RKRVIKRWR	9	Sequence 847 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10822	RSFWWMWFK	9	Sequence 848 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10823	WRINIFKRI	9	Sequence 849 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10824	RWRVLKRRK	9	Sequence 850 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10825	RWWVIWWWK	9	Sequence 851 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10826	KLIRIWWWW	9	Sequence 852 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10827	FKRKRWWGI	9	Sequence 853 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10828	VWHWWRWRW	9	Sequence 854 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10829	WKRWLIIGR	9	Sequence 855 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10830	AYRWWTRFK	9	Sequence 856 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10831	SWWWIWLKK	9	Sequence 857 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10832	FVIWKYIRV	9	Sequence 858 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10833	RWVRTRRRR	9	Sequence 859 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10834	RRSWWYKRR	9	Sequence 860 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10835	RKYVWWKSI	9	Sequence 861 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10836	WWKRYIVKK	9	Sequence 862 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10837	WFIRVWRYR	9	Sequence 863 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10838	WKMWLRKHW	9	Sequence 864 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10839	RRFFWKKGI	9	Sequence 865 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10840	KRWTFWSRR	9	Sequence 866 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10841	AVQRWRWVV	9	Sequence 867 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10842	IWKYGWRYK	9	Sequence 868 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10843	IIKWWRRWR	9	Sequence 869 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10844	AFRKVKRWG	9	Sequence 870 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10845	MGFTRKWQF	9	Sequence 871 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10846	NWIRWRKWR	9	Sequence 872 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10847	RIGRKLRIR	9	Sequence 873 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10848	RWWRWRHVI	9	Sequence 874 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10849	RLVSKRRRK	9	Sequence 875 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10850	RRKYWKKYR	9	Sequence 876 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10851	IILWWYRRK	9	Sequence 877 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10852	IYFWWWRIR	9	Sequence 878 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10853	HKRKWWRFR	9	Sequence 879 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10854	IGRFWRRWL	9	Sequence 880 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10855	RIRRVLVYV	9	Sequence 881 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10856	WWLRGRRWL	9	Sequence 882 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10857	VRIRKRRWR	9	Sequence 883 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10858	WWRRKWWRR	9	Sequence 884 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10859	WWWRSFRKR	9	Sequence 885 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10860	VGQKWRKRT	9	Sequence 886 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10861	FRRRYRVYR	9	Sequence 887 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10862	RIRRKRKGR	9	Sequence 888 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10863	WKWVTRMYI	9	Sequence 889 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10864	KVVRKKRLR	9	Sequence 890 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10865	RKRRKHWRY	9	Sequence 891 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10866	RVTRTWQRW	9	Sequence 892 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10867	RRRITRKRI	9	Sequence 893 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10868	RLILIKKKW	9	Sequence 894 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10869	WKRRWSRSR	9	Sequence 895 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10870	MWWWFLWRR	9	Sequence 896 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10871	RWVRIWKKK	9	Sequence 897 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10872	KRRVWRMWR	9	Sequence 898 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10873	WHWWIRWWR	9	Sequence 899 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10874	WWRRLRWLV	9	Sequence 900 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10875	KWWIWKRRR	9	Sequence 901 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10876	RYGRKWMIW	9	Sequence 902 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10877	RVKKIKLFI	9	Sequence 903 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10878	RIRYIQRVW	9	Sequence 904 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10879	RLIRWWRKR	9	Sequence 905 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10880	QRGRWLRRG	9	Sequence 906 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10881	RRRRWIRKK	9	Sequence 907 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10882	LGRRWRYRR	9	Sequence 908 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10883	FKIVHVKVR	9	Sequence 909 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10884	FRKKYRVRR	9	Sequence 910 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10885	WKYKYRIRL	9	Sequence 911 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10886	HVRRWWRII	9	Sequence 912 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10887	RFKWWRRYW	9	Sequence 913 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10888	RRRRMRKKI	9	Sequence 914 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10889	RRIRGRVGR	9	Sequence 915 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10890	AFWRWIRFK	9	Sequence 916 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10891	VKKRKIVIY	9	Sequence 917 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10892	KRVKWTWRK	9	Sequence 918 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10893	TGVGRGYRI	9	Sequence 919 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10894	LSWKWWRRV	9	Sequence 920 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10895	IKTFIKRWR	9	Sequence 921 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10896	KMRLKWKRR	9	Sequence 922 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10897	WRWYVTRRK	9	Sequence 923 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10898	IYRRRRKLR	9	Sequence 924 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10899	VWWKWWRWW	9	Sequence 925 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10900	KYKKGWRVV	9	Sequence 926 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10901	KWRRWYYWR	9	Sequence 927 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10902	RRWVFGRRY	9	Sequence 928 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10903	GFTWKKKRR	9	Sequence 929 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10904	YKKIRIKRR	9	Sequence 930 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10905	VWIRRIKRR	9	Sequence 931 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10906	WWKWIRKIV	9	Sequence 932 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10907	WRRKWWSRW	9	Sequence 933 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10908	VTRRRTRIK	9	Sequence 934 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10909	RKRWFVYIW	9	Sequence 935 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10910	IIKWKRIMI	9	Sequence 936 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10911	FNRWWWKKI	9	Sequence 937 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10912	RYKSRRVRR	9	Sequence 938 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10913	VKVIKKFVR	9	Sequence 939 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10914	KWKWLQGRR	9	Sequence 940 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10915	KVRWWYNIK	9	Sequence 941 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10916	FWFRIRKLK	9	Sequence 942 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10917	KRRKQRKYR	9	Sequence 943 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10918	AKNSKRRLW	9	Sequence 944 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10919	RNRRIFRYS	9	Sequence 945 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10920	RWTKWFLVR	9	Sequence 946 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10921	RIRRTRRTR	9	Sequence 947 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10922	KIRWWRISI	9	Sequence 948 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10923	YKGRWGRRW	9	Sequence 949 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10924	MYYRIKQKW	9	Sequence 950 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10925	WRIQRWRWQ	9	Sequence 951 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10926	IRRWSYRRW	9	Sequence 952 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10927	VRIWKIIWW	9	Sequence 953 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10928	RWRWWWLWK	9	Sequence 954 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10929	TKRRWIWIT	9	Sequence 955 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10930	RRWHYWKGW	9	Sequence 956 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10931	WRIRKWWMR	9	Sequence 957 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10932	KRRTRWWVR	9	Sequence 958 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10933	RKWRVWKRR	9	Sequence 959 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10934	WRVWKIRVR	9	Sequence 960 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10935	KYWGIGGWR	9	Sequence 961 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10936	RLISRRRKK	9	Sequence 962 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10937	VSRRIVRRM	9	Sequence 963 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10938	ITKWWRKRR	9	Sequence 964 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10939	KWKIQLWKI	9	Sequence 965 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10940	KKWTWWYVI	9	Sequence 966 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10941	SWKKNRKIW	9	Sequence 967 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10942	HKRQYRKWF	9	Sequence 968 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10943	IFKWFYRRK	9	Sequence 969 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10944	ILKWKWPWWKWRR	13	Sequence 973 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10945	ILPWKWRWWKWRR	13	Sequence 974 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10946	FLPKKFRWWKYRK	13	Sequence 975 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10947	FIKWKFRWWKWRK	13	Sequence 976 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10948	KWPWWPWRR	9	Sequence 977 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10949	KWPWWPWRK	9	Sequence 978 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10950	KFPWWPWRR	9	Sequence 979 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10951	KKPWWPWRR	9	Sequence 980 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10952	KWRWWPWRR	9	Sequence 981 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10953	KWPKWPWRR	9	Sequence 982 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10954	KWPWKPWRR	9	Sequence 983 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10955	KWPWWKWRR	9	Sequence 984 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10956	KWPWWPKRR	9	Sequence 985 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10957	KFRWWPWRR	9	Sequence 987 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10958	KFRWWKWRR	9	Sequence 988 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10959	KWRWWKKRR	9	Sequence 989 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10960	KKKWWKWRR	9	Sequence 990 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10961	KFHWWIWRK	9	Sequence 991 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10962	KFHWWKWRK	9	Sequence 992 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10963	KFKWWKYRK	9	Sequence 993 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10964	KFKFFKYRK	9	Sequence 994 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10965	KFKFFKFRK	9	Sequence 995 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10966	PWWPWRR	7	Sequence 996 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10967	KWWPWRR	7	Sequence 997 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10968	RWWPWRR	7	Sequence 999 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10969	PKWPWRR	7	Sequence 1000 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10970	PWKPWRR	7	Sequence 1001 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10971	PWWPKRR	7	Sequence 1003 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10972	PWWPWRK	7	Sequence 1004 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10973	RWWKWRR	7	Sequence 1005 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10974	RWWKWRK	7	Sequence 1006 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10975	RFWKWRR	7	Sequence 1007 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10976	RWWIKRR	7	Sequence 1008 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10977	RWWIYRR	7	Sequence 1009 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10978	RFFKFRR	7	Sequence 1010 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10979	KWWKWKK	7	Sequence 1011 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10980	KFFKFKK	7	Sequence 1012 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10981	RWRWKRWWW	9	Sequence 1013 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10982	RWRRWKWWW	9	Sequence 1014 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10983	RWWRWRKWW	9	Sequence 1015 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10984	RWRRKWWWW	9	Sequence 1016 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10985	RWRWWKRWY	9	Sequence 1017 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10986	RRKRWWWWW	9	Sequence 1018 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10987	RWRIKRWWW	9	Sequence 1019 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10988	KIWWWWRKR	9	Sequence 1020 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10989	RWRRWKWWL	9	Sequence 1021 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10990	KRWWKWIRW	9	Sequence 1022 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10991	KRWWWWWKR	9	Sequence 1023 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10992	IRWWKRWWR	9	Sequence 1024 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10993	IKRWWRWWR	9	Sequence 1025 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10994	RRKWWWRWW	9	Sequence 1026 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10995	RKWWRWWRW	9	Sequence 1027 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10996	KRWWWWRFR	9	Sequence 1028 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10997	IKRWWWRRW	9	Sequence 1029 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10998	KRWWWVWKR	9	Sequence 1030 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10999	KWRRWKRWW	9	Sequence 1031 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11000	WRWWKIWKR	9	Sequence 1032 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11001	WRWRWWKRW	9	Sequence 1033 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11002	WKRWKWWKR	9	Sequence 1034 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11003	RIKRWWWWR	9	Sequence 1035 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11004	IWKRWWRRW	9	Sequence 1036 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11005	KWWKIWWKR	9	Sequence 1037 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11006	RKRWLWRWW	9	Sequence 1038 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11007	KRWRWWRWW	9	Sequence 1039 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11008	KKRWLWWWR	9	Sequence 1040 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11009	RWWRKWWIR	9	Sequence 1041 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11010	KWWRWWRKW	9	Sequence 1042 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11011	KRWWIRWWR	9	Sequence 1043 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11012	KIWWWWRRR	9	Sequence 1044 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11013	RRRKWWIWW	9	Sequence 1045 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11014	RRRWWWWWW	9	Sequence 1046 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11015	RWWIRKWWR	9	Sequence 1047 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11016	KRWWKWWRR	9	Sequence 1048 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11017	KRWWRKWWR	9	Sequence 1049 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11018	RRIWRWWWW	9	Sequence 1050 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11019	IRRRKWWWW	9	Sequence 1051 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11020	KRKIWWWIR	9	Sequence 1052 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11021	RKIWWWRIR	9	Sequence 1053 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11022	KRWWIWRIR	9	Sequence 1054 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11023	RWFRWWKRW	9	Sequence 1055 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11024	WRWWWKKWR	9	Sequence 1056 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11025	WKRWWKKWR	9	Sequence 1057 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11026	WKRWRWIRW	9	Sequence 1058 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11027	WRWWKWWRR	9	Sequence 1059 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11028	WKKWWKRRW	9	Sequence 1060 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11029	WRWYWWKKR	9	Sequence 1061 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11030	WRRWWKWWR	9	Sequence 1062 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11031	IRMWVKRWR	9	Sequence 1063 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11032	RIWYWYKRW	9	Sequence 1064 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11033	FRRWWKWFK	9	Sequence 1065 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11034	RVRWWKKRW	9	Sequence 1066 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11035	RLKKVRWWW	9	Sequence 1067 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11036	RWWLKIRKW	9	Sequence 1068 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11037	LRWWWIKRI	9	Sequence 1069 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11038	TRKVWWWRW	9	Sequence 1070 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11039	KRFWIWFWR	9	Sequence 1071 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11040	KKRWVWVIR	9	Sequence 1072 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11041	KRWVWYRYW	9	Sequence 1073 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11042	IRKWRRWWK	9	Sequence 1074 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11043	RHWKTWWKR	9	Sequence 1075 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11044	RRFKKWYWY	9	Sequence 1076 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11045	RIKVIWWWR	9	Sequence 1077 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11046	RKRLKWWIY	9	Sequence 1078 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11047	LVFRKYWKR	9	Sequence 1079 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11048	RRRWWWIIV	9	Sequence 1080 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11049	KKRWVWIRY	9	Sequence 1081 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11050	RWRIKFKRW	9	Sequence 1082 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11051	KWKIFRRWW	9	Sequence 1083 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11052	IWKRWRKRL	9	Sequence 1084 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11053	RRRKWWIWG	9	Sequence 1085 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11054	RWLVLRKRW	9	Sequence 1086 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11055	RKWIWRWFL	9	Sequence 1087 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11056	KRRRIWWWK	9	Sequence 1088 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11057	IWWKWRRWV	9	Sequence 1089 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11058	LRWRWWKIK	9	Sequence 1090 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11059	RWKMWWRWV	9	Sequence 1091 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11060	VKRYYWRWR	9	Sequence 1092 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11061	RWYRKRWSW	9	Sequence 1093 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11062	KRKLIRWWW	9	Sequence 1094 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11063	RWRWWIKII	9	Sequence 1095 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11064	KFRKRVWWW	9	Sequence 1096 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11065	IWIWRKLRW	9	Sequence 1097 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11066	LRFILWWKR	9	Sequence 1098 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11067	RVWFKRRWW	9	Sequence 1099 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11068	RRWFVKWWY	9	Sequence 1100 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11069	KWWLVWKRK	9	Sequence 1101 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11070	RWILWWWRI	9	Sequence 1102 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11071	KRWLTWRFR	9	Sequence 1103 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11072	RKWRWRWLK	9	Sequence 1104 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11073	IRRRWWWIV	9	Sequence 1105 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11074	IKWWWRMRI	9	Sequence 1106 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11075	RWKIFIRWW	9	Sequence 1107 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11076	IRQWWRRWW	9	Sequence 1108 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11077	RRRKTWYWW	9	Sequence 1109 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11078	RRWWMRWWV	9	Sequence 1110 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11079	RRFKFIRWW	9	Sequence 1112 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11080	INRKRRLRW	9	Sequence 1113 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11081	RRMKKLRRK	9	Sequence 1114 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11082	RKVRWKIRV	9	Sequence 1115 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11083	VRIVRVRIR	9	Sequence 1116 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11084	IKRVKRRKR	9	Sequence 1117 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11085	RVKTWRVRT	9	Sequence 1118 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11086	RVFVKIRMK	9	Sequence 1119 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11087	IRGRIIFWV	9	Sequence 1120 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11088	ATWIWVFRR	9	Sequence 1121 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11089	KKSKQLWKR	9	Sequence 1122 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11090	MINRVRLRW	9	Sequence 1123 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11091	GGIRRLRWY	9	Sequence 1124 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11092	RLVHWIRRV	9	Sequence 1125 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11093	AWKIKKGRI	9	Sequence 1126 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11094	FVVMKRIVW	9	Sequence 1127 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11095	GIKWRSRRW	9	Sequence 1128 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11096	RWMVSKIWY	9	Sequence 1129 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11097	IVVRVWVVR	9	Sequence 1130 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11098	RWIGVIIKY	9	Sequence 1131 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11099	WIRKRSRIF	9	Sequence 1132 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11100	GWKILRKRK	9	Sequence 1133 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11101	YQRLFVRIR	9	Sequence 1134 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11102	AVWKFVKRV	9	Sequence 1135 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11103	IRKKRRRWT	9	Sequence 1136 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11104	ILRVISKRR	9	Sequence 1137 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11105	AWRFKNIRK	9	Sequence 1138 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11106	HYKFQRWIK	9	Sequence 1139 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11107	RRIRRVRWG	9	Sequence 1140 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11108	VLVKKRRRR	9	Sequence 1141 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11109	RWRGIVHIR	9	Sequence 1142 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11110	WRNRKVVWR	9	Sequence 1143 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11111	KFWWWNYLK	9	Sequence 1144 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11112	KRIMKLKMR	9	Sequence 1145 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11113	IRRRKKRIK	9	Sequence 1146 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11114	RKWMGRFLM	9	Sequence 1147 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11115	RRVQRGKWW	9	Sequence 1148 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11116	WHGVRWWKW	9	Sequence 1149 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11117	WVRFVYRYW	9	Sequence 1150 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11118	RKRTKVTWI	9	Sequence 1151 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11119	IRRIVRRKI	9	Sequence 1152 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11120	KIRRKVRWG	9	Sequence 1153 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11121	AIRRWRIRK	9	Sequence 1154 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11122	WRFKVLRQR	9	Sequence 1155 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11123	RSGKKRWRR	9	Sequence 1156 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11124	FMWVYRYKK	9	Sequence 1157 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11125	RGKYIRWRK	9	Sequence 1158 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11126	WVKVWKYTW	9	Sequence 1159 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11127	VVLKIVRRF	9	Sequence 1160 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11128	GKFYKVWVR	9	Sequence 1161 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11129	SWYRTRKRV	9	Sequence 1162 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11130	KNRGRWFSH	9	Sequence 1163 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11131	AFRGSRHRM	9	Sequence 1164 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11132	GRNGWYRIN	9	Sequence 1165 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11133	AGGMRKRTR	9	Sequence 1166 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11134	ATRKGYSKF	9	Sequence 1167 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11135	SSGVRWSWR	9	Sequence 1168 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11136	RVWRNGYSR	9	Sequence 1169 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11137	WGRTRWSSR	9	Sequence 1170 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11138	GKRVWGRGR	9	Sequence 1171 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11139	SFNWKRSGK	9	Sequence 1172 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11140	WGRGGWTNR	9	Sequence 1173 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11141	ANRWGRGIR	9	Sequence 1174 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11142	WGGHKRRGW	9	Sequence 1175 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11143	WHGGQKWRK	9	Sequence 1176 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11144	FVWQKGTNR	9	Sequence 1177 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11145	HGVWGNRKR	9	Sequence 1178 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11146	TRGWSLGTR	9	Sequence 1179 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11147	GRRVMNQKR	9	Sequence 1180 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11148	RNKFGGNWR	9	Sequence 1181 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11149	GVRVQRNSK	9	Sequence 1182 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11150	NQKWSGRRR	9	Sequence 1183 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11151	RQNGVWRVF	9	Sequence 1184 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11152	GRMRLWNGR	9	Sequence 1185 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11153	WHYRSQVGR	9	Sequence 1186 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11154	GWNTMGRRW	9	Sequence 1187 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11155	RRMGNGGFR	9	Sequence 1188 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11156	SKNVRTWRQ	9	Sequence 1189 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11157	ARGRWINGR	9	Sequence 1190 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11158	GSRRSVWVF	9	Sequence 1191 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11159	WSQNVRTRI	9	Sequence 1192 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11160	GMRRWRGKN	9	Sequence 1193 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11161	RGRTSNWKM	9	Sequence 1194 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11162	WGKRRGWNT	9	Sequence 1195 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11163	AMLGGRQWR	9	Sequence 1197 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11164	QRNKGLRHH	9	Sequence 1198 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11165	ARGKSIKNR	9	Sequence 1199 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11166	NRRNGQMRR	9	Sequence 1200 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11167	RGRRQIGKF	9	Sequence 1201 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11168	ASKRVGVRN	9	Sequence 1202 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11169	GRIGGKNVR	9	Sequence 1203 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11170	NKTGYRWRN	9	Sequence 1204 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11171	VSGNWRGSR	9	Sequence 1205 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11172	GWGGKRRNF	9	Sequence 1206 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11173	KNNRRWQGR	9	Sequence 1207 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11174	GRTMGNGRW	9	Sequence 1208 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11175	GRQISWGRT	9	Sequence 1209 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11176	GGRGTRWHG	9	Sequence 1210 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11177	GVRSWSQRT	9	Sequence 1211 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11178	GSRRFGWNR	9	Sequence 1212 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11179	LVRAIQVRAVIR	12	Sequence 1213 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11180	VQRWLIVWRIRK	12	Sequence 1214 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11181	IVWKIKRWWVGR	12	Sequence 1215 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11182	RFWKVRVKYIRF	12	Sequence 1216 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11183	VQLRIRVAV	9	Sequence 1217 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11184	VQLRIWVRR	9	Sequence 1218 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11185	WNRVKWIRR	9	Sequence 1219 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11186	RIKWIVRFR	9	Sequence 1220 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11187	AIRVVRARLVRR	12	Sequence 1221 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11188	IRWRIRVWVRRI	12	Sequence 1222 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11189	RRWVVWRIVQRR	12	Sequence 1223 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11190	IFWRRIVIVKKF	12	Sequence 1224 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11191	VRLRIRVAV	9	Sequence 1225 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11192	RQVIVRRW	8	Sequence 1226 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11193	VLIRWNGKK	9	Sequence 1227 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11194	LRIRWIFKR	9	Sequence 1228 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11195	KRIVRRLVARIV	12	Sequence 1229 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11196	VRLIVAVRIWRR	12	Sequence 1230 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11197	IVVWRRQLVKNK	12	Sequence 1231 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11198	VRLRIRWWVLRK	12	Sequence 1232 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11199	LRIRVIVWR	9	Sequence 1234 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11200	IRVWVLRQR	9	Sequence 1235 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11201	RIRVIVLKK	9	Sequence 1236 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11202	RRIVKKFQIVRR	12	Sequence 1237 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11203	VQWRIRVRVIKK	12	Sequence 1238 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11204	KKQVSRVKVWRK	12	Sequence 1239 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11205	LIQRIRVRNIVK	12	Sequence 1240 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11206	KQFRIRVRV	9	Sequence 1241 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11207	FRIRVRVIR	9	Sequence 1242 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11208	WRWRVRVWR	9	Sequence 1243 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11209	IRVRVIWRK	9	Sequence 1244 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11210	RRVIVKKFRIRR	12	Sequence 1245 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11211	KQFRNRLRIVKK	12	Sequence 1246 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11212	KRWRWIVRNIRR	12	Sequence 1247 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11213	VQFRIRVIVIRK	12	Sequence 1248 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11214	KRFRIRVRV	9	Sequence 1249 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11215	IVVRRVIRK	9	Sequence 1250 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11216	IWVIRRVWR	9	Sequence 1251 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11217	FQVVKIKVR	9	Sequence 1252 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11218	VIWIRWR	7	Sequence 1253 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11219	IVWIWRR	7	Sequence 1254 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11220	WIVIWRR	7	Sequence 1255 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11221	RRWIVWI	7	Sequence 1256 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11222	RWWRIVI	7	Sequence 1257 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11223	WIRVIRW	7	Sequence 1258 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11224	IIRRWWV	7	Sequence 1259 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11225	IRWVIRW	7	Sequence 1260 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11226	ILRWKWRWWRWRR	13	Sequence 1261 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11227	RWRWWRWRR	9	Sequence 1262 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11228	KWKWWKWKK	9	Sequence 1263 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11229	RWWRWRR	7	Sequence 1264 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11230	RIRVAV	6	Sequence 1265 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11231	WKWPWWPW	8	Sequence 1266 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11232	KIWVIRWWR	9	Sequence 1267 from Patent US 2011023642	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP11233	FFWLIKGAIHAGKAIHGLIHRRRH	24	Sequence 1 from Patent US 20110269669	Chrysophrys major	Antimicrobial	US 2011/0269669 A1	Patent Application	2011##11##3	US8394762	Self-decontaminating coatings containing antimicrobial peptides.	Disclosed herein is a composition having: a polymeric material and an antimicrobial peptide derived from Chrysophrys major. Also disclosed herein is a method of: combining the polymeric material and antimicrobial peptide to form a coating material, and applying the coating material to a surface.
DRAMP11234	FFWLIKGAIHAGKAIHGLIH	20	Sequence 2 from Patent US 20110269669	Chrysophrys major	Antimicrobial	US 2011/0269669 A1	Patent Application	2011##11##3	US8394762	Self-decontaminating coatings containing antimicrobial peptides.	Disclosed herein is a composition having: a polymeric material and an antimicrobial peptide derived from Chrysophrys major. Also disclosed herein is a method of: combining the polymeric material and antimicrobial peptide to form a coating material, and applying the coating material to a surface.
DRAMP11235	FIGLLISAGKAIHDLIRRRH	20	Sequence 3 from Patent US 20110269669	Chrysophrys major	Antimicrobial	US 2011/0269669 A1	Patent Application	2011##11##3	US8394762	Self-decontaminating coatings containing antimicrobial peptides.	Disclosed herein is a composition having: a polymeric material and an antimicrobial peptide derived from Chrysophrys major. Also disclosed herein is a method of: combining the polymeric material and antimicrobial peptide to form a coating material, and applying the coating material to a surface.
DRAMP11236	FIGLLISAGKAIHDLI	16	Sequence 4 from Patent US 20110269669	Chrysophrys major	Antimicrobial	US 2011/0269669 A1	Patent Application	2011##11##3	US8394762	Self-decontaminating coatings containing antimicrobial peptides.	Disclosed herein is a composition having: a polymeric material and an antimicrobial peptide derived from Chrysophrys major. Also disclosed herein is a method of: combining the polymeric material and antimicrobial peptide to form a coating material, and applying the coating material to a surface.
DRAMP11237	KRRLIARILRLAARALVKKR	20	Sequence 1 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11238	KRKLIFLAAFLAALALFKKR	20	Sequence 2 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11239	KRRLAAFRAFRGALKSVLKK	20	Sequence 3 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11240	KRRLIARILRLAIRALVKKR	20	Sequence 4 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11241	KRRLILRILRLAIRALVKKR	20	Sequence 5 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11242	KRRLILRILRLAIRILVKKR	20	Sequence 6 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11243	KRRLIFRILKLFFRFLVKKR	20	Sequence 7 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11244	KRRILIRILKLIIKLILKKR	20	Sequence 8 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11245	KRRKLIKILKLIIKLIRKKR	20	Sequence 9 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11246	KRRKLIKILKLIAKLIRKKR	20	Sequence 10 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11247	KRRKAIKILKLIAKLIRKKR	20	Sequence 11 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11248	KRRKAIKILKLIAKAIRKKR	20	Sequence 12 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11249	KRRLALFRAFRLALKSVLKK	20	Sequence 13 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11250	KRRLALFRLFRLALKLVLKK	20	Sequence 14 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11251	KRRLFLFRLFRLFLRLFLKK	20	Sequence 15 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11252	KRRKLAFRAFRFALKAVLKK	20	Sequence 16 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11253	KRRKLAFRLFRLFLKLVLKK	20	Sequence 17 from Patent US 20110294721	Synthetic construct	Antimicrobial	US 2011/0294721 A1	Patent Application	2011##12##1	EP2168590A1, EP2341920A1, WO2010034786A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid resi
DRAMP11254	RKKRLKLLKRLV	12	Sequence 1 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11255	RKKRLKLLKRLL	12	Sequence 2 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11256	RKKRVKLLKRLV	12	Sequence 3 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11257	RKKKVKLLKRLV	12	Sequence 4 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11258	RKKRLKVVKRLV	12	Sequence 5 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11259	RKKRLRVVRRLV	12	Sequence 6 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11260	RKKKLKVVKRLV	12	Sequence 7 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11261	RKKKLKIIKRLI	12	Sequence 8 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11262	RKKKIKIIKRLI	12	Sequence 9 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11263	RKKKIKIIKKII	12	Sequence 10 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11264	RKKKAKIIKKII	12	Sequence 11 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11265	RKKKLKFFKRLF	12	Sequence 12 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11266	RKKKFKFFKRLF	12	Sequence 13 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11267	RKKKFKFFKRFF	12	Sequence 14 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11268	RKKKFKIFKRLF	12	Sequence 15 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11269	KRKKLLKRLL	10	Sequence 16 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11270	KRKKLLKRLI	10	Sequence 17 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11271	KKKKIIKRLI	10	Sequence 18 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11272	RKKRKKLLKRLL	12	Sequence 19 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11273	RKKRKKLIKRLI	12	Sequence 20 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11274	RKKRKKLLKRLI	12	Sequence 21 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11275	RKKKKKIIKKLI	12	Sequence 22 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11276	KKKKKKIIKKII	12	Sequence 23 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11277	RKRAARLLKRLV	12	Sequence 24 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11278	RKRFARFAKRAV	12	Sequence 25 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11279	KKKAARALKRAL	12	Sequence 26 from Patent US 20110294722	Synthetic construct	Antimicrobial	US 2011/0294722 A1	Patent Application	2011##12##1	EP2168976A1, EP2342213A1, WO2010034784A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity. Furthermore, the invention relates to a nucleic acid mol
DRAMP11280	KFKRWLA	7	Sequence 1 from Patent US 20110294724	Synthetic construct	Antimicrobial	US 2011/0294724 A1	Patent Application	2011##12##1	Unknown	Low hemolytic antimicrobial peptide, pharmaceutical composition and use thereof.	Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; X2 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; P2 is selected from the group consisting of basic amino acids including Arg and Lys; and the numbers of M and X are respectively 0˜2; when N>2, A1 is Ala and the Ala residues are less than N−2.
DRAMP11281	KFRAWVR	7	Sequence 3 from Patent US 20110294724	Synthetic construct	Antimicrobial	US 2011/0294724 A1	Patent Application	2011##12##1	Unknown	Low hemolytic antimicrobial peptide, pharmaceutical composition and use thereof.	Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; X2 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; P2 is selected from the group consisting of basic amino acids including Arg and Lys; and the numbers of M and X are respectively 0˜2; when N>2, A1 is Ala and the Ala residues are less than N−2.
DRAMP11282	KWKIWLK	7	Sequence 5 from Patent US 20110294724	Synthetic construct	Antimicrobial	US 2011/0294724 A1	Patent Application	2011##12##1	Unknown	Low hemolytic antimicrobial peptide, pharmaceutical composition and use thereof.	Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; X2 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; P2 is selected from the group consisting of basic amino acids including Arg and Lys; and the numbers of M and X are respectively 0˜2; when N>2, A1 is Ala and the Ala residues are less than N−2.
DRAMP11283	KKWRAWLKWLAKK	13	Sequence 7 from Patent US 20110294724	Synthetic construct	Antimicrobial	US 2011/0294724 A1	Patent Application	2011##12##1	Unknown	Low hemolytic antimicrobial peptide, pharmaceutical composition and use thereof.	Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; X2 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; P2 is selected from the group consisting of basic amino acids including Arg and Lys; and the numbers of M and X are respectively 0˜2; when N>2, A1 is Ala and the Ala residues are less than N−2.
DRAMP11284	KKWRKWLRAIAKK	13	Sequence 9 from Patent US 20110294724	Synthetic construct	Antimicrobial	US 2011/0294724 A1	Patent Application	2011##12##1	Unknown	Low hemolytic antimicrobial peptide, pharmaceutical composition and use thereof.	Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; X2 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; P2 is selected from the group consisting of basic amino acids including Arg and Lys; and the numbers of M and X are respectively 0˜2; when N>2, A1 is Ala and the Ala residues are less than N−2.
DRAMP11285	KKFRRFVRFIAKK	13	Sequence 11 from Patent US 20110294724	Synthetic construct	Antimicrobial	US 2011/0294724 A1	Patent Application	2011##12##1	Unknown	Low hemolytic antimicrobial peptide, pharmaceutical composition and use thereof.	Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; X2 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; P2 is selected from the group consisting of basic amino acids including Arg and Lys; and the numbers of M and X are respectively 0˜2; when N>2, A1 is Ala and the Ala residues are less than N−2.
DRAMP11286	KKWRRWLKWLAKK	13	Sequence 13 from Patent US 20110294724	Synthetic construct	Antimicrobial	US 2011/0294724 A1	Patent Application	2011##12##1	Unknown	Low hemolytic antimicrobial peptide, pharmaceutical composition and use thereof.	Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; X2 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; P2 is selected from the group consisting of basic amino acids including Arg and Lys; and the numbers of M and X are respectively 0˜2; when N>2, A1 is Ala and the Ala residues are less than N−2.
DRAMP11287	RCICGRGICRCICGRGIC	18	Sequence 11 from Patent US 20110302675	Synthetic construct	Antimicrobial	US 2011/0302675 A1	Patent Application	2011##12##8	Unknown	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11288	RCICGKGICRCICGRGIC	18	Sequence 12 from Patent US 20110302675	Synthetic construct	Antimicrobial	US 2011/0302675 A1	Patent Application	2011##12##8	Unknown	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11289	RCICGKGICRCICGKGIC	18	Sequence 13 from Patent US 20110302675	Synthetic construct	Antimicrobial	US 2011/0302675 A1	Patent Application	2011##12##8	Unknown	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11290	RGGRLCYCRRRFCVCVGR	18	Sequence 14 from Patent US 20110302675	Synthetic construct	Antimicrobial	US 2011/0302675 A1	Patent Application	2011##12##8	Unknown	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11291	RGGRLCYCRRRFCVCV	16	Sequence 15 from Patent US 20110302675	Synthetic construct	Antimicrobial	US 2011/0302675 A1	Patent Application	2011##12##8	Unknown	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11292	RGGGLCYCRRRFCVCVGR	18	Sequence 16 from Patent US 20110302675	Synthetic construct	Antimicrobial	US 2011/0302675 A1	Patent Application	2011##12##8	Unknown	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11293	RGGRLCYCRGWICFCVGR	18	Sequence 17 from Patent US 20110302675	Synthetic construct	Antimicrobial	US 2011/0302675 A1	Patent Application	2011##12##8	Unknown	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11294	RGGRLCYCRPRFCVCVGR	18	Sequence 18 from Patent US 20110302675	Synthetic construct	Antimicrobial	US 2011/0302675 A1	Patent Application	2011##12##8	Unknown	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11295	GICRCICGKGICRCICGR	18	Sequence 21 from Patent US 20110302675	Synthetic construct	Antimicrobial	US 2011/0302675 A1	Patent Application	2011##12##8	Unknown	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP18753	RCICRRGVC	9	Sequence 33 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP11297	GFCWYVCVYRNGVRVCYRRCN	21	Sequence 2 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11298	GACWYVCVYRNGVRVCYRRCN	21	Sequence 3 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11299	GFCAYVCVYRNGVRVCYRRCN	21	Sequence 4 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11300	GFCEYVCVYRNGVRVCYRRCN	21	Sequence 5 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11301	GFCGYVCVYRNGVRVCYRRCN	21	Sequence 6 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11302	GFCSYVCVYRNGVRVCYRRCN	21	Sequence 7 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11303	GFCTYVCVYRNGVRVCYRRCN	21	Sequence 8 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11304	GFCYYVCVYRNGVRVCYRRCN	21	Sequence 9 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11305	GFCWKVCVYRNGVRVCYRRCN	21	Sequence 10 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11306	GFCWNVCVYRNGVRVCYRRCN	21	Sequence 11 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11307	GFCWRVCVYRNGVRVCYRRCN	21	Sequence 12 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11308	GFCWYACVYRNGVRVCYRRCN	21	Sequence 13 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11309	GFCWYECVYRNGVRVCYRRCN	21	Sequence 14 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11310	GFCWYGCVYRNGVRVCYRRCN	21	Sequence 15 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11311	GFCWYLCVYRNGVRVCYRRCN	21	Sequence 16 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11312	GFCWYNCVYRNGVRVCYRRCN	21	Sequence 17 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11313	GFCWYRCVYRNGVRVCYRRCN	21	Sequence 18 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11314	GFCWYSCVYRNGVRVCYRRCN	21	Sequence 19 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11315	GFCWYWCVYRNGVRVCYRRCN	21	Sequence 20 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11316	GFCWYVCAYRNGVRVCYRRCN	21	Sequence 21 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11317	GFCWYVCGYRNGVRVCYRRCN	21	Sequence 22 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11318	GFCWYVCHYRNGVRVCYRRCN	21	Sequence 23 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11319	GFCWYVCSYRNGVRVCYRRCN	21	Sequence 24 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11320	GFCWYVCYYRNGVRVCYRRCN	21	Sequence 25 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11321	GFCWYVCVIRNGVRVCYRRCN	21	Sequence 26 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11322	GFCWYVCVKRNGVRVCYRRCN	21	Sequence 27 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11323	GFCWYVCVRRNGVRVCYRRCN	21	Sequence 28 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11324	GFCWYVCVYRNGARVCYRRCN	21	Sequence 29 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11325	GFCWYVCVYRNGGRVCYRRCN	21	Sequence 30 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11326	GFCWYVCVYRNGKRVCYRRCN	21	Sequence 31 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11327	GFCWYVCVYRNGLRVCYRRCN	21	Sequence 32 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11328	GFCWYVCVYRNGPRVCYRRCN	21	Sequence 33 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11329	GFCWYVCVYRNGQRVCYRRCN	21	Sequence 34 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11330	GFCWYVCVYRNGRRVCYRRCN	21	Sequence 35 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11331	GFCWYVCVYRNGSRVCYRRCN	21	Sequence 36 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11332	GFCWYVCVYRNGVRACYRRCN	21	Sequence 37 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11333	GFCWYVCVYRNGVRGCYRRCN	21	Sequence 38 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11334	GFCWYVCVYRNGVRHCYRRCN	21	Sequence 39 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11335	GFCWYVCVYRNGVRKCYRRCN	21	Sequence 40 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11336	GFCWYVCVYRNGVRNCYRRCN	21	Sequence 41 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11337	GFCWYVCVYRNGVRQCYRRCN	21	Sequence 42 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11338	GFCWYVCVYRNGVRRCYRRCN	21	Sequence 43 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11339	GFCWYVCVYRNGVRSCYRRCN	21	Sequence 44 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11340	GFCWYVCVYRNGVRTCYRRCN	21	Sequence 45 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11341	GFCWYVCVYRNGVRVCHRRCN	21	Sequence 46 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11342	GFCWYVCVYRNGVRVCKRRCN	21	Sequence 47 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11343	GFCWYVCVYRNGVRVCNRRCN	21	Sequence 48 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11344	GFCWYVCVYRNGVRVCRRRCN	21	Sequence 49 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11345	GFCWYVCVYRNGVRVCYRRCH	21	Sequence 50 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11346	GFCWYVCVYRNGVRVCYRRCK	21	Sequence 51 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11347	GFCWYVCVYRNGVRVCYRRCR	21	Sequence 52 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11348	GFCWYVCVYRNGVRVCYRRCS	21	Sequence 53 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11349	GFCWYVCVYRNGVRVCYRRCT	21	Sequence 54 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11350	RFCWYVCVYRNGVRVCYRRCR	21	Sequence 55 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11351	GFCFYVCVYRNGVRVCRRRCN	21	Sequence 56 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11352	GFCAHVCVYRNGVRVCYRRCN	21	Sequence 57 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11353	GFCARVCVYRNGVRVCYRRCN	21	Sequence 58 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11354	GFCFYVCVRRNGVRVCYRRCN	21	Sequence 59 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11355	GFCGHVCVYRNGVRVCYRRCN	21	Sequence 60 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11356	GFCGRVCVYRNGVRVCYRRCN	21	Sequence 61 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11357	GFCSYVCVYRNGVRACYRRCN	21	Sequence 62 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11358	GFCSRVCVYRNGVRVCYRRCN	21	Sequence 63 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11359	GFCYRVCVYRNGVRVCYRRCN	21	Sequence 64 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11360	GFCWFVCVYRNGVRQCYRRCN	21	Sequence 65 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11361	GFCWHVCVYRNGVRSCYRRCN	21	Sequence 66 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11362	GFCWHVCVYRNGVRVCRRRCN	21	Sequence 67 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11363	GFCWKVCVYRNGVRVCSRRCN	21	Sequence 68 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11364	GFCWNVCVYRNGVRSCYRRCN	21	Sequence 69 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11365	GFCWNVCVYRNGVRVCHRRCN	21	Sequence 70 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11366	GFCWRVCVYRNGVRPCYRRCN	21	Sequence 71 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11367	GFCWRACVYRNGVRVCYRRCN	21	Sequence 72 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11368	GFCWRVCGYRNGVRVCYRRCN	21	Sequence 73 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11369	GFCWRVCHYRNGVRVCYRRCN	21	Sequence 74 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11370	GFCWRVCSYRNGVRVCYRRCN	21	Sequence 75 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11371	GFCWRVCVYRNGVRVCHRRCN	21	Sequence 76 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11372	GFCWRVCVYRNGVRVCNRRCN	21	Sequence 77 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11373	GFCWSVCVYRNGVRSCYRRCN	21	Sequence 78 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11374	GFCWYACVYRNGARVCYRRCN	21	Sequence 79 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11375	GFCWYACVYRNGKRVCYRRCN	21	Sequence 80 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11376	GFCWYACVYRNGVRACYRRCN	21	Sequence 81 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11377	GFCWYACVYRNGVRVCHRRCN	21	Sequence 82 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11378	GFCWYMCGYRNGVRVCYRRCN	21	Sequence 83 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11379	GFCWYVCAYRNGVRACYRRCN	21	Sequence 84 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11380	GFCWYVCSYRNGKRVCYRRCN	21	Sequence 85 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11381	GFCWYVCVKRNGARVCYRRCN	21	Sequence 86 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11382	GFCWYVCVKRNGVRSCYRRCN	21	Sequence 87 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11383	GFCWYVCVYKNGVRSCYRRCN	21	Sequence 88 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11384	GFCWYVCVYKNGVRVCHRRCN	21	Sequence 89 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11385	GFCWYVCVYPNGGRVCYRRCN	21	Sequence 90 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11386	GFCWYVCVYRRGVRQCYRRCN	21	Sequence 91 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11387	GFCWYVCVYRNGARVCCRRCN	21	Sequence 92 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11388	GFCWYVCVYRNGGRKCYRRCN	21	Sequence 93 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11389	GFCWYVCVYRNGVRLCHRRCN	21	Sequence 94 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11390	AFCWNVCVYRNGVRVCHRRCN	21	Sequence 95 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11391	DFCWNVCVYRNGVRVCHRRCN	21	Sequence 96 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11392	FFCWNVCVYRNGVRVCHRRCN	21	Sequence 97 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11393	HFCWNVCVYRNGVRVCHRRCN	21	Sequence 98 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11394	IFCWNVCVYRNGVRVCHRRCN	21	Sequence 99 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11395	KFCWNVCVYRNGVRVCHRRCN	21	Sequence 100 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11396	MFCWNVCVYRNGVRVCHRRCN	21	Sequence 101 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11397	QFCWNVCVYRNGVRVCHRRCN	21	Sequence 102 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11398	RFCWNVCVYRNGVRVCHRRCN	21	Sequence 103 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11399	SFCWNVCVYRNGVRVCHRRCN	21	Sequence 104 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11400	TFCWNVCVYRNGVRVCHRRCN	21	Sequence 105 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11401	VFCWNVCVYRNGVRVCHRRCN	21	Sequence 106 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11402	WFCWNVCVYRNGVRVCHRRCN	21	Sequence 107 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11403	YFCWNVCVYRNGVRVCHRRCN	21	Sequence 108 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11404	GGCWNVCVYRNGVRVCHRRCN	21	Sequence 109 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11405	GHCWNVCVYRNGVRVCHRRCN	21	Sequence 110 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11406	GICWNVCVYRNGVRVCHRRCN	21	Sequence 111 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11407	GLCWNVCVYRNGVRVCHRRCN	21	Sequence 112 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11408	GMCWNVCVYRNGVRVCHRRCN	21	Sequence 113 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11409	GPCWNVCVYRNGVRVCHRRCN	21	Sequence 114 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11410	GVCWNVCVYRNGVRVCHRRCN	21	Sequence 115 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11411	GWCWNVCVYRNGVRVCHRRCN	21	Sequence 116 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11412	GYCWNVCVYRNGVRVCHRRCN	21	Sequence 117 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11413	GFLQYVCVYRNGVRVCHRRCN	21	Sequence 118 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11414	GFCAYACVKRNGVRVCYRRCN	21	Sequence 119 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11415	GFCAKVCVYRNGVRSCYRRCN	21	Sequence 120 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11416	GFCARVCVYRNGVRACYRRCN	21	Sequence 121 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11417	GFCARVCVYRNGVRSCYRRCN	21	Sequence 122 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11418	GFCARVCVYRNGVRTCYRRCN	21	Sequence 123 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11419	GFCARVCSYRNGVRVCYRRCN	21	Sequence 124 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11420	GFCARVCVKRNGVRVCYRRCN	21	Sequence 125 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11421	GFCAWVCVYRNGVRQCYRRCN	21	Sequence 126 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11422	GFCAYVCVRRNGVRSCYRRCN	21	Sequence 127 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11423	GFCFYVCAYRNGVRSCYRRCN	21	Sequence 128 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11424	GFCFHVCVYRNGVRSCYRRCN	21	Sequence 129 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11425	GFCFNVCVYRNGVRSCYRRCN	21	Sequence 130 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11426	GFCFNVCVYRNGVRVCHRRCN	21	Sequence 131 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11427	GFCFRVCVYRNGVRKCYRRCN	21	Sequence 132 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11428	GFCFRVCVYRNGVRQCYRRCN	21	Sequence 133 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11429	GFCFRVCVYRNGVRSCYRRCN	21	Sequence 134 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11430	GFCFRVCVYRNGVRVCHRRCN	21	Sequence 135 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11431	GFCFRVCVYRNGVRVCQRRCN	21	Sequence 136 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11432	GFCFYVCVKRNGVRVCHRRCN	21	Sequence 137 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11433	GFCGHVCVYRNGVRVCYRRCA	21	Sequence 138 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11434	GFCGHVCVYRNGVRVCYRRCK	21	Sequence 139 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11435	GFCGHVCVYRNGVRVCYRRCL	21	Sequence 140 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11436	GFCGHVCVYRNGVRVCYRRCM	21	Sequence 141 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11437	GFCGHVCVYRNGVRVCYRRCP	21	Sequence 142 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11438	GFCGHVCVYRNGVRVCYRRCR	21	Sequence 143 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11439	GFCGHVCVYRNGVRVCYRRCS	21	Sequence 144 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11440	GFCGHVCVYRNGVRVCYRRCY	21	Sequence 145 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11441	GFCGHVCVYRNGVRACYRRCN	21	Sequence 146 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11442	GFCGHVCVYRNGVRFCYRRCN	21	Sequence 147 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11443	GFCGHVCVYRNGVRGCYRRCN	21	Sequence 148 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11444	GFCGHVCVYRNGVRHCYRRCN	21	Sequence 149 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11445	GFCGHVCVYRNGVRICYRRCN	21	Sequence 150 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11446	GFCGHVCVYRNGVRLCYRRCN	21	Sequence 151 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11447	GFCGHVCVYRNGVRMCYRRCN	21	Sequence 152 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11448	GFCGHVCVYRNGVRNCYRRCN	21	Sequence 153 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11449	GFCGHVCVYRNGVRQCYRRCN	21	Sequence 154 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11450	GFCGHVCVYRNGVRRCYRRCN	21	Sequence 155 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11451	GFCGHVCVYRNGVRSCYRRCN	21	Sequence 156 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11452	GFCGHVCVYRNGVRTCYRRCN	21	Sequence 157 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11453	GFCGHVCVYRNGVRWCYRRCN	21	Sequence 158 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11454	GFCGHVCVYRNGVRYCYRRCN	21	Sequence 159 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11455	GFCGHVCVYRNGVRVCFRRCN	21	Sequence 160 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11456	GFCGHVCVYRNGVRVCGRRCN	21	Sequence 161 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11457	GFCGHVCVYRNGVRVCIRRCN	21	Sequence 162 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11458	GFCGHVCVYRNGVRVCLRRCN	21	Sequence 163 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11459	GFCGHVCVYRNGVRVCMRRCN	21	Sequence 164 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11460	GFCGHVCVYRNGVRVCTRRCN	21	Sequence 165 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11461	GFCGHVCVYRNGVRVCVRRCN	21	Sequence 166 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11462	GFCGHVCVYRNGVRVCWRRCN	21	Sequence 167 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11463	GFCGKVCVYRNGVRHCYRRCN	21	Sequence 168 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11464	GFCGRVCVYRNGVRLCYRRCN	21	Sequence 169 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11465	GFCGRVCVYRNGVRRCYRRCN	21	Sequence 170 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11466	GFCGRVCVYRNGVRTCYRRCN	21	Sequence 171 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11467	GFCGRVCVRRNGVRVCYRRCN	21	Sequence 172 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11468	GFCGSVCVYRNGVRACYRRCN	21	Sequence 173 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11469	GFCGSVCVYRNGVRKCYRRCN	21	Sequence 174 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11470	GFCGSVCVYRNGVRRCYRRCN	21	Sequence 175 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11471	GFCGYVCVRRNGVRSCYRRCN	21	Sequence 176 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11472	GFCINVCVYRNGVRVCHRRCN	21	Sequence 177 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11473	GFCLHVCVYRNGVRQCYRRCN	21	Sequence 178 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11474	GFCLKVCVYRNGVRKCYRRCN	21	Sequence 179 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11475	GFCLRVCVYRNGVRQCYRRCN	21	Sequence 180 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11476	GFCLRVCVYRNGVRSCYRRCN	21	Sequence 181 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11477	GFCMEVCVYRNGVRVCTRRCN	21	Sequence 182 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11478	GFCMHVCVYRNGVRSCYRRCN	21	Sequence 183 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11479	GFCMNVCVYRNGVRVCHRRCN	21	Sequence 184 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11480	GFCMRVCVYRNGVRTCYRRCN	21	Sequence 185 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11481	GFCMSVCVYRNGVRQCYRRCN	21	Sequence 186 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11482	GFCMSVCVYRNGVRRCYRRCN	21	Sequence 187 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11483	GFCNRVCVYRNGVRICYRRCN	21	Sequence 188 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11484	GFCSKVCVYRNGVRRCYRRCN	21	Sequence 189 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11485	GFCSRVCVYRNGVRICYRRCN	21	Sequence 190 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11486	GFCTNVCVYRNGVRACYRRCN	21	Sequence 191 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11487	GFCTRVCVYRNGVRRCYRRCN	21	Sequence 192 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11488	GFCTRVCVYRNGVRTCYRRCN	21	Sequence 193 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11489	GFCTSVCVYRNGVRHCYRRCN	21	Sequence 194 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11490	GFCTYVCVKRNGVRKCYRRCN	21	Sequence 195 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11491	GFCVHVCVYRNGVRPCYRRCN	21	Sequence 196 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11492	GFCVHVCVYRNGVRVCHRRCN	21	Sequence 197 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11493	GFCVKVCVYRNGVRQCYRRCN	21	Sequence 198 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11494	GFCVNVCVYRNGVRVCHRRCN	21	Sequence 199 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11495	GFCVRVCVYRNGVRGCYRRCN	21	Sequence 200 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11496	GFCVRVCVYRNGVRPCYRRCN	21	Sequence 201 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11497	GFCVRVCVYRNGVRQCYRRCN	21	Sequence 202 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11498	GFCVRVCVYRNGVRRCYRRCN	21	Sequence 203 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11499	GFCVRVCVYRNGVRTCYRRCN	21	Sequence 204 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11500	GFCYHVCVYRNGVRYCYRRCN	21	Sequence 205 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11501	GFCYKVCVYRNGVRSCYRRCN	21	Sequence 206 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11502	GFCYNVCVYRNGVRRCYRRCN	21	Sequence 207 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11503	GFCYNVCVYRNGVRVCHRRCN	21	Sequence 208 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11504	GFCYRVCVYRNGVRTCYRRCN	21	Sequence 209 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11505	GFCYRVCVYRNGVRVCHRRCN	21	Sequence 210 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11506	GFCYRVCVYRNGVRVCSRRCN	21	Sequence 211 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11507	GFCYWVCVYRNGVRSCYRRCN	21	Sequence 212 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11508	GFCWHVCVYRNGARSCYRRCN	21	Sequence 213 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11509	GFCWHVCVYRNGSRSCYRRCN	21	Sequence 214 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11510	GFCWHVCVYRNGVRSCSRRCN	21	Sequence 215 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11511	GFCWHVCAYRNGKRVCYRRCN	21	Sequence 216 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11512	GFCWHVCAYRNGVRSCYRRCN	21	Sequence 217 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11513	GFCWHVCARRNGVRVCYRRCN	21	Sequence 218 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11514	GFCWHVCHYRNSVRVCYRRCN	21	Sequence 219 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11515	GFCWHVCVSRNGVRKCYRRCN	21	Sequence 220 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11516	GFCWKVCVSRNGVRVCSRRCN	21	Sequence 221 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11517	GFCWNVCVYRNAVRVCHRRCN	21	Sequence 222 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11518	GFCWNVCVYRNDVRVCHRRCN	21	Sequence 223 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11519	GFCWNVCVYRNEVRVCHRRCN	21	Sequence 224 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11520	GFCWNVCVYRNFVRVCHRRCN	21	Sequence 225 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11521	GFCWNVCVYRNHVRVCHRRCN	21	Sequence 226 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11522	GFCWNVCVYRNKVRVCHRRCN	21	Sequence 227 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11523	GFCWNVCVYRNRVRVCHRRCN	21	Sequence 228 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11524	GFCWNVCVYRNYVRVCHRRCN	21	Sequence 229 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11525	GFCWNVCVYRAGVRVCHRRCN	21	Sequence 230 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11526	GFCWNVCVYRGGVRVCHRRCN	21	Sequence 231 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11527	GFCWNVCVYRHGVRVCHRRCN	21	Sequence 232 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11528	GFCWNVCVYRQGVRVCHRRCN	21	Sequence 233 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11529	GFCWNVCVYRRGVRVCHRRCN	21	Sequence 234 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11530	GFCWNVCVYRNGARVCHRRCN	21	Sequence 235 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11531	GFCWNVCVYRNGFRVCHRRCN	21	Sequence 236 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11532	GFCWNVCVYRNGHRVCHRRCN	21	Sequence 237 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11533	GFCWNVCVYRNGQRVCHRRCN	21	Sequence 238 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11534	GFCWNVCVYRNGRRVCHRRCN	21	Sequence 239 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11535	GFCWNVCVYRNGTRVCHRRCN	21	Sequence 240 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11536	GFCWNVCVYRNGWRVCHRRCN	21	Sequence 241 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11537	GFCWNVCVYRNGYRVCHRRCN	21	Sequence 242 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11538	GFCWNVCVYRNGVRACHRRCN	21	Sequence 243 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11539	GFCWNVCVYRNGVRCCHRRCN	21	Sequence 244 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11540	GFCWNVCVYRNGVRFCHRRCN	21	Sequence 245 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11541	GFCWNVCVYRNGVRGCHRRCN	21	Sequence 246 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11542	GFCWNVCVYRNGVRHCHRRCN	21	Sequence 247 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11543	GFCWNVCVYRNGVRICHRRCN	21	Sequence 248 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11544	GFCWNVCVYRNGVRLCHRRCN	21	Sequence 249 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11545	GFCWNVCVYRNGVRMCHRRCN	21	Sequence 250 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11546	GFCWNVCVYRNGVRNCHRRCN	21	Sequence 251 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11547	GFCWNVCVYRNGVRRCHRRCN	21	Sequence 252 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11548	GFCWNVCVYRNGVRWCHRRCN	21	Sequence 253 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11549	GFCWNVCVYRNGVRYCHRRCN	21	Sequence 254 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11550	GFCWNACVYRNGVRNCYRRCN	21	Sequence 255 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11551	GFCWNACVYRNGVRSCYRRCN	21	Sequence 256 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11552	GFCWNACVYRNGVRVCHRRCN	21	Sequence 257 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11553	GFCWNACVKRNGVRVCYRRCN	21	Sequence 258 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11554	GFCWNCCVYRNGVRVCHRRCN	21	Sequence 259 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11555	GFCWNFCVYRNGVRVCHRRCN	21	Sequence 260 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11556	GFCWNHCVYRNGVRVCHRRCN	21	Sequence 261 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11557	GFCWNICVYRNGVRVCHRRCN	21	Sequence 262 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11558	GFCWNLCVYRNGVRVCHRRCN	21	Sequence 263 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11559	GFCWNMCVYRNGVRVCHRRCN	21	Sequence 264 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11560	GFCWNQCVYRNGVRVCHRRCN	21	Sequence 265 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11561	GFCWNTCVYRNGVRVCHRRCN	21	Sequence 266 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11562	GFCWNWCVYRNGVRVCHRRCN	21	Sequence 267 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11563	GFCWNYCVYRNGVRVCHRRCN	21	Sequence 268 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11564	GFCWNVCAYRNGARVCYRRCN	21	Sequence 269 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11565	GFCWNVCAYRNGVRSCYRRCN	21	Sequence 270 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11566	GFCWNVCAYRNGVRVCHRRCN	21	Sequence 271 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11567	GFCWNVCFYRNGVRVCHRRCN	21	Sequence 272 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11568	GFCWNVCGYRNGVRVCHRRCN	21	Sequence 273 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11569	GFCWNVCIYRNGVRVCHRRCN	21	Sequence 274 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11570	GFCWNVCLYRNGVRVCHRRCN	21	Sequence 275 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11571	GFCWNVCWYRNGVRVCHRRCN	21	Sequence 276 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11572	GFCWNVCYYRNGVRVCHRRCN	21	Sequence 277 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11573	GFCWNVCVYRNGVRVCHRRCA	21	Sequence 278 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11574	GFCWNVCVYRNGVRVCHRRCC	21	Sequence 279 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11575	GFCWNVCVYRNGVRVCHRRCF	21	Sequence 280 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11576	GFCWNVCVYRNGVRVCHRRCG	21	Sequence 281 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11577	GFCWNVCVYRNGVRVCHRRCH	21	Sequence 282 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11578	GFCWNVCVYRNGVRVCHRRCI	21	Sequence 283 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11579	GFCWNVCVYRNGVRVCHRRCK	21	Sequence 284 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11580	GFCWNVCVYRNGVRVCHRRCL	21	Sequence 285 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11581	GFCWNVCVYRNGVRVCHRRCM	21	Sequence 286 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11582	GFCWNVCVYRNGVRVCHRRCP	21	Sequence 287 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11583	GFCWNVCVYRNGVRVCHRRCQ	21	Sequence 288 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11584	GFCWNVCVYRNGVRVCHRRCR	21	Sequence 289 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11585	GFCWNVCVYRNGVRVCHRRCS	21	Sequence 290 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11586	GFCWNVCVYRNGVRVCHRRCW	21	Sequence 291 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11587	GFCWNVCVYRNGVRVCHRRCY	21	Sequence 292 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11588	GFCWNVCVYRNGVRVCHRDCN	21	Sequence 293 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11589	GFCWNVCVYRNGVRVCHRHCN	21	Sequence 294 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11590	GFCWNVCVYRNGVRVCHRKCN	21	Sequence 295 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11591	GFCWNVCVYRNGVRVCHRMCN	21	Sequence 296 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11592	GFCWNVCVYRNGVRVCHRTCN	21	Sequence 297 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11593	GFCWNVCVYRNGVRVCHRYCN	21	Sequence 298 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11594	GFCWNVCVARNGVRVCHRRCN	21	Sequence 299 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11595	GFCWNVCVDRNGVRVCHRRCN	21	Sequence 300 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11596	GFCWNVCVFRNGVRVCHRRCN	21	Sequence 301 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11597	GFCWNVCVGRNGVRVCHRRCN	21	Sequence 302 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11598	GFCWNVCVHRNGVRVCHRRCN	21	Sequence 303 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11599	GFCWNVCVIRNGVRVCHRRCN	21	Sequence 304 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11600	GFCWNVCVKRNGVRVCHRRCN	21	Sequence 305 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11601	GFCWNVCVMRNGVRVCHRRCN	21	Sequence 306 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11602	GFCWNVCVQRNGVRVCHRRCN	21	Sequence 307 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11603	GFCWNVCVRRNGVRVCHRRCN	21	Sequence 308 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11604	GFCWNVCVSRNGVRVCHRRCN	21	Sequence 309 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11605	GFCWNVCVTRNGVRVCHRRCN	21	Sequence 310 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11606	GFCWNVCVVRNGVRVCHRRCN	21	Sequence 311 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11607	GFCWNVCVWRNGVRVCHRRCN	21	Sequence 312 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11608	GFCWRVCVYRNGARKCYRRCN	21	Sequence 313 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11609	GFCWRVCVYRNGARVCSRRCN	21	Sequence 314 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11610	GFCWRVCVYRNGVRKCHRRCN	21	Sequence 315 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11611	GFCWRVCVYRNGVRSCHRRCN	21	Sequence 316 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11612	GFCWRVCVYRNGVRSCSRRCN	21	Sequence 317 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11613	GFCWRACVYRNSVRVCYRRCN	21	Sequence 318 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11614	GFCWRACVYRNGVRACYRRCN	21	Sequence 319 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11615	GFCWRACVYRNGVRSCYRRCN	21	Sequence 320 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11616	GFCWRACVYRNGVRVCHRRCN	21	Sequence 321 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11617	GFCWRACVKRNGVRVCYRRCN	21	Sequence 322 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11618	GFCWRCCVYRNGVRSCYRRCN	21	Sequence 323 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11619	GFCWRSCVYRNGVRVCHRRCN	21	Sequence 324 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11620	GFCWRVCAYRNGVRSCYRRCN	21	Sequence 325 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11621	GFCWRVCGYRNGVRVCHRRCN	21	Sequence 326 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11622	GFCWRVCHYRNSVRVCYRRCN	21	Sequence 327 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11623	GFCWRVCHYRNGKRVCYRRCN	21	Sequence 328 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11624	GFCWRVCSYRNGARVCYRRCN	21	Sequence 329 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11625	GFCWRVCSYRNGSRVCYRRCN	21	Sequence 330 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11626	GFCWRVCSYRNGVRKCYRRCN	21	Sequence 331 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11627	GFCWRVCSRRNGVRVCYRRCN	21	Sequence 332 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11628	GFCWRVCSSRNGVRVCYRRCN	21	Sequence 333 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11629	GFCWRVCVRRNGARVCYRRCN	21	Sequence 334 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11630	GFCWRVCVRRNGVRVCHRRCN	21	Sequence 335 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11631	GFCWRVCVSRNGVRVCHRRCN	21	Sequence 336 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11632	GFCWRVCVSRNGVRVCSRRCN	21	Sequence 337 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11633	GFCWYACVYRNSKRVCYRRCN	21	Sequence 338 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11634	GFCWYACVYRNGARSCYRRCN	21	Sequence 339 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11635	GFCWYACVYRNGKRACYRRCN	21	Sequence 340 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11636	GFCWYACVYRNGKRVCHRRCN	21	Sequence 341 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11637	GFCWYACVYRNGVRKCHRRCN	21	Sequence 342 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11638	GFCWYACAYRNGVRACYRRCN	21	Sequence 343 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11639	GFCWYRCHYSNGVRVCYRRCN	21	Sequence 344 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11640	GFCWYSCVRRNGVRSCYRRCN	21	Sequence 345 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11641	GFCWYTCVKRNGLRVCYRRCN	21	Sequence 346 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11642	GFCWYVCAYKNGVRVCHRRCN	21	Sequence 347 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11643	GFCWYVCAYRNGVRACHRRCN	21	Sequence 348 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11644	GFCWYVCAYRNGVRSCHRRCN	21	Sequence 349 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11645	GFCWYVCARRNGARVCYRRCN	21	Sequence 350 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11646	GFCWYVCARRNGVRSCYRRCN	21	Sequence 351 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11647	GFCWYVCFYRNHVRVCHRRCN	21	Sequence 352 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11648	GFCWYVCVFRNGVRACHRRCN	21	Sequence 353 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11649	GFCWYVCVKRNGARVCSRRCN	21	Sequence 354 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11650	GFCWYVCVRRNGVRSCSRRCN	21	Sequence 355 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11651	GFCWYVCVYKNGKRSCYRRCN	21	Sequence 356 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11652	GFCWYVCVYRNGKRACHRRCN	21	Sequence 357 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11653	RFCWNVCVYRHGVRVCHRRCN	21	Sequence 358 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11654	RFCWNVCVYRNGVRVCHRHCN	21	Sequence 359 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11655	GFCAYACVKRNGARVCYRRCN	21	Sequence 360 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11656	GFCAHVCVYRNGARKCYRRCN	21	Sequence 361 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11657	GFCAHVCVKRNGARVCYRRCN	21	Sequence 362 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11658	GFCARVCAKRNGVRVCYRRCN	21	Sequence 363 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11659	GFCARVCVKRNGVRSCYRRCN	21	Sequence 364 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11660	GFCARVCVRRNGVRKCYRRCN	21	Sequence 365 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11661	GFCARVCVRRNGVRSCYRRCN	21	Sequence 366 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11662	GFCFYACVRRNGVRSCYRRCN	21	Sequence 367 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11663	GFCFYVCASRNGVRSCYRRCN	21	Sequence 368 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11664	GFCFHVCAYRNGVRVCHRRCN	21	Sequence 369 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11665	GFCFHVCSYRNGVRKCYRRCN	21	Sequence 370 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11666	GFCFNACVYRNGVRSCYRRCN	21	Sequence 371 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11667	GFCFNVCARRNGVRVCYRRCN	21	Sequence 372 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11668	GFCFRVCVYRNGVRKCHRRCN	21	Sequence 373 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11669	GFCFRVCVYRNGVRSCSRRCN	21	Sequence 374 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11670	GFCFRACVKRNGVRVCYRRCN	21	Sequence 375 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11671	GFCFRSCVYRNGARVCYRRCN	21	Sequence 376 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11672	GFCFRSCVRRNGVRVCYRRCN	21	Sequence 377 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11673	GFCFRVCAYRNGVRKCYRRCN	21	Sequence 378 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11674	GFCFRVCAYRNGVRVCHRRCN	21	Sequence 379 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11675	GFCFRVCASRNGVRVCYRRCN	21	Sequence 380 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11676	GFCFRVCVKRNGVRKCYRRCN	21	Sequence 381 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11677	GFCFYVCVRRNGVRSCHRRCN	21	Sequence 382 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11678	GFCGHVCVYRNGVRMCYRRCH	21	Sequence 383 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11679	GFCGKVCVRRNGLRVCYRRCN	21	Sequence 384 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11680	GFCGRVCVYRNGKRACYRRCN	21	Sequence 385 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11681	GFCGRVCVYRNGKRSCYRRCN	21	Sequence 387 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11682	GFCGRVCVRRNGVRKCYRRCN	21	Sequence 388 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11683	GFCTRVCVRRNGLRVCYRRCN	21	Sequence 389 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11684	GFCWHVCVYKNGKRSCYRRCN	21	Sequence 390 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11685	GFCWHACVRRNGVRSCYRRCN	21	Sequence 391 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11686	GFCWHVCAYRNGKRACYRRCN	21	Sequence 392 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11687	GFCWHVCAKRNGLRVCYRRCN	21	Sequence 393 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11688	GFCWHVCARRNGARVCYRRCN	21	Sequence 394 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11689	GFCWHVCARRNGVRVCHRRCN	21	Sequence 395 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11690	GFCWHVCSKRNGLRVCYRRCN	21	Sequence 396 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11691	GFCWHVCVRRNGARKCYRRCN	21	Sequence 397 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11692	GFCWHVCVRRNGARSCYRRCN	21	Sequence 398 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11693	GFCWHVCVRRNGARVCSRRCN	21	Sequence 399 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11694	GFCWHVCVSRNGLRKCYRRCN	21	Sequence 400 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11695	GFCWKACVYKNGVRVCHRRCN	21	Sequence 401 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11696	GFCWKACVYRNGARSCYRRCN	21	Sequence 402 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11697	GFCWKACAYRNGARVCYRRCN	21	Sequence 403 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11698	GFCWKVCVKRNGARKCYRRCN	21	Sequence 404 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11699	GFCWKVCVRRNGARVCSRRCN	21	Sequence 405 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11700	GFCWNACAYRNGKRVCYRRCN	21	Sequence 406 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11701	GFCWNACARRNGVRVCYRRCN	21	Sequence 407 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11702	GFCWNACVRRNGVRSCYRRCN	21	Sequence 408 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11703	GFCWNFCVYRYGVRVCHRRCN	21	Sequence 409 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11704	GFCWNVCAYRQGVRVCHRRCN	21	Sequence 410 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11705	GFCWNVCAYRNGKRACYRRCN	21	Sequence 411 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11706	GFCWNVCVRRNGARSCYRRCN	21	Sequence 412 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11707	GFCWRVCVYRNSKRVCHRRCN	21	Sequence 413 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11708	GFCWRVCVYKNGKRVCHRRCN	21	Sequence 414 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11709	GFCWRACVYRNGKRSCYRRCN	21	Sequence 415 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11710	GFCWRACVYRNGVRACHRRCN	21	Sequence 416 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11711	GFCWRACAYRNGKRVCYRRCN	21	Sequence 417 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11712	GFCWRACAYRNGVRACYRRCN	21	Sequence 418 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11713	GFCWRACAYRNGVRVCHRRCN	21	Sequence 419 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11714	GFCWRACARRNGVRVCYRRCN	21	Sequence 420 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11715	GFCWRACHYRNGVRSCYRRCN	21	Sequence 421 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11716	GFCWRACVRRNGVRKCYRRCN	21	Sequence 422 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11717	GFCWRSCVYRNGARSCYRRCN	21	Sequence 423 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11718	GFCWRVCAYRNSVRSCYRRCN	21	Sequence 424 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11719	GFCWRVCAYSNGKRVCYRRCN	21	Sequence 425 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11720	GFCWRVCAYRNGARVCHRRCN	21	Sequence 426 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11721	GFCWRVCAYRNGKRACYRRCN	21	Sequence 427 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11722	GFCWRVCAYRNGKRVCHRRCN	21	Sequence 428 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11723	GFCWRVCAYRNGVRACHRRCN	21	Sequence 429 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11724	GFCWRVCAYRNGVRSCHRRCN	21	Sequence 430 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11725	GFCWRVCAKRNGVRKCYRRCN	21	Sequence 431 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11726	GFCWRVCAKRNGVRSCYRRCN	21	Sequence 432 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11727	GFCWRVCAKRNGVRVCHRRCN	21	Sequence 433 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11728	GFCWRVCARRNGVRSCYRRCN	21	Sequence 434 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11729	GFCWRVCASRNGLRVCYRRCN	21	Sequence 435 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11730	GFCWRVCGYRNSKRVCYRRCN	21	Sequence 436 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11731	GFCWRVCHYRNSKRVCYRRCN	21	Sequence 437 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11732	GFCWRVCHYKNGKRVCYRRCN	21	Sequence 438 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11733	GFCWRVCHYSNGKRVCYRRCN	21	Sequence 439 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11734	GFCWRVCSKRNGVRKCYRRCN	21	Sequence 440 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11735	GFCWRVCVKRNGARKCYRRCN	21	Sequence 441 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11736	GFCWRVCVKRNGVRSCSRRCN	21	Sequence 442 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11737	GFCWRVCVRRNGARKCYRRCN	21	Sequence 443 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11738	GFCWRVCVRRNGARSCYRRCN	21	Sequence 444 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11739	GFCWRVCVRRNGLRKCYRRCN	21	Sequence 445 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11740	GFCWRVCVRRNGLRVCHRRCN	21	Sequence 446 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11741	GFCWRVCVRRNGVRSCSRRCN	21	Sequence 447 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11742	GFCWRVCVRRNGVRVCSRHCN	21	Sequence 448 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11743	GFCWRVCVSRNGARVCSRRCN	21	Sequence 449 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11744	GFCWYACAKRNGLRVCYRRCN	21	Sequence 450 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11745	GFCWYACVSRNGLRSCYRRCN	21	Sequence 451 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11746	GFCWYVCAYSNGVRSCHRRCN	21	Sequence 452 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11747	GFCWYVCARRNGLRSCYRRCN	21	Sequence 453 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11748	GFCWYVCVKRNGARKCHRRCN	21	Sequence 454 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11749	GFCARVCVKRNGARKCYRRCN	21	Sequence 455 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11750	GFCARVCVKRNGARVCHRRCN	21	Sequence 456 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11751	GFCARVCVSRNGLRKCYRRCN	21	Sequence 457 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11752	GFCAYVCVSRNGARSCHRRCN	21	Sequence 458 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11753	GFCFHVCARRNGVRKCYRRCN	21	Sequence 459 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11754	GFCFHVCARRNGVRVCHRRCN	21	Sequence 460 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11755	GFCFHVCVKRNGVRKCSRRCN	21	Sequence 461 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11756	GFCFKVCSYRNGLRKCYRRCN	21	Sequence 462 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11757	GFCFKVCSKRNGVRKCYRRCN	21	Sequence 463 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11758	GFCFNVCARRNGVRVCSRRCN	21	Sequence 464 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11759	GFCFRVCVYRNGARKCSRRCN	21	Sequence 465 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11760	GFCFRACAYRNGVRVCHRRCN	21	Sequence 466 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11761	GFCFRACTSRNGVRVCYRRCN	21	Sequence 467 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11762	GFCFRACVKRNGARVCYRRCN	21	Sequence 468 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11763	GFCFRACVRRNGVRVCHRRCN	21	Sequence 469 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11764	GFCFRACVSRNGVRSCYRRCN	21	Sequence 470 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11765	GFCFRSCARRNGVRVCYRRCN	21	Sequence 471 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11766	GFCFRSCASRNGVRVCYRRCN	21	Sequence 472 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11767	GFCFRVCAYRNGARSCYRRCN	21	Sequence 473 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11768	GFCFRVCAYRNGARVCHRRCN	21	Sequence 474 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11769	GFCFRVCAYRNGARVCSRRCN	21	Sequence 475 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11770	GFCFRVCAYRNGVRKCHRRCN	21	Sequence 476 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11771	GFCFRVCAKRNGARVCYRRCN	21	Sequence 477 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11772	GFCFRVCAKRNGVRKCYRRCN	21	Sequence 478 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11773	GFCFRVCAKRNGVRVCHRRCN	21	Sequence 479 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11774	GFCFRVCASRNGVRKCYRRCN	21	Sequence 480 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11775	GFCFRVCSYRNGARSCYRRCN	21	Sequence 481 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11776	GFCFRVCSYRNGLRKCYRRCN	21	Sequence 482 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11777	GFCFRVCSKRNGARVCYRRCN	21	Sequence 483 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11778	GFCFRVCSKRNGVRVCHRRCN	21	Sequence 484 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11779	GFCFRVCSRRNGLRVCYRRCN	21	Sequence 485 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11780	GFCFRVCSSRNGARVCYRRCN	21	Sequence 486 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11781	GFCFRVCSSRNGVRKCYRRCN	21	Sequence 487 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11782	GFCFRVCVKRNGARSCYRRCN	21	Sequence 488 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11783	GFCFRVCVRRNGVRKCSRRCN	21	Sequence 489 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11784	GFCFYVCVSRNGARKCHRRCN	21	Sequence 490 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11785	GFCGKVCVKRNGLRKCYRRCN	21	Sequence 491 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11786	GFCGRVCVYRNSKRSCYRRCN	21	Sequence 492 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11787	GFCGRVCVYKNGKRACYRRCN	21	Sequence 493 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11788	GFCSYSCAYRNGSRSCYRRCN	21	Sequence 494 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11789	GFCSNSCVKRNGVRVCSRRCN	21	Sequence 495 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11790	GFCTNVCAKRNGARVCYRRCN	21	Sequence 496 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11791	GFCWHACVRRNGARSCYRRCN	21	Sequence 497 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11792	GFCWHACVRRNGLRKCYRRCN	21	Sequence 498 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11793	GFCWHACVRRNGLRVCHRRCN	21	Sequence 499 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11794	GFCWHVCAYKNGVRACHRRCN	21	Sequence 500 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11795	GFCWHVCARRNGLRVCSRRCN	21	Sequence 501 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11796	GFCWKRCVYRNGLRKCHRRCN	21	Sequence 502 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11797	GFCWKSCVRRNGLRSCYRRCN	21	Sequence 503 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11798	GFCWKVCARRNGARSCYRRCN	21	Sequence 504 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11799	GFCWKVCSSRNGLRSCYRRCN	21	Sequence 505 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11800	GFCWKVCVSRNGARKCSRRCN	21	Sequence 506 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11801	GFCWNVCARRNGLRVCHRRCN	21	Sequence 507 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11802	GFCWNVCVRRNGLRKCHRRCN	21	Sequence 508 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11803	GFCWRVCVYSNGKRSCHRRCN	21	Sequence 509 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11804	GFCWRACVYKNSKRVCYRRCN	21	Sequence 510 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11805	GFCWRACVYKNGVRACHRRCN	21	Sequence 511 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11806	GFCWRACAYRNGKRACYRRCN	21	Sequence 512 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11807	GFCWRACAYRNGKRSCYRRCN	21	Sequence 513 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11808	GFCWRACASRNGVRVCHRRCN	21	Sequence 514 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11809	GFCWRACSRRNGLRVCYRRCN	21	Sequence 515 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11810	GFCWRACVKRNGARVCSRRCN	21	Sequence 516 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11811	GFCWRACVKRNGLRSCYRRCN	21	Sequence 517 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11812	GFCWRACVRRNGARSCYRRCN	21	Sequence 518 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11813	GFCWRACVRRNGLRSCYRRCN	21	Sequence 519 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11814	GFCWRACVSRNGARSCYRRCN	21	Sequence 520 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11815	GFCWRACVSRNGLRVCSRRCN	21	Sequence 521 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11816	GFCWRRCVRRNGARSCYRRCN	21	Sequence 522 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11817	GFCWRVCAYKNGKRSCYRRCN	21	Sequence 523 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11818	GFCWRVCARRNGLRVCHRRCN	21	Sequence 524 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11819	GFCWRVCASRNGARVCSRRCN	21	Sequence 525 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11820	GFCWRVCGYKNGVRACHRRCN	21	Sequence 526 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11821	GFCWRVCGYRNGKRACHRRCN	21	Sequence 527 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11822	GFCWRVCSYSNSKRVCYRRCN	21	Sequence 528 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11823	GFCWRVCSRRNGLRSCYRRCN	21	Sequence 529 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11824	GFCWRVCVRRNGLRSCSRRCN	21	Sequence 530 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11825	GFCWRVCVSRNGARKCSRRCN	21	Sequence 531 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11826	GFCWRVCVSRNGLRSCSRRCN	21	Sequence 532 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11827	GLCWRVCAYSNGKRACYRRCN	21	Sequence 533 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11828	GFCFNVCVSRNGARKCHRRCN	21	Sequence 534 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11829	GFCFRACARRNGVRSCYRRCN	21	Sequence 535 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11830	GFCFRACSKRNGLRVCYRRCN	21	Sequence 536 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11831	GFCFRACVKRNGLRKCYRRCN	21	Sequence 537 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11832	GFCFRACVKRNGLRVCHRRCN	21	Sequence 538 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11833	GFCFRVCAKRNGARSCYRRCN	21	Sequence 539 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11834	GFCFRVCASRNGVRKCHRRCN	21	Sequence 540 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11835	GFCFRVCSKRNGARKCYRRCN	21	Sequence 541 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11836	GFCGHRCSRRNGVRKCYRRCN	21	Sequence 542 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11837	GFCSHRCSYRNSVRACYRRCN	21	Sequence 543 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11838	GFCSRVCSYRNGSRACHRRCN	21	Sequence 544 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11839	GFCWRACASRNGLRVCSRRCN	21	Sequence 545 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11840	GFCSNRCHYSNGSRACHRRCN	21	Sequence 546 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11841	GFCWGAVNYTSNCRACKRRCN	21	Sequence 547 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11842	GSCWGAVNYTSNCRACKRRCN	21	Sequence 548 from Patent US 20110306750	Synthetic construct	Antimicrobial	US 2011/0306750 A1	Patent Application	2011##12##15	CN103068840A, WO2011154525A1	Control of viral and bacterial infection by antimicrobial peptides retrocylin and/or protegrin expressed in chloroplasts.	Disclosed herein are antimicrobial compositions containing one or more antimicrobial peptides having been expressed in chloroplasts. Exemplified herein are the expression and use of retrocylin and protegrin. Disclosed herein are methods of engineering chloroplasts to express such antimicrobial peptides such that they are properly processed and active. Plants containing such chloroplasts are disclosed as well. The chloroplast expressed peptides are useful to delay, prevent or treat viral and bacterial infections.
DRAMP11843	MASRAAGLAARLARLALR	18	Sequence 1 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11844	MASRAAGLAARLARLALRA	19	Sequence 2 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11845	MASRAAGLAARLARLALRAL	20	Sequence 3 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11846	ASRAAGLAARLARLALR	17	Sequence 4 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11847	MVSRAAGLAARLARLALR	18	Sequence 5 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11848	MVSRAAGLAARLARLALRA	19	Sequence 6 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11849	MVSRAAGLAARLARLALRAL	20	Sequence 7 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11850	MASRAAGLARRLARLARR	18	Sequence 8 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11851	MASRAAGLARRLARLARRA	19	Sequence 9 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11852	MASRAAGLARRLARLARRAL	20	Sequence 10 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11853	MAARAAGLAARLAALALR	18	Sequence 11 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11854	MAARAAGLAARLAALALRA	19	Sequence 12 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11855	MAARAAGLAARLAALALRAL	20	Sequence 13 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11856	SRAAGLAARLARLAL	15	Sequence 14 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11857	MGECVRGRCPSGMCCSQFGYCGKGPKYCG	29	Sequence 15 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11858	MASRAARLAARLARLALR	18	Sequence 16 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11859	MASRAARLAARLARLALRA	19	Sequence 17 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11860	ASRAARLAARLARLALR	17	Sequence 18 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11861	MVSRAARLAARLARLALR	18	Sequence 19 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11862	MVSRAARLAARLARLALRA	19	Sequence 20 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11863	MVSRAARLAARLARLALRAL	20	Sequence 21 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11864	MASRAARLARRLARLARR	18	Sequence 22 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11865	MASRAARLARRLARLARRA	19	Sequence 23 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11866	MASRAARLARRLARLARRAL	20	Sequence 24 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11867	MAARAARLAARLAALALR	18	Sequence 25 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11868	MAARAARLAARLAALALRA	19	Sequence 26 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11869	MAARAARLAARLAALALRAL	20	Sequence 27 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11870	SRAARLAARLARLAL	15	Sequence 28 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11871	RLARLARRLARLA	13	Sequence 29 from Patent US 20120003119	Synthetic construct	Antimicrobial	US 2012/0003119 A1	Patent Application	2012##1##5	WO2009026112A2, WO2009026112A3	Antimicrobial peptides.	The present invention is directed to a method for disinfecting or sterilizing food, particularly, fresh produce, fruits and vegetables, by applying antimicrobial polypeptides (AMP). The AMP used in the present invention consists of from 13 to 20 amino acids and has an amphipathic alpha helix structure, wherein 3 or more of the amino acids form a positively charged domain extending axially along the alpha helix.
DRAMP11872	LLKALKKLLKKLL	13	Sequence 1 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11873	LRFLKKILKHLF	12	Sequence 2 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11874	LRALAKALKHKL	12	Sequence 3 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11875	LKALRKALKHLA	12	Sequence 4 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11876	LRFLKKILKKLF	12	Sequence 5 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11877	LRFLKKALKKLF	12	Sequence 6 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11878	LRFAKKALKKLF	12	Sequence 7 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11879	LRFIKKILKKLI	12	Sequence 8 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11880	LRIIKKILKKLI	12	Sequence 9 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11881	LRIIRRILRRLI	12	Sequence 10 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11882	LRILRRLLRRLF	12	Sequence 11 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11883	LRFLRRILRRLL	12	Sequence 12 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11884	LRFARRALRRLF	12	Sequence 13 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11885	LRKLKKILKKLF	12	Sequence 14 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11886	LRKAKKIAKKLF	12	Sequence 15 from Patent US 20120020940	Synthetic construct	Antimicrobial	US 2012/0020940 A1	Patent Application	2012##1##26	EP2168592A1, EP2341921A1, WO2010034787A1	Antimicrobial peptides.	The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well a
DRAMP11887	APKAMKLLKKLLKLQKKGI	19	Sequence 1 from Patent US 20120088733	Synthetic construct	Antimicrobial	US 2012/0088733 A1	Patent Application	2012##4##12	Unknown	Novel use of antimicrobial peptides in regeneration of skin cells.	Disclosed are novel antimicrobial peptides which can promote the regeneration of skin cells, thus healing wounds. Pharmaceutical compositions comprising the peptides as active ingredients are also provided for wound healing and skin rejuvenation. The antimicrobial peptides exhibit inhibitory activity against antibiotic-resistant strains, and their antimicrobial activity is maintained without loss of structural stability even under a high salt condition. Also, being proven to promote the migration and regeneration of skin cells in mice as well as in vitro, the antimicrobial peptides may be widely used as an agent for regenerating skin cells. Further, they can find applications in various fields including the medical industry and the cosmetic industry. Hence, the novel antimicrobial peptides are anticipated to have considerable repercussions in the market for antibiotics, wound healing agents and cosmetics.
DRAMP11888	APKAMRLLRRLLRLQKKGI	19	Sequence 2 from Patent US 20120088733	Synthetic construct	Antimicrobial	US 2012/0088733 A1	Patent Application	2012##4##12	Unknown	Novel use of antimicrobial peptides in regeneration of skin cells.	Disclosed are novel antimicrobial peptides which can promote the regeneration of skin cells, thus healing wounds. Pharmaceutical compositions comprising the peptides as active ingredients are also provided for wound healing and skin rejuvenation. The antimicrobial peptides exhibit inhibitory activity against antibiotic-resistant strains, and their antimicrobial activity is maintained without loss of structural stability even under a high salt condition. Also, being proven to promote the migration and regeneration of skin cells in mice as well as in vitro, the antimicrobial peptides may be widely used as an agent for regenerating skin cells. Further, they can find applications in various fields including the medical industry and the cosmetic industry. Hence, the novel antimicrobial peptides are anticipated to have considerable repercussions in the market for antibiotics, wound healing agents and cosmetics.
DRAMP11889	APKAMXXXXXXXXLQKKGI	19	Sequence 3 from Patent US 20120088733	Synthetic construct	Antimicrobial	US 2012/0088733 A1	Patent Application	2012##4##12	Unknown	Novel use of antimicrobial peptides in regeneration of skin cells.	Disclosed are novel antimicrobial peptides which can promote the regeneration of skin cells, thus healing wounds. Pharmaceutical compositions comprising the peptides as active ingredients are also provided for wound healing and skin rejuvenation. The antimicrobial peptides exhibit inhibitory activity against antibiotic-resistant strains, and their antimicrobial activity is maintained without loss of structural stability even under a high salt condition. Also, being proven to promote the migration and regeneration of skin cells in mice as well as in vitro, the antimicrobial peptides may be widely used as an agent for regenerating skin cells. Further, they can find applications in various fields including the medical industry and the cosmetic industry. Hence, the novel antimicrobial peptides are anticipated to have considerable repercussions in the market for antibiotics, wound healing agents and cosmetics.
DRAMP11890	NQVSLTCLVK	10	Sequence 1 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11891	TCRVDHRGLTF	11	Sequence 2 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11892	HEAL	4	Sequence 3 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11893	GQYGNLWFAY	10	Sequence 4 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11894	AQYGNLWFAY	10	Sequence 5 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11895	GAYGNLWFAY	10	Sequence 6 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11896	GQAGNLWFAY	10	Sequence 7 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11897	GQYANLWFAY	10	Sequence 8 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11898	GQYGALWFAY	10	Sequence 9 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11899	GQYGNAWFAY	10	Sequence 10 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11900	GQYGNLAFAY	10	Sequence 11 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11901	GQYGNLWAAY	10	Sequence 12 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11902	GQYGNLWFAA	10	Sequence 13 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11903	AQVSLTCLVK	10	Sequence 14 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11904	NAVSLTCLVK	10	Sequence 15 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11905	NQASLTCLVK	10	Sequence 16 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11906	NQVALTCLVK	10	Sequence 17 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11907	NQVSATCLVK	10	Sequence 18 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11908	NQVSLACLVK	10	Sequence 19 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11909	NQVSLTALVK	10	Sequence 20 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11910	NQVSLTCAVK	10	Sequence 21 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11911	NQVSLTCLAK	10	Sequence 22 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11912	NQVSLTCLVA	10	Sequence 23 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11913	NQVSLTCSVK	10	Sequence 24 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11914	NQVSATCSVK	10	Sequence 25 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11915	MSTAVSKCAT	10	Sequence 26 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11916	ACRVDHRGLTF	11	Sequence 27 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11917	TARVDHRGLTF	11	Sequence 28 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11918	TCAVDHRGLTF	11	Sequence 29 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11919	TCRADHRGLTF	11	Sequence 30 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11920	TCRVAHRGLTF	11	Sequence 31 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11921	TCRVDARGLTF	11	Sequence 32 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11922	TCRVDHAGLTF	11	Sequence 33 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11923	TCRVDHRALTF	11	Sequence 34 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11924	TCRVDHRGATF	11	Sequence 35 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11925	TCRVDHRGLAF	11	Sequence 36 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11926	TCRVDHRGLTA	11	Sequence 37 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11927	CRVD	4	Sequence 38 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11928	HRGL	4	Sequence 39 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11929	TCLV	4	Sequence 40 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11930	QYGN	4	Sequence 41 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11931	VDHRGL	6	Sequence 42 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11932	VSLTCL	6	Sequence 43 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11933	GNLWFA	6	Sequence 44 from Patent US 20120121574	Synthetic construct	Antimicrobial	US 2012/0121574 A1	Patent Application	2012##5##17	Unknown	Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore.	Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.
DRAMP11934	MAQFLLFVYSLIIFLSLFFGEAAFERTETRMLTIPCTSDANCPKVISPCHTKCFDGFCGWYIEGSYEGP	69	Sequence 1 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11935	CFGEAAFETTEPMLTTYLILCVSEADCPKVVKPNYTMCAGGICWQSVQGSNQGP	54	Sequence 2 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11936	TQFLLFIYSLIIFLSLFLGEAALERTRTTMLTSYNIGCKSDADCPKAIEPHYTRCVDGHCWLYFGEGPKLHN	72	Sequence 3 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11937	MAQFLLFIYSLIIFLSLFLGEAWFKRTETGEIIWVVRCVTDTDCPKMGEPQYFKCLNGVCLEHIRELP	68	Sequence 4 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11938	GEAALERTETTMHNVQPSHFIPCFTAADCPMIDEPHYIECVTGFCWALMRNLH	53	Sequence 5 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11939	MAQVIMFVGALIIFLSLFLVETKKTDIPCDSRNDCPQQILPRYVLCVNGLCRIYFP	56	Sequence 6 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11940	MAQFLLFIYSLIIFLSLFFGEAAYERTEPIMHNGEPINLIPCVTVADCPRMDEPLHMTCLVGACWPCIRSLY	72	Sequence 7 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11941	MAQFLLFIYSLIIFLSPFLGEAVFKRTETGEIIWTLPCATDTDCPKMGEPMYFKCLNGFCLEHIRELHD	69	Sequence 8 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11942	MAQILKLVYAFTIFLFIFLVVTNGQECKDDGDCPTNMCLPSLVSKCINFICECTHSMSTD	60	Sequence 9 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11943	MAQIIMFFYALIIFLSPFLVDRRSFPSSFVSPKSYTSEIPCKATRDCPYELYYETKCVDSLCTYW	65	Sequence 10 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11944	MAQIIPFLGALIIFLSLFLVESKQTNIPCKSAEDCPKPIYPRYVLCSYGFCRIFFP	56	Sequence 11 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11945	MAQFLMFIYVLIIFLYLFYVEAAMFELTKSTIRCVTDADCPNVVKPLKPKCVDGFCEYT	59	Sequence 12 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11946	MAQFLLFVYFIIIIVSLFLVEAREPTKIPCVSDSDCHKVKKPLLLTCIDGICQYTLEATPFD	62	Sequence 13 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11947	MAHILMFVYALIIFLSPFLIGRKGGPPGGRTYIPCISDDDCIVAQPPYVLLCVNNFCTYFKDDDLPQR	68	Sequence 14 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11948	MVQYLMFLYAFIIFLSLFVVQKAQIYITFFTIFSIFVFYTTFYHLTLTTFFSFHNAGYLPCSSDDDCPKEMKPVVVKCIHNFCEHFMVGEYEGP	94	Sequence 15 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11949	FFDHLFFFCGLAETKRTNIPCFSDDDCPKTCPPLVFEVR	39	Sequence 16 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11950	MTQFLFFIFVLMIFLSPFLVEMEKTHVRCITADDCPKVERPLKMKCIGNYCHYFLNNF	58	Sequence 17 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11951	MAKIANFVYSMIIFLSLFLVATKAEWYYPCNTDSDCPQNMCPPDMEPRCWTGYCSSCYIRWGK	63	Sequence 18 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11952	MQRLDNMAKNVKFIYVIILLLFIFLVIIVCDSAFVPNSGPCTTDKDCKQVKGYIARCRKGYCMQSVKRTWSSYSR	75	Sequence 20 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11953	MAATRKFIYVLSHFLFLFLVTKITDARVCKSDKDCKDIIIYRYILKCRNGECVKIKI	57	Sequence 21 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11954	MVKILKFIYVMIIFLSLFLVATNVNAINKCSQDSHCPKDMCKKPSKPRCVVSPKLPLSSKSGVCTCV	67	Sequence 22 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11955	MAKIVKFIYVMIILIFLFLVSTNIDAIRNKCFRPSDCPPSMYCDAGFQIGCVRKICTCLRILAPIDFVPT	70	Sequence 23 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11956	MQKEKNMAKTFEFVYAMIIFILLFLVENNFAAYIIECQTDDDCPKSQLEMFAWKCVKNGCHLFGMYEDDDDP	72	Sequence 24 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11957	MVKTLKLVNYMIFFLSIFLVVKNVDGDDVVFQYVFDGCRIDADCPISGLQLLKWMCINNECEFNHVRPRYV	71	Sequence 25 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11958	MAKTLNFVCAMILFISLFLVSKNVALYIIECKTDADCPISKLNMYNWRCIKSSCHLYKVIQFMV	64	Sequence 26 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11959	MVEIVKFVYIINIFIFLFLVATNVEAKFTRCFRDSDCPKTLCHSPGKAKCMHHSICKCIFFGYNI	65	Sequence 27 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11960	MTKILMLFYAMIVFHSIFLVASYTDECSTDADCEYILCLFPIIKRCIHNHCKCVPMGSIEPMSTIPNGVHKFHIINN	77	Sequence 28 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11961	MVKTFKFIYSIIIFLSPFLVVMNVDGELIKCTMDADCPTSLNRKWLCINNICRKMCVTNV	60	Sequence 29 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11962	MAESPKFVYVLILFISIFNVIIVCDFAFLPTSRNCITNKDCRQVRNYIARCRKGQCLQSPVR	62	Sequence 30 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11963	MAKTTKLIYVMILFLSLFLVAKNVTAQIRCNDAFECRRSAICNFPNKWKCNDHKCECV	58	Sequence 31 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11964	ETPKLVYVLILFLSIIFSIIVSNSFPDKIFIGDCKTDKDCKPKRGVNFRCRKGKCYPR	58	Sequence 32 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11965	MQRTKNMAETLKFVYVLILFISLFLVLIVCDSAFVANTETCITDKDCPNGRNYIGRCRKGHCQQRLVR	68	Sequence 33 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11966	MSKILKFVYVPILYFSILLVLTIHDQVYFNNNSPPCVTDKDCPRPQFRKSNVRCRNGHCVNLGN	64	Sequence 34 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11967	MVKTPKLVYVLILFLSIFLSMIVSNSSFLGTFISSCKRDKDCPKLYGANFRCRKGTCVPPI	61	Sequence 35 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11968	MAKILKFVYVPILYFSILLVLTIYDQAYFNDPRPCVSDKDCPRPKFQKSNVRCRKGYCVNLDG	63	Sequence 36 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11969	MAKILKFVYVPILYLSILLVLTIYDQVYFNNSPPCVTDKDCPRPQFRKSNVRCRNGYCVNLGN	63	Sequence 37 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11970	MAKIMKYVNVPILFLSILLVLMSYGSNYSPTPFPCLTDKDCTRRKGFSVTCRKGFCVEFKHF	62	Sequence 38 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11971	MAKTIKCLNVLILFLYMFLVLTLLDFGSSTTPTPCRTDQDCPRKKKFSVTCRKGFCAEIRHVY	63	Sequence 39 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11972	GETLKSVYLLILFISLFLVIIVSHSVTSPWVLKQHCVTDKDCPQMGKIKIRCRNGECVQGF	61	Sequence 40 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11973	MQIGKNMVETQKLVYVILLFLSIFLFTNSPLSQIIFSECKTDKDCPKYQRANIRCRKGQCVRI	63	Sequence 41 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11974	MVETPKFVYNLILLIYIFLFIIICDSTYLPTTRICITDKDCPSVKNYIGRCRKGYCQASKLR	62	Sequence 42 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11975	MVQTPKLVYVIVLLLSIFLGMTICNSSFSHFFEGACKSDKDCPKLHRSNVRCRKGQCVQI	60	Sequence 43 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11976	MTETLKFVYILILFIFIFLVLMVCDSAFIQLSKPCISDKECSIVKNYRARCRKGYCVRRRIR	62	Sequence 44 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11977	MADTLKFVHVLILLISIFLVIIVSSFIFLPCITDKDCQTLKKNKGKGRCRKGFCVDGLIG	60	Sequence 45 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11978	ILFLSIFLCIIVSNSSFSKTFDRACKTDKDCPKLRGVNVRCRKDQCVTV	49	Sequence 46 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11979	MTETLKFVYVLILFISIFLVIIVCESSFFPSSPVCKTDKDCPQLRGYTARCRKTQCLLIPRG	62	Sequence 47 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11980	LVIIVCDSIHFHVSRPCMTDDDCAPEKYYNIRCRKGFCVQIRKY	44	Sequence 48 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11981	LVIILCDSAYFPNSRPCKTDKNCAQVKNYISKCLKGLCVQEE	42	Sequence 49 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11982	VYILILFICIFLVMIVCDSAYLPLSRSCITDKDCSRVKNYNARCRKGYCQYLQY	54	Sequence 50 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11983	MAEIIKFICLTILFLSLFLVAAEEDIGGHLECVEDEDCMEESCPIFSVHKCKNSGCECDEMFR	63	Sequence 51 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11984	MAETLKFVYVMILFLSIFLVITISNSNPYIINILCKTDKDCPKVQGANIRCRSGKCVQV	59	Sequence 52 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11985	MTHISKFVFALIIFLSIYVGVNDCKRIPCKDNNDCNNNWQLLACRFEREVPRCINSICKCMPM	63	Sequence 53 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11986	MTYISKVVYALIIFLSIYVGVNDCMLVTCEDHFDCRQNVQQVGCSFREIPQCINSICKCMKG	62	Sequence 54 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11987	MTHIFKFVYALIIFLSIYVAVNDCIRIHCKDDFDCIENRLQVGCRLQREKPRCVNLVCRCLRR	63	Sequence 55 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11988	MKSQNHAKFISFYKNDLFKIFQNNDSHFKVFFALIIFLYTYLHVTNGVFVSCNSHIHCRVNNHKIGCNIPEQYLLCVNLFCLWLDY	86	Sequence 56 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11989	MNHISKFVYALIIFLSVYLVVLDGRPVSCKDHYDCRRKVKIVGCIFPQEKPMCINSMCTCIREIVP	66	Sequence 57 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11990	MAQISKFVYALIIFFSLILAVTNAGLFRCKVDIDCPQILCFDEQIAKCIARMCECDYE	58	Sequence 58 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11991	MDLVHMFVYAFIIFLSIPLPPARSDFPCKTKDDCAQQIDYIAECIIGFCRYFTPFEHPF	59	Sequence 59 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11992	MTQISISFYALIIFFSLFLVVTNGRNKTCNYSSECLFHNCPLGWVMKCFTYFCACSRL	58	Sequence 60 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11993	MHTRKNMDLVHMFVYAFTIFLSIPLPPVRSDFPCKTKVDCPQHKKYIAECIFGFCRHFKPLEHPF	65	Sequence 61 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11994	MQRRKNMAQILLFAYVFIISISLFLVVTNGVKIPCVKDTDCPTLPCPLYSKCVDGFCKMLSI	62	Sequence 62 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11995	LHMLIYAFIIFLSIPLPPTRKTIPCKTKVDCPQQIYYVVECLDGFCDYWRD	51	Sequence 63 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11996	MQTMRNMNLVYMFVYAFIIFLSIHFPPRIKCNTEADCPQRFDNIVECLFGICHFYIK	57	Sequence 64 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11997	MARVISLFYALIIFLFLFLVATNGDLSPCLRSGDCSKDECPSHLVPKCIGLTCYCI	56	Sequence 65 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11998	FLWIIIPSILLIVSDRIPCIDDMDCPDMFPSLNTQCIDNFCDVVLGYN	48	Sequence 66 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP11999	SQILMFVSVLIIFLSLFLADTKQTNIPCENKRDCPQPLYPKFVTCFEGLCRMHYPLKKI	59	Sequence 67 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12000	MAQILMFVYFLIIFLSLFLVESIKIFTEHRCRTDADCPARELPEYLKCQGGMCRLLIKKD	60	Sequence 68 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12001	MAQLIIFVYALIIFLYLLFVEAQITKLPCVTVDDCPKVEKPIPMVAKCFGKSFSRHCHYFYF	62	Sequence 69 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12002	MFVYVLIIFLSLFLIEASIKTKIACVTDNDCPRAIKPVVMWCINNYCHYYLYGYQ	55	Sequence 70 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12003	MAQNKYLFCAFIIFLSLFFVLTKSSIPCKTRTQCPEKMCRLPKFVWCIDGSCVCA	55	Sequence 71 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12004	MTLLLKFLYALIIFISLLFVVTNGAQFLCSDDSDCPRDLCVRNSLTLRCVNYICQCR	57	Sequence 72 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12005	MQRKTNMTQFIFFIYVLMIFLSLFLVESEKLDIRCATVDDCPKVTKPVVMMCTGKFCHYFFVRKQIL	67	Sequence 73 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12006	MARISLFVYALIIFFSLFFVLTNGELEIRCVSDADCPLFPLPLHNRCIDDVCHLFTS	57	Sequence 74 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12007	MAQILKFVDALILFLSLFFILINGDRIPCATDADGPPKILPIIHKCINNFCKLKLYN	57	Sequence 75 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12008	MNQIPMFGYTLIIFFSLFPVITNGDRIPCVTNGDCPVMRLPLYMRCITYSCELFFDGPNLCAVERI	66	Sequence 76 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12009	MAHFLMFVYALITCLSLFLVEMGHLSIHCVSVDDCPKVEKPITMKCINNYCKYFVDHKL	59	Sequence 77 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12010	MVHILMFVYALIFSNFIFLVEANMVVLGCVSDDDCPKVPLPRFLKCIANLCCLVRKKDL	59	Sequence 78 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12011	MVKTLKFVYYMILFLSLFLFIKNVDGAFVKCETDDDCPKYNGFRKYECVNNWCRLTGLH	59	Sequence 79 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12012	MSKTIMFLYAMTLFLFLLHIEKSSGVLIDCKTVKDCPTSYTKIYRCEDNKCRFSFVIGL	59	Sequence 80 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12013	MTETLKFVVTKKKTLKFVYAMILFLSFFLIASEVGAHFGCETDADCPRSTDKNFFLRCINKKCEWAAKRH	70	Sequence 81 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12014	MTKIFKFIHAMILFLSLFLVAESYFADILCKVHEDCPQKSTHKYYCIDDECFLYYWEAP	59	Sequence 82 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12015	MAEIIKFVYTMILLLSLFLVTTKVGAYIACQSEIDCPPNYSFLFAIRCIKQKCVTVGRYL	60	Sequence 83 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12016	MTKTLKFICIMILFLSLFLVAESFATGMPCKTDKECPNTSTHKYKCINDDCFCFYIYWPLGNSLV	65	Sequence 84 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12017	MQMEKNMTKTLKFIYVMILFLSLFLVAESFFVDIMCKVHEDCPQKSTHKYYCVDDKCFLYYWEGKP	66	Sequence 85 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12018	MANTHKLVSMILFIFLFLVANNVEGYVNCETDADCPPSTRVKRFKCVKGECRWTRMSYA	59	Sequence 86 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12019	MAHKLVYTIILFIFLFLVANNVEGDIVCITDNDCPPNTLVQGYRCIDGKCESVFLSYR	58	Sequence 87 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12020	MAKTLNFMFALILFISLFLVSKNVAIDIFVCQTDADCPKSELSMYTWKCIDNECNLFKVMQQMV	64	Sequence 88 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12021	MAKTCKLVFALILFVSLYLVSMSAELGGPCRSDEECPQLSLRFFAIKCRENVCIYVDLDPYKPRAEKNQFLH	72	Sequence 89 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12022	MKRGKNMSKILKFIYATLVLYLFLVVTKASDDECKIDGDCPISWQKFHTYKCINQKCKWVLRFHEY	66	Sequence 90 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12023	MAKTLKFFYTIILFLSLFLVLQRKLTGCEVDGDCPKVFKLKVMILFIKCINNKCVRGLLSQTGTQCPDFFFLKRTLPRFYF	81	Sequence 91 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12024	MIKILTFLYALVLFLSLFIFSIAAQNLMKCNTDDECPKFDDKFPLSFKCINDGCRMVINDKYKHKTVQKLL	71	Sequence 92 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12025	MAKIVKYVYVIIIFLSLFLVATKIEGYYYKCFKDSDCVKLLCRIPLRPKCMYRHICKCKVVLTQNNYVLT	70	Sequence 93 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12026	MSNTLMFVITFIVLVTLFLGPKNVYAFQPCVTTADCMKTLKTDENIWYECINDFCIPFPIPKGRK	65	Sequence 94 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12027	MAEILKFIYNAILFVSLYFIVIYGELVCDTDDDCLKFFPDNPYPMECINSICLSLTD	57	Sequence 95 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12028	MARTLKFVYAVILFLSLFLVAKGDDVKIKCVVAANCPDLMYPLVYKCLNGICVQFTLTFPFV	62	Sequence 96 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12029	MSQIFMFAYVLIIFLSLFHVETNIHKIGCKTSEDCPYLGKCIEDFCQFKK	50	Sequence 97 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12030	MAKIVYFVYSMIIFLSLFLVTTKAAERIYRCLDHSHCPTFMCSPGLKPKCMNPKVCKCVPVQSRKYYALT	70	Sequence 98 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12031	MAQKFMFFYALIIFLSSFYVIINTIDPPHHITNHEIPCKYNHDCPTILDYISICPYHYCEFWRTY	65	Sequence 99 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12032	MIETLKFVYAMILFLSLFLITSEVGGLYIGCETDRDYPPLANKTFYLKCIDKKCEWTVTDSLSTRSGRMQKLSI	74	Sequence 100 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12033	MVRTLKFVYVIILILSLFLVAKGGGKKIYCENAASCPRLMYPLVYKCLDNKCVKFMMKSRFV	62	Sequence 101 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12034	MAEIVKYVYVIIIFPSLILFATNIEAIIRCFHDADCVHKICHPPQIRKCVSKICKCRLMITQKDYVLT	68	Sequence 102 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12035	MAKIVNFVYSMIIFVSLFLVATKGGSKPFLTRPYPCNTGSDCPQNMCPPGYKPGCEDGYCNHCYKRW	67	Sequence 103 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12036	EDFLYSMIIFLSLFLVATKSEPGGHRCSTDSFCPPNMCPPGMTPKCVRFRCKCVPIGWKNLSHVLA	66	Sequence 104 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12037	MAEILKFVYIVILFISILLVVETEQYCVDDADCQKLYPFHRQLSLKCIRAFCVKLVGQANDDLFPSTVHAADATGLGIDAK	81	Sequence 105 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12038	MAKIVNFIYSMIIFLSLFLVETNAQCIYPACFKDHMCRQLKCSPGRTPKCVNYQCRCSPQALGSYHLLT	69	Sequence 106 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12039	MAKTLKFVYAMIIFLSLFLMATNIDSALIECQIDDDCPPIKFAKYLCINYKCRKICLGE	59	Sequence 107 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12040	MAGTLNFVYAMILFLSLFLVARGEEIIIIKCQTAKDCPDIYNLFPLVYKCIDNICVDVKLEPPYDMSITPNSVHK	75	Sequence 108 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12041	MVEKMVGILKFVCPFLFLYFLLLSMLVISGKHDYHMFFQRIPCPKDKILDCNLLECWCK	59	Sequence 109 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12042	MTKTLIFIYALFIVVSLFLVVTSETRIPCVSRNDCPKRPYPLFMKCIDNFCEIWKIGKE	59	Sequence 110 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12043	MAQRFMFIYALIIFLSQFFVVINTSMSIYITFKKFIIDFIHNVYHPSITSNFSLFNNAGDIPNNSNRNSPKEDVFCNSNDDCPTILYYVSKCVYNFCEYW	100	Sequence 111 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12044	MEDIVKFVYVIIIFLSIFIIATNMEAKTICIGDSDCRNERCMPGIKPVCSEGWCDCIGFIP	61	Sequence 112 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12045	MAKTLKVMYTMVLFFSLFLVAKNVDAYVWCETVEDCFKSQYFIFDCINNQCINVGKNPKEPRYPGIPRDQ	70	Sequence 113 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12046	MIKVVKFIYVMIIILSLFQLSINAREKVNCLDDADCLEVSCLNGSNAECVGNSCVCVFVFYRENFDEQFRR	71	Sequence 114 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12047	MNPNIRLFYDLIIFLSLLLVLTDGSVPCLTSFGCPRSTCYPPSTPNCILRICECI	55	Sequence 115 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12048	MGETLKFVYTMSIFLSLFLVVTSIVGEEWNSHSWNSEFYLKKSCSSDFDCPRTMCIKLSLARCFNDFCHCY	71	Sequence 116 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12049	MARILKNVYTIIHFLIINFLLLFHVLNVRRQTEPPGPLIPCEFDYDCPLIDCIRTSDSRCINGNCHCRE	69	Sequence 117 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12050	MQMRKNMAQILFYVYALLILFSPFLVARIMVVNPNNPCVTDADCQRYRHKLATRMVCNIGFCLMDFTHDPYAPSLP	76	Sequence 118 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12051	MQIGRKKMGETPKLVYVIILFLSIFLCTNSSFSQMINFRGCKRDKDCPQFRGVNIRCRSGFCTPIDS	67	Sequence 119 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12052	MAKFVNFVYSMIIFLSLLVVAMNAKRNYQCDPCFGHPDDMINFCPPGTAPKCFHGLIKCVPIMRGTNRMFA	71	Sequence 120 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12053	MDAILKFIYAMFLFLFLFVTTRNVEALFECNRDFVCGNDDECVYPYAVQCIHRYCKCLKSRN	62	Sequence 121 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12054	MAVILKFVYIMIIFLFLLYVVNGTRCNRDEDCPFICTGPQIPKCVSHICFCLSSGKEAY	59	Sequence 122 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12055	MQKARNMAKLVKLVYVIIVFYTLFLVATEIVSGIPCNDDVDCPQTLCEQLIADFKYMIDFKSECVSRMCACTGSPV	76	Sequence 123 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12056	MAHILKFVYATILVLFLFFVATKVDGAVHKECKTDVDCRQIWFVTKCINHECQPIL	56	Sequence 124 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12057	MAKLVKFVYVIIVFYTLFLVGTEIVSGHACTVNADCEQSMCDPFCVGGYHFTPICVIGWCVCVGNRVAPVL	71	Sequence 125 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12058	MIQILIFVYALIIFISLFLVVTSETHIPCVHHDDCPKRPYPRFMKCVDNFCETWIIGWE	59	Sequence 126 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12059	MLRRKNTVQILMFVSALLIYIFLFLVITSSANIPCNSDSDCPWKIYYTYRCNDGFCVYKSIDPSTIPQYMTDLIFPR	77	Sequence 127 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12060	MAQTLMLVYALIIFTSLFLVVISRQTDIPCKSDDACPRVSSHHIECVKGFCTYWKLD	57	Sequence 128 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12061	MQRKKNMGQILIFVFALINFLSPILVEMTTTTIPCTSIDDCPKMPLVVKCIDNFCNYFEIK	61	Sequence 129 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12062	MVKTFNFVCTMVLLFFLFLTAKKVYAYHLCKTRFDCPRTYLLFFPRMWKCINRRCRYVYFFE	62	Sequence 130 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12063	MAQIFKFFYVMTIFIYLFLVSTTVDAGMRCNHVSDCPKDTFCWLDSHMQCIKHQCKCVRIFEPIDPA	67	Sequence 131 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12064	MAISYKFVYAIIFFIFLFLVANNVEGYIVCITDNDCPENTEVRQYECIEGRCRLSRVLNP	60	Sequence 132 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12065	MAQILILFYVMTIFIYLFLVSTNVDAGIRCRNVYDCPKATYCRAGSHRVQCIKHQCKCVRIFESIDPA	68	Sequence 133 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12066	LSKTLKFFYAMILFLSLFLVAKEIEGCEDDSDCPQIFNFHPFICKCINNECEKVILQKGYMSMKPKILHKRYTRKNEFLH	80	Sequence 134 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12067	MAEIVKLIYVMIIFFYVFLVSMNVDASDECVKVSDCSPTKYCLPGRRMICSKGKCKCLRNMFIPIPE	67	Sequence 135 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12068	MAHKFVYAIILFIFLFLVAKNVKGYVVCRTVDDCPPDTRDLRYRCLNGKCKSYRLSYG	58	Sequence 136 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12069	DKTLKFVYIMILFLSIFYILIVCDSNAFGMTLRPCLTDKDCPRMPPHNIKCRKGHCVPIGKPFK	64	Sequence 137 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12070	MAKFSMFVYALINFLSLFLVETAITNIRCVSDDDCPKVIKPLVMKCIGNYCYFFMIYEGP	60	Sequence 138 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12071	MAQILFYVYALIILFSPFLAALVIIDHHKPCVSDTDCAFYLDIPPTVKYCSDGLCAWYFPDNPLP	65	Sequence 139 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12072	MAQILMFFYSLIIFISLLTSHPCISDDDCPEALSPQFPKCIHNVCVYFVEE	51	Sequence 142 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12073	MAETLKFVYVLILFISILFVVIVCDSSYIPISHPCTTVKDCPEVKNYKSRCLKGLCISGRLR	62	Sequence 143 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12074	MQRRKKSMAKMLKFFFAIILLLSLFLVATEVGGAYIECEVDDDCPKPMKNSHPDTYYKCVKHRCQWAWK	69	Sequence 144 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12075	MFVYDLILFISLILVVTGINAEADTSCHSFDDCPWVAHHYRECIEGLCAYRILY	54	Sequence 145 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12076	MQIRKIMSGVLKFVYAIILFLFLFLVAREVGGLETIECETDGDCPRSMIKMWNKNYRHKCIDGKCEWIKKLP	72	Sequence 146 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12077	MQRVKKMSETLKFVYVLILFISIFHVVIVCDSIYFPVSRPCITDKDCPNMKHYKAKCRKGFCISSRVR	68	Sequence 147 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12078	MAKTLNYVYVLILFISIFLSITVYGYIPGIVNKPCKTDKDCPKKPPHNIRCRKGQCVEIL	60	Sequence 148 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12079	MAQSLIFVYALIIFLFLFRVEAEHLKIRCVTDDDCPKVEKPLYMYCGNHWCAYKLHFV	58	Sequence 149 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12080	MAGIPCYFYGSIIFLSLFLLAAFFEKGYMIPCATSDDCLKNMCRPPLTPRCIEHNCKCK	59	Sequence 150 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12081	FFGSSIPSILLIVSDRIPCIDDMDCPDMFPSLNTQCIDNFCDVVLGYN	48	Sequence 151 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12082	AEIFKFVYKWILFVSLFLVIVAKEDDIECVTDADCYEKLPALQRAVMKCIQGFCKIHI	58	Sequence 152 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12083	MAQLSYIFYAFIIFLCVFFVPTKSNSIPCTTHAQCPGDMCELPQIVWCVVGFCECA	56	Sequence 153 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12084	AWNLKFVYVMVLFFSLLIVVINIDAYRSCKTDDDCPDYLCTSPKIGKCMDNDCYCI	56	Sequence 154 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12085	MVEALKLVNVLILFLSIFLSIIVSTSSFPWKLYPCVTDKDCPRKNRHVVKCRKGYCVGVQII	62	Sequence 155 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12086	MQSVENMAEVIKFVNVIIIFISLFPFAMTVDANMVICTQDFDCQTKICPFDLQPKCTILFEFLLSLCGCV	70	Sequence 156 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12087	MAAIIKFIYTMFLFIFLFVVPTKVDALAGCITDADCVIKKCSSSCRIKCIDFRCLCPTGF	60	Sequence 157 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12088	MARILSFFYALLIFVSLFLVTTNGSLPDAPPCLFTPECPPDMCPTDLTLKCINLSCQCTIEYDIDPDVVPS	71	Sequence 158 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12089	MANITKFVYIAILFLSLFFIGMNDAAILECREDSHCVTKIKCVLPRKPECRNNACTCYKGGFSFHH	66	Sequence 159 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12090	MAQIPRYFYAFIIFLYLFHVATTNRFLYRIGCDTSNDCPSYMCPPPLSPRCTKFYCKCI	59	Sequence 160 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12091	MAEILKFVYIVILFISILLVVETEQCVYDADCEKIYPLHRQHLFKCIKAFCVRSS	55	Sequence 161 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12092	MARILYFFYTLLIFVSLFMIAINGSLPDAPPCLFTPECPPDMCPTDLTLKCINLTCQCTSEYDID	65	Sequence 162 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12093	MAKIIKFVYVMIIIISFFLVATNAKDDCLVDADCVTLVCEFDERPQCVINTCRCRPLRFSGFYYEQLH	68	Sequence 163 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12094	MQKRRNMAAILKFVYIMIIYLFVLLVAVKAFEECKEDADCHPVCSVPGCSNICTLPDVPTCIDNNCFCI	69	Sequence 164 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12095	MARTLKFVYSMILFLSLFLVANGLKIFCIDVADCPKDLYPLLYKCIYNKCIVFTRIPFPFDWI	63	Sequence 165 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12096	KIINFVYNMIIFFSLFLVATNAGGCNPCLVTCPDDLLNRCPPGMEPICEYGVIKCYPIGKETNRVLT	67	Sequence 166 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12097	MARILCFFYGLLIFVSLFMVATNQSIPDVLPCLFSNECPPDLCPTDLFAKCINLTCQCTAEYDLD	65	Sequence 167 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12098	MASILKFVYIMIIYLSVLLVVIEGYPFQECKVDADCPTVCTLPGCPDICSFPDVPTCIDNNCFCT	65	Sequence 168 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12099	MGEMFKFIYTFILFVHLFLVVIFEDIGHIKYCGIVDDCYKSKKPLFKIWKCVENVCVLWYK	61	Sequence 169 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12100	MQIGSNMAETMKLVYVIILFLSIFLGITLSNSAFSHFIPGCKTDKDCPKFYGSNVRCRKGKCVQLG	66	Sequence 170 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12101	MGEIMKFVYVMIIYLFMFNVATGSEFIFTKKLTSCDSSKDCRSFLCYSPKFPVCKRGICECI	62	Sequence 171 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12102	MANVTKFVYIAIYFLSLFFIAKNDATATFCHDDSHCVTKIKCVLPRTPQCRNEACGCYHSNKFR	64	Sequence 172 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12103	MAYISRIFYVLIIFLSLFFVVINGVKSLLLIKVRSFIPCQRSDDCPRNLCVDQIIPTCVWAKCKCKNYND	70	Sequence 173 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12104	MAVVIKFVNVMLIFISLFPFAMNVDANIISCTQDFDCQTKICPFHLKPKCIVLEILPHSLSGGICGCD	68	Sequence 174 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12105	MAEILKCFYTMNLFIFLIILPAKIRGEHIQCVIDDDCPKSLNKLLIIKCINHVCQYVGNLPDFASQIPKSTKMPYKGE	78	Sequence 175 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12106	MAHIFNYVYALLVFLSLFLMVTNGIHIGCDKDRDCPKQMCHLNQTPKCLKNICKCV	56	Sequence 176 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12107	MFKILLFTSSIIVFLSLFFVTYEDFWNVCAYNSDCQSYPCDLGESRNCTLNRCICVYNI	59	Sequence 177 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12108	MGEILKFVYNVILFGSLYLLVIYAERECDTDADCQKKFPGSNQHLLWCNNGFCDCRTH	58	Sequence 178 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12109	MXNLRILIILIIFIFIFLVLIVCDSTFIHFSIPCITDKDCSILQNYKARCRKGYCLRRKIR	61	Sequence 179 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12110	MVQIGCFFYALIILLSPFLVATHQSIDDVIPCVLNTDCPRDMCPIHLFPKCINLLCRCSYWEDN	64	Sequence 180 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12111	MYREKNMAKTLKFVYVIVLFLSLFLAAKNIDGRVSYNSFIALPVCQTAADCPEGTRGRTYKCINNKCRYPKLLKPIQ	77	Sequence 181 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12112	AFFIFLSIAHRPPANTIPCFGTKDKCPFNLYYKVECIDGFCYYPV	45	Sequence 182 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12113	MVKTPKLVYVLILFLSICFSITISNSSFGRIVYWNCKTDKDCKQHRGFNFRCRSGNCIPIRR	62	Sequence 183 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12114	MQIVKNMVKTPKLVYVLILFLSIFFSITVSNSFNSKIVFTDCKTDKDCQNHRGFNFRCRKGNCVAKIR	68	Sequence 184 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12115	MAKTLMFIYIVILLTCVLAVIDINAFSFPCKTNSDCPSYLCHYPKNPECVERECICW	57	Sequence 185 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12116	FIVLLSQFLVVINGSIPCETTADCPVAVPPEYYKCMYKVCVLIR	44	Sequence 186 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12117	MAHIIMFVYALIYALIIFSSLFVRDGIPCLSDDECPEMSHYSFKCNNKICEYDLGEMSDDDYYLEMSRE	69	Sequence 187 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12118	MTEILKFVCIMIIFLSSFIVSQNIDAGGNRKCFRDSDCPKFMCPSYLAVKCIGRLCRCGRPELQVELNPK	70	Sequence 188 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12119	MTEILKFVCVMIIFISSFIVSKSLNGGGKDKCFRDSDCPKHMCPSSLVAKCINRLCRCRRPELQVQLNP	69	Sequence 189 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12120	VNFIYSMIIFLFLFPVATKTQFLPNYYEFYHCYNHSDCQGSMCPTGSKPKCVDQVCECILIRM	63	Sequence 190 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12121	KKKIIIVLCTLFYHLSNNFQLFDNTDTATCITDADCPYDGKCIDGFCRFNVKNNNQV	57	Sequence 191 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12122	MAKIFNYVYALIMFLSLFLMGTSGMKNGCKHTGHCPRKMCGAKTTKCRNNKCQCV	55	Sequence 192 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12123	MARTLQFVYVMILFFSLFLVAKGDDVKIKCVSAIDCMDLFNLLPIVYKCINNICVYEQSSQRLI	64	Sequence 193 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12124	MDEILKFVFCMIIFLSLFLIATKVGGEHNECETDADCPKHTTIFFVMKCIDHICRCMKTSI	61	Sequence 194 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12125	FKVLNIVYAMIIFLSISFSITNSFKMFCRYDEDCPPRMCRLPQVPQCNEFICDCGMPVYKPYQNKYIKK	69	Sequence 195 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12126	MAEIGKYIYVIIFFISLFFITTSVEGWRCKTKYDCIKIRFCKFPTIARCTKPDFLFLEYDRGFCTCDD	68	Sequence 196 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12127	MQRLENTTEVVMLIYVMIIFLCLLLVTMNVNAVIKCFQDSDCPKYMCMFPLKPKCVYILVFPPPWTAQCICD	72	Sequence 197 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12128	MAQISKSFYALIIFLSLILVVTGIKLIKCTVSDDCPMNFRCPPNTFVRCISDLCTCRSLLDEQS	64	Sequence 198 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12129	MQIGKNMVETLKLVYVIILFFSIFLCIAVSNSSFSEIIDSACKTDKDCPKLHKVNVRCRKGKCVAI	66	Sequence 199 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12130	MAKVTKFGYIIIHFLSLFFLAMNVAGGRECHANSHCVGKITCVLPQKPECWNYACVCYDSNKYR	64	Sequence 200 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12131	MAKIIKFVYIMILCVSLLLIVEAGGKECVTDVDCEKIYPGNKKPLICSTGYCYSLYEEPPRYHK	64	Sequence 201 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12132	ERTLKLVLLDALETQIVQKACVILLPNRSVCTNPYVNVYESSPKEIMCIHEHVCLPYLRAYTNYIPS	67	Sequence 202 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12133	MAEIIKFVYILILCVSLLLIGEASGKECVTDADCENLYYGNKWPLICSNIGYCLSSYEEPPHK	63	Sequence 203 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12134	KIMKFVHAMILFLFLFAINVTAFRDPCNFDFDCRNSNCTAPYVATCMYEHCYC	53	Sequence 204 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12135	MGQIEKFVYSLIIILSLALVVTCNGIPICQTYMDCPSDMCTRPKHAYCVSYKCYCV	56	Sequence 205 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12136	MAEIIKFVYIMILCVSLLLIAEASGKECVTDADCENLYPGNKKPMFCNNTGYCMSLYKEPSRYM	64	Sequence 206 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12137	YAMILFISMFLAARNVDAYLKCKTVHDCPKSQVVYKCVGNYCRAVKIRRWNLS	53	Sequence 207 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12138	TRAKVHKFIYIMIVFLSIFHVVNSYVVMCEKDSDCVDSFCVPPNVPKCRVVCKCLPK	57	Sequence 208 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12139	MNTILKFIFVVFLFLSIFLSAGNSKSYGPCTTLQDCETHNWFEVCSCIDFECKCWSLL	58	Sequence 209 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12140	MTKILKCVYAMILFLPLFVVAMEVGRRANVECESDKDCQEHWSEFFIIQCIDNICVPSERPL	62	Sequence 210 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12141	NAILFVSLYLLVIYGDRECDTDTECQKKFPGVNAHHLWCDNGNCVSYPK	49	Sequence 211 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12142	MDKTIKFTYVMIIFVYLFLIATNVEAYKNRCFRDSDCPKEMCNHPKIPKCVNNAYCKCVVAMYFPPK	67	Sequence 212 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12143	MAEIIKFVYIMILFVSLLLIVEAGGNECVTDVDCEKLYPGNKKPLICNIGYCLSLYKEPPRYM	63	Sequence 213 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12144	MAEIVKFVYVMIIFASPFLFSMNLDSENICDGDYDCNPNEWWCPPNYVLKCINYQCSCIGFTPAIYALD	69	Sequence 214 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12145	MDAVLKFVYTMILYLFLLHVIAEDFPFHKCEKDEDCLEICADDQMAMCILNVCFCY	56	Sequence 215 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12146	MTTILKFAYVMIICLFLLQVAAQEVLEKEIFPCQTDGECDHMCVTPGIPKCVANMCFCFDNL	62	Sequence 216 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12147	MRKSMATILKFVYVIMLFIYSLFVIESFGHRFLIYNNCKNDTECPNDCGPHEQAKCILYACYCVE	65	Sequence 217 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12148	MAKVTKFVYIAIHILSLFFIAMNDAVIFECSEDSHCVTKIKCVLPRKPECRNTQCTCYRGYKGSFTLHH	69	Sequence 218 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12149	MAGILKFFYIAIIYVSLYLVVIEGKDGCKTNFDCLIKYPDHNEDILQCIGGHCLCLTN	58	Sequence 219 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12150	MAEILKILYVFIIFLSLILAVISQHPFTPCETNADCKCRNHKRPDCLWHKCYCY	54	Sequence 220 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12151	MAEILKFVYNATLFFSLYLVVYNSKLWCDTDADCQEKFPGPSKYPIKCMKGICKCVIN	58	Sequence 221 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12152	MPEMIQFDYLMILFIFLIFVVTNIMAWRPDCKENNDCPTFYCATWINTCIKFKCYCIRPWG	61	Sequence 222 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12153	MRINRTPAIFKFVYTIIIYLFLLRVVAKDLPFNICEKDEDCLEFCAHDKVAKCMLNICFCF	61	Sequence 223 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12154	MVGTLKFLRVHISFLTILLMIIICAFYFIPDSGPCVTNKDCEQEIGYIVKCDTNTGFCVKILQRS	65	Sequence 224 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12155	EILKFIFVIIILFLSISLVSADFDLHNDSYDYLYEFQECEVDNDCPQDPLPMKCINYICVVHNEEPSDNL	70	Sequence 225 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12156	MAATFKLVYVMILLISLYHVAGNFEDISIECMFSIDCPQIKSNIFRFKCIEDRCKIEFIYQRKKYEI	67	Sequence 226 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12157	MTTFLKVAYIMIICVFVLHLAAQVDSQKRWHGCKEDRDCDNICSVHAVTKCIGNMCRCLANVK	63	Sequence 227 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12158	MTTILKFAYIMIICLFLFLLHVAAQKDLKVFTCQRDEDCKVACATYGGDPWCFRNVCFCKHYNEGGTLHAELH	73	Sequence 228 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12159	MDKILKFVHIVILFVFLLLVLVAAEQHFVTLYKKKEKCALDVDCLELFPNSYKYLMKCVGGDCISLSKGFSHDEIKE	77	Sequence 229 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12160	MTKIVKFIYVMIIILSLFQLSKNAKVNCLDDADCLEVLCVFGSKAECVVNICICVPPRFGKFDEHFR	67	Sequence 230 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12161	HEAQISKSFYALIIFLSLILVVTSKDITCTVAGDCPNFFVCPPNNFVRCIRNLCKCRSLSYKQP	64	Sequence 231 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12162	MAKFVIVVCSVIIFLSSFLVAENSQPCNLSVTDTRDICPPGTTLQFVYKVCRCYPMKWRLDHVLT	65	Sequence 232 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12163	IFFLYLFIFATNINAICECEEDIDCPRTWCFGQFFVKCITNECICVHEDRLLPRIPWDPWIPMI	64	Sequence 233 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12164	MQKRKSMTEVLKLVYIMIIFLYIFLVVADTDPFAFCIKDSNCGQDLCTSPNEVPECRLLKCQCIKS	66	Sequence 234 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12165	MAEIVKFVYLMIIFLSTFLVSTKILEKHKCVTDGVEILEKGKCFTDWECVRNSWLCPVDLVVRCIKETCKCIKILEPINVVPT	83	Sequence 235 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12166	MVETLRLFYIMILFVSLYLVVVDGVSKLAQSCSEDFECYIKNPHAPFGQLRCFEGYCQRLDKPT	64	Sequence 236 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12167	MAKLMKLFYVMIHFISLLLITRNVRAYDDCYNHAECTNKIKCVPPRIAQCVRFKCDCIRLNNGPKTPWSARPKRVHISPTRKNDF	85	Sequence 237 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12168	MQMKKMATILKFVYLIILLIYPLLVVTEESHYMKFSICKDDTDCPTLFCVLPNVPKCIGSKCHCKLMVN	69	Sequence 238 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12169	MQKDKSMVQIVKFVYVMIIVLSSFVVAINSDGYLECTTDYDCREEWLCPPDMEAKCFVSFALARFLSKGKCLCV	74	Sequence 239 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12170	MVAVTKLINVMLIFLTLFLGALSIFPEHNECRTSFDCRKYFCQLPLRPTCNYVEIFRHYYDTTCGCA	67	Sequence 240 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12171	MTAILKVAYIIMIICLFLLHDAASDDYLKYIYRCQNDGDCDQICATHGISKCVATMCFCNLNL	63	Sequence 241 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12172	MVEIHNFIYAMILLVFMFIVVVDSWSWGLTTECVTELDCYKKYRLPAEKKMKCIRGSCYRVRE	63	Sequence 242 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12173	MDKIHKFIYALIFFLALFLVVNARNGCIVDPRCPYQQCRRPLYCRRR	47	Sequence 243 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12174	MRYSLSVSILAIILEFIYIVVLFFSPCLLVTDAYNITCNSALDCASNRCILPGMPICVTNKCLCV	65	Sequence 244 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12175	MAGILKFFYIVIIYVSLFLFVVESERECVTDADCQKKLPFPHANHFICMNGLCALVFHD	59	Sequence 245 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12176	MAQFLIFVYTLIIFISLFLNAVQRPCVTVADCPPVKKPLKMWCIRQTCFYGFGKRPDL	58	Sequence 246 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12177	MVGILKLVYIVIIYVSFFLVVCKGETCVTVDDCQGKHHLPPGYHFICMNSRCVLIYYN	58	Sequence 247 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12178	MNIIFKCVYHMIVILLLLLVATEAGTGNIRQSCEFDVDCENKYCPPSHDGKCVWE	55	Sequence 248 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12179	IKIIKFVYAMTFLIFLFLFITDTAGECITFLDCLHLPCMPTETQLCVDKKCICMGLTIKSKNNYIT	66	Sequence 249 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12180	MAKIITIIQIFTIIMLFIFVIVTDASYPCKIHRDCTTITCSYPLVPRCLIQKCYCGFN	58	Sequence 250 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12181	LKLVYIAIIYVSFFLVVCEGEKCVTADDCQGKHHMPAGYHFICMNARCVLVYYN	54	Sequence 251 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12182	MKLFYVLIYFISLFLVINVQAFFDCENHDDCKNKIKYVLPRIAECRDYKCNCFPLNLSKTLWSASTKRVHKSLAQTNDFLH	81	Sequence 252 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12183	MTTILKFPYIMVICLLLLHVAAYEDFEKEIFDCKKDGDCDHMCVTPGIPKCTGNQRFSVWVFGGSFLQHWSCHSSRS	77	Sequence 253 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12184	MDQISKSFYALMIFLSLILVVTSNDIKCTVAGDCPDFFRCPPNTFVRCISNICICRLVYLNTFLEVIIDKVFVF	74	Sequence 254 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12185	MDQISKSFYALMIFLSLILVVTSNDIKCTVAGDCPDFFRCPPNTFVRCISNICICRSLSH	60	Sequence 255 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12186	MAQISKSFYALIILLCLSLIVTGKDITCNVAGDCPEYFRCPPNTFVRCVSNICECRGLSHQQP	63	Sequence 256 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12187	MAQILISVHALSVFIFPFLVVIIRDKPAPIPCKFHADCPIMLSIVVECINNVCEFIYI	58	Sequence 257 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12188	MDEVFKFVYVMIIFPFLILDVATNAEKIRRCFNDAHCPPDMCTLGVIPKCSRFTICIC	58	Sequence 259 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12189	MAGILKIFYIAIIYVSLFLVVIEDERECVTDADCQKKYPGPYEHLLKCVSGYCVGVTGF	59	Sequence 260 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12190	MQRRKLNMVEILKFSHALIIFLFLSALVTNANIFFCSTDEDCTWNLCRQPWVQKCRLHMCSCEKN	65	Sequence 261 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12191	MVNILKFIYVIIFFILMFFVLIDVDGHVLVECIENRDCEKGMCKFPFIVRCLMDQCKCVRIHNLI	65	Sequence 262 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12192	LILFISLFLDVVKGHDQRECYTNYDCCVKYSCPYKHMVKCVGGYCLGFRNDYGKKNLY	58	Sequence 263 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12193	VSLFLAVVKSYDSKECYSDSDWHKKYSCPYTHMMKCVGGYC	41	Sequence 264 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12194	MAIIKFIYTMFLFILLFVVPTKVDGRITHDPSTRSTVSGGFGKCVRDADCVDEVCSPGCNKRCVGFECQCPL	72	Sequence 265 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12195	MALKFYSLFYIQLFIPFHLLNFLAYITAVYGCNDDTDCPPSCTTRGCPDSCAYPHVLRCIGKNCVCT	67	Sequence 266 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12196	MAEIFKFFYALIIFISLILSVANADPMYCFNDDDCRELKCSHPRVRKCRMFLCRCEEVDKEDEK	64	Sequence 267 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12197	MGDIIKVVFAMIIYLYMLTIVTNAVTICDSDQDCRRYRCDPPEYPRCLGILCKCVYVSG	59	Sequence 268 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12198	MAKLMMFFYVMIYFFVLVACQKRRRSTECRNDSDCEKMVKCVLPRIARCIKYRCQCRNFLESFE	64	Sequence 269 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12199	MVEVTKLVNVMLIFLTLFVVALSNDTEYTDCLQHSDCQAYACELPFKPDCLMVEYAPQFFRLACGCV	67	Sequence 270 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12200	MAENYKFVYVVIFFVSLFLDVVDGEKGTIVDIETTGQCADDYECYRLFSCPREVAFKCINGWCKCIL	67	Sequence 271 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12201	FDRRFICFDNSDCPQHLCHELIIPRCKIGVCVCLP	35	Sequence 272 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12202	MNNMVETCKYFYVVILFLFIFIMATDGVYLCEDDEDCHIMPCMVPEYAKCIRMICQCC	58	Sequence 273 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12203	MQRRKNMANNHMLIYAMIICLFPYLVVTFKTAITCDCNEDCLNFFTPLDNLKCIDNVCEVFM	62	Sequence 274 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12204	MTGIHKFFHMVIHFVFLFLVVYGSGIAEKECITDDDCNRKYPMHANRGLQCLNGECKSSRIIKSR	65	Sequence 275 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12205	MTPITKNIFDMIIFISPLIVTMSMRVLCGRDGRCPKFMCRTFL	43	Sequence 276 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12206	FVWLLIIFLSLFLFEITVGGRYTTPWCVRDIDCPKEKCKHPFKPRCLTHSCVCRLWGSQDVI	62	Sequence 277 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12207	IKFMYVIIIVLFVFLSVRKNTDAKNICIDDVHCQKYKCSPGLYPTCINGWCECK	54	Sequence 278 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12208	MKFVYVMILFLSLFIVSTNGYEKISCQNDFDCPESMCEFGMIRRCISYKCQCHEAY	56	Sequence 279 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12209	MDKVYKFVYVMIIFFSQIIVATNAQKIRRCFNDAHCPPDMCTPGVIPKCKFTICKC	56	Sequence 280 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12210	MGQIQKFISSLIIIISLVLVVTCNCIPMIHPLLYKKRVVPNCQTIVDCPDNMCTHPKEVYCIGYRCYCLK	70	Sequence 281 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12211	MDEILKFVYTLIIFFSLFFAANNVDANIMNCQSTFDCPRDMCSHIRDVICIFKKCKCAGGRYMPQVP	67	Sequence 282 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12212	MAQILYYFFAFLIFVSLFLVVTNQSIPDVLPCLFSNECPPDLCPIDLFPKCINLSCQCSAEFYNID	66	Sequence 283 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12213	DMIIFLSPLIVTMSMKVLCGRDGTCPRFMCGPGIIPKCVGRYCEC	45	Sequence 284 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12214	MVKIIKFVYFMTLFLSMLLVTTKEDGSVECIANIDCPQIFMLPFVMRCINFRCQIVNSEDT	61	Sequence 285 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12215	MAKIIKFVYVLAIFFSLFLVAKNVNGWTCVEDSDCPANICQPPMQRMCFYGECACVRSKFCT	62	Sequence 286 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12216	MTGVLKFVYTMVFFLSLFLIAIDIKVAAFLRCDFDLDCPPKMCYSHLYFVPMCVDNHCDCTQWKDIIPTIP	71	Sequence 287 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12217	TTFHPILVILFYSLFPFIPAPIRCNRVSDCPKIRCNIGFVLRCLYNQCKCVRITQLVDYVLK	62	Sequence 288 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12218	MAIIKFIYTMFLFIFLFVIPTKVDGRITHETLPLPVSKPIPILGGECISDADCKHPECDNCRGVCLNSRCICMARSGWTYTIPQN	85	Sequence 289 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12219	AIIYLSLFLFVFEDKRECDTNFDCQQKFSTQAEDLLWCIRGYCMSIPN	48	Sequence 290 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12220	MILCFSVFLFAKNIDALHCNNDNECPPSTWKPFVRCKMNRCIYSRVQPPWAC	52	Sequence 291 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12221	FSFLFLVVATLIEECVTDADCYKIYPEASFLHMFCIDGVCKTPIPL	46	Sequence 292 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12222	MAEILKFVFGIIIFLPIFLVAMDIVDKIDECESNVDCPKSYIINWDKNYVHKCINNRCEWIKIIRRR	67	Sequence 293 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12223	LYLVDLGCVTDADCKDKFPGNKYPIKCINGICKSVPN	37	Sequence 294 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12224	MTEIRKFFYMLIHVFFLFIVRKYGSECISDTDCNVLYPMYINRRLRCIQGICHTTTARRR	60	Sequence 295 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12225	MDETLKFVYILILFVSLCLVVADGVKNINRECTQTSDCYKKYPFIPWGKVRCVKGRCRLDM	61	Sequence 296 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12226	MAHKLVYAITLFIFLFLIANNIEDDIFCITDNDCPPNTLVQRYRCINGKCNLSFVSYG	58	Sequence 297 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12227	AIHCNDVNDCPPDISDPFVRCESNRCIYSRLEPPFGC	37	Sequence 298 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12228	MRKNMTKILMIGYALMIFIFLSIAVSITGNLARASRKKPVDVIPCIYDHDCPRKLYFLERCVGRVCKYL	69	Sequence 299 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12229	MTIIIKFVNVLIIFLSLFHVAKNDDNKLLLSFIEEGFLCFKDSDCPYNMCPSPLKEMCYFIKCVCGVYGPIRERRLYQSHNPMIQ	85	Sequence 300 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12230	ISLFLVVYCEKECANDIDCYKIFLGPPLIPMKCIDGECKRIT	42	Sequence 301 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12231	MAEIFKFVYSVILFVSLYLFVIYAEKECDTDADCRKKFAGANQHLLWCNNGYCECHTH	58	Sequence 302 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12232	MTETLKFFYAMILFLSLFLITTNVGGSYYGCETDADCPRSMNKDFYLKCVDKKCEWTAKI	60	Sequence 303 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12233	FRAIHECRAHSHCVARINCVLPRKPQCRNYACGCYDSNKYR	41	Sequence 304 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12234	MQRSRNMTTIFKFAYIMIICVFLLNIAAQEIENGIHPCKKNEDCNHMCVMPGLPWCHENNLCFCYENAYGNTR	73	Sequence 305 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12235	MIKQFSVCYIQMRRNMTTILKFPYIMVICLLLLHVAAYEDFEKEIFDCKKDGDCDHMCVTPGIPKCTGYVCFCFENL	77	Sequence 306 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12236	GLFSFFIPTGWRCKKTDDCLKIEFCKFPKIARGTKPKFLFFEFGTGFCTWDD	52	Sequence 307 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12237	MAKVYMFVYALIIFVSPFLLATFRTRLPCEKDDDCPEAFLPPVMKCVNRFCQYEILE	57	Sequence 308 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12238	MQRRKKKAQVVMFVHDLIICIYLFIVITTRKTDIRCRFYYDCPRLEYHFCECIEDFCAYIRLN	63	Sequence 309 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12239	MANTHKLVSMILFIFLFLASNNVEGYVNCETDADCPPSTRVKRFKCVKGECRWTRMSYA	59	Sequence 310 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12240	MAGIIKFVHVLIIFLSLFHVVKNDDGSFCFKDSDCPDEMCPSPLKEMCYFLQCKCGVDTIA	61	Sequence 311 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12241	MQREKNMAKIFEFVYAMIIFILLFLVEKNVVAYLKFECKTDDDCQKSLLKTYVWKCVKNECYFFAKK	67	Sequence 312 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12242	MNHISKFVYALIIFLSIYLVVLDGLPISCKDHFECRRKINILRCIYRQEKPMCINSICTCVKLL	64	Sequence 313 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12243	MQMRKNMAQILFYVYALLILFTPFLVARIMVVNPNNPCVTDADCQRYRHKLATRMICNQGFCLMDFTHDPYAPSLP	76	Sequence 314 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12244	MQKRKNMAQIIFYVYALIILFSPFLAARLVFVNPEKPCVTDADCDRYRHESAIYSDMFCKDGYCFIDYHHDPYP	74	Sequence 315 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12245	MTAILKKFINAVFLFIVLFLATTNVEDFVGGSNDECVYPDVFQCINNICKCVSHHRT	57	Sequence 316 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12246	MFEIFKFVYVVVIFLSLYILSIEVGGALIECEIDLDCPKSYIKLWDRNYAHRCVNNICEWVKKPRIY	67	Sequence 317 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12247	MFEIFKFVYVVVIFLSLYILSTLIECEIDLDCPKSYIKLWDKNYAHRCVNNICEWVKKPRIY	62	Sequence 318 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12248	MQIGRKKKGETPKLVYVIILFLSIFLCTNSSFSQMINFSGCKRDKDCPQFRGVNIRCRSGFCTPIDS	67	Sequence 319 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12249	MQIGKNMVETPKLVYFIILFLSIFLCITVSNSSFSQIFNSACKTDKDCPKFGRVNVRCRKGNCVPI	66	Sequence 320 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12250	MTTSLKFVYVAILFLSLLLVVMGGIRKKECRQDSDCPSYFCEKLTIAKCIHSTCLCK	57	Sequence 321 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12251	MTTSLKFVYVAILFLSLLLVVMGGIRRFECRQDSDCPSYFCEKLTVPKCFWSKCYCK	57	Sequence 322 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12252	MATILMYVYITILFISILTVLTEGLYEPLYNFRRDPDCRRNIDCPSYLCVAPKVPRCIMFECHCKDIPSDH	71	Sequence 323 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12253	MQMRQNMATILNFVFVIILFISLLLVVTKGYREPFSSFTEGPTCKEDIDCPSISCVNPQVPKCIMFECHCKYIPTTLK	78	Sequence 324 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12254	MFHAQAENMAKVSNFVCIMILFLALFFITMNDAARFECREDSHCVTRIKCVLPRKPECRNYACGCYDSNKYR	72	Sequence 325 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12255	MVEILKNFYAMNLFIFLIILAVKIRGAHFPCVTDDDCPKPVNKLRVIKCIDHICQYARNLPDFASEISESTKMPCKGE	78	Sequence 326 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12256	MAEILKDFYAMNLFIFLIILPAKIRGETLSLTHPKCHHIMLPSLFITEVFQRVTDDGCPKPVNHLRVVKCIEHICEYGYNYRPDFASQIPESTKMPRKRE	100	Sequence 327 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12257	MAEIIKFVYIMILCVSLLLIEVAGEECVTDADCDKLYPDIRKPLMCSIGECYSLYKGKFSLSIISKTSFSLMVYNVVTLVICLRLAYISLLLKFL	95	Sequence 328 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12258	MAEILKFVYIVILFVSLLLIVVASERECVTDDDCEKLYPTNEYRMMCDSGYCMNLLNGKIIYLLCLKKKKFLIIISVLL	79	Sequence 329 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12259	MLRLYLVSYFLLKRTLLVSYFSYFSTYIIECKTDNDCPISQLKIYAWKCVKNGCHLFDVIPMMYE	65	Sequence 330 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12260	MQIGKNMVETPKLDYVIIFFFLYFFFRQMIILRLNTTFRPLNFKMLRFWGQNRNIMKHRGQKVHFSLILSDCKTNKDCPKLRRANVRCRKSYCVPI	96	Sequence 331 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12261	MAKIVNFVYSMIVFLFLFLVATKAARGYLCVTDSHCPPHMCPPGMEPRCVRRMCKCLPIGWRKYFVP	67	Sequence 332 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12262	MVETLRLFYIMILFVSLCLVVVDGESKLEQTCSEDFECYIKNPHVPFGHLRCFEGFCQQLNGPA	64	Sequence 333 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12263	MYKVVESIFIRYMHRKPNMTKFFKFVYTMFILISLFLVVTNANAHNCTDISDCSSNHCSYEGVSLCMNGQCICIYE	76	Sequence 334 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12264	MAKIMKFVYNMIPFLSIFIITLQVNVVVCEIDADCPQICMPPYEVRCVNHRCGWVNTDDSLFLTQEFTRSKQYIIS	76	Sequence 335 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12265	MTKIVVFIYVVILLLTIFHVSAKKKRYIECETHEDCSQVFMPPFVMRCVIHECKIFNGEHLRY	63	Sequence 336 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12266	MAKTLKFVYGLVLFLYLFLIEKGVDGKTFLMAEYIKCDTDADCPIVIHHSFYKCIDNLCKRFRRQKHLV	69	Sequence 337 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12267	MAQLIIFVYALMVFLSIFLVESYKTKTPCKSLNDCPKAIKPIFVKCLGNICQYSIGRI	58	Sequence 338 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12268	MANDLKFIYVIISFLSMFLVTKEVDGAFAGWIKCKVDEDCPNVFTYSYYKCVNELCEIFLREIPKKPYM	69	Sequence 339 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12269	MAKTLKFLCGLVLFVYLFFIKKDVAGNTFLMADNIECDTDAGCPKMVHHIFYKCIDNKCKQFRRS	65	Sequence 340 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12270	MAKIFKFIYGLVIFLYLFLIQKEVAGYIQCDFDADCPEMFRHIFYLCIDKLCRQFVTL	58	Sequence 341 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12271	MTQILLFVYFFIIFLSLSFVVTSYRTRIPCVSDYDCPKASYPLFIKCIYNFCEIWGSP	58	Sequence 342 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12272	MQRRTNMTQIVILFYVLIIFLILFPISCVSDDDCPKVPYPLYIKCEDNFCDIWASPY	57	Sequence 343 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12273	MAQILMFFYSLIIFFFLFLVETKRTNIPCFSDDDCPKTSPPLVLKCDDYFCRYFREKNLI	60	Sequence 344 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12274	MAKTLKFVYVVILFISIFLVLTVYDSKYFQIASPCVNDKDCPRFKNNNVRCRKGFCVNLCN	61	Sequence 345 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12275	MAKTLKFVYVVILFISIFLVLTVYDSKYFQIASPCVNDKDCPQFKNNNVRCRRGFCVNSGGATQKCLGCPSLK	73	Sequence 346 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12276	MAQFFMFVYILIIFLSSFLIEASTAATPCTSDKDCRLERYNVWCINGYCKYKFTPID	57	Sequence 347 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12277	MAQMLMFVYTLIIFLSLFLVITNSVRIPCVTVADCPPTILPVFYECIDKFCMLHIE	56	Sequence 348 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12278	MFLYALITFLFLFLVETSTTNTKTTIPCKFDNDCPEISYPLILMCIDDFCEYLLA	55	Sequence 349 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12279	MVETLKLVYVLIIFYSIFLGIIVCNSSTIMYYDVPCEKDKDCPAPPRFNIRCRKGYCVRI	60	Sequence 350 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12280	MTQILLFVHVLISFLSLLLIVTNSVEIPETPCESDAECPYYSPSLYARCIDGFCTLFLS	59	Sequence 351 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12281	MQRKKNMGQILIFVFALINFLSPILVEMTTTATIPCTSIDDCPKMPLVVKCIDNFCNYFEIK	62	Sequence 352 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12282	MVELLKFVYVMILFLFLFFVTTEACGGKTHYSEIIECKNDADCPIGYKCIDEMCKYG	57	Sequence 353 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12283	MVETLKYVYVMFLFLSIFQLMVVYDSIYFRKPPPCITDKDCPQMKINNVRCRKGFCIQIHKFTP	64	Sequence 354 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12284	MQIGKNMVETLKFVYVILLFLSIFLFNKSPFSQIMFSDCKTDKDCPQFRRANIRCRKGQCVKL	63	Sequence 355 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12285	MAHILMFTYVLIIFLFSFRSMTFLTQCKFSCKTIFNCPALVYHQHASCLDGFCWYEEKFEDE	62	Sequence 356 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12286	MTKTMKFLYVLIIFISIFVVASVYDSIPYVNSGPCVTDKDCPKVSQYNIRCRKGQCARIRV	61	Sequence 357 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12287	MTTIVNFVCGMIIFLSEFMVATNFKRKQIPFYFFIREFYPCFIDGNCPRNMCKVYQIPKCVGGLCRCIPLRCGRWEK	77	Sequence 358 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12288	MPKIMEFVYVMIIFLSIFVVITNVNAHIECKNDFDCPKNMCLAPRVAWCVNNKCECVLTYGPKYSTMKEKLLQKEKI	77	Sequence 359 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12289	MNKILKFVYEMILFLSLFHLAREVPHTDIPCEPDADCPKSLHEYFEMKCIDKKCEWSRKTSLIP	64	Sequence 360 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12290	MQRGKHMVEILEFVYAMILFLPLFLVITEVDGVDIYCETDADCPQITDWFYVVKCVDHKCELTKKLRRLYEYQTQKSAETPYI	83	Sequence 361 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12291	MTQILKLVYIVILFCFHICFVAEAEQCVSDADCQIKFPGPRQHLLRCTQGNCVMLVGQGKNYFSIMSKTLFSLLVIIFLLL	81	Sequence 362 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12292	MPKSLKFVYTMILFIFLFLITKNVDALHDCEYDDDCPKSTSKRTYRCINKKCRSYFTRVEK	61	Sequence 363 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12293	MNKNMPQILMFVYTFIIFFSPFFVVTNGTTSCITDDDCPKAVSFLVFKCIDNICVRVEIL	60	Sequence 364 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12294	MAKILKFVYVPILYLSILLVLTIYDQVYFNYNPPCVSDKDCPSPKSPKSNIRCRQGYCVNLYS	63	Sequence 365 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12295	MAQLHKLIYALTIFLSLFIVGAVRIPRPLIDPLNCHIDIHCIYKECRRPFKPSCLNFKCDCGKE	64	Sequence 366 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12296	MRIGKKMVETLKLIYVIHLFLSIFLFTNSPFGQIIFRQCKTDKDCPKLGRANIRCREGYCVRI	63	Sequence 367 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12297	MAQIYMFVYVLIIFLSLFLVIINCTPIPCNTPADCPKRVCIYPLRAKCINFNCECDYVKK	60	Sequence 368 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12298	MTKTLKFILTMILLLSLFLVAESGDIPCESREQCPNTATRRYACLNKLCYCYDNNYPNGWNPFEP	65	Sequence 369 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12299	MFNTLTFAFVIILLVTLFLVPKNVDAFVKCETTDDCPKSDYIRQYECVNNWCRLARLHEFQPKKSTLTS	69	Sequence 370 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12300	MQRENNMAKTIKFVYTMILFLSLFIVAKEVHAYPGCETDAECPKIYELYPLIYKCENKFCILSQVLPYIV	70	Sequence 372 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12301	MKIGKNMAETLKFVYVILFISLFLMIIVSDSFNPLIRQYCVTDKDCPKFKKYNIRCRKGFCVQVNGG	67	Sequence 373 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12302	MTKIIKFVYALVLFLSLFIVSQAAQNDWMKCKTDDECPKVSNPPLYFKCIDRGCRIVIKMRF	62	Sequence 374 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12303	MATILKIVYAMILFISLFLVAMNVDAYVECETDADCQPNMCKWPFIVQCYKNVCICVHHTNPYL	64	Sequence 375 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12304	MVQILKFVCVRILFISLFLIATKFGVASDECQIDADCPKSGNLFYIYKCINHKCELVAAHLRFY	64	Sequence 376 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12305	MTNYIVIFFLALFLIVIDVSAILECIFDIDCPTKKCAPPLVAKCDMYECYCRCPPNN	57	Sequence 377 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12306	MAQIQKFVYTLIMFLSLFVMVTNGMVSTNAYIHRCIHQDDCPKYMCEISVLPECINGFCTCV	62	Sequence 378 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12307	MSQILKFFFATVLIFALFLSATNGQKFNECYEDTDCPIQMCGYPFNVDCVGNKCTCVYNP	60	Sequence 379 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12308	MQKKGKYMAKLVTFVYVMIYFLSLFLVTKGAYYECSNDSACQATTKCVLPRVPRCIKYKCLCGNSNGSGNRWSTRPNRIQKGSTESNYF	89	Sequence 380 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12309	MDKTLKFIYAMFSCLYLFMVTKEVYVIYIFFHFLILAKSICKVDDDCPQRFVMYPLMFMCIKNICRLVNE	70	Sequence 381 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12310	MAQLLKFVYAIIFLFSLCLAATKEKFHSCVNANDCPYDFCSPPKYAKCVYNSCYCEDQGRL	61	Sequence 382 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12311	MQKRENMTVIVKFVCVMIIFLSLCVFSMHIETVTTCIYDSDCPEDMCYPPKKSFCSTFEILSIERKVGVCECI	73	Sequence 383 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12312	MNTIPKFVYITILFISLLLVVTGAVRKPECRQNSDCPPYFCIKPTVPKCIKFKCLCK	57	Sequence 384 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12313	MAEILKFVCFMIIFLSSFIVSESLNGNRHGKDRCFKDSDCPKYMCPSSLVAKCIKKLCSCRKPGLQIQLNPK	72	Sequence 385 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12314	MAESFKFICVIIIFLCSFIAAKNIDEKCFRDDDCAKNMCPSYLVVKCVNGIYKCVRP	57	Sequence 386 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12315	MVEIQKLVYVLILFLSIFLEMIVSNCTFIGFQDNPCKTDNDCRKVRGVNLRCRNGHCVMILQ	62	Sequence 387 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12316	MAEIVKYVYVIIIFLSTILVATNIEGTMSCFHDADCVHKRCQLPQIPKCVGKKCRCRGQYQANPMG	66	Sequence 388 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12317	MAEFLHMTYVMIIFIFLFLSLIDAEVHRCIEYTDCPEDMCHLPLVVVCHDHICKCLRLP	59	Sequence 389 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12318	MAKIIKIVYVMIVFFFIFLSVTNSSAFSGCMNDSDCPDLFCLPPLDMKCHELVCKCR	57	Sequence 390 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12319	MKNMSAIIKFIYAMSLILFIANEHYRELICKTDDNCPRRGTNKYFIHKCIDYRCQWIPR	59	Sequence 391 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12320	MQRRKNMAQILFYVYALIILFSPSLVVPLKVIIPSSTCDSDYDCLRYEEALNVITCCNNGLCVMFCPDFD	70	Sequence 392 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12321	MTNIIKFVKVMIYFLSIFLISTYFKVKLSCFEDSDCPYDMCYAGFQPKCVNGWCDC	56	Sequence 393 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12322	MTNSIKFVYVMMYFLSIFLISTYFETKLNCIDDSDCPYDMCDPGLLPRCLNGWCDCSRFQPWPMDSMSSNLREFTLPN	78	Sequence 394 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12323	MSKNILFNCAIILFLSLFLVTYFERFGPCSSDSDCPSFLCDHDGVMKCFSNGCSCVDPSD	60	Sequence 395 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12324	MVKILKFIHIMIIFLIFIIVTNASNPCVSTRDCTTHTCNPPLVARCINLRCYCGYK	56	Sequence 396 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12325	MGGIIKIVYAFVIFISLILIVTSNVHSLLPCGTDDDCANDPCIHPEYPHCHTEQCHCV	58	Sequence 397 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12326	MQKKKNMAQMHLFVYIFIIILSLFIAVTNALIFCFEDINCPFDKCFPQLPKCINSFCECV	60	Sequence 399 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12327	MSMTIKFLYAMTLFLFLFHIEKSSALIDCKTVDDCPSSWTKIYKCIDNKCRYSVVKGLII	60	Sequence 400 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12328	MSKTIKFLYAITLFLFLFLIEKNNVLIDCKHVRDCPKGIWRSCRYKCIDNKCVFTYWPH	59	Sequence 401 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12329	MTHKLVYAIILFIFLFLVANNVEGYILCKTVNDCPPNTRNLRYRCIDGKCKSHRVLYEWDESHTQDITITPCIEE	75	Sequence 402 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12330	MTEILKFVCVMIIFLSSFIVSQNIDSGGNRRCFRDSDCPKNMCPSYLVVKCLRSNCKCVRPGLQVRLNPN	70	Sequence 403 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12331	MAEILKFICFMIIFLSSFIVSESLNGHGRNRCFRDSDCPKVMCPSYLVTKCFKKHCRCRKPGLQVQLNPK	70	Sequence 404 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12332	MSTIVNYVCSMMIICLFQFTVATNFERKQISFSFFMKEYWPCVTDDDCPSDLCKKVDQIPKCVGGLCKCFPIRFGQWER	79	Sequence 405 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12333	MAEIFKVFYTLIIFASLYYVVALVQNECVTDGDCRRLYPHLIPRYPMCNEGTCVCIFE	58	Sequence 406 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12334	MAQIFKFVYVMIIFIYLFLVLTNVDAGIRCHDVSECPKGLYCNVGSHMECVKHQCKCIKNFEPIDLA	67	Sequence 407 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12335	MAETFKFVYIVILLVSLCLVVVDGIRTYRECENASDCYSIYWRAPYGTMRCVKGHCKQIKDVKVMKFLYCV	71	Sequence 408 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12336	MTHISMFVYSLIIFLSIYLVVTDGIILCKDHFDCYENIRKLRCDFDTEKPFCISLNVCQCIKQ	63	Sequence 409 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12337	MAEFVKFVYVMIIFIFLCLVVENIDGFRCLRNLDCPDSMCSSAYTPRCRHRTCVCLNNDEIKIL	64	Sequence 410 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12338	MKMEENRAKTFKFVYGMVIFLYLYHVAKRVEAAIPCITDANCPCVFPLKPRCNFGYCICEEMIP	64	Sequence 411 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12339	MAEIVKFIYVMIIFLYLFLVSTNIEARQGCKIDYDCIKVVCKDGHAARCIMRRCECVEILNPIDLGST	68	Sequence 412 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12340	MAKIVKFVYVTIIFLYMFHISTNIEAGNYKCQTNYDCLRMWCPIGISPRCIKRRCKCIETLVQ	63	Sequence 413 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12341	MAGTLNFVYAMILFISLFLVAGGEEIIIIKCQTAKDCPDIYNLFPLVYKCIDNICVDVRLEPPYDMSISPKSVHK	75	Sequence 414 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12342	MVKIAKFLYVLIISLSLFLFAITVDGAYVTRFWCYRDLDCRKDMCKPPFNPRCHNHICICRLWGL	65	Sequence 415 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12343	MAKTIKFVNLLILFIFTFLVVADASATTRCVRNSDCRHHICMYPLVPRCKYPLCRCV	57	Sequence 416 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12344	MVKIIKYVNLLILFISIFLVVTDVSAHKRCRVDFDCRMRMCVYPTVSVCIDRLCRCRRPPNM	62	Sequence 417 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12345	MVKIIKYVNLLILFISIFLVVTDVSAQKRCKEDFDCRIRSCAYPLIPVCIDPFCRCRRASI	61	Sequence 418 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12346	MGKIIKFVNLSILFIFMFLVVVDVNAERTCKEDFDCRMRYCVYPTIPLCDVKHCRCRRPPNL	62	Sequence 419 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12347	MAKVLKLVNVMIIFLALVLVAMNVNADVINCTQDSDCQSIGCLSHLKPKCTMLGFFFNAFVGICECDQVM	70	Sequence 420 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12348	MAKILMFVYALIIFISLVITGRSTINVMCYYDHDCPFVLDHIAECKGGVCEYTAFFYE	58	Sequence 421 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12349	MQRKKLMAQIHLCVYALIIFLSPFLALTNDRIVYHGCYSDDQCPNECPAILMRCIHSLCVEFIKTDPLFI	70	Sequence 422 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12350	MQRMEHTTKIQFCVYVLIIFLSLFLVVTNGDKPRYTPRNAVKIAECVSYTDCQGGCPACYMRCIDGQCEPFIIKFI	76	Sequence 423 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12351	MQRMEHMTKIQFGVYVLIIFLSLFLVKVYECYNYIDCPVGCRACYMRCIDGQCIPFIKKLILFHLYVIVE	70	Sequence 424 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12352	MAQILMFIYDLIIFLSIFIIVTNGGLIPCVSDADCPEELALVMKCINKLCELVME	55	Sequence 425 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12353	MIKDVKFVYVMIIFLSLFLVAMSIDDSHCPHDICPFHLKPKCIFTKVVGQKFFSFSLDGKCGCM	64	Sequence 426 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12354	MAEILKFVYIIIIFLFITEIKGDKFVFDKNGADRCRSILDCPQDKCFPLLTLVCVNFACDCLHV	64	Sequence 427 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12355	MNKTLKFVYVLILFISLSIVSKSVAQYNIGCKTDDDCQKYYTKMFGMKCFKSWCITGILD	60	Sequence 428 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12356	MTKTLGIVYAIILFISLFLVLQNTEFEDYYYIECQRDFDCPQLNSEIFAFKCIEKLCKLEFIYQQAPFLLGQV	73	Sequence 429 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12357	MAHLKFVYVMILFLFLFLITKNIEAYKCNIDVDCPITPSPKFKWKCINKRCLYIRFDEIWTSDPRE	66	Sequence 430 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12358	MAKTLKFSYPMILFIFLFLVAYKIEALTKCETDANCPEISIFSPFFYKCINNGCVLIML	59	Sequence 431 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12359	MTKTLKFVYSIILFITLFLVAKNVDALKKCITFEDCPISKTRVYKCLHGECRYTIPYIPKVPKVK	65	Sequence 432 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12360	MSQILTFVYAMILFISIFLVAAEVDWIYHLCDTDTDCPEHWSKFFIYKCVNHVCDSISKVTTDSKEYKNFP	71	Sequence 433 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12361	MAKLLTFVYVMIYFLSLFLVTKGAHVECHNDSACEKTVKCMLPRIPRCIKYQCLCGYSDDPGNRWSTRPKRIQKGSTERKGFLY	84	Sequence 434 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12362	MDKTLKYMYTLISFISLFFIAKNDAVYIKCKTDADCPKSESTIFAMKCNNYRCIYDYIHKRNSYAT	66	Sequence 435 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12363	MPSFLKFVYAIILFVSLFLAATNVNATYDAYDECQTELDCPKNIDCVYPKSMKCIDKKCICVGARMIIPRVL	72	Sequence 436 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12364	MVAILKFIYSILLFIFLHLVSTNGYRNIKYCFIDTDCPRSMCHYPEIVRCVDQCKCVRIMP	61	Sequence 437 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12365	MTEILKLFYAMILFASLFLVAMEIGESFGCTEHRHCEIAMCKFPFIVRCSMNECNCERVHYLI	63	Sequence 438 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12366	MTIKTLKFVYVIILFFSLFLVAKNEPEPKFIECVTDADCLNSQSKMYALICEKNRCIYEFLKSMHYNLS	69	Sequence 439 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12367	MQNAKNMTEILKFVYVMFLFISMFIVTTEVGGECINDIDCPQTGNLFYVFICKNRICELINKYPQNL	67	Sequence 440 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12368	MVQLLKFVYAMILFISIVFLIRTQLSDIYEECETDDYCPKYRDLLYVFKCIDKRCELVEAHA	62	Sequence 441 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12369	MNKILKFVYEMILFLSLFHLAREVHDVAHTDIPCEPDADCPKSLHEYFEMKCIDKKCEWSRKTSLIP	67	Sequence 442 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12370	MVEIHKFVFAMIQFISLFLITIEVGRLRYGCETDADCPRYTHNNFSLKCINKKCEWSAKLH	61	Sequence 444 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12371	MAEIIKFVYVMILFLFLFLVAAEDIGGNCECIRDEDCFKQKRDEDCHKEYCMIFYVHKCENYKCVCAGMFN	71	Sequence 445 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12372	MTTILKFAYIMITCLFLLHIAAQEVLQYELFDCNEDRDCDNVICVAGGIPKCITPFCFCF	60	Sequence 446 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12373	MQRVKNMAETLKFVYVLILFISIFLVVIGCDSIYYPISRPCKTDKDCPNRKNYKGKCRKGFCMSSRLR	68	Sequence 447 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12374	MAETLKIVYIVILLVSLCLVVVDGISIYVRCASTNECYTTFKFAPLGSMRCVEGYCKHLKDFKVKTPLQIKEITPLLLHFP	81	Sequence 448 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12375	MAKTLKFVYVMILFTSLFLFAKNVVGYINCKTDDDCPKLESRMVVLKCTNSRCAAVILH	59	Sequence 449 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12376	MQMGESMAKIVKFVYFVIIFASPFVVANHEISGWITELPFGMCTSILDCPMDSCTHPQQPWCELHGVPILYHGSEIGLCICI	82	Sequence 450 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12377	MQRGESMGKIVKFVYFMIIFISPFVVANHAISGLLPKLPFGCCTSNLDCPRHMCTHPQQPWCIFYGNRIMYRGSRLGICKCS	82	Sequence 451 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12378	MQTGESMTKIIKFVYFMTIFISPFVVASLHEISGYVLGLPAGYCTSNHHCPVYNCTHPKQPWCKLVRLQLLFHGSLIGLCDCI	83	Sequence 452 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12379	MAEIVKFVYVMIIFLSLFLVSIHINALNECTQDYDCPIEMCPFPFQPKCIMLKNLSIFSNSGICSCT	67	Sequence 453 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12380	MGTIHKFLYAMILFIHITLVVSGNFFEFFHKCTQDSDCPSLLCRNKSELPKCIAGFMCRCPNV	63	Sequence 454 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12381	MADVLKFVYIVFLFVSQFCAEPDDNQKNCVSDSDCYKKFHLPRHFIMKCIKNRCTFV	57	Sequence 455 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12382	MIIFLFIFFVAMLVKVSHSHCVIDAHCPRNMCGFHFPPRCVEGDCVC	47	Sequence 456 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12383	MTKTFKFVIATILFLTLFFIVKNVDAQVKCKTVKDCPIRRNRKYYCLFGICKYDVM	56	Sequence 457 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12384	MSEIIKFVYAMFIFIFMFTVATETDALCDSNRDCRGYHCNWPKFPICVRMICECI	55	Sequence 458 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12385	MTIIIKFVYIMILLFFPFLVVSQIFPKWCLYDKDCPQNMCRPGRIPKCIFGHCNCVKQRS	60	Sequence 459 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12386	MIKFLKFVYGMIILISLFFAVRDVSAAPPVYCIEDEDCYDLCTSPLVEICTNYQCICLKRF	61	Sequence 460 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12387	MVELVKFVYVMITLLSIVVVAKNSQGNKENICFKDADCPQDICSYPFKPKCNIYGYCSC	59	Sequence 461 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12388	MAGNLKIVYALMILVSLILVVTSHSFLPCVTKDDCAYDECISPRKPTCYLETCHCL	56	Sequence 462 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12389	MAEIGKYIYVIIIFISLFFITMSVEGWRCKKTDDCIKIEFCKFPKIARCTKPKFLFLEFGTGFCTCDD	68	Sequence 463 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12390	AFERTETRMLTIPCTSDANCPKVISPCHTKCFDGFCGWYIEGSYEGP	47	Sequence 464 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12391	AFETTEPMLTTYLILCVSEADCPKVVKPNYTMCAGGICWQSVQGSNQGP	49	Sequence 465 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12392	ALERTRTTMLTSYNIGCKSDADCPKAIEPHYTRCVDGHCWLYFGEGPKLHN	51	Sequence 466 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12393	WFKRTETGEIIWVVRCVTDTDCPKMGEPQYFKCLNGVCLEHIRELP	46	Sequence 467 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12394	ALERTETTMHNVQPSHFIPCFTAADCPMIDEPHYIECVTGFCWALMRNLH	50	Sequence 468 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12395	KKTDIPCDSRNDCPQQILPRYVLCVNGLCRIYFP	34	Sequence 469 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12396	AYERTEPIMHNGEPINLIPCVTVADCPRMDEPLHMTCLVGACWPCIRSLY	50	Sequence 470 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12397	VFKRTETGEIIWTLPCATDTDCPKMGEPMYFKCLNGFCLEHIRELHD	47	Sequence 471 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12398	QECKDDGDCPTNMCLPSLVSKCINFICECTHSMSTD	36	Sequence 472 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12399	RSFPSSFVSPKSYTSEIPCKATRDCPYELYYETKCVDSLCTYW	43	Sequence 473 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12400	KQTNIPCKSAEDCPKPIYPRYVLCSYGFCRIFFP	34	Sequence 474 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12401	AMFELTKSTIRCVTDADCPNVVKPLKPKCVDGFCEYT	37	Sequence 475 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12402	REPTKIPCVSDSDCHKVKKPLLLTCIDGICQYTLEATPFD	40	Sequence 476 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12403	RKGGPPGGRTYIPCISDDDCIVAQPPYVLLCVNNFCTYFKDDDLPQR	47	Sequence 477 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12404	AQIYITFFTIFSIFVFYTTFYHLTLTTFFSFHNAGYLPCSSDDDCPKEMKPVVVKCIHNFCEHFMVGEYEGP	72	Sequence 478 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12405	FFCGLAETKRTNIPCFSDDDCPKTCPPLVFEVR	33	Sequence 479 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12406	EKTHVRCITADDCPKVERPLKMKCIGNYCHYFLNNF	36	Sequence 480 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12407	YYPCNTDSDCPQNMCPPDMEPRCWTGYCSSCYIRWGK	37	Sequence 481 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12408	LTVPCENPTTCPEDFCTPPMITRCINFICLCDGPEYAEPEYDGPVEEYDHKGDFLSVKPKVINENMMMRERHMIKEIEV	79	Sequence 482 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12409	AFVPNSGPCTTDKDCKQVKGYIARCRKGYCMQSVKRTW	38	Sequence 483 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12410	RVCKSDKDCKDIIIYRYILKCRNGECVKIKI	31	Sequence 484 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12411	INKCSQDSHCPKDMCKKPSKPRCVVSPKLPLSSKSGVCTCV	41	Sequence 485 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12412	IRDKCFRPSDCPPSMYCDAGFQIGCVRKICTCLRILAPIDFVPT	44	Sequence 486 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12413	AYIIECQTDDDCPKSQLEMFAWKCVKNGCHLFGMYEDDDDP	41	Sequence 487 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12414	DDVVFQYVFDGCRIDADCPISGLQLLKWMCINNECEFNHVRPRYV	45	Sequence 488 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12415	LYIIECKTDADCPISKLNMYNWRCIKSSCHLYKVIQFMV	39	Sequence 489 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12416	KFTRCFRDSDCPKTLCHSPGKAKCMHHSICKCIFFGYNI	39	Sequence 490 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12417	YTDECSTDADCEYILCLFPIIKRCIHNHCKCVPMGSIEPMSTIPNGVHKFHIINN	55	Sequence 491 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12418	ELIKCTMDADCPTSLNRKWLCINNICRKMCVTNV	34	Sequence 492 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12419	AFLPTSRNCITNKDCRQVRNYIARCRKGQCLQSPVR	36	Sequence 493 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12420	QIRCNDAFECRRSAICNFPNKWKCNDHKCECV	32	Sequence 494 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12421	FPDKIFIGDCKTDKDCKPKRGVNFRCRKGKCYPR	34	Sequence 495 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12422	AFVANTETCITDKDCPNGRNYIGRCRKGHCQQRLVR	36	Sequence 496 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12423	IHDQVYFNNNSPPCVTDKDCPRPQFRKSNVRCRNGHCVNLGN	42	Sequence 497 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12424	SFLGTFISSCKRDKDCPKLYGANFRCRKGTCVPPI	35	Sequence 498 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12425	YFNDPRPCVSDKDCPRPKFQKSNVRCRKGYCVNLDG	36	Sequence 499 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12426	NNSPPCVTDKDCPRPQFRKSNVRCRNGYCVNLGN	34	Sequence 500 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12427	SNYSPTPFPCLTDKDCTRRKGFSVTCRKGFCVEFKHF	37	Sequence 501 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12428	TTPTPCRTDQDCPRKKKFSVTCRKGFCAEIRHVY	34	Sequence 502 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12429	VTSPWVLKQHCVTDKDCPQMGKIKIRCRNGECVQGF	36	Sequence 503 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12430	QIIFSECKTDKDCPKYQRANIRCRKGQCVRI	31	Sequence 504 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12431	TYLPTTRICITDKDCPSVKNYIGRCRKGYCQASKLR	36	Sequence 505 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12432	NSSFSHFFEGACKSDKDCPKLHRSNVRCRKGQCVQI	36	Sequence 506 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12433	AFIQLSKPCISDKECSIVKNYRARCRKGYCVRRRIR	36	Sequence 507 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12434	FIFLPCITDKDCQTLKKNKGKGRCRKGFCVDGLIG	35	Sequence 508 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12435	KTFDRACKTDKDCPKLRGVNVRCRKDQCVTV	31	Sequence 509 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12436	SFFPSSPVCKTDKDCPQLRGYTARCRKTQCLLIPRG	36	Sequence 510 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12437	HFHVSRPCMTDDDCAPEKYYNIRCRKGFCVQIRKY	35	Sequence 511 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12438	AYFPNSRPCKTDKNCAQVKNYISKCLKGLCVQEE	34	Sequence 512 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12439	AYLPLSRSCITDKDCSRVKNYNARCRKGYCQYLQY	35	Sequence 513 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12440	EEDIGGHLECVEDEDCMEESCPIFSVHKCKNSGCECDEMFR	41	Sequence 514 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12441	NPYIINIVCKTDKDCPKVQGANIKCRSGKCVQA	33	Sequence 515 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12442	KRIPCKDNNDCNNNWQLLACRFEREVPRCINSICKCMPM	39	Sequence 516 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12443	MLVTCEDHFDCRQNVQQVGCSFREIPQCINSICKCMKG	38	Sequence 517 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12444	VNDCIRIHCKDDFDCIENRLQVGCRLQREKPRCVNLVCRCLRR	43	Sequence 518 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12445	VFVSCNSHIHCRVNNHKIGCNIPEQYLLCVNLFCLWLDY	39	Sequence 519 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12446	RPVSCKDHYDCRRKVKIVGCIFPQEKPMCINSMCTCIREIVP	42	Sequence 520 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12447	GLFRCKVDIDCPQILCFDEQIAKCIARMCECDYE	34	Sequence 521 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12448	DFPCKTKDDCAQQIDYIAECIIGFCRYFTPFEHPF	35	Sequence 522 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12449	RNKTCNYSSECLFHNCPLGWVMKCFTYFCACSRL	34	Sequence 523 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12450	DFPCKTKVDCPQHKKYIAECIFGFCRHFKPLEHPF	35	Sequence 524 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12451	VKIPCVKDTDCPTLPCPLYSKCVDGFCKMLSI	32	Sequence 525 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12452	IPCKTKVDCPQQIYYVVECLDGFCDYWRD	29	Sequence 526 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12453	PRIKCNTEADCPQRFDNIVECLFGICHFYIK	31	Sequence 527 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12454	DLSPCLRSGDCSKDECPSHLVPKCIGLTCYCI	32	Sequence 528 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12455	DRIPCIDDMDCPDMFPSLNTQCIDNFCDVVLGYN	34	Sequence 529 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12456	KQTNIPCENKRDCPQPLYPKFVTCFEGLCRMHYPLKKI	38	Sequence 530 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12457	IKIFTEHRCRTDADCPARELPEYLKCQGGMCRLLIKKD	38	Sequence 531 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12458	QITKLPCVTVDDCPKVEKPIPMVAKCFGKRFSRHCHYFYF	40	Sequence 532 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12459	SIKTKIACVTDNDCPRAIKPVVMWCINNYCHYYLYGYQ	38	Sequence 533 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12460	SIPCKTRTQCPEKMCRLPKFVWCIDGSCVCA	31	Sequence 534 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12461	AQFLCSDDSDCPRDLCVRNSLTLRCVNYICQCR	33	Sequence 535 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12462	EKLDIRCATVDDCPKVTKPVVMMCTGKFCHYFFVRKQIL	39	Sequence 536 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12463	ELEIRCVSDADCPLFPLPLHNRCIDDVCHLFTS	33	Sequence 537 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12464	DRIPCATDADGPPKILPIIHKCINNFCKLKLYN	33	Sequence 538 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12465	DRIPCVTNGDCPVMRLPLYMRCITYSCELFFDGPNLCAVERI	42	Sequence 539 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12466	SIHCVSVDDCPKVEKPITMKCINNYCKYFVDHKL	34	Sequence 540 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12467	NMVVLGCVSDDDCPKVPLPRFLKCIANLCCLVRKKDL	37	Sequence 541 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12468	AFVKCETDDDCPKYNGFRKYECVNNWCRLTGLH	33	Sequence 542 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12469	VLIDCKTVKDCPTSYTKIYRCKDNKCRFSFVIGL	34	Sequence 543 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12470	HFGCETDADCPRSTDKNFFLRCINKKCEWAAKRH	34	Sequence 544 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12471	DILCKVHEDCPQKSTHKYYCIDDECFLYYWEAP	33	Sequence 545 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12472	YIACQSEIDCPPNYSFLFAIRCIKQKCVTVGRYL	34	Sequence 546 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12473	FATGMPCKTDKECPNTSTHKYKCINDDCFCFYIYWPLGNSLV	42	Sequence 547 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12474	FFVDIMCKVHEDCPQKSTHKYYCVDDKCFLYYWEGKP	37	Sequence 548 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12475	YVNCETDADCPPSTRVKRFKCVKGECRWTRMSYA	34	Sequence 549 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12476	DIVCITDNDCPPNTLVQGYRCIDGKCESVFLSYR	34	Sequence 550 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12477	IDIFVCQTDADCPKSELSMYTWKCIDNECNLFKVMQQMV	39	Sequence 551 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12478	AELGGPCRSDEECPQLSLRFFAIKCRENVCIYVDLDPYKPRAEKNQFLH	49	Sequence 552 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12479	SDDECKIDGDCPISWQKFHTYKCINQKCKWVLRFHEY	37	Sequence 553 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12480	KLTGCEVDGDCPKVFKLKVMILFIKCINNKCVRGLLSQTGTQCPDFFFLKRTLPRFYF	58	Sequence 554 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12481	QNLMKCNTDDECPKFDDKFPLSFKCINDGCRMVINDKYKHKTVQKLL	47	Sequence 555 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12482	YYYKCFKDSDCVKLLCRIPLRPKCMYRHICKCKVVLTQNNYVLT	44	Sequence 556 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12483	FQPCVTTADCMKTLKTDENIWYECINDFCIPFPIPKGRK	39	Sequence 557 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12484	ELVCDTDDDCLKFFPDNPYPMECINSICLSLTD	33	Sequence 558 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12485	DDVKIKCVVAANCPDLMYPLVYKCLNGICVQFTLTFPFV	39	Sequence 559 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12486	NIHKIGCKTSEDCPYLGKCIEDFCQFKK	28	Sequence 560 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12487	AERIYRCLDHSHCPTFMCSPGLKPKCMNPKVCKCVPVQSRKYYALT	46	Sequence 561 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12488	IDPPHHITNHEIPCKYNHDCPTILDYISICPYHYCEFWRTY	41	Sequence 562 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12489	LYIGCETDRDYPPLANKTFYLKCIDKKCEWTVTDSLSTRSGRMQKLSI	48	Sequence 563 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12490	KKIYCENAASCPRLMYPLVYKCLDNKCVKFMMKSRFV	37	Sequence 564 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12491	IIRCFHDADCVHKICHPPQIRKCVSKICKCRLMITQKDYVLT	42	Sequence 565 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12492	KPFLTRPYPCNTGSDCPQNMCPPGYKPGCEDGYCNHCYKRW	41	Sequence 566 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12493	EPGGHRCSTDSFCPPNMCPPGMTPKCVRFRCKCVPIGWKNLSHVLA	46	Sequence 567 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12494	EQYCVDDADCQKLYPFHRQLSLKCIRAFCVKLVGQANDDLFPSTVHAADATGLGIDAK	58	Sequence 568 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12495	QCIYPACFKDHMCRQLKCSPGRTPKCVNYQCRCSPQALGSYHLLT	45	Sequence 569 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12496	ALIECQIDDDCPPIKFAKYLCINYKCRKICLGE	33	Sequence 570 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12497	EEIIIIKCQTAKDCPDIYNLFPLVYKCIDNICVDVKLEPPYDMSITPNSVHK	52	Sequence 571 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12498	KHDYHMFFQRIPCPKDKILDCNLLECWCK	29	Sequence 572 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12499	RIPCVSRNDCPKRPYPLFMKCIDNFCEIWKIGKE	34	Sequence 573 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12500	IYITFKKFIIDFIHNVYHPSITSNFSLFNNAGDIPNNSNRNSPKEDVFCNSNDDCPTILYYVSKCVYNFCEYW	73	Sequence 574 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12501	KTICIGDSDCRNERCMPGIKPVCSEGWCDCIGFIP	35	Sequence 575 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12502	YVWCETVEDCFKSQYFIFDCINNQCINVGKNPKEPRYPGIPRDQ	44	Sequence 576 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12503	REKVNCLDDADCLEVSCLNGSNAECVGNSCVCVFVFYRENFDEQFRR	47	Sequence 577 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12504	SVPCLTSFGCPRSTCYPPSTPNCILRICECI	31	Sequence 578 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12505	EEWNSHSWNSEFYLKKSCSSDFDCPRTMCIKLSLARCFNDFCHCY	45	Sequence 579 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12506	QTEPPGPLIPCEFDYDCPLIDCIRTSDSRCINGNCHCRE	39	Sequence 580 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12507	RIMVVNPNNPCVTDADCQRYRHKLATRMVCNIGFCLMDFTHDPYAPSLP	49	Sequence 581 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12508	QMINFRGCKRDKDCPQFRGVNIRCRSGFCTPIDS	34	Sequence 582 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12509	KRNYQCDPCFGHPDDMINFCPPGTAPKCFHGLIKCVPIMRGTNRMFA	47	Sequence 583 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12510	LFECNRDFVCGNDDECVYPYAVQCIHRYCKCLKSRN	36	Sequence 584 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12511	TRCNRDEDCPFICTGPQIPKCVSHICFCLSSGKEAY	36	Sequence 585 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12512	IPCNDDVDCPQTLCEQLIADFKYMIDFKSECVSRMCACTGSPV	43	Sequence 586 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12513	AVHKECKTDVDCRQIWFVTKCINHECQPIL	30	Sequence 587 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12514	HACTVNADCEQSMCDPFCVGGYHFTPICVIGWCVCVGNRVAPVL	44	Sequence 588 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12515	HIPCVHHDDCPKRPYPRFMKCVDNFCETWIIGWE	34	Sequence 589 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12516	NIPCNSDSDCPWKIYYTYRCNDGFCVYKSIDPSTIPQYMTDLIFPR	46	Sequence 590 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12517	RQTDIPCKSDDACPRVSSHHIECVKGFCTYWKLD	34	Sequence 591 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12518	EMTTTTIPCTFIDDCPKMPLVVKCIDNFCNYFEIK	35	Sequence 592 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12519	YHLCKTRFDCPRTYLLFFPRMWKCINRRCRYVYFFE	36	Sequence 593 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12520	GMRCNHVSDCPKDTFCWLDSHMQCIKHQCKCVRIFEPIDPA	41	Sequence 594 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12521	YIVCITDNDCPENTEVRQYECIEGRCRLSRVLNP	34	Sequence 595 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12522	GIRCRNVYDCPKATYCRAGSHRVQCIKHQCKCVRIFESIDPA	42	Sequence 596 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12523	CEDDSDCPQIFNFHPFICKCINNECEKVILQKGYMSMKPKILHKRYTRKNEFLH	54	Sequence 597 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12524	SDECVKVSDCSPTKYCLPGRRMICSKGKCKCLRNMFIPIPE	41	Sequence 598 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12525	YVVCRTVDDCPPDTRDLRYRCLNGKCKSYRLSYG	34	Sequence 599 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12526	MTLRPCLTDKDCPRMPPHNIKCRKGHCVPIGKPFK	35	Sequence 600 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12527	NIRCVSDDDCPKVIKPLVMKCIGNYCYFFMIYEGP	35	Sequence 601 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12528	LVIIDHHKPCVSDTDCAFYLDIPPTVKYCSDGLCAWYFPDNPLP	44	Sequence 602 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12529	PCISDDDCPEALSPQFPKCIHNVCVYFVEE	30	Sequence 605 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12530	SYIPISHPCTTVKDCPEVKNYKSRCLKGLCISGRLR	36	Sequence 606 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12531	AYIECEVDDDCPKPMKNSHPDTYYKCVKHRCQWAWK	36	Sequence 607 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12532	EADTSCHSFDDCPWVAHHYRECIEGLCAYRILY	33	Sequence 608 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12533	LETIECETDGDCPRSMIKMWNKNYRHKCIDGKCEWIKKLP	40	Sequence 609 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12534	IYFPVSRPCITDKDCPNMKHYKAKCRKGFCISSRVR	36	Sequence 610 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12535	YIPGIVNKPCKTDKDCPKKPPHNIRCRKGQCVEIL	35	Sequence 611 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12536	KIRCVTDDDCPKVEKPLHMYCGNHWCAYKLHFV	33	Sequence 612 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12537	IPCATSDDCLKNMCRPPLTPRCIEHNCKCK	30	Sequence 613 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12538	KEDDIECVTDADCYEKLPALQRAVMKCIQGFCKIHI	36	Sequence 615 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12539	NSIPCTTHAQCPGDMCELPQIVWCVVGFCECA	32	Sequence 616 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12540	YRSCKTDDDCPDYLCTSPKIGKCMDNDCYCI	31	Sequence 617 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12541	FPWKLYPCVTDKDCPRKNRHVVKCRKGYCVGVQII	35	Sequence 618 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12542	NMVICTQDFDCQTKICPFDLQPKCTILFEFLLSLCGCV	38	Sequence 619 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12543	LAGCITDADCVIKKCSSSCRIKCIDFRCLCPTGF	34	Sequence 620 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12544	SLPDAPPCLFTPECPPDMCPTDLTLKCINLSCQCTIEYDIDPDVVPS	47	Sequence 621 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12545	AILECREDSHCVTKIKCVLPRKPECRNNACTCYKGGFSFHH	41	Sequence 622 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12546	NRFLYRIGCDTSNDCPSYMCPPPLSPRCTKFYCKCI	36	Sequence 623 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12547	EQCVYDADCEKIYPLHRQHLFKCIKAFCVRSS	32	Sequence 624 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12548	DAPPCLFTPECPPDMCPTDLTLKCINLTCQCTSEYDID	38	Sequence 625 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12549	KDDCLVDADCVTLVCEFDERPQCVINTCRCRPLRFSGFYYEQLH	44	Sequence 626 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12550	FEECKEDADCHPVCSVPGCSNICTLPDVPTCIDNNCFCI	39	Sequence 627 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12551	LKIFCIDVADCPKDLYPLLYKCIYNKCIVFTRIPFPFDWI	40	Sequence 628 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12552	CNPCLVTCPDDLLNRCPPGMEPICEYGVIKCYPIGKETNRVLT	43	Sequence 629 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12553	IPDVLPCLFSNECPPDLCPTDLFAKCINLTCQCTAEYDLD	40	Sequence 630 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12554	YPFQECKVDADCPTVCTLPGCPDICSFPDVPTCIDNNCFCT	41	Sequence 631 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12555	EDIGHIKYCGIVDDCYKSKKPLFKIWKCVENVCVLWYK	38	Sequence 632 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12556	NSAFSHFIPGCKTDKDCPKFYGSNVRCRKGKCVQLG	36	Sequence 633 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12557	SEFIFTKKLTSCDSSKDCRSFLCYSPKFPVCKRGICECI	39	Sequence 634 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12558	TFCHDDSHCVTKIKCVLPRTPQCRNEACGCYHSNKFR	37	Sequence 635 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12559	VKSLLLIKVRSFIPCQRSDDCPRNLCVDQIIPTCVWAKCKCKNYND	46	Sequence 636 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12560	NIISCTQDFDCQTKICPFHLKPKCIVLEILPHSLSGGICGCD	42	Sequence 637 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12561	EHIQCVIDDDCPKSLNKLLIIKCINHVCQYVGNLPDFASQIPKSTKMPYKGE	52	Sequence 638 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12562	IHIGCDKDRDCPKQMCHLNQTPKCLKNICKCV	32	Sequence 639 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12563	YNSDCQSYPCDLGESRNCTLNRCICVYNI	29	Sequence 640 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12564	ERECDTDADCQKKFPGSNQHLLWCNNGFCDCRTH	34	Sequence 641 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12565	TFIHFSIPCITDKDCSILQNYKARCRKGYCLRRKIR	36	Sequence 642 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12566	HQSIDDVIPCVLNTDCPRDMCPIHLFPKCINLLCRCSYWEDN	42	Sequence 643 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12567	KNIDGRVSYNSFIALPVCQTAADCPEGTRGRTYKCINNKCRYPKLLKPIQ	50	Sequence 644 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12568	IPCFGTKDKCPFNLYYKVECIDGFCYYPV	29	Sequence 645 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12569	ITISNSSFGRIVYWNCKTDKDCKQHRGFNFRCRSGNCIPIRR	42	Sequence 646 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12570	FNSKIVFTDCKTDKDCQNHRGFNFRCRKGNCVAKIR	36	Sequence 647 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12571	VIDINAFSFPCKTNSDCPSYLCHYPKNPECVERECICW	38	Sequence 648 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12572	SIPCETTADCPVAVPPEYYKCMYKVCVLIR	30	Sequence 649 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12573	IPCLSDDECPEMSHYSFKCNNKICEYDLGEMSDDDYYLEMSRE	43	Sequence 650 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP09788	LPFNLAKPELYIFVQ	15	Sequence 11 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09789	GRFLIRVTSSPLGPD	15	Sequence 12 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09790	TGSGLYLHQMVYLYQ	15	Sequence 13 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09791	FLIDSPLASIGPTSM	15	Sequence 14 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09792	FMIDSPLASIGPTSM	15	Sequence 15 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09793	FLSDPPAPPTSPGVV	15	Sequence 16 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09794	VLAWFSPLTLESSRL	15	Sequence 17 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09795	VIDLSGTRKSSSGTM	15	Sequence 18 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09796	VRKTTSHPPSYALLH	15	Sequence 19 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09797	TPPYRAALATPVLLL	15	Sequence 20 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09798	LSAPSPMFLPPVNPH	15	Sequence 21 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09799	HRPVKTPANAPTTMM	15	Sequence 22 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09800	CFNDPLDIVPPMLLL	15	Sequence 23 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09801	AHAPCSLFFPLSLRP	15	Sequence 24 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09802	KALYALHVPSMQVFA	15	Sequence 25 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09803	RPSRWPWQEPLPISI	15	Sequence 26 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09804	KVQIIPKDTLAPLPP	15	Sequence 27 from Patent US 20100190719	Synthetic construct	Antimicrobial	US 2010/0190719 A1	Patent Application	2010##7##29	CA2687159A1, CN101861329A, EP2160400A1, EP2160400A4, WO2009000017A1	Peptides as antimicrobial agents towards campylobacter spp.	The present invention relates to peptides that exhibit antimicrobial properties towards Campylobacter spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing Campylobacter spp. and for the diagnosis, prevention and treatment of Campylobacter infection.
DRAMP09805	RRRQRRKKR	9	Sequence 2 from Patent US 20100215591	Synthetic construct	Antimicrobial	US 2010/0215591 A1	Patent Application	2010##8##26	CA2694046A1, CN101842107A, CN102872447A, EP2178549A1, WO2009015385A1	Antimicrobial peptide, compositions, and methods of use.	The present invention provides antimicrobial peptides that exhibit a broad range of antimicrobial activity to gram positive and gram negative bacteria, as well as fungi, mold, and virus. The antimicrobial peptide of the invention is a cationic peptide, and may contain an HIV-TAT or reverse HIV-TAT sequence, or derivative thereof. The present invention further provides antimicrobial compositions containing the cationic peptide. Such compositions are especially useful for topical application to the skin, hair, nail, vagina, urethra, ear, oral cavity, nasal passage, respiratory system, opthalmic region, and various mucosal regions. The compositions of the present invention improve the condition and/or appearance of the treated region, and are suited for long-term and/or routine use to, for example, prevent or prevent the recurrence of microbial infection. The present invention further provides kits for use in improving the condition or appearance of skin, nail, or treated area. These kits may facilit
DRAMP09806	RKKRRQRRRGKKKKKKKKKKKKKKKKKKKKGRKKRRQRRR	40	Sequence 3 from Patent US 20100215591	Synthetic construct	Antimicrobial	US 2010/0215591 A1	Patent Application	2010##8##26	CA2694046A1, CN101842107A, CN102872447A, EP2178549A1, WO2009015385A1	Antimicrobial peptide, compositions, and methods of use.	The present invention provides antimicrobial peptides that exhibit a broad range of antimicrobial activity to gram positive and gram negative bacteria, as well as fungi, mold, and virus. The antimicrobial peptide of the invention is a cationic peptide, and may contain an HIV-TAT or reverse HIV-TAT sequence, or derivative thereof. The present invention further provides antimicrobial compositions containing the cationic peptide. Such compositions are especially useful for topical application to the skin, hair, nail, vagina, urethra, ear, oral cavity, nasal passage, respiratory system, opthalmic region, and various mucosal regions. The compositions of the present invention improve the condition and/or appearance of the treated region, and are suited for long-term and/or routine use to, for example, prevent or prevent the recurrence of microbial infection. The present invention further provides kits for use in improving the condition or appearance of skin, nail, or treated area. These kits may facilit
DRAMP09807	RRRQRRKKRGKKKKKKKKKKKKKKKKKKKKGRRRQRRKKR	40	Sequence 4 from Patent US 20100215591	Synthetic construct	Antimicrobial	US 2010/0215591 A1	Patent Application	2010##8##26	CA2694046A1, CN101842107A, CN102872447A, EP2178549A1, WO2009015385A1	Antimicrobial peptide, compositions, and methods of use.	The present invention provides antimicrobial peptides that exhibit a broad range of antimicrobial activity to gram positive and gram negative bacteria, as well as fungi, mold, and virus. The antimicrobial peptide of the invention is a cationic peptide, and may contain an HIV-TAT or reverse HIV-TAT sequence, or derivative thereof. The present invention further provides antimicrobial compositions containing the cationic peptide. Such compositions are especially useful for topical application to the skin, hair, nail, vagina, urethra, ear, oral cavity, nasal passage, respiratory system, opthalmic region, and various mucosal regions. The compositions of the present invention improve the condition and/or appearance of the treated region, and are suited for long-term and/or routine use to, for example, prevent or prevent the recurrence of microbial infection. The present invention further provides kits for use in improving the condition or appearance of skin, nail, or treated area. These kits may facilit
DRAMP09808	RKKRRQRRRGKKKKKKKKKKKKKKKGRKKRRQRRR	35	Sequence 5 from Patent US 20100215591	Synthetic construct	Antimicrobial	US 2010/0215591 A1	Patent Application	2010##8##26	CA2694046A1, CN101842107A, CN102872447A, EP2178549A1, WO2009015385A1	Antimicrobial peptide, compositions, and methods of use.	The present invention provides antimicrobial peptides that exhibit a broad range of antimicrobial activity to gram positive and gram negative bacteria, as well as fungi, mold, and virus. The antimicrobial peptide of the invention is a cationic peptide, and may contain an HIV-TAT or reverse HIV-TAT sequence, or derivative thereof. The present invention further provides antimicrobial compositions containing the cationic peptide. Such compositions are especially useful for topical application to the skin, hair, nail, vagina, urethra, ear, oral cavity, nasal passage, respiratory system, opthalmic region, and various mucosal regions. The compositions of the present invention improve the condition and/or appearance of the treated region, and are suited for long-term and/or routine use to, for example, prevent or prevent the recurrence of microbial infection. The present invention further provides kits for use in improving the condition or appearance of skin, nail, or treated area. These kits may facilit
DRAMP09809	SSRASHFQSHSSERQRHGSSQVWKHGSYGPAEYDYGHTGYGPSGGSRKSISNSHLSWSTDSTANKQLSRH	70	Sequence 2 from Patent US 20110015118	Homo sapiens	Antimicrobial	US 2011/0015118 A1	Patent Application	2011##1##20	DE102007059891A1, EP2217262A2, WO2009074133A2, WO2009074133A3	C-Terminal Ifapsoriasin Fragments as Antimicrobial Peptides, the Production Thereof and Use Thereof.	The present invention relates to novel C-terminal ifapsoriasin fragments as antimicrobially acting peptides and their production and use as pharmaceuticals.
DRAMP09810	SSRASHFQSHSSERQRHGSSQVWKHGSYGPAEYDYGHTGYGPSGGSRKSISNSHL	55	Sequence 3 from Patent US 20110015118	Homo sapiens	Antimicrobial	US 2011/0015118 A1	Patent Application	2011##1##20	DE102007059891A1, EP2217262A2, WO2009074133A2, WO2009074133A3	C-Terminal Ifapsoriasin Fragments as Antimicrobial Peptides, the Production Thereof and Use Thereof.	The present invention relates to novel C-terminal ifapsoriasin fragments as antimicrobially acting peptides and their production and use as pharmaceuticals.
DRAMP09811	KWKSFLKTFSKAKKKVLKTALKAISK	26	Sequence 63 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09812	KWKSFLKTFSKLKKKKLKTLLKLISK	26	Sequence 64 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09813	KWKSFLKTFSKLKKKKLKTLLKAISK	26	Sequence 65 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09814	KWKSFLKTFSKAKKKKLKTLLKAISK	26	Sequence 66 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09815	KLKSLLKTLSKAKKKLLKTALKALSK	26	Sequence 67 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09816	KLKSLLKTLSKAKKKKLKTLLKALSK	26	Sequence 68 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09817	SWSSFLSTFSKAKKKALKTLLSAISS	26	Sequence 69 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09818	SWSSFLKTFSKAKKKALKTLLSAISS	26	Sequence 70 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09819	SWSSFLKTFSKAKKKALKTLLKAISS	26	Sequence 71 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09820	SWKSFLKTFSKAKKKALKTLLKAISS	26	Sequence 72 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09821	SWKSFLKTFSKAKKKALKTLLKAISK	26	Sequence 73 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09822	KWKSFLKTFSKAKKKALKTLLKAISK	26	Sequence 74 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09823	KLKSLLKTLSKLKKKKLKTLLKALSK	26	Sequence 75 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09824	KLKSLLKTLSKLKKKKLKTLLKLLSK	26	Sequence 76 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09825	KXKSXLKTXSKXKKKXLKTXLKXXSK	26	Sequence 77 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09826	XWXSFLXTFSKXKKKXLKTLLXXXSX	26	Sequence 78 from Patent US 20110028386	Synthetic construct	Antimicrobial	US 2011/0028386 A1	Patent Application	2011##2##3	CA2764490A1, EP2437770A2, WO2010141760A2, WO2010141760A3	Antimicrobial Peptides.	Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation. Compositions disclosed herein are useful as antibiotics, incl
DRAMP09827	GIINTLQKYYXRVRGGRXXVLSALPKEEQIGKXSTRGRKXXRRXX	45	Sequence 2 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09828	GIINTLQKYYXRVRGGRXAVLSXLPKEEQIGKXSTRGRKXXRR	43	Sequence 3 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09829	KYYXRVRGGRXAVLSXLPKEEQIGKXSTRGRKXXRRXX	38	Sequence 4 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09830	YXRVRGGRXAVLSXLPKEEQIGKXSTRGRKXXRRXX	36	Sequence 5 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09831	LQKYYXRVRGGRXAVLSXLPKEEQIGKXSTRGRKXXRRXX	40	Sequence 6 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09832	RXAVLSXLPKEEQIGKXSTRGRKXXRRXX	29	Sequence 7 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09833	KEEQIGKXSTRGRKXXRRXX	20	Sequence 8 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09834	KXSTRGRKXXRRXX	14	Sequence 9 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09835	GIINTLQKYYWRVRGGRWAVLSWLPKEEQIGKWSTRGRKWWRRXX	45	Sequence 12 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09836	GIINTLQKYYFRVRGGRFAVLSFLPKEEQIGKFSTRGRKFFRRXX	45	Sequence 13 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09837	GIINTLQKYYYRVRGGRYAVLSYLPKEEQIGKYSTRGRKYYRRXX	45	Sequence 14 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09838	GIINTLQKYYSRVRGGRSAVLSSLPKEEQIGKSSTRGRKSSRRXX	45	Sequence 15 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09839	GIINTLQKYYARVRGGRAAVLSALPKEEQIGKASTRGRKAARRXX	45	Sequence 16 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09840	RGRKXXRRXX	10	Sequence 25 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09841	RGRKWWRRXX	10	Sequence 26 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09842	RGRKFFRRXX	10	Sequence 27 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09843	RGRKYYRRXX	10	Sequence 28 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09844	RGRKLLRRXX	10	Sequence 29 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09845	RGRKIIRRXX	10	Sequence 30 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09846	RGRKHHRRXX	10	Sequence 31 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09847	RGRKVVRRXX	10	Sequence 33 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09848	RGRKCCRRXX	10	Sequence 34 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09849	RGRKXXRR	8	Sequence 36 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09850	RGRKWWRR	8	Sequence 37 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09851	RGRKFFRR	8	Sequence 38 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09852	RGRKYYRR	8	Sequence 39 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09853	RGRKLLRR	8	Sequence 40 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09854	RGRKIIRR	8	Sequence 41 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09855	RGRKHHRR	8	Sequence 42 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09856	RGRKVVRR	8	Sequence 44 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09857	RGRKVVRRVV	10	Sequence 46 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09858	RGRKYYRRYY	10	Sequence 47 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09859	RGRKWWRRWW	10	Sequence 48 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09860	RVRKVVRR	8	Sequence 49 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09861	RRRKVVRR	8	Sequence 50 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09862	RDRKVVRR	8	Sequence 51 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09863	RGRKEERR	8	Sequence 52 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09864	RGRKKKRR	8	Sequence 53 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09865	RRRRRRRRRR	10	Sequence 54 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09866	VVVV	4	Sequence 55 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09867	YYYY	4	Sequence 56 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09868	RRVVKRGR	8	Sequence 57 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09869	RRVVKRGRK	9	Sequence 58 from Patent US 20110039760	Synthetic construct	Antimicrobial	US 2011/0039760 A1	Patent Application	2011##2##17	EP2279202A1, EP2279202A4, WO2009131548A1, WO2009131548A8	Multimeric forms of antimicrobial peptides.	The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
DRAMP09870	KKIRVRLSA	9	Sequence 1 from Patent US 20110190198	Synthetic construct	Antimicrobial	US 2011/0190198 A1	Patent Application	2011##8##4	CN102170899A, EP2344178A1, WO2010038220A1	Peptide sequnces, their branched form and use thereof for antimicrobial applications.	The present invention relates to an antibacterial peptide having from the amino to the carboxylic terminal an amino acid sequences selected from the group of: KKIRVRLSA, SEQ ID NO. 1, RRIRVRLSA, SEQ ID NO. 2, KRIRVRLSA, SEQ ID NO. 3, RKIRVRLSA, SEQ ID NO. 4 or a derivative thereof and uses thereof.
DRAMP09871	RRIRVRLSA	9	Sequence 2 from Patent US 20110190198	Synthetic construct	Antimicrobial	US 2011/0190198 A1	Patent Application	2011##8##4	CN102170899A, EP2344178A1, WO2010038220A1	Peptide sequnces, their branched form and use thereof for antimicrobial applications.	The present invention relates to an antibacterial peptide having from the amino to the carboxylic terminal an amino acid sequences selected from the group of: KKIRVRLSA, SEQ ID NO. 1, RRIRVRLSA, SEQ ID NO. 2, KRIRVRLSA, SEQ ID NO. 3, RKIRVRLSA, SEQ ID NO. 4 or a derivative thereof and uses thereof.
DRAMP09872	KRIRVRLSA	9	Sequence 3 from Patent US 20110190198	Synthetic construct	Antimicrobial	US 2011/0190198 A1	Patent Application	2011##8##4	CN102170899A, EP2344178A1, WO2010038220A1	Peptide sequnces, their branched form and use thereof for antimicrobial applications.	The present invention relates to an antibacterial peptide having from the amino to the carboxylic terminal an amino acid sequences selected from the group of: KKIRVRLSA, SEQ ID NO. 1, RRIRVRLSA, SEQ ID NO. 2, KRIRVRLSA, SEQ ID NO. 3, RKIRVRLSA, SEQ ID NO. 4 or a derivative thereof and uses thereof.
DRAMP09873	RKIRVRLSA	9	Sequence 4 from Patent US 20110190198	Synthetic construct	Antimicrobial	US 2011/0190198 A1	Patent Application	2011##8##4	CN102170899A, EP2344178A1, WO2010038220A1	Peptide sequnces, their branched form and use thereof for antimicrobial applications.	The present invention relates to an antibacterial peptide having from the amino to the carboxylic terminal an amino acid sequences selected from the group of: KKIRVRLSA, SEQ ID NO. 1, RRIRVRLSA, SEQ ID NO. 2, KRIRVRLSA, SEQ ID NO. 3, RKIRVRLSA, SEQ ID NO. 4 or a derivative thereof and uses thereof.
DRAMP09874	QKKIRVRLSA	10	Sequence 5 from Patent US 20110190198	Synthetic construct	Antimicrobial	US 2011/0190198 A1	Patent Application	2011##8##4	CN102170899A, EP2344178A1, WO2010038220A1	Peptide sequnces, their branched form and use thereof for antimicrobial applications.	The present invention relates to an antibacterial peptide having from the amino to the carboxylic terminal an amino acid sequences selected from the group of: KKIRVRLSA, SEQ ID NO. 1, RRIRVRLSA, SEQ ID NO. 2, KRIRVRLSA, SEQ ID NO. 3, RKIRVRLSA, SEQ ID NO. 4 or a derivative thereof and uses thereof.
DRAMP09875	SDDPKESEGDLHCVCVKTTSLVRPRHITNLELIKAGGHCPTANLIATKKNGRKLCLDLQAALYKKKIIKKLLES	74	Sequence 1 from Patent US 20110190474	Oryctolagus cuniculus	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09876	SDDPKESEGDLHCVCVKTTSLVRPGHITNLELIKAGGHCPTANLIATKKNGRKLCLDLQAALYKKKIIKKLLES	74	Sequence 2 from Patent US 20110190474	Oryctolagus cuniculus	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09877	ALYKKFKKKLLKSLKRLG	18	Sequence 3 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09878	ARYKKFKKKLLKS	13	Sequence 4 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09879	KLYRKFKNKLLKLK	14	Sequence 5 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09880	ARYRKFKNKILKS	13	Sequence 6 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09881	ARYRKFRNKILRS	13	Sequence 7 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09882	KLYKKWKKKLLKLK	14	Sequence 8 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09883	ALYKKWKNKLLKS	13	Sequence 9 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09884	KLYKKWKNKLKRSLKRLG	18	Sequence 10 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09885	ALYKKLFKKLLKR	13	Sequence 11 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09886	GLYKRLFKKLLKS	13	Sequence 12 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09887	ALYKRLFKKLKKF	13	Sequence 13 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09888	ATKKNGRKLCLDLQAAL	17	Sequence 14 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09889	RFEKSKIK	8	Sequence 15 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09890	SAIHPSSILKLEVICIGVLQ	20	Sequence 16 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09891	YAERLCTCSIKAEV	14	Sequence 17 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09892	KFKHYFFWKYK	11	Sequence 18 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09893	KGYFYFLFKFK	11	Sequence 19 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09894	KWKWWWWWKWK	11	Sequence 20 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09895	PRIKKIVQKKLAG	13	Sequence 21 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09896	KWVREYINSLEMSKKGLAG	19	Sequence 22 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09897	EWVQKYVSDLELSAWKKILK	20	Sequence 23 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09898	SWVQEYVYDLEL	12	Sequence 24 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09899	ADSGEGDFLAEGGGVR	16	Sequence 25 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09900	ADSGEGDFLAEGGGVRKLIK	20	Sequence 26 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09901	EGVNDNEEGFFSA	13	Sequence 27 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09902	KFDKSKLKKTETQEKNPL	18	Sequence 28 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09903	ANLIATKKNGRKLCL	15	Sequence 29 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09904	IATKKNGRKLCLDLQAALYKKKIIKKLLES	30	Sequence 30 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09905	TNLELIKAGGHCPTANLIATKKNGRKLCLDLQAALYKKKIIKKLLES	47	Sequence 31 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09906	NLIATKKNGRKLCLDLQAALYKKKIIKKLLES	32	Sequence 32 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09907	QAALYKKKIIKKLLES	16	Sequence 33 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09908	ALYKKFKKKLLKSLKRLGALYKKKL	25	Sequence 34 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09909	ALYKKFKKKLLKSLKRLGATKKNGRKLCLDLQAAL	35	Sequence 35 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09910	ATKKNGRKLCLDLQAALY	18	Sequence 36 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09911	CALYKKFKKKLLKSLKRLG	19	Sequence 37 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09912	ALYKKFKKKLLKCLKRLG	18	Sequence 38 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09913	ALYKKFKKKLLKSLKRLGC	19	Sequence 39 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09914	CALYKKFKKKLLKSLKRLGC	20	Sequence 40 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09915	ARYKKFKKKLLKSLKRLG	18	Sequence 41 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09916	ALYKKFKKKFLKSLKRLG	18	Sequence 42 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09917	ARYKKFKKKFLKSLKRLG	18	Sequence 43 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09918	GLRKLSKLLKKKFKKYLA	18	Sequence 44 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09919	LAAQLDLCLKRGNKKTA	17	Sequence 45 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09920	ALYKKFKKKLCLDLQAAL	18	Sequence 46 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09921	ATKKNGRKLCLKSLKRLG	18	Sequence 47 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09922	ATKKNGRKLCLDLQAALYKKK	21	Sequence 48 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09923	ATRRNGRRLCLDLQAALYRRR	21	Sequence 49 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09924	ATKKNGKKLCLDLQAALYKKK	21	Sequence 50 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09925	ATKKNGRKLCLELQAALYKKK	21	Sequence 51 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09926	ATEENGRELCLDLQAALYEEE	21	Sequence 52 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09927	ATKKNGRKLCLKLQAALYKKK	21	Sequence 53 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09928	ATKKNGEKLCLDLQAALYKKK	21	Sequence 54 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09929	ATKKNGGKLCLDLQAALYKKK	21	Sequence 55 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09930	ATKKNGRKLCLGLQAALYKKK	21	Sequence 56 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09931	ATKKNGRKLCLDLQAALFKKK	21	Sequence 57 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09932	ATKKNGRKLCLDLQAALWKKK	21	Sequence 58 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09933	KKKYLAAQLDLCLKRGNKKTA	21	Sequence 59 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09934	ATKKNGRKLCLDLQAALYKK	20	Sequence 60 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09935	ATRRNGRRLCLDLQAALYRR	20	Sequence 61 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09936	ATKKNGKKLCLDLQAALYKK	20	Sequence 62 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09937	ATKKNGRKLCLELQAALYKK	20	Sequence 63 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09938	ATEENGRELCLDLQAALYEE	20	Sequence 64 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09939	ATKKNGRKLCLKLQAALYKK	20	Sequence 65 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09940	ATKKNGEKLCLDLQAALYKK	20	Sequence 66 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09941	ATKKNGGKLCLDLQAALYKK	20	Sequence 67 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09942	ATKKNGRKLCLGLQAALYKK	20	Sequence 68 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09943	ATKKNGRKLCLDLQAALFKK	20	Sequence 69 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09944	ATKKNGRKLCLDLQAALWKK	20	Sequence 70 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09945	KKYLAAQLDLCLKRGNKKTA	20	Sequence 71 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09946	TKKNGRKLCLDLQAALYKKK	20	Sequence 72 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09947	TRRNGRRLCLDLQAALYRRR	20	Sequence 73 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09948	TKKNGKKLCLDLQAALYKKK	20	Sequence 74 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09949	TKKNGRKLCLELQAALYKKK	20	Sequence 75 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09950	TEENGRELCLDLQAALYEEE	20	Sequence 76 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09951	TKKNGRKLCLKLQAALYKKK	20	Sequence 77 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09952	TKKNGEKLCLDLQAALYKKK	20	Sequence 78 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09953	TKKNGGKLCLDLQAALYKKK	20	Sequence 79 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09954	TKKNGRKLCLGLQAALYKKK	20	Sequence 80 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09955	TKKNGRKLCLDLQAALFKKK	20	Sequence 81 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09956	TKKNGRKLCLDLQAALWKKK	20	Sequence 82 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09957	TKKNGRKLCLDLQAALYKK	19	Sequence 84 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09958	TRRNGRRLCLDLQAALYRR	19	Sequence 85 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09959	TKKNGKKLCLDLQAALYKK	19	Sequence 86 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09960	TKKNGRKLCLELQAALYKK	19	Sequence 87 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09961	TEENGRELCLDLQAALYEE	19	Sequence 88 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09962	TKKNGRKLCLKLQAALYKK	19	Sequence 89 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09963	TKKNGEKLCLDLQAALYKK	19	Sequence 90 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09964	TKKNGGKLCLDLQAALYKK	19	Sequence 91 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09965	TKKNGRKLCLGLQAALYKK	19	Sequence 92 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09966	TKKNGRKLCLDLQAALFKK	19	Sequence 93 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09967	TKKNGRKLCLDLQAALWKK	19	Sequence 94 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09968	KKYLAAQLDLCLKRGNKKT	19	Sequence 95 from Patent US 20110190474	Oryctolagus cuniculus	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09969	SDDPKESEGDLHCVCVKTTSLV	22	Sequence 96 from Patent US 20110190474	Oryctolagus cuniculus	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09970	SDDPKESEGDLHCVCVKTTSLVRPRHITNLELIKAGG	37	Sequence 97 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09971	SDDPKESEGDLHCVCVKTTSKV	22	Sequence 98 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09972	SDDPKESEGELRCVCVKTTSLV	22	Sequence 99 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09973	SDDPKESEGELRCVCVKTTSKV	22	Sequence 100 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09974	SDDPKESEGDLHCCVKTTSKV	21	Sequence 101 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09975	SDDPKESEGELRCCVKTTSLV	21	Sequence 102 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09976	SDDPKESEGELRCCVKTTSKV	21	Sequence 103 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09977	ALYKKFKKKLLKSLKRLGSDDPKESEGDLHCVCVKTTSLV	40	Sequence 104 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09978	ALYKRLFKKLKKFSDDPKESEGDLHCVCVKTTSLV	35	Sequence 105 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09979	ALTKKFKKKLLKSLKRLGSDDPKESEGELRCVCVKTTSKV	40	Sequence 106 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09980	EWVQKYVSNLELSAWKKILK	20	Sequence 107 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09981	SWVQEYVYNLEL	12	Sequence 108 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09982	ANSGEGNFLAEGGGVR	16	Sequence 109 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09983	ANSGEGNFLAEGGGVRKLIK	20	Sequence 110 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09984	KFNKSKLKKTETQEKNPL	18	Sequence 111 from Patent US 20110190474	Synthetic construct	Antimicrobial	US 2011/0190474 A1	Patent Application	2011##8##4	US7820619, WO2002055554A2, WO2002055554A3	Antimicrobial peptides and derived metapeptides.	The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
DRAMP09985	QRLRIRVAVIRA	12	Sequence 1 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09986	VQLRIRVAVIRA	12	Sequence 2 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09987	VRFRIRVAVIRA	12	Sequence 3 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09988	VRWRIRVAVIRA	12	Sequence 4 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09989	VRLWIRVAVIRA	12	Sequence 5 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09990	VRLRIRVWVIRA	12	Sequence 6 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09991	VRLRIRVAVRRA	12	Sequence 7 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09992	VRLRIRVAVIRK	12	Sequence 8 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09993	VQLRIRVRVIRK	12	Sequence 9 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09994	KRFRIRVAVRRA	12	Sequence 10 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09995	VRLRIRVRVIRK	12	Sequence 11 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09996	KQFRIRVRVIRK	12	Sequence 12 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09997	HQFRFRFRVRRK	12	Sequence 13 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09998	HQWRIRVAVRRH	12	Sequence 14 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP09999	KRFRIRVRVIRK	12	Sequence 15 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10000	KRWRIRVRVIRK	12	Sequence 16 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10001	KIWVRWK	7	Sequence 17 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10002	IWVIWRR	7	Sequence 18 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10003	ALPWKWPWWPWRR	13	Sequence 19 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10004	IAPWKWPWWPWRR	13	Sequence 20 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10005	ILAWKWPWWPWRR	13	Sequence 21 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10006	ILPAKWPWWPWRR	13	Sequence 22 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10007	ILPWAWPWWPWRR	13	Sequence 23 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10008	ILPWKAPWWPWRR	13	Sequence 24 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10009	ILPWKWAWWPWRR	13	Sequence 25 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10010	ILPWKWPAWPWRR	13	Sequence 26 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10011	ILPWKWPWAPWRR	13	Sequence 27 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10012	ILPWKWPWWAWRR	13	Sequence 28 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10013	ILPWKWPWWPARR	13	Sequence 29 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10014	ILPWKWPWWPWAR	13	Sequence 30 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10015	ILPWKWPWWPWRA	13	Sequence 31 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10016	DLPWKWPWWPWRR	13	Sequence 32 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10017	IDPWKWPWWPWRR	13	Sequence 33 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10018	ILDWKWPWWPWRR	13	Sequence 34 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10019	ILPDKWPWWPWRR	13	Sequence 35 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10020	ILPWDWPWWPWRR	13	Sequence 36 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10021	ILPWKDPWWPWRR	13	Sequence 37 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10022	ILPWKWDWWPWRR	13	Sequence 38 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10023	ILPWKWPDWPWRR	13	Sequence 39 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10024	ILPWKWPWDPWRR	13	Sequence 40 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10025	ILPWKWPWWDWRR	13	Sequence 41 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10026	ILPWKWPWWPDRR	13	Sequence 42 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10027	ILPWKWPWWPWDR	13	Sequence 43 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10028	ILPWKWPWWPWRD	13	Sequence 44 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10029	ELPWKWPWWPWRR	13	Sequence 45 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10030	IEPWKWPWWPWRR	13	Sequence 46 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10031	ILEWKWPWWPWRR	13	Sequence 47 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10032	ILPEKWPWWPWRR	13	Sequence 48 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10033	ILPWEWPWWPWRR	13	Sequence 49 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10034	ILPWKEPWWPWRR	13	Sequence 50 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10035	ILPWKWEWWPWRR	13	Sequence 51 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10036	ILPWKWPEWPWRR	13	Sequence 52 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10037	ILPWKWPWEPWRR	13	Sequence 53 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10038	ILPWKWPWWEWRR	13	Sequence 54 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10039	ILPWKWPWWPERR	13	Sequence 55 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10040	ILPWKWPWWPWER	13	Sequence 56 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10041	ILPWKWPWWPWRE	13	Sequence 57 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10042	FLPWKWPWWPWRR	13	Sequence 58 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10043	IFPWKWPWWPWRR	13	Sequence 59 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10044	ILFWKWPWWPWRR	13	Sequence 60 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10045	ILPFKWPWWPWRR	13	Sequence 61 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10046	ILPWFWPWWPWRR	13	Sequence 62 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10047	ILPWKFPWWPWRR	13	Sequence 63 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10048	ILPWKWFWWPWRR	13	Sequence 64 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10049	ILPWKWPFWPWRR	13	Sequence 65 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10050	ILPWKWPWFPWRR	13	Sequence 66 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10051	ILPWKWPWWFWRR	13	Sequence 67 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10052	ILPWKWPWWPFRR	13	Sequence 68 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10053	ILPWKWPWWPWFR	13	Sequence 69 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10054	ILPWKWPWWPWRF	13	Sequence 70 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10055	GLPWKWPWWPWRR	13	Sequence 71 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10056	IGPWKWPWWPWRR	13	Sequence 72 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10057	ILGWKWPWWPWRR	13	Sequence 73 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10058	ILPGKWPWWPWRR	13	Sequence 74 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10059	ILPWGWPWWPWRR	13	Sequence 75 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10060	ILPWKGPWWPWRR	13	Sequence 76 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10061	ILPWKWGWWPWRR	13	Sequence 77 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10062	ILPWKWPGWPWRR	13	Sequence 78 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10063	ILPWKWPWGPWRR	13	Sequence 79 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10064	ILPWKWPWWGWRR	13	Sequence 80 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10065	ILPWKWPWWPGRR	13	Sequence 81 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10066	ILPWKWPWWPWGR	13	Sequence 82 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10067	ILPWKWPWWPWRG	13	Sequence 83 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10068	HLPWKWPWWPWRR	13	Sequence 84 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10069	IHPWKWPWWPWRR	13	Sequence 85 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10070	ILHWKWPWWPWRR	13	Sequence 86 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10071	ILPHKWPWWPWRR	13	Sequence 87 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10072	ILPWHWPWWPWRR	13	Sequence 88 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10073	ILPWKHPWWPWRR	13	Sequence 89 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10074	ILPWKWHWWPWRR	13	Sequence 90 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10075	ILPWKWPHWPWRR	13	Sequence 91 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10076	ILPWKWPWHPWRR	13	Sequence 92 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10077	ILPWKWPWWHWRR	13	Sequence 93 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10078	ILPWKWPWWPHRR	13	Sequence 94 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10079	ILPWKWPWWPWHR	13	Sequence 95 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10080	ILPWKWPWWPWRH	13	Sequence 96 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10081	IIPWKWPWWPWRR	13	Sequence 97 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10082	ILIWKWPWWPWRR	13	Sequence 98 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10083	ILPIKWPWWPWRR	13	Sequence 99 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10084	ILPWIWPWWPWRR	13	Sequence 100 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10085	ILPWKIPWWPWRR	13	Sequence 101 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10086	ILPWKWIWWPWRR	13	Sequence 102 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10087	ILPWKWPIWPWRR	13	Sequence 103 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10088	ILPWKWPWIPWRR	13	Sequence 104 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10089	ILPWKWPWWIWRR	13	Sequence 105 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10090	ILPWKWPWWPIRR	13	Sequence 106 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10091	ILPWKWPWWPWIR	13	Sequence 107 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10092	ILPWKWPWWPWRI	13	Sequence 108 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10093	KLPWKWPWWPWRR	13	Sequence 109 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10094	IKPWKWPWWPWRR	13	Sequence 110 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10095	ILKWKWPWWPWRR	13	Sequence 111 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10096	ILPKKWPWWPWRR	13	Sequence 112 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10097	ILPWKKPWWPWRR	13	Sequence 113 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10098	ILPWKWKWWPWRR	13	Sequence 114 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10099	ILPWKWPKWPWRR	13	Sequence 115 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10100	ILPWKWPWKPWRR	13	Sequence 116 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10101	ILPWKWPWWKWRR	13	Sequence 117 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10102	ILPWKWPWWPKRR	13	Sequence 118 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10103	ILPWKWPWWPWKR	13	Sequence 119 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10104	ILPWKWPWWPWRK	13	Sequence 120 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10105	LLPWKWPWWPWRR	13	Sequence 121 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10106	ILLWKWPWWPWRR	13	Sequence 122 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10107	ILPLKWPWWPWRR	13	Sequence 123 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10108	ILPWLWPWWPWRR	13	Sequence 124 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10109	ILPWKLPWWPWRR	13	Sequence 125 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10110	ILPWKWLWWPWRR	13	Sequence 126 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10111	ILPWKWPLWPWRR	13	Sequence 127 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10112	ILPWKWPWLPWRR	13	Sequence 128 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10113	ILPWKWPWWLWRR	13	Sequence 129 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10114	ILPWKWPWWPLRR	13	Sequence 130 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10115	ILPWKWPWWPWLR	13	Sequence 131 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10116	ILPWKWPWWPWRL	13	Sequence 132 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10117	MLPWKWPWWPWRR	13	Sequence 133 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10118	IMPWKWPWWPWRR	13	Sequence 134 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10119	ILMWKWPWWPWRR	13	Sequence 135 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10120	ILPMKWPWWPWRR	13	Sequence 136 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10121	ILPWMWPWWPWRR	13	Sequence 137 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10122	ILPWKMPWWPWRR	13	Sequence 138 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10123	ILPWKWMWWPWRR	13	Sequence 139 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10124	ILPWKWPMWPWRR	13	Sequence 140 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10125	ILPWKWPWMPWRR	13	Sequence 141 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10126	ILPWKWPWWMWRR	13	Sequence 142 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10127	ILPWKWPWWPMRR	13	Sequence 143 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10128	ILPWKWPWWPWMR	13	Sequence 144 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10129	ILPWKWPWWPWRM	13	Sequence 145 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10130	NLPWKWPWWPWRR	13	Sequence 146 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10131	INPWKWPWWPWRR	13	Sequence 147 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10132	ILNWKWPWWPWRR	13	Sequence 148 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10133	ILPNKWPWWPWRR	13	Sequence 149 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10134	ILPWNWPWWPWRR	13	Sequence 150 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10135	ILPWKNPWWPWRR	13	Sequence 151 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10136	ILPWKWNWWPWRR	13	Sequence 152 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10137	ILPWKWPNWPWRR	13	Sequence 153 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10138	ILPWKWPWNPWRR	13	Sequence 154 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10139	ILPWKWPWWNWRR	13	Sequence 155 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10140	ILPWKWPWWPNRR	13	Sequence 156 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10141	ILPWKWPWWPWNR	13	Sequence 157 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10142	ILPWKWPWWPWRN	13	Sequence 158 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10143	PLPWKWPWWPWRR	13	Sequence 159 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10144	IPPWKWPWWPWRR	13	Sequence 160 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10145	ILPPKWPWWPWRR	13	Sequence 161 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10146	ILPWPWPWWPWRR	13	Sequence 162 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10147	ILPWKPPWWPWRR	13	Sequence 163 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10148	ILPWKWPPWPWRR	13	Sequence 164 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10149	ILPWKWPWPPWRR	13	Sequence 165 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10150	ILPWKWPWWPPRR	13	Sequence 166 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10151	ILPWKWPWWPWPR	13	Sequence 167 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10152	ILPWKWPWWPWRP	13	Sequence 168 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10153	QLPWKWPWWPWRR	13	Sequence 169 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10154	IQPWKWPWWPWRR	13	Sequence 170 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10155	ILQWKWPWWPWRR	13	Sequence 171 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10156	ILPQKWPWWPWRR	13	Sequence 172 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10157	ILPWQWPWWPWRR	13	Sequence 173 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10158	ILPWKQPWWPWRR	13	Sequence 174 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10159	ILPWKWQWWPWRR	13	Sequence 175 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10160	ILPWKWPQWPWRR	13	Sequence 176 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10161	ILPWKWPWQPWRR	13	Sequence 177 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10162	ILPWKWPWWQWRR	13	Sequence 178 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10163	ILPWKWPWWPQRR	13	Sequence 179 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10164	ILPWKWPWWPWQR	13	Sequence 180 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10165	ILPWKWPWWPWRQ	13	Sequence 181 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10166	RLPWKWPWWPWRR	13	Sequence 182 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10167	IRPWKWPWWPWRR	13	Sequence 183 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10168	ILRWKWPWWPWRR	13	Sequence 184 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10169	ILPRKWPWWPWRR	13	Sequence 185 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10170	ILPWRWPWWPWRR	13	Sequence 186 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10171	ILPWKRPWWPWRR	13	Sequence 187 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10172	ILPWKWRWWPWRR	13	Sequence 188 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10173	ILPWKWPRWPWRR	13	Sequence 189 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10174	ILPWKWPWRPWRR	13	Sequence 190 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10175	ILPWKWPWWRWRR	13	Sequence 191 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10176	ILPWKWPWWPRRR	13	Sequence 192 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10177	SLPWKWPWWPWRR	13	Sequence 193 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10178	ISPWKWPWWPWRR	13	Sequence 194 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10179	ILSWKWPWWPWRR	13	Sequence 195 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10180	ILPSKWPWWPWRR	13	Sequence 196 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10181	ILPWSWPWWPWRR	13	Sequence 197 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10182	ILPWKSPWWPWRR	13	Sequence 198 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10183	ILPWKWSWWPWRR	13	Sequence 199 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10184	ILPWKWPSWPWRR	13	Sequence 200 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10185	ILPWKWPWSPWRR	13	Sequence 201 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10186	ILPWKWPWWSWRR	13	Sequence 202 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10187	ILPWKWPWWPSRR	13	Sequence 203 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10188	ILPWKWPWWPWSR	13	Sequence 204 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10189	ILPWKWPWWPWRS	13	Sequence 205 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10190	TLPWKWPWWPWRR	13	Sequence 206 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10191	ITPWKWPWWPWRR	13	Sequence 207 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10192	ILTWKWPWWPWRR	13	Sequence 208 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10193	ILPTKWPWWPWRR	13	Sequence 209 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10194	ILPWTWPWWPWRR	13	Sequence 210 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10195	ILPWKTPWWPWRR	13	Sequence 211 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10196	ILPWKWTWWPWRR	13	Sequence 212 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10197	ILPWKWPTWPWRR	13	Sequence 213 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10198	ILPWKWPWTPWRR	13	Sequence 214 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10199	ILPWKWPWWTWRR	13	Sequence 215 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10200	ILPWKWPWWPTRR	13	Sequence 216 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10201	ILPWKWPWWPWTR	13	Sequence 217 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10202	ILPWKWPWWPWRT	13	Sequence 218 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10203	VLPWKWPWWPWRR	13	Sequence 219 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10204	IVPWKWPWWPWRR	13	Sequence 220 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10205	ILVWKWPWWPWRR	13	Sequence 221 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10206	ILPVKWPWWPWRR	13	Sequence 222 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10207	ILPWVWPWWPWRR	13	Sequence 223 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10208	ILPWKVPWWPWRR	13	Sequence 224 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10209	ILPWKWVWWPWRR	13	Sequence 225 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10210	ILPWKWPVWPWRR	13	Sequence 226 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10211	ILPWKWPWVPWRR	13	Sequence 227 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10212	ILPWKWPWWVWRR	13	Sequence 228 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10213	ILPWKWPWWPVRR	13	Sequence 229 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10214	ILPWKWPWWPWVR	13	Sequence 230 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10215	ILPWKWPWWPWRV	13	Sequence 231 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10216	WLPWKWPWWPWRR	13	Sequence 232 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10217	IWPWKWPWWPWRR	13	Sequence 233 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10218	ILWWKWPWWPWRR	13	Sequence 234 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10219	ILPWWWPWWPWRR	13	Sequence 235 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10220	ILPWKWWWWPWRR	13	Sequence 236 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10221	ILPWKWPWWWWRR	13	Sequence 237 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10222	ILPWKWPWWPWWR	13	Sequence 238 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10223	ILPWKWPWWPWRW	13	Sequence 239 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10224	YLPWKWPWWPWRR	13	Sequence 240 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10225	IYPWKWPWWPWRR	13	Sequence 241 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10226	ILYWKWPWWPWRR	13	Sequence 242 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10227	ILPYKWPWWPWRR	13	Sequence 243 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10228	ILPWYWPWWPWRR	13	Sequence 244 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10229	ILPWKYPWWPWRR	13	Sequence 245 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10230	ILPWKWYWWPWRR	13	Sequence 246 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10231	ILPWKWPYWPWRR	13	Sequence 247 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10232	ILPWKWPWYPWRR	13	Sequence 248 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10233	ILPWKWPWWYWRR	13	Sequence 249 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10234	ILPWKWPWWPYRR	13	Sequence 250 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10235	ILPWKWPWWPWYR	13	Sequence 251 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10236	ILPWKWPWWPWRY	13	Sequence 252 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10237	ARLRIRVAVIRA	12	Sequence 253 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10238	DRLRIRVAVIRA	12	Sequence 254 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10239	ERLRIRVAVIRA	12	Sequence 255 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10240	FRLRIRVAVIRA	12	Sequence 256 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10241	GRLRIRVAVIRA	12	Sequence 257 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10242	HRLRIRVAVIRA	12	Sequence 258 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10243	IRLRIRVAVIRA	12	Sequence 259 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10244	KRLRIRVAVIRA	12	Sequence 260 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10245	LRLRIRVAVIRA	12	Sequence 261 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10246	MRLRIRVAVIRA	12	Sequence 262 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10247	NRLRIRVAVIRA	12	Sequence 263 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10248	PRLRIRVAVIRA	12	Sequence 264 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10249	RRLRIRVAVIRA	12	Sequence 266 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10250	SRLRIRVAVIRA	12	Sequence 267 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10251	TRLRIRVAVIRA	12	Sequence 268 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10252	WRLRIRVAVIRA	12	Sequence 269 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10253	YRLRIRVAVIRA	12	Sequence 270 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10254	VALRIRVAVIRA	12	Sequence 271 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10255	VDLRIRVAVIRA	12	Sequence 272 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10256	VELRIRVAVIRA	12	Sequence 273 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10257	VFLRIRVAVIRA	12	Sequence 274 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10258	VGLRIRVAVIRA	12	Sequence 275 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10259	VHLRIRVAVIRA	12	Sequence 276 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10260	VILRIRVAVIRA	12	Sequence 277 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10261	VKLRIRVAVIRA	12	Sequence 278 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10262	VLLRIRVAVIRA	12	Sequence 279 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10263	VMLRIRVAVIRA	12	Sequence 280 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10264	VNLRIRVAVIRA	12	Sequence 281 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10265	VPLRIRVAVIRA	12	Sequence 282 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10266	VSLRIRVAVIRA	12	Sequence 284 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10267	VTLRIRVAVIRA	12	Sequence 285 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10268	VVLRIRVAVIRA	12	Sequence 286 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10269	VWLRIRVAVIRA	12	Sequence 287 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10270	VYLRIRVAVIRA	12	Sequence 288 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10271	VRARIRVAVIRA	12	Sequence 289 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10272	VRDRIRVAVIRA	12	Sequence 290 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10273	VRERIRVAVIRA	12	Sequence 291 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10274	VRGRIRVAVIRA	12	Sequence 293 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10275	VRHRIRVAVIRA	12	Sequence 294 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10276	VRIRIRVAVIRA	12	Sequence 295 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10277	VRKRIRVAVIRA	12	Sequence 296 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10278	VRMRIRVAVIRA	12	Sequence 297 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10279	VRNRIRVAVIRA	12	Sequence 298 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10280	VRPRIRVAVIRA	12	Sequence 299 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10281	VRQRIRVAVIRA	12	Sequence 300 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10282	VRRRIRVAVIRA	12	Sequence 301 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10283	VRSRIRVAVIRA	12	Sequence 302 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10284	VRTRIRVAVIRA	12	Sequence 303 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10285	VRVRIRVAVIRA	12	Sequence 304 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10286	VRYRIRVAVIRA	12	Sequence 306 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10287	VRLAIRVAVIRA	12	Sequence 307 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10288	VRLDIRVAVIRA	12	Sequence 308 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10289	VRLEIRVAVIRA	12	Sequence 309 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10290	VRLFIRVAVIRA	12	Sequence 310 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10291	VRLGIRVAVIRA	12	Sequence 311 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10292	VRLHIRVAVIRA	12	Sequence 312 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10293	VRLIIRVAVIRA	12	Sequence 313 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10294	VRLKIRVAVIRA	12	Sequence 314 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10295	VRLLIRVAVIRA	12	Sequence 315 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10296	VRLMIRVAVIRA	12	Sequence 316 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10297	VRLNIRVAVIRA	12	Sequence 317 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10298	VRLPIRVAVIRA	12	Sequence 318 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10299	VRLQIRVAVIRA	12	Sequence 319 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10300	VRLSIRVAVIRA	12	Sequence 320 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10301	VRLTIRVAVIRA	12	Sequence 321 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10302	VRLVIRVAVIRA	12	Sequence 322 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10303	VRLYIRVAVIRA	12	Sequence 324 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10304	VRLRARVAVIRA	12	Sequence 325 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10305	VRLRDRVAVIRA	12	Sequence 326 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10306	VRLRERVAVIRA	12	Sequence 327 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10307	VRLRFRVAVIRA	12	Sequence 328 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10308	VRLRGRVAVIRA	12	Sequence 329 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10309	VRLRHRVAVIRA	12	Sequence 330 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10310	VRLRKRVAVIRA	12	Sequence 331 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10311	VRLRLRVAVIRA	12	Sequence 332 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10312	VRLRMRVAVIRA	12	Sequence 333 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10313	VRLRNRVAVIRA	12	Sequence 334 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10314	VRLRPRVAVIRA	12	Sequence 335 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10315	VRLRQRVAVIRA	12	Sequence 336 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10316	VRLRRRVAVIRA	12	Sequence 337 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10317	VRLRSRVAVIRA	12	Sequence 338 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10318	VRLRTRVAVIRA	12	Sequence 339 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10319	VRLRVRVAVIRA	12	Sequence 340 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10320	VRLRWRVAVIRA	12	Sequence 341 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10321	VRLRYRVAVIRA	12	Sequence 342 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10322	VRLRIAVAVIRA	12	Sequence 343 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10323	VRLRIDVAVIRA	12	Sequence 344 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10324	VRLRIEVAVIRA	12	Sequence 345 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10325	VRLRIFVAVIRA	12	Sequence 346 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10326	VRLRIGVAVIRA	12	Sequence 347 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10327	VRLRIHVAVIRA	12	Sequence 348 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10328	VRLRIIVAVIRA	12	Sequence 349 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10329	VRLRIKVAVIRA	12	Sequence 350 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10330	VRLRILVAVIRA	12	Sequence 351 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10331	VRLRIMVAVIRA	12	Sequence 352 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10332	VRLRINVAVIRA	12	Sequence 353 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10333	VRLRIPVAVIRA	12	Sequence 354 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10334	VRLRIQVAVIRA	12	Sequence 355 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10335	VRLRISVAVIRA	12	Sequence 356 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10336	VRLRITVAVIRA	12	Sequence 357 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10337	VRLRIVVAVIRA	12	Sequence 358 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10338	VRLRIWVAVIRA	12	Sequence 359 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10339	VRLRIYVAVIRA	12	Sequence 360 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10340	VRLRIRAAVIRA	12	Sequence 361 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10341	VRLRIRDAVIRA	12	Sequence 362 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10342	VRLRIREAVIRA	12	Sequence 363 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10343	VRLRIRFAVIRA	12	Sequence 364 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10344	VRLRIRGAVIRA	12	Sequence 365 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10345	VRLRIRHAVIRA	12	Sequence 366 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10346	VRLRIRIAVIRA	12	Sequence 367 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10347	VRLRIRKAVIRA	12	Sequence 368 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10348	VRLRIRLAVIRA	12	Sequence 369 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10349	VRLRIRMAVIRA	12	Sequence 370 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10350	VRLRIRNAVIRA	12	Sequence 371 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10351	VRLRIRPAVIRA	12	Sequence 372 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10352	VRLRIRQAVIRA	12	Sequence 373 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10353	VRLRIRRAVIRA	12	Sequence 374 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10354	VRLRIRSAVIRA	12	Sequence 375 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10355	VRLRIRTAVIRA	12	Sequence 376 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10356	VRLRIRWAVIRA	12	Sequence 377 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10357	VRLRIRYAVIRA	12	Sequence 378 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10358	VRLRIRVDVIRA	12	Sequence 379 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10359	VRLRIRVEVIRA	12	Sequence 380 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10360	VRLRIRVFVIRA	12	Sequence 381 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10361	VRLRIRVGVIRA	12	Sequence 382 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10362	VRLRIRVHVIRA	12	Sequence 383 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10363	VRLRIRVIVIRA	12	Sequence 384 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10364	VRLRIRVKVIRA	12	Sequence 385 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10365	VRLRIRVLVIRA	12	Sequence 386 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10366	VRLRIRVMVIRA	12	Sequence 387 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10367	VRLRIRVNVIRA	12	Sequence 388 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10368	VRLRIRVPVIRA	12	Sequence 389 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10369	VRLRIRVQVIRA	12	Sequence 390 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10370	VRLRIRVRVIRA	12	Sequence 391 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10371	VRLRIRVSVIRA	12	Sequence 392 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10372	VRLRIRVTVIRA	12	Sequence 393 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10373	VRLRIRVVVIRA	12	Sequence 394 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10374	VRLRIRVYVIRA	12	Sequence 396 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10375	VRLRIRVAAIRA	12	Sequence 397 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10376	VRLRIRVADIRA	12	Sequence 398 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10377	VRLRIRVAEIRA	12	Sequence 399 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10378	VRLRIRVAFIRA	12	Sequence 400 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10379	VRLRIRVAGIRA	12	Sequence 401 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10380	VRLRIRVAHIRA	12	Sequence 402 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10381	VRLRIRVAIIRA	12	Sequence 403 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10382	VRLRIRVAKIRA	12	Sequence 404 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10383	VRLRIRVANIRA	12	Sequence 407 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10384	VRLRIRVAPIRA	12	Sequence 408 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10385	VRLRIRVAQIRA	12	Sequence 409 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10386	VRLRIRVARIRA	12	Sequence 410 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10387	VRLRIRVASIRA	12	Sequence 411 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10388	VRLRIRVATIRA	12	Sequence 412 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10389	VRLRIRVAWIRA	12	Sequence 413 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10390	VRLRIRVAYIRA	12	Sequence 414 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10391	VRLRIRVAVARA	12	Sequence 415 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10392	VRLRIRVAVDRA	12	Sequence 416 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10393	VRLRIRVAVERA	12	Sequence 417 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10394	VRLRIRVAVFRA	12	Sequence 418 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10395	VRLRIRVAVGRA	12	Sequence 419 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10396	VRLRIRVAVHRA	12	Sequence 420 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10397	VRLRIRVAVKRA	12	Sequence 421 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10398	VRLRIRVAVLRA	12	Sequence 422 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10399	VRLRIRVAVMRA	12	Sequence 423 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10400	VRLRIRVAVNRA	12	Sequence 424 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10401	VRLRIRVAVPRA	12	Sequence 425 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10402	VRLRIRVAVQRA	12	Sequence 426 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10403	VRLRIRVAVSRA	12	Sequence 428 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10404	VRLRIRVAVTRA	12	Sequence 429 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10405	VRLRIRVAVVRA	12	Sequence 430 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10406	VRLRIRVAVWRA	12	Sequence 431 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10407	VRLRIRVAVYRA	12	Sequence 432 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10408	VRLRIRVAVIAA	12	Sequence 433 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10409	VRLRIRVAVIDA	12	Sequence 434 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10410	VRLRIRVAVIEA	12	Sequence 435 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10411	VRLRIRVAVIFA	12	Sequence 436 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10412	VRLRIRVAVIGA	12	Sequence 437 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10413	VRLRIRVAVIHA	12	Sequence 438 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10414	VRLRIRVAVIIA	12	Sequence 439 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10415	VRLRIRVAVIKA	12	Sequence 440 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10416	VRLRIRVAVILA	12	Sequence 441 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10417	VRLRIRVAVIMA	12	Sequence 442 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10418	VRLRIRVAVINA	12	Sequence 443 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10419	VRLRIRVAVIPA	12	Sequence 444 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10420	VRLRIRVAVIQA	12	Sequence 445 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10421	VRLRIRVAVISA	12	Sequence 446 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10422	VRLRIRVAVITA	12	Sequence 447 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10423	VRLRIRVAVIVA	12	Sequence 448 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10424	VRLRIRVAVIWA	12	Sequence 449 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10425	VRLRIRVAVIYA	12	Sequence 450 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10426	VRLRIRVAVIRD	12	Sequence 451 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10427	VRLRIRVAVIRE	12	Sequence 452 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10428	VRLRIRVAVIRF	12	Sequence 453 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10429	VRLRIRVAVIRG	12	Sequence 454 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10430	VRLRIRVAVIRH	12	Sequence 455 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10431	VRLRIRVAVIRI	12	Sequence 456 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10432	VRLRIRVAVIRL	12	Sequence 458 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10433	VRLRIRVAVIRM	12	Sequence 459 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10434	VRLRIRVAVIRN	12	Sequence 460 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10435	VRLRIRVAVIRP	12	Sequence 461 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10436	VRLRIRVAVIRQ	12	Sequence 462 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10437	VRLRIRVAVIRR	12	Sequence 463 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10438	VRLRIRVAVIRS	12	Sequence 464 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10439	VRLRIRVAVIRT	12	Sequence 465 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10440	VRLRIRVAVIRV	12	Sequence 466 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10441	VRLRIRVAVIRW	12	Sequence 467 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10442	VRLRIRVAVIRY	12	Sequence 468 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10443	RRRRVKWWR	9	Sequence 469 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10444	WLRKKQGRL	9	Sequence 470 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10445	KWVRVYLRW	9	Sequence 471 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10446	GKVMISIVR	9	Sequence 472 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10447	IKVVRWRWR	9	Sequence 473 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10448	RRRRRWVRR	9	Sequence 474 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10449	HMNRFRTVY	9	Sequence 475 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10450	VRKRGSWRM	9	Sequence 476 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10451	RIIRTYKRG	9	Sequence 477 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10452	WWRWRLRLI	9	Sequence 478 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10453	WLNRLYIRL	9	Sequence 479 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10454	IWRWTKWFW	9	Sequence 480 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10455	RFKGSWKYR	9	Sequence 481 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10456	VWVIRKKKW	9	Sequence 482 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10457	RGRRVWRLF	9	Sequence 483 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10458	WRWRKVKQW	9	Sequence 484 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10459	WWKYWRKVI	9	Sequence 485 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10460	WLVRIRKRI	9	Sequence 486 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10461	WWRWWQRRW	9	Sequence 487 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10462	RKKWWWKIR	9	Sequence 488 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10463	WVRKKIRRR	9	Sequence 489 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10464	RYRRRWYIR	9	Sequence 490 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10465	LYRWVWKVG	9	Sequence 491 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10466	VRRRWFKWL	9	Sequence 492 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10467	RRLWWWKWL	9	Sequence 493 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10468	WRFKWTRRG	9	Sequence 494 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10469	KWWRHRRMW	9	Sequence 495 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10470	RRKRWWWRT	9	Sequence 496 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10471	WRRKIVRVW	9	Sequence 497 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10472	KLRRGSLWR	9	Sequence 498 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10473	RVIWWWRRK	9	Sequence 499 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10474	TWRVWKVRW	9	Sequence 500 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10475	QRGIVIWRK	9	Sequence 501 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10476	GKWWKWGIW	9	Sequence 502 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10477	RVRRWWFVR	9	Sequence 503 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10478	FWRRRVKWR	9	Sequence 504 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10479	FRRYQNIVR	9	Sequence 505 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10480	RFWRWIFKW	9	Sequence 506 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10481	KRNVKRNWK	9	Sequence 507 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10482	WYSLIIFKR	9	Sequence 508 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10483	RKNRRIRVV	9	Sequence 509 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10484	FFRKRRWRI	9	Sequence 510 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10485	WKIRKVIKW	9	Sequence 511 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10486	IKWYWRKKK	9	Sequence 512 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10487	KRGWRKRWW	9	Sequence 513 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10488	RKWMGRRIR	9	Sequence 514 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10489	WKGKKRRVI	9	Sequence 515 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10490	KVIRYKVYI	9	Sequence 516 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10491	RRTRKWILR	9	Sequence 517 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10492	YNWNWLRRW	9	Sequence 518 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10493	KWKHWRWQW	9	Sequence 519 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10494	RKIVVKVRV	9	Sequence 520 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10495	QYLGWRFKW	9	Sequence 521 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10496	KIKTRKVKY	9	Sequence 522 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10497	VWIRWRRRW	9	Sequence 523 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10498	WGVRVRRLI	9	Sequence 524 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10499	WWKRVWKFI	9	Sequence 525 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10500	YWIYSRLRR	9	Sequence 526 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10501	RRYWKFKRR	9	Sequence 527 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10502	IVRRVIIRV	9	Sequence 528 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10503	ARRRGLKVW	9	Sequence 529 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10504	RRWVRRWWR	9	Sequence 530 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10505	WKWKWKWQS	9	Sequence 531 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10506	RWKVKQRRR	9	Sequence 532 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10507	YWTKFRLRI	9	Sequence 533 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10508	WVIKVRIRW	9	Sequence 534 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10509	ARVQVYKYR	9	Sequence 535 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10510	KWRWHWVYV	9	Sequence 536 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10511	KVKYKFRRW	9	Sequence 537 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10512	RFRKRKNRI	9	Sequence 538 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10513	MFRRRFIWK	9	Sequence 539 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10514	WRLRRFRLW	9	Sequence 540 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10515	WIQRIRIWV	9	Sequence 541 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10516	RRYHWRIYI	9	Sequence 542 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10517	SRFWRRWRK	9	Sequence 543 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10518	YRVWIIRRK	9	Sequence 544 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10519	WRVSWLIWR	9	Sequence 545 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10520	RFVKRKIVW	9	Sequence 546 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10521	RIYKIRWII	9	Sequence 547 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10522	RKFWHRGTI	9	Sequence 548 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10523	AWVVWRKRW	9	Sequence 549 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10524	WVWGKVRWG	9	Sequence 550 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10525	FGIRFRRMV	9	Sequence 551 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10526	FWIRKVFRI	9	Sequence 552 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10527	KRWKVRVVW	9	Sequence 553 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10528	KIRIWRIWV	9	Sequence 554 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10529	RGRWKRIKK	9	Sequence 555 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10530	RLWFLVLRR	9	Sequence 556 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10531	IIRVTRWTK	9	Sequence 557 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10532	AMWRWKWRK	9	Sequence 558 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10533	TRKYFGRFV	9	Sequence 559 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10534	ARRVKKKRR	9	Sequence 560 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10535	RWWKIWKRR	9	Sequence 561 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10536	RWRYKIQKW	9	Sequence 562 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10537	RVGIKIKMK	9	Sequence 563 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10538	WVLKLRYKW	9	Sequence 564 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10539	FRRKWIFKK	9	Sequence 565 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10540	WIQKLWRQR	9	Sequence 566 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10541	RIVRLHVRK	9	Sequence 567 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10542	VRIGWRRVK	9	Sequence 568 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10543	RRRIGIKRF	9	Sequence 569 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10544	RRRRKKVRI	9	Sequence 570 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10545	KLWRYKRWR	9	Sequence 571 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10546	RIRRFIKKW	9	Sequence 572 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10547	LWHKKKKIW	9	Sequence 573 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10548	LTRRFWLRR	9	Sequence 574 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10549	RRRYVIRRR	9	Sequence 575 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10550	WGWRWIWIK	9	Sequence 576 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10551	RWRWQRGRF	9	Sequence 577 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10552	RRKKWKVRI	9	Sequence 578 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10553	KMKLYKGSM	9	Sequence 579 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10554	GTIRWWRRR	9	Sequence 580 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10555	SLRRYIWRF	9	Sequence 581 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10556	GRYWKKWRR	9	Sequence 582 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10557	WIRQFRWKK	9	Sequence 583 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10558	AKVRRIKHW	9	Sequence 584 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10559	YSRRKTWWI	9	Sequence 585 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10560	RGRWWIRRQ	9	Sequence 586 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10561	WVFRWVWWR	9	Sequence 587 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10562	VYRVWWLKW	9	Sequence 588 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10563	WWVRRRVGW	9	Sequence 589 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10564	WFKIKRLYL	9	Sequence 590 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10565	WKMWKRGWT	9	Sequence 591 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10566	RWWRKSRRL	9	Sequence 592 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10567	FWRIRWWRW	9	Sequence 593 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10568	VWWFGKRTT	9	Sequence 594 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10569	VRIIWWIWR	9	Sequence 595 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10570	WWVRIWRWM	9	Sequence 596 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10571	RKWKKWFHR	9	Sequence 597 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10572	RKWKFWGYK	9	Sequence 598 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10573	FWYIWSKRV	9	Sequence 599 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10574	YWRQFRRKQ	9	Sequence 600 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10575	WWWKVKSRR	9	Sequence 601 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10576	WRLWIWWIR	9	Sequence 602 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10577	QFRVNRRKY	9	Sequence 603 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10578	RYRFWWVRR	9	Sequence 604 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10579	THIWLRRRR	9	Sequence 605 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10580	RRRFRKRRM	9	Sequence 606 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10581	LYTRVRRYS	9	Sequence 607 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10582	WSIRRLWWL	9	Sequence 608 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10583	YKIKRRRYG	9	Sequence 609 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10584	WKRIQFRRK	9	Sequence 610 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10585	HKKRRIWRK	9	Sequence 611 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10586	WRLIRWWIR	9	Sequence 612 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10587	LRKNWWWRR	9	Sequence 613 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10588	VKRIRIWML	9	Sequence 614 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10589	IRYRNWKWL	9	Sequence 615 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10590	GRILSRRWK	9	Sequence 616 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10591	KHWKIHVRW	9	Sequence 617 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10592	WIYWKVWRR	9	Sequence 618 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10593	KLWKVRNRR	9	Sequence 619 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10594	RRVYYYKWV	9	Sequence 620 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10595	WRWGVFRLR	9	Sequence 621 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10596	IWRVLKKRV	9	Sequence 622 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10597	AKKFWRNWI	9	Sequence 623 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10598	RQWRKVVKK	9	Sequence 624 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10599	GWKRWWVML	9	Sequence 625 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10600	KWRRTRRRK	9	Sequence 626 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10601	FRRMKRFLR	9	Sequence 627 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10602	RSWNWWWIR	9	Sequence 628 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10603	WRRRIWINR	9	Sequence 629 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10604	RWKWFYLKR	9	Sequence 630 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10605	RKRTIWRII	9	Sequence 631 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10606	RRRVWWRRR	9	Sequence 632 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10607	KWRFKWWKR	9	Sequence 633 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10608	KWIWGWRRW	9	Sequence 634 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10609	WIKRKWKMR	9	Sequence 635 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10610	MWKKVLRRV	9	Sequence 636 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10611	WRWRIFHWL	9	Sequence 637 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10612	KIQRWKGKR	9	Sequence 638 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10613	LWYKYWRWR	9	Sequence 639 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10614	YVRRIWKIT	9	Sequence 640 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10615	RWRQYRSRW	9	Sequence 641 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10616	VGRWKRRRW	9	Sequence 642 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10617	KSSRIYILF	9	Sequence 643 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10618	AKWWWYRKI	9	Sequence 644 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10619	FYWWRWFRV	9	Sequence 645 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10620	RTRWLRYRR	9	Sequence 646 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10621	WNIIWWIRR	9	Sequence 647 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10622	KRGFWWWRI	9	Sequence 648 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10623	RRRKKYIIR	9	Sequence 649 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10624	VWKVGWYYR	9	Sequence 650 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10625	LKFSTGRVR	9	Sequence 651 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10626	RRVWVRRKR	9	Sequence 652 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10627	RFWYMWKYV	9	Sequence 653 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10628	WYVRWMGRR	9	Sequence 654 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10629	WKRRMRRRK	9	Sequence 655 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10630	RVLRRVSWV	9	Sequence 656 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10631	RRLRKKWGW	9	Sequence 657 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10632	WYKKIRLII	9	Sequence 658 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10633	IYIIIWRTK	9	Sequence 659 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10634	TWRMRVKVS	9	Sequence 660 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10635	AWWKIRWRI	9	Sequence 661 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10636	RVRRYRWSW	9	Sequence 662 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10637	IWRIRRFRI	9	Sequence 663 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10638	KIRRKWWWF	9	Sequence 664 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10639	RRFWWIKIR	9	Sequence 665 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10640	WYWWRVRRV	9	Sequence 666 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10641	WYKLWRRKV	9	Sequence 667 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10642	WWFSWRWRV	9	Sequence 668 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10643	RFKTRRGWR	9	Sequence 669 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10644	WIWIVRRRV	9	Sequence 670 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10645	RRFKKWMYW	9	Sequence 671 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10646	RWYRVIRWK	9	Sequence 672 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10647	YRWMVRWVR	9	Sequence 673 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10648	KVRRYNRRR	9	Sequence 674 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10649	WFVWNRRVV	9	Sequence 675 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10650	RWKWRWRWY	9	Sequence 676 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10651	ARWRVRKWW	9	Sequence 677 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10652	KIKFWIIRR	9	Sequence 678 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10653	WYWRVRLQW	9	Sequence 679 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10654	YWWWKRRRR	9	Sequence 680 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10655	FIKRVRRRW	9	Sequence 681 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10656	VSVVFRRRY	9	Sequence 682 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10657	KFRVMVRVL	9	Sequence 683 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10658	WMYYKRRRR	9	Sequence 684 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10659	IWIWWRWRW	9	Sequence 685 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10660	WKKKKIIRV	9	Sequence 686 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10661	RRGWRRRRR	9	Sequence 687 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10662	WRWRKIWKW	9	Sequence 688 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10663	WWRWKRRII	9	Sequence 689 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10664	WKVRWKIRR	9	Sequence 690 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10665	RFWVRGRRS	9	Sequence 691 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10666	RRWVLWRRR	9	Sequence 692 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10667	KYIWKKRRY	9	Sequence 693 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10668	KWQWIRKIR	9	Sequence 694 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10669	YWIRRRWRL	9	Sequence 695 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10670	RVKWIKWLH	9	Sequence 696 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10671	YVRQWKKRR	9	Sequence 697 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10672	WKIVGVFRV	9	Sequence 698 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10673	VIKYVRMWW	9	Sequence 699 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10674	RRRRVWRVR	9	Sequence 700 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10675	RRRKIRVYR	9	Sequence 701 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10676	RRNRWRRIR	9	Sequence 702 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10677	IRKWIWRRV	9	Sequence 703 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10678	QRWRVRRRY	9	Sequence 704 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10679	WWMIIKIRN	9	Sequence 705 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10680	ARRRGRRVM	9	Sequence 706 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10681	RRWHWRKRK	9	Sequence 707 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10682	KRFLRKRRF	9	Sequence 708 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10683	RWKGWYLRT	9	Sequence 709 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10684	WSWRGRRKF	9	Sequence 710 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10685	KIIMKRRRW	9	Sequence 711 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10686	VWKRFLHWR	9	Sequence 712 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10687	RLKRRKKWR	9	Sequence 713 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10688	AVRKFRRVT	9	Sequence 714 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10689	IKQRFWWRT	9	Sequence 715 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10690	WKIVVWIIK	9	Sequence 716 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10691	LYRWIVWKR	9	Sequence 717 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10692	WWWRWRIRK	9	Sequence 718 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10693	RLWRKWQWN	9	Sequence 719 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10694	RVKLRWGWR	9	Sequence 720 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10695	AWRYKRRIF	9	Sequence 721 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10696	KRWQIRGIT	9	Sequence 722 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10697	KRWRWRWRW	9	Sequence 723 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10698	KRWVYKYRV	9	Sequence 724 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10699	VHWRWRFWK	9	Sequence 725 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10700	FVGKTKRKR	9	Sequence 726 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10701	RLRFGWFLF	9	Sequence 727 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10702	AKRWIWIQV	9	Sequence 728 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10703	RKYVRRWVY	9	Sequence 729 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10704	YRVYWWWWR	9	Sequence 730 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10705	KRRKKRRVR	9	Sequence 731 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10706	KKVRFTITW	9	Sequence 732 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10707	KLWYWKKVV	9	Sequence 733 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10708	WRWGLRWWQ	9	Sequence 734 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10709	AFFYRWWIR	9	Sequence 735 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10710	WYWRRRRLK	9	Sequence 736 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10711	YKFRWRIYI	9	Sequence 737 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10712	WLRKVWNWR	9	Sequence 738 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10713	RVRFKVYRV	9	Sequence 739 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10714	RWLSKIWKV	9	Sequence 740 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10715	RRRLGWRRG	9	Sequence 741 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10716	KKWGGGLVK	9	Sequence 742 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10717	YWWLWRKKR	9	Sequence 743 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10718	WIRLWVKWR	9	Sequence 744 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10719	GRRSTHWRI	9	Sequence 745 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10720	KKKLFINTW	9	Sequence 746 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10721	VYRRRRVKG	9	Sequence 747 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10722	KGWIIWKIV	9	Sequence 748 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10723	VFHRIRRIK	9	Sequence 749 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10724	RLRLWKSKR	9	Sequence 750 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10725	RRKVFKLRR	9	Sequence 751 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10726	VWLKVYWFK	9	Sequence 752 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10727	VRWGRRRWV	9	Sequence 753 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10728	RYNWVRRKK	9	Sequence 754 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10729	KIRWRKYHL	9	Sequence 755 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10730	VIWRWRKFY	9	Sequence 756 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10731	RRWWKWWWR	9	Sequence 757 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10732	WRVKGKRSK	9	Sequence 758 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10733	RWRTRRNIV	9	Sequence 759 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10734	WWFSIRLWR	9	Sequence 760 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10735	YTWYIKKKR	9	Sequence 761 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10736	VWRRKKYWR	9	Sequence 762 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP10737	YLTRFVKYF	9	Sequence 763 from Patent US 20110236429	Synthetic construct	Antimicrobial	US 2011/0236429 A1	Patent Application	2011##9##29	CA2660668A1, EP2061886A4, US8343475, US20110236429, WO2008022444A1	Small Cationic Antimicrobial Peptides.	The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.
DRAMP12574	QNIDAGGNRKCFRDSDCPKFMCPSYLAVKCIGRLCRCGRPELQVELNPK	49	Sequence 651 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12575	LNGGGKDKCFRDSDCPKHMCPSSLVAKCINRLCRCRRPELQVQLNP	46	Sequence 652 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12576	KTQFLPNYYEFYHCYNHSDCQGSMCPTGSKPKCVDQVCECILIRM	45	Sequence 653 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12577	FQLFDNTDTATCITDADCPYDGKCIDGFCRFNVKNNNQV	39	Sequence 654 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12578	MKNGCKHTGHCPRKMCGAKTTKCRNNKCQCV	31	Sequence 655 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12579	DDVKIKCVSAIDCMDLFNLLPIVYKCINNICVYEQSSQRLI	41	Sequence 656 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12580	EHNECETDADCPKHTTIFFVMKCIDHICRCMKTSI	35	Sequence 657 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12581	FKMFCRYDEDCPPRMCRLPQVPQCNEFICDCGMPVYKPYQNKYIKK	46	Sequence 658 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12582	WRCKTKYDCIKIRFCKFPTIARCTKPDFLFLEYDRGFCTCDD	42	Sequence 659 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12583	VIKCFQDSDCPKYMCMFPLKPKCVYILVFPPPWTAQCICD	40	Sequence 660 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12584	IKLIKCTVSDDCPMNFRCPPNTFVRCISDLCTCRSLLDEQS	41	Sequence 661 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12585	SFSEIIDSACKTDKDCPKLHKVNVRCRKGKCVAI	34	Sequence 662 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12586	GRECHANSHCVGKITCVLPQKPECWNYACVCYDSNKYR	38	Sequence 663 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12587	KECVTDVDCEKIYPGNKKPLICSTGYCYSLYEEPPRYHK	39	Sequence 664 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12588	LETQIVQKACVILLPNRSVCTNPYVNVYESSPKEIMCIHEHVCLPYLRAYTNYIPS	56	Sequence 665 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12589	KECVTDADCENLYYGNKWPLICSNIGYCLSSYEEPPHK	38	Sequence 666 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12590	FRDPCNFDFDCRNSNCTAPYVATCMYEHCYC	31	Sequence 667 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12591	IPICQTYMDCPSDMCTRPKHAYCVSYKCYCV	31	Sequence 668 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12592	KECVTDADCENLYPGNKKPMFCNNTGYCMSLYKEPSRYM	39	Sequence 669 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12593	LKCKTVHDCPKSQVVYKCVGNYCRAVKIRRWNLS	34	Sequence 670 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12594	YVVMCEKDSDCVDSFCVPPNVPKCRVVCKCLPK	33	Sequence 671 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12595	KSYGPCTTLQDCETHNWFEVCSCIDFECKCWSLL	34	Sequence 672 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12596	MEVGRRANVECESDKDCQEHWSEFFIIQCIDNICVPSERPL	41	Sequence 673 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12597	DRECDTDTECQKKFPGVNAHHLWCDNGNCVSYPK	34	Sequence 674 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12598	YKNRCFRDSDCPKEMCNHPKIPKCVNNAYCKCVVAMYFPPK	41	Sequence 675 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12599	GGNECVTDVDCEKLYPGNKKPLICNIGYCLSLYKEPPRYM	40	Sequence 676 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12600	ENICDGDYDCNPNEWWCPPNYVLKCINYQCSCIGFTPAIYALD	43	Sequence 677 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12601	EDFPFHKCEKDEDCLEICADDQMAMCILNVCFCY	34	Sequence 678 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12602	QEVLEKEIFPCQTDGECDHMCVTPGIPKCVANMCFCFDNL	40	Sequence 679 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12603	HRFLIYNNCKNDTECPNDCGPHEQAKCILYACYCVE	36	Sequence 680 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12604	VIFECSEDSHCVTKIKCVLPRKPECRNTQCTCYRGYKGSFTLHH	44	Sequence 681 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12605	KDGCKTNFDCLIKYPDHNEDILQCIGGHCLCLTN	34	Sequence 682 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12606	QHPFTPCETNADCKCRNHKRPDCLWHKCYCY	31	Sequence 683 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12607	KLWCDTDADCQEKFPGPSKYPIKCMKGICKCVIN	34	Sequence 684 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12608	WRPDCKENNDCPTFYCATWINTCIKFKCYCIRPWG	35	Sequence 685 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12609	KDLPFNICEKDEDCLEFCAHDKVAKCMLNICFCF	34	Sequence 686 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12610	YFIPDSGPCVTNKDCEQEIGYIVKCDTNTGFCVKILQRS	39	Sequence 687 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12611	DFDLHNDSYDYLYEFQECEVDNDCPQDPLPMKCINYICVVHNEEPSDNL	49	Sequence 688 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12612	NFEDISIECMFSIDCPQIKSNIFRFKCIEDRCKIEFIYQRKKYEI	45	Sequence 689 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12613	QKRWHGCKEDRDCDNICSVHAVTKCIGNMCRCLANVK	37	Sequence 690 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12614	QKDLKVFTCQRDEDCKVACATYGGDPWCFRNVCFCKHYNEGGTLHAELH	49	Sequence 691 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12615	EQHFVTLYKKKEKCALDVDCLELFPNSYKYLMKCVGGDCISLSKGFSHDEIKE	53	Sequence 692 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12616	AKVNCLDDADCLEVLCVFGSKAECVVNICICVPPRFGKFDEHFR	44	Sequence 693 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12617	KDITCTVAGDCPNFFVCPPNNFVRCIRNLCKCRSLSYKQP	40	Sequence 694 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12618	ENSQPCNLSVTDTRDICPPGTTLQFVYKVCRCYPMKWRLDHVLT	44	Sequence 695 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12619	ICECEEDIDCPRTWCFGQFFVKCITNECICVHEDRLLPRIPWDPWIPMI	49	Sequence 696 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12620	DTDPFAFCIKDSNCGQDLCTSPNEVPECRLLKCQCIKS	38	Sequence 697 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12621	KILEKHKCVTDGVEILEKGKCFTDWECVRNSWLCPVDLVVRCIKETCKCIKILEPINVVPT	61	Sequence 698 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12622	VSKLAQSCSEDFECYIKNPHAPFGQLRCFEGYCQRLDKPT	40	Sequence 699 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12623	YDDCYNHTECTNKIKCVPPRIAQCFRFKCDCIRLNNGPKTPWSATPKRVHISPTRKNDF	59	Sequence 700 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12624	EESHYMKFSICKDDTDCPTLFCVLPNVPKCIGSKCHCKLMVN	42	Sequence 701 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12625	INSDGYLECTTDYDCREEWLCPPDMEAKCFVSFALARFLSKGKCLCV	47	Sequence 702 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12626	IFPEHNECRTSFDCRKYFCQLPLRPTCNYVEIFRHYYDTTCGCA	44	Sequence 703 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12627	DDYLKYIYRCQNDGDCDQICATHGISKCVATMCFCNLNL	39	Sequence 704 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12628	WSWGLTTECVTELDCYKKYRLPAEKKMKCIRGSCYRVRE	39	Sequence 705 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12629	RNGCIVDPRCPYQQCRRPLYCRRR	24	Sequence 706 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12630	YNITCNSALDCASNRCILPGMPICVTNKCLCV	32	Sequence 707 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12631	ERECVTDADCQKKLPFPHANHFICMNGLCALVFHD	35	Sequence 708 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12632	RPCVTVADCPPVKKPLKMWCIRQTCFYGFGKRPDL	35	Sequence 709 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12633	ETCVTVDDCQGKHHLPPGYHFICMNSRCVLIYYN	34	Sequence 710 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12634	GTGNIRQSCEFDVDCENKYCPPSHDGKCVWE	31	Sequence 711 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12635	GECITFLDCLHLPCMPTETQLCVDKKCICMGLTIKSKNNYIT	42	Sequence 712 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12636	SYPCKIHRDCTTITCSYPLVPRCLIQKCYCGFN	33	Sequence 713 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12637	EKCVTADDCQGKHHMPAGYHFICMNARCVLVYYN	34	Sequence 714 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12638	FFDCENHDDCKNKIKYVLPRIAECRDYKCNCFPLNLSKTLWSASTKRVHKSLAQTNDFLH	60	Sequence 715 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12639	NDIKCTVAGDCPDFFRCPPNTFVRCISNICICRLVYLNTFLEVIIDKVFVF	51	Sequence 716 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12640	NDIKCTVAGDCPDFFRCPPNTFVRCISNICICRSLSH	37	Sequence 717 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12641	KDITCNVAGDCPEYFRCPPNTFVRCVSNICECRGLSHQQP	40	Sequence 718 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12642	KPAPIPCKFHADCPIMLSIVVECINNVCEFIYI	33	Sequence 719 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12643	EKIRRCFNDAHCPPDMCTLGVIPKCSRFTICIC	33	Sequence 721 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12644	ERECVTDADCQKKYPGPYEHLLKCVSGYCVGVTGF	35	Sequence 722 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12645	NIFFCSTDEDCTWNLCRQPWVQKCRLHMCSCEKN	34	Sequence 723 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12646	HVLVECIENRDCEKGMCKFPFIVRCLMDQCKCVRIHNLI	39	Sequence 724 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12647	HDQRECYTNYDCCVKYSCPYKHMVKCVGGYCLGFRNDYGKKNLY	44	Sequence 725 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12648	YDSKECYSDSDWHKKYSCPYTHMMKCVGGYC	31	Sequence 726 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12649	RITHDPSTRSTVSGGFGKCVRDADCVDEVCSPGCNKRCVGFECQCPL	47	Sequence 727 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12650	CNDDTDCPPSCTTRGCPDSCAYPHVLRCIGKNCVCT	36	Sequence 728 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12651	DPMYCFNDDDCRELKCSHPRVRKCRMFLCRCEEVDKEDEK	40	Sequence 729 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12652	VTICDSDQDCRRYRCDPPEYPRCLGILCKCVYVSG	35	Sequence 730 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12653	QKRRRSTECRNDSDCEKMVKCVLPRIARCIKYRCQCRNFLESFE	44	Sequence 731 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12654	NDTEYTDCLQHSDCQAYACELPFKPDCLMVEYAPQFFRLACGCV	44	Sequence 732 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12655	EKGTIVDIETTGQCADDYECYRLFSCPREVAFKCINGWCKCIL	43	Sequence 733 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12656	VYLCEDDEDCHIMPCMVPEYAKCIRMICQCC	31	Sequence 735 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12657	FKTAITCDCNEDCLNFFTPLDNLKCIDNVCEVFM	34	Sequence 736 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12658	EKECITDDDCNRKYPMHANRGLQCLNGECKSSRIIKSR	38	Sequence 737 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12659	MRVLCGRDGRCPKFMCRTFL	20	Sequence 738 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12660	GRYTTPWCVRDIDCPKEKCKHPFKPRCLTHSCVCRLWGSQDVI	43	Sequence 739 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12661	KNICIDDVHCQKYKCSPGLYPTCINGWCECK	31	Sequence 740 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12662	YEKISCQNDFDCPESMCEFGMIRRCISYKCQCHEAY	36	Sequence 741 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12663	QKIRRCFNDAHCPPDMCTPGVIPKCKFTICKC	32	Sequence 742 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12664	IPMIHPLLYKKRVVPNCQTIVDCPDNMCTHPKEVYCIGYRCYCLK	45	Sequence 743 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12665	NIMNCQSTFDCPRDMCSHIRDVICIFKKCKCAGGRYMPQVP	41	Sequence 744 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12666	SIPDVLPCLFSNECPPDLCPIDLFPKCINLSCQCSAEFYNID	42	Sequence 745 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12667	KVLCGRDGTCPRFMCGPGIIPKCVGRYCEC	30	Sequence 746 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12668	KEDGSVECIANIDCPQIFMLPFVMRCINFRCQIVNSEDT	39	Sequence 747 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12669	WTCVEDSDCPANICQPPMQRMCFYGECACVRSKFCT	36	Sequence 748 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12670	VAAFLRCDFDLDCPPKMCYSHLYFVPMCVDNHCDCTQWKDIIPTIP	46	Sequence 749 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12671	PIRCNRVSDCPKIRCNIGFVLRCLYNQCKCVRITQLVDYVLK	42	Sequence 750 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12672	RITHETLPLPVSKPIPILGGECISDADCKHPECDNCRGVCLNSRCICMARSGWTYTIPQN	60	Sequence 751 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12673	KRECDTNFDCQQKFSTQAEDLLWCIRGYCMSIPN	34	Sequence 752 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12674	LHCNNDNECPPSTWKPFVRCKMNRCIYSRVQPPWAC	36	Sequence 753 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12675	LIEECVTDADCYKIYPEASFLHMFCIDGVCKTPIPL	36	Sequence 754 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12676	MDIVDKIDECESNVDCPKSYIINWDKNYVHKCINNRCEWIKIIRRR	46	Sequence 755 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12677	DLGCVTDADCKDKFPGNKYPIKCINGICKSVPN	33	Sequence 756 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12678	ECISDTDCNVLYPMYINRRLRCIQGICHTTTARRR	35	Sequence 757 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12679	VKNINRECTQTSDCYKKYPFIPWGKVRCVKGRCRLDM	37	Sequence 758 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12680	NNIEDDIFCITDNDCPPNTLVQRYRCINGKCNLSFVSYG	39	Sequence 759 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12681	VSITGNLARASRKKPVDVIPCIYDHDCPRKLYFLERCVGRVCKYL	45	Sequence 761 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12682	DDNKLLLSFIEEGFLCFKDSDCPYNMCPSPLKEMCYFIKCVCGVYGPIRERRLYQSHNPMIQ	62	Sequence 762 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12683	EKECANDIDCYKIFLGPPLIPMKCIDGECKRIT	33	Sequence 763 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12684	EKECDTDADCRKKFAGANQHLLWCNNGYCECHTH	34	Sequence 764 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12685	SYYGCETDADCPRSMNKDFYLKCVDKKCEWTAKI	34	Sequence 765 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12686	AIHECRAHSHCVARINCVLPRKPQCRNYACGCYDSNKYR	39	Sequence 766 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12687	QEIENGIHPCKKNEDCNHMCVMPGLPWCHENNLCFCYENAYGNTR	45	Sequence 767 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12688	YEDFEKEIFDCKKDGDCDHMCVTPGIPKCTGYVCFCFENL	40	Sequence 768 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12689	WRCKKTDDCLKIEFCKFPKIARGTKPKFLFFEFGTGFCTWDD	42	Sequence 769 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12690	TFRTRLPCEKDDDCPEAFLPPVMKCVNRFCQYEILE	36	Sequence 770 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12691	DIRCRFYYDCPRLEYHFCECIEDFCAYIRLN	31	Sequence 771 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12692	DDGSFCFKDSDCPDEMCPSPLKEMCYFLQCKCGVDTI	37	Sequence 773 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12693	YLKFECKTDDDCQKSLLKTYVWKCVKNECYFFAKK	35	Sequence 774 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12694	LPISCKDHFECRRKINILRCIYRQEKPMCINSICTCVKLL	40	Sequence 775 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12695	RIMVVNPNNPCVTDADCQRYRHKLATRMICNQGFCLMDFTHDPYAPSLP	49	Sequence 776 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12696	ARLVFVNPEKPCVTDADCDRYRHESAIYSDMFCKDGYCFIDYHHDPYP	48	Sequence 777 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12697	NVEDFVGGSNDECVYPDVFQCINNICKCVSHHRT	34	Sequence 778 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12698	LIECEIDLDCPKSYIKLWDRNYAHRCVNNICEWVKKPRIY	40	Sequence 779 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12699	EIDLDCPKSYIKLWDKNYAHRCVNNICEWVKKPRIY	36	Sequence 780 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12700	QMINFSGCKRDKDCPQFRGVNIRCRSGFCTPIDS	34	Sequence 781 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12701	SFSQIFNSACKTDKDCPKFGRVNVRCRKGNCVPI	34	Sequence 782 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12702	GIRKKECRQDSDCPSYFCEKLTIAKCIHSTCLCK	34	Sequence 783 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12703	GIRRFECRQDSDCPSYFCEKLTVPKCFWSKCYCK	34	Sequence 784 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12704	LYEPLYNFRRDPDCRRNIDCPSYLCVAPKVPRCIMFECHCKDIPSDH	47	Sequence 785 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12705	YREPFSSFTEGPTCKEDIDCPSISCVNPQVPKCIMFECHCKYIPTTLK	48	Sequence 786 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12706	ARFECREDSHCVTRIKCVLPRKPECRNYACGCYDSNKYR	39	Sequence 787 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12707	AHFPCVTDDDCPKPVNKLRVIKCIDHICQYARNLPDFASEISESTKMPCKGE	52	Sequence 788 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12708	ETLSLTHPKCHHIMLPSLFITEVFQRVTDDGCPKPVNHLRVVKCIEHICEYGYNYRPDFASQIPESTKMPRKRE	74	Sequence 789 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12709	EECVTDADCDKLYPDIRKPLMCSIGECYSLYKGKFSLSIISKTSFSLMVYNVVTLVICLRLAYISLLLKFL	71	Sequence 790 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12710	ERECVTDDDCEKLYPTNEYRMMCDSGYCMNLLNGKIIYLLCLKKKKFLIIISVLL	55	Sequence 791 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12711	VSYFSYFSTYIIECKTDNDCPISQLKIYAWKCVKNGCHLFDVIPMMYE	48	Sequence 792 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12712	RLNTTFRPLNFKMLRFWGQNRNIMKHRGQKVHFSLILSDCKTNKDCPKLRRANVRCRKSYCVPI	64	Sequence 793 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12713	YLCVTDSHCPPHMCPPGMEPRCVRRMCKCLPIGWRKYFVP	40	Sequence 794 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12714	ESKLEQTCSEDFECYIKNPHVPFGHLRCFEGFCQQLNGPA	40	Sequence 795 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12715	HNCTDISDCSSNHCSYEGVSLCMNGQCICIYE	32	Sequence 796 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12716	EIDADCPQICMPPYEVRCVNHRCGWVNTDDSLFLTQEFTRSKQYIIS	47	Sequence 797 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12717	KKKRYIECETHEDCSQVFMPPFVMRCVIHECKIFNGEHLRY	41	Sequence 798 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12718	KTFLMAEYIKCDTDADCPIVIHHSFYKCIDNLCKRFRRQKHLV	43	Sequence 799 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12719	YKTKTPCKSLNDCPKAIKPIFVKCLGNICQYSIGRI	36	Sequence 800 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12720	AFAGWIKCKVDEDCPNVFTYSYYKCVNELCEIFLREIPKKPYM	43	Sequence 801 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12721	GNTFLMADNIECDTDAGCPKMVHHIFYKCIDNKCKQFRRS	40	Sequence 802 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12722	YIQCDFDADCPEMFRHIFYLCIDKLCRQFVTL	32	Sequence 803 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12723	YRTRIPCVSDYDCPKASYPLFIKCIYNFCEIWGSP	35	Sequence 804 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12724	DDDCPKVPYPLYIKCEDNFCDIWASPY	27	Sequence 805 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12725	KRTNIPCFSDDDCPKTSPPLVLKCDDYFCRYFREKNLI	38	Sequence 806 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12726	KYFQIASPCVNDKDCPRFKNNNVRCRKGFCVNLCN	35	Sequence 807 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12727	VYDSKYFQIASPCVNDKDCPQFKNNNVRCRRGFCVNSGGATQKCLGCPSLK	51	Sequence 808 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12728	ATPCTSDKDCRLERYNVWCINGYCKYKFTPID	32	Sequence 809 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12729	VRIPCVTVADCPPTILPVFYECIDKFCMLHIE	32	Sequence 810 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12730	KTTIPCKFDNDCPEISYPLILMCIDDFCEYLLA	33	Sequence 811 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12731	STIMYYDVPCEKDKDCPAPPRFNIRCRKGYCVRI	34	Sequence 812 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12732	VEIPETPCESDAECPYYSPSLYARCIDGFCTLFLS	35	Sequence 813 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12733	EMTTTATIPCTSIDDCPKMPLVVKCIDNFCNYFEIK	36	Sequence 814 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12734	GKTHYSEIIECKNDADCPIGYKCIDEMCKYG	31	Sequence 815 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12735	IYFRKPPPCITDKDCPQMKINNVRCRKGFCIQIHKFTP	38	Sequence 816 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12736	QIMFSDCKTDKDCPQFRRANIRCRKGQCVKL	31	Sequence 817 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12737	FLTQCKFSCKTIFNCPALVYHQHASCLDGFCWYEEKFEDE	40	Sequence 818 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12738	VYDSIPYVNSGPCVTDKDCPKVSQYNIRCRKGQCARIRV	39	Sequence 819 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12739	TNFKRKQIPFYFFIREFYPCFIDGNCPRNMCKVYQIPKCVGGLCRCIPLRCGRWEK	56	Sequence 820 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12740	HIECKNDFDCPKNMCLAPRVAWCVNNKCECVLTYGPKYSTMKEKLLQKEKI	51	Sequence 821 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12741	VPHTDIPCEPDADCPKSLHEYFEMKCIDKKCEWSRKTSLIP	41	Sequence 822 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12742	VDIYCETDADCPQITDWFYVVKCVDHKCELTKKLRRLYEYQTQKSAETPYI	51	Sequence 823 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12743	EQCVSDADCQIKFPGPRQHLLRCTQGNCVMLVGQGKNYFSIMSKTLFSLLVIIFLLL	57	Sequence 824 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12744	LHDCEYDDDCPKSTSKRTYRCINKKCRSYFTRVEK	35	Sequence 825 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12745	TTSCITDDDCPKAVSFLVFKCIDNICVRVEIL	32	Sequence 826 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12746	NYNPPCVSDKDCPSPKSPKSNIRCRQGYCVNLYS	34	Sequence 827 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12747	VRIPRPLIDPLNCHIDIHCIYKECRRPFKPSCLNFKCDCGKE	42	Sequence 828 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12748	QIIFRQCKTDKDCPKLGRANIRCREGYCVRI	31	Sequence 829 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12749	TPIPCNTPADCPKRVCIYPLRAKCINFNCECDYVKK	36	Sequence 830 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12750	GDIPCESREQCPNTATRRYACLNKLCYCYDNNYPNGWNPFEP	42	Sequence 831 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12751	FVKCETTDDCPKSDYIRQYECVNNWCRLARLHEFQPKKSTLTS	43	Sequence 832 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12752	FTFSILCQVNSDCLGEICLPPKTHWCNKILLEIYISCHLVTMLEPNNLYLLPFLISWTRNNLYIILGLSLFSRTNSLVLSWR	82	Sequence 833 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12753	YPGCETDAECPKIYELYPLIYKCENKFCILSQVLPYIV	38	Sequence 834 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12754	FNPLIRQYCVTDKDCPKFKKYNIRCRKGFCVQVNGG	36	Sequence 835 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12755	AQNDWMKCKTDDECPKVSNPPLYFKCIDRGCRIVIKMRF	39	Sequence 836 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12756	YVECETDADCQPNMCKWPFIVQCYKNVCICVHHTNPYL	38	Sequence 837 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12757	DECQIDADCPKSGNLFYIYKCINHKCELVAAHLRFY	36	Sequence 838 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12758	ILECIFDIDCPTKKCAPPLVAKCDMYECYCRCPPNN	36	Sequence 839 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12759	MVSTNAYIHRCIHQDDCPKYMCEISVLPECINGFCTCV	38	Sequence 840 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12760	QKFNECYEDTDCPIQMCGYPFNVDCVGNKCTCVYNP	36	Sequence 841 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12761	AYYECSNDSACQATTKCVLPRVPRCIKYKCLCGNSNGSGNRWSTRPNRIQKGSTESNYF	59	Sequence 842 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12762	KSICKVDDDCPQRFVMYPLMFMCIKNICRLVNE	33	Sequence 843 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12763	ATKEKFHSCVNANDCPYDFCSPPKYAKCVYNSCYCEDQGRL	41	Sequence 844 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12764	MHIETVTTCIYDSDCPEDMCYPPKKSFCSTFEILSIERKVGVCECI	46	Sequence 845 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12765	VRKPECRQNSDCPPYFCIKPTVPKCIKFKCLCK	33	Sequence 846 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12766	LNGNRHGKDRCFKDSDCPKYMCPSSLVAKCIKKLCSCRKPGLQIQLNPK	49	Sequence 847 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12767	KNIDEKCFRDDDCAKNMCPSYLVVKCVNGIYKCVRP	36	Sequence 848 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12768	NCTFIGFQDNPCKTDNDCRKVRGVNLRCRNGHCVMILQ	38	Sequence 849 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12769	IEGTMSCFHDADCVHKRCQLPQIPKCVGKKCRCRGQYQANPMG	43	Sequence 850 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12770	EVHRCIEYTDCPEDMCHLPLVVVCHDHICKCLRLP	35	Sequence 851 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12771	SAFSGCMNDSDCPDLFCLPPLDMKCHELVCKCR	33	Sequence 852 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12772	HYRELICKTDDNCPRRGTNKYFIHKCIDYRCQWIPR	36	Sequence 853 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12773	LKVIIPSSTCDSDYDCLRYEEALNVITCCNNGLCVMFCPDFD	42	Sequence 854 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12774	FEDSDCPYDMCYAGFQPKCVNGWCDC	26	Sequence 855 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12775	IDDSDCPYDMCDPGLLPRCLNGWCDCSRFQPWPMDSMSSNLREFTLPN	48	Sequence 856 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12776	DSDCPSFLCDHDGVMKCFSNGCSCVDPSD	29	Sequence 857 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12777	SNPCVSTRDCTTHTCNPPLVARCINLRCYCGYK	33	Sequence 858 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12778	LLPCGTDDDCANDPCIPPEYPHCHMEQCHCV	31	Sequence 859 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12779	LYVCRSVSDCPENFCVPPLTIQCINYTCICDDPPYGEPEYDNNDDFVTLNREKAKIKNEEMMMRERDMMIEIETYSVADDLDPHL	85	Sequence 860 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12780	LIFCFEDINCPFDKCFPQLPKCINSFCECV	30	Sequence 861 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12781	LIDCKTVDDCPSSWTKIYKCIDNKCRYSVVKGLII	35	Sequence 862 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12782	KHVRDCPKGIWRSCRYKCIDNKCVFTYWPH	30	Sequence 863 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12783	YILCKTVNDCPPNTRNLRYRCIDGKCKSHRVLYEWDESHTQDITITPCIEE	51	Sequence 864 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12784	QNIDSGGNRRCFRDSDCPKNMCPSYLVVKCLRSNCKCVRPGLQVRLNPN	49	Sequence 865 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12785	LNGHGRNRCFRDSDCPKVMCPSYLVTKCFKKHCRCRKPGLQVQLNPK	47	Sequence 866 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12786	TNFERKQISFSFFMKEYWPCVTDDDCPSDLCKKVDQIPKCVGGLCKCFPIRFGQWER	57	Sequence 867 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12787	LVQNECVTDGDCRRLYPHLIPRYPMCNEGTCVCIFE	36	Sequence 868 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12788	GIRCHDVSECPKGLYCNVGSHMECVKHQCKCIKNFEPIDLA	41	Sequence 869 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12789	IRTYRECENASDCYSIYWRAPYGTMRCVKGHCKQIKDVKVMKFLYCV	47	Sequence 870 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12790	IILCKDHFDCYENIRKLRCDFDTEKPFCISLNVCQCIKQ	39	Sequence 871 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12791	FRCLRNLDCPDSMCSSAYTPRCRHRTCVCLNNDEIKIL	38	Sequence 872 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12792	AIPCITDANCPCVFPLKPRCNFGYCICEEMIP	32	Sequence 873 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12793	RQGCKIDYDCIKVVCKDGHAARCIMRRCECVEILNPIDLGST	42	Sequence 874 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12794	GNYKCQTNYDCLRMWCPIGISPRCIKRRCKCIETLVQ	37	Sequence 875 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12795	EEIIIIKCQTAKDCPDIYNLFPLVYKCIDNICVDVRLEPPYDMSISPKSVHK	52	Sequence 876 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12796	AYVTRFWCYRDLDCRKDMCKPPFNPRCHNHICICRLWGL	39	Sequence 877 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12797	TTRCVRNSDCRHHICMYPLVPRCKYPLCRCV	31	Sequence 878 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12798	HKRCRVDFDCRMRMCVYPTVSVCIDRLCRCRRPPNM	36	Sequence 879 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12799	QKRCKEDFDCRIRSCAYPLIPVCIDPFCRCRRASI	35	Sequence 880 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12800	ERTCKEDFDCRMRYCVYPTIPLCDVKHCRCRRPPNL	36	Sequence 881 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12801	DVINCTQDSDCQSIGCLSHLKPKCTMLGFFFNAFVGICECDQVM	44	Sequence 882 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12802	TINVMCYYDHDCPFVLDHIAECKGGVCEYTAFFYE	35	Sequence 883 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12803	NDRIVYHGCYSDDQCPNECPAILMRCIHSLCVEFIKTDPLFI	42	Sequence 884 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12804	DKPRYTPRNAVKIAECVSYTDCQGGCPACYMRCIDGQCEPFIIKFI	46	Sequence 885 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12805	YNYIDCPVGCRACYMRCIDGQCIPFIKKLILFHLYVIVE	39	Sequence 886 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12806	GLIPCVSDADCPEELALVMKCINKLCELVME	31	Sequence 887 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12807	IDDSHCPHDICPFHLKPKCIFTKVVGQKFFSFSLDGKCGCM	41	Sequence 888 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12808	DKFVFDKNGADRCRSILDCPQDKCFPLLTLVCVNFACDCLHV	42	Sequence 889 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12809	QYNIGCKTDDDCQKYYTKMFGMKCFKSWCITGILD	35	Sequence 890 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12810	EDYYYIECQRDFDCPQLNSEIFAFKCIEKLCKLEFIYQQAPFLLGQV	47	Sequence 891 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12811	YKCNIDVDCPITPSPKFKWKCINKRCLYIRFDEIWTSDPRE	41	Sequence 892 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12812	LTKCETDANCPEISIFSPFFYKCINNGCVLIML	33	Sequence 893 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12813	LKKCITFEDCPISKTRVYKCLHGECRYTIPYIPKVPKVK	39	Sequence 894 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12814	EVDWIYHLCDTDTDCPEHWSKFFIYKCVNHVCDSISKVTTDSKEYKNFP	49	Sequence 895 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12815	AHVECHNDSACEKTVKCMLPRIPRCIKYQCLCGYSDDPGNRWSTRPKRIQKGSTERKGFLY	61	Sequence 896 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12816	VYIKCKTDADCPKSESTIFAMKCNNYRCIYDYIHKRNSYAT	41	Sequence 897 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12817	TYDAYDECQTELDCPKNIDCVYPKSMKCIDKKCICVGARMIIPRVL	46	Sequence 898 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12818	NGYRNIKYCFIDTDCPRSMCHYPEIVRCVDQCKCVRIMP	39	Sequence 899 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12819	CTEHRHCEIAMCKFPFIVRCSMNECNCERVHYLI	34	Sequence 900 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12820	KNEPEPKFIECVTDADCLNSQSKMYALICEKNRCIYEFLKSMHYNLS	47	Sequence 901 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12821	ECINDIDCPQTGNLFYVFICKNRICELINKYPQN	34	Sequence 902 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12822	DIYEECETDDYCPKYRDLLYVFKCIDKRCELVEAHA	36	Sequence 903 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12823	VHDVAHTDIPCEPDADCPKSLHEYFEMKCIDKKCEWSRKTSLIP	44	Sequence 904 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12824	CETDADCPRYTHNNFSLKCINKKCEWSAKLH	31	Sequence 906 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12825	EDIGGNCECIRDEDCFKQKRDEDCHKEYCMIFYVHKCENYKCVCAGMFN	49	Sequence 907 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12826	QEVLQYELFDCNEDRDCDNVICVAGGIPKCITPFCFCF	38	Sequence 908 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12827	IYYPISRPCKTDKDCPNRKNYKGKCRKGFCMSSRLR	36	Sequence 909 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12828	ISIYVRCASTNECYTTFKFAPLGSMRCVEGYCKHLKDFKVKTPLQIKEITPLLLHFP	57	Sequence 910 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12829	YINCKTDDDCPKLESRMVVLKCTNSRCAAVILH	33	Sequence 911 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12830	NHEISGWITELPFGMCTSILDCPMDSCTHPQQPWCELHGVPILYHGSEIGLCICI	55	Sequence 912 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12831	NHAISGLLPKLPFGCCTSNLDCPRHMCTHPQQPWCIFYGNRIMYRGSRLGICKCS	55	Sequence 913 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12832	SLHEISGYVLGLPAGYCTSNHHCPVYNCTHPKQPWCKLVRLQLLFHGSLIGLCDCI	56	Sequence 914 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12833	LNECTQDYDCPIEMCPFPFQPKCIMLKNLSIFSNSGICSCT	41	Sequence 915 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12834	GNFFEFFHKCTQDSDCPSLLCRNKSELPKCIAGFMCRCPNV	41	Sequence 916 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12835	EPDDNQKNCVSDSDCYKKFHLPRHFIMKCIKNRCTFV	37	Sequence 917 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12836	HCVIDAHCPRNMCGFHFPPRCVEGDCVC	28	Sequence 918 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12837	QVKCKTVKDCPIRRNRKYYCLFGICKYDVM	30	Sequence 919 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12838	LCDSNRDCRGYHCNWPKFPICVRMICECI	29	Sequence 920 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12839	QIFPKWCLYDKDCPQNMCRPGRIPKCIFGHCNCVKQRS	38	Sequence 921 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12840	APPVYCIEDEDCYDLCTSPLVEICTNYQCICLKRF	35	Sequence 922 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12841	KNSQGNKENICFKDADCPQDICSYPFKPKCNIYGYCSC	38	Sequence 923 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12842	FLPCVTKDDCAYDECISPRKPTCYLETCHCL	31	Sequence 924 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12843	WRCKKTDDCIKIEFCKFPKIARCTKPKFLFLEFGTGFCTCD	41	Sequence 925 from Patent US 20120157374	Synthetic construct	Antimicrobial	US 2012/0157374 A1	Patent Application	2012##6##21	EP2269627A1, EP2442823A1, WO2010146067A1	Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same.	The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
DRAMP12844	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	47	Sequence 2 from Patent US 20120213764	Homo sapiens	Antimicrobial	US 2012/0213764 A1	Patent Application	2012##8##23	EP2480245A1, WO2011036174A1	Novel method for the production of a antimicrobial peptide.	The present invention relates to a method of producing a peptide consisting of the amino acids 63 to 110 of dermcidin (SEQ ID NO: 3) comprising (a) culturing a host cell carrying a nucleic acid molecule encoding the peptide in an expressible form, and (b) optionally isolating the peptide from the culture. Furthermore, the invention relates to a nucleic acid molecule encoding a fusion protein comprising or consisting of (a) a peptide heterologous with regard to dermcidin protein-tag; and, C-terminally thereof (b) a peptide having the antimicrobial activity of dermcidin wherein the fusion protein contains an arginine residue located immediately N-terminally of the peptide of (b).
DRAMP12845	SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	48	Sequence 3 from Patent US 20120213764	Homo sapiens	Antimicrobial	US 2012/0213764 A1	Patent Application	2012##8##23	EP2480245A1, WO2011036174A1	Novel method for the production of a antimicrobial peptide.	The present invention relates to a method of producing a peptide consisting of the amino acids 63 to 110 of dermcidin (SEQ ID NO: 3) comprising (a) culturing a host cell carrying a nucleic acid molecule encoding the peptide in an expressible form, and (b) optionally isolating the peptide from the culture. Furthermore, the invention relates to a nucleic acid molecule encoding a fusion protein comprising or consisting of (a) a peptide heterologous with regard to dermcidin protein-tag; and, C-terminally thereof (b) a peptide having the antimicrobial activity of dermcidin wherein the fusion protein contains an arginine residue located immediately N-terminally of the peptide of (b).
DRAMP12846	SSLLEKGLDGAKKAVGGLGKLGKDA	25	Sequence 4 from Patent US 20120213764	Homo sapiens	Antimicrobial	US 2012/0213764 A1	Patent Application	2012##8##23	EP2480245A1, WO2011036174A1	Novel method for the production of a antimicrobial peptide.	The present invention relates to a method of producing a peptide consisting of the amino acids 63 to 110 of dermcidin (SEQ ID NO: 3) comprising (a) culturing a host cell carrying a nucleic acid molecule encoding the peptide in an expressible form, and (b) optionally isolating the peptide from the culture. Furthermore, the invention relates to a nucleic acid molecule encoding a fusion protein comprising or consisting of (a) a peptide heterologous with regard to dermcidin protein-tag; and, C-terminally thereof (b) a peptide having the antimicrobial activity of dermcidin wherein the fusion protein contains an arginine residue located immediately N-terminally of the peptide of (b).
DRAMP12847	SSLLEKGLDGAKKAVGGLGKLGK	23	Sequence 5 from Patent US 20120213764	Homo sapiens	Antimicrobial	US 2012/0213764 A1	Patent Application	2012##8##23	EP2480245A1, WO2011036174A1	Novel method for the production of a antimicrobial peptide.	The present invention relates to a method of producing a peptide consisting of the amino acids 63 to 110 of dermcidin (SEQ ID NO: 3) comprising (a) culturing a host cell carrying a nucleic acid molecule encoding the peptide in an expressible form, and (b) optionally isolating the peptide from the culture. Furthermore, the invention relates to a nucleic acid molecule encoding a fusion protein comprising or consisting of (a) a peptide heterologous with regard to dermcidin protein-tag; and, C-terminally thereof (b) a peptide having the antimicrobial activity of dermcidin wherein the fusion protein contains an arginine residue located immediately N-terminally of the peptide of (b).
DRAMP12848	YDPEAASAPGSGNPCHEASAAQKENAGEDPGLARQAPKPRKQRSSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV	90	Sequence 6 from Patent US 20120213764	Homo sapiens	Antimicrobial	US 2012/0213764 A1	Patent Application	2012##8##23	EP2480245A1, WO2011036174A1	Novel method for the production of a antimicrobial peptide.	The present invention relates to a method of producing a peptide consisting of the amino acids 63 to 110 of dermcidin (SEQ ID NO: 3) comprising (a) culturing a host cell carrying a nucleic acid molecule encoding the peptide in an expressible form, and (b) optionally isolating the peptide from the culture. Furthermore, the invention relates to a nucleic acid molecule encoding a fusion protein comprising or consisting of (a) a peptide heterologous with regard to dermcidin protein-tag; and, C-terminally thereof (b) a peptide having the antimicrobial activity of dermcidin wherein the fusion protein contains an arginine residue located immediately N-terminally of the peptide of (b).
DRAMP12849	YDPEAASAPGSGNPCHEASAAQKENAGEDPGLARQAPKPRKQRSSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL	91	Sequence 7 from Patent US 20120213764	Homo sapiens	Antimicrobial	US 2012/0213764 A1	Patent Application	2012##8##23	EP2480245A1, WO2011036174A1	Novel method for the production of a antimicrobial peptide.	The present invention relates to a method of producing a peptide consisting of the amino acids 63 to 110 of dermcidin (SEQ ID NO: 3) comprising (a) culturing a host cell carrying a nucleic acid molecule encoding the peptide in an expressible form, and (b) optionally isolating the peptide from the culture. Furthermore, the invention relates to a nucleic acid molecule encoding a fusion protein comprising or consisting of (a) a peptide heterologous with regard to dermcidin protein-tag; and, C-terminally thereof (b) a peptide having the antimicrobial activity of dermcidin wherein the fusion protein contains an arginine residue located immediately N-terminally of the peptide of (b).
DRAMP12850	GDDPDEDAINNALNKVCSTG	20	Sequence 1 from Patent US 20120245082	Gallus gallus	Antimicrobial	US 2012/0245082 A1	Patent Application	2012##9##27	WO2012129165A2, WO2012129165A3	Novel Antimicrobial Activity of Chicken NK-2 Peptide Against Apicomplexan Protozoa.	NK-2 synthetic peptide derived from cationic core region of porcine NK-lysin has an antimicrobial and antitumor polypeptide that is considered to play a pivotal role in innate defense immunity. To evaluate the antimicrobial properties of synthetic chicken NK-lysin peptides, we investigated cytolytic activity against apicomplexan parasites like Eimeria sporozoites, Neospora tachyzoites and Cryptosporidum sporozoites. The chicken NK-2 (cNK-2) lytic peptide which corresponds to amino acid residues of porcine NK-2 peptide significantly disrupted Eimeria and Cryptosporidum sporozoites and Neospora tachyzoites. In contrast, no bactericidal activity was observed on E. coli BMH71-18. The cNK-2 lytic peptide is novel antimicrobial agent which can be used to intervene and treat economically costly infections in the animal industry.
DRAMP12851	RRQRSICKQLLKKLRQQLSDALQNNDD	27	Sequence 2 from Patent US 20120245082	Gallus gallus	Antimicrobial	US 2012/0245082 A1	Patent Application	2012##9##27	WO2012129165A2, WO2012129165A3	Novel Antimicrobial Activity of Chicken NK-2 Peptide Against Apicomplexan Protozoa.	NK-2 synthetic peptide derived from cationic core region of porcine NK-lysin has an antimicrobial and antitumor polypeptide that is considered to play a pivotal role in innate defense immunity. To evaluate the antimicrobial properties of synthetic chicken NK-lysin peptides, we investigated cytolytic activity against apicomplexan parasites like Eimeria sporozoites, Neospora tachyzoites and Cryptosporidum sporozoites. The chicken NK-2 (cNK-2) lytic peptide which corresponds to amino acid residues of porcine NK-2 peptide significantly disrupted Eimeria and Cryptosporidum sporozoites and Neospora tachyzoites. In contrast, no bactericidal activity was observed on E. coli BMH71-18. The cNK-2 lytic peptide is novel antimicrobial agent which can be used to intervene and treat economically costly infections in the animal industry.
DRAMP12852	VCSTGRRQRSICKQLLKKLRQQ	22	Sequence 3 from Patent US 20120245082	Gallus gallus	Antimicrobial	US 2012/0245082 A1	Patent Application	2012##9##27	WO2012129165A2, WO2012129165A3	Novel Antimicrobial Activity of Chicken NK-2 Peptide Against Apicomplexan Protozoa.	NK-2 synthetic peptide derived from cationic core region of porcine NK-lysin has an antimicrobial and antitumor polypeptide that is considered to play a pivotal role in innate defense immunity. To evaluate the antimicrobial properties of synthetic chicken NK-lysin peptides, we investigated cytolytic activity against apicomplexan parasites like Eimeria sporozoites, Neospora tachyzoites and Cryptosporidum sporozoites. The chicken NK-2 (cNK-2) lytic peptide which corresponds to amino acid residues of porcine NK-2 peptide significantly disrupted Eimeria and Cryptosporidum sporozoites and Neospora tachyzoites. In contrast, no bactericidal activity was observed on E. coli BMH71-18. The cNK-2 lytic peptide is novel antimicrobial agent which can be used to intervene and treat economically costly infections in the animal industry.
DRAMP12853	AINNALNKVCSTGRRQRSICKQLLKKLRQQ	30	Sequence 4 from Patent US 20120245082	Gallus gallus	Antimicrobial	US 2012/0245082 A1	Patent Application	2012##9##27	WO2012129165A2, WO2012129165A3	Novel Antimicrobial Activity of Chicken NK-2 Peptide Against Apicomplexan Protozoa.	NK-2 synthetic peptide derived from cationic core region of porcine NK-lysin has an antimicrobial and antitumor polypeptide that is considered to play a pivotal role in innate defense immunity. To evaluate the antimicrobial properties of synthetic chicken NK-lysin peptides, we investigated cytolytic activity against apicomplexan parasites like Eimeria sporozoites, Neospora tachyzoites and Cryptosporidum sporozoites. The chicken NK-2 (cNK-2) lytic peptide which corresponds to amino acid residues of porcine NK-2 peptide significantly disrupted Eimeria and Cryptosporidum sporozoites and Neospora tachyzoites. In contrast, no bactericidal activity was observed on E. coli BMH71-18. The cNK-2 lytic peptide is novel antimicrobial agent which can be used to intervene and treat economically costly infections in the animal industry.
DRAMP12854	AGPAYXVGYXGNXGXVT	17	Sequence 1 from Patent US 20120263688	Ruminococcus gnavus	Antimicrobial	US 2012/0263688 A1	Patent Application	2012##10##18	CA2689050A1, CN101679984A, EP2152881A2, WO2008152252A2, WO2008152252A3	Rumc peptides with antimicrobial activity.	The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from Ruminococcus gnavus E1.
DRAMP12855	AGPAYXVGYXGNNGAVT	17	Sequence 2 from Patent US 20120263688	Ruminococcus gnavus	Antimicrobial	US 2012/0263688 A1	Patent Application	2012##10##18	CA2689050A1, CN101679984A, EP2152881A2, WO2008152252A2, WO2008152252A3	Rumc peptides with antimicrobial activity.	The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from Ruminococcus gnavus E1.
DRAMP12856	AGXIXSGSVAV	11	Sequence 3 from Patent US 20120263688	Ruminococcus gnavus	Antimicrobial	US 2012/0263688 A1	Patent Application	2012##10##18	CA2689050A1, CN101679984A, EP2152881A2, WO2008152252A2, WO2008152252A3	Rumc peptides with antimicrobial activity.	The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from Ruminococcus gnavus E1.
DRAMP12857	MRKIVAGKLQTGADFEGSKWGCVCSGSTAVANSHNAGPAYCVGYCGNNGVVTRNANANVAKTA	63	Sequence 4 from Patent US 20120263688	Ruminococcus gnavus	Antimicrobial	US 2012/0263688 A1	Patent Application	2012##10##18	CA2689050A1, CN101679984A, EP2152881A2, WO2008152252A2, WO2008152252A3	Rumc peptides with antimicrobial activity.	The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from Ruminococcus gnavus E1.
DRAMP12858	MRKIVAGKLQTGADFEGSKGGCKCSGGAVVENSHNAGPAYCVGYCGNNGVVTRNANANLARTK	63	Sequence 5 from Patent US 20120263688	Ruminococcus gnavus	Antimicrobial	US 2012/0263688 A1	Patent Application	2012##10##18	CA2689050A1, CN101679984A, EP2152881A2, WO2008152252A2, WO2008152252A3	Rumc peptides with antimicrobial activity.	The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from Ruminococcus gnavus E1.
DRAMP12859	MKLVETKTTKTGTNFEGNRAGCICNGTVAVANSHNAGPAYCVGYCGNSGVVTRNANANVAKTA	63	Sequence 6 from Patent US 20120263688	Ruminococcus gnavus	Antimicrobial	US 2012/0263688 A1	Patent Application	2012##10##18	CA2689050A1, CN101679984A, EP2152881A2, WO2008152252A2, WO2008152252A3	Rumc peptides with antimicrobial activity.	The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from Ruminococcus gnavus E1.
DRAMP12860	AGVIXXGTXAV	11	Sequence 10 from Patent US 20120263688	Ruminococcus gnavus	Antimicrobial	US 2012/0263688 A1	Patent Application	2012##10##18	CA2689050A1, CN101679984A, EP2152881A2, WO2008152252A2, WO2008152252A3	Rumc peptides with antimicrobial activity.	The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from Ruminococcus gnavus E1.
DRAMP12861	AGPAY	5	Sequence 11 from Patent US 20120263688	Ruminococcus gnavus	Antimicrobial	US 2012/0263688 A1	Patent Application	2012##10##18	CA2689050A1, CN101679984A, EP2152881A2, WO2008152252A2, WO2008152252A3	Rumc peptides with antimicrobial activity.	The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from Ruminococcus gnavus E1.
DRAMP12862	AGXVXSGSTAV	11	Sequence 12 from Patent US 20120263688	Ruminococcus gnavus	Antimicrobial	US 2012/0263688 A1	Patent Application	2012##10##18	CA2689050A1, CN101679984A, EP2152881A2, WO2008152252A2, WO2008152252A3	Rumc peptides with antimicrobial activity.	The present invention relates to the RumC1, RumC2 and RumC3 peptides with antimicrobial activity, and also to the genes encoding these peptides and isolated from Ruminococcus gnavus E1.
DRAMP12863	QSFEWIYKQIKKLWA	15	Sequence 1 from Patent US 20120308638	Synthetic constructn	Antimicrobial	US 2012/0308638 A1	Patent Application	2012##12##6	EP2513139A1, WO2011073663A1	Antimicrobial peptides.	The present invention provides novel therapeutic antimicrobial peptides that are bactericides and have an inhibitory effect on biofilms produced by biofilm-forming bacteria and especially biofilm-forming staphyloccocal bacteria. The invention includes the nucleic acids encoding the polypeptides, methods of treating bacterial infections, medical devices or implants or prosthetics impregnated with, covered or coated in the polypeptides, and means of delivery of the peptide to the oral cavity.
DRAMP12864	MAAFMKLIQFLATKGQKYVSLAWKHKGTILKWINAGQSFEWIYKQIKKLWA	51	Sequence 3 from Patent US 20120308638	Synthetic constructn	Antimicrobial	US 2012/0308638 A1	Patent Application	2012##12##6	EP2513139A1, WO2011073663A1	Antimicrobial peptides.	The present invention provides novel therapeutic antimicrobial peptides that are bactericides and have an inhibitory effect on biofilms produced by biofilm-forming bacteria and especially biofilm-forming staphyloccocal bacteria. The invention includes the nucleic acids encoding the polypeptides, methods of treating bacterial infections, medical devices or implants or prosthetics impregnated with, covered or coated in the polypeptides, and means of delivery of the peptide to the oral cavity.
DRAMP12865	MAGFLKVVQILAKYGSKAVQWAWANKGKILDWINAGQAIDWVVEKIKQILGIK	53	Sequence 4 from Patent US 20120308638	Lactococcus lactis QU 14	Antimicrobial	US 2012/0308638 A1	Patent Application	2012##12##6	EP2513139A1, WO2011073663A1	Antimicrobial peptides.	The present invention provides novel therapeutic antimicrobial peptides that are bactericides and have an inhibitory effect on biofilms produced by biofilm-forming bacteria and especially biofilm-forming staphyloccocal bacteria. The invention includes the nucleic acids encoding the polypeptides, methods of treating bacterial infections, medical devices or implants or prosthetics impregnated with, covered or coated in the polypeptides, and means of delivery of the peptide to the oral cavity.
DRAMP12866	MAGFLKVVQLLAKYGSKAVQWAWANKGKILDWLNAGQAIDWVVSKIKQILGIK	53	Sequence 5 from Patent US 20120308638	Lactococcus lactis QU 5	Antimicrobial	US 2012/0308638 A1	Patent Application	2012##12##6	EP2513139A1, WO2011073663A1	Antimicrobial peptides.	The present invention provides novel therapeutic antimicrobial peptides that are bactericides and have an inhibitory effect on biofilms produced by biofilm-forming bacteria and especially biofilm-forming staphyloccocal bacteria. The invention includes the nucleic acids encoding the polypeptides, methods of treating bacterial infections, medical devices or implants or prosthetics impregnated with, covered or coated in the polypeptides, and means of delivery of the peptide to the oral cavity.
DRAMP12867	MNMNFTKLFAIVLLAALVLLGQTEAGGLKKLGKKLEGAGKRVFKASEKALPVVVGIKAIGK	61	Sequence 1 from Patent US 20120316102	Synthetic constructs	Antimicrobial	US 2012/0316102 A1	Patent Application	2012##12##13	EP2531522A1, WO2011095939A1	Antimicrobial peptides of the cecropin family and therapeutic uses thereof.	The present invention relates to an antimicrobial peptide characterised in that said peptide includes the sequence SEQ ID No. 1 or the sequence SEQ ID No. 2, the sequence SEQ ID No. 2 representing a fragment of the sequence SEQ ID No. 1, for use as a drug. Advantageously according to the invention, the peptide having sequence SEQ ID No. 1 is used specifically for treating bacterial, viral and/or parasitic infections, and the peptide having sequence SEQ No. 2 is used for treating bacterial and/or viral infections.
DRAMP12868	GGLKKLGKKLEGAGKRVFKASEKALPVVVGIKAIGK	36	Sequence 2 from Patent US 20120316102	Synthetic constructs	Antimicrobial	US 2012/0316102 A1	Patent Application	2012##12##13	EP2531522A1, WO2011095939A1	Antimicrobial peptides of the cecropin family and therapeutic uses thereof.	The present invention relates to an antimicrobial peptide characterised in that said peptide includes the sequence SEQ ID No. 1 or the sequence SEQ ID No. 2, the sequence SEQ ID No. 2 representing a fragment of the sequence SEQ ID No. 1, for use as a drug. Advantageously according to the invention, the peptide having sequence SEQ ID No. 1 is used specifically for treating bacterial, viral and/or parasitic infections, and the peptide having sequence SEQ No. 2 is used for treating bacterial and/or viral infections.
DRAMP12869	MNMNFTKLFAIVLLAALVLLGQTEA	25	Sequence 3 from Patent US 20120316102	Synthetic constructs	Antimicrobial	US 2012/0316102 A1	Patent Application	2012##12##13	EP2531522A1, WO2011095939A1	Antimicrobial peptides of the cecropin family and therapeutic uses thereof.	The present invention relates to an antimicrobial peptide characterised in that said peptide includes the sequence SEQ ID No. 1 or the sequence SEQ ID No. 2, the sequence SEQ ID No. 2 representing a fragment of the sequence SEQ ID No. 1, for use as a drug. Advantageously according to the invention, the peptide having sequence SEQ ID No. 1 is used specifically for treating bacterial, viral and/or parasitic infections, and the peptide having sequence SEQ No. 2 is used for treating bacterial and/or viral infections.
DRAMP12870	GIGKFLHSAKKFGKAFVGEIMNSK	24	Sequence 1 from Patent US 5221732	Synthetic construct	Antimicrobial	US 5221732 A	Granted Patent	1993##6##22	Unknown	Antimicrobial magainin modified peptides.	Peptides which exhibit improved broad spectrum antimicrobial activity are designed and synthesized based on the peptide sequences of magainin or PGS peptides. The modified peptide analogues are synthesized by replacing low helical potential amino acid residues with high helical potential residues and modifying the two termini in order to enhance the amphiphilic structures as well as to prolong antimicrobial activity by lowering their susceptibility to protease degradation. For example, low propensity residues within a strategic region of magainin II, e.g. Ser.sup.8, Gly.sup.13 and Gly.sup.18 are modified with Ala which is known to have high propensity. Amidation of Ser.sup.23, and acylation of Gly.sup.1 with acetyl or beta-alanyl and substitution of Gly.sup.1 with beta-alanine are carried out in order to lower the susceptibility to exopeptidase action. A D-Ala modification for disrupting a stretch of the helical structure is also prepared so as to demonstrate the importance of an amphiphilic helic
DRAMP12871	IGKFLHAAKKFAKAFVAEIMNS	22	Sequence 2 from Patent US 5221732	Synthetic construct	Antimicrobial	US 5221732 A	Granted Patent	1993##6##22	Unknown	Antimicrobial magainin modified peptides.	Peptides which exhibit improved broad spectrum antimicrobial activity are designed and synthesized based on the peptide sequences of magainin or PGS peptides. The modified peptide analogues are synthesized by replacing low helical potential amino acid residues with high helical potential residues and modifying the two termini in order to enhance the amphiphilic structures as well as to prolong antimicrobial activity by lowering their susceptibility to protease degradation. For example, low propensity residues within a strategic region of magainin II, e.g. Ser.sup.8, Gly.sup.13 and Gly.sup.18 are modified with Ala which is known to have high propensity. Amidation of Ser.sup.23, and acylation of Gly.sup.1 with acetyl or beta-alanyl and substitution of Gly.sup.1 with beta-alanine are carried out in order to lower the susceptibility to exopeptidase action. A D-Ala modification for disrupting a stretch of the helical structure is also prepared so as to demonstrate the importance of an amphiphilic helic
DRAMP12872	GIGKFLHAAKKFAKAFVAEIMNS	23	Sequence 3 from Patent US 5221732	Synthetic construct	Antimicrobial	US 5221732 A	Granted Patent	1993##6##22	Unknown	Antimicrobial magainin modified peptides.	Peptides which exhibit improved broad spectrum antimicrobial activity are designed and synthesized based on the peptide sequences of magainin or PGS peptides. The modified peptide analogues are synthesized by replacing low helical potential amino acid residues with high helical potential residues and modifying the two termini in order to enhance the amphiphilic structures as well as to prolong antimicrobial activity by lowering their susceptibility to protease degradation. For example, low propensity residues within a strategic region of magainin II, e.g. Ser.sup.8, Gly.sup.13 and Gly.sup.18 are modified with Ala which is known to have high propensity. Amidation of Ser.sup.23, and acylation of Gly.sup.1 with acetyl or beta-alanyl and substitution of Gly.sup.1 with beta-alanine are carried out in order to lower the susceptibility to exopeptidase action. A D-Ala modification for disrupting a stretch of the helical structure is also prepared so as to demonstrate the importance of an amphiphilic helic
DRAMP12873	GIGKFLHSAKKFAKAFVAEIMNS	23	Sequence 4 from Patent US 5221732	Synthetic construct	Antimicrobial	US 5221732 A	Granted Patent	1993##6##22	Unknown	Antimicrobial magainin modified peptides.	Peptides which exhibit improved broad spectrum antimicrobial activity are designed and synthesized based on the peptide sequences of magainin or PGS peptides. The modified peptide analogues are synthesized by replacing low helical potential amino acid residues with high helical potential residues and modifying the two termini in order to enhance the amphiphilic structures as well as to prolong antimicrobial activity by lowering their susceptibility to protease degradation. For example, low propensity residues within a strategic region of magainin II, e.g. Ser.sup.8, Gly.sup.13 and Gly.sup.18 are modified with Ala which is known to have high propensity. Amidation of Ser.sup.23, and acylation of Gly.sup.1 with acetyl or beta-alanyl and substitution of Gly.sup.1 with beta-alanine are carried out in order to lower the susceptibility to exopeptidase action. A D-Ala modification for disrupting a stretch of the helical structure is also prepared so as to demonstrate the importance of an amphiphilic helic
DRAMP12874	IGKFLHSAKKFAKAFAFVAEIMNS	24	Sequence 5 from Patent US 5221732	Synthetic construct	Antimicrobial	US 5221732 A	Granted Patent	1993##6##22	Unknown	Antimicrobial magainin modified peptides.	Peptides which exhibit improved broad spectrum antimicrobial activity are designed and synthesized based on the peptide sequences of magainin or PGS peptides. The modified peptide analogues are synthesized by replacing low helical potential amino acid residues with high helical potential residues and modifying the two termini in order to enhance the amphiphilic structures as well as to prolong antimicrobial activity by lowering their susceptibility to protease degradation. For example, low propensity residues within a strategic region of magainin II, e.g. Ser.sup.8, Gly.sup.13 and Gly.sup.18 are modified with Ala which is known to have high propensity. Amidation of Ser.sup.23, and acylation of Gly.sup.1 with acetyl or beta-alanyl and substitution of Gly.sup.1 with beta-alanine are carried out in order to lower the susceptibility to exopeptidase action. A D-Ala modification for disrupting a stretch of the helical structure is also prepared so as to demonstrate the importance of an amphiphilic helic
DRAMP12875	FQWQRN	6	Sequence 1 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12876	FQWQR	5	Sequence 2 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12877	QWQR	4	Sequence 3 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12878	RRWQW	5	Sequence 5 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12879	RRWQ	4	Sequence 6 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12880	WQWR	4	Sequence 7 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12881	LRWQND	6	Sequence 9 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12882	LRWQN	5	Sequence 10 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12883	LRWQ	4	Sequence 11 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12884	FQWQRX	6	Sequence 13 from Patent US 5424396	Synthetic construct	Antimicrobial	US 5424396 A	Granted Patent	1995##6##13	CA2066997A1, CA2066997C, DE69223844D1, DE69223844T2, EP0510912A1, EP0510912B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing an amino acid sequence comprising at least from three to six arbitrary amino acid residues, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 2 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof.
DRAMP12885	RWQWR	5	Sequence 1 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12886	RRQWR	5	Sequence 2 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12887	KVSWR	5	Sequence 3 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12888	RNMRK	5	Sequence 4 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12889	RWQEK	5	Sequence 5 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12890	RRWQWR	6	Sequence 6 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12891	RRRQWR	6	Sequence 7 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12892	KTVSWR	6	Sequence 8 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12893	KRNMRK	6	Sequence 9 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12894	RWQEMK	6	Sequence 10 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12895	KTRRWQWRMKK	11	Sequence 11 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12896	KSRRRQWRMKK	11	Sequence 12 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12897	KTVSWQTYMKK	11	Sequence 13 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12898	KTFQWQRNMRK	11	Sequence 14 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12899	KTLRWQNEMRK	11	Sequence 15 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12900	RWQWX	5	Sequence 16 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12901	RRWQWX	6	Sequence 17 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12902	KTRRWQWRMKX	11	Sequence 18 from Patent US 5428016	Synthetic construct	Antimicrobial	US 5428016 A	Granted Patent	1995##6##27	CA2063063A1, CA2063063C, DE69220397D1, DE69220397T2, EP0503939A1, EP0503939B1	Antimicrobial peptide and antimicrobial agent.	An antimicrobial peptide containing at least the following amino acid sequence, or a derivative thereof, an antimicrobial agent containing said antimicrobial peptide or a derivative thereof as active components at a concentration of at least 1 µM, an antimicrobial composition containing said antimicrobial peptide or a derivative thereof, and a method for processing products which uses the antimicrobial agent containing at least said antimicrobial peptide or a derivative thereof: EQU A--X--A (where, A is an arginine residue or a lysine residue; and X is an amino acid sequence comprising at least from three to nine arbitrary amino acid residues other than cysteine residues).
DRAMP12903	IIGGR	5	Sequence 1 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12904	IVGGR	5	Sequence 2 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12905	HPQYNQR	7	Sequence 3 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12906	HPAYNPK	7	Sequence 5 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12907	HPAYNPR	7	Sequence 6 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12908	HPAYNQR	7	Sequence 7 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12909	HPQYAQR	7	Sequence 8 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12910	HPQYNQA	7	Sequence 9 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12911	HPQYNAR	7	Sequence 10 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12912	HAQYNQR	7	Sequence 11 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12913	HPQYNQ	6	Sequence 12 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12914	RHPQYNQR	8	Sequence 13 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12915	HPQYNQRTIQNDIMLLQLSR	20	Sequence 14 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12916	APQYNQR	7	Sequence 15 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12917	IIGGRESRPHSRPYMAYLQI	20	Sequence 16 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12918	QSPAGQSRCGGFLVREDFVL	20	Sequence 17 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12919	TAAHCWGSNINVTLGAHNIQ	20	Sequence 18 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12920	RRENTQQHITARRAIRHPQY	20	Sequence 19 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12921	RVRRNRNVNPVALPRAQEGL	20	Sequence 21 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12922	RPGTLCTVAGWGRVSMRRGT	20	Sequence 22 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12923	DTLREVQLRVQRDRQCLRIF	20	Sequence 23 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12924	GSYDPRRQICVGDRRERKAA	20	Sequence 24 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12925	FKGDSGGPLLCNNVAHGIVSY	21	Sequence 25 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12926	GKSSGVPPEVFTRFVSSFLPWIRTTMR	27	Sequence 26 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12927	IIGGH	5	Sequence 28 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12928	IIGGV	5	Sequence 29 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12929	HPQYNPQ	7	Sequence 30 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12930	HHQYNQR	7	Sequence 31 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12931	HPQANQR	7	Sequence 32 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12932	HPQKNTY	7	Sequence 33 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12933	HPQFNQR	7	Sequence 34 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12934	HPNYNQR	7	Sequence 35 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12935	HPEYNQR	7	Sequence 36 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12936	HPLYNQR	7	Sequence 37 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12937	RPGLTLCTVAGWG	13	Sequence 38 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12938	CTVAGWGRVSMRRGT	15	Sequence 39 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12939	WGRVSMRRGT	10	Sequence 40 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12940	KPGQTCSVAGWGQTAPLGKS	20	Sequence 42 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12941	KPQDVCYVAGWGRMAPMGKY	20	Sequence 43 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12942	EAQTRCQVAGWGSQSRSGGR	20	Sequence 44 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12943	GNGVQCLAMGWGLLGRNRGI	20	Sequence 45 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12944	PHGTQCLAMGWGRVGAHPPP	20	Sequence 46 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12945	AAGTTCVTTGWGLTRYTNAN	20	Sequence 47 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12946	GIGKFLHSAKKFKAFVGEIMN	21	Sequence 48 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12947	HPQYNPK	7	Sequence 49 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12948	HPQYNPR	7	Sequence 50 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12949	YPCYDPA	7	Sequence 51 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12950	HPAYNAK	7	Sequence 52 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12951	HPDYNQR	7	Sequence 53 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12952	YPCYDEY	7	Sequence 54 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12953	HPDYNPK	7	Sequence 55 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12954	HPDYNPD	7	Sequence 56 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12955	HPDYNAT	7	Sequence 57 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12956	HPAYDDK	7	Sequence 58 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12957	HPAFDRK	7	Sequence 59 from Patent US 5447914	Synthetic construct	Antimicrobial	US 5447914 A	Granted Patent	1995##9##5	CA2145313A1, CA2145313C, DE69331953D1, EP0665754A1, EP0665754A4, EP0665754B1, US5798336, WO1994007523A1	Antimicrobial peptides.	Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:22). It is active against Pseudomonas aeruginosa, Neisseria gonorrhoeae and Staphylococcus aureus. RRENTQQHITARRAIRHPQY (SEQ ID NO:19) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:20) also exhibited potent activity against P, aeruginosa strains, including clinical isolates. IIGGR (SEQ ID NO:1) and IVGGR (SEQ ID NO:2) act against both gram-negative and gram-positive bacterial strains. HPQYNQR (SEQ ID NO:3) and certain related peptides are also active against both gram-negative and gram-positive bacteria, including, but not limited to, strains of Escherichia coli, Neisseria gonorrhoeae, Staphylococcus aureus, Capnocytophage sputigena and Pseudomonas aeruginosa. The peptides of the present invention will be useful in pharmaceutical co
DRAMP12958	DFASCHTNGGICLPNRCPGHMIQIGICFRPRVKCCRSW	38	Sequence 1 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12959	VRNHVTCRINRGFCVPIRCPGRTRQIGTCFGPRIKCCRSW	40	Sequence 2 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12960	EGVRNHVTCRINRGFCVPIRCPGRTRQIGTCFGPRIKCCRSW	42	Sequence 3 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12961	ERVRNPQSCRWNMGVCIPFLCRVGMRQIGTCFGPRVPCCRR	41	Sequence 4 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12962	EVVRNPQSCRWNMGVCIPISCPGNMRQIGTCFGPRVPCCR	40	Sequence 5 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12963	EGVRNHVTCRIYGGFCVPIRCPGRTRQIGTCFGRPVKCCRRW	42	Sequence 6 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12964	EGVRNFVTCRINRGFCVPIRCPGHRRQIGTCLGPRIKCCR	40	Sequence 7 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12965	VRNFVTCRINRGFCVPIRCPGHRRQIGTCLGPQIKCCR	38	Sequence 8 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12966	EGVRNFVTCRINRGFCVPIRCPGHRRQIGTCLGPQIKCCR	40	Sequence 9 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12967	EGVRSYLSCWGNRGICLLNRCPGRMRQIGTCLAPRVKCCR	40	Sequence 10 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12968	GPLSCRRNGGVCIPIRCPGPMRQIGTCFGRPVKCCRSW	38	Sequence 11 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12969	YCXXNXGHCHPIRCPGXXRQIGTCHGZXHKCCR	33	Sequence 14 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12970	QIGTCFGRPVK	11	Sequence 17 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12971	NGGVCIPIR	9	Sequence 18 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12972	PVPMR	5	Sequence 19 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12973	PTHG	4	Sequence 20 from Patent US 5459235	Synthetic construct	Antimicrobial	US 5459235 A	Granted Patent	1995##10##17	CA2155739A1, DE69431654D1, DE69431654T2, EP0689550A1, EP0689550A4, EP0689550B1, US5821224, US6211148, WO1994021672A1	Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils.	The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
DRAMP12974	SKMIEGVFAKGFKGASHLFKGIG	23	Sequence 9 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12975	SNMIEGVFAKGFKKASHLFKGIG	23	Sequence 10 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12976	XXMIEXVFAKXFKXAXXLFKGIG	23	Sequence 12 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12977	RPGGQIAIAIGESIRKKASNELKKATKSLWS	31	Sequence 13 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12978	KAIQTAQGVVAVAPGAKIIGDRINQGVKEIKKFLKWK	37	Sequence 14 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12979	LAKLAVKAIKGAIAGAKSAMG	21	Sequence 15 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12980	RNSLPKVAYATA	12	Sequence 16 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12981	RQIIVFMRKKNFVTKILKKQR	21	Sequence 17 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12982	AKSRWY	6	Sequence 18 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12983	IGEDVYTPGISGDSLR	16	Sequence 19 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12984	GIGKFLREAGKFGKAFVGEIMKP	23	Sequence 20 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12985	MGRIARGSKMSSLIVSLLVVLVSLNLASETTA	32	Sequence 21 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12986	MGKNGSLCCFSLLLLLLLAGLASGHQVL	28	Sequence 22 from Patent US 5519115	Synthetic construct	Antimicrobial	US 5519115 A	Granted Patent	1996##5##21	CA2060455A1, CA2060455C, EP0497366A2, EP0497366A3, EP0919566A2, EP0919566A3	Reverse antimicrobial peptides.	The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.
DRAMP12987	KKIEKAIKHIPKKIKAGPGVTIGIAHAKSQLW	32	Sequence 1 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12988	KLKKALRALARHWKAGPGVTIGIAHAKSQLW	31	Sequence 2 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12989	QRAVRRIYRAIRHIPRRIRIRALAGPGVTIGIAHAKSQLW	40	Sequence 3 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12990	QRAVKKIEKAIKHIPKKIKIRALAGPGVTIGIAHAKSQLW	40	Sequence 4 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12991	IQRVAQKLKKALRALARHWKRALAGPGVTIGIAHAKSQLW	40	Sequence 5 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12992	IRALQRAVRHPRAIRRIYRGWKKAIRAGPGVTIGIAHAKSQLW	43	Sequence 6 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12993	KLIRKLIRWLRRKIRALQRAVAGPGVTIGIAHAKSQLW	38	Sequence 7 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12994	QRAVGWLRRIGRRIERVGQHLRALAGPGVTIGIAHAKSQLW	41	Sequence 8 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12995	RRIYRAIRHIPRRIRGWLRRIGRRIERVGQH	31	Sequence 9 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12996	KKIEKAIKHIPKKIKLKKALRALARHWK	28	Sequence 10 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12997	GWLRRIGRRIERVGQHKLKKALRALARHWK	30	Sequence 11 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12998	KLKKALRALARHWKGWLRRIGRRIERVGQH	30	Sequence 12 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP12999	AIAKFAKKALKSMLALMGEAVQT	23	Sequence 13 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13000	AIAIFKRIAKINFKALMGEAVQT	23	Sequence 14 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13001	AIANFERLMKKLIWALMGEAVQT	23	Sequence 15 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13002	KLKKALRALARHWK	14	Sequence 16 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13003	IQRVAQKLKKALRALARHWKRAL	23	Sequence 17 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13004	IRALQRAVRHPRAIRRIYRGWKKAIR	26	Sequence 18 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13005	KWKKALRALARHLK	14	Sequence 19 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13006	KLKKALRWLARHAK	14	Sequence 20 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13007	GAYRAIRHIPRRIR	14	Sequence 21 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13008	RRIYRAIRHIPRRIR	15	Sequence 22 from Patent US 5607914	Synthetic construct	Antimicrobial	US 5607914 A	Granted Patent	1997##3##4	CA2180657A1, CA2180657C, EP0738320A1, US5717061, WO1995018855A2	Synthetic antimicrobial peptides.	Synthetic polypeptides exhibiting amphipathic alpha-helices provide cell-expressible antimicrobial activity.
DRAMP13009	IVGGRKARPRQFPFLASIQNQGRHF	25	Sequence 2 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13010	IVGGHEAXXPSDPYMDSLDM	20	Sequence 3 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13011	IHNFNINY	8	Sequence 4 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13012	TCRYLLVRSLQTFSQAWFTCRRCYRGNLVSIHNFNINYRI	40	Sequence 7 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13013	IVGGHEAQPHSRPYMASLEM	20	Sequence 8 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13014	IVGGRKARPHQFPFLASIQN	20	Sequence 9 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13015	IVGGHEAQPHSRPYMASLZM	20	Sequence 10 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13016	CYCRIPACIAGERRY	15	Sequence 11 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13017	VXSXRLVFXRRTGLR	15	Sequence 12 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13018	XPPQFTRAQWFAIQH	15	Sequence 13 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13019	IIGGRESRPHSRPYM	15	Sequence 14 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13020	TCRYLLVRSLQTFSQ	15	Sequence 16 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13021	IVGGRKARPRQFPFL	15	Sequence 17 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13022	IVGGHEAXXPSDPYM	15	Sequence 18 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13023	VNCETSCVQQPPCFP	15	Sequence 19 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13024	IVGGRRARPHAXPXM	15	Sequence 20 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13025	VNPGVVVRISQKGLD	15	Sequence 21 from Patent US 5654167	Synthetic construct	Antimicrobial	US 5654167 A	Granted Patent	1997##8##5	Unknown	Antimicrobial proteins, compositions containing same and uses thereof.	The present invention provides purified polypeptides useful as antimicrobial agents. These polypeptides comprise human polymorphonuclear leukocyte polypeptides having molecular weights of about 25,000 daltons, 29,000 daltons and 54,000 daltons. These polypeptides have respiratory burst-independent, antibacterial activity at a pH from about 5.0 to about 8.0, at calcium ion concentrations up to about 10 mM, and at sodium chloride concentrations up to about 0.3M.
DRAMP13026	RVIEVVQGACRAIRHIPRRIRQGLERIL	28	Sequence 1 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13027	YHRLRDLLLIVTRIVELLGRR	21	Sequence 2 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13028	DLWETLRRGGRWILAIPRRIRQGLELTL	28	Sequence 3 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13029	FLIRQLIRLLTWLFSNCRTLLSRVY	25	Sequence 4 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13030	LLSRVYQILQPILQRLSATLQRIREVLR	28	Sequence 5 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13031	RIAGYGLRGLAVIIRICIRGLNLIFEIIR	29	Sequence 6 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13032	RVIEVVQGACRAIRHIPRRIR	21	Sequence 7 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13033	VVQGACRAIRHIPRRIR	17	Sequence 8 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13034	GACRAIRHIPRRIR	14	Sequence 9 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13035	RVIRVVQGACRAIRHIPRRIR	21	Sequence 10 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13036	RVIEVVRGACRAIRHIPRRIR	21	Sequence 11 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13037	RVIEVVQGICRAIRHIPRRIR	21	Sequence 12 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13038	RVISVVQGACRAIRRIPRRIR	21	Sequence 13 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13039	RVIRVVQGACRAIRHIPRRIRQGLERIL	28	Sequence 14 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13040	RVIEVVRGACRAIRHIPRRIRQGLERIL	28	Sequence 15 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13041	RVIEVVQGICRAIRHIPRRIRQGLERIL	28	Sequence 16 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13042	RVISVVQGACRAIRRIPRRIRQGLERIL	28	Sequence 17 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13043	RVIEVVQGACRAIRHIPRRIRQILERIL	28	Sequence 18 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13044	RVIEVVQGACRAIRHIPRRIRQGLRRIL	28	Sequence 19 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP18752	RCLCGRGFC	9	Sequence 32 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18750	RCLCGLGVC	9	Sequence 30 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18751	RCLCGRGVC	9	Sequence 31 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18749	RCLCVRGIC	9	Sequence 29 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP13048	RVIEVVQGACRAIRRIPRRIR	21	Sequence 23 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP18747	RCLCRRGVC	9	Sequence 27 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18748	RCLCTRGIC	9	Sequence 28 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18746	RCICGRGFC	9	Sequence 26 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18744	RCICGLGIC	9	Sequence 24 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18745	RCICGRGVC	9	Sequence 25 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP13052	RVIEVVQGACRAIRRIPRRIRQGLERIL	28	Sequence 27 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13053	VVRGACRAIRHIPRRIR	17	Sequence 28 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13054	VVQGICRAIRHIPRRIR	17	Sequence 29 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13055	VVQRACRAIRRIPRRIR	17	Sequence 30 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13056	VVRGACRAIRHIPRRIRGLERIL	23	Sequence 31 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13057	VVQGICRAIRHIPRRIRGLERIL	23	Sequence 32 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13058	VVQGACRAIRRIPRRIRGLERIL	23	Sequence 33 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13059	GACRAIRRIPRRIR	14	Sequence 34 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13060	GACRAIRRIPRRIRGLERIL	20	Sequence 35 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13061	VVQRACRAIRHIPRRIR	17	Sequence 36 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13062	RACRAIRHIPRRIR	14	Sequence 37 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13063	RVIRVVRGACRAIRHIPRRIR	21	Sequence 38 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP18743	RCICVRGIC	9	Sequence 23 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP13065	RRIRHIPRAIRVVQGAC	17	Sequence 40 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13066	RIRRPIHRIARCAGQVVEIVR	21	Sequence 41 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13067	LIRELGQRIRRPIHRIARCAGQVVEIVR	28	Sequence 42 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13068	LIRELGQRIRRPIHRIARCAGQVVRIVR	28	Sequence 43 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13069	LIRELGQRIRRPIHRIARCAGRVVEIVR	28	Sequence 44 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13070	LIRELGQRIRRPIHRIARCIGQVVEIVR	28	Sequence 45 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13071	LIRELGQRIRRPIRRIARCAGQVVEIVR	28	Sequence 46 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13072	LIRELGIRIRRPIHRIARCAGQVVEIVR	28	Sequence 47 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13073	LIRRLGQRIRRPIHRIARCAGQVVEIVR	28	Sequence 48 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP18741	RCICRRGIC	9	Sequence 21 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18742	RCICTRGIC	9	Sequence 22 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP13075	RIRRPIHRIARCAGQVVRIVR	21	Sequence 50 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13076	RIRRPIHRIARCAGRVVEIVR	21	Sequence 51 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13077	RIRRPIHRIARCIGQVVEIVR	21	Sequence 52 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13078	RIRRPIRRIARCAGQVVEIVR	21	Sequence 53 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13079	RIRRPIHRIIRCIGQVVRIVR	21	Sequence 54 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13080	RIRRPIRRIIRCIGQVVEIVR	21	Sequence 55 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13081	LIRELGQRIRRPIHRIARCAGQVV	24	Sequence 56 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13082	LIRELRQRIRRPIHRIARCARQVV	24	Sequence 57 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13083	LIRELGQRIRRPIHRIARCAGRVV	24	Sequence 58 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13084	LIRELGQRIRRPIHRIARCIGQVV	24	Sequence 59 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13085	LIRELGQRIRRPIRRIARCAGQVV	24	Sequence 60 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13086	LIRELGIRIRRPIHRIARCAGQVV	24	Sequence 61 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13087	LIRRLGQRIRRPIHRIARCAGQVV	24	Sequence 62 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13088	LIRELGQRIRRPIHRIARCAG	21	Sequence 63 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13089	LIRELGQRIRRPIHRIARCAR	21	Sequence 64 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13090	LIRELGQRIRRPIHRIARCAI	21	Sequence 65 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13091	LIRELGQRIRRPIHRIARCIG	21	Sequence 66 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13092	LIRELGQRIRRPIRRIARCAG	21	Sequence 67 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13093	LIRELGIRIRRPIHRIARCAG	21	Sequence 68 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13094	LIRRLGQRIRRPIHRIARCAG	21	Sequence 69 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13095	RAIRRAIRGAPRAIL	15	Sequence 70 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13096	RAIRRAIRGAPRAILRAIL	19	Sequence 71 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13097	KVIEVVQGACKAIKHIPKKIKQGLEKIL	28	Sequence 72 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13098	LWETLRRGGRWILAIPRRIR	20	Sequence 73 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13099	DLWETLRRIIRWILAIPRRIRQGLELTL	28	Sequence 74 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13100	DLWETLRRGGRWILAIPRRIRQGLELCL	28	Sequence 75 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13101	DLWETLRRGCRWILAIPRRIRQGLELTL	28	Sequence 76 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13102	DLWETLRRIIRWILAIPRRIRQGLELCL	28	Sequence 77 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13103	LWETLRRGGRWILAIPRRIRQGLELTL	27	Sequence 78 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13104	LWETLRRGGRWILAIPRRIRQGLELCL	27	Sequence 79 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13105	LWETLRRGCRWILAIPRRIRQGLELTL	27	Sequence 80 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13106	LWRTLRRGGRWILAIPRRIRQGLELTL	27	Sequence 81 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13107	LWETLRRGGRWILAIPRRIRQGLRLTL	27	Sequence 82 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13108	LWETLRRGGRWILAIPRRIRRGLELTL	27	Sequence 83 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13109	LWETLRRGGRWILAIPRRIRRQIELTL	27	Sequence 84 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13110	LWELLRRGGRWILAIPRRIRQGLELTL	27	Sequence 85 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13111	LWRLLRRGGRWILAIPRRIRQGLELTL	27	Sequence 86 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13112	DLWETLRRIIRWILAIPRRIR	21	Sequence 87 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13113	DLWETLRRGGRWILAIPRRIR	21	Sequence 88 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13114	DLWETLRRGCRWILAIPRRIR	21	Sequence 89 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP18740	RCLCGRGIC	9	Sequence 20 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP13116	LWETLRRIIRWILAIPRRIR	20	Sequence 91 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13117	LWETLRRGCRWILAIPRRIR	20	Sequence 92 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP18738	MRTFALLTAMLLLVALHAQAEARQARADEAAAQQQPGADDQGMAHSFTRPENAALPLSESARGLRCLCRRGVCQLL	76	Sequence 17 from Patent US 20090264344	Macaca mulatta	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18739	RCICGRGIC	9	Sequence 19 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18737	MRTFALLTAMLLLVALHAQAEARQARADEAAAQQQPGTDDQGMAHSFTWPENAALPLSESAKGLRCICTRGFCRLL	76	Sequence 15 from Patent US 20090264344	Macaca mulatta	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18736	MRIIALLAAILLVALQVRAGPLQARGDEAPGQEQRGPEDQDISISFAWDKSSALQVSGSTRGMVCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRVD	97	Sequence 13 from Patent US 20090264344	Homo sapiens	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP13121	LWELLRRGGRWILAIPRRIR	20	Sequence 96 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13122	LWRLLRRGGRWILAIPRRIR	20	Sequence 97 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13123	LRRGGRWILAIPRRIR	16	Sequence 98 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13124	LWETLRRGGRWILAIPRAIL	20	Sequence 99 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13125	LRRGGRWILAIPRAIL	16	Sequence 100 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13126	LWETLRRGGRWILAIPREIL	20	Sequence 101 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13127	LRRGGRWILAIPREIL	16	Sequence 102 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13128	WILAIPRRIRGGRLWETL	18	Sequence 103 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13129	WETLPRRIRGGRLWILAI	18	Sequence 104 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13130	RIRRPIALIWRGGRRLTEWL	20	Sequence 105 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13131	DLWETLKKGGRWILAIPRRIKQGLELTL	28	Sequence 106 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13132	LWETLGRVGRWVLAIPRRIRQGLELAL	27	Sequence 107 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13133	YHRLRRLLLIVTRIVELLGRR	21	Sequence 108 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13134	YHRLRDLLRIVTRIVELLGRR	21	Sequence 109 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13135	YHRLRDLLLIVRRIVELLGRR	21	Sequence 110 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13136	YHRLRDLLLIVTRIVRLLGRR	21	Sequence 111 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13137	YHRLRDLLLIVTRIVCLLGRR	21	Sequence 112 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13138	YHRLRDLLLIVRRIVCLLGRR	21	Sequence 113 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13139	YHRLLRDLLIVTRIVELLGRR	21	Sequence 114 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13140	YHRLRRLLLIVTRIVELL	18	Sequence 115 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13141	YHRLRDLLRIVTRIVELL	18	Sequence 116 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13142	YHRLRDLLLIVRRIVELL	18	Sequence 117 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13143	YHRLRDLLLIVTRIVRLL	18	Sequence 118 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13144	YHRLRDLLLIVTRIVCLL	18	Sequence 119 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13145	YHRLRDLLLIVRRIVCLL	18	Sequence 120 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13146	YHRLLRDLLIVTRIVELL	18	Sequence 121 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13147	YHRLRDLLLIVTRIVELL	18	Sequence 122 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13148	RRGLLEVIRTVILPRRLLDRL	21	Sequence 123 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13149	YHRLRDLALIVTRIVELL	18	Sequence 124 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13150	RRGLLRVIRTVILALDIL	18	Sequence 125 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13151	RRGLLEVIRTVILLLDRLRHY	21	Sequence 126 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13152	RRGLLEVIRTVILALDRLRHY	21	Sequence 127 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13153	RRGLLEVIRTVILALDRL	18	Sequence 128 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13154	YHRLRDLLLIVCRIVELL	18	Sequence 129 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13155	YHRLRDLLLIVCRIVELLGRR	21	Sequence 130 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP18734	RGCICRCIGRGCICRCIG	18	Sequence 10 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18735	AQAEPLQARADEAAAQEQPGADDQEMAHAFTWHESAALPLSDSARGLRCICGRGICRLL	59	Sequence 12 from Patent US 20090264344	Homo sapiens	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP13157	RRGLLEVIRCVILLLDRL	18	Sequence 132 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13158	RRGLLRVIRTVILLLDRL	18	Sequence 133 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13159	RRGLLEVIRTVILLLRRL	18	Sequence 134 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13160	RRGLLEVIRCVILLLDRLRHY	21	Sequence 135 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13161	RRGLLRVIRTVILLLDRLRHY	21	Sequence 136 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13162	RRGLLEVIRTVILLLRRLRHY	21	Sequence 137 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13163	YHKLKLLLIVTKIVELLGKK	20	Sequence 138 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13164	FLIRQLIRQLLTWQPILQYILQ	22	Sequence 139 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13165	FLIRQLIRLLTWLFSNCRTLLSEVY	25	Sequence 140 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13166	FLIRQLIRLLTWLFSNCRTLL	21	Sequence 141 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13167	LLTRCNSFLWTLLRILQRILF	21	Sequence 142 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13168	FLIRQLIRLLTWLFPNCRTLLSRVY	25	Sequence 143 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13169	YVRSLLTRCNSFLWTLLRILQRILF	25	Sequence 144 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13170	FLIKQLIKLLTWLFSNCKTLLSKVY	25	Sequence 145 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13171	RLVERIRQLTASRQLIPQLIQYV	23	Sequence 146 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13172	RLVRRIRQLTASRQLIPQLIQYV	23	Sequence 147 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13173	LLSRVYQILQPILQRLSATLQAIREVL	27	Sequence 148 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13174	LLSRVYQILQPILQRLCATLQRIREVLR	28	Sequence 149 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13175	RLVERIRQLTASLRQLIPQLIQYVRSLL	28	Sequence 150 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13176	LLSKVYQILQPILQKLSATLQKIKEVLK	28	Sequence 151 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13177	RLLTWLFSNCRTLLSRVYQILQPIL	25	Sequence 152 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13178	RLLTWLFSNRRTLLSRVYQILQEIL	25	Sequence 153 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13179	RLLTWLRRTLLSRVYQILQEIL	22	Sequence 154 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13180	RIAGYGLRGLAVIIRCIIRGLNLIFEIIR	29	Sequence 155 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13181	RIAGYGLRGLAVIIRIICRGLNLIFEIIR	29	Sequence 156 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13182	RIAGYGLRGLAVIPRRICIRGLNLIFEIIR	30	Sequence 157 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13183	RIIEFILNLGRICIRIIVALGRLGYGAIR	29	Sequence 158 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13184	KIAGYGLKGLAVIIKICIKGLNLIFEIIK	29	Sequence 159 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13185	RVIRVVQGACRAIRHIPRRIRQGLRRIL	28	Sequence 160 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13186	RVIEVVQGACRAIEHIPRRIEQGLERIL	28	Sequence 161 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13187	RVIEVVQGACRAIEHIPRRIRQGLERIL	28	Sequence 162 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13188	RVIEVVQGACRAIRHIPRRIEQGLERIL	28	Sequence 163 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13189	RVIEVVQGACRASRHIPRRIRQGLERIL	28	Sequence 164 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13190	RVIEVVQGACRAIRHIPRRSRQGLERIL	28	Sequence 165 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13191	FLIRQLIELLTWLFSNCRTLLSEVY	25	Sequence 166 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13192	LLSEVYQILQPILQELSATLQRIREVLR	28	Sequence 167 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13193	YHELRDLLLIVTRIVELLGRE	21	Sequence 168 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13194	RVIEVVQGAYRAIRHIPRRIRQGLERIL	28	Sequence 169 from Patent US 5714577	Synthetic construct	Antimicrobial	US 5714577 A	Granted Patent	1998##2##3	US5945507	Antimicrobial peptides.	The invention is directed to antimicrobial peptides which correspond in sequence to selective amino acid sequences in viral transmembrane proteins. In particular, the proteins are derived from lentiviruses, primarily HIV and SIV. The peptides comprise arginine-rich sequences, which, when modeled for secondary structure, display a high amphipathicity and hydrophobic moment. They are highly inhibitory to microorganisms, while being significantly less active in regard to mammalian cells. As a result, the peptides of the invention may be defined as selective antimicrobial agents. The invention is also directed to antimicrobial peptides which are structural and functional analogs and homologs of the peptides and which exhibit selective inhibitory activity towards microorganisms. The invention is also directed to pharmaceutical compositions comprising the antimicrobial peptides of the invention and to methods for their use in inhibiting microbial growth and treatment of microbial infections.
DRAMP13195	GFFKKAXRKVKHAGRRVLDTAKGVGRHYVNNXLNRYR	37	Sequence 1 from Patent US 5734015	Synthetic construct	Antimicrobial	US 5734015 A	Granted Patent	1998##3##31	CA2224976A1, EP0833841A1, WO1997000269A1	Family of linear antimicrobial peptides from hagfish intestine.	A new family of linear antimicrobial peptide from hagfish intestine is described. This invention relates to proteins with antimicrobial properties isolated from hagfish intestine and their corresponding chemical sequences. The antibiotics obtained include, but are not limited to, peptides having a sequence selected from the group consisting of: ##STR1##.
DRAMP13196	GFFKKAXRKVKHAGRRVLDTAKGVGRHYVNNWLNRYR	37	Sequence 2 from Patent US 5734015	Synthetic construct	Antimicrobial	US 5734015 A	Granted Patent	1998##3##31	CA2224976A1, EP0833841A1, WO1997000269A1	Family of linear antimicrobial peptides from hagfish intestine.	A new family of linear antimicrobial peptide from hagfish intestine is described. This invention relates to proteins with antimicrobial properties isolated from hagfish intestine and their corresponding chemical sequences. The antibiotics obtained include, but are not limited to, peptides having a sequence selected from the group consisting of: ##STR1##.
DRAMP13197	GXFKKAXRKVKNAGRRVLKGVGIHYGVGLI	30	Sequence 3 from Patent US 5734015	Synthetic construct	Antimicrobial	US 5734015 A	Granted Patent	1998##3##31	CA2224976A1, EP0833841A1, WO1997000269A1	Family of linear antimicrobial peptides from hagfish intestine.	A new family of linear antimicrobial peptide from hagfish intestine is described. This invention relates to proteins with antimicrobial properties isolated from hagfish intestine and their corresponding chemical sequences. The antibiotics obtained include, but are not limited to, peptides having a sequence selected from the group consisting of: ##STR1##.
DRAMP13198	GFFKKAWRKVKHAGRRVLDTAKGVGRHYVNNWLNRYR	37	Sequence 4 from Patent US 5734015	Synthetic construct	Antimicrobial	US 5734015 A	Granted Patent	1998##3##31	CA2224976A1, EP0833841A1, WO1997000269A1	Family of linear antimicrobial peptides from hagfish intestine.	A new family of linear antimicrobial peptide from hagfish intestine is described. This invention relates to proteins with antimicrobial properties isolated from hagfish intestine and their corresponding chemical sequences. The antibiotics obtained include, but are not limited to, peptides having a sequence selected from the group consisting of: ##STR1##.
DRAMP13199	LCNERPSQTWSGNCGNTAHCDKQCQDWEKASHGACHKRENHWKCFCYFNC	50	Sequence 2 from Patent US 5750504	Synthetic construct	Antimicrobial	US 5750504 A	Granted Patent	1998##5##12	CA2177854A1, CN1080303C, CN1139454A, DE69434071D1, DE69434071T2, EP0736096A1, EP0736096B1, US5919918, WO1995018229A1	Antimicrobial proteins.	Antimicrobial proteins capable of isolation from seeds of Heuchera or Aesculus show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.
DRAMP13200	ZKLCERPSGTWSGVCGNNNACKNQCINLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 3 from Patent US 5750504	Synthetic construct	Antimicrobial	US 5750504 A	Granted Patent	1998##5##12	CA2177854A1, CN1080303C, CN1139454A, DE69434071D1, DE69434071T2, EP0736096A1, EP0736096B1, US5919918, WO1995018229A1	Antimicrobial proteins.	Antimicrobial proteins capable of isolation from seeds of Heuchera or Aesculus show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.
DRAMP13201	ZKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 4 from Patent US 5750504	Synthetic construct	Antimicrobial	US 5750504 A	Granted Patent	1998##5##12	CA2177854A1, CN1080303C, CN1139454A, DE69434071D1, DE69434071T2, EP0736096A1, EP0736096B1, US5919918, WO1995018229A1	Antimicrobial proteins.	Antimicrobial proteins capable of isolation from seeds of Heuchera or Aesculus show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.
DRAMP13202	ELCEKASKTWSGNCGNTGHCDNQCKSWEGAAHGACHVRNGKHMCFCYFNC	50	Sequence 5 from Patent US 5750504	Synthetic construct	Antimicrobial	US 5750504 A	Granted Patent	1998##5##12	CA2177854A1, CN1080303C, CN1139454A, DE69434071D1, DE69434071T2, EP0736096A1, EP0736096B1, US5919918, WO1995018229A1	Antimicrobial proteins.	Antimicrobial proteins capable of isolation from seeds of Heuchera or Aesculus show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.
DRAMP15055	MERIYVIPLRKAKNVPRTIRAPKAVKIVREFLMKHMKADTVKLDESINEKLWERGIQKIPPRIKVKAVKDEDGVVEATLEE	81	Sequence 889 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15056	MKKAIHFQSQPVVFNCASCNSNFTIDSTAKQKDLAIDICGKCHPFYIGQLTKQTVHGRAEKLSQKFNAGKAFLENKTKKSNQAKVEKQTRHRSINEL	97	Sequence 890 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15057	MKANIHPAYAETTVVCGCGNTFQTRSTKPGGRIVVEVCSQCHPFYTGKQKILDSGGRVARFEKRYGKRKVGVDQVAAYPEQNNK	84	Sequence 891 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15058	MKKDFHFPSQSVSFKCASCSNSFTIESTLKQKEITIDICGKCHPFYIGELTKQTVHGRAEKLSGKFNAGKAFLENKTPKKAKGKTEEYTKHRSLNEL	97	Sequence 892 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15059	MKSDIHPAYEETTVVCGCGNTFQTRSTKPGGRIVVEVCSQCHPFYTGKQKILDSGGRVARFEKRYGKRKVGADKAVSTGK	80	Sequence 893 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15060	MPKADIHPTWYPDAKVTCNGEVIMTVGSTKPEINVEIWSGNHPFYTGTQKIIDTEGRVDRFMRKYGMKEKTTGDKQDKKKK	81	Sequence 895 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15061	AVPFRRTSKTRKRLRRTHFKLQVPGMVQCPNCGEWKLAHRVCKACGTYKGRDVVNK	56	Sequence 896 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15062	AVPFRRTSKMKKRLRRTHFKLNVPGMTECPSCGEMKLSHRVCKACGSYNGKDINVKSN	58	Sequence 897 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15063	MAKHPVPKKKTSKSKRDMRRSHHALTAPNLTECPQCHGKKLSHHICPNCGYYDGRQVLAV	60	Sequence 898 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15064	AVQQNKPTRSKRGMRRSHDALTAVTSLSVDKTSGEKHLRHHITADGYYRGRKVIAK	56	Sequence 903 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15065	AVQQNKKSRSRRDMRRSHDALTTAAVSVDKASGETHLRHHVTADGYYRGRKVINK	55	Sequence 904 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15066	MAVPDRRVSKTRAAKRRTHYSVKLAKPIKAKDGTWKLPHHINKFTKEY	48	Sequence 905 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15067	MAVPARHTSSAKKNRRRTHYKLTAPTVTFDETTGDYRHSHRVSLKGYYKGRKVRDDTK	58	Sequence 907 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15068	AVQQRRSSKHRRDKRRSHDALTLQTLSVCKKCGKKKLSHRVCSCGMYGELRVKKAH	56	Sequence 911 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15069	AVQQRRSSKHRRDKRRSHDALTAQALSVCQKCGKKKLFHRVCSCGMYGDLRVKKAY	56	Sequence 912 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15070	AVPKKKTSKAKRDQRRAHWRRQASSQAQKALSLGKSILSGRSTFLYPPAEEEGEEE	56	Sequence 913 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15071	AKHPVPKKKTSKARRDARRSHHALTPPILVPCPECKAMKPPHTVCPECGYYAGRKVLEV	59	Sequence 914 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15072	MKKKVTLACKNCGSRNYTTMKSSAALAERLEVKKYCNNCNSHTVHLETK	49	Sequence 916 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15073	MRVNITLACTECGERNYITSKNKRNNPERLELKKYCPRDRKVTLHRETK	49	Sequence 917 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15074	MRKKITLACKTCGNRNYTTMKSSASAAERLEVKKYCSTCNSHTAHLETK	49	Sequence 918 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15075	AKGIREKIKLVSSAGTGHFYTTTKNKRTKPEKLELKKFDPVVRQHVIYKEAKIK	54	Sequence 919 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15076	MAAKGAREKIRLVSTAETGHFYTTDKNKRNMPEKMEIKKFDPVVRKHVIYKEAKIK	56	Sequence 920 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15077	MKVKIGLKCSDCEDINYSTTKNAKTNTEKLELKKFCPRENKHTLHKEIKLKS	52	Sequence 921 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15078	MRVKITLICSSCGNKNYISSKNKATHPEKVETMKFCPKERIVTLHREG	48	Sequence 922 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15079	MRVNITLEHKESGERLYLTQKNKRNTPDKLELKKYSKKLRKHVIFKEVK	49	Sequence 923 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15080	MRSSTNKKATLVCVECLSRNYSVNKSGLTQKQRLEIKKFCTTCNAHTLHKETR	53	Sequence 924 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15081	MAVKRSTRLGCNECSEINYLTFKNVKKNPEKLALNKFCSRCRKVVLHKEVKRK	53	Sequence 925 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15082	MAVKRSTRLGCNDCREINYLTFKNVKKNPEKLALNKFCSRCRKVVVHKEVKRK	53	Sequence 926 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15083	MASSTDVRPKITLACEVCKHRNYITKKNRRNDPDRLELKKFCPNCGKHQAHRETR	55	Sequence 927 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15084	MAKKGKGARLVITLECTECRSNPDKRSNGVNRYTTMKNRRNTTARLELKKFCTHCNKHTIHKETK	65	Sequence 928 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15085	MRVKVALKCSQCGNKNYYTTRNKDKRAKLELRKYCPKCNAHTIHTETKA	49	Sequence 929 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15086	MASEVRIKLLLECTECKRRNYATEKNKRNTPNKLELRKYCPWCRKHTVHREVKI	54	Sequence 930 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15087	MKRTYQPNRRKRSKVHGFRARMSTKNGRKVLARRRRKGRKVLSA	44	Sequence 933 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15088	MKRTFQPNNRKRSKVHGFRSRMSSKNGRLVLARRRRKGRKVLSA	44	Sequence 934 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15089	MKRTYQPSRVKRNRKFGFRARMKTKGGRLILSRRRAKGRMKLTVSDEKKKY	51	Sequence 935 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15090	MKRTFQPSILKRNRSHGFRTRMATKNGRYILSRRRAKLRTRLTVSSK	47	Sequence 936 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15091	MKRTYQPSKQKRNRTHGFRARMATKNGRQVLNRRRAKGRKRLTV	44	Sequence 937 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15092	MKRTFQPSVLKRNRSHGFRARMATKNGRQVLARRRAKGRARLTVSK	46	Sequence 938 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15093	MKRTFQPSVLKRSRTHGFRARMATKNGRQVLARRRAKGRKSLSA	44	Sequence 939 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15094	MKRTYQPHNTPRKRTHGFLVRMKTKNGRKVINARRAKGRKKLSV	44	Sequence 940 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15095	MPAPRYRSRSYRRIYRRTPGGRIVIHYKRRKPGKPKCAICGAELHGVPRGRPVEIRKLPKSQRRPERPYGGYLCPRCLKRLMIQKARNL	89	Sequence 942 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15096	MPELRYRSRSYKRIFKKTPGGRTVTHYRRKKPSKHVCAGCGKPLHGVPRGRPYEIRKLSKSKKRPNRPYGGYYCSSCARKVFKKEARS	88	Sequence 943 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15097	MTKRTFQPNNRRRARKHGFRARMRTRAGRAILSARRGKNRAELSA	45	Sequence 944 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15098	MKRTWQPSKLKHARVHGFRARMATKNGRKVIKARRAKGRVRLSA	44	Sequence 945 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15099	MKRTYQPSKLKRAKTHGFMARMATAQGRKVLRQRRFKNRAQLTVSSER	48	Sequence 946 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15100	MRKGKRTFQPNNRRRARVHGFRLRMRTRAGRSIVSDRRRKGRRTLTA	47	Sequence 947 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15101	MKRTYQPSKLKRAKTHGFLARMATASGRKVLKLRRKKQRAQLTVSSER	48	Sequence 948 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15102	MAKGKRTFQPNNRRRALIHGFRARMRTRADRAIVAHRRSKGRRAPTA	47	Sequence 949 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15103	MTKGKRTFQPNNRRRARVHGFRLRMRTRAGRSIVSSRRRKGRRTLSA	47	Sequence 950 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15104	MKRTFQPSVLKRNRNHGFRARMATKNGRQVLARRRAKGRARLTVSSK	47	Sequence 952 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15105	MKRTFQPSTIKRARTHGFRARMATKNGRAVLSRRRAKGRKRLAI	44	Sequence 953 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15106	MSKRTFQPNNRRRAKTHGFRLRMRTRAGRAILANRRAKGRASLSA	45	Sequence 955 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15107	MSKRTFQPNNRRRAKTHGFRLRMRTRAGRAILATRRSKGRARLSA	45	Sequence 956 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15108	MPSPQQRSGSFRKVFVKLPSGKSTIHYERRKDNIARCGMCKKPLNGVKNNYTYKYSKTEKRPERVYGGYLCHKCLESLIKMTIRGIS	87	Sequence 957 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15109	MTQRTLGGTNRKQKRTSGFRARMRTHNGRKVIQARRSKGRHRLAV	45	Sequence 958 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15110	PKMKTHRGSAKRFKKTASGKLKRGHAYTSHLFANKTKKQKRHLRKATLVSPGDFKRIRQMLDNLK	65	Sequence 962 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15111	PKMKTHRGSAKRFKKTGSGKLKRSHAYTSHLFANKSQKQKRKLRKSAVVSAGDFKRIKQMLANIK	65	Sequence 963 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15112	MPKIKTLRSAAKRFKKTASGKFKRKQANLRHILTKKTTTKKRHLRPKILVSKGDISKVKSFLPYF	65	Sequence 964 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15113	PKIKTVRGAAKRFKKTGKGGFKHKHANLRHILTKKATKRKRHLRPKAMVSKGDLGLVIACLPYA	64	Sequence 966 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15114	PKIKTVRGAAKRFKKTASGGFKRKQSHLRHILTKKTTKRKRHLRHKSMVAKADQVLVVACLPYA	64	Sequence 967 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15115	MPKMKTNRGASKRFKVKKNLIKRGSAFKSHILTKKSPKRKANLNAPKHVHHTNAHSVMSLLCRA	64	Sequence 968 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15116	PKMKTKSALKKRIKITGTGKIMREQAYRSHLSQNKTTKQKRQARKSVQMHSSDVKRFKALI	61	Sequence 970 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15117	MKTKSAAVKRFKLTKSGQIKRKHAYTSHLAPHKSTKQKRHLRKQATVSNSELKRIGILI	59	Sequence 971 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15118	MKVKSAAKKRFKLTKSGQIKRKHAYTSHLAPHKTTKQKRHLRKQGTVSASDFKRIGNLI	59	Sequence 972 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15119	MPKMKTKSGAAKRFLKTANGIKHKHAFKSHILTKMSTKRKRQLRGSSLLHPSDVAKVERMLRLR	64	Sequence 973 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15120	MPKLKTRKAAAKRFRPTGSGKKIIRRKAFKNHLLEHKSSEQKHRRLSNLALVHEADEKNVRLMLPYM	67	Sequence 975 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15121	MKVRPSVKPICEKCKVIRRRGKVMVICENPKHKQRQG	37	Sequence 977 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15122	MKVRPSVKPICEKCKVIRRKGKVMVICENPKHKQKQG	37	Sequence 978 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15123	MAKSGIAAGVNKGRKTTAKEVAPKISYRKGASSQRTVFVRSIVKEVAGLAPYERRLIELIRNAGEKRAKKLAKKRLGTHKRALRKVEEMTQVIAESRRH	99	Sequence 980 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15124	MKVRASIKRICKDCKIIKRHGVNRVICINFKHKQRQG	37	Sequence 981 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15125	MKVRASVKKLCRNCKIVKRDGVIRVICSAEPKHKQRQG	38	Sequence 983 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15126	MKVRASVKKMCRNCKIVKREGVVRVLCSDPKHKQRQG	37	Sequence 984 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15127	MKVRPSVKKMCDNCKIIKRRGVIRVICATPKHKQRQG	37	Sequence 985 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15128	MKVRPSVKPICEYCKVIRRNGRVMVICPANPKHKQRQG	38	Sequence 986 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15129	MKVRASVKPICKDCKIIKRHRILRVICKTKKHKQRQG	37	Sequence 988 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15130	MKVRASVKPICKDCKIIKRHQIVRVICKTQKHKQRQG	37	Sequence 989 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15131	MKVNPSVKPICDKCRLIRRHGRVMVICSDPRHKQRQG	37	Sequence 990 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15132	MKVRASVRKICEKCRVIKRRGRVMVICANPKHKQRQG	37	Sequence 992 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15133	MKVRASVKKMCDKCRVIRRRGRVMVICSANPKHKQRQG	38	Sequence 993 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15134	MKVRASVKRICDKCKVIRRHGRVYVICENPKHKQRQG	37	Sequence 994 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15135	MKVRASVKKICRNCKVIKRNGVVRVICSEPKHKQRQG	37	Sequence 995 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15136	MGKGTASFGKRRNKSHTLCVRCGRRSFHIQKSRCSACAYPAARKRTYNWSVKAIRRKTTGTGRMRYLRNVPRRFKTCFREGTQATPRNKAAASSS	95	Sequence 996 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15137	MTKGTQAFGKKHVKSHTLCKRCGKSSFHIQKKRCASCGYQDAKKRTYNWGAKSIRRRTTGTGRTRHLRDVNARFRNGFRGTTPKPRAQPTN	91	Sequence 997 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15138	TGAGTPSQGKKNTTTHTKCRRCGEKSYHTKKKVCSSCGFGKSAKRRDYEWQSKAGE	56	Sequence 998 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15139	TKGTSSFGKRRNKTHTLCRRCGSKAYHLQKSTCGKCGYPAKRKRKYNWSAKAKRRNTTGTGRMRHLKIVYRRFRHGFREGTTPKPKRAAVAASSSS	96	Sequence 999 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15140	TKGTTSMGQRHGRTHILCRRCGRNSYHVQWERCAACAYPRASRRRYNWSVKAIKRRRTGTGRCRYLKVVNRRIANHFKTPKA	82	Sequence 1000 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15141	MSKGTPSMGKRNKGSYHIRCRRCGRRAYHVRKKRCAACGFPNKRMRKYSWQNKKVNGKRIK	61	Sequence 1001 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15142	MPKQIHEIKDFLLTARRKDARSVKIKRSKDIVKFKVRCSRYLYTLCVFDQEKADKLKQSLPPGLSVQDL	69	Sequence 1002 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15143	PRKIEEIKDFLLTARRKDAKSVKIKKNKDNVKFKVRCSRYLYTLVITDKEKAEKLKQSLPPGLAVKELK	69	Sequence 1003 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15144	MPKQIHEIKDFLLTARRKDARTVKIKKNKDMVKFKVRCSKYLYTLCVSDFEKADKLKQSLPPGLSVQDL	69	Sequence 1004 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15145	MPRQVTDIKLFLQLAHRGDATSARVKKNQNKAVKFKLRCSRYLYTLVVADAKKAEKLRQSLPPALTVTEVGKKA	74	Sequence 1005 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15146	MAREITDIKQFLELTRRADVKTATVKINKKLNKAGKPFRQTKFKVRGSSSLYTLVINDAGKAKKLIQSLPPTLKVNRL	78	Sequence 1006 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15147	MPSHKSFMIKKKLGKKMRQNRPIPHWIRLRTDNTIRYNAKHRHWRRTKLGF	51	Sequence 1007 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15148	MGKKTVGVKKRLAKAYKQNRRAPVWITVKTKRSVFGSPKRRHWRRSKLKV	50	Sequence 1008 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15149	MSALKKSFIKRKLAKKQKQNRPMPQWVRMKTGNTMKYNAKRRHWRRTKLKL	51	Sequence 1009 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15150	MAAHKSFRIKQKLAKKLKQNRSVPQWVRLATGNTIRYNAKRRHWRRTKLKL	51	Sequence 1010 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15151	GKKSKATKKRLAKLDNQNSRVPAWVMLKTDREVQRNHKRRHWRRNDTDE	49	Sequence 1011 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15152	SSHKTFRIKRFLAKKQKQNRPIPQWIRMKTGNKIRYNSKRRHWRRTKLGL	50	Sequence 1012 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15153	MPSHKTFRIKKKLAKKMRQNRPIPYWIRMRTDNTIRYNAKRRHWRRTKLGF	51	Sequence 1013 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15154	MMGSNKPLGKKVRLAKALKQNRRVPLFVIVKTRGRVRFHPKMRYWRRKKLKA	52	Sequence 1014 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15155	MSRNKHVARKLRMAKANRQNRRVPAWVMVKTNYRVRSHPKMRHWRRTKLKV	51	Sequence 1015 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15156	SKHKSLGKKLRLGKALKRNSPIPAWVIIKTQAEIRFNPLRRNWRRNNLKV	50	Sequence 1016 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15157	TVKTGIAIGLNKGKKVTSMTPAPKISYKKGAASNRTKFVRSLVREIAGLSPYERRLIDLIRNSGEKRARKVAKKRLGSFTRAKAKVEEMNNIIAASRRH	99	Sequence 1017 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15158	VIEPSLQVLARKYNCDKVVCRKCYARLHPRAVNCRKKKCGHSNHWRPKKKLK	52	Sequence 1027 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15159	IIEPSLMMLARKYNQDKMICRKCYARLHPRAVNCRKKKCGHSNQLRPKKKIK	52	Sequence 1028 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15160	IIEPSLMALARKYNQAKMICRKCYARLHPRAVNCRKKKCGHSNQLRPKKKIK	52	Sequence 1029 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15161	IIEPSLRQLAQKYNCDKQICRKCYARLPPRASNCRKKKCGHSSELRIKKKLK	52	Sequence 1030 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15162	IIEPSLQALARKYNQEKMICRKCYARLHPRAKNCRKKSCGHTNQLRPKKKLK	52	Sequence 1031 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15163	IIEPSLKALASKYNCEKQICRKCYARLPPRATNCRKRKCGHSSQIRPKKALKK	53	Sequence 1032 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15164	IEPSLVILARKYKCDKMICRKCYARLHPRAVNCRKKKCGHSNNLRPKKKLLK	52	Sequence 1033 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15165	IIEPSLRILAQKYNCDKMICRKCYARLHPRATNCRKKKCGHTNNLRPKKKLK	52	Sequence 1034 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15166	IIEPSLALLASKYNCEKKICRKCYARLPPRATNCRKKKCGHTSQLRPKKKPKN	53	Sequence 1035 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15167	IIEPSLRQLAQKYNCDKMICRKCYARLHPRAVNCRKKKCGHTNNLRPKKKVK	52	Sequence 1036 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15168	VMEPTLVALAKKYNWEKKVCRRCYARLPVRATNCRKKACGHCSNLRMKKKLR	52	Sequence 1037 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15169	MPFEEAMKRLFMKKICMRCNARNPWRATKCRKCGYKGLRPKAKEPRG	47	Sequence 1038 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15170	MARFEEAENRLFNIKICLKCNARNPPTAKTCRKCGYKGLRYKAKEPRG	48	Sequence 1039 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15171	IIEPSLMALARKYNQDKMICRKCYARLHPRAVNCRRKKCGHSNQLRPKKKIK	52	Sequence 1040 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15172	IIEPSLQALARKYNQDKMICRKCTARLHPRAVNCRKKKCGHSNQLRPKKKIKN	53	Sequence 1041 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15173	GMEPTIAALAKKYNCEKKVCRDCYARLPPKATNCRKRKCGHSNSLRLKKKPKE	53	Sequence 1042 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15174	IIEPSLKALASKFNCDKMICRKCYVRCPRRTPQRTCRVLTWIPQARLPPRATNCRKRKCGHTNHVRPKKKLK	72	Sequence 1043 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15175	VMEPTLEALAKKYNWEKKVCRRCYARLPVRATNCRKKGCGHCSNLRMKKKLR	52	Sequence 1044 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15176	VMEPTLEALAKKYNWEKKVCRRCYARLPVRASNCRKKACGHCSNLRMKKKLR	52	Sequence 1045 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15177	IIEPSLKALASKYNCDKSVCRKCYARLPPRATNCRKRKCGHTNQLRPKKKLK	52	Sequence 1046 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15178	MREKWKKKRSRRLRRKRRKMRARSK	25	Sequence 1047 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15179	MRAKWRKKRMRRLKRKRRKMRQRSK	25	Sequence 1048 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15180	MRWKWYKKRLRRLKRERKRARS	22	Sequence 1049 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15181	MRAKWKKKRMRRLKRKRRKMRQRSK	25	Sequence 1050 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15182	AKSKNHTAHNQTRKAHRNGIKKPKTYKYPSLKGVDPKFRRNHKHALHGTAKALAAAKK	58	Sequence 1052 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15183	VNVPKTKRAFCKGCKKHMMMKVTQYKTGKASLYAQGKRRYDRKQSGYGGQTKPVFHKKAKTTKKIVLRMQCQECKQTCMKGLKRCKHFEIGGDKKKGN	98	Sequence 1057 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15184	MQMPRRFNTYCPHCNEHQEHEVEKVRSGRQTGMKWIDRQRERNSGIGNDGKFSKVPGGDKPTKKTDLKYRCGECGKAHLREGWRAGRLEFQE	92	Sequence 1060 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15185	MKIPKKVRRYCPYCKKHTIHIVEKAKKGKPSELTWGQRQFRRVTAGYGGFPRPLPDRSKPVKKIDLRFKCTECGKMHTKANGCFRSGRFEFVEK	94	Sequence 1064 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15186	MKIPKERRTYCPNCRKHTVHEVLESKRRKASELKWGQRQFRRVTAGYRGYPRPLPSGNKPVKKLDLRLKCKECGKSHIKKKSFRAGRVEYVA	92	Sequence 1065 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15187	AAKKSFIIKQKLAKAKNQNRPLPQWFRLKTNNTIRYNAKRRHWRRTKLVC	50	Sequence 1070 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15188	AAQKSFRIKQKMAKAKKQNRPLPQWIRLRTNNTIRYNAKRRNWRRTKMNI	50	Sequence 1071 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15189	MAKIFRITGIMSKKGKDPLYFRKEYKALKPEDALEILYSEFGGRYKVKRSRIKILNIEEIKPEDVTDPVLKKLVTA	76	Sequence 1102 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15190	MKMKTKIFRVKGKFLMGDKLQPFTKELNAIREEEIYERLYSEFGSKHRVPRSKVKIEEIEEISPEEVQDPVVKALVQR	78	Sequence 1103 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15191	AEVKIFMVRGTAIFSASRFPTSQKFTKYVRALNEKQAIEYIYSQLGGKNKIKRYNIHIQEIKEVKEDEITDKTIRDLAKLDKIIM	85	Sequence 1104 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15192	AEVKIFMVRGTAIFSASRFPTSQKYVRALNEKQAIEYIYSQLGGKNKINDTTYTYKRSKKLRKMKSQTRQ	70	Sequence 1105 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15193	VFYKVTLSRSLIGVPHTTKSIVKSLGLGKRGSIVYKKVNPAIAGSLAKVKELVKVEVTEHELTPSQQRELRKSNPGFIVEKRTID	85	Sequence 1119 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15194	VKVKSKNSVIKLLSTAASGYSRYISIKKGAPLVTQVRYDPVVKRHVLFKEAKKRKVAERKPLDFLRTAK	69	Sequence 1122 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15195	MITKYFSKVIVRFNPFGKEAKVARLVLAAIPPTQRNMGTQIQSEIISDYNKVKPLVKVTYKDKKEMEVDPSNMNFQELANHFDRHSKQLDLKHMLEMH	98	Sequence 1123 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15196	MSKKSIIEREKKRKSLVKKYKNLRNFIKKEIKNELNFFEKIFLNFKLQKFPRDSSPCRLHNRCYLTGRPRGYYRFFGLSRHIFRDMAHYGLLPGVTKSSW	100	Sequence 1164 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15197	MAKKSMIERDRKRARLITKYAAKRKNLLVEIKTATSLEDKFNLHRKLQQLPRNSAPVRSHNRCTITGRPRGYFRDFGLSRHVLREYALQGFLPGVVKASW	100	Sequence 1165 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15198	MAKKSMIERDKKRENLMNKYLVKRQQLKTRLNETDSVEEKLLLNQELQKLPRNSAPSRVRIRCWLTGRPRGNYRDFGVSRHVLREMAHQGLLPGVTKSSW	100	Sequence 1166 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15199	MARKSLIQREKGRLKLENKYHFIRRSSKNEISKVPSLSDKWEIYGKLESPPRNSAPTRLRRRCFYTGRPRANYRDFGLCGHILREMVNACLLPGATRSSW	100	Sequence 1167 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15200	MSKKSLIARQRKRIILVLIHSHNRYVYRTNGKDEKSFEKKLRIYSFLQKLPRNSLRCRLRNRCYVTGRSRGYFRTFGLSRHILRDMAHYGLLPGVTKASW	100	Sequence 1168 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15201	MAKKSLIQREKKRQNLEKKYKILRNSLKKKITETSSLDEKWEFQKKLQSLPRNSAPTRLHRRCFLTGRPKANYRDFGLSRHLLREMAHACLLPGVTKSSW	100	Sequence 1170 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15202	MAKKSMIEREKKRIKLNNKYTPKRNTLLQAYRQTEDFQSRLDIHSKIQKLPRNSAKNRIRNRCWKTGRPRGFYRDFGVSRHVLREMAHSCLLPGVTKSSW	100	Sequence 1171 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15203	MAKKSLIAREKKRKKLEEKFYLIRRYPTKEMSKGGSLSESWEIQGKLEALPRNSAPTRLHRRCFLTGRPRANVRDFGLSGHILREMVHICLLPGATRSSW	100	Sequence 1173 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15204	MARKSLIQREKKRQALERKYHLIRQSLEEKSKVSSLDDKWEIHRKLQSSPRNSAPTRLHRRCSSTGRPRANYRDFGLSGHILREMAHACLLPGIKKSSW	99	Sequence 1174 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15205	MAKKNMIQREIKREKLEKKYYLKRLAIKEQLKKTTSFAEKIELRQKLQEMPRNSAPVRSRNRCWLTGRSRGYYRDFGLSRHVFREMSHECLLPGVTKSSW	100	Sequence 1175 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15206	MARKSLIQREKKRRNLEQKYHLIRRSSKQEIRKVTSLSDKWEIHGKLQSPPRNSAPARLHRRCFLTGRPRANIRDFGLSGHILREMVHTCLLPGATRSSW	100	Sequence 1176 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15207	MARKSLIQREKKRQKLEQKYHSIRRSSKKEISKVPSLSDKWEIYGKLQSPPRNSAPTRLHRRCFLTGRPRANYRDFGLSGHILREMVHACLLPGATRSSW	100	Sequence 1177 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15208	MKKKGGRKIFGFMVKEEKEENRGSVEFQVFSFTNKIRRLASHLELHKKDFSSERGLRRLLGKRQRLLAYLAKKNRVRYKKLISQLDIREK	90	Sequence 1178 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15209	MSKNLFMDLSSISEKEKGSVEFQIFRLTNRVVKLTYHFKKHGKDYSSQRGLWKILGKRKRLLAYLFKTNFVSYENLIIQLGIRGLKKN	88	Sequence 1179 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15210	MKKKGGRKIFGFMVKEEKEENWGSVEFQVFSFTNKIRRLASHLELHKKDFSSERGLRRLLGKRQRLLAYLAKKNRVRYKKLISQLDIRER	90	Sequence 1180 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15211	MINNLSISSSLIPDKQRGSVESQVFYLTNRVLRLTQHLQLHGRDYSSQRGLWKILSKRKQLLVYLSKRDKLRYDDLIGQLGIRGLKTR	88	Sequence 1181 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15212	MKKKGGRKIFGFMVKEEKEENRGSVEFQVFSFTNKIRRLASHLELHKKDFSSERGLRRLLGKRRRLLAYLAKKNRVRYKKLIGQLNIREQ	90	Sequence 1182 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15213	MVKNSVISVISQEEKRGSVEFQVFNFTNKIRRLTSHLELHKKDYLSQRGLKKILGKRQRLLAYLSKKNRVRYKELINQLDIRETKTR	87	Sequence 1183 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15214	MLKIRLKRCGRKKQTSFKIVVMNNLDKRDGQAIEELGFMNPRTKEKYLNINKINHYLRLGAKPTKTVFDLLNKAKII	77	Sequence 1184 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15215	MVKLRLKRYGRKGQVTYRIVAMNNLSRRDGKAIEELGFYNPRTNESSLNIANIKRRIEQGAQPTNTVRYILAKANIL	77	Sequence 1185 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15216	MVKLRLKRCGRKQQAVYRIVAIDVRSRREGRDLRKVGFYDPIKNQTCLNVPAILYFLEKGAQPTRTVYDILRKAEFFKEKERTLS	85	Sequence 1186 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15217	MVKLRLKRCGRKQQAIYRIVAIDVRSRREGRDLRKVGFYDPIKNQTCLNVPAILYFLEKGAQPTRTVYDILRKAEFFKDKERTLS	85	Sequence 1187 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15218	MLKLRLKRSGRKKQPSYRLVVMENTTRRDGRPVEQVGYYNTITKESYFDVIKIKKWLNYGAKPTQTVLNLLKKAKIIDQ	79	Sequence 1188 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15219	MLKLRLKRCGRKQRFYDPIKNQTCLNVPAILYFLEKGAQPTRTVSDILRKAEFFKEKERTLS	62	Sequence 1189 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15220	MVKLRLKRYGRKQQPSYRIVAMDSRSKRDGKAIEELGFYNPITNETRIDIAKILKRLKQGAQTTRTVKNILNEAQIIAKENS	82	Sequence 1190 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15221	MVKLRLKRCGRKQRAVYRIVAIDVRSRREGRDLRKVGFYDPITNQTYLNLPAILDFLKKGAQPTRTVHDISKKAGIFTELNLNKTKLN	88	Sequence 1191 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15222	MVKLRLKRCGRKQRAVYRIVAIDVRSRREGKDLQKVGFYDPIKNQTYLNVPAILYFLEKGAQPTETVQDILKKAEVFKELRLNQPKFN	88	Sequence 1192 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15223	MVKLRLKRCGRKQRAVYRIVAIDVRSRREGKDLRKVGFYDPIKNQTYLNVPAILYFLEKGAQPTGTVQDILKKAEVFKELRPNQS	85	Sequence 1193 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15224	MASKERVGVVIRNPQEKTVIVAVNNRVRHNKYSKIIIRTKKYQVHDHSHICKLGDEVKISEVKPISKTKRWIISEVLSSTVNPEKFGD	88	Sequence 1195 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15225	MPVKEKVGIVVSNKMQKTIVVKVESRYSHPIYSKTMTKTRKYLAHDEMGECNIGDQVLVQECRPLSKRKRWTLSKVLSKSSLVS	84	Sequence 1196 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15226	MPLKETTGKVVSDKMNKTIVVAVENRISHRKYAKTMTRTKKYKAHDENNECAVGDIVTIQETRPLSRTKCWTMVNILSKSFHN	83	Sequence 1197 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15227	MSVYRRRLSPLKPNQVIDYQDVELLRTFITDQGKILPRRVTGLTAKQQRAVTKAIKQARVLALLPFVNRES	71	Sequence 1199 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15228	MYKFKRSFRRRLSPIGSGNLIYYRNMSLISRFISEQGKILSRRVNRLTLKQQRLITIAIKQARILSLLPFINNEKQFERIESITRVKGFIKK	92	Sequence 1200 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15229	MKYPALIDYKNVNILRRFINFQGKIIPKRLNKPKLTYKQHRLLRKSVKQARYLGLLPFKTKDFF	64	Sequence 1201 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15230	MNKSKRSSRRRMPPIRSGEIIDYKNISLLRRFVSEQGKILSRRMNRLTSKQQRLLTIAIKRARVLALLPFLNNEN	75	Sequence 1202 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15231	MLAQKQKLSPISVNQKIDYKDIDLLKLFITEQGKILPRRATGVTVQQQRQIAKAIKRARVLSLLPFVASNSI	72	Sequence 1203 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15232	MKQTMDKPKQSFRRHFKPIRRRFKPIRRYLKPIRRHLSPIRSGDRIDYKNMSLISRFISEQGKILSGRVNRLTSKQQRLMTNAIKRARILSLLPFLYNEN	100	Sequence 1206 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15233	MAVYRKKISPIKPTEAVDYKDIDLLRKFITEQGKILPKRSTGLTSKQQKKLTKAIKQARILSLLPFLNKD	70	Sequence 1207 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15234	MARSLKKAPFVANHLLEKVERLNTQGDKKVIKTWSRSSTIVPLMIGHTIAVHNGREHIPVFITDQMVGHKLGEFAPTRTFRGHVKKDKKSKR	92	Sequence 1210 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15235	MARSLKKGPFIAHHLLKKVELLNTSGKTEVIKTWSRASTILPMMVGHTIAVHNGRQHLPVFITDQMVGHKLGEFAPTRTFKGHTKSDKKARR	92	Sequence 1211 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15236	MIHSPTLKKNLFVANHLRAKINKLNNKKKKEIIVTWSRASTIIPIMIGHMISIHNGKEHLPIYITDHMVGHKLGEFVPTLNFRGHAKSDNRSRR	94	Sequence 1212 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15237	MSRSLKKGPFVFYSLIKKVDQMNSNRFKSVILTWSRSCTIIPIMIGNTIGVYNGKEHIPVLVSDQMIGHKLGEFVQTRNYRGHKKHDKKTKTKR	94	Sequence 1213 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15238	TRKKTNPFVARHLLAKIEKVNMKEEKEIIVTWSRASSILPAMVGHTIAIHNGKEHIPIYITNPMVGRKLGEFVPTRHFTSYESTRKDTKSRR	92	Sequence 1214 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15239	TRSIKKGPFVADHLLKKIENLNLKKEKKIIITWSRASTIVPTMIGHTIAVHNGQEHLPIYITDRMVGHKLGEFAPTRTFRGHAKNDKKSRR	91	Sequence 1215 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15240	MPRSLKKGPFVAYHLLKKIDKMNASGKKDVITTWSRTSTILPTMVGHTIAVYNGRQHVPIFISDQLVGHKLGEFVSTRTFKSHIKTDKKTKR	92	Sequence 1216 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15241	TRKKTNPFVAHHLLAKIEKVNMKEEKETIVTWSRASSILPAMVGHTIAIHNGKEHIPIYITNPMVGRKLGEFVPTRHFTSYESARKDTKSRR	92	Sequence 1217 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15242	TRSRKKNPFVANHLLKKIKKLNTKGEKAIIKTWSRKSTIIPIMIGHTIAIHNGKEHLPVYITDRMVGHKLGEFSPTLNFGGFAKNDNKSRR	91	Sequence 1218 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15243	MARSLKKNPFVANHSLRKIKNLNIKEEKKIIVTWSRASVIVPAMIGHTIAVHNGREHLPIYVTDRMVDHKLGEFAPTLLFQGHARNDKKSRR	92	Sequence 1219 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15244	MSRSIHKGPFIDVSLLTRIEALNTSGKKEVIKTWSRASTIIPDMIGHTIAVYNGKQHFPVFVSDQMVGHKLGEFVPTRTFRTHVKGDRKARR	92	Sequence 1220 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15245	TRKKTNPFVAHHLLAKIEKVNMKEEKETIVTWSRASSILPTMVGHTIAIHNGKEHIPIYITNPMVGRKLGEFVPTRHFTSYENARKDTKSRR	92	Sequence 1221 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15246	TRSLKKNPFVANHLLRKINKLNTKAEKDIIITWSRASTIIPTMIGHTIAIHNGKEHLPIYITDRMVGHKLGEFSPTLNFRGHAKNDNRSRR	91	Sequence 1222 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15247	TRSLKKNPFVANHLLRKIEKLNKKAEKEIIVTWSRASTIIPTMIGHTIAIHNGREHLPIYITDRMVGHKLGEFAPTLNFRGHAKNDNKSRR	91	Sequence 1223 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15248	TRSLKKNPFVANHLLKKIDKLNTKAEKEIIVTWSRASTIIPTMIGHTIAIHNGKEHLPIYITDSMVGHKLGEFAPTLNFRGHAKSDNRSRR	91	Sequence 1224 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15249	MANTKSAIKRIKTIERNRIRNCAYKSVVKTFIKKYLKVLSDYTNAPNSNGVENIQTTLGIVYTKIDKAVKRGVYHSNKAARMKSKLALKYNVIKK	95	Sequence 1225 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15250	MANNASAEKRILINERNRLQNRFYKSSVRTLTKLYLKDLEVYKISRNPSDKEKAKNRLSLVYSLIDKGSKRNVFHKNTAARKKSKLASQLKIA	93	Sequence 1226 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15251	MAKNLSAIKRIKTSERNRLINRKYKSVVKTLTKRCLMNIENLENSNLNDVQLSISQVYSKIDKAIKKGAFHPNTGARKKARLARIFAYAQKQQN	94	Sequence 1227 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15252	MSATKKYEMMILLTEEFNDSELKTWAFNYAKALRKLSASEISVISRGKRDLSYYINNQKKGNFIQINFSSMPKYVDNFSKNLKFDSNVLRFLILNK	96	Sequence 1233 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15253	MQKARIKLSSTKHEELDSVCNQIKAIAEKTGVDMAGPIPLPTKSLKITTRKSTDGEGSSSFDRWTMRVHKRVIDIEADERTMKHIMKVKNS	91	Sequence 1276 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15254	MAKKSMIIKQKRTPKFKVRAYTRCERCGRPHSVYRKFKLCRICFRELAYKGQLPGIKKASW	61	Sequence 1381 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15255	AKKSMIAKQQRTPKFKVQEYTRCERCGRPHSVIRKFKLCRICFRELAYKGQIPGVKKASW	60	Sequence 1382 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15256	AKQSMKAREVKRVALADKYFAKRAELKAIISDVNASDEDRWNAVLKLQTLPRDSSPSRQRNRCRQTGRPHGFLRKFGLSRIKVREAAMRGEIPGLKKASW	100	Sequence 1386 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15257	AKQSMKARDVKRVKLAEKFYAKRVELKKIISDVNASDEDRWDAVLKLQTLPRDSSPSRQRNRCRQTGRPHGVLRKFGLSRIKVREAAMRGEIPGLKKASW	100	Sequence 1387 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15258	MAKKSMIAKAQRKPKFQVRAYTRCRICGRPHSVYRDFGLCRVCLRKMGSEGLIPGLRKASW	61	Sequence 1388 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15259	MAKKPWKKKYGYGIRPCQRCGHVGPGLIRKYGLNLCRQCFREIAHKLGFKKLD	53	Sequence 1392 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15260	MIVLPRKYGKASRKCSRCGDHSALVRRYGLMLCRQCFRELAPKIGFKKYN	50	Sequence 1393 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15261	MTKEPFKTKYGQGSKVCKRCGRKGPGIIRKYGLDLCRQCFRELAPKLGFKKYD	53	Sequence 1394 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15262	MAKKSLKVKQAKHPKFNVRNYTRCNHCGRPHAVLKKFGICRLCFRKFAYEGQIPGIKKAS	60	Sequence 1395 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15263	MAKKSLKVKQSRPNKFSVRDYTRCLRCGRARAVLSHFGVCRLCFRELAYAGAIPGVKKASW	61	Sequence 1396 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15264	MAKKALVNKAARKPKFTVRGYTRCSKCGRPRAVFRKFGLCRICLREMAHAGELPGVQKSSW	61	Sequence 1397 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15265	MAKKSLKVKQTRIPKFAVRAYTRCQRCGRARAVLSHFGVCRLCFRELAYAGAIPGVKKASW	61	Sequence 1398 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15266	MAKKAMVERDRKRKKLVEKYAAKREALKEQFAAATSQSERLELHRKLQQLPRNSAPNRVRNRCWVTGRPRGYYRDFGLCRNVLREMAHQGLLPGVVKSSW	100	Sequence 1403 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15267	MAKKSMIERDKRRSRLVAKYAAKREALKEEFRQAETLEDKLAVHQKLQDLPRNSAPNRRRNRCQVTGRPRSYYRDFGLCRNVLREWAHQGLLPGVTKSSW	100	Sequence 1404 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15268	ARKALIEKAKRTPKFKVRAYTRCVRCGRARSVYRFFGLCRICLRELAHKGQLPGVRKASW	60	Sequence 1405 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15269	ALTQERKREIIEQFKVHENDTGSPEVQIAILTEQINNLNEHLRVHKKDHHSRRGLLKMVGKRRRLLAYLRNKDVARYREIVEKLGLRR	88	Sequence 1408 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15270	AITQERKNQLINEFKTHESDTGSPEVQIAILTDSINNLNEHLRTHKKDHHSRRGLLKMVGKRRNLLTYLRNKDVTRYRELINKLGLRR	88	Sequence 1409 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15271	MALDSAKKAEIVAKFAKKPGDTGSTEVQVALLTARIAELTEHLKIYKNDFSSRLGLLKLVGQRKRLLSYLKRKDYNSYSKLITELNLRDK	90	Sequence 1410 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15272	SLSTEATAKIVSEFGRDANDTGSTEVQVALLTAQINHLQGHFAEHKKDHHSRRGLLRMVSQRRKLLDYLKRKDVARYTQLIERLGLRR	88	Sequence 1411 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15273	SLSTEKKAAIVAEFGRDAKDTGSSEVQIALLTAQINHLQTHFAEHKKDHHGRRGLLRMVSRRRKLLDYLKRTDLALYQSTIARLGLRR	88	Sequence 1412 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15274	MALNLEKKQEIIKAFATKENDTGSCEVQVALLNERIKLLTEHLKANPKDHSSRLGLLKLVAQRRNLLKYIKRTNHARYVVLIEKLGIKDR	90	Sequence 1413 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15275	MITKAKKAEIITRFGKSEKNTGDISVQIALLPEDIEKLKLHFEKNKKDKHSMRGFIAKVNKRKKLLNYLKEKNFASYKETIEALNIRK	88	Sequence 1416 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15276	MKIDKEQIIKAHQLHKNDVGSVQVQISILTDQIKKLTDHLLANKKDFISKRGLYTKVSKRKRLLKYLKERNIETYRDLIKNLNLRG	86	Sequence 1417 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15277	MISKARKQEIILKFGKNPKNTGNTSVQIALLTEDIERLKLHFLKNKKDKHSMRGFIAKVNKRKKLLNYLRINSFDTYKETIEALNIRK	88	Sequence 1418 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15278	MALTSEQKKEILSSYGLHATDTGSPEAQIALLTKRIADLTEHLKVHKHDHHSRRGLLLLVGRRRRLIKYLSLIDVQRYRSLIERLGLRR	89	Sequence 1419 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15279	MQIDKNGIIKSAQLHDKDVGSIQVQVSLLTSQIKQLTDHLLANKKDFISKRGLYAKVSKRKRLLKYLKHNDLEAYRNLVKTLNLRG	86	Sequence 1420 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15280	MALTAEQKKEILRSYGLHETDTGSPEAQIALLTKRIADLTEHLKVHKHDHHSRRGLLLLVGRRRRLIKYISQIDVERYRSLIERLGLRR	89	Sequence 1421 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15281	SLSTEAKAQIIAEFGRDANDSGSSEVQVALLTAQINHLQGHFSEHKKDHHSRRGLLRMVSQRRKLLDYLKRKNVTSYTALIGRLGLRR	88	Sequence 1423 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15282	MSLTQIRKQELMTEYQAHETDTGSADLQVAFLTERITQLTGHLKANPKDHASRRGLLKMIGRRKRLLSFINAREPERYQALIKRLGIRR	89	Sequence 1425 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15283	PITKEEKQKVIQEFARFPGDTGSTEVQVALLTLRINRLSEHLKVHKKDHHSHRGLLMMVGQRRRLLRYLQREDPERYRALIEKLGIRG	88	Sequence 1426 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15284	SLSVEAKAKIVADFGRDANDTGSSEVQVALLTAQINHLQGHFSEHKKDHHSRRGLLRMVSTRRKLLDYLKRKDVASYVSLIERLGLRR	88	Sequence 1430 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15285	AVKIRLKRMGAKKSPFYRIVVADSRSPRDGRFIETVGTYNPVAKPAEVKIDEELALKWLQTGAKPSDTVRNLFSSQGIMEKFHNAKQGK	89	Sequence 1432 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15286	MVTIRLARHGAKKRPFYQVVVADSRNARNGRFIERVGFFNPIASEKEEGTRLDLDRIAHWVGQGATISDRVAALIKEVNKAA	82	Sequence 1434 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15287	MVTIRLSRGGAKKRPFYQIVVADSRSPRDGRFIERVGFFNPIAQGNAERLRINLERVNHWVAQGASLSDRVASLVKEAQKAA	82	Sequence 1437 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15288	MTVIRLTRIGRKKKPFYRVVVTDSRKRRDGGWIESIGYYNPLSEPKDIKIDKERLNYWKGVGAKMSERVEKLSQKA	76	Sequence 1438 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15289	MRMGRVHYPLYRIVAVDSRVKRNGKYIALIGHLNPALKENKCKLDETVALDWLNKGAIPTDTVRSLFSESGLWKKFIESKNKKETSPKK	89	Sequence 1442 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15290	MRMGRVHYPTYRIVAVDSRVKRDGKYIALIGHLNPALKENKCKIDEAVALEWLNKGAKPTDTVRSLFSQTGLWKKFVESKKKPVAKSK	88	Sequence 1444 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15291	MVTIRLARHGAKKRPFYQVVVTDSRNARNGRFIERVGFFNPIASEKEEGTRLDLDRIAHWVGQGATISDRVAALIKEVKKAA	82	Sequence 1447 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15292	MIKLRLKRFGKKREVSYRIVAMHSTTRRDGRPLEELGFYNPRTDETRLDVPAIVKRLKEGAQPTDTVRSILTKAQVFEQLKA	82	Sequence 1448 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15293	TDKIRSVQGRVVSDKMEKSFVVAIERKVKHPLYGKFIRRTTKLHVHDENNEAKLGDLVEVRECRPISKTKSWTLVRVVEKAVIA	84	Sequence 1449 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15294	MTDVIRTLQGRVVSHKMEKSIVVAIERTVKHPIYGKFIKRTTKLHVHDENNECGIGDVVEIRECRPLSKTKSWTLVRVVDKAIL	84	Sequence 1450 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15295	SERNQRKVYVGRVVSDKMDKTITVLVETYKKHPLYGKRVKYSKKYKAHDEHNEAKVGDIVKIMETRPLSATKRFRLVEIVEKAVVL	86	Sequence 1451 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15296	SERNQRKVYQGRVVSDKMDKTITVVVETYKKHTLYGKRVKYSKKFKAHDENNQAKIGDIVKIMETRPLSATKRFRLVEVVEEAVII	86	Sequence 1452 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15297	MASDVRGRRKTKIGVVVSSKMEKTVVVRVERVYSHPQYAKVVRDSSKYYAHNELDVKEGDTVRIQETRPLSKTKRWRVVGRVN	83	Sequence 1454 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15298	TDKIRTLQGRVVSDKMEKSIVVAIERFVKHPIYGKFIKRTTKLHVHDENNECGIGDVVEIRECRPLSKTKSWTLVRVVEKAVL	83	Sequence 1458 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15299	TDKIRSVQGKVVSDKMEKSFVVAIERKVKHPLYGKFIRRTTKLHVHDENNEAKVGDTVEIRECRPLSKTKSWTLVRVVEKAVIA	84	Sequence 1459 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15300	MNTKEPHKRLVQGKVISKFAEKSAVILVERKVVHEKYRKIVKKFKKYTIHDENNQVKVGDFVSAIECRPLSKTKSFTLKEILVVGV	86	Sequence 1460 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15301	MQRNSRRVLIGKVVSDKMDKTITVLVETYKNHPIYKKRVKYSKKYKAHDENQVAQMGDKVEIMETRPLSKTKNFRLVRVIEKATL	85	Sequence 1466 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15302	MKRNQRKQLIGTVVSTKNAKTATVKVTSRFKHPLYHKSVIRHKKYHVHNFGELVANDGDRVQIIETRPLSALKRWRIVKIIERAK	85	Sequence 1467 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15303	MKRNQRKVLIGIVKSTKNAKTATVQVESRFKHPLYHKSVVRHKKYQAHNEGEVLAKDGDKVQIVETRPLSATKRFRIAKIIERAK	85	Sequence 1469 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15304	MERNSRKVLQGRVISDNLKKTITVLVETYKNHPLYKKRVKYSKKYLAHDEQNQAHIGDKVSIMETRPLSKTKHFRLIEVIEKAIG	85	Sequence 1472 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15305	MAVKERVGVVVSDKMDKTVVVAIEDRTAHPKYGKIVVRTKRYKAHDEDNRAKTGDRVRIQETRPLSRTKRWTVAEILESVGA	82	Sequence 1473 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15306	MAIKERVGIVVSNKMDKTVVVAVESRSPHPKYGKIVVKTKKFKAHDEENQCQEGDKVRIQETRPLSKTKRWQVINIMSHSS	81	Sequence 1474 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15307	AGRKGGRGKRRKVCYFTANNITHIDYKDVDLLKKFISERGKILPRRVTGTSAKYQRKLTVAIKRARQMALLPYVADE	77	Sequence 1478 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15308	AGGRRGGRAKRRKVCYFTSNGITHIDYKDVDLLKKFVSERGKILPRRVTGTNAKYQRKLTAAIKRARQMALLPYVSGE	78	Sequence 1479 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15309	MNRPVHNEHRRKRFAKKCPFVSAGWKTIDYKDVVTLKRFITERGKILPRRITGVSSRFQALLAQAVKRARHVGLLLS	77	Sequence 1481 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15310	ARYFRRRKFCRFTAEGVQEIDYKDIATLKNYITESGKIVPSRITGTRAKYQRQLARAIKRARYLSLLPYTDRHQ	74	Sequence 1483 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15311	ARYFRRRKFCRFTAENVVEIDYKDIATLKNYISESGKIVPSRITGTRAKYQRQLARAIKRARYLALLPYTDNHQ	74	Sequence 1485 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15312	MERKRYSKRYCKYTEAKISFIDYKDLDMLKHTLSERYKIMPRRLTGNSKKWQERVEVAIKRARHMALIPYIVDRKKVVDSPFKQH	85	Sequence 1486 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15313	MAKSSKRRPAPEKPVKTRKCVFCAKKDQAIDYKDTALLRTYISERGKIRARRVTGNCVQHQRDIALAVKNAREVALLPFTSSVR	84	Sequence 1490 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15314	MARQSFKRRKFCRFTAEKIQEVDYKQVDLLKDFISENGKIIPARITGTKAFYQRQLAVAVKRARFLALLPYTDQHK	76	Sequence 1491 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15315	MNYYRKRLSPLPPNQPIDYKDTELLRKFITERGKILPRRITGLTAKQQRDLTTAVKRSRLVALLPFVNKEI	71	Sequence 1492 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15316	GRSLKKGPFCDEHLMKKIEKLNETGQKQVIKTWSRRSTIFPQFVGHTIAVYDGRRHVPVYITEDMVGHKLGEFAPTATFRGHAGDDKKTKR	91	Sequence 1494 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15317	ARSLKKGPFVDGHLMTKIEKLNETDKKQVVKTWSRRSTIFPQFIGHTIAVYDGRKHVPVFISEDMVGHKLGEFAPTRTYKGHASDDKKTRR	91	Sequence 1495 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15318	MARSIKKGPFIEKSLYQKVLSSFGSEKRVVIKTYSRSSTIIPEMVSLTISVYNAKTFIPIYITEDLVGHKLGEFSPTRIFRGHAKSDKKGRK	92	Sequence 1496 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15319	PRSLKKGPFIDLHLLKKVEKAVESGDKKPLRTWSRRSTIFPNMIGLTIAVHNGRQHVPVFVTDEMVGHKLGEFAPTRTYRGHAADKKAKKK	91	Sequence 1498 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15320	PRSLKKGPFLDLHLLKKVEKAVESGDKKPIKTWSRRSMIIPSMIGLTIAVHNGRQHVPVYVSDEMIGHKLGEFAPTRTYRGHAADKKAKK	90	Sequence 1501 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15321	MSRSIKKGPFIDDHLMKKTLKAKEGKDNRPIKTWSRRSTILPEMIGFTYNVHNGRVFIPVYITENHVGYKLGEFAPTRTFKGHKGSVQKKIGK	93	Sequence 1502 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15322	MPRSLKKGPFVDEHLLKKVDVQNEKNTKQVIKTWSRRSTIIPDFIGHTFAVHDGRKHVPVFVTESMVGHKLGEFAPTRRFKGHIKDDRKSKRR	93	Sequence 1507 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15323	MARSLKKGPFVDENLFKKVTSAKDGEVIKTWSRRSTIFPEFIGKTFGVYNGKEFIPVYITEDMVGNKLGEFAPTRKFGGHGDDKGKKK	88	Sequence 1508 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15324	MSRSSKKGAFVDAHLLKKVIEMNKQAKKKPIKTWSRRSTIFPEFVGNTFSVHNGKTFINVYVTDDMVGHKLGEFSPTRNFKQHTANR	87	Sequence 1509 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15325	MPRSLKKGPFVDDHLLKKVDVQNEKNTKQVIKTWSRRSTIIPDFIGHTFAVHDGRKHVPVFVTEAMVGHKLGEFAPTRTFKGHIKDDRKAKRR	93	Sequence 1510 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15326	MSRSAKKGAFVDAHLLKKVIDMNKQEKKRPIKTWSRRSTIFPEFVGNTFAVHNGKTFINVYVTDDMVGHKLGEFSPTRNFKQHTANR	87	Sequence 1511 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15327	MARSLKKGPFVADHLLRKVEKLNAKGDKQVIKTWSRASTILPQMIGHTIAVHNGRQHVPVYVTEQMVGHKLGEFAPTRTFRGHTKDKKAGR	91	Sequence 1514 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15328	MGRSLKKGPFVAASLLRKIDKLNDKGDKQVVKTWSRASTILPQMVGHTIAVHNGRQHVPVFVSEQMVGHKLGEFAPTRTFRSHSKSDKKARK	92	Sequence 1515 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15329	MGRSRKKGPYVDRKLLEKIRKLNETGEKKVIKTWSRASMIIPKWVGHGIAVYNGMKHIPVYITENMIGHRLGEFAPTRRFGGHADKKAKKGELKK	95	Sequence 1516 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15330	PNIKSAIKRTKTNNERGVHNATIKSAMRTAIKQVEASVANNEADKAKTALTEAAKRIDKAVKTGLVHKNTAARYKSRLAKKVNGLSA	87	Sequence 1526 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15331	MRKNASALKRSRQNLKRKIRNVSVKSELKTIEKRCINMIKAGKKDEAIEFFKFVAKKLDTAARKRIIHKNKAARKKSRLNVLLLK	85	Sequence 1527 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15332	ANIKSAKKRAIQSEKARKHNASRRSMMRTFIKKVYAAIEAGDKAAAQKAFNEMQPIVDRQAAKGLIHKNKAARHKANLTAQINKLA	86	Sequence 1529 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15333	ANIKSAKKRAVQSEKRRQHNASQRSMMRTYIKKVYAQVAAGEKSAAEAAFVEMQKVVDRMASKGLIHANKAANHKSKLAAQIKKLA	86	Sequence 1530 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15334	MANHKSAEKRIRQTIKRTERNRFYKTKIKNIIKAVREAVAVNDVAKAQERLKIANKELHKFVSKGILKKNTASRKVSRLNASVKKIALA	89	Sequence 1531 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15335	MANIKSNEKRLRQDIKRNLNNKGQKTKLKTNVKKFNKEINLDNLSSVYSQADRLARKGIISLNRAKRLKSKNAVILHKSNTNSTAKKQ	88	Sequence 1533 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15336	MTNIKSQQKRNRTNERARLRNKSVKSSLRTAVRAFREAVHAGEKEKAAKLLVSTSRKLDKAASKGVIHKNQAANKKSALARTLNKL	86	Sequence 1534 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15337	MANIKSNEKRLRQNIKRNLNNKGQKTKLKTNVKNFHKEINLDNLGNVYSQADRLARKGIISTNRARRLKSRNVAVLNKTQVTAVEGK	87	Sequence 1535 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15338	MANTTSAKKATRKIARRSAVNKARRSRIRSFVRKVEEAIASGDQALAAAALKAAQPELMRPATKGVMHSNTASRKVSRLAQRVKSLSA	88	Sequence 1537 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15339	MANIKSALKRIEIAERNRLQNKSYKSAIKTLMKKTFQSVEAYASDPNPEKLDTINTSMAAAFSKIDKAVKCKVIHKNNAARKKARLAKALQSALPAA	97	Sequence 1538 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15340	MTQIVVGENEHIESALRRFKREVSKAGIFQDMRKHRHFETPIEKSKRKKLALHKQSKRRFRT	62	Sequence 1540 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15341	SKTIVRKNESIDDALRRFKRAVSKTGTLQEVRKREFYEKPSVRRKKKSEAARKRK	55	Sequence 1541 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15342	SKTVVRKNESLEDALRRFKRSVSKTGTLQEARKREFYEKPSVKRKKKSEAARKRKF	56	Sequence 1542 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15343	MTTILLKENEPFEVAIRRFRRAIEKNGLIAELRERQAYEKPTAVRKRKKAAAVKRLHKRLRSQMLPKKLH	70	Sequence 1543 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15344	MQNDAGQTVELYVPRKCSSSNRIIGPKDHASVQIDFVDVDPETGRMIPGKSTRYAICGAIRRMGESDDAILRLAQKDGLVPRDDVKSN	88	Sequence 1544 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15345	PVIKVRENEPFDVALRRFKRSCEKAGVLAEVRRREFYEKPTTERKRAKASAVKRHAKKLARENARRTRLY	70	Sequence 1545 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15346	PVIKVRENESFDVALRRFKRSCEKAGILAEVRAREFYEKPTTIRKRENATLAKRHAKRNARENARNTRLY	70	Sequence 1546 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15347	MPGIKVREGDAFDEAYRRFKKQTDRNLVVTECRARRFFESKTEKRKKQKISAKKKVLKRLYMLRRYESRL	70	Sequence 1547 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15348	MQNDAGEFVDLYVPRKCSASNRIIGAKDHASIQMNVAEVDKVTGRFNGQFKTYAICGAIRRMGESDDSILRLAKADGIVSKNF	83	Sequence 1548 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15349	MQNEEGKTVDLYVPRKCSATNRIITAKDHASVQINIGHLDANGLYDGHFTTFALSGFVRAQGDADSSLDRLWQKKKAEIKQ	81	Sequence 1549 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15350	MPGIRVKEGESIESALKRFKKATEKAGILSEIRKREHYEKPSVKRKKKALAAKKRAVKKARKSF	64	Sequence 1550 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15351	MQNEEGQMVDLYVPRKCSATNRIITAKDHASVQINIGHVDENGLYDGRFTTFALSGFIRAQGDADSALDRLWQKRKAEVKQQ	82	Sequence 1551 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15352	MQNDAGEFVDLYVPRKCSASNRIIAAKDHASIQMNVAEVDRSTGRFNGQFKTYGICGAIRRMGESDDSILRLAKADGIVSKNF	83	Sequence 1552 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15353	MTQVVVGQNEPIESALRRFKRQVAKAGIYTDFKKHQFFETPQEKHKRKEATRRRQRSRRR	60	Sequence 1553 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15354	MKSNRQARHILGLDHKISNQRKIVTEGDKSSVVNNPTGRKRPAEK	45	Sequence 1554 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15355	MVLSSDIDLLNPPAELEKTKHKRKRLVQSPNSFFMDVKCQGCFNITTVFSHSQTVVMCGSCSSVLCTPTGWPRRLTEGCSFRRKSD	86	Sequence 1580 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15356	MPLIEVDLLNPTAASEAKAHKMKRLVPTPNSYFLEIKCPKCGATTTTFSHAHRQILCQKCGQPLGQPTGGKLKLTQQCKFRIKK	84	Sequence 1581 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15357	PLAKDLLHPSPSEEKRKCKLKRLVQHPNSYFMDVKCPGCFKISTVFSHAQTVVACVGCATVLCQPTGGKAKLTDGCSFRKKQN	83	Sequence 1582 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15358	MVLQNDIDLLNPPAELEKLKHKKKRLVQSPNSFFMDVKCQGCFNITTVFSHSQTVVVCPGCQTVLCQPTGGKARLTEGSPSVARATKPVANWKSKPLLN	99	Sequence 1583 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15359	PLAKDLLHPSPEEEKRKHKKKRLVQSPNSYFMDVKCPGCYKITTVFSHAQTVVLCVGCSTVLCQPTGGKARLTEGCSFRRKQH	83	Sequence 1584 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15360	MMELIPQPRTKFLRVQCPECNNEQIVFGSPATVVKCLTCGKVLVEPRGGKGKVKAKILEILG	62	Sequence 1585 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15361	PLARDLLHPSLEEEKKKHKKKRLVQSPNSYFMDVKCPGCYKITTVFSHAQTVVLCVGCSTVLCQPTGGKARLTEGCSFRRKQH	83	Sequence 1586 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15362	PLAKDLLHPTPEEEKRKHKKKRLVQSPNSYFMDVKCPGCYKITTVFSHAQTVVLCVGCSTVLCQPTGGKARLTEGCSFRRKQH	83	Sequence 1587 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15363	MDSQIKHAVVVKVMGRTGSRGQVTQVRVKFTDSDRFIMRNVKGPVREGDVLTLLESEREARRLR	64	Sequence 1588 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15364	MDTSRVQPIKLARVTKVLGRTGSQGQCTQVRVEFMDDTSRSIIRNVKGPVREGDVLTLLESEREARRLR	69	Sequence 1589 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15365	MDTQVKLAVVVKVMGRTGSRGQVTQVRVKFLDDQNRLIMRNVKGPVCEGDILTLLESEREARRLR	65	Sequence 1590 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15366	MMRMEDEFVYKEAVAAEVIEVIGRTGVTGGIIQVRCKILGGKDTGRVLVRNVKGPVKVGDIIMLRETEREARPLDRRR	78	Sequence 1591 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15367	MDSSKVPVKLAKVIKVLGRTGSRGGVTQVRVEFMDDTSRSIIRNVKGPVREDDILVLLESEREARRLR	68	Sequence 1592 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15368	GHQQLYWSHPRKFGQGSRSCRVCSNRHGLIRKYGLNMCRQCFRQYAKDIGFIKLD	55	Sequence 1594 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15369	KVHGSLARAGKVRGRHQKVAKQDKKKKPRGRAHKRLQHNRRFVTAVVGFGKKRGPNSSEK	60	Sequence 1595 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15370	KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPNANS	59	Sequence 1596 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15371	AKVHGSLARAGKVKSQTPKVEKTEKPKKPKGRAYKRLLYTRRFVNVTLVNGKRRMNPGPSVQ	62	Sequence 1597 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15372	MDTKTPVTLAKVIKVLGRTGSRGGVTQVRVEFLEDTTRTIVRNVKGPVREGDILVLMESEREARRLR	67	Sequence 1599 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15373	MDSKTPVTLAKVIKVLGRTGSRGGVTQVRVEFLEDTTRTIVRNVKGPVREGDILVLMESEREARRLR	67	Sequence 1600 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15374	MDSKTPVTLAKVIKVLGRTGSRGGVTQVRVEFLEDTSRTIVRNVKGPVRENDILVLMESEREARRLR	67	Sequence 1601 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15375	GKKRKKKVYTTPKKIKHKHKKVKLAVLSYYKVDAEGKVTKLRRECSNPTCGAGVFLANHKDRLYCGKCHSVYKVNA	76	Sequence 1602 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15376	MRPYEIMVILDPTLDERTVAPSLETFLNVVRKDGGKVEKVDIWGKRRLAYEIAKHAEGIYVVIDVKAAPATVSELDRQLSLNESVLRTKVMRTDKH	96	Sequence 1618 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15377	GKGDRRTRRGKIWRGTYGKYRPRKKK	26	Sequence 1680 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15378	MRVLFLYGLCVRFLYFCLVLYFSPRLPSSGNRRCLYAICYMFNILWFFCVFCCVCFLNHLLFIVEGGGFIDLPGVKYFSRFFLNA	85	Sequence 1703 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15379	MLFYCVLLYGLCLRFLLFSFRYFMCPRLPSSGNRMIGCLLLLLFYSFWLLRCFFIFFLVSCFIYVVEGGGFIDLPSLRYFTRLFYFV	87	Sequence 1716 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15380	MKYLLIKNKKLYKLFFKFELKRLQYKSVMLNTRLPNYIRQKAFMYINKLDKNTSYVAIKQRCFLSNNGRSVLNHFKLSRIKLRLLISNNYVNGVKKFNK	99	Sequence 1725 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15381	MSEKQNSRDHKRRLLAAKFELRRKLYKAFCKDPDLPSDMRDKHRYKLSKLPRNSSFARVRNRCISTGRPRSVSEFFRIYRIVFRGLASRGSLMGIKKSSW	100	Sequence 1726 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15382	MSNQIIRDHKRRLLVAKYELKRMHYKAICQDRNLPNKIRYEYFFKLSKLPRNSSKTRVRNRCIFTGRPRSVYKLFRISRIVFRELASKGSLIGINKSCW	99	Sequence 1728 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15383	MEKRNIRDHKRRLLATKYELRRKLYKAFCNDPALPSDMRDKHRYKLSKLPRNSSFARVRNRCISTGRPRSVYEFFRISRIVFRGLASRGPLMGIKKSSW	99	Sequence 1729 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15384	MFNSIKRDLKRRKLYKKYESKRLLYKALISDCNLNQDLRFILTQKLNKLPRNSSQVRVKNRCILTGRGHSVYKFCRISRIKFRDLANQGLIQGCVKSSW	99	Sequence 1731 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15385	MSEKRNIRDHKRRLLAAKYELRRKLYKAFCKDSDLPSDMRDKLRYKLSKLPRNSSFARVRNRCISTGRPRSVYELFRISRIVFRSLASRGPLMGIKKSSW	100	Sequence 1732 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15386	MRSVWKGCFYKNNNNGLSKSSTVINTMLKKKFTLHDGKSYKSILIDRSMVGLKIGEFVFTRKMGVLHKKKVLKKKGKK	78	Sequence 1734 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15387	MTRSIWKGPFVDTCLFKQKKIRWRIWSRRSCILPQFVGCYAQIYNGKGFVGLKITEEMVGHKFGEFASTRKTSSLGKRALPSKTKIKPIKKVR	93	Sequence 1735 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15388	MPRRSIWKGSFVDAFLLRMKKKRDLLFNRKIWSRRSSILPEFVDCFVRIYNGKTFVRCKITEGKVGHKFGEFAFTRKRRPSRTNIGPGRKRGKK	94	Sequence 1736 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15389	MSRAIWKGPFIDPFFFRKNGSSNSNNKIYSRRSVVSPKFIGREVEIYNGHKWITIKIKEDMIGHKFGEFAFTRKATIHKKKTK	83	Sequence 1737 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15390	MARSLSKPPFCEVKLATNNSVTKIWSRRSAILPQFVGKTVSIHNGRIFIPCKISPEMIGHKFGEFAVTRKKPIHKKKK	78	Sequence 1738 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15391	MFMSYDKVSQAKSIIIGTKQTVKALKRGSVKEVVVAKDADPILTSSVVSLAEDQGISVSMVESMKKLGKACGIEVGAAAVAIIL	84	Sequence 1741 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15392	MKPNIHPEYRTVVFHDTSVDEYFKIGSTIKTDREIELDGVTYPYVTIDVSSKSHPFYTGKLRTVASEGNVARFTQRFGRFVSTKKGA	87	Sequence 1744 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15393	MSGMEWFPLLGLANRARKVVSGEDLVIKEIRNARAKLVLLTEDASSNTAKKVTDKCNYYKVPYKKVESRAVLGRSIGKEARVVVAVTDQGFANKLISLLD	100	Sequence 1745 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15394	MQPAARLLSRSVWKGPNIVPLPIREAMTKGTPIRTNARAATILPQFVGLKFQIHNGKEYVPIEISEDMVGHKLGEFAPTRKRFSYTQTKNK	91	Sequence 1749 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15395	RTCENLADKYRGPCFSGCDTHCTTKENAVSGRCRDDFRCWCTKRC	45	Sequence 2 from Patent US 7728190	Synthetic construct	Antimicrobial, Antifungal	US 7728190 B1	Granted Patent	2010##6##1	US8067542	Amino acid sequence variant alfalfa antifungal protein and its use in plant disease control.	The present invention relates to an antifungal protein, AlfAFP1, which is a modified form of an antifungal protein isolated from Medicago plants, the modified form exhibiting enhanced anti-fungal activity for controlling fungal pathogenesis in plants. A method for inhibiting fungal colonization of plants is described which includes preparation of nucleotide sequences encoding the modified antifungal protein, preparation of vectors containing the nucleotide coding sequence, and methods for transforming plants with the nucleotide sequences. The polypeptide can be formulated into compositions useful in controlling plant pathogenic fungi.
DRAMP15396	RTCENLARKYRGPCFSGCDTHCTTKENAVSGRCRDDFRCWCTKRC	45	Sequence 4 from Patent US 7728190	Synthetic construct	Antimicrobial, Antifungal	US 7728190 B1	Granted Patent	2010##6##1	US8067542	Amino acid sequence variant alfalfa antifungal protein and its use in plant disease control.	The present invention relates to an antifungal protein, AlfAFP1, which is a modified form of an antifungal protein isolated from Medicago plants, the modified form exhibiting enhanced anti-fungal activity for controlling fungal pathogenesis in plants. A method for inhibiting fungal colonization of plants is described which includes preparation of nucleotide sequences encoding the modified antifungal protein, preparation of vectors containing the nucleotide coding sequence, and methods for transforming plants with the nucleotide sequences. The polypeptide can be formulated into compositions useful in controlling plant pathogenic fungi.
DRAMP15397	KICRRRSAGFKGPCMSNKNCAQVCQQEGWGGGNCDGPFRRCKCIRQC	47	Sequence 5 from Patent US 7728190	Synthetic construct	Antimicrobial, Antifungal	US 7728190 B1	Granted Patent	2010##6##1	US8067542	Amino acid sequence variant alfalfa antifungal protein and its use in plant disease control.	The present invention relates to an antifungal protein, AlfAFP1, which is a modified form of an antifungal protein isolated from Medicago plants, the modified form exhibiting enhanced anti-fungal activity for controlling fungal pathogenesis in plants. A method for inhibiting fungal colonization of plants is described which includes preparation of nucleotide sequences encoding the modified antifungal protein, preparation of vectors containing the nucleotide coding sequence, and methods for transforming plants with the nucleotide sequences. The polypeptide can be formulated into compositions useful in controlling plant pathogenic fungi.
DRAMP15398	EMSWIXSVLWFADFPKGESLXVLTNRKRTSLSXKGKDDFIQEPIPEAAIXEIWRRLEAPXARLGKIILTPFGGKXSEMAEYVXPFP	86	Sequence 39 from Patent WO 1998013478	Arabidopsis thaliana	Antimicrobial, Antifungal	WO 1998/013478 A2	Patent Application	1998##4##2	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, US20020168735, WO1998013478A3	Antifungal proteins, dna coding therefore, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has antifungal activity, specifically anti-Phytophthora activity and/or anti-Pythium activity and a molecular weight of about 55-65 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterised in that it comprises an open reading frame which is capable of encoding a protein depicted in SEQ ID NO. 16, SEQ ID NO. 57, SEQ ID NO. 70, SEQ ID NO. 72 or SEQ ID NO. 74 or muteins thereof, and DNA capable of hybridising therewith under stringent conditions. The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention, and wherein the protein is expressed. Also shown is the carbohydrate and preferably hexose oxidating activity of said protein. Also methods are provided for combating fungi, especially Phytophthora and Pythium species, using 
DRAMP15399	SWKVRLVQVXTTVTVFVVGRNVDQGAADVVARWQDVAPSLPPELTIRVIVRGQRATFQSLYLGSCADLVPTMSSMFPELGMTI	83	Sequence 49 from Patent WO 1998013478	Oryza sativa Japonica Gro	Antimicrobial, Antifungal	WO 1998/013478 A2	Patent Application	1998##4##2	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, US20020168735, WO1998013478A3	Antifungal proteins, dna coding therefore, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has antifungal activity, specifically anti-Phytophthora activity and/or anti-Pythium activity and a molecular weight of about 55-65 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterised in that it comprises an open reading frame which is capable of encoding a protein depicted in SEQ ID NO. 16, SEQ ID NO. 57, SEQ ID NO. 70, SEQ ID NO. 72 or SEQ ID NO. 74 or muteins thereof, and DNA capable of hybridising therewith under stringent conditions. The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention, and wherein the protein is expressed. Also shown is the carbohydrate and preferably hexose oxidating activity of said protein. Also methods are provided for combating fungi, especially Phytophthora and Pythium species, using 
DRAMP15400	DSHAKRHHGYKRKFHEKHHSHRGY	24	Sequence 1 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15401	KRKFHEKHHSHRGY	14	Sequence 2 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15402	KRLFKELKFSLRKY	14	Sequence 3 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15403	KRLFKELLFSLRKY	14	Sequence 4 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15404	XXLFXELXXSLXXY	14	Sequence 7 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15405	XXLFXELLXSLXXY	14	Sequence 8 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15406	KRLFKKLKFSLRKY	14	Sequence 9 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15407	KRLFKKLLFSLRKY	14	Sequence 10 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15408	LLLFLLKKRKKRKY	14	Sequence 11 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15409	KRKFHEKHHSHRGYCCYGRHSHHKEHFKRK	30	Sequence 14 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15410	YGRHSHHKEHFKRKCCKRKFHEKHHSHRGY	30	Sequence 15 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15411	KRKFHEKHHSHRGYKRKFHEKHHSHRGYK	29	Sequence 16 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15412	KRLFKELKFSLRKYKRLFKELKFSLRKYK	29	Sequence 17 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15413	KRLFKKLKFSLRKYKRLFKKLKFSLRKYK	29	Sequence 18 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15414	KRLFKKLLFSLRKYKRLFKKLLFSLRKYK	29	Sequence 19 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15415	LLLFLLKKRKKRKYLLLFLLKKRKKRKYK	29	Sequence 20 from Patent US 20020111305	Synthetic construct	Antimicrobial, Antiviral	US 2002/0111305 A1	Patent Application	2008##1##1	CA2353530A1, EP1147132A2, WO2000032629A2, WO2000032629A3	Antiviral peptides.	The invention relates to peptides for use as antiviral agent, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain are positively charged amino acids and the majority of the amino acids of the other half of the domain are uncharged amino acids. The invention further relates to oligomers of these peptides consisting of at least two such peptides which are coupled to each other, optionally via a spacer, for use as antiviral agent, in addition to the use of the peptides and/or oligomers for the manufacture of a medicine for treating viral infections.
DRAMP15416	GICRCICGRGICRCICGR	18	Sequence 1 from Patent US 20030144184	Homo sapiens	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18733	GICICICGRGICYCICGR	18	Sequence 9 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP15418	GICRCYCGRGICRCICGR	18	Sequence 3 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15419	GICRCICGRGICRCYCGR	18	Sequence 4 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15420	GYCRCICGRGICRCICGR	18	Sequence 5 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15421	GICRCICGRGYCRCICGR	18	Sequence 6 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15422	GICYCICGRGICRCICGR	18	Sequence 7 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15423	GICICICGYGICRCICGR	18	Sequence 8 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15424	GICICICGRGICYCICGR	18	Sequence 9 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15425	RGCICRCIGRGCICRCIG	18	Sequence 10 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15426	AQAEPLQARADEAAAQEQPGADDQEMAHAFTWHESAALPLSDSARGLRCICGRGICRLL	59	Sequence 12 from Patent US 20030144184	Homo sapiens	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15427	MRIIALLAAILLVALQVRAGPLQARGDEAPGQEQRGPEDQDISISFAWDKSSALQVSGSTRGMVCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRVD	97	Sequence 13 from Patent US 20030144184	Homo sapiens	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15428	MRTFALLTAMLLLVALHAQAEARQARADEAAAQQQPGTDDQGMAHSFTWPENAALPLSESAKGLRCICTRGFCRLL	76	Sequence 15 from Patent US 20030144184	Macaca mulatta	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15429	MRTFALLTAMLLLVALHAQAEARQARADEAAAQQQPGADDQGMAHSFTRPENAALPLSESARGLRCLCRRGVCQLL	76	Sequence 17 from Patent US 20030144184	Macaca mulatta	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15430	RCICGRGIC	9	Sequence 19 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15431	RCLCGRGIC	9	Sequence 20 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15432	RCICRRGIC	9	Sequence 21 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15433	RCICTRGIC	9	Sequence 22 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15434	RCICVRGIC	9	Sequence 23 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15435	RCICGLGIC	9	Sequence 24 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15436	RCICGRGVC	9	Sequence 25 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15437	RCICGRGFC	9	Sequence 26 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15438	RCLCRRGVC	9	Sequence 27 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15439	RCLCTRGIC	9	Sequence 28 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15440	RCLCVRGIC	9	Sequence 29 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15441	RCLCGLGVC	9	Sequence 30 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15442	RCLCGRGVC	9	Sequence 31 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15443	RCLCGRGFC	9	Sequence 32 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15444	RCICRRGVC	9	Sequence 33 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15445	RCICRRGFC	9	Sequence 34 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15446	RCICTRGVC	9	Sequence 35 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15447	RCICTRGFC	9	Sequence 36 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15448	RCICTLGIC	9	Sequence 37 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15449	RCICVLGFC	9	Sequence 38 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15450	RCICRLGIC	9	Sequence 39 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15451	RCICVRGVC	9	Sequence 40 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15452	RCICGLGFC	9	Sequence 42 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15453	RCICGLGVC	9	Sequence 43 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15454	RCLCRLGIC	9	Sequence 44 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15455	RCLCRRGFC	9	Sequence 46 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15456	RCLCTLGIC	9	Sequence 47 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15457	RCLCTRGVC	9	Sequence 48 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15458	RCLCTRGFC	9	Sequence 49 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15459	RCLCVLGIC	9	Sequence 50 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15460	RCLCVRGVC	9	Sequence 51 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15461	RCICRLGVC	9	Sequence 53 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15462	RCICRLGFC	9	Sequence 54 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15463	RCICTLGVC	9	Sequence 55 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15464	RCICTLGFC	9	Sequence 56 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15465	RCICVLGVC	9	Sequence 57 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15466	RCLCGLGIC	9	Sequence 60 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15467	RCLCTLGVC	9	Sequence 61 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15468	RCLCVLGVC	9	Sequence 63 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15469	RCICGRRIC	9	Sequence 74 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15470	RCLCGRRIC	9	Sequence 75 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15471	RCICRRRIC	9	Sequence 76 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15472	RCICTRRIC	9	Sequence 77 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15473	RCICVRRIC	9	Sequence 78 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15474	RCICGLRIC	9	Sequence 79 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15475	RCICGRRVC	9	Sequence 80 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15476	RCICGRRFC	9	Sequence 81 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15477	RCLCRRRVC	9	Sequence 82 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15478	RCLCTRRIC	9	Sequence 83 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15479	RCLCVRRIC	9	Sequence 84 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15480	RCLCGLRVC	9	Sequence 85 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15481	RCLCGRRVC	9	Sequence 86 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15482	RCLCGRRFC	9	Sequence 87 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15483	RCICRRRVC	9	Sequence 88 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15484	RCICRRRFC	9	Sequence 89 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15485	RCICTRRVC	9	Sequence 90 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15486	RCICTRRFC	9	Sequence 91 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15487	RCICTLRIC	9	Sequence 92 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15488	RCICVLRFC	9	Sequence 93 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15489	RCICRLRIC	9	Sequence 94 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15490	RCICVRRVC	9	Sequence 95 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15491	RCICGLRFC	9	Sequence 97 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15492	RCICGLRVC	9	Sequence 98 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15493	RCLCRLRIC	9	Sequence 99 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15494	RCLCRRRFC	9	Sequence 101 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15495	RCLCTLRIC	9	Sequence 102 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15496	RCLCTRRFC	9	Sequence 104 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15497	RCLCVLRIC	9	Sequence 105 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15498	RCLCVRRVC	9	Sequence 106 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15499	RCICRLRVC	9	Sequence 108 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15500	RCICRLRFC	9	Sequence 109 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15501	RCICTLRVC	9	Sequence 110 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15502	RCICTLRFC	9	Sequence 111 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15503	RCICVLRVC	9	Sequence 112 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15504	RCLCGLRIC	9	Sequence 115 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15505	RCLCTLRVC	9	Sequence 116 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15506	RCLCVLRVC	9	Sequence 118 from Patent US 20030144184	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2003/0144184 A1	Patent Application	2003##7##31	EP1513544A2, EP1513544A4, EP1513544B1, US6713078, WO2004033479A2, WO2004033479A3	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP18732	GICICICGYGICRCICGR	18	Sequence 8 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18731	GICYCICGRGICRCICGR	18	Sequence 7 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18730	GICRCICGRGYCRCICGR	18	Sequence 6 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18729	GYCRCICGRGICRCICGR	18	Sequence 5 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18728	GICRCICGRGICRCYCGR	18	Sequence 4 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18727	GICRCYCGRGICRCICGR	18	Sequence 3 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18726	GICRCICGKGICRCICGR	18	Sequence 2 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP18857	KWKSFIKNLEKVLKKGPILANLVSIV	26	Sequence 6 from Patent US 6906035	Not specified	Antimicrobial, Antiproliferative	US 6906035 B2	Granted Patent	2005##6##14	US4810777, US6057291, US6465429, CA2040510, WO8911290,  WO9628559A1,  WO9638473A	Antimicrobial Cationic Peptides	A novel class of cationic peptides having antimicrobial activity is provided. Examples of such peptides include NH2KWKSFIKKLTTAVKKVLTTGLPALISCOOHand NH2KWKSFIKKLTSAAKKVVTTAKPLISSCOOH. Also provided are methods for inhibiti2936, utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject.
DRAMP18725	GICRCICGRGICRCICGR	18	Sequence 1 from Patent US 20090264344	Homo sapiens	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins, antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV1 retrovirus or other sexuallytransmitted pathogens.
DRAMP15613	GICRCICGKGICRCYCGR	18	Sequence 126 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15614	GICKCICGKGICKCICGR	18	Sequence 127 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15615	GICRCICGKRICRCICGR	18	Sequence 128 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15616	GICRCICGKKICRCICGR	18	Sequence 129 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15617	GICRCICGRKICRCICGR	18	Sequence 130 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15618	GICRCICGRRICKCICGR	18	Sequence 131 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15619	GICKCICGRRICRCICGR	18	Sequence 132 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15620	GICRCICGRRICRCICGK	18	Sequence 133 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15621	GVCRCICGRGVCRCICRR	18	Sequence 134 from Patent US 20090264344	Orangutan	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15622	GVCRCICGRGVCRCICGR	18	Sequence 135 from Patent US 20090264344	Orangutan	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15623	RXICGXXIC	9	Sequence 136 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15624	GICYCICGKGICRCICGR	18	Sequence 137 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15625	GICRCICGRYICRCICGR	18	Sequence 138 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15626	RYICRCICGRGICRCICG	18	Sequence 139 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15627	GICRCICGRRICRCICGR	18	Sequence 140 from Patent US 20090264344	Synthetic construct	Antimicrobial, Antibacterial, Antiviral	US 2009/0264344 A1	Patent Application	2009##10##22	US7314858, US7718610, US20050272645, WO2006052637A1	Retrocyclins: antiviral and antimicrobial peptides.	Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
DRAMP15628	CVHAYRS	7	Sequence 1 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15629	CVHAYRA	7	Sequence 2 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15630	CVHAFRS	7	Sequence 3 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15631	CVHAFRA	7	Sequence 4 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15632	CVHSYRS	7	Sequence 5 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15633	CVHSYRA	7	Sequence 6 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15634	CVHSFRS	7	Sequence 7 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15635	CVHSFRA	7	Sequence 8 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15636	CVHTYRS	7	Sequence 9 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15637	CVHTYRA	7	Sequence 10 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15638	CVHTFRS	7	Sequence 11 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15639	CVHTFRA	7	Sequence 12 from Patent US 20040043936	Sos scrofus (Pig)	Antimicrobial, Antiviral, Anticancer	US 2004/0043936 A1	Patent Application	2004##3##4	DE69937998D1, DE69937998T2, EP1091753A1, EP1091753A4, EP1091753B1, US7476649	Antiproliferative and antiviral proteins and peptides.	The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.
DRAMP15640	TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQLLGI	59	Sequence 1 from Patent US 20040091855	Human immunodeficiency vi	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15641	NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ	38	Sequence 2 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15642	GSTMGARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT	43	Sequence 3 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15643	GSTMGARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARI	54	Sequence 4 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15644	GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLL	36	Sequence 5 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15645	GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQL	38	Sequence 6 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15646	GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV	40	Sequence 7 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15647	GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARI	50	Sequence 8 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15648	ARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQ	36	Sequence 9 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15649	RSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQL	36	Sequence 10 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15650	SMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT	36	Sequence 11 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15651	MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT	35	Sequence 12 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15652	MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV	36	Sequence 13 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15653	TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLT	34	Sequence 14 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15654	TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV	35	Sequence 15 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15655	TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVW	36	Sequence 16 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15656	TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWG	37	Sequence 17 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15657	TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGI	38	Sequence 18 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15658	TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQAR	44	Sequence 19 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15659	LTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWG	36	Sequence 20 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15660	QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL	42	Sequence 21 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15661	QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERY	47	Sequence 22 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15662	QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLK	49	Sequence 23 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15663	QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ	51	Sequence 24 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15664	SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL	36	Sequence 25 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15665	SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ	45	Sequence 26 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15666	QQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ	41	Sequence 27 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15667	RAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ	34	Sequence 28 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15668	QQQNNLLRAIEAQQHLLQLTAWGIKQLQARILAVERYLKDQ	41	Sequence 29 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15669	QQQNNLLRAIEAQQHLLQLTVAGIKQLQARILAVERYLKDQ	41	Sequence 30 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15670	QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVFGIRQLQARILAVERYLK	49	Sequence 31 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15671	QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGIKQLQARILAVERYLK	49	Sequence 32 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15672	WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL	36	Sequence 33 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15673	QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGIKQLQARILAVERYLKDQ	51	Sequence 34 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15674	QARQLVSGLVQQQNNILRALEATQHAVQALVWGVKQLQARVLALERYIK	49	Sequence 35 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15675	QIRQLLSGIVQQQNNLLRAIEAIQHALQAIVWGIKQLQARILAVERYLK	49	Sequence 36 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15676	QARQLVSGLVQQQNNILRALEATQHAVQALVWGVRQLQARVLALERYIK	49	Sequence 37 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15677	QARQLLSGIVQQQNNLLRAIEATQHAVQALVWGVKQLQARVLALERYIKDQ	51	Sequence 38 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15678	QARQLVSGLVQQQNNILRALEAQQHALQATVWGIKQLQARVLALERYIKDQ	51	Sequence 39 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15679	QARQLLSGIVQQQNNLLRAIEAQQHALQATVWGVKQLQARILAVERYLKDQ	51	Sequence 40 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15680	QARQLVSGLVQQQNNILRALEATQHLVQLLVWGVKQLQARVLALERYIK	49	Sequence 41 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15681	QIRQLLSGIVQQQNNLLRAIEAIQHLLQLIVWGIKQLQARILAVERYLK	49	Sequence 42 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15682	QQQNNLLRAIEAQQHLLQLTVFGIKQLQARILAVERYLKDQ	41	Sequence 43 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15683	QQQNNLLRAIEAQQHLLQLTVWGIAQLQARILAVERYLKDQ	41	Sequence 44 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15684	QQQNNLLRAIEAQQHLLQLTVWGIKQLAARILAVERYLKDQ	41	Sequence 45 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15685	QQQNNLLRAIEAQQHALQLTVWGIKQLQARILAVERYLKDQ	41	Sequence 46 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15686	QARQLLSGIVQQQNNLLRAIEAQQHLLQATVWGIKQLQARILAVERYLKDQ	51	Sequence 47 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15687	QQQNNLLRAIEAQQHLLQATVWGIKQLQARILAVERYLKDQ	41	Sequence 48 from Patent US 20040091855	Synthetic construct	Antimicrobial, Antiviral	US 2004/0091855 A1	Patent Application	2004##5##13	Unknown	Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom.	Provided is a method for identifying or producing a molecule having antiviral activity against HIV. More particularly, provided is a method for identifying or producing a molecule that can inhibit the binding between HR1 and HR2 regions of HIV gp41, wherein complex formation is observed in vitro between a trimer with HR2 peptide in the presence of the molecule, and detected in vitro is the ability of the molecule to inhibit complex formation as an indicator of the antiviral activity of the molecule. The trimer is comprised of synthetic peptide comprising an amino acid sequence derived from the HR1 region of HIV-1 gp41 and further comprising one or more amino acid substitutions in a hydrophobic domain of the HR1 region of HIV which enable the synthetic peptide to self-assemble in solution into trimers.
DRAMP15688	LEQVLQSVLLQLQI	14	Sequence 1 from Patent US 20040102605	Pseudomonas sp.	Antimicrobial, Antiviral	US 2004/0102605 A1	Patent Application	2004##5##27	EP1369426A1, EP1369426A4, EP1369426B1, EP2116552A2, EP2116552A3, US7268209, WO2002062831A1	Novel peptides, derivatives thereof, process for producing the same, novel strain producing the same, and antiviral agent comprising the same	Peptides having, as constitutive amino acids, (1) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue and 5 leucine residues, and having a 3-hydroxydecanoyl group bonded, via an amide linkage, to the N-terminal leucine residue thereof; (2) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 3 valine residues, and 5 leucine residues, and having a 3-hydroxydecanoyl group bonded, via an amide linkage, to the N-terminal leucine residue thereof; or (3) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue and 5 leucine residues, and having a 3-hydroxydodec-5-enoyl group bonded, via an amide linkage, to the N-terminal leucine residue thereof. The peptides have an antiviral activity. A strain capable of producing the above peptides and belonging to a new species of genus Pseudomonas.
DRAMP15689	LEQVLQSVVLQLQL	14	Sequence 4 from Patent US 20040102605	Pseudomonas sp.	Antimicrobial, Antiviral	US 2004/0102605 A1	Patent Application	2004##5##27	EP1369426A1, EP1369426A4, EP1369426B1, EP2116552A2, EP2116552A3, US7268209, WO2002062831A1	Novel peptides, derivatives thereof, process for producing the same, novel strain producing the same, and antiviral agent comprising the same	Peptides having, as constitutive amino acids, (1) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue and 5 leucine residues, and having a 3-hydroxydecanoyl group bonded, via an amide linkage, to the N-terminal leucine residue thereof; (2) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 3 valine residues, and 5 leucine residues, and having a 3-hydroxydecanoyl group bonded, via an amide linkage, to the N-terminal leucine residue thereof; or (3) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue and 5 leucine residues, and having a 3-hydroxydodec-5-enoyl group bonded, via an amide linkage, to the N-terminal leucine residue thereof. The peptides have an antiviral activity. A strain capable of producing the above peptides and belonging to a new species of genus Pseudomonas.
DRAMP15690	RRKKAAVALLPAVLLALLAP	20	Sequence 1 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15691	RRKKAAVALLAVLLALLAPP	20	Sequence 3 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15692	RRKKPAVLLALLA	13	Sequence 4 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15693	KLALKLALKALKAALKLA	18	Sequence 5 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15694	RQIKIWFPNRRMKWKKPGYAGAVVNDL	27	Sequence 7 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15695	RQIKIWFPNRRMKWKK	16	Sequence 8 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15696	RQIKIFFPNRRMKFKK	16	Sequence 9 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15697	YGRKKRRQRRRPGYAGAVVNDL	22	Sequence 10 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15698	YGRKKRRQRRRPGDVYANGLVA	22	Sequence 11 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15699	GWTLNSAGYLLGKINLKALAALAKKIL	27	Sequence 12 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15700	DPKGDPKGVTVTVTVTVTGKGDPKPD	26	Sequence 13 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15701	RRKK	4	Sequence 16 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15702	RRKKLAALPLVLAAPLAVLA	20	Sequence 17 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15703	RRKKAAVALLP	11	Sequence 18 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15704	RRKKAVAVAVPAVLLALLAP	20	Sequence 19 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15705	RRKKPAVLLA	10	Sequence 20 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15706	RRKKPAVLLALLALLA	16	Sequence 22 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15707	RRKKALLPAVLLALLAP	17	Sequence 23 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15708	RRKKPAVLLALLAP	14	Sequence 24 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15709	RRKKLLALLAP	11	Sequence 25 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15710	RRKKLLAP	8	Sequence 26 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15711	RRKKAAVALLPAVLLAL	17	Sequence 27 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15712	RRKKAAVAVVPAVL	14	Sequence 28 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15713	RRKKAAVAVVP	11	Sequence 29 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15714	RRKKAAVA	8	Sequence 30 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15715	PGYAGAVVNDL	11	Sequence 31 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15716	PGDVYANGLVA	11	Sequence 32 from Patent US 20050130884	Synthetic construct	Antimicrobial, Antiviral	US 2005/0130884 A1	Patent Application	2005##6##16	CA2399676A1, CA2399676C, DE60130641D1, DE60130641T2, EP1272510A2, EP1272510B1, US7371809, US20120157376, WO2001057072A2, WO2001057072A3	Pharmacologically active antiviral peptides and methods of their use.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP15717	HGVSGWGQHGTHG	13	Sequence 1 from Patent US 20070293424	Synthetic construct	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15718	HGGGWGQPHGGG	12	Sequence 2 from Patent US 20070293424	Tragelaphus strepsiceros	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15719	GGGGWGQGGTHG	12	Sequence 3 from Patent US 20070293424	Tragelaphus strepsiceros	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15720	GGGWGQPHVGG	11	Sequence 4 from Patent US 20070293424	Tragelaphus strepsiceros	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15721	VGGWGQPHGGG	11	Sequence 5 from Patent US 20070293424	Tragelaphus strepsiceros	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15722	GGGWGQPHGGG	11	Sequence 8 from Patent US 20070293424	Bos taurus	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15723	QGGGGWGQPHGGGWG	15	Sequence 9 from Patent US 20070293424	Homo sapiens	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15724	HGGGWGQPHGGGWG	14	Sequence 10 from Patent US 20070293424	Homo sapiens	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15725	HGGGWGQGGGTHS	13	Sequence 11 from Patent US 20070293424	Homo sapiens	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15726	HGVSGHGQHGVHG	13	Sequence 12 from Patent US 20070293424	Calliphora vicina	Antimicrobial, Antitumor, Antiviral	US 2007/0293424 A1	Patent Application	2007##12##20	EP1705182A1, EP1705182A4, EP1705182B1, US8372406, WO2005068491A1	Antitumoral and Antiviral Peptides.	The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid. The inventive compositions produce an antitumoral and antiviral effect by suppressing a tumoral cells proliferation, potentiating the action of other antitumoral preparations and by stimulating antitumoral and antiviral immunologic mechanisms.
DRAMP15727	SWLRDVWDWICTVL	14	Sequence 2 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15728	SWLRDVWDWVCTIL	14	Sequence 3 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15729	SWLRDIWEWVLSIL	14	Sequence 4 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15730	SWLRIIWDWVCSWC	14	Sequence 5 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15731	SWLRTIWDWVCSVC	14	Sequence 6 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15732	SWLHDIWDWVCIVC	14	Sequence 7 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15733	SWLWDVWDWVLHVL	14	Sequence 8 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15734	SWLYDIVNWVCTVC	14	Sequence 9 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15735	SWLRDIWDWVCTVC	14	Sequence 10 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15736	SWLRDIWDWICEVL	14	Sequence 11 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15737	LRDIWDWICEVLSDFKTWLKA	21	Sequence 12 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15738	WLRDVWDWICTVLTDFKTWLQSKL	24	Sequence 13 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15739	WLRDVWDWVCTILTDFKNWLTSKL	24	Sequence 14 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15740	WLRDIWEWVLSILTDFKNWLSAKL	24	Sequence 15 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15741	WLRIIWDWVCSVVSDFKTWLSAKI	24	Sequence 16 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15742	WLRTIWDWVCSVLADFKAWLSAKI	24	Sequence 17 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15743	WLHDIWDWVCIVLSDFKTWLSAKI	24	Sequence 18 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15744	WLWDVWDWVLHVLSDFKTCLKAKF	24	Sequence 19 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15745	WLYDIVNWVCTVLADFKLWLGAKI	24	Sequence 20 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15746	WLRDIWDWVCTVLSDFRVWLKSKL	24	Sequence 21 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15747	SWLRDVWDWICTVLTDFKTWLQSKL	25	Sequence 22 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15748	SWLRDVWDWVCTILTDFKNWLTSKL	25	Sequence 23 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15749	SWLRDIWEWVLSILTDFKNWLSAKL	25	Sequence 24 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15750	SWLRIIWDWVCSWSDFKTWLSAKI	24	Sequence 25 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15751	SWLRTIWDWVCSVLADFKAWLSAKI	25	Sequence 26 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15752	SWLHDIWDWVCIVLSDFKTWLSAKI	25	Sequence 27 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15753	SWLWDVWDWVLHVLSDFKTCLKAKF	25	Sequence 28 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15754	SWLYDIVNWVCTVLADFKLWLGAKI	25	Sequence 29 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15755	SWLRDIWDWVCTVLSDFRVWLKSKL	25	Sequence 30 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15756	SGSLRDIWDWICEVLSDFKTWLKA	24	Sequence 31 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15757	SGSWLRDVWDWICTVLTDFKTWLQSKL	27	Sequence 32 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15758	SGSWLRDVWDWVCTILTDFKNWLTSKL	27	Sequence 33 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15759	SGSWLRDIWEWVLSILTDFKNWLSAKL	27	Sequence 34 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15760	SGSWLRIIWDWVCSWSDFKTWLSAKI	26	Sequence 35 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15761	SGSWLRTIWDWVCSVLADFKAWLSAKI	27	Sequence 36 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15762	SGSWLHDIWDWVCIVLSDFKTWLSAKI	27	Sequence 37 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15763	SGSWLWDVWDWVLHVLSDFKTCLKAKF	27	Sequence 38 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15764	SGSWLYDIVNWVCTVLADFKLWLGAKI	27	Sequence 39 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15765	SGSWLRDIWDWVCTVLSDFRVWLKSKL	27	Sequence 40 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15766	GSWLRDVWDWICTVLTDFKTWLQSKL	26	Sequence 41 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15767	GSWLRDVWDWVCTILTDFKNWLTSKL	26	Sequence 42 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15768	GSWLRDIWEWVLSILTDFKNWLSAKL	26	Sequence 43 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15769	GSWLRIIWDWVCSWSDFKTWLSAKI	25	Sequence 44 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15770	GSWLRTIWDWVCSVLADFKAWLSAKI	26	Sequence 45 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15771	GSWLHDIWDWVCIVLSDFKTWLSAKI	26	Sequence 46 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15772	GSWLWDVWDWVLHVLSDFKTCLKAKF	26	Sequence 47 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15773	GSWLYDIVNWVCTVLADFKLWLGAKI	26	Sequence 48 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP13964	NLCEKASKTWSGNCGNTKHCDTQCRNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 225 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13965	NLCERASKTWSGNCGNTKHCDTQCRSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 226 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13966	NLCEKASKTWSGNCGNTKHCDNQCRSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 227 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13967	NLCEKASKTWSGNCGNTKHCDTQCKNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 229 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13968	NLCEKASKTWSGNCGNTKHCDNQCKSWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 230 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13969	NLCERASKTWSGNCGNTKHCDNQCKSWEGAQHGACHVRNGKHKCFCYFNC	50	Sequence 231 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13970	NLCERASKTWSGNCGNTKHCDTQCRNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 232 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13971	NLCERASKTWTGNCGNTKHCDTQCRSWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 233 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13972	NLCEKASKTWTGNCGNTKHCDNQCKSWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 234 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13973	NLCEKASKTWSGNCGNTKHCDTQCKSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 235 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13974	NLCERASKTWSGNCGNTKHCDNQCISWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 236 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13975	NLCERASKTWTGNCGNTKHCDNQCKNWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 238 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13976	NLCERASKTWAGNCGNTKHCDNQCRSWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 239 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13977	NLCEKASKTWSGNCGNTKHCDNQCKSWEGAAHGACHKRSGKWKCFCYFNC	50	Sequence 240 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13978	NLCEKASKTWSGNCGNTNHCDNQCRSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 241 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13979	NLCERASKTWSGNCGSTKHCDNQCKNWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 242 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13980	NLCERASKTWSGNCGNTKHCDNQCKNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 244 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13981	NLCERASKTWTGNCGNTKHCDNQCKSWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 245 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13982	NLCERASKTWTGNCGNTKHCDTQCRSWEGAAHGACHVRGGKHKCFCYFNC	50	Sequence 246 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13983	NLCEKASKTWTGNCGNTKHCDNQCRSWEGAKHGACHVRSGKHKCFCYFNC	50	Sequence 247 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13984	NLCERASKTWSGNCGNTKHCDNQCRSWEGAAHGACHKRNGKWKCFCYFNC	50	Sequence 248 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13985	NLCEKASKTWTGNCGNTKHCDNQCKSWEGAAHGACHKRNGKWKCFCYFNC	50	Sequence 249 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13986	NLCERASKTWSSNCGNTKHCDTQCKNWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 250 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13987	NLCERASKTWSGNCGNTKHCDTQCKNWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 251 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13988	NLCERASKTWSGDCGNTKHCDNQCRNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 252 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13989	NLCEKASKTWTGNCGNTKHCDNQCKSWEGAKHGACHKRGGKWKCFCYFNC	50	Sequence 253 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13990	NLCERASKTWTGNCGNTKHCDNQCKSWEGAKHGACHVRNGKWKCFCYFNC	50	Sequence 254 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13991	NLCERASKTWSGNCGNTKHCDNQCKNWEGAAHGACHVRSGKHKCFCYFNC	50	Sequence 255 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13992	NLCEKASKTWTGNCGNTKHCDNQCKSWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 256 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13993	NLCEKASKTWSGNCGNTKHCDTQCKNWEGAKHGACHVRSGKWKCFCYFNC	50	Sequence 257 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13994	NLCEKASKTWTGNCGNTKHCDNQCRSWEGAAHGACHVRNGKHKCFCYFNC	50	Sequence 258 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13995	NLCERASKTWSGNCGNTKHCDNQCRNWEGAKHGACHVRSGKWKCFCYFNC	50	Sequence 259 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13996	NLCERASKTWTGNCGNTKHCDTQCRNWEGARHGACHVRNGKWKCFCYFNC	50	Sequence 260 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13997	NLCERASKTWSGNCGNTKHCDNQCRSWEGAAHGACHVRNGKWKCFCYFNC	50	Sequence 261 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13998	NLCEKASKTWTGNCGNTKHCDNQCRSWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 262 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP13999	NLCERASKTWTGNCGNTKHCDNQCRSWEGAKHGACHKRSGKWKCFCYFNC	50	Sequence 263 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14000	NLCEKASKTWSGNCGNTKHCDTQCKSWEGAAHGACHKRNGKWKCFCYFNC	50	Sequence 264 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14001	NLCERASKTWTGNCGNTKHCDNQCRNWEGAKHGACHVRSGKWKCFCYFNC	50	Sequence 265 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14002	NLCERASKTWTGNCGNTKHCDNQCKNWEGAAHGACHKRSGKWKCFCYFNC	50	Sequence 266 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14003	NLCERASKTWTGNCGNTKHCDNQCRSWEGAAHGACHKRSGKWKCFCYFNC	50	Sequence 267 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14004	NLCERASKTWTGNCGNTKHCDNQCKNWEGAAHGACHVRSGKHKCFCYFNC	50	Sequence 268 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14005	NLCEKASKTWSGNCGNTKHCDNQCRNWEGAEHGACHVRNGKHKCFCYFNC	50	Sequence 269 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14006	NLCERASKTWSGNCGNTKHCDNQCKSWEGAKHGACHVRNGKHKCFCYFNC	50	Sequence 270 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14007	NLCEKASKTWSGNCGNTKHCDNQCKSWEGAAHGACHKRNGKWKCFCYFNC	50	Sequence 271 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14008	NLCEKASKTWSGNCGNTKHCDNQCKSWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 272 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14009	NLCERASRTWSGNCGNTKHCDNQCKSWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 273 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14010	NLCERASKTWSGNCGITKHCDNQCKSWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 274 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14011	NLCERASKTWSGNCSNTKHCDNQCKSWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 275 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14012	NLCERASKTWSGNCGNTKHCDNQCKNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 276 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14013	NLCEKASKTWSGNCGNTKHCDNQCKNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 277 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14014	NLCERASKTWSGNCGNTKHCDNQCKGWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 278 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14015	DGVKLCERPSQTWTGNCGNTKHCDKQCKSWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 280 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14016	DGVKLCEKPSQTWTGHCGNTKHCDTQCRSWEGAAHGACHKRSGKWKCFCYFNC	53	Sequence 281 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14017	DGVKLCERASKTWTGNCGNTKHCDKQCKNWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 282 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14018	DGVKLCEKASKTWSGNCGNTKHCDKQCRSWEKAKHGACHVRNGKHKCFCYFNC	53	Sequence 283 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14019	NLCERASKTWSGHCGNTKHCDNQCRNWEGAKHGACHKRNGKWKCFCYFNC	50	Sequence 284 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14020	DGVKLCERPSKTWSGNCGNTKHCDKQCKNWEKAKHGACHVRNGKWKCFCYFNC	53	Sequence 285 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14021	DGVKLCEKPSKTWSGHCGNTKHCDKQCKNWEKAKHGACHKRNGKWKCFCYFNC	53	Sequence 286 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14022	NLCEKASQTWTGHCGNTKHCDKQCKSWEGAAHGACHVRSGKWKCFCYFNC	50	Sequence 287 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14023	DGVKLCERPSQTWSGNCGNTKHCDKQCRNWEKAKHGACHKRNGKWKCFCYFNC	53	Sequence 288 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14024	DGVKLCEKPSKTWTGHCGNTKHCDNQCKNWEKAAHGACHVRSGKWKCFCYFNC	53	Sequence 289 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14025	DGVKLCEKPSKTWTGHCGNTKHCDKQCKNWEKAAHGACHVRNGKWKCFCYFNC	53	Sequence 290 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14026	DGVKLCERASQTWSGHCGNTKHCDKQCKNWEKAAHGACHVRSGKWKCFCYFNC	53	Sequence 291 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14027	DGVKLCERASQTWTGHCGNTKHCDKQCKSWEKAKHGACHVRNGKWKCFCYFNC	53	Sequence 292 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14028	DGVKLCERASQTWSGHCGNTKHCDKQCRNWEGAAHGACHVRNGKWKCFCYFNC	53	Sequence 293 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14029	DGVKLCEKASQTWSGNCGNTKHCDTQCRNWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 294 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14030	DGVKLCERASQTWTGHCGNTKHCDNQCKNWEGAKHGACHKRSGKWKCFCYFNC	53	Sequence 295 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14031	DGVKLCEKPSQTWTGHCGNTKHCDKQCKNWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 296 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14032	DGVKLCERASQTWTGHCGNTKHCDKQCRNWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 297 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14033	NLCERASHTWSGHCGNTKHCDKQCRSWEGAAHGACHVRNGKRKCFCYFNC	50	Sequence 298 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14034	DGVKLCEKPSKTWSGHCGNTKHCDNQCRNWEKAAHGACHVRNGKWKCFCYFNC	53	Sequence 299 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14035	QKLCEKASQTWTGHCGNTKHCDNQCRNWEKAAHGACHVRNGKWKCFCYFNC	51	Sequence 300 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14036	DGVKLCERASQTWTGHCGNTKHCDTQCRSWEGAAHGACHKRNGKWKCFCYFNC	53	Sequence 301 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14037	DGVKLCERASKTWSGHCGNTKHCDNQCRSWEGAKHGACHVRSGKHKCFCYFNC	53	Sequence 302 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14038	DGVKLCERASKTWSGHCGNTKHCDKQCKNWEKAKHGACHKRSGKWKCFCYFNC	53	Sequence 303 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14039	DGVKLCEKPSQTWSHCGNTKHCDNQCKNWEGAAHGACHKRSGKWKCFCYFNC	52	Sequence 304 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14040	DGVKLCERASQTWTGHCGNTKHCDNQCRNWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 305 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14041	DGVKLCEKASQTWSGHCGNTKHCDNQCKNWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 306 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14042	DGVKLCEKPSKTWSGHCGNTKHCDTQCRNWEKAKHGACHVRNGKWKCFCYFNC	53	Sequence 307 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14043	DGVKLCEKASQTWSGHCGNTKHCDNQCKNWEGAKHGACHKRSGKWKCFCYFNC	53	Sequence 308 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14044	DGVKLCEKPSQTWTGNCGNTKHCDTQCRNWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 309 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14045	DGVKLCERASQTWTGHCGNTKHCDKQCKNWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 310 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14046	DGVKLCERASKTWTGNCGNTKHCDKQCKNWEGAKHGACHVRNGKWKCFCYFNC	53	Sequence 312 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14047	DGVKLCERASKTWSGHCGNTKHCDNQCRSWEGAKHGACHVRNGKWKCFCYFNC	53	Sequence 313 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14048	DGVKLCERPSQTWTGNCGNTKHCDKQCKNWEKAKHGACHVRNGKWKCFCYFNC	53	Sequence 314 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14049	NLCERPSKTWTGHCGNTKHCDKQCKSWEGAKHGACHVRSGKWKCFCYFNC	50	Sequence 315 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14050	DGVKLCEKPSQTWSGNCGNTKHCDKQCKSWEGAKHGACHVRNGKWKCFCYFNC	53	Sequence 316 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14051	DGVKLCEKASQTWTGHCGNTKHCDKQCKSWEGAKHGACHKRSGKWKCFCYFNC	53	Sequence 317 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14052	QKLCERASKTWTGHCGNTKHCDKQCKNWEKAKHGACHVRNGKWKCFCYFNC	51	Sequence 318 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14053	DGVKLCERPSQTWTGNCGNTKHCDKQCRNWEGAKHGACHVRNGKWKCFCYFNC	53	Sequence 319 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14054	DGVKLCEKASQTWTGNCGNTKHCDNQCKNWEKAKHGACHKRSGKWKCFCYFNC	53	Sequence 320 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14055	QKLCERPSQTWTGHCGNTKHCDTQCKSWEGAKHGACHKRNGKWKCFCYFNC	51	Sequence 321 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14056	DGVKLCEKPSQTWTGNCGNTKHCDKQCRNWEKAKHGACHKRNGKWKCFCYFNC	53	Sequence 322 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14057	DGVKLCEKPSKTWSGNCGNTKHCDNQCRSWEKAKHGACHKRSGKWKCFCYFNC	53	Sequence 323 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14058	DGVKLCERPSKTWSGNCGNTKHCDKQCRSWEGAKHGACHVRSGKHKCFCYFNC	53	Sequence 324 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14059	DGVKLCERASQTWSGHCGNTKHCDNQCKSWEKAKHGACHVRSGKHKCFCYFNC	53	Sequence 325 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14060	QKLCEKASKTWTGNCGNTKHCDKQCRSWEKAKHGACHVRNGKWKCFCYFNC	51	Sequence 326 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14061	DGVKLCEKASKTWSGNCGNTKHCDKQCRSWEKAAHGACHVRSGKWKCFCYFNC	53	Sequence 327 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14062	DGVKLCEKASKTWTGHCGNTKHCDKQCKNWEGAKHGACHKRSGKWKCFCYFNC	53	Sequence 328 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14063	DGVKLCEKASKTWSGNCGNTKHCDKQCKNWEGAAHGACHKRNGKWKCFCYFNC	53	Sequence 329 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14064	DGVKLCEKASQTWTGHCGNTKHCDKQCKSWEGAKHGACHKRNGKWKCFCYFNC	53	Sequence 330 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14065	DGVKLCERASKTWTGNCGNTKHCDNQCKSWEGAKHGACHVRNGKHKCFCYFNC	53	Sequence 331 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14066	DGVKLCERPSKTWTGHCGNTKHCDKQCRNWEGAAHGACHVRNGKHKCFCYFNC	53	Sequence 332 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14067	DGVKLCERPSKTWSGNCGNTKHCDNQCRNWEGAKHGACHKRSGKWKCFCYFNC	53	Sequence 333 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14068	DGVKLCERASQTWTGHCGNTKHCDNQCRSWEGAAHGACHKRSGKWKCFCYFNC	53	Sequence 334 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14069	DGVKLCERPSQTWTGHCGNTKHCDKQCRNWEGAAHGACHKRSGKWKCFCYFNC	53	Sequence 335 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14070	DGVKLCERPSQTWSGHCGNTKHCDKQCRNWEGAKHGACHVRNGKWKCFCYFNC	53	Sequence 336 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14071	QKLCERPSQTWTGHCGNTKHCDKQCKNWEGAKHGACHVRNGKWKCFCYFNC	51	Sequence 337 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14072	DGVKLCERASKTWSGHCGNTKHCDKQCKNWEKAAHGACHVRNGKWKCFCYFSC	53	Sequence 338 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14073	DGVKLCERPSKTWSGHCGNTKHCDKQCRSWEGAAHGACHVRNGKWKCFCYFNC	53	Sequence 339 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14074	QKLCEKPSGTWSGVCGNSNACKNQCINLEGAKHGSCNYVFPAHKCICYFPC	51	Sequence 341 from Patent US 7785828	Arabidopasis thaiana	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14075	QKLCEKPSGTWSGVCGNSNACKNQCINLEGAKHGSCNYVFPAHKCICYVPC	51	Sequence 342 from Patent US 7785828	Arabidopasis thaiana	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14076	QKLCERPSGTWSGVCGNNNACKNQCINLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 343 from Patent US 7785828	Raphanus sativus	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14077	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 344 from Patent US 7785828	Raphanus sativus	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14078	QKLCERSSGTWSGVCGNNNACKNQCIRLEGAQHGSCNYVFPAHKCICYFPC	51	Sequence 345 from Patent US 7785828	Raphanus sativus	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14079	QKLCERSSGTWSGVCGNNNACKNQCINLEGARHGSCNYIFPYHRCICYFPC	51	Sequence 346 from Patent US 7785828	Raphanus sativus	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14080	ELCEKASKTWSGNCGNTKHCDDQCKSWEGAAHGACHVRNGKHMCFCYFNCN	51	Sequence 349 from Patent US 7785828	Cnicus benedictus	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14081	ELCEKASKTWSGNCGNTKHCDNKCKSWEGAAHGACHVRSGKHMCFCYFNC	50	Sequence 350 from Patent US 7785828	Cnicus benedictus	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14082	QKLCERPSRTWSGVCGNNNACKNQCINLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 354 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14083	QKLCERPSGTWSGVCGNNNACKNQCINLEKARHGSCNYRFPAHKCICYFPC	51	Sequence 355 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14084	QKLCERPSRTWSGVCGNNNACKNQCINLEKARHGSCNYRFPAHKCICYFPC	51	Sequence 356 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14085	QKLCMRPSGTWSGVCGNNNACKNQCINLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 357 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14086	QKLCERPSGTWSGVCMNNNACKNQCINLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 358 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14087	QKLCQRPSRTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 359 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14088	QKLCQRPSRTWSGVCGNNNACKNQCIRLEKARHGSCNYRFPAHKCICYFPC	51	Sequence 361 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14089	QKLCMRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 362 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14090	QKLCQRPSGTWSGVCMNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 363 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14091	KLCERSSRTWSGVCGNNNACKNQCIRLEGAQHGSCNYVFPAHKCICYFPC	50	Sequence 364 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14092	KLCERSSGTWSGVCGNNNACKNQCIRLEGAQHGSCNYRFPAHKCICYFPC	50	Sequence 365 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14093	KLCERSSRTWSGVCGNNNACKNQCIRLEGAQHGSCNYRFPAHKCICYFPC	50	Sequence 366 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14094	KLCMRSSGTWSGVCGNNNACKNQCIRLEGAQHGSCNYVFPAHKCICYFPC	50	Sequence 367 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14095	KLCERSSGTWSGVCMNNNACKNQCIRLEGAQHGSCNYVFPAHKCICYFPC	50	Sequence 368 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14096	QKLCERSSRTWSGVCGNNNACKNQCINLEGARHGSCNYIFPYHRCICYFPC	51	Sequence 369 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14097	QKLCERSSGTWSGVCGNNNACKNQCINLEGARHGSCNYRFPYHRCICYFPC	51	Sequence 370 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14098	QKLCERSSRTWSGVCGNNNACKNQCINLEGARHGSCNYRFPYHRCICYFPC	51	Sequence 371 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14099	QKLCMRSSGTWSGVCGNNNACKNQCINLEGARHGSCNYIFPYHRCICYFPC	51	Sequence 372 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14100	QKLCERSSGTWSGVCMNNNACKNQCINLEGARHGSCNYIFPYHRCICYFPC	51	Sequence 373 from Patent US 7785828	Synthetic construct	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14101	MAKVASIVALLFPALVIFAAFEAPTMVEAQKLCERPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	80	Sequence 374 from Patent US 7785828	Brassica oleracea	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14102	MAKSAAIITFLFAALVLFAAFEAPIMVEAQKLCEKPSGTWSGVCGNSNACKNQCINLEGAKHGSCNYVFPAHKCICYFPC	80	Sequence 375 from Patent US 7785828	Arabidopsis thaliana	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14103	MAKFVSIITLFFAALVLFAAFEAPTMVKAQKLCERSSGTWSGVCGNNNACKNQCINLEGARHGSCNYVFPYHRCICYFPC	80	Sequence 376 from Patent US 7785828	Brassica rapa	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14104	MAKFASIIALLFAALVLFSAFEAPSMVEAQKLCEKSSGTWSGVCGNNNACKNQCINLEGARHGSCNYIFPYHRCICYFPC	80	Sequence 377 from Patent US 7785828	Wasabia japonica	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14105	MAKFASIITLLFAALVVFAAFEAPTMVEAKLCERSSGTWSGVCGNNNACKNQCIRLEGAQHGSCNYVFPAHKCICYFPC	79	Sequence 378 from Patent US 7785828	Brassica napus	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14106	QKLCQRPSGTWSGVCGNNNACRNQCINLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 379 from Patent US 7785828	Sinapis alba	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14107	MAKSATIVTLFFAALVFFAALEAPMVVEAQKLCERPSGTWSGVCGNSNACKNQCINLEKARHGSCNYVFPAHKCICYFPC	80	Sequence 380 from Patent US 7785828	Arabidopsis thaliana	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14108	MAKFASIITLIFAALVLFAAFDAPAMVEAQKLCEKPSGTWSGVCGNSNACKNQCINLEGAKHGSCNYVFPAHKCICYVPC	80	Sequence 381 from Patent US 7785828	Arabidopsis thaliana	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14109	QKLCEKPSGTWSGVCGNSNACKNQCINLERARHGSCNYVFPAHKCICYFPC	51	Sequence 383 from Patent US 7785828	Descurainia sophia	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14110	ELCEKASKTWSGKCGNTRHCDDQCKSWEGAAHGACHVRGGKHMCFCYFNC	50	Sequence 384 from Patent US 7785828	Helianthus annuus	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14111	ELCEKPSKTWSGNCGNTGHCDGQCKSWEGGAHGACHVRGGKHMCFCYFNC	50	Sequence 387 from Patent US 7785828	Lactuca sativa	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14112	ELCEKXXKKWSGNCXNTGHCDGQCKSWEGGAHGACHVRGGKHMCFCYFNC	50	Sequence 388 from Patent US 7785828	Lactuca sativa	Antimicrobial	US 7785828 B1	Granted Patent	2010##8##31	WO2004072239A2, WO2004072239A3	Production of antimicrobial proteins in fusion proteins.	The invention relates to a method of producing cysteine containing polypeptides in fusion proteins by recombinantly expressing in a host cell sequences encoding an antifungal polypeptide, a maltose binding protein, and a histidine tag. The method is carried out in the presence of a reducing agent to prevent misfolding of the fusion proteins.
DRAMP14113	VFRLKKWIQK	10	Sequence 2 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14114	THVFRLKKWIQKVIDQFGE	19	Sequence 3 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14115	NHVFRLKKWIQKVIDQFGE	19	Sequence 4 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14116	SHVFRLKKWIQKVIDQFGE	19	Sequence 5 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14117	THVFRLKKWIKKVIKQFGE	19	Sequence 6 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14118	VFRLKKWIQKVIDQFG	16	Sequence 7 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14119	VFRLKKWIRKVTRQFG	16	Sequence 8 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14120	LFRLKKWIRKVTRLFG	16	Sequence 9 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14121	LFRLKKWLRKVTKQFG	16	Sequence 10 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14122	LTRLKKWIRKVTKQFGE	17	Sequence 11 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14123	LTRLKKWLRKVTDQFGE	17	Sequence 12 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14124	LFRLKKWIRKVTRQFGR	17	Sequence 13 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14125	LFRLKKWIRKVTKQFGR	17	Sequence 14 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14126	LFRLKKWIRKVIRQFGE	17	Sequence 15 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14127	LFRLKKWIRKVTRQFGE	17	Sequence 16 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14128	LFRLKKWLRKVTDQFGR	17	Sequence 17 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14129	LFRLKKWIRKVTDQFGR	17	Sequence 18 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14130	LFRLKKWIRKVIKQFGE	17	Sequence 19 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14131	LFRLKKWLRKVIKQFGE	17	Sequence 20 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14132	VFRLKKWIRKVTRQFGE	17	Sequence 21 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14133	LFRLKKWIRKVTKQFGE	17	Sequence 22 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14134	VFRLKKWLRKVTRQFGE	17	Sequence 23 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14135	LFRLKKWLRKVTKQFGE	17	Sequence 24 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14136	LFRLKKWIKKVTRQFGE	17	Sequence 25 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14137	VFRLKKWIRKVTKQFGE	17	Sequence 26 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14138	VFRLKKWLRKVTKQFGE	17	Sequence 27 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14139	LFRLKKWIKKVTKQFGE	17	Sequence 28 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14140	LFRLKKWLKKVTKQFGE	17	Sequence 29 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14141	LFRLKKWLQKVTRQFGE	17	Sequence 30 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14142	LFRLKKWIQKVTRQFGE	17	Sequence 31 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14143	LFRLKKWIRKVTRLFGE	17	Sequence 32 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14144	LFRLKKWLRKVTDQFGE	17	Sequence 33 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14145	LFRLKKWLQKVTKQFGE	17	Sequence 34 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14146	LFRLKKWLRKVTKLFGE	17	Sequence 35 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14147	LFRLKKWLKKVTDQFGE	17	Sequence 36 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14148	VFRLKKWLRKVTDQFGE	17	Sequence 37 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14149	VKRLKKWIQKVIDQFGE	17	Sequence 39 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14150	VFRLKKWIQKVIKQFGE	17	Sequence 40 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14151	VFRLKKWIQKVIDQFGK	17	Sequence 41 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14152	VKRLKKWIQKVIKQFGK	17	Sequence 42 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14153	VKRLKKWIQKVIKLFGK	17	Sequence 43 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14154	VKRLKKWIKKVIKLFGK	17	Sequence 44 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14155	VRRLKKWIQKVIRQFGR	17	Sequence 45 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14156	VRRLKKWIQKVIRLFGR	17	Sequence 46 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14157	VKRLKKWIKKVIKIFGK	17	Sequence 47 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14158	VRRLKKWIQKVIRIFGR	17	Sequence 48 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14159	VSWGEGCDRDGKYGFYTHVFRLKKWIQKVIDQFGE	35	Sequence 49 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14160	GKYGIYTKVSRYVNWIKEKTKLT	23	Sequence 50 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14161	GKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPEVITSSPLK	42	Sequence 51 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14162	ERPGVYTNVVEYVDWILEKTQAV	23	Sequence 52 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14163	GHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP	35	Sequence 53 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14164	NKPGVYTDVAYYLAWIREHTVS	22	Sequence 54 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14165	GKYGFYTHVFRLKKWIQKVIDQFGE	25	Sequence 55 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14166	EQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA	33	Sequence 56 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14167	HNYGVYTKVSRYLDWIHGHIRDKEAPQKSWAP	32	Sequence 57 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14168	CQKRYRGHKITHKMIC	16	Sequence 58 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14169	NWRENLDRDIALMKLKKP	18	Sequence 60 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14170	EQPGVYTKVAEYMDWILEKTQSSDG	25	Sequence 65 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14171	HVFRLKKWIQKVIDQFGE	18	Sequence 66 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14172	NVVEYVDWILEKTQAV	16	Sequence 67 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14173	KVAEYMDWILEKTQSSDG	18	Sequence 68 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14174	KVSRYVNWIKEKTKLT	16	Sequence 69 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14175	CKDSTRIRITDNMFC	15	Sequence 70 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14176	NRPGIFVRVAYYAKWIHKIILTYKV	25	Sequence 71 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14177	RVAYYAKWIHKIILTYKV	18	Sequence 72 from Patent US 8076286	Synthetic construct	Antimicrobial	US 8076286 B2	Granted Patent	2011##12##13	CA2637221A1, EP1987056A1, EP1987056B1, US20090143299, WO2007091959A1	Antimicrobial peptides and use thereof.	The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.
DRAMP14178	MALLNKLLCFALVFMIFGEFVTPDCYEDWSRCTPGTSFLTGILWKDCHSRCKELGHRGGRCVDSPSKHCPGVLKNNKQCHCY	82	Sequence 2 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14179	MFSKYERQKDKRSYGERFSMFTGPQFISPPERIKPNKILQWDGEGMPIYATSGAAAE	57	Sequence 4 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14180	MELKSGLSILLCFGICIAVINAGCFEDWSRCSPSTSRGTGVLWRDCDSYCKVCFKADRGECFDSPSLNCPQRLPNNKQCRCINARTAKDNRNPTCWA	97	Sequence 6 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14181	CFEDWSRCSPSTASATGVLWRSCDSYCKVCFKADRGECYDSPSLNCPHRLPNNKQCRCINARTAKDNRNPTCWA	74	Sequence 8 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14182	MDKKAANGGKEKGPLEACWDEWSRCTGWSSAGTGVLWKSCDDQCKKLGKSGGECVLTPSTCPFTRTDKAYQCQCKK	76	Sequence 10 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14183	MSLCISDYLYLTLTFSKYERQKDKRPYSERKNQYTGPQFLYPPERIPPQKVIKWNEEGLPIYEIPGEGGHAEPAAA	76	Sequence 12 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14184	MYSKYERQKDKRPYSERKDQYTGPQFLYPPDRIPPSKAIKWNEEGLPMYEVLPDGAGAKTAVEAAAE	67	Sequence 14 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14185	GCYEDWSRCTPSTSWLTGILWKSCTNRCKEQGHRGGNCRDSPSPCPGLQNNKQCYCF	57	Sequence 15 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14186	NVIGRCWDTWSRCSTWSRWFTGRVWLTRDGKCRELGKRGGNCVMTPSTCPLSSEAFQCQCYT	62	Sequence 16 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14187	DCYEDWSRCTPGTSFLTGILWKDCHSRCKELGHRGGRCVDSPSKHCPGVLKNNKQCHCY	59	Sequence 28 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14188	GCFEDWSRCSPSTSRGTGVLWRDCDSYCKVCFKADRGECFDSPSLNCPQRLPNNKQCRCINARTAKDNRNPTCWA	75	Sequence 37 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14189	GCFEDWSRCSPSTASATGVLWRSCDSYCKVCFKADRGECYDSPSLNCPHRLPNNKQCRCINARTAKDNRNPTCWA	75	Sequence 38 from Patent US 8173768	Synthetic construct	Antimicrobial	US 8173768 B2	Granted Patent	2012##5##8	US20110009329	Peptides having antimicrobial and neurotrophic activity and uses thereof.	A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide.
DRAMP14190	ASIIKTTIKVSKAVCKTLTCICTGSCSNCK	30	Sequence 1 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14191	ASIIKTTIKVSKAVCKTLTCICTGCCSNSK	30	Sequence 2 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14192	ASIIKTTIKVCKAVSKTLTCICTGSCSNCK	30	Sequence 3 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14193	ASIIKTTIKVCKAVSKTLTCICTGCCSNSK	30	Sequence 4 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14194	AXIIKXXIKVAKAVAKXLXAIAXGAAXNAK	30	Sequence 5 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14195	XXXXXXXXXVAXAVAXXXXAXAXGAAANAX	30	Sequence 6 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14196	XXLLKXXLKVAKAVAKXLXALAXGAAANAK	30	Sequence 7 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14197	XXXXKXXXKVAKAVAKXXXAXAXGAAXNAX	30	Sequence 8 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14198	XXIIKXXIKVAKAVAKXIXAIAXGAAANAK	30	Sequence 9 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14199	XTXXTXXLLX	10	Sequence 10 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14200	IXAIXLAXPGAKXGALMGANMKXAXAHASIHVXK	34	Sequence 11 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14201	IAAKFIAXPGAAKXGAFNAYA	21	Sequence 12 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14202	AGPAIRAAVKQAQKXLKAXRLFXVAAKGKNGAK	33	Sequence 13 from Patent US 8299020	Synthetic construct	Antimicrobial	US 8299020 B2	Granted Patent	2012##10##30	DE602007013922D1, EP2069473A2, EP2069473A4, EP2069473B1, EP2116251A1, US20110245152, US20120141423, WO2008091416A2, WO2008091416A3	Antimicrobial peptides and methods of their use.	The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.
DRAMP14203	MKAFSVAVVLVIACMFILESTAVPFSE	27	Sequence 282 from Patent WO 2004018706	Unidentified	Antimicrobial	WO 2004018706 A2	Patent Application	2004##3##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2	A genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP14204	EPFRFKRQIHLSLCGLCCNCCHNIGCGFCCKF	32	Sequence 283 from Patent WO 2004018706	Unidentified	Antimicrobial	WO 2004018706 A2	Patent Application	2004##3##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2	A genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP14205	VRTEEVGSFDSPVGEHQQPGGESMHLP	27	Sequence 284 from Patent WO 2004018706	Unidentified	Antimicrobial	WO 2004018706 A2	Patent Application	2004##3##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2	A genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP14206	MHFRFKRQSHLSLCRWCCNCCHNKGCGFCCKF	32	Sequence 285 from Patent WO 2004018706	Unidentified	Antimicrobial	WO 2004018706 A2	Patent Application	2004##3##4	CA2495794A1, CN1678632A, EP1534745A2, WO2004018706A2	A genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish.	There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening a wide range of nucleic acid sequences to identify candidate sequences capable of being amplified using the primers from step e). In some instances the antimicrobial peptide is a hepcidin or a pleurocidin.
DRAMP14207	MKTVLAFLFLTFIAFTYAESYEDVKEEIKNEVEKEIFEDLEEESDALDSSVREFNDAKPWRFRRAIRRVRWRKVAPYIPFVVKTVGKK	88	Sequence 2 from Patent WO 2010063250	Hydra magnipapillat	Antimicrobial	WO 2010063250 A1	Patent Application	2010##6##10	DE102008060844A1	Antimicrobial peptides made of hydra.	A nucleic acid molecule, selected from the group consisting of a) a nucleic acid molecule having the nucleotide sequence shown in SEQ ID:NO 1, 4 or 6, b) a nucleic acid molecule coding a peptide with the amino acid sequence shown in SEQ ID:NO 2, 3, 5, 7 or 8, c) a nuclei acid molecule, the complementary strand of which hybridizes a nucleic acid molecule according to a) or b) and codes a peptide with antimicrobial activity, and d) a nucleic acid molecule, the nucleotide sequence of which varies from the nucleotide sequence of a nucleic acid molecule according to c) due to degenerated genetic code.
DRAMP14208	MKTVLAFLFLTFIAFTHAESYEDVKEEIKNEVEREIFEDLEEESDVLESNVRELNDAKPWRFRRAIRRVRWRKVAPYIPFVVRTVGKK	88	Sequence 5 from Patent WO 2010063250	Hydra magnipapillat	Antimicrobial	WO 2010063250 A1	Patent Application	2010##6##10	DE102008060844A1	Antimicrobial peptides made of hydra.	A nucleic acid molecule, selected from the group consisting of a) a nucleic acid molecule having the nucleotide sequence shown in SEQ ID:NO 1, 4 or 6, b) a nucleic acid molecule coding a peptide with the amino acid sequence shown in SEQ ID:NO 2, 3, 5, 7 or 8, c) a nuclei acid molecule, the complementary strand of which hybridizes a nucleic acid molecule according to a) or b) and codes a peptide with antimicrobial activity, and d) a nucleic acid molecule, the nucleotide sequence of which varies from the nucleotide sequence of a nucleic acid molecule according to c) due to degenerated genetic code.
DRAMP14209	MKTVLAFLFLTFIAFTYAESYEDVKEEIKNEVEREIFEDLEEESDVLDSNVREFNDAKPWRFRRAIRRVRWRKVAPYIPFVVRTVGKK	88	Sequence 7 from Patent WO 2010063250	Hydra magnipapillat	Antimicrobial	WO 2010063250 A1	Patent Application	2010##6##10	DE102008060844A1	Antimicrobial peptides made of hydra.	A nucleic acid molecule, selected from the group consisting of a) a nucleic acid molecule having the nucleotide sequence shown in SEQ ID:NO 1, 4 or 6, b) a nucleic acid molecule coding a peptide with the amino acid sequence shown in SEQ ID:NO 2, 3, 5, 7 or 8, c) a nuclei acid molecule, the complementary strand of which hybridizes a nucleic acid molecule according to a) or b) and codes a peptide with antimicrobial activity, and d) a nucleic acid molecule, the nucleotide sequence of which varies from the nucleotide sequence of a nucleic acid molecule according to c) due to degenerated genetic code.
DRAMP14212	KLCERSSGTWSGVCGNNNACKNQCIRLEGAQHGSCNYVFPAHKCICYFPC	50	Sequence 10 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14214	QKLCERPSGTWSGVCGNNNACKNQCIN	27	Sequence 12 from Patent US 20020152498	Brassica rapa	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14215	QKLCERPSGTXSGVCGNNNACKNQCIR	27	Sequence 13 from Patent US 20020152498	Brassica rapa	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14216	QKLCERPSGTWSGVCGNNNACKNQCINLEK	30	Sequence 14 from Patent US 20020152498	Brassica napus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14217	QKLCERPSGTWSGVCGNNNACKN	23	Sequence 15 from Patent US 20020152498	Brassica napus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14218	QKLCERPSGTWSGVCGNNNACKNQC	25	Sequence 16 from Patent US 20020152498	Sinapis alba	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14219	QKLCQRPSGTWSGVCGNNNACRNQCI	26	Sequence 17 from Patent US 20020152498	Sinapis alba	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14220	QKLCERPSGTWSGVCGNSNACKNQCIN	27	Sequence 18 from Patent US 20020152498	Arabidopsis thaliana	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14221	RVCMKGSAGFKGLCMRDQNCAQVCLQEGWGGGNCDGVMRQCKCIRQC	47	Sequence 21 from Patent US 20020152498	Sorghum bicolor	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14223	QKLCQRPSGGWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 23 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14224	QKLCQRPSGTSSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 24 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14226	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKWRHGSCNYVFPAHKCICYFPC	51	Sequence 26 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14227	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNGVFPAHKCICYFPC	51	Sequence 27 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14228	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVMPAHKCICYFPC	51	Sequence 28 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14229	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHQCICYFPC	51	Sequence 29 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14230	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVPPAHKCICIFPC	51	Sequence 30 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14231	QKLCQRPSGAWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 31 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14232	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARAGSCNYVFPAHKCICYFPC	51	Sequence 32 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14233	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNAVFPAHKCICYFPC	51	Sequence 33 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14234	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVAPAHKCICYFPC	51	Sequence 34 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14235	QKLCQRSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	50	Sequence 35 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14236	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVPAHKCICYFPC	50	Sequence 36 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14237	QKLCQRRSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 37 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14239	QKLCQRPSGTWRGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 39 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14240	QKLCQRPSGTWSGVCGNNNACKNQCRRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 40 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14241	QKLCQRPSGTWSGVCGNNNACKNQCIRREKARHGSCNYVFPAHKCICYFPC	51	Sequence 41 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14242	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCRYVFPAHKCICYFPC	51	Sequence 42 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14243	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYRFPAHKCICYFPC	51	Sequence 43 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14244	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPRHKCICYFPC	51	Sequence 44 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14245	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCRCYFPC	51	Sequence 45 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14246	QKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYRPC	51	Sequence 46 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14263	XKLCQRPSGTWSGVCGNNNACKNQCIRLEKARHGSCNYVFPAHKCICYFPC	51	Sequence 77 from Patent US 20020152498	Raphanus sativus	Antimicrobial, Antifungal	US 2002/0152498 A1	Patent Application	2002##10##17	CA2239873A1, CN1145696C, CN1204367A, EP0866863A1, US6372888, US6864068, WO1997021814A1	Antifungal proteins.	Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14264	SINVDIEQETAWVQAGATLGEVYYR	25	Sequence 1 from Patent US 20020168735	Helianthus annuus	Antimicrobial, Antifungal	US 2002/0168735 A1	Patent Application	2002##11##14	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal proteins, dna coding therefore, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has antifungal activity, specifically anti-Phytophthora activity and/or anti-Pythium activity and a molecular weight of about 55-65 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein depicted in SEQ ID NO. 16, SEQ ID NO. 57, SEQ ID NO. 70, SEQ ID NO. 72 or SEQ ID NO. 74 or muteins thereof, and DNA capable of hybridizing therewith under stringent conditions The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention and wherein the protein is expressed. Also shown is the carbohydrate and preferably hexose oxidating activity of said protein. Also methods are provided for combating fungi, especially Phytophthora and Pythium species, using a 
DRAMP14265	DPSFPITGEVYTPGXSSFPTVLQNY	25	Sequence 2 from Patent US 20020168735	Helianthus annuus	Antimicrobial, Antifungal	US 2002/0168735 A1	Patent Application	2002##11##14	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal proteins, dna coding therefore, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has antifungal activity, specifically anti-Phytophthora activity and/or anti-Pythium activity and a molecular weight of about 55-65 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein depicted in SEQ ID NO. 16, SEQ ID NO. 57, SEQ ID NO. 70, SEQ ID NO. 72 or SEQ ID NO. 74 or muteins thereof, and DNA capable of hybridizing therewith under stringent conditions The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention and wherein the protein is expressed. Also shown is the carbohydrate and preferably hexose oxidating activity of said protein. Also methods are provided for combating fungi, especially Phytophthora and Pythium species, using a 
DRAMP14266	TSTSIIDRFTQXLNNRADPXX	21	Sequence 49 from Patent US 20020168735	Lactuca sativa	Antimicrobial, Antifungal	US 2002/0168735 A1	Patent Application	2002##11##14	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal proteins, dna coding therefore, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has antifungal activity, specifically anti-Phytophthora activity and/or anti-Pythium activity and a molecular weight of about 55-65 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein depicted in SEQ ID NO. 16, SEQ ID NO. 57, SEQ ID NO. 70, SEQ ID NO. 72 or SEQ ID NO. 74 or muteins thereof, and DNA capable of hybridizing therewith under stringent conditions The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention and wherein the protein is expressed. Also shown is the carbohydrate and preferably hexose oxidating activity of said protein. Also methods are provided for combating fungi, especially Phytophthora and Pythium species, using a 
DRAMP14267	XIXVXIEDETAXVQAGATLGEVYX	24	Sequence 50 from Patent US 20020168735	Lactuca sativa	Antimicrobial, Antifungal	US 2002/0168735 A1	Patent Application	2002##11##14	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal proteins, dna coding therefore, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has antifungal activity, specifically anti-Phytophthora activity and/or anti-Pythium activity and a molecular weight of about 55-65 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein depicted in SEQ ID NO. 16, SEQ ID NO. 57, SEQ ID NO. 70, SEQ ID NO. 72 or SEQ ID NO. 74 or muteins thereof, and DNA capable of hybridizing therewith under stringent conditions The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention and wherein the protein is expressed. Also shown is the carbohydrate and preferably hexose oxidating activity of said protein. Also methods are provided for combating fungi, especially Phytophthora and Pythium species, using a 
DRAMP14268	ADPSFPLSGQLYYP	14	Sequence 51 from Patent US 20020168735	Lactuca sativa	Antimicrobial, Antifungal	US 2002/0168735 A1	Patent Application	2002##11##14	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal proteins, dna coding therefore, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has antifungal activity, specifically anti-Phytophthora activity and/or anti-Pythium activity and a molecular weight of about 55-65 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein depicted in SEQ ID NO. 16, SEQ ID NO. 57, SEQ ID NO. 70, SEQ ID NO. 72 or SEQ ID NO. 74 or muteins thereof, and DNA capable of hybridizing therewith under stringent conditions The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention and wherein the protein is expressed. Also shown is the carbohydrate and preferably hexose oxidating activity of said protein. Also methods are provided for combating fungi, especially Phytophthora and Pythium species, using a 
DRAMP14269	DKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFANVNCWCET	44	Sequence 1 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14270	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFANVNCWCET	44	Sequence 2 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14271	NKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFANVNCWCET	44	Sequence 3 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14272	DKLIGTCVWGAVNYTSDCNGECKRRGYKGGHCGSFANVNCWCET	44	Sequence 4 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14273	DKLIGSCVWGAVNYTTDCNGECKRRGYKGGHCGSFANVNCWCET	44	Sequence 5 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14274	DKLIGSCVWGAVNYTRDCNGECKRRGYKGGHCGSFANVNCWCET	44	Sequence 6 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14275	DKLIGSCVWGAVNYTSDCRGECKRRGYKGGHCGSFANVNCWCET	44	Sequence 7 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14276	DKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFINVNCWCET	44	Sequence 8 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14277	DKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFLNVNCWCET	44	Sequence 10 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14278	DKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFLNINCWCET	44	Sequence 11 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14279	DKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFANVNCWCER	44	Sequence 12 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14280	DKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFANVNCWCQT	44	Sequence 13 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14281	NKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFANVNCWCQT	44	Sequence 14 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14282	NKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFLNVNCWCQT	44	Sequence 15 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14283	NKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFINVNCWCQT	44	Sequence 16 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14284	NKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFANVNCWCET	44	Sequence 17 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14285	DKLIGSCVWGAVNYTRNCNAECKRRGYKGGHCGSFANVNCWCET	44	Sequence 18 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14286	DKLIGSCVWLAVNYTSNCNAECKRRGYKGGHCGSFANVNCWCET	44	Sequence 19 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14287	DKLIGSCVWGAVNYTSRCNAECKRRGYKGGHCGSFANVNCWCET	44	Sequence 20 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14288	DKLIGSCVWGAVNYTSNCRAECKRRGYKGGHCGSFANVNCWCET	44	Sequence 21 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14289	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFINVNCWCET	44	Sequence 22 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14290	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFANINCWCET	44	Sequence 23 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14291	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFLNINCWCET	44	Sequence 24 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14292	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFLNVNCWCET	44	Sequence 25 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14293	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFANVNCWCQT	44	Sequence 26 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14294	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFANVNCWCER	44	Sequence 27 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14295	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFLNVNCWCQT	44	Sequence 28 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14296	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFINVNCWCQT	44	Sequence 29 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14297	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFLNVNCWCER	44	Sequence 30 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14298	DKLIGSCVWGAVNYTSNCNAECKRRGYKGGHCGSFINVNCWCER	44	Sequence 31 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14299	DKLIGSCVWLAVNYTSNCNAECKRRGYKGGHCGSFLNVNCWCET	44	Sequence 32 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14300	DKLIGSCVWLAVNYTSNCNAECKRRGYKGGHCGSFANVNCWCQT	44	Sequence 33 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14301	DKLIGSCVWLAVNYTSNCNAECKRRGYKGGHCGSFLNVNCWCQT	44	Sequence 34 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14302	DKLIGSCVWGAVRYTSDCNGECKRRGYKGGHCGSFANVNCWCET	44	Sequence 37 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14303	DKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFANINCWCET	44	Sequence 41 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14304	NKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFANLNCWCQT	44	Sequence 47 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14305	NKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFANINCWCQT	44	Sequence 48 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14306	RRKCEANCNSTYNVA	15	Sequence 70 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14307	SFINVNCWCET	11	Sequence 74 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14308	SFLNVNCWCET	11	Sequence 77 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14309	SFANVNCWCQT	11	Sequence 80 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14310	SFANVNCWCER	11	Sequence 86 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14311	SFLNVNCWCQT	11	Sequence 89 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14312	SFLNVNCWCER	11	Sequence 92 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14313	SLDKRNKLIG	10	Sequence 96 from Patent US 20030208035	Synthetic construct	Antimicrobial, Antifungal	US 2003/0208035 A1	Patent Application	2003##11##6	CA2264567A1, CN1155714C, CN1233290A, DE69731655D1, DE69731655T2, US6864076, WO1998013478A2, WO1998013478A3	Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants.	The invention concerns peptides derived from helimomicine by substitution of one or several amnio acids, characterised in that the peptides correspond to formula (I) : X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , C 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , C 18 , X 19 , X 20 , X 21 , C 22 , X 23 , X 24, X25, X 26 , X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 , X 39 , C 40 , X 41 , C 42 , X 43 , X 44 wherein X 1 , X 17 , X 21 , X 43 are amino acids; X 16 , X 44 are small polar amino acids; X 19 is a large polar amino acid; X 36 is a small or lightly hydophobic amino acid; X 38 is a lightly hydrophobic or small amino acid; the substitutions being such that: at least one of X 1 , X 17 , X 21 , X 43 is a basic or polar, advantageously large polar amino acid, and/or at least one of the amnio acids X 16 , X 44 is a basic amino acid or a large polar amino acid, and/or X 19 is a basic amino acid, and/or at least one of the amino acids X 36 , X 38 
DRAMP14314	CKNQCIRLEKARHGS	15	Sequence 1 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14315	CIRLEKARHGSCNYV	15	Sequence 2 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14316	EKARHGSCNYVFPAH	15	Sequence 3 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14317	HGSCNYVFPAHKCIC	15	Sequence 4 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14318	CNYVFPAHKC	10	Sequence 5 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14319	FPAHKC	6	Sequence 6 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14320	AHKCIC	6	Sequence 7 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14321	HKCICY	6	Sequence 8 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14322	QCIRLEKAR	9	Sequence 9 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14323	CIRLEKARH	9	Sequence 10 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14324	RHGSCNYVF	9	Sequence 11 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14325	CNYVFPAHK	9	Sequence 12 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14326	FPAHKCICY	9	Sequence 13 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14327	PAHKCICYF	9	Sequence 14 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14328	AHKCICYFP	9	Sequence 15 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14329	HKCICYFPC	9	Sequence 16 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14330	CIRLEKARHGSC	12	Sequence 17 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14331	EKARHGSCNYVF	12	Sequence 18 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14332	KARHGSCNYVFP	12	Sequence 19 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14333	RHGSCNYVFPAH	12	Sequence 20 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14334	HGSCNYVFPAHK	12	Sequence 21 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14335	ARHGSCNYVFPAHKCICYF	19	Sequence 22 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14336	ASHGACHKRENHWKCFCYF	19	Sequence 23 from Patent US 20030226169	Aesculus hippocastanum	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14337	AAHGACHVRNGKHMCFCYF	19	Sequence 24 from Patent US 20030226169	Dahlia merckii	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14338	ARHGSXNYVFPAHKXIXYF	19	Sequence 26 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14339	ASHGAXHKRENHWKXFXYF	19	Sequence 27 from Patent US 20030226169	Aesculus hippocastanum	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14340	KARHGSXNYVFPAHKXIXYF	20	Sequence 29 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14341	AAHGAXHVRNGKHMXFXYF	19	Sequence 30 from Patent US 20030226169	Dahlia merckii	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14342	RHGSXNYVFPAHKXIXYF	18	Sequence 31 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14343	QKLCQRPSGTWSGVC	15	Sequence 46 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14344	QRPSGTWSGVCGNNN	15	Sequence 47 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14345	GTWSGVCGNNNACKN	15	Sequence 48 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14346	GVCGNNNACKNQCIR	15	Sequence 49 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14347	NNNACKNQCIRLEKA	15	Sequence 50 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14348	NYVFPAHKCICYFPC	15	Sequence 55 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14349	DGVKLCDVPSGTWSGHCGSSSKCSQQCKDREHFAYGGACHYQFPSVKCFCKRQC	54	Sequence 56 from Patent US 20030226169	Huechera sanguinea	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14352	IRLEKARHGSXNY	13	Sequence 59 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14353	RLEKARHGSXNYV	13	Sequence 60 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14354	LEKARHGSXNYVF	13	Sequence 61 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14355	EKARHGSXNYVFP	13	Sequence 62 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14356	KARHGSXNYVFPA	13	Sequence 63 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14357	ARHGSXNYVFPAH	13	Sequence 64 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14358	RHGSXNYVFPAHK	13	Sequence 65 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14359	HGSXNYVFPAHKX	13	Sequence 66 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14360	GSXNYVFPAHKXI	13	Sequence 67 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14361	SXNYVFPAHKXIX	13	Sequence 68 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14362	XNYVFPAHKXIXY	13	Sequence 69 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14363	NYVFPAHKXIXYF	13	Sequence 70 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14364	IRLEKARHGSXNYV	14	Sequence 71 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14365	RLEKARHGSXNYVF	14	Sequence 72 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14366	LEKARHGSXNYVFP	14	Sequence 73 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14367	EKARHGSXNYVFPA	14	Sequence 74 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14368	KARHGSXNYVFPAH	14	Sequence 75 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14369	ARHGSXNYVFPAHK	14	Sequence 76 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14370	RHGSXNYVFPAHKX	14	Sequence 77 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14371	HGSXNYVFPAHKXI	14	Sequence 78 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14372	GSXNYVFPAHKXIX	14	Sequence 79 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14373	SXNYVFPAHKXIXY	14	Sequence 80 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14374	XNYVFPAHKXIXYF	14	Sequence 81 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14375	IRLEKARHGSXNYVF	15	Sequence 82 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14376	RLEKARHGSXNYVFP	15	Sequence 83 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14377	LEKARHGSXNYVFPA	15	Sequence 84 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14378	EKARHGSXNYVFPAH	15	Sequence 85 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14379	KARHGSXNYVFPAHK	15	Sequence 86 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14380	ARHGSXNYVFPAHKX	15	Sequence 87 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14381	RHGSXNYVFPAHKXI	15	Sequence 88 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14382	HGSXNYVFPAHKXIX	15	Sequence 89 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14383	GSXNYVFPAHKXIXY	15	Sequence 90 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14384	SXNYVFPAHKXIXYF	15	Sequence 91 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14385	IRLEKARHGSXNYVFP	16	Sequence 92 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14386	RLEKARHGSXNYVFPA	16	Sequence 93 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14387	LEKARHGSXNYVFPAH	16	Sequence 94 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14388	EKARHGSXNYVFPAHK	16	Sequence 95 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14389	KARHGSXNYVFPAHKX	16	Sequence 96 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14390	ARHGSXNYVFPAHKXI	16	Sequence 97 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14391	RHGSXNYVFPAHKXIX	16	Sequence 98 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14392	HGSXNYVFPAHKXIXY	16	Sequence 99 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14393	GSXNYVFPAHKXIXYF	16	Sequence 100 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14394	IRLEKARHGSXNYVFPA	17	Sequence 101 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14395	RLEKARHGSXNYVFPAH	17	Sequence 102 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14396	LEKARHGSXNYVFPAHK	17	Sequence 103 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14397	EKARHGSXNYVFPAHKX	17	Sequence 104 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14398	KARHGSXNYVFPAHKXI	17	Sequence 105 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14399	ARHGSXNYVFPAHKXIX	17	Sequence 106 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14400	RHGSXNYVFPAHKXIXY	17	Sequence 107 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14401	HGSXNYVFPAHKXIXYF	17	Sequence 108 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14402	IRLEKARHGSXNYVFPAH	18	Sequence 109 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14403	RLEKARHGSXNYVFPAHK	18	Sequence 110 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14404	LEKARHGSXNYVFPAHKX	18	Sequence 111 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14405	EKARHGSXNYVFPAHKXI	18	Sequence 112 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14406	KARHGSXNYVFPAHKXIX	18	Sequence 113 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14407	ARHGSXNYVFPAHKXIXY	18	Sequence 114 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14408	IRLEKARHGSXNYVFPAHK	19	Sequence 116 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14409	RLEKARHGSXNYVFPAHKX	19	Sequence 117 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14410	LEKARHGSXNYVFPAHKXI	19	Sequence 118 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14411	EKARHGSXNYVFPAHKXIX	19	Sequence 119 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14412	KARHGSXNYVFPAHKXIXY	19	Sequence 120 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14413	IRLEKARHGSXNYVFPAHKX	20	Sequence 122 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14414	RLEKARHGSXNYVFPAHKXI	20	Sequence 123 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14415	LEKARHGSXNYVFPAHKXIX	20	Sequence 124 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14416	EKARHGSXNYVFPAHKXIXY	20	Sequence 125 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14417	CICYFP	6	Sequence 129 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14418	ICYFPC	6	Sequence 130 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14419	VFPAHKCICYFP	12	Sequence 131 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14420	FPAHKCICYFPC	12	Sequence 132 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14421	QKLCQR	6	Sequence 133 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14422	KLCQRP	6	Sequence 134 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14423	LCQRPS	6	Sequence 135 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14424	QKLCQRPSG	9	Sequence 136 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14425	KLCQRPSGT	9	Sequence 137 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14426	LCQRPSGTW	9	Sequence 138 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14427	QKLCQRPSGTWS	12	Sequence 139 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14428	KLCQRPSGTWSG	12	Sequence 140 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14429	LCQRPSGTWSGV	12	Sequence 141 from Patent US 20030226169	Raphanus sativus	Antimicrobial, Antifungal	US 2003/0226169 A1	Patent Application	2003##12##4	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US6605698, WO1997021815A2, WO1997021815A3	DNA sequences encoding antifungal proteins.	The present invention provides DNA sequences encoding antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence (SEQ ID NO: 35) or a substantially homologous protein. The peptides are useful for combating fungal diseases in agricultureal, pharmaceutical or perservative applications.
DRAMP14430	KARHGSCNYVFPAHKCICYF	20	Sequence 29 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14431	RHGSCNYVFPAHKCICYF	18	Sequence 31 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14432	IRLEKARHGSCNY	13	Sequence 59 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14433	RLEKARHGSCNYV	13	Sequence 60 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14434	LEKARHGSCNYVF	13	Sequence 61 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14435	EKARHGSCNYVFP	13	Sequence 62 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14436	KARHGSCNYVFPA	13	Sequence 63 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14437	ARHGSCNYVFPAH	13	Sequence 64 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14438	RHGSCNYVFPAHK	13	Sequence 65 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14439	HGSCNYVFPAHKC	13	Sequence 66 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14440	GSCNYVFPAHKCI	13	Sequence 67 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14441	SCNYVFPAHKCIC	13	Sequence 68 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14442	CNYVFPAHKCICY	13	Sequence 69 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14443	NYVFPAHKCICYF	13	Sequence 70 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14444	IRLEKARHGSCNYV	14	Sequence 71 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14445	RLEKARHGSCNYVF	14	Sequence 72 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14446	LEKARHGSCNYVFP	14	Sequence 73 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14447	EKARHGSCNYVFPA	14	Sequence 74 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14448	KARHGSCNYVFPAH	14	Sequence 75 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14449	ARHGSCNYVFPAHK	14	Sequence 76 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14450	RHGSCNYVFPAHKC	14	Sequence 77 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14451	HGSCNYVFPAHKCI	14	Sequence 78 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14452	GSCNYVFPAHKCIC	14	Sequence 79 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14453	SCNYVFPAHKCICY	14	Sequence 80 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14454	CNYVFPAHKCICYF	14	Sequence 81 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14455	IRLEKARHGSCNYVF	15	Sequence 82 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14456	RLEKARHGSCNYVFP	15	Sequence 83 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14457	LEKARHGSCNYVFPA	15	Sequence 84 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14458	KARHGSCNYVFPAHK	15	Sequence 86 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14459	ARHGSCNYVFPAHKC	15	Sequence 87 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14460	RHGSCNYVFPAHKCI	15	Sequence 88 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14461	GSCNYVFPAHKCICY	15	Sequence 90 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14462	SCNYVFPAHKCICYF	15	Sequence 91 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14463	IRLEKARHGSCNYVFP	16	Sequence 92 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14464	RLEKARHGSCNYVFPA	16	Sequence 93 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14465	LEKARHGSCNYVFPAH	16	Sequence 94 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14466	EKARHGSCNYVFPAHK	16	Sequence 95 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14467	KARHGSCNYVFPAHKC	16	Sequence 96 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14468	ARHGSCNYVFPAHKCI	16	Sequence 97 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14469	RHGSCNYVFPAHKCIC	16	Sequence 98 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14470	HGSCNYVFPAHKCICY	16	Sequence 99 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14471	GSCNYVFPAHKCICYF	16	Sequence 100 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14472	IRLEKARHGSCNYVFPA	17	Sequence 101 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14473	RLEKARHGSCNYVFPAH	17	Sequence 102 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14474	LEKARHGSCNYVFPAHK	17	Sequence 103 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14475	EKARHGSCNYVFPAHKC	17	Sequence 104 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14476	KARHGSCNYVFPAHKCI	17	Sequence 105 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14477	ARHGSCNYVFPAHKCIC	17	Sequence 106 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14478	RHGSCNYVFPAHKCICY	17	Sequence 107 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14479	HGSCNYVFPAHKCICYF	17	Sequence 108 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14480	IRLEKARHGSCNYVFPAH	18	Sequence 109 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14481	RLEKARHGSCNYVFPAHK	18	Sequence 110 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14482	LEKARHGSCNYVFPAHKC	18	Sequence 111 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14483	EKARHGSCNYVFPAHKCI	18	Sequence 112 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14484	KARHGSCNYVFPAHKCIC	18	Sequence 113 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14485	ARHGSCNYVFPAHKCICY	18	Sequence 114 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14486	IRLEKARHGSCNYVFPAHK	19	Sequence 116 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14487	RLEKARHGSCNYVFPAHKC	19	Sequence 117 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14488	LEKARHGSCNYVFPAHKCI	19	Sequence 118 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14489	EKARHGSCNYVFPAHKCIC	19	Sequence 119 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14490	KARHGSCNYVFPAHKCICY	19	Sequence 120 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14491	IRLEKARHGSCNYVFPAHKC	20	Sequence 122 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14492	RLEKARHGSCNYVFPAHKCI	20	Sequence 123 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14493	LEKARHGSCNYVFPAHKCIC	20	Sequence 124 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14494	EKARHGSCNYVFPAHKCICY	20	Sequence 125 from Patent US 6605698	Synthetic construct	Antimicrobial, Antifungal	US 6605698 B1	Granted Patent	2003##8##12	CA2239731A1, CN1145695C, CN1204366A, EP0866864A2, US20030226169	Antifungal peptides and composition thereof.	Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.
DRAMP14495	VKRGLKL	7	Sequence 1 from Patent US 20050277589	Synthetic construct	Antimicrobial, Antifungal	US 2005/0277589 A1	Patent Application	2005##12##15	CA2491011A1, DE60313970D1, DE60313970T2, EP1519951A2, EP1519951B1, US7884070, WO2004005339A2, WO2004005339A3	Linear cationic peptides having antibacterial and/or antifungal properties.	A peptide including a first peptide sequence of formula KLAKLAK in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula βxxβ in which β is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.
DRAMP14496	KHLKKHLKKHLK	12	Sequence 2 from Patent US 20050277589	Synthetic construct	Antimicrobial, Antifungal	US 2005/0277589 A1	Patent Application	2005##12##15	CA2491011A1, DE60313970D1, DE60313970T2, EP1519951A2, EP1519951B1, US7884070, WO2004005339A2, WO2004005339A3	Linear cationic peptides having antibacterial and/or antifungal properties.	A peptide including a first peptide sequence of formula KLAKLAK in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula βxxβ in which β is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.
DRAMP14497	GKRKKKGKLGKKRDP	15	Sequence 3 from Patent US 20050277589	Synthetic construct	Antimicrobial, Antifungal	US 2005/0277589 A1	Patent Application	2005##12##15	CA2491011A1, DE60313970D1, DE60313970T2, EP1519951A2, EP1519951B1, US7884070, WO2004005339A2, WO2004005339A3	Linear cationic peptides having antibacterial and/or antifungal properties.	A peptide including a first peptide sequence of formula KLAKLAK in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula βxxβ in which β is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.
DRAMP14498	KLAKLAKKLAKLAK	14	Sequence 4 from Patent US 20050277589	Synthetic construct	Antimicrobial, Antifungal	US 2005/0277589 A1	Patent Application	2005##12##15	CA2491011A1, DE60313970D1, DE60313970T2, EP1519951A2, EP1519951B1, US7884070, WO2004005339A2, WO2004005339A3	Linear cationic peptides having antibacterial and/or antifungal properties.	A peptide including a first peptide sequence of formula KLAKLAK in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula βxxβ in which β is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.
DRAMP14499	VKRGLKLKLAKLAKKLAKLAK	21	Sequence 6 from Patent US 20050277589	Synthetic construct	Antimicrobial, Antifungal	US 2005/0277589 A1	Patent Application	2005##12##15	CA2491011A1, DE60313970D1, DE60313970T2, EP1519951A2, EP1519951B1, US7884070, WO2004005339A2, WO2004005339A3	Linear cationic peptides having antibacterial and/or antifungal properties.	A peptide including a first peptide sequence of formula KLAKLAK in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula βxxβ in which β is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.
DRAMP14500	KLAKLAKKLAKLAKKHLKKHLKKHLK	26	Sequence 8 from Patent US 20050277589	Synthetic construct	Antimicrobial, Antifungal	US 2005/0277589 A1	Patent Application	2005##12##15	CA2491011A1, DE60313970D1, DE60313970T2, EP1519951A2, EP1519951B1, US7884070, WO2004005339A2, WO2004005339A3	Linear cationic peptides having antibacterial and/or antifungal properties.	A peptide including a first peptide sequence of formula KLAKLAK in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula βxxβ in which β is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.
DRAMP14501	KLAKLAKKLAKLAKGKRKKKGKLGKKRDP	29	Sequence 10 from Patent US 20050277589	Synthetic construct	Antimicrobial, Antifungal	US 2005/0277589 A1	Patent Application	2005##12##15	CA2491011A1, DE60313970D1, DE60313970T2, EP1519951A2, EP1519951B1, US7884070, WO2004005339A2, WO2004005339A3	Linear cationic peptides having antibacterial and/or antifungal properties.	A peptide including a first peptide sequence of formula KLAKLAK in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula βxxβ in which β is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.
DRAMP14502	KLAKLAK	7	Sequence 11 from Patent US 20050277589	Synthetic construct	Antimicrobial, Antifungal	US 2005/0277589 A1	Patent Application	2005##12##15	CA2491011A1, DE60313970D1, DE60313970T2, EP1519951A2, EP1519951B1, US7884070, WO2004005339A2, WO2004005339A3	Linear cationic peptides having antibacterial and/or antifungal properties.	A peptide including a first peptide sequence of formula KLAKLAK in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula βxxβ in which β is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.
DRAMP14511	NQGRHFTGGALIHARFVMTAASCFQ	25	Sequence 9 from Patent US 20070135341	Homo sapiens	Antimicrobial, Antifungal	US 2007/0135341 A1	Patent Application	2007##6##14	CA2633755A1, CN101300022A, EP1931368A2, EP1931368A4, US7745401B2, WO2007016593A2, WO2007016593A3	Antifungal peptides and methods of use thereof.	A method of treating fungal infections by treatment with CAP37 peptides and derivatives thereof, including peptide analogs having serine or threonine substitutions at least one of the two cysteine residues therein. Other substitutions of the amino acid residues of the peptide are also contemplated.
DRAMP14512	NQGRHFCGGALIHARFVMTAASTFQ	25	Sequence 10 from Patent US 20070135341	Homo sapiens	Antimicrobial, Antifungal	US 2007/0135341 A1	Patent Application	2007##6##14	CA2633755A1, CN101300022A, EP1931368A2, EP1931368A4, US7745401B2, WO2007016593A2, WO2007016593A3	Antifungal peptides and methods of use thereof.	A method of treating fungal infections by treatment with CAP37 peptides and derivatives thereof, including peptide analogs having serine or threonine substitutions at least one of the two cysteine residues therein. Other substitutions of the amino acid residues of the peptide are also contemplated.
DRAMP14513	NQGRHFTGGALIHARFVMTAASTFQ	25	Sequence 11 from Patent US 20070135341	Homo sapiens	Antimicrobial, Antifungal	US 2007/0135341 A1	Patent Application	2007##6##14	CA2633755A1, CN101300022A, EP1931368A2, EP1931368A4, US7745401B2, WO2007016593A2, WO2007016593A3	Antifungal peptides and methods of use thereof.	A method of treating fungal infections by treatment with CAP37 peptides and derivatives thereof, including peptide analogs having serine or threonine substitutions at least one of the two cysteine residues therein. Other substitutions of the amino acid residues of the peptide are also contemplated.
DRAMP14514	RHFTGGALIHARFVMTAASC	20	Sequence 12 from Patent US 20070135341	Homo sapiens	Antimicrobial, Antifungal	US 2007/0135341 A1	Patent Application	2007##6##14	CA2633755A1, CN101300022A, EP1931368A2, EP1931368A4, US7745401B2, WO2007016593A2, WO2007016593A3	Antifungal peptides and methods of use thereof.	A method of treating fungal infections by treatment with CAP37 peptides and derivatives thereof, including peptide analogs having serine or threonine substitutions at least one of the two cysteine residues therein. Other substitutions of the amino acid residues of the peptide are also contemplated.
DRAMP14515	RHFCGGALIHARFVMTAAST	20	Sequence 13 from Patent US 20070135341	Homo sapiens	Antimicrobial, Antifungal	US 2007/0135341 A1	Patent Application	2007##6##14	CA2633755A1, CN101300022A, EP1931368A2, EP1931368A4, US7745401B2, WO2007016593A2, WO2007016593A3	Antifungal peptides and methods of use thereof.	A method of treating fungal infections by treatment with CAP37 peptides and derivatives thereof, including peptide analogs having serine or threonine substitutions at least one of the two cysteine residues therein. Other substitutions of the amino acid residues of the peptide are also contemplated.
DRAMP14516	RHFTGGALIHARFVMTAAST	20	Sequence 14 from Patent US 20070135341	Homo sapiens	Antimicrobial, Antifungal	US 2007/0135341 A1	Patent Application	2007##6##14	CA2633755A1, CN101300022A, EP1931368A2, EP1931368A4, US7745401B2, WO2007016593A2, WO2007016593A3	Antifungal peptides and methods of use thereof.	A method of treating fungal infections by treatment with CAP37 peptides and derivatives thereof, including peptide analogs having serine or threonine substitutions at least one of the two cysteine residues therein. Other substitutions of the amino acid residues of the peptide are also contemplated.
DRAMP14517	GTRCQVAGWGSQRSGGRLSRFPRFVNV	27	Sequence 16 from Patent US 20070135341	Homo sapiens	Antimicrobial, Antifungal	US 2007/0135341 A1	Patent Application	2007##6##14	CA2633755A1, CN101300022A, EP1931368A2, EP1931368A4, US7745401B2, WO2007016593A2, WO2007016593A3	Antifungal peptides and methods of use thereof.	A method of treating fungal infections by treatment with CAP37 peptides and derivatives thereof, including peptide analogs having serine or threonine substitutions at least one of the two cysteine residues therein. Other substitutions of the amino acid residues of the peptide are also contemplated.
DRAMP14518	MKFTGIFFIIMAIIALFIGSNEAAPKVNVNAIKKGGKAIGKGFKVISAASTAHDVYEHIKNRRH	64	Sequence 1 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14519	MNFTGIFFMIMAIIALFIGSNEAAPKVNVNAIKKGGKAIGKGFKVISAASTAHDVYEHIKNRRH	64	Sequence 2 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14520	MRLSIILVVVMMVMAMFVSSGDAAPGKIPVKAIKKGGQIIGKALRGINIASTAHDIISQFKPKKKKNH	68	Sequence 3 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14521	KVNVNAIKKGGKAIGKGFKVISAASTAHDVYEHIKNRRH	39	Sequence 4 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14522	GGQIIGKALRGINIASTAHDIISQFKPKKKKNH	33	Sequence 5 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14523	MKLTKVFVILIVVVALLVPSEAAPGKIPVKAIKKAGAAIGKGLRAINIASTAHDVYSFFKPKHKKKH	67	Sequence 14 from Patent US 20080032924	Spodoptera litura	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14524	MKLTSLFIFVIVALSLLFSSTDAAPGKIPVKAIKQAGKVIGKGLRAINIAGTTHDVVSFFRPKKKKH	67	Sequence 15 from Patent US 20080032924	Manduca sexta	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14525	MNILKFFFVFIVAMSLVSCSTAAPAKIPIKAIKTVGKAVGKGLRAINIASTANDVFNFLKPKKRKH	66	Sequence 16 from Patent US 20080032924	Bombyx mori	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14526	GKIPIGAIKKAGKAIGKGLRAVNIASTAHDVYTFFKPKKRH	41	Sequence 17 from Patent US 20080032924	Heliothis virescens	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14527	MYFLKYFIVVLVALSLMICSGQADPKIPVKSLKKGGKVIAKGFKVLTAAGTAHEVYSHVRNRGNQG	66	Sequence 18 from Patent US 20080032924	Bombyx mori	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14528	KVNVNAIKKGGKAIGKGFKVISAASTAHDVYE	32	Sequence 19 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14529	GGQIIGKALRGINIASTAHDIISQFKPK	28	Sequence 20 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14530	KVPIGAIKKGGKIIKKGLGVIGAAGTAHEVYS	32	Sequence 30 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14531	MKLTGLFFMIMAMLALFVGAGQADPKVPIGAIKKGGKIIKKGLGVIGAAGTAHEVYSHVKNRH	63	Sequence 47 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14532	KVPIGAIKKGGKIIKKGLGVIGAAGTAHEVYSHVKNRH	38	Sequence 48 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14533	MKLTGLFLMIMAVLALFVGAGQADPKVPIGAIKKGGKIIKKGLGVLGAAGTAHEVYNHVRNRQ	63	Sequence 52 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14534	KVPIGAIKKGGKIIKKGLGVLGAAGTAHEVYNHVRNRQ	38	Sequence 53 from Patent US 20080032924	Galleria mellonella	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14535	MKLTKVFVIVIVVVALLVPSEAAPGKIPVKAIKKAGTAIGKGLRAINIASTAHDVYSFFKPKHKKKH	67	Sequence 57 from Patent US 20080032924	Spodoptera exigua	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14536	AMSLVSCSTAAPAKIPIKAIKTVGKAVGKGLRAINIASTANDVFNFLKPKKRKH	54	Sequence 58 from Patent US 20080032924	Hyblaea puera	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14537	GKIPINAIRKGAKAVGHGLRALNIASTAHDIASAFHRKRKH	41	Sequence 59 from Patent US 20080032924	Caligo illioneus	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14538	RKIPVEAIKKGASRAWRALDLASTAYDIASIFNRKRE	37	Sequence 60 from Patent US 20080032924	Caligo illioneus	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14539	GKIPVEALKKGAKVAGRAWRALDLASTAYDIAHLFDRKRN	40	Sequence 61 from Patent US 20080032924	Caligo illioneus	Antimicrobial, Antifungal	US 2008/0032924 A1	Patent Application	2008##2##7	CA2557333A1, CN1950396A, EP1730180A1, EP1730180A4, WO2005080423A1	Antifungal Peptides.	The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage. In particular, the invention provides transgenic plants that produce an antifungal peptide, said plants having increased resistance to fungal infections/growth.
DRAMP14540	MQFTKIAIFLFAAMGAVANPIAAESGDLDVRDVQLSKYGGECSLQHNTCTYLKGGKNQVVHCGSAANQKCKSDRHHCEYDEHHKTVNCQTPV	92	Sequence 2 from Patent US 20080161225	Monascus pilosus	Antimicrobial, Antifungal	US 2008/0161225 A1	Patent Application	2008##7##3	CN101210046A, CN101210046B, US7790188	Antifungal protein and usage thereof.	The present invention relates to an antifungal protein gene and cDNA sequence thereof, which is obtained by mining the whole genome sequences of Monascus pilosus BCRC 38072 and the unigene database. The gene can encode an antifungal protein MAFP1. A purified protein obtained from M. pilosus culture broth having molecular weight of about 7 kDa is identified as MAFP1 by N-terminal protein sequencing and comparative analysis. The purified MAFP1 protein can inhibit the growth of pathogens such as Paecilomyces variotii BCRC 33174 and Helminthosporium panici BCRC 35004. In addition, it is found by PCR test that the gene of this antifungal protein exists in other Monascus species such as M. Barkeri, M. floridanus, M. lunisporas, M. pilosus, M. ruber and the like. It is also been proved that the mafp1 gene and cDNA thereof in four Monascus strains, M. pilosus (BCRC 38072, BCRC 38093 and BCRC 31502) and M. ruber BCRC 31533, have the same DNA sequences.
DRAMP14541	LSKYGGECSLQHNTCTYLKGGKNQVVHCGSAANQKCKSDRHHCEYDEHHKTVNCQTPV	58	Sequence 3 from Patent US 20080161225	Monascus pilosus	Antimicrobial, Antifungal	US 2008/0161225 A1	Patent Application	2008##7##3	CN101210046A, CN101210046B, US7790188	Antifungal protein and usage thereof.	The present invention relates to an antifungal protein gene and cDNA sequence thereof, which is obtained by mining the whole genome sequences of Monascus pilosus BCRC 38072 and the unigene database. The gene can encode an antifungal protein MAFP1. A purified protein obtained from M. pilosus culture broth having molecular weight of about 7 kDa is identified as MAFP1 by N-terminal protein sequencing and comparative analysis. The purified MAFP1 protein can inhibit the growth of pathogens such as Paecilomyces variotii BCRC 33174 and Helminthosporium panici BCRC 35004. In addition, it is found by PCR test that the gene of this antifungal protein exists in other Monascus species such as M. Barkeri, M. floridanus, M. lunisporas, M. pilosus, M. ruber and the like. It is also been proved that the mafp1 gene and cDNA thereof in four Monascus strains, M. pilosus (BCRC 38072, BCRC 38093 and BCRC 31502) and M. ruber BCRC 31533, have the same DNA sequences.
DRAMP14542	LSKYGGECSLQHNTC	15	Sequence 5 from Patent US 20080161225	Monascus pilosus	Antimicrobial, Antifungal	US 2008/0161225 A1	Patent Application	2008##7##3	CN101210046A, CN101210046B, US7790188	Antifungal protein and usage thereof.	The present invention relates to an antifungal protein gene and cDNA sequence thereof, which is obtained by mining the whole genome sequences of Monascus pilosus BCRC 38072 and the unigene database. The gene can encode an antifungal protein MAFP1. A purified protein obtained from M. pilosus culture broth having molecular weight of about 7 kDa is identified as MAFP1 by N-terminal protein sequencing and comparative analysis. The purified MAFP1 protein can inhibit the growth of pathogens such as Paecilomyces variotii BCRC 33174 and Helminthosporium panici BCRC 35004. In addition, it is found by PCR test that the gene of this antifungal protein exists in other Monascus species such as M. Barkeri, M. floridanus, M. lunisporas, M. pilosus, M. ruber and the like. It is also been proved that the mafp1 gene and cDNA thereof in four Monascus strains, M. pilosus (BCRC 38072, BCRC 38093 and BCRC 31502) and M. ruber BCRC 31533, have the same DNA sequences.
DRAMP14543	MVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	52	Sequence 1 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14544	ARSVPLVSTISXFLLHLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	75	Sequence 2 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14545	TCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRXRCFCTTHC	46	Sequence 3 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14546	PSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	54	Sequence 4 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14547	MARSVFLVSTIFVFLLVLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	76	Sequence 5 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14548	SDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	32	Sequence 6 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14549	MARSVSLVFTIFVFLLLVVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	76	Sequence 7 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14550	RFSGGHCRGFRRRCFCTTHC	20	Sequence 8 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14551	STIFVFLLFLVATGPSVVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	68	Sequence 9 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14552	NCASVCQTERFSGGHCRGFRRRCFCTTHC	29	Sequence 10 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14553	MVAEARTCESQSHKFKGPCANDHNCASVCQTERFSGGHCRGFRRRCFCTTHW	52	Sequence 11 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14554	MGSFSSFGFTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	76	Sequence 12 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14555	SHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	41	Sequence 13 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14556	VFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	64	Sequence 15 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14557	LVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	70	Sequence 16 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14558	TSLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	72	Sequence 17 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14559	GTSLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	73	Sequence 18 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14560	HQVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	71	Sequence 20 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14561	IFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	66	Sequence 21 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14562	SMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	53	Sequence 23 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14563	VPLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	72	Sequence 25 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14564	GSVPLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	74	Sequence 26 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14565	MARSVPLVSTIFVFLLLLVATG	22	Sequence 27 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14566	GPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	55	Sequence 28 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14567	ATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	57	Sequence 30 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14568	SVPLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	73	Sequence 32 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14569	MARSVPLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFFGGHCRGFRRRCFCTTHC	76	Sequence 33 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14570	FVCQTERFFGGHXRGFRXXCFCTTHC	26	Sequence 34 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14571	ARGDHNCASVCQTERFSGGH	20	Sequence 35 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14572	CRGFRRRCFCTTHC	14	Sequence 36 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14573	QTERFFGGHCRGFRRXCFCTTHC	23	Sequence 38 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14574	ATGPSMVAXARTCESQSHKFKGPXXSDHNXXXVCQTERFFGGHCRGFRRXCFCTTHC	57	Sequence 39 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14575	GFRRRCFCTTHC	12	Sequence 40 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14576	LVAXGPSMVAEARTCESQSXKFKGPCXSDXNCAXVCQTERFFGGHXRGFRRRCFCTTHC	59	Sequence 41 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14577	IPHEGGFRRRCFCTTHC	17	Sequence 42 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14578	SARGARSVPLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTL	59	Sequence 43 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14579	VFLLLLVATGPSMVAEARTCESQSHKFKGPCASD	34	Sequence 44 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14580	FVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQ	43	Sequence 45 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14581	ARSVPLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	75	Sequence 46 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14582	MARSVPLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	76	Sequence 47 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14583	MARSVPLVSTIFVFLLLLVATGPSMVGEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	76	Sequence 56 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14584	MARSVPLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRXCFCTTHC	76	Sequence 57 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14585	RTCESQSHKFKGPCASDHNCASVCQTERFSGGHCRGFRRRCFCTTHC	47	Sequence 71 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14586	RTCESQSHKFKGPCASDHNCASVCQTERFFGGHCRGFRRRCFCTTHC	47	Sequence 105 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14587	MARSVPLVSTIFVFFLLIVATEMGPSMVAARTCETPSNSFKGACFSDTNCASVCQTEGFPGGHCEGFRQRCFCTTHC	77	Sequence 113 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14588	RTCETPSNSFKGACFSDTNCASVCQTEGFPGGHCEGFRQRCFCTTHC	47	Sequence 114 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14589	MARSVPLVSTIFVFFLLLVATEMGPIMVAEARTCETPSNNFKGLCVSDTNCASVCQTEGFPGGHCEGFRQRCFCTTHC	78	Sequence 115 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14590	RTCETPSNNFKGLCVSDTNCASVCQTEGFPGGHCEGFRQRCFCTTHC	47	Sequence 116 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14591	MARSVPLVSTIFVFLLLLVATGPSMVAEA	29	Sequence 117 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14592	MARSVPLVSTIFVFFLLIVATEMGPSMVAA	30	Sequence 119 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14593	MARSVPLVSTIFVFFLLLVATEMGPIMVAEA	31	Sequence 120 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14594	MARSVFLVSTIFVFLLVLVATGPSMVAEA	29	Sequence 121 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14595	MARSVSLVFTIFVFLLLVVATGPSMVAEA	29	Sequence 122 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14596	MARSVPLVSTIFVFLLLLVATGPSMVGEA	29	Sequence 123 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14597	RTCESQSHKFKGPCASDHNCASVCQTERFSGGRCRGFRRRCFCTTHC	47	Sequence 125 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14598	RTSESQSHKFKGPCASDHNCASVCQTERFSGGRCRGFRRRCFCTTHS	47	Sequence 135 from Patent US 20080201800	Synthetic construct	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14599	RTCESQSHKFKGPSASDHNCASVCQTERFSGGRSRGFRRRCFCTTHC	47	Sequence 136 from Patent US 20080201800	Synthetic construct	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14600	RTCESQSHKFKGPCASDHNSASVCQTERFSGGRCRGFRRRSFCTTHC	47	Sequence 137 from Patent US 20080201800	Synthetic construct	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14601	RTCESQSHKFKGPCASDHNCASVSQTERFSGGRCRGFRRRCFSTTHC	47	Sequence 138 from Patent US 20080201800	Synthetic construct	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14602	MARSVPLVSTIFVFLLLLVATGPSMVAEARTCESQSHKFKGPCASDHNCASVCQTERFSGGRCRGFRRRCFCTTHC	76	Sequence 151 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14603	RTCESQSHKFKGPCASDHNSASVCQTERFSGGRCRGF	37	Sequence 152 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14604	SHKFKGPCASDHNSASVCQTERFSGGRCRGFRRRSF	36	Sequence 153 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14605	TCESQSHKFKGPCASDHNSASVCQTERFSGGRCRGFR	37	Sequence 154 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14606	RTCESQSHKFKGPCASDHNCASVSQTERFSGGRCRGF	37	Sequence 155 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14607	TCESQSHKFKGPCASDHNCASVSQTERFSGGRCRGFR	37	Sequence 156 from Patent US 20080201800	Medicago truncatula	Antimicrobial, Antifungal	US 2008/0201800 A1	Patent Application	2008##8##21	US7825297, US8163979, US20110010802, US20120180160, WO2008080014A2, WO2008080014A3	Antifungal Plant Proteins and Methods of Their Use.	DNA constructions that provide for production of potent antifungal proteins in transgenic plants and transformed yeast cells are described. Methods of using the DNA constructs to produce transgenic plants that inhibit growth of plant pathogenic fungi are also disclosed. The use of transformed yeast cells containing the DNA constructs to produce the antifungal proteins and methods of isolating the antifungal proteins are also described.
DRAMP14608	ACMSHTWGERNL	12	Sequence 21 from Patent US 20100015663	Synthetic construct	Antimicrobial, Antifungal	US 2010/0015663 A1	Patent Application	2010##1##21	EP2132319A1, EP2132319B1, US20120196324, WO2008101847A1	Method for producing an antifungal peptide in a filamentous fungal host cell.	The present invention provides a method for producing an antifungal peptide in a filamentous fungal host cell by expressing the antifungal peptide in a host cell which is deficient or partially deficient in the expression of an endogenous glucosyl-ceramide synthase (gcs) gene.
DRAMP14609	HGWGEDANLAMNPS	14	Sequence 22 from Patent US 20100015663	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0015663 A1	Patent Application	2010##1##21	EP2132319A1, EP2132319B1, US20120196324, WO2008101847A1	Method for producing an antifungal peptide in a filamentous fungal host cell.	The present invention provides a method for producing an antifungal peptide in a filamentous fungal host cell by expressing the antifungal peptide in a host cell which is deficient or partially deficient in the expression of an endogenous glucosyl-ceramide synthase (gcs) gene.
DRAMP14610	GSVIKKRRKRMSKKKHRKMLRRTRVQRRKLGK	32	Sequence 1 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14611	NYRLVNAIFSKIFKKKFIKF	20	Sequence 2 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14612	YIQFHLNQQPRPKVKKIKIFL	21	Sequence 3 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14613	GSVIKKRRKRMAKKKHRKLLKKTRIQRRRAGK	32	Sequence 4 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14614	MRFGSLALVAYDSAIKHSWPRPSSVRRLRM	30	Sequence 5 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14615	FESKILNASKELDKEKKVNTALSFNSHQDFAKAYQNGKI	39	Sequence 6 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14616	KGKSLMPLLKQINQWGKLYL	20	Sequence 7 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14617	WSRVPGHSDTGWKVWHRW	18	Sequence 8 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14618	MGIIAGIIKFIKGLIEKFTGK	21	Sequence 9 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14619	ILNKKPKLPLWKLGKNYFRRFYVLPTFLA	29	Sequence 10 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14620	RESKLIAMADMIRRRI	16	Sequence 11 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14621	LDPLEPRIAPPGDRSHQGAPACHRDPLRGRSARDAER	37	Sequence 12 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14622	MPVSKKRYMLSSAYATALGICYGQVATDEKESEITAIPDLLDYLSVEEYLL	51	Sequence 13 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14623	LSLATFAKIFMTRSNWSLKRFNRL	24	Sequence 14 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14624	MIRIRSPTKKKLNRNSISDWKSNTSGRFFY	30	Sequence 15 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14625	MKRRRCNWCGKLFYLEEKSKEAYCCKECRKKAKKVKK	37	Sequence 16 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14626	VLPFPAIPLSRRRACVAAPRPRSRQRAS	28	Sequence 17 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14627	KNKKQTDILEKVKEILDKKKKTKSVGQKLY	30	Sequence 18 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14628	SLQSQLGPCLHDQRH	15	Sequence 19 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14629	WKRLWPARILAGHSRRRMRWMVVWRYFAAT	30	Sequence 20 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14630	KFQGEFTNIGQSYIVSASHMSTSLNTGK	28	Sequence 21 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14631	TKKIELKRFVDAFVKKSYENYILERELKKLIKAINEELPTK	41	Sequence 22 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14632	KFSDQIDKGQDALKDKLGDL	20	Sequence 23 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14633	LSEMERRRLRKRA	13	Sequence 24 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14634	RRGCTERLRRMARRNAWDLYAEHFY	25	Sequence 25 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14635	SKFKVLRKIIIKEYKGELMLSIQKQR	26	Sequence 26 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14636	FELVDWLETNLGKILKSKSA	20	Sequence 27 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14637	LVLRICTDLFTFIKWTIKQRKS	22	Sequence 28 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14638	VYSFLYVLVIVRKLLSMKKRIERL	24	Sequence 29 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14639	GIVLIGLKLIPLLANVLR	18	Sequence 30 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14640	VMQSLYVKPPLILVTKLAQQN	21	Sequence 31 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14641	SFMPEIQKNTIPTQMK	16	Sequence 32 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14642	LGLTAGVAYAAQPTNQPTNQPTNQPTNQPTNQPTNQPRW	39	Sequence 33 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14643	CGKLLEQKNFFLKTR	15	Sequence 34 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14644	ASKQASKQASKQASKQASKQASRSLKNHLL	30	Sequence 35 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14645	PDAPRTCYHKPILAALSRIVVTDR	24	Sequence 36 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14646	NYAVVSHT	8	Sequence 37 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14647	ILVLLALQVELDSKFQY	17	Sequence 38 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14648	YVNYNQSFNSGW	12	Sequence 39 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14649	FQKPFTGEEVEDFQDDDEIPTII	23	Sequence 40 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14650	GGGG	4	Sequence 41 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14651	GGGGG	5	Sequence 42 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14652	GGSGGS	6	Sequence 43 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14653	PSPSP	5	Sequence 44 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14654	ASASA	5	Sequence 45 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14655	KKKK	4	Sequence 47 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14656	RRRR	4	Sequence 48 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14657	GGGGS	5	Sequence 49 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14658	GGGGSGGGGS	10	Sequence 50 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14659	GGGGSGGGGSGGGGS	15	Sequence 51 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14660	GGGGSGGGGSGGGGSGGGGS	20	Sequence 52 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14661	GGGGSGGGGSGGGGSGGGGSGGGGS	25	Sequence 53 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14662	GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS	30	Sequence 54 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14663	TFFRLFNRSFTQALGK	16	Sequence 55 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14664	TFFRLFNR	8	Sequence 56 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14665	NIFEYFLE	8	Sequence 57 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14666	KFINGVLSQFVLERK	15	Sequence 58 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14667	YSKTLHFAD	9	Sequence 59 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14668	GKAKPYQVRQVLRAVDKLETRRKKGGR	27	Sequence 60 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14669	SKRGRKRKDRRKKKANHGKRPNS	23	Sequence 61 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14670	HSSHL	5	Sequence 62 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14671	DLRKAK	6	Sequence 63 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14672	LVRLA	5	Sequence 64 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14673	EVYSSPTNNVAITVQNN	17	Sequence 65 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14674	SKFELVNYASGCSCGADCKCASETECKCASKK	32	Sequence 66 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14675	GVGIGFIMMGVVGYAVKLVHIPIRYLIV	28	Sequence 67 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14676	HARAAVGVAELPRGAAVEVELIAAVRP	27	Sequence 68 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14677	VVRRFQGM	8	Sequence 69 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14678	NILFGIIGFVVAMTAAVIVTAISIAK	26	Sequence 70 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14679	MPKARPVNHNKKKSKITIKSNFTLFYMFNP	30	Sequence 71 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14680	MIHLTKQNTMEALHFIKQFYDMFFILNFNV	30	Sequence 72 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14681	RFFNFEIKKSTKVDYVFAHVDLSDV	25	Sequence 73 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14682	EILNNNQVIKELTMKYKTQFESNLGGWTARARR	33	Sequence 74 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14683	VYRHLRFIDGKLVEIRLERK	20	Sequence 76 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14684	KLRSASKKSLQEKSCGIMPEKPAG	24	Sequence 77 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14685	FRSPCINNNSLQPPGVYPAR	20	Sequence 78 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14686	YVEEAVRAALKKEARISTEDTPVNLPSFDC	30	Sequence 79 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14687	MTCHQAPTTTHQSNMA	16	Sequence 80 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14688	MVILVFSLIFIFTDNYLVYQSKSIKEDVMI	30	Sequence 81 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14689	KKIIPLITLFVVTLVG	16	Sequence 82 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14690	DKSTQDKDIKQAKLLAQELGL	21	Sequence 83 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14691	ISLIIFIMLFVVALFKCITNYKHQS	25	Sequence 84 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14692	GMPQIPRLRI	10	Sequence 85 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14693	IDMR	4	Sequence 86 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14694	DSFDSLSPFRERGGEREDGCDAMPLP	26	Sequence 87 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14695	NDDAQ	5	Sequence 88 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14696	ALALLKQDLLNFEGRGRIITSTYLQFNEGCVP	32	Sequence 89 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14697	FSLNFSKQKYVTVN	14	Sequence 90 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14698	ALAGLAGLISGK	12	Sequence 91 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14699	DVILRVEAQ	9	Sequence 92 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14700	GLAAIATVFALY	12	Sequence 93 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14701	PMNAAEPE	8	Sequence 94 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14702	PPSSFLV	7	Sequence 95 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14703	LIIYFSKTGNTARATRQI	18	Sequence 96 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14704	SKKYNHILNQENR	13	Sequence 97 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14705	NNAIVYIS	8	Sequence 98 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14706	PALVDLSNKEAVWAVLDDHS	20	Sequence 99 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14707	GGTKEIVYQRG	11	Sequence 100 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14708	NRQAQGERAHGEQQG	15	Sequence 101 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14709	AIEGVIKKGACFKLLRHEMF	20	Sequence 102 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14710	RLARGRPTNLCGRRG	15	Sequence 104 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14711	RLTSNQFLTRITPFVFAQH	19	Sequence 105 from Patent US 20100184681	Synthetic construct	Antimicrobial, Antifungal, Antibacterial	US 2010/0184681 A1	Patent Application	2010##7##22	CA2749082A1, CN102405053A, EP2381953A1, US8303962, US20100184683, US20100184684, US20110039761, US20110039762, US20110039763, WO2010080819A1, WO201008	Antibacterial and antifungal peptides.	This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
DRAMP14712	KVPVGAIKKGGKAIKTGLGVVGAAGTAHEVYSHIRNRH	38	Sequence 1 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14713	MKLTGLFLMIMAVIALFIDVGQADPKVPVGAIKKGGKAIKTGLGVVGAAGTAHEVYSHIRNRH	63	Sequence 2 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14714	MKLTGLFLMIMAVVALFISVGQADPKVPVGAIKKGGKAIKTGLGVVGAAGTAHEVYSHIRNRH	63	Sequence 4 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14715	KVPIGAIKKGGKIIKKGLGVIGAAGTAHEVYSHVKNRQ	38	Sequence 5 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14716	MKLTGLFLMIMAVLALFVGAGQADPKVPIGAIKKGGKIIKKGLGVIGAAGTAHEVYSHVKNRQ	63	Sequence 6 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14717	KGIGSALKKGGKIIKGGLGALGAIGTGQQVYEHVQNRQ	38	Sequence 7 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14718	MKFFNLVLMVFAVVALMLNGTNAEPKGIGSALKKGGKIIKGGLGALGAIGTGQQVYEHVQNRQ	63	Sequence 8 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14719	KGIGSALKRGGKIIKGGLGALGAIGTGQQVYEHVQNRQ	38	Sequence 9 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14720	MKFFNLVLMVFAVLALMLNGTNAEPKGIGSALKRGGKIIKGGLGALGAIGTGQQVYEHVQNRQ	63	Sequence 10 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14721	KGIGSALKKGGKIIKGGLGALGAIGTGQQVYE	32	Sequence 24 from Patent US 20100204098	Galleria mellonella	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14722	AKIPIKAIKTVGKAVGKGLRAINIASTANDVFNFLEPKKRKH	42	Sequence 32 from Patent US 20100204098	Antheraea pernyi	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14723	MKVFSFFCVVLAMLVLIMGGTSAAPEPKGIGKIIRKGGKVIKHGLTAIGVGAAGHEVYQDSKNSG	65	Sequence 44 from Patent US 20100204098	Bombyx mori	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14724	MKVFSLFCVVLAMLVLIMGGTSAAPEPKGIGKIIRKGGKVIKHGLTAIGVGAAGHEVYQDSKNSG	65	Sequence 45 from Patent US 20100204098	Bombyx mori	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14725	MKVFSIFCVVLAMLVLIMGGTSAAPEPKGIGKIIRKGGKVIKHGLTVIGVGAAGHEVYQESKNSG	65	Sequence 46 from Patent US 20100204098	Bombyx mori	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14726	MKVFSIFCVVLAMLVLIMGGTSAAPEPKGIGKIIRKGGKVIKHGLTVIGVGAAGHDAYQQSQNSG	65	Sequence 47 from Patent US 20100204098	Bombyx mori	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14727	MKVFSLFCVVLAMLVLIMGGTSAAPEPKGIGKIIRKGGKIIKHGLTVIGVGAAGHDAYQQSQNSG	65	Sequence 48 from Patent US 20100204098	Bombyx mori	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14728	MKLFNFFIVFFALMALMLGGTNAAPKGAGKAIRKGGKIIKHGLTAIGIIGTGHEVYREAKNQG	63	Sequence 49 from Patent US 20100204098	Lonomia obliqua	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14729	MYFLKYFIVVLVALSLMICSGQADPKIPVKSLKKGGKIIAKGFKVLTAAGTAHEVYSHVRNRGNQG	66	Sequence 51 from Patent US 20100204098	Bombyx mori	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14730	MDFLKYFIVVLVALSLMVCSGQADPKIPVKSLKKGGKIIAKGFKVLTAAGTAHEVYSHVRNRGNQG	66	Sequence 52 from Patent US 20100204098	Bombyx mori	Antimicrobial, Antifungal	US 2010/0204098 A1	Patent Application	2010##8##12	CA2681921A1, CN101743251A, WO2008116265A1	Peptides with antifungal activity.	The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of animals, especially humans, and prevention of food spoilage.
DRAMP14731	KWKLFKKIPKFLHLAKKF	18	Sequence 3 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14732	RWKLFKKIPKFLHLAKKF	18	Sequence 4 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14733	FKKLFKKIPKFLHAAKKF	18	Sequence 5 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14734	KWKLLKKIPKFKKLALKF	18	Sequence 6 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14735	KWKLFKKIPKFLHAAKKF	18	Sequence 7 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14736	KWKKFLKIPKFLHAAKKF	18	Sequence 8 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14737	KWKKLLKIPKFLHAAKKF	18	Sequence 9 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14738	KWKKLPKKLLKLL	13	Sequence 10 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14739	FKKALHLFKPIKKFLKWK	18	Sequence 11 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14740	KFLHLAKKFPKWKLFKKI	18	Sequence 12 from Patent US 20120065126	Synthetic construct	Antimicrobial, Antifungal	US 2012/0065126 A1	Patent Application	2012##3##15	CA2761854A1, CN102458439A, EP2429564A1, WO2010139539A1	Pharmaceutical Compositions Containing Antifungal Peptides.	The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions.
DRAMP14741	LKYTGTCTRANNQCKYKGQNDRDTFVKCPTFANKKCTRDGAPCSFDSYSRAVTCD	55	Sequence 2 from Patent US 20120102595	Penicillium simplicissimu	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14742	LKYTGTCTRKNNQCKYRGQNNRDTFVKCPTFANKRCTRDGAPCSFDSYSRAVTCD	55	Sequence 4 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14743	LKYTGTCRRANNQCKYKGQNNRDTFVKCPTFANKKCTRDGAKCSFDSYSRAVTCD	55	Sequence 6 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14744	LKYTGTCRRANNQCKYKGQNNRDTFVKCPTFANKKCTRDGEKCSFDSYSRAVTCD	55	Sequence 8 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14745	LSKFGGECSLKHNTCTYLKGGKNHVVNCGSAANKKCKSDRHHCEYDEHHKRVDCQTPV	58	Sequence 10 from Patent US 20120102595	Monascus ruber	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14746	LSKYGGECSLKHNTCTYRKGGKNQVVNCGTAANKKCKTDRHHCEYDEYHKRVDCQTPV	58	Sequence 12 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14747	LSKYGGECSRKHNTCTYKKGGKNQIVNCPTAANKRCKTDRHHCEYDEYHRRVDCQTPV	58	Sequence 14 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14748	LSKYGGECSRAHNTCTYRKGGKNQVVNCPSAANKKCKSDRHHCEYDEYHKRVDCQTPV	58	Sequence 16 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14749	LSKYGGECSREHNTCTYKKGGKNQVVACGKAANKKCKTDRHHCEYDSYHKKVDCQTPV	58	Sequence 18 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14750	LSKYGGECSREHNTCTYLKGGKNQVVACGSAANKKCKRDRHHCEYDDYHKTVDCQTPV	58	Sequence 20 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14751	LSKYGGECSRAHNTCTYRKGGKNQVVKCGTAANKKCKSDRHHCEYDDYHKRVDCQTPV	58	Sequence 22 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14752	LSKYGGECSKEHNTCKYLKGGKNQVVACPKAANKKCKTDRHHCEYDEYHKTVDCQTPV	58	Sequence 24 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14753	LKYTGTCTRANNQCKYKGQNNRDTFVKCPTFANKKCTRDGAPCSFDSYSRAVTCD	55	Sequence 25 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14754	LSKYGGECSRXHNTCTYRKGGKNQVVNCGSAANKKCKSDRHHCEYDEYHKRVDCQTPV	58	Sequence 26 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14755	MANKHLSLSLFLVLLGLSASLASG	24	Sequence 28 from Patent US 20120102595	Hordeum vulgare	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14756	KDEL	4	Sequence 29 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14757	SEKDEL	6	Sequence 30 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14758	HDEL	4	Sequence 31 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14759	HDEF	4	Sequence 32 from Patent US 20120102595	Synthetic construct	Antimicrobial, Antifungal	US 2012/0102595 A1	Patent Application	2012##4##26	Unknown	Novel Antifungal Proteins and Methods of Use.	Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.
DRAMP14760	KAHWLRLKALAKRK	14	Sequence 1 from Patent US 5464944	Synthetic construct	Antimicrobial, Antifungal	US 5464944 A	Granted Patent	1995##11##7	CA2165986A1, EP0705343A1, WO1995000653A1	Synthetic antifungal peptides.	Two synthetic polypeptides provide cell-expressible antifungal activity.
DRAMP14761	KHRKKRKAWLLALA	14	Sequence 2 from Patent US 5464944	Synthetic construct	Antimicrobial, Antifungal	US 5464944 A	Granted Patent	1995##11##7	CA2165986A1, EP0705343A1, WO1995000653A1	Synthetic antifungal peptides.	Two synthetic polypeptides provide cell-expressible antifungal activity.
DRAMP14762	AVFTVVNQCPFTVWAASVPVGGGRQLNRGE	30	Sequence 1 from Patent US 5521153	Synthetic construct	Antimicrobial, Antifungal	US 5521153 A	Granted Patent	1996##5##28	EP0738324A1, US5559034, US5703044, US5981844, WO1995018859A1	Synergistic antifungal protein and compositions containing same.	Novel plant proteins (SAFPs) which synergize the activity of antifungal antibiotics are identified. SAFPs are demonstrated to synergize antifungal antibiotics, such as nikkomycins, polyoxins and amphotericins. SAFPs alone also display antifungal activity against several species of fungi, including strains of Candida, Trichoderma, Neurospora and strains of the plant pathogens Fusarium, Rhizoctonia and Chaetomium. Synergistic antifungal compositions containing SAFP and antifungal antibiotics are provided. In particular, synergistic compositions of corn-SAFP (zeamatin), sorghum-SAFP (sormatin) or oat-SAFP (avematin) and nikkomycin are found to be effective as antifungal compositions, especially against the opportunistic human pathogen Candida albicans. Method for employing SAFPs and synergistic compositions containing them for the inhibition of fungi are provided. In addition, a method for purifying SAFP from grain meal is provided.
DRAMP14763	AVFTVVNRCPYTVWAASVPVGG	22	Sequence 2 from Patent US 5521153	Synthetic construct	Antimicrobial, Antifungal	US 5521153 A	Granted Patent	1996##5##28	EP0738324A1, US5559034, US5703044, US5981844, WO1995018859A1	Synergistic antifungal protein and compositions containing same.	Novel plant proteins (SAFPs) which synergize the activity of antifungal antibiotics are identified. SAFPs are demonstrated to synergize antifungal antibiotics, such as nikkomycins, polyoxins and amphotericins. SAFPs alone also display antifungal activity against several species of fungi, including strains of Candida, Trichoderma, Neurospora and strains of the plant pathogens Fusarium, Rhizoctonia and Chaetomium. Synergistic antifungal compositions containing SAFP and antifungal antibiotics are provided. In particular, synergistic compositions of corn-SAFP (zeamatin), sorghum-SAFP (sormatin) or oat-SAFP (avematin) and nikkomycin are found to be effective as antifungal compositions, especially against the opportunistic human pathogen Candida albicans. Method for employing SAFPs and synergistic compositions containing them for the inhibition of fungi are provided. In addition, a method for purifying SAFP from grain meal is provided.
DRAMP14764	WTAFXGPVGPXGRDS	15	Sequence 1 from Patent US 5994625	Synthetic construct	Antimicrobial, Antifungal	US 5994625 A	Granted Patent	1999##11##30	CA2145984A1, WO1994008009A1	Antifungal chitin binding proteins and DNA coding therefor.	Chimeric genes encoding antifungal chitin binding proteins (antifungal CBPs) with very low chitinase activity (10% or less than that of the class-I chitinases from tobacco). Also substantially pure DNA sequences encoding antifungal CBP are provided for the obtention of transgenic plants producing antifungal CBP. Plants expressing an antifungal CBP gene, optionally in combination with a plant expressible glucanase gene, show reduced susceptibility to fungi.
DRAMP14765	EYXSPSQGXQSQXSGGGGXGGGGGGGGAQN	30	Sequence 2 from Patent US 5994625	Synthetic construct	Antimicrobial, Antifungal	US 5994625 A	Granted Patent	1999##11##30	CA2145984A1, WO1994008009A1	Antifungal chitin binding proteins and DNA coding therefor.	Chimeric genes encoding antifungal chitin binding proteins (antifungal CBPs) with very low chitinase activity (10% or less than that of the class-I chitinases from tobacco). Also substantially pure DNA sequences encoding antifungal CBP are provided for the obtention of transgenic plants producing antifungal CBP. Plants expressing an antifungal CBP gene, optionally in combination with a plant expressible glucanase gene, show reduced susceptibility to fungi.
DRAMP14766	RSVCRQIKICRRRGGCYYLCTNRPY	25	Sequence 1 from Patent US 6127336	Synthetic construct	Antimicrobial, Antifungal	US 6127336 A	Granted Patent	2000##10##3	CA2245518A1, CN1216047A, EP0882063A2, US6331522, WO1997030082A2, WO1997030082A3	Antibacterial and antifungal peptide.	The present invention provides a peptide with antibacterial and antifungal properties, and compositions containing the peptide. Methods of making and using the antibacterial and antifungal peptide are also provided.
DRAMP14767	RSVXRQIKIXRRRGGXYYKXTNRPT	25	Sequence 2 from Patent US 6127336	Synthetic construct	Antimicrobial, Antifungal	US 6127336 A	Granted Patent	2000##10##3	CA2245518A1, CN1216047A, EP0882063A2, US6331522, WO1997030082A2, WO1997030082A3	Antibacterial and antifungal peptide.	The present invention provides a peptide with antibacterial and antifungal properties, and compositions containing the peptide. Methods of making and using the antibacterial and antifungal peptide are also provided.
DRAMP14768	EDPYRFFERNVTYGTIYPLGVPQQXILINGQF	32	Sequence 1 from Patent US 6291647	Synthetic construct	Antimicrobial, Antifungal	US 6291647 B1	Granted Patent	2001##9##18	CA2182778A1, DE69528575D1, EP0746622A1, EP0746622B1, WO1995021929A1	Antifungal proteins, DNA coding therefor, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has anti-Phytophthora activity and a molecular weight of about 60±5 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein as represented by amino acids 1 to 540 of SEQ ID NO: 6, or the precursor of said protein, and DNA capable of hybridising therewith under stringent conditions. The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention, and wherein the protein is expressed. Also methods are provided for combatting fungi, especially Phytophthora infestans , using a protein or a host cell capable of producing the protein.
DRAMP14769	EKGVYGTTXPXPPGKRFTYILQMKDQIXSXXY	32	Sequence 2 from Patent US 6291647	Synthetic construct	Antimicrobial, Antifungal	US 6291647 B1	Granted Patent	2001##9##18	CA2182778A1, DE69528575D1, EP0746622A1, EP0746622B1, WO1995021929A1	Antifungal proteins, DNA coding therefor, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has anti-Phytophthora activity and a molecular weight of about 60±5 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein as represented by amino acids 1 to 540 of SEQ ID NO: 6, or the precursor of said protein, and DNA capable of hybridising therewith under stringent conditions. The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention, and wherein the protein is expressed. Also methods are provided for combatting fungi, especially Phytophthora infestans , using a protein or a host cell capable of producing the protein.
DRAMP14770	TXLSASGPRPNXQGXYXYGX	20	Sequence 15 from Patent US 6291647	Synthetic construct	Antimicrobial, Antifungal	US 6291647 B1	Granted Patent	2001##9##18	CA2182778A1, DE69528575D1, EP0746622A1, EP0746622B1, WO1995021929A1	Antifungal proteins, DNA coding therefor, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has anti-Phytophthora activity and a molecular weight of about 60±5 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein as represented by amino acids 1 to 540 of SEQ ID NO: 6, or the precursor of said protein, and DNA capable of hybridising therewith under stringent conditions. The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention, and wherein the protein is expressed. Also methods are provided for combatting fungi, especially Phytophthora infestans , using a protein or a host cell capable of producing the protein.
DRAMP14771	IPVPFPDPADDYTLLIGDWYK	21	Sequence 16 from Patent US 6291647	Synthetic construct	Antimicrobial, Antifungal	US 6291647 B1	Granted Patent	2001##9##18	CA2182778A1, DE69528575D1, EP0746622A1, EP0746622B1, WO1995021929A1	Antifungal proteins, DNA coding therefor, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has anti-Phytophthora activity and a molecular weight of about 60±5 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein as represented by amino acids 1 to 540 of SEQ ID NO: 6, or the precursor of said protein, and DNA capable of hybridising therewith under stringent conditions. The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention, and wherein the protein is expressed. Also methods are provided for combatting fungi, especially Phytophthora infestans , using a protein or a host cell capable of producing the protein.
DRAMP14772	EDPYRFFE	8	Sequence 17 from Patent US 6291647	Synthetic construct	Antimicrobial, Antifungal	US 6291647 B1	Granted Patent	2001##9##18	CA2182778A1, DE69528575D1, EP0746622A1, EP0746622B1, WO1995021929A1	Antifungal proteins, DNA coding therefor, and hosts incorporating same.	The present invention provides an isolated protein obtainable from a plant source which has anti-Phytophthora activity and a molecular weight of about 60±5 kDa as judged by SDS PAGE-electrophoresis, an isolated DNA sequence comprising an open reading frame capable of encoding a protein according to the invention, preferably characterized in that it comprises an open reading frame which is capable of encoding a protein as represented by amino acids 1 to 540 of SEQ ID NO: 6, or the precursor of said protein, and DNA capable of hybridising therewith under stringent conditions. The invention further comprises plants incorporating chimeric DNA capable of encoding a protein according to the invention, and wherein the protein is expressed. Also methods are provided for combatting fungi, especially Phytophthora infestans , using a protein or a host cell capable of producing the protein.
DRAMP14773	MARSIYFMAFLVLATLFVAYGVQGKEICCKELTKPVKCSSDPLCQKLCMEKEKYEDGHCFTILSKCLCMKRCNAKTLATELLA	83	Sequence 2 from Patent US 6300489	Synthetic construct	Antimicrobial, Antifungal	US 6300489 B1	Granted Patent	2001##10##9	EP1101771A1	Small and cysteine rich antifungal defensin and thionine-like protein genes highly expressed in the incompatible interaction.	The present invention related to two cDNA clones, designated to PepDef (pepper defensin protein gene) and PepThi (pepper thionin-like protein gene) and individual component; thereof including its coding region and its gene product; modification thereto; application of said gene, coding region and modification thereto; DNA construct, vectors and transformed plants each comprising the gene or part thereof.
DRAMP14774	MAGFSKVVATIFLMMKVFATDMMAEAKICEALSGNFKGLCLSSRDCGNVCRREGFTDGSCIGFRLQCFCTKPCA	74	Sequence 4 from Patent US 6300489	Synthetic construct	Antimicrobial, Antifungal	US 6300489 B1	Granted Patent	2001##10##9	EP1101771A1	Small and cysteine rich antifungal defensin and thionine-like protein genes highly expressed in the incompatible interaction.	The present invention related to two cDNA clones, designated to PepDef (pepper defensin protein gene) and PepThi (pepper thionin-like protein gene) and individual component; thereof including its coding region and its gene product; modification thereto; application of said gene, coding region and modification thereto; DNA construct, vectors and transformed plants each comprising the gene or part thereof.
DRAMP14775	DSHAKRHHGYKRKFHEKHHSHRGYRSNYLYDN	32	Sequence 1 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14776	DSHAKRHHGYKRKFHEKHHSHRG	23	Sequence 2 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14777	AKRHHGYKR	9	Sequence 3 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14778	AKRFHGYKRKFH	12	Sequence 4 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14779	AKRHFGYKRKFH	12	Sequence 5 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14780	AKRHHGYKRKFF	12	Sequence 6 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14781	AKRFFGYKRKFH	12	Sequence 7 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14782	AKRFFGYKRKFF	12	Sequence 8 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14783	AKRHHKYKRKFH	12	Sequence 9 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14784	AKRHHGYHRKFH	12	Sequence 10 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14785	AKRHHKYHRKFH	12	Sequence 11 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14786	AKRHHGYFRKFH	12	Sequence 12 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14787	AKRYYGYKRKFY	12	Sequence 13 from Patent US 6531573	Homo sapiens	Antimicrobial, Antifungal	US 6531573 B1	Granted Patent	2003##3##11	CA2315250A1, DE69836500D1, DE69836500T2, EP1040120A1, EP1040120A4, EP1040120B1, WO1999031123A1	Antifungal and antibacterial peptides.	Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent;
DRAMP14788	VKVGLATKAERASRQQRKQRKNRQKTLRGTAKVKGAKAKK	40	Sequence 1 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14789	VKVGLATKAERASRQQRKQRKNRQKTLMGTAKVKGAKAKK	40	Sequence 19 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14790	VKVGLATKAERASRQQRKQRKNRQKTRRGTAKVKGAKAKK	40	Sequence 20 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14791	VKVGLATKAERASRQQRKQRKNRQKTLRGTAQVKGAKAKK	40	Sequence 21 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14792	VKVGLATKAERASRQQRKQRKNRQKTLRGTRKVKGAKAKK	40	Sequence 22 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14793	VKVGLATKAERASRQQRKQRKNRQKTLMGTAQVKGAKAKK	40	Sequence 23 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14794	VKVGLATKAERASRQQRKQRKNRQKTRRGTRKVKGAKAKK	40	Sequence 24 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14795	MAVPKKRTSISKKRIRKKIWKRKGYWTSLKAFSLGKSLSTGNSKSFFVQQNK	52	Sequence 31 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14796	MKIRASIRRISGKSRPIRRRKRVMIISSNPRHKQKQG	37	Sequence 32 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14797	MNSHRLPGKGRRMGPIMGHTMHYRRMIITLQSSYSIPPLRKKRT	44	Sequence 33 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14798	MAAQKSFRIKQKMAKAKKQNRPLPQWIRLRTNNTIRYNAKRRNWRRTKMN	50	Sequence 34 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14799	MRAKWRKKRTRRLKRKRRKVRARSK	25	Sequence 35 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14800	MPLTKDLLHPSPEEKRKHKKKRLVQSPNSYFMDVKCPRCYKITTVFSHAQTVVLCVGCSTVLCQPIGGKARLTEGCSFRRKQH	83	Sequence 38 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14801	MGKYKPPAERRFGKGVQLCKRCGSRDSVMQKYGLYLCRQCFREVAYPMGFRKTR	54	Sequence 41 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14802	MPGKYGVRYGASLRRDVRKIEVQQHSRYQCPFCGRLTVKRTAAGIWKCSGKGCSKTLAGGAWTVTTAAATSARSTIRRLREMVEV	85	Sequence 42 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14803	MGKVHGSLARAGKVKSQTPKVEKQEKPKQPKGRAYKRLLYVRRFVNVTNMVGGKRRMNPSS	61	Sequence 44 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14804	MGSYSIYNAHPRNYGNGSRTCRKCGARKGLIRKYGLDLCRRCLREKAVEIGFQKLD	56	Sequence 46 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14805	MAHKKGSGSSKNGRDSNAKYLGIKKFGKQIVTPGQIIVRQRGTKIKPGLNVGLGRDYTIFSMIAGRVNYSTQKNKKIVSVDPSYGKIQAIEIRKASHFAT	100	Sequence 48 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14806	MTRSIWKGPHVDSSLLSKLNKIRKTDSKKKINTWSRRSVILPQFIGLSFNIYNGNKWVSVTVTEDMIGHKLGEFSLTRKAVKHKKK	86	Sequence 58 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14807	MISHFSIKDKKRRFLYLKYEWKRLQLKAIAENMLLPMDIRFKARLEINELPKDSSKVRIRNRCIITGRPRGVHKYWRLSRIKIRELMAQNKIPGLRKSSW	100	Sequence 60 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14808	MATKKSGGSSRNGRDSKGRRLGVKLFGGEYATIGSIIVRQRGTKILPYKNVGLGRDHTIFALKEGIVSYYKDKTKTYVSIV	81	Sequence 65 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14809	MKRTFQPSTLVKKRKHGFLNRNKTKNGKALLKRRFLKGRKVI	42	Sequence 66 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14810	MKKGIHPLKRSLDVIMTNGSFVKTIIVSSYIKKNLKLDIDTNKHPCWNPHKKVFVLDSSNLLQKFKSKYQI	71	Sequence 67 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14811	MGNIRTSFVKRIAKEMIETHPGKFTDDFDTNKKLVEEFSTVSTKHLRNKIAGYITRIISQQK	62	Sequence 78 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14812	MIGVIFYNTKGNFLRVKCLDCGNQQVVFDRAASYVQCIICGKTLVEPTGGKSKIKAQILEVLD	63	Sequence 79 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14813	MKFEVRGAFKTLEGWQKFTKVVEANNERYALEKVYSLIGSNHKVKRNLIKIEEVKQA	57	Sequence 84 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14814	MKKERTKVFGRGANECRRCGRRRGLIRMYGLYLCRQCFREVASELGFKKYW	51	Sequence 87 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14815	MAKGAESIYRYYEIKGEKVVRKKKFCPRCGEGVFLAEHKDRLSCGKCGYTEFKKK	55	Sequence 89 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14816	MGTVKPAYIKVIARELLKKYPEVFTGNFDENKRLVAELTNIQSKTVRNRVAGYITRRVNRGLVNV	65	Sequence 91 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14817	MADEEDIQPAEVVELVGRTGMHGEVTQVKVRVLAGENKGRVITRNVFGPVKVGDIIMIKETAREARKLAVR	71	Sequence 93 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14818	MTKGTQSFGMRHNKSHTICRRCGKRSFHIQKSTCACCGYPAAKTRSYNWGAKAKRRRTTGTGRMSYLKKVHRSFKNGFRAGKPTSAATA	89	Sequence 98 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14819	MFFVRSYCLYGFCVRFCFVFLCIYVSPRLPSSGNRRVYVVCFNLYSFVIYCFLFGCCVICYSQSFYFLCEGGGFVDLPCIKLYVRVPIA	89	Sequence 101 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14820	MASVCEICAKGELSGNNVSHSHLKTRRTWKPNIQRVRAVVEGEVKRVNVCTRCLRSGKVQRAL	63	Sequence 104 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14821	MYKDRDTNQRDSRFENQQDGFKKNSNFRFFKRKSCKFCDSGKHPDYKDFDFLKKFITEQGKILPKRITGTSAKHQRRLALEIKRARYMALLPFVKK	96	Sequence 105 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14822	MPAVKVKENEPFDVALRRFKRSCEKAGVLAEVRSREFYEKPTAERKRKAAAAVKRHAKKVQREQRRAVRLY	71	Sequence 108 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14823	MSRSSKKGAFVEASLYKKVLDMNAQQKKKIIKTWSRRSTIFPDFVGHTFAVHNGKKFINVYVTEDMIGHKLGEFSPTRTFKGHSSNR	87	Sequence 110 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14824	MRNSRKVLMGVVVSDKMQKTATVKVESKNRHPFYHKLVISHKKYHVHNEEGENAAKVGDKVLIMETRPLSATKRWRIAKIIERAK	85	Sequence 111 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14825	MAKTSLKIKQARHAKFKVRAYTRCKRCGRPHAVYRKFGICRLCFRHLAYNGSLPGVKKSSW	61	Sequence 112 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14826	MAKSTKRRPAPEKPAKARKCVFCAKKNQQIDYKDTTLLRTYISERGKIRARRVTGNCVQHQRDIAIAVKNAREVALLPFTSSAR	84	Sequence 113 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14827	MTKGTQAFGKKHVKSHTLCKRCGKSSFHIQKKRCASCGYPDAKKRTYNWGAKSIRRRTTGTGRTRHLRDVNARFRNGFREGTTPKPRAQPTN	92	Sequence 132 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14828	MVLQNDIDLLNPPAELEKRKHKLKRLVQSPNSFFMDVKCQGCFNITTVFSHSQTVVMCGNCQTLLCTPTGGKAKLTEGCSFRKK	84	Sequence 136 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14829	MAERRRTNHRVSRFNYWLRIHASVQINVGHLDESGVYNGHFSTFALCGFTRAQEMLTVELTACGRKKKLNLSIDDMITSCCVLLTDLCVSSTFP	94	Sequence 141 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14830	MVVRAPKKKVCMYCEQKREPDYKNYEELRNFLTERGRIKDRKQTGLCAKHQRRLAVQIKRARQLGLLPYVVY	72	Sequence 146 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14831	MKVRSSVKKRCAKCKIIRRKGRVMVICEIPSHKQKTGVTEVRNGENSGR	49	Sequence 150 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14832	MADSEICGKRPVVGRRVTLSGERNRRIFKPNVHKMRVMLPDGTVKRMYVCTKCLKAGKVMKAPRIPKEG	69	Sequence 151 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14833	MVTEGLKPHISIKKKKRKSGFLARMRTKSGRKIIARRRRKGRKRLAP	47	Sequence 153 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14834	MVLPKDVKWDLIRQFQRHEQDTGSPEVQIAILTERINRLTEHMKKHKKDIHSRRGLIAMVNKRRKLLEYLRETDYAKYLEVVQKLNLKVK	90	Sequence 154 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14835	MAKVKMKTNRSAAKRFKVTAKGKIKRWKSGGAHYNTKKSSKRKRHLRKHTYVKDNMLKHVKALLKEF	67	Sequence 156 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14836	MVTVIVQEGEPIEKVLKRFKARVEQEQILTELKRREYYEPPSERKKKRERNRRKKILKALKKQQQLI	67	Sequence 157 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14837	MAVPKAKTSKWRRNQRRAQNFFNKFRRSLPSLSVCSNCGERIIPHRVCPYCGHYKGKEVIETE	63	Sequence 159 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14838	MYAVIKTGGKQYKVEKGMKLKVEKLPYEVGQTVEFEALMLRKDDGSIEFNKGKVIAEVKAHGRGKKLIVFKYRPKKNYKRWKGHRQPYTEIEIKDILP	98	Sequence 160 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14839	MPRKAKVAKDLMYYPKWKSRKKNRCPICGRPRAFIRYFNMCRICFREHALRGDLPGVRKASW	62	Sequence 165 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14840	MASKASGGSTRNGRDSISKRLGVKRYDGQFVKAGNIIVRQRGTRIYPGKNVGMGSDYTLFALKDGYVYFETRRKKKFVSVLSPEEWEKVMAQKNGKVH	98	Sequence 168 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14841	MATKPFFRRRKVCPFSGDNAPKIDYKDVRLLQRYISERGKIVPARITAVSAKKQRELAQAIKRARFLALLPYAVK	75	Sequence 176 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14842	MPKMKNNKGAAKRFKKTAGGIKYKHATKRHILTKRTTKNKRQLRPNAILPKCELAAVARMLPYA	64	Sequence 177 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14843	MAEKRKYSRKYCKYTEAKVEFIDYKDTAMLKHALSERFKIMPRRLTGTSKKYQEMVEVAIKRARHVALIPYIVDRKEVINNPFEGL	86	Sequence 179 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14844	MEVKVFRVSGYFEKDGRKFKFTKEYRALKEEHVKELVYSDIGSRHKVKRRKIFIKEIREIKPEEAEDIVVRRLSLEL	77	Sequence 185 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14845	MVQKPHSFRRKTRKKLRKHPRRRGLPPLTRFLQEFEVGQKVHIVIEPSYHKGMPDPRFHGRTGTVVGKRGDAYIVEVPDGNKVKTLFIHPVHLRPQK	97	Sequence 186 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14846	MARFPEAEARIFKKYICLRCGATNPWGAEKCRKCGYKRLRPKAREPRGGGR	51	Sequence 187 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14847	MAEDEGYPAEVIEIIGRTGTTGDVTQVKVRILEGRDKGRVIRRNVRGPVRVGDILILRETEREAREIKSRR	71	Sequence 188 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14848	MAKADYNKRKPRKFGKGARRCIRCGQYGPIIRIHGLMLCRHCFREVAPKLGFRKYE	56	Sequence 190 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14849	MSIEEIDAKIRELRLQLAKERGMLTMGTSLENPMVIRNLRRDIARLLTIKKEKLREMGKK	60	Sequence 191 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14850	MDPYKVIIRPVVTEKAISLIEKENKLTFIVDRRATKTDIKKAIEEIFNVKVEKVNTLITPKGEKKAYVKLKPEYSASEIAARLGLF	86	Sequence 192 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14851	MAPKKKWSKGKVKDKAQHATVFDKSIIDRINKEVPAFKFISVSVLVDRMKINGSLARIAIRDLAERGVIQKVDQHSKQAIYTRAAASA	88	Sequence 193 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14852	MAKKNKARLLVKLLSTAGTGFFYVRSRPKAAPKLAFIKYDPKIHKRVLFEESKMK	55	Sequence 194 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14853	MTKGTQSFGMRHNKSHTICRRCGKRSFHIQKSTCACCGYPAAKTRSYNWGAKAKRRRTTGTGRMSYLKKVHRSFKNGFRSGKPAAAVAASA	91	Sequence 195 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14854	MFLSAVFFAKSKSKNILVRMVSEAGTGFCFNTKRNRLREKLTLLHYDPVVKQRVLFVEKKKIRSL	65	Sequence 198 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14855	MLKKKIIKYNIFGNVLSDGSFHFCLLTNSYLKESLNYKSVDILNHPVWTGKRQKEQTEISLFIGRLTSK	69	Sequence 207 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14856	MIVINLAGKVHGSLARAGKVRGQTPKVAKQDKKKKPRGRAHKRLQHNRRFVTAVVGFGKKRGPNSSEK	68	Sequence 214 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14857	MKDPRDIIKRPIITENTMNLIGQKKYTFEVDVKANKTEVKDAVEKIFGVKVAKVNIMNYKGKFKRVGRYSGYTNRRRKAIVTLTPDSKEIELFEV	95	Sequence 218 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14858	MQHMHRIIGQMIRTRGLKNVRCMAVEGKHNGRKNGARA	38	Sequence 219 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14859	MSKKCALTGRKPRRGYSYAIRGISKKKKGIGLKVTGRTKRRFFPNMMTKRLWSTEENRFLKLKISAAALRLVDKLGLDQVVARAKSKGF	89	Sequence 223 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14860	MASKNREIIKLKSTESSEMYWTVKNKRKTSGRLELKKYDRKLRKHVIFKEAK	52	Sequence 226 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14861	MPSVKVRVGEPIDRALRILKKKIDKEGILKTSKSHRFYDKPSVKKRAKSKAAAKYRGR	58	Sequence 228 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14862	MAHKKGQGASRNGRDSESKRLGLKVGAGQRVSTGSILVRQRGTKWHPAVNVGRGKDDTLFALVDGIVVMKKTDRTYVSVIPQA	83	Sequence 229 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14863	MGAKKNLLAELREKSSEELDEFIRDNKKALFALRAEAALQNKVVKTHQFSLYKKSIARALTIKQEKKDRVHG	72	Sequence 242 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14864	MSRSLRKGPFVDHHLLKKVRDMNALEKKTPIKTWSRRSMITPEMIGHTFEVHNGRKFLTVFVSETMVGHKLGEFSPTRMFKSHPVKKG	88	Sequence 245 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14865	MAPRKPSKKVGPQKRPSAEKRVITSKKKQLRNQSFKSKVRTILKKFELAVQSGDVESISAGLRSVYSIADKAVKRGIFKKGKADRVKSRTSERACPAA	98	Sequence 247 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14866	MKRTYQPSKRKRRNSVGFRARMATKSGRNLLNRRRRHGRHSLIDL	45	Sequence 248 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14867	MRVSSSIKADPSKGDKLVRRKGRLYVINKKDPNRKQRQAGPARKK	45	Sequence 249 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14868	MNRPVHNEHRRKRFAKKCPFVSAGWKTIDYKDVTTLKRFITERGKILPRRITGVSSRFQALLAQAVKRARHVGLLPFVGED	81	Sequence 252 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14869	MAVPRNRHSNARKNIRRSHHAKKACSAAVCSNCKQAFIPHTVCASCGFYKGKAVITVEK	59	Sequence 253 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14870	MPKMKSNKSVAARFKLTGSGQLKRTRPGKRHKLSKRSSQQKRNLSKQPLVDQGQVGMYKRMMLV	64	Sequence 254 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14871	MTKRTLRGSVRKKKRTSGFRARMETPTGRRVIKARRSRGRVRLTTV	46	Sequence 258 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14872	MSLDAAVKKQIITEFGTKEGDTGSPEVQVALLSRRISDLTEHLKTHKHDHHSRRGLLILVGQRRRLLQYLAKKDIQRFRALVERLGIRRGAAGAR	95	Sequence 259 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14873	MKVKPSVKKICDKCRVIRRHGRVMVICDNPRHKQRQG	37	Sequence 260 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14874	MALSVEEKAQIVAEYQQTAGDTGSPEVQVALLTANINKLQGHLKPTTKTTTPVRGLIRMVNHRRKLLDYLKGKDTTRYSALIGRLGLRR	89	Sequence 266 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14875	MPKNKSHSGASKRFKITGSGKVLRERAGKRHLLEHKSSRVTRRLTGNAEMAPGDAAKIKKLLGK	64	Sequence 268 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14876	MFFPLSTMGFQNLWFSHPRKFGPGSRSCRVCAGHHGLIRKYGLDLCRRCFREQARDIGFKKQPASTSATASSNLVIVNFMSSINKLLA	88	Sequence 270 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14877	MPRRSIWKGSFVDAFLFRIKKNRESLMSRKIWSRRSSISPEFVDCSVLIYNGKTPVRCKITEGKVGHKFGEFAFTRRRRPYQTNRGKGRKGKK	93	Sequence 271 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14878	MQNEEGKTVDLYVPRKCSATNRIITAKDHASVQINIGHLDANGLYDGHFTTFALSGFVRAQGDADSSLDRLRQKKKADIKQ	81	Sequence 273 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14879	MPKQIHEIKGLPPDGEEEGREVGADQEDQGRRQVQGALLQVPLHPLRLRRRQGQQAQAVAPPRFDCPGGLSIKARPCCL	79	Sequence 274 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14880	MVRSRWKGIYVAKELQNYNTVTNPTIVTTERSSVIVPYYLTKTIYVYNGRKYVGVKITEKSLGRKLGEYVLTKKVEKYKASGKSKKK	87	Sequence 286 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14881	MKKRSSIKKICNKCKLIKRFKKLHIICINKKHKQTQ	36	Sequence 287 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14882	MYIIFFIRGFYLYGLCLRLFIFLCVYYISPRLPSSGNRRLCCSIFWLSNIIFYVSVFFCCIYFVVFSQQLFIVEGGGFIDLPGIKYYSRFFY	92	Sequence 288 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14883	MPAGSSERARTRDLFARPFRKKGYIPLSTYLRTFKVGRLRRCQGNGAIHKGSLISSTMVVLVASGISLTCVV	72	Sequence 294 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14884	MYNYYNPASLITHGFGVHRFIFRRISNKAIEFIQV	35	Sequence 296 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14885	MGMRGGLTRLIEELSCPSQHARYAEGRCALRPPDRYWNRNGKFISARATGSISSTSKTCRCSRA	64	Sequence 297 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14886	MVQNNDVDGAFGLLNRLMDSEGMLKIIRRTQFYQKPYMQRKTLSMEASTAIFNEDMNRKMKFLVRKNRPDKHPGQVTS	78	Sequence 303 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14887	MPAIEVGRVCIKTAGREAGKVCVIVDILDKNFVIVDGLVKRRRCNIKHLEPTEKKVDIPKGASTEEVKLALDAAGLLKEE	80	Sequence 312 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14888	MMGRIRQTLIKRTAMELIKKYRDLFTTDFETNKRVLEEVAQISTKRLRNRIAGYITHKMRQLQ	63	Sequence 320 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14889	MPEWRTCSFCGYEIEPGKGKMVVEKDGTVLYFCSSKCEKSYRMGRNPRKLKWTKVYQDMKAELKKAQESQ	70	Sequence 332 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14890	MVLVQDLLHPTAASEARKHKLKTLVQGPRSYFLDVKCPGCLNITTVFSHAQTAVTCESCSTILCTPTGGKAKLSEGTSFRRK	82	Sequence 335 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14891	MVLVQDLLHPTAASEARKHKLKTLVQGPRSYFLDVKCPGCLNITTVFSHAQTAVTCESCSTVLCTPTGGKAKLSEGTSFRRK	82	Sequence 336 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14892	AKKRKKKTYTKPKKIKHKHKKVKLAVLQFYKIDGSGKVQRLRKECPNATCGAGTFMASHFDRHYCGKCGLTYVYQKEGVEA	81	Sequence 337 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14893	AKKRKKKTYTKPKKIKHKKKKVKLAVLQFYKVDDTGKVIRLRKECPNAECGAGTFMANHKDRHYCGKCGLTYVYQKGE	78	Sequence 338 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14894	AKKRKKKVYTTPKKNKRKPKKVKLAVLKYYKVDENGKITRLRKECQQPSCGGGVFMAQHANRHYCGRCHDTLVVDTATAAATSGEKGGKKGKK	93	Sequence 339 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14895	AKKRKKKVYTTPKKNKRKPKKVKLAVLKYYKIDENGKITRLRKECQQPSCGGGVFMAQHANRHYCGRCHDTLVVDTATAAATSGEKGGKKGKK	93	Sequence 340 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14896	GGKKKKKKTYATPKVLKRKLRKVKLAVLKYYKFDENGKIKRVLRECPAETCGAGVFMAQHANRQYCGKCHSTLVKKSK	78	Sequence 341 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14897	AKKRKKKNYSTPKKIKHKRKKVKLAVLKYYKVDENGKIHRLRRECPGENCGAGVFMAAHEDRHYCGKCNLTFVFSKPEEK	80	Sequence 342 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14898	AKKRKKKTYTKPKKQKHKHKKVKLAVLQFYKVDDATGKVTRLRKECPNADCGAGTFMANHFDRHYCGKCGLTYVYNQKA	79	Sequence 343 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14899	AKKRKKKSYTTPKKNKHKRKKVKLAVLKYYKVDENGKISRLRRECPSDECGAGVFMASHFDRHYCGKCCLTYCFNKPEDK	80	Sequence 344 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14900	AKKRKKKTYTKPKKIKHKHKKVKLAVLQFYKVDDSGKVQRLRKECPNTECGAGTFMANHFDRHYCGKCGKTYVYQKADA	79	Sequence 345 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14901	AKKRKKKTYTKPKKIKHKKKKVKLAVLQFYKVDDTGKVQRLRKECPNAECGAGTFMANHFDRHYCGKCGLTYVYNKAGGD	80	Sequence 346 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14902	AKKRKKKTYTKPKKIKHKHKKVKLAVLQFYKVDDATGKVTRLRKECPNTECGAGVFMANHFDRHYCGKCGLTYVYNQKA	79	Sequence 347 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14903	AKKRKKKNYSTPKKIKHKKKKVKLAVLRFYKVDENGKIHRLRRECTGEQCGAGVFMAVMEDRHYCGKCHSTMVFKDDDK	79	Sequence 348 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14904	MTKGKKTAKYKYYKIEGDKVIRLKKTCPRCGPGVFMAEHLNRYACGKCGYMEWKQPQKKE	60	Sequence 349 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14905	MKKFELYEVKDGKLVRKNPFCVRCSNGVFMADHGDRYACGKCGYTEWKNRE	51	Sequence 350 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14906	GKKRKKKVYTTPKKIKHKRKKTKLAVLKYYKVDSDGKIDRLRRECPNETCGAGVFMAAMQDRQYCGRCHLTYVFEKSS	78	Sequence 351 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14907	AKKRKKKTYTKPKKIKHKHKKVKLAVLQFYKVDDATGKVTRLRKECPNHDCGAGTFMANHFDRHYCRKCRLTYVYNQKA	79	Sequence 352 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14908	AKKRKKKSYTTPKKNKHKRKKVKLAVLKYYKVDENGKISRLRRECPSDECGAGVFMGSHFDRHYCGKCCLTYCFNKPEDK	80	Sequence 353 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14909	AHENVWFSHPRRYGKGSRQCRVCSSHTGLIRKYGLNICRQCFREKANDIGFNKFR	55	Sequence 355 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14910	AHENVWFSHPRRFGKGSRQCRVCSSHTGLVRKYDLNICRQCFREKANDIGFHKYR	55	Sequence 356 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14911	MSIKGVVLSYRRSKENQHNNVMIIKPLDVNSREEASKLIGRLVLWKSPSGKILKGKIVRVHGTKGAVRARFEKGLPGQALGDYVEIV	87	Sequence 359 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14912	AKRTKKVGIVGKYGTRYGASIRKQIKKMEVSQHSKYFCEFCGKYGVKRKAVGIWGCKDCGKVKAGGAYTMNTASAVTVRSHTIRRLREQIEG	92	Sequence 364 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14913	AKRTKKVGIVGKYGTRYGASLRKMVKKIEISQHAKYTCSFCGKTKMKRKAVGIWHCGSCMKTVAGGAWTYNTTSAVTVKSAIRRLKELKDQ	91	Sequence 365 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14914	AKRTKKVGIVGKYGTRYGASLRKMVKKIEISQHAKYTCSFCGKTKMKRRAVGIWHCGSCMKTVAGGAWTYNTTSAVTVKSAIRRLKELKDQ	91	Sequence 366 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14915	MFSHTKKVGPTGRFGPRYGLKIRVRVRDVEIKAKKKYKCPVCGFPKLKRASTSIWVCGKCGAKIAGGAYTPETGAGKAVMKAIRRIVERKEE	92	Sequence 367 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14916	MARTKKVGITGRFGPRYGRKAKRAVKKIEEEMKRKHVCPSCDRPGVKRESRGIWKCRKCGAVFTGGAYLPVTPMGKTAARNIKRIVGGK	89	Sequence 368 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14917	AKRTKKVGITGKYGVRYGSSLRRQVKKLEIQQHARYDCSFCGKKTVKRGAAGIWTCSCCKKTVAGGAYTVSTAAAATVRSTIRRLREMVEA	91	Sequence 369 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14918	GKGTPSFGKRHNKSHTLCNRCGRRSFHVQKKTCSSCGYPAAKTRSYNWGAKAKRRHTTGTGRMRYLKHVSRRFKNGFQTGSASKASA	87	Sequence 373 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14919	GKGTPSFGKRHNKSHTLCNRCGRRSFHVQKKTCSSCGYPSAKTRSHNWAAKAKRRHTTGTGRMRYLKHVSRRFKNGFQTGSAKATSA	87	Sequence 374 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14920	MIQPQTRLNVADNSGARELMCIRIIGASNRRYAHIGDIIVARRNPKGTRVFGAIAHELRELSFTKIVSLAPEVL	74	Sequence 387 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14921	MDGIKYAVFTDKSIRLLGKNQYTFNVESGSTRTEIKHWVELFFGVMVIAMNSHRLPGKVKRMGPILGHTMHYRRMIITLQPGYSIPPLRKKRT	93	Sequence 448 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14922	MLNFVRIFLPFLKYQVFTDKTNDLLKYNIYVFDVDKKLNKLQIKNIIEYIFNIKIYSINTYIKNNKYCCFNKIKGLKTNYKRAFIRLKSVNIIPYFSC	98	Sequence 449 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14923	MMLDLVKYPVIRTEKTTRLVENNQLSFDVDVRITKPQIRKIIEEFFNVKVLAVNTHRPPRKTNRLGSKPSYKRVIVTVDSDVTLLK	86	Sequence 450 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14924	MFYFISRKFYDQFKYGILTDKTNKLLKNNVYTFDVDIQMSKRQFKDLIETAFSVKITSVNSYVKSSKYYRSNNFEGMKKYYKRMFIKLNDLETIPFFSCL	100	Sequence 451 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14925	MDGIKYAVFTEKSLRLLGKNQYTFNVESGFTKTEIKHWVELFFGVKVVAVNSHRLPGKGRRMGPILGHTMHYRRMIITLQPGYSIPLLDRETN	93	Sequence 452 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14926	MNQVKYPVLTEKTIRLLEKNQYSFDVNIDSNKTQIKKWIELFFNVKVISVNSHRLPKKKKKIGTTTGYTVRYKRMIIKLQSGYSIPLFSNK	91	Sequence 453 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14927	MDGIKYAVFTEKSLRLLGKNQYTFNVESGFTKTEIKHWVELFFGVKVVAVNSHRLPGKGRRMGPILGHTMHYRRMIITLQPGYSIPLLDREKN	93	Sequence 455 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14928	MDEVKYPVLTEKSIRLLERNQYTFNVDSQSNKTKIKNWIENFFDVKVIAMNSYRLPEKGGKRVSMIGHPIRCKRVIITLRTGDSIPLFSEQ	91	Sequence 456 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14929	MDGIKYAVFTDKSIRLLGKNQYTFNVESGSTRTEIKHWVELFFGVKVIAMNSHRLPGKVKRMGPILGHTMHYRRMIITLQPGYSIPPLRKKRT	93	Sequence 458 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14930	MDGIKYAVFTDKSIQLLGKKQYTSNVESRSTRTEIKHWVELWNSYEMNSHRLPGKGRRMGPIMGHTMHYRRMIITLQSSYSIPPLRKKRT	90	Sequence 459 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14931	MDGIKYAVFTDKSIRLLGKNQYTSNVESGSTRTEIKHWVELFFGVKVIAMNSHRLPGKSRRMGPIMGHTMHYRRMIITLQPGYSIPPLRKKRT	93	Sequence 460 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14932	MDGIKYAVFTEKSLRLLGKNQYTFNVESGFTKTEIKHWVELFFGVKVVAVNSHRLPGKGRRIGPILGHTMHYRRMIITLQPGYSIPLLDREKN	93	Sequence 461 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14933	MRKQQKIHVKIGDNVKIITGFDKNKIGKVSKIDRNTGKIIVKGINFKFKHIKPNAENEVGEIKQFEAPIHHSNVKLN	77	Sequence 462 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14934	MKSSLIKNTVNKKVKFKKGDLVQILSGSDKKKTGEIIAIIHKTSKVIVKGINLKVEASKDLSKKVETGEITKFEAPIHSSNVMLFSQKNNISSRF	95	Sequence 463 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14935	MAHKKGAGSTKNGRDSNAKRLGVKRFGGQRVKAGNILVRQRGMKFTPGLNVGCGKDFTLYALTDGIVNFDYKNAQQKRINIIG	83	Sequence 465 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14936	MAHKKGAGSTKNGRDSNSKRLGVKVYGDQPVKKGGIIIRQRGLTFKPGINVAVGRDYTLFALQEGDVKFETIADRKFVSVIK	82	Sequence 466 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14937	MAHKKGSGSTRNGRDSNSKRLGVKKYGGEQVTAGNILIRQRGTKVKPGQNVGKGKDDTLFALIDGFVLFEKSNQKQKTISVYSSKN	86	Sequence 467 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14938	MARQCELTGKKANNGYTVSHSHRRTKCLQKANLQTKRIWSPTLKRWLKLQVSTKVIKDLKRKSIDALLKI	70	Sequence 469 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14939	MSKKCQLTGKVANNGYAVSHSHKRTKKLQNVNLQYKKVWSTEQNKWIKMLISTKAIKTLTKAL	63	Sequence 470 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14940	MSTVQFNEMIALPNSEISQAIIQTEKELFQLQFKKATRQPFKPHEIKKAKRRLAQLKTILTSRLDALEKKRGNTVMKLIKKQNYMTGNF	89	Sequence 472 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14941	MTLPKILDVIQMDDSSLSEEIIAIKRQLFDLRLKRATRQDFKPHLFKHSKHRLAQLLTVEKSRAQSN	67	Sequence 473 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14942	MAKVDIHPIWYPDAKVYCDGQLIMTIGSTKPELHVDIWSGNHPFFTGSQRIIDTEGRVERFMRKYKMEKD	70	Sequence 474 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14943	AVPKKKMSHSKSNSRKSNWKRKVIKKINFAVTLGKSLSFGKLSKFYLDD	49	Sequence 475 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14944	AVPKKRTSISKKRIRKKIWKRKGYWTSLKAFSLGKSLSTGNSKSFFVQQNK	51	Sequence 476 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14945	AVPKKRKSKMKTRLRKAQWKSEASREAAKALSKAKTVIKSLLAANSANLESNSENSN	57	Sequence 477 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14946	AVPKKRTSKSKKKSRRSHWINKAKTRIRNFLNLAKSISNKKATSFAYSTIKN	52	Sequence 478 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14947	AVPKKKMSKSRRNSRKSNWKKKVLKKVLFALSLGKSFEANTNVNFSFGDKLPQ	53	Sequence 479 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14948	AVPKKRTSMSKKRIRKNLWKKKTYFSIVQSYSLAKSRSFSRGNEHPKPKGFSGQQANK	58	Sequence 480 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14949	AVPKKRTSKSKTRIRKAIWKNKANKSALRAFSLAKSILTNRSKSFYYTINDKLLNSSKSISTSKLDES	68	Sequence 481 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14950	AVPKKRTSKAKKNARKSVWKKKADKAAKKSLSLAKSVLQGKTTSFVYSLYIDELFSI	57	Sequence 482 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14951	AVPKKRTSMSKKRIRKNLWKKKTYFSIVQSYSLAKSRSFSGVSEHPKPKGFSRQQTNNRVLG	62	Sequence 483 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14952	AVPKKRTSRSKKKIRKNVRKGKAYRAAIKAFSLAKSISTGHSKSFYCIVNDDSSGSSESKLTAIDLDDP	69	Sequence 484 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14953	MAVPKKRTSKAKKNARKANWKNQAKTEAQKALSLAKSVLTGKSNGFVYNTLEVADAIVE	59	Sequence 485 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14954	AVPKKRTSTSKKRIRKNIWKRKGYSIALKAFSLAKSLSTGNSKSFFVRQTKINK	54	Sequence 486 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14955	MPVPKKRTSISKKKIRKNFWKKKGYKAALKAFSLADSILTGTSKVIVL	48	Sequence 487 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14956	MARAKGVRILVTLECTECRSNGERLGGGVSRYATKKNRRNTPNRLELNKFCPYCKKHVLHREIK	64	Sequence 488 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14957	MAKSKDARVAVILECTSCIRNSVNKVLTGISRYITQKNRRNTPNRLELRKFCPYCYKHMIHGEIKK	66	Sequence 489 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14958	AKGKDVRIRVILECISCVRKGTNKESTGISRYSTQKNRHNTPGQLELRKFCRYCRKHTTHNEIKK	65	Sequence 490 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14959	AKSKDIRVTINLECINCAQNDEKRKKGISRYTTQKNRRNTPIRLELKKFCCYCNKHTIHKEIKK	64	Sequence 491 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14960	MGKAKGIRILITLECTECRSNTNKRSNGVSRYTTQKNRRNNPERIELKKYCPHCNKSTIHKEIK	64	Sequence 492 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14961	AKGKDVRIRVILQCVSCVRKGANEESAGISRYSTQKNRHNTPGQLELRKFCRYCRKHTIHAEIKK	65	Sequence 493 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14962	AKSGDIRVTITLECTSCTQDSVYKRFPGISRYTTRKNRRNTPIRLESNKFCPYCYKHTIHGEIKKRD	67	Sequence 494 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14963	MAKSKGARIVITLECSNKSVDISQKRKAGVFRYTTTKNRRNTPGRIELKKFCPNCNSHCVFKEIK	65	Sequence 495 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14964	AKGKDVRVTVILECTSCVRNSVDKVSRGISRYITQKNRHNTPNRLELKKFCPYCYKHTIHGEIKK	65	Sequence 496 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14965	MIQRTLTGTNRKKTKRSGFRSRMLQTEEEKLLILDVMKKRYYLVK	45	Sequence 497 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14966	MSKRTLEGSHRKKVRKSGFLSRSQSPTGRRILKARRKKGRKMLVKY	46	Sequence 498 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14967	MTKRTLSNKTRYSILKLSGFRARMSTAQGRKTLKARRKKGRKQLAVRR	48	Sequence 499 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14968	MTKRTLEGTKRKSIRKSGFRARMATKLGRKVLNKRRQKGENS	42	Sequence 500 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14969	MTKGTLQGSKRKKIRISGFRARMKTPSGRSILNERRRKGRKKIMAS	46	Sequence 501 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14970	MYKLKTRKAAAKRYKAVGNKKISRRKAFRSHLLQKKSTNRKRQLSQVVIASPGDTKKIYLMLPYL	65	Sequence 502 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14971	MPKLKTRKAALKRYKKTATGKFLRRHAYKGHLLMKKSKTQKRKLSQIICVSNNDSKPIKLMLPY	64	Sequence 503 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14972	MPKLKTSKAIAKRFKVSSSGKILRHKASKSHLLQKKSSKHRRHLSSTCQVDSRDAKNISINLPYL	65	Sequence 504 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14973	MKVYSSVRKICKSCGLIRRHGKLFVRCINSKHNQRQN	37	Sequence 506 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14974	MKVRPSVKKMCDKCRLIKRKGTLRVICQNPKHKQRQG	37	Sequence 507 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14975	MKVRASVRKMCEKCRTIRRKGRVMVICSNSKHKQRQG	37	Sequence 508 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14976	MKIRASIRKICEKCRLICRRRRIIVICSNPRHKQRQG	37	Sequence 509 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14977	MKIRSSVKKICNKCYLIRRKNNLLVVCINNKHKQRQG	37	Sequence 510 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14978	MKIRASVRKICENCRLIRRRRRIMVVCSNPKHKQRQG	37	Sequence 511 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14979	MKVRPSVKKMCDKCRVIKRKGKIMVICPNAKHKQRQG	37	Sequence 512 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14980	MKIRASVRKICTKCRLIRRRGRIRVICSNPKHKQRQG	37	Sequence 513 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14981	MKVAASVRKICEKCRLIRRRGRLLVICSNPKHKQRQG	37	Sequence 514 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14982	MKIRASIRRICGKCRPIRRRKRVMIICSNPRHKQKQG	37	Sequence 515 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14983	MKVRPSVRKMCEKCRIIRRHRKVMVICNNPKHKQRQG	37	Sequence 516 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14984	MKIRASVRPICEKCRLIRRRGRIIVICSNPKHKQRQG	37	Sequence 517 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14985	MKIRASVRKICEKCRLIRRRGRIIVICSNPRHKQRQG	37	Sequence 518 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14986	PSSNGPLEGTRGKLKNKPRDRGTSPPQRAVEEFDDGEKVHLKIDPSVPNGRFHPRFDGQTGTVEGKQGDAYKVDIVDGGKEKTIIVTAAHLRRQE	95	Sequence 703 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14987	MVQMSEGFRRKTRKKLSKHPRERGLYPITRALREFKEGEYVHIVIDPSVHKGMPHPRFHGRTGIVVGKQGRAFIVKVRDGGKYKQIIAYPQHLRPATA	98	Sequence 706 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14988	MRRSRGFRSKTRHKLQKVKRPGRSNPITRKIQSFNEGDLVHIIIDPSIHRGQPHPRFHGKTGRVVGMMGKSYVVALKDGNKDKQLVVRPEHLQMQE	96	Sequence 707 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14989	MHAIVVCGAKQYLVHENESIFVEKLAGKVGQEIQLDKVLMLDEKIGKPYLEKAKVVCVIEKHGLKSKIKLIKHISQKHHLKRYGHRQPYTKLKVVRFIHD	100	Sequence 709 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14990	MHAIVVCGSKQYLVHENDTFFVEKLEAPVGKEIQLDKVLMLDEKIGAPYLEKARVVCVVEKHGLQRKVNVIKHISQKHHLKKYGHRQPYTKLKVVRFVHD	100	Sequence 710 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14991	MSQERLLKVLKAPHISEKATNNAEKSNTIVFKVALDANKVEITNAVEQLFEVKVDSVRTVVVKGKTKRRGAKIGRRSDWKKAYVTLQEGQSLDFVEGAAE	100	Sequence 738 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14992	MKDPRDIIKRPIITENTMNLIGQKKYTFEVDVKANKTEVKDAVEKIFGVKVEKVNIMNYKGKFKRVGRYSGYTNRRKKAIVTLTPDSKEIELFEV	95	Sequence 739 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14993	MKDPRDVLKRPVITERSADLMTEEKYTFEVDVRANKTEAKDAVESIFGVKVDKVNIMNYKGKSKRVGRYTGMTSRRRKAIVKLTADSKEIEIFEA	95	Sequence 740 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14994	MIREERLLKVLRAPHVSEKASTAMEKSNTIVLKVAKDATKAEIKAAVQKLFEVEVEVVNTLVVKGKVKRHGQRIGRRSDWKKAYVTLKEGQNLDFVGGAE	100	Sequence 745 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14995	MSQERLLSVLRAPHISEKATNNAEKSNTVVLKVALDANKAEIAAAVAQLFEVKVDSVRTVVVKGKTKRRGNKMGRRSDWKKAYVTLAEGQNLDFVDSAE	99	Sequence 746 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14996	MADIMDIKSILYTEKSLGLQEKGVLVVQTAQNVTKNQLKEVFKTYFGFEPLKINSLKQEGKVKRFRGKLGQRKSFKKFYVKVPEGASIAALGA	93	Sequence 747 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14997	MDAFDVIKAPVVTEKTVRMIEEENKLVFYVDRRATKQDIKRAMKELFDVEVEKVNTLITPKGEKKAYVKLKEGYDASKIAASLGIY	86	Sequence 749 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14998	MATLADPRDIILAPVISEKSYGLLDDNVYTFLVRPDSNKTQIKIAVEKIFGVKVASVNTANRQGKRKRTRTGYGKRKSTKRAIVTLAPGSRPIDLFGAPA	100	Sequence 750 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP14999	MHITEVLKKPVLTEKSFAGHKDNVYTFLVDKKANKVQIKKTFEEIFEVKVESVRTINYDAKEKRLGKYVGKKPSYKKAIITLKEGQKLDVLSDL	94	Sequence 751 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15000	MATIADSRDIILAPVISEKSYGLLDDNVYTFVVHPDSNKTQIKIAIEKIFSVKVASVNTSNRKGKCKRTRTGFGRRKNTKRAIVTLAPGSKSIDLFGTPA	100	Sequence 753 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15001	MAEANIRALADIIRRPIITEKATRLLENNQYTFEVDPRASKPEIKAAIEALFQVKVVGLSTQLPPRKARRVGRFAGHRAQVKRAVARLADGDSITLFPEV	100	Sequence 754 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15002	MKQEKLSLHDVLIRPIITEKALILREQRKYVFEVNPLANKNLVKEAVEKLFNVKVEKVNILNMKPKPKRRGIFEGKTRSWKKAVVTLKEGYTIKELEGEH	100	Sequence 756 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15003	MIREERLLKVLRAPHVSEKASAAMEKNNTIVLKVAKDATKAEIKAAVQKLFEVEVEDVNTLLVKGKSKRHGQRVGRRSDWKKAYVTLKEGQNLDFIGGAE	100	Sequence 759 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15004	MIREERLLKVLRSPHVSEKASAAMEKNNTIVLKVAKDATKAEIKAAVQKLFEVEVEDVNTLLVKGKSKRHGQRVGRRSDWKKAYVTLKEGQNLDFIGGAE	100	Sequence 760 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15005	MKSEIKKNDIVKVIAGDDKGKVAKVLAVLPKTSQVVVEGCKVVKKAIKPTDDNPKGGFIHKEKPMHISNVKKA	73	Sequence 767 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15006	MFTINAEVRKEQGKGASRRLRAANKFPAIIYGGKEAPLAIELDHDKVMNMQAKAEFYSEVLTIVVDGKEIKVKAQDVQRHPYKPKLQHIDFVRA	94	Sequence 783 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15007	MAFKFNAEVRTAQGKGASRRLRHNGQIPAIVYGGSEEPVSIILNHDELNNAQAHESFYSEVITLVVEGKEVAVKVQAMQRHPFKPKLVHIDFKRA	95	Sequence 784 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15008	ASKKGVGSTKDGRDSIAKRLGAKRADGQFVTGGSILYRQRGTKVHPGLNVGRGGDDTLYAKIDGIVRFERLGRDRKRVSVYPVSQEA	87	Sequence 794 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15009	MLRLDLQFFASKKGVGSTKNGRDSEAKRLGAKRADGQFVTGGSILYRQRGTKIYPGENVGRGGDDTLFAKIDGTVKFERFGRDRKKVSVYPVAQ	94	Sequence 795 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15010	AHKKAGGSTRNGRDSEAKRLGVKRFGGESVLAGSIIVRQRGTKFHAGANVGCGRDHTLFAKADGKVKFEVKGPKNRKFISIEAE	84	Sequence 797 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15011	ATKKAGGSTRNGRDSEAKRLGVKRFGGESVLAGSIIVRQRGTKFHAGNNVGMGRDHTLFATADGKVKFEVKGEKSRKYVVIVTE	84	Sequence 798 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15012	MAHKKGQGSTQNNRDSAGRRLGVKKFGSEFVRAGNIIVRQRGTKMHPGNNVGMGKDHTLYALIDGVVKFEHKDRNRKKVSVVSQNFGE	88	Sequence 799 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15013	MAHKKGASSTRNGRDSNAQRLGVKRFGGQAVNAGEILVRQRGTHFHPGTGVGRGGDDTLFALAAGAVQFGTHRGRKVVNIVPLAV	85	Sequence 806 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15014	MAHKKGTGSTRNGRDSNAQRLGVKRYGGQTVTAGSIIVRQRGTQVHPGNNVGRGKDDTLFALIDGVVKFEHKTRSRRKVSVYPATAE	87	Sequence 807 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15015	AKCFITGKKKSFGNTRSHAMNASRRDWKANLQKVRILVDGKPKRVWVSARALKSGKVKRV	60	Sequence 809 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15016	MARKCVITGKKTTAGNNRSHAMNASKRTWGANLQKVRILVNGKPKKVYVSARALKSGKVERV	62	Sequence 810 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15017	SRVCQVTGKRPVTGNNRSHALNATKRRFLPNLHSHRFWVESEKRFVTLRVSAKGMRVIDKKGIDTVLAELRARGEKY	77	Sequence 811 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15018	SRVCQVTGKRPAVGNNRSHAMNATRRRFLPNLHTHRFWVESENRFVTLRLTAKGMRIIDKKGIDAVLAEIRARGEKI	77	Sequence 812 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15019	MAKRCALTFKGPMIGNHVSHANNKNKRRLLPNLRSIKIQLDDGTTKRIKVAASTLRTMRKGA	62	Sequence 813 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15020	MAKKDQLTLRGPLYGNNRSHSKTITRRKWNVNLQSCKIKDTNGKVTRILVSTKTIRTLKKQNRF	64	Sequence 816 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15021	MAKKDQLTLRGPLYGNNRSHSKTITRRKWNVNLQPCKVKTADGKTTRILVSTRTLRTLKKHNRLS	65	Sequence 817 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15022	MSARCQITGRTVGFGKAVSHSHRRTRRRWPPNIQLKAYYLPSEDRRIKVRVSAQGIKVIDRDGHRGRRRAARAGSAPAHFARQAGSSLRTAAIL	94	Sequence 818 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15023	MARRCQLTGKKANNGFAVSHSHRRTKKLQQANLQWKRVWWPEGNRFVRLRLSTTAIKTLESKGINAMAKEAGINLNKF	78	Sequence 820 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15024	MKAQELRTKSVEELNAELVNLLGEQFKLRMQAATGQLQQTHQLKQVRRSIAQIKTVLTEKAGE	63	Sequence 821 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15025	MKAQELREKGVEELNTELLNLLREQFNLRMQGASGQLQQTHLLKQVRRNVARVKTLLTEKAGV	63	Sequence 822 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15026	MKAKEIRELTTAEIEQKIKALKEELFNLRFQLATGQLENTARIRQVRKDIARMKTIIRERELAANK	66	Sequence 823 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15027	MKANEIRDLTTAEIEQKVKSLKEELFNLRFQLATGQLENTARIREVRKAIARMKTVIREREIAANK	66	Sequence 824 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15028	MGAKKNLLAELREKSSEELDEFIRDNKKALFALRAEAALQNKVVKTHQFSLYKKSIARALIIKQEKKGRVHG	72	Sequence 825 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15029	MAKSKNHTNHNQNKKAHRNGIKRPLRKRHESTLGMDVKFLINQRYARKGNLSREESVKRYNERIASQKGKPKPVTL	76	Sequence 826 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15030	MKAKELREKSVEELNTELLNLLREQFNLRMQAASGQLQQSHLLKQVRRDVARVKTLLNEKAGA	63	Sequence 827 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15031	MKAQDLRTKSVEELNAELVNLLGEQFKLRMQTATGQLQQTHQAKQVRRDIARVKTVLTEKAGE	63	Sequence 828 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15032	MKYTELKDKSIKELEELLHAKKAELFELRVKLKAMQLSNPNEIKKARRNIARINTAINAHYSSSVE	66	Sequence 829 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15033	MAILRADELRGMSMEELKEKLVELKRELLKERASKAVAGAPSNPGRMREIRRTIARILTIMNEKKRMTSQ	70	Sequence 830 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15034	MAILRSEEIREMDGEELQKKLDELKAEYARYISKSAAAGIHENPGKMREIRRTIARVLTIMNEK	64	Sequence 831 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15035	MAVGVSPGELRELTDEELAERLRESKEELFNLRFQMATGQLNNNRRLRTVRQEIARIYTVSARTRTGSGGDWARW	75	Sequence 833 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15036	MALPKIEDVRNLSDADLAEKIAEAKRELFDLRFQRATRQLEKPHLFKHTKHRLAQLLTVERERQ	64	Sequence 837 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15037	MALPNIADARKLGDEELATEILATKQRLFQLRFQQATRRPENPHEFKHARHRLAQLLTVERERQLENSPSEEA	73	Sequence 838 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15038	MKASELRNYTDEELKNLLEEKKRQLMELRFQLAMGQLKNTSLIKLTKRDIARIKTILRERELGIRR	66	Sequence 839 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15039	MAKTIKVTQVRSSIGRLPKHKATLLGLGLRRIGHTVEREDTPALRGMINLVSYMVKVEE	59	Sequence 862 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15040	AKKLAITLTRSVIGRPEDQRITVRTLGLRKMHQTVVHNDNPAIRGMINKVAHLVKVKEIEEE	62	Sequence 863 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15041	AKLEITLKRSVIGRPEDQRVTVRTLGLKKTNQTVVHEDNAAIRGMINKVSHLVSVKEQ	58	Sequence 864 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15042	AKTIKITQTRSAIGRLPKHKATLLGLGLRRIGHTVEREDTPAIRGMINAVSFMVKVEE	58	Sequence 866 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15043	AKTIKVTQVRSSIARLPKHKATLRGLGLRHIHHTVELIDTPAVRGMINQVSYMVKVEE	58	Sequence 867 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15044	MFESTRKNIQPSDATLVITQTRGVTGSKQNHRDTLRSLGLKRIGHQVTRKADAVTVGMVNTVPHLVSVEEVNNG	74	Sequence 874 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15045	MASLKITQVRSTIGVRWKQRESLRTLGLRRIRHSVIREDNLQTRGLIAVVRHLVEVEPATGGSTPVGGGRD	71	Sequence 875 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15046	MAKLQITLTRSVIGRPETQRKTVEALGLKKTNSSVVVEDNPAIRGQINKVKHLVTVEEK	59	Sequence 877 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15047	MAQLKITQVKSYIGSKQNHRDTLRSLGLKGINTQVVKEDRPEFRGMVHTVRHLVTVEEVD	60	Sequence 878 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15048	MPRLKVKLVKSPIGYPKDQKAALKALGLRRLQQERVLEDTPAIRGNVEKVAHLVRVEVVE	60	Sequence 879 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15049	MKAGIHPNFKKATVKCACGNEFETGSVKEEVRVEICSECHPFYTGRQKFASADGRVDRFNKKYGLK	66	Sequence 881 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15050	MKKDIHPKYEEITASCSCGNVMKIRSTVGHDLNLDVCSKCHPFFTGKQRDVATGGRVDRFNKRFNIPGSK	70	Sequence 883 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15051	MKQGIHPEYKEITATCSCGNVIKTRSTVEKNLNLDVCGNCHPFYTGKQRVVDTGGRVERFNKRFNIPSTK	70	Sequence 884 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15052	MKQGIHPEYKEITATCSCGNVIKTRSTLGKDINLDVCGNCHPFYTGKQRVVDTGGRVERFNSRFKIPSTK	70	Sequence 885 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15053	MKKGIHPEYIPCKVTCVTSGKEIEVLSTKPEMRIDISSFCHPFYTGSDKIADTAGRVEKFKQRYNLK	67	Sequence 886 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15054	MEVLMMEERIYTIPLRDVINKSVRTKRAPRAIKKIKQFLKRHMKAEIVKIDNELNEKIWERGIQKPPARVRVKAVKEGNVVIATLAE	87	Sequence 888 from Patent US 6573361	Synthetic construct	Antimicrobial, Antifungal	US 6573361 B1	Granted Patent	2003##6##3	US7332596	Antifungal proteins and methods for their use.	A novel protein was isolated from Fusarium culmorum and characterized. The protein, termed FCWP1, demonstrated significant antifungal activity against several fungal species. Mutations in proteolytic consensus sequences contained within FCWP1 improved the stability of its antifungal activity. In addition, a class of proteins related to FCWP1 was identified and characterized. This class is made up of ribosomal proteins and displayed similar values for pI and molecular weight. A representative number of proteins from this class were tested and found to have significant antifungal activities. The antifungal proteins disclosed herein are useful in controlling fungal infections in plants. Transgenic plants may be produced that are more resistant to fungal infections relative to non-transgenic plants of the same species. Alternatively, the proteins may be applied to plants exogenously.
DRAMP15774	GSWLRDIWDWVCTVLSDFRVWLKSKL	26	Sequence 49 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15775	SWLRDVWDWICTVLT	15	Sequence 50 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15776	SWLRDVWDWVCTILT	15	Sequence 51 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15777	SWLRDIWEWVLSILT	15	Sequence 52 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15778	SWLRIIWDWVCSWSD	15	Sequence 53 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15779	SWLRTIWDWVCSVLA	15	Sequence 54 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15780	SWLHDIWDWVCIVLS	15	Sequence 55 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15781	SWLWDVWDWVLHVLS	15	Sequence 56 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15782	SWLYDIVNWVCTVLA	15	Sequence 57 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15783	SWLRDIWDWVCTVLS	15	Sequence 58 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15784	SWLRDVWDWICTVLTD	16	Sequence 59 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15785	SWLRDVWDWVCTILTD	16	Sequence 60 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15786	SWLRDIWEWVLSILTD	16	Sequence 61 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15787	SWLRIIWDWVCSWSDF	16	Sequence 62 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15788	SWLRTIWDWVCSVLAD	16	Sequence 63 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15789	SWLHDIWDWVCIVLSD	16	Sequence 64 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15790	SWLWDVWDWVLHVLSD	16	Sequence 65 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15791	SWLYDIVNWVCTVLAD	16	Sequence 66 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15792	SWLRDIWDWVCTVLSD	16	Sequence 67 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15793	SWLRDVWDWICTVLTDF	17	Sequence 68 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15794	SWLRDVWDWVCTILTDF	17	Sequence 69 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15795	SWLRDIWEWVLSILTDF	17	Sequence 70 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15796	SWLRIIWDWVCSWSDFK	17	Sequence 71 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15797	SWLRTIWDWVCSVLADF	17	Sequence 72 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15798	SWLHDIWDWVCIVLSDF	17	Sequence 73 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15799	SWLWDVWDWVLHVLSDF	17	Sequence 74 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15800	SWLYDIVNWVCTVLADF	17	Sequence 75 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15801	SWLRDIWDWVCTVLSDF	17	Sequence 76 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15802	SGSWLRDVWDWICTVLTDFKTWLQSKLDYK	30	Sequence 77 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15803	QDVLKEVKAAASKVKANLLSVEE	23	Sequence 79 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15804	DVRCHARKAVAHINSVWKD	19	Sequence 80 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15805	IEQGMMLAEQFKQKALGLLQTASRHAEV	28	Sequence 81 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15806	LRDVWDWICTVLTDFKT	17	Sequence 83 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15807	LRDVWDWICT	10	Sequence 84 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15808	DVWDWICTVLTD	12	Sequence 85 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15809	SWLRDVWDWIC	11	Sequence 86 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15810	LCLAGRGLQEAEGLLLELLSEHHPLLDV	28	Sequence 87 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15811	ELGFQPGLKVAQHLAYPVPDVP	22	Sequence 88 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15812	SGSWLRDVWDWICTVLTDFKTWLQSKLDYKD	31	Sequence 89 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15813	SGSWLRDDWDWECTVLTDDKTWLQSKLDYKD	31	Sequence 90 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15814	SGSWLRDDWDWECTVLTDDKTWLQSKL	27	Sequence 91 from Patent US 20090105151	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0105151 A1	Patent Application	2009##4##23	WO2009014615A2, WO2009014615A3	Amphipathic alpha-helical peptide compositions as antiviral agents.	The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
DRAMP15815	RLLLRLLLGY	10	Sequence 3 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15816	RVLLRLLLGY	10	Sequence 4 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15817	RILLRLLLGY	10	Sequence 5 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15818	RLVLRLLLGY	10	Sequence 6 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15819	RLILRLLLGY	10	Sequence 7 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15820	RLLVRLLLGY	10	Sequence 8 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15821	RLLIRLLLGY	10	Sequence 9 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15822	RLLLRVLLGY	10	Sequence 10 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15823	RLLLRILLGY	10	Sequence 11 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15824	RLLLRLVLGY	10	Sequence 12 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15825	RLLLRLILGY	10	Sequence 13 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15826	RLLLRLLVGY	10	Sequence 14 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15827	RLLLRLLIGY	10	Sequence 15 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15828	RWLLRLLLGY	10	Sequence 16 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15829	RLWLRLLLGY	10	Sequence 17 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15830	RLLWRLLLGY	10	Sequence 18 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15831	RLLLRWLLGY	10	Sequence 19 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15832	RLLLRLWLGY	10	Sequence 20 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15833	RLLLRLLWGY	10	Sequence 21 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15834	RYLLRLLLGY	10	Sequence 22 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15835	RLYLRLLLGY	10	Sequence 23 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15836	RLLYRLLLGY	10	Sequence 24 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15837	RLLLRYLLGY	10	Sequence 25 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15838	RLLLRLYLGY	10	Sequence 26 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15839	RLLLRLLYGY	10	Sequence 27 from Patent US 20090215699	Synthetic construct	Antimicrobial, Antiviral	US 2009/0215699 A1	Patent Application	2009##8##27	CA2592888A1, EP1838333A1, WO2006072579A1	Pharmaceutically Active Antiviral Peptides.	The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.
DRAMP15840	KYKETDLLILFKDDYFAKKNEERK	24	Sequence 1 from Patent US 20090233868	Homo sapiens	Antimicrobial, Antiviral	US 2009/0233868 A1	Patent Application	2009##9##17	CA2606668A1, EP1877431A1, US20110091966, WO2006117805A1	Small antiviral peptides against hepatitis C virus.	Disclosed herein is a small 7 amino-acid peptide, corresponding to the C terminus of RRM2 of the human La protein that binds to the IRES element of hepatitis C virus RNA and its derivatives. This disclosure demonstrates that this 7-mer interacts with the HCV IRES element both in vitro and in vivo and can compete against cellular La protein in binding to the HCV RNA. It is also shown here that this 7-mer peptide is able to inhibit HCV-IRES mediated translation in vivo which, in turn, leads to decreased viral replication.
DRAMP15841	KYKETDL	7	Sequence 2 from Patent US 20090233868	Homo sapiens	Antimicrobial, Antiviral	US 2009/0233868 A1	Patent Application	2009##9##17	CA2606668A1, EP1877431A1, US20110091966, WO2006117805A1	Small antiviral peptides against hepatitis C virus.	Disclosed herein is a small 7 amino-acid peptide, corresponding to the C terminus of RRM2 of the human La protein that binds to the IRES element of hepatitis C virus RNA and its derivatives. This disclosure demonstrates that this 7-mer interacts with the HCV IRES element both in vitro and in vivo and can compete against cellular La protein in binding to the HCV RNA. It is also shown here that this 7-mer peptide is able to inhibit HCV-IRES mediated translation in vivo which, in turn, leads to decreased viral replication.
DRAMP15842	RQARRNRRRRWR	12	Sequence 1 from Patent US 20090258815	Human immunodeficiency vi	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15843	RKKRRQRRR	9	Sequence 2 from Patent US 20090258815	Human immunodeficiency vi	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15844	PKKKRKV	7	Sequence 3 from Patent US 20090258815	Simian virus 40	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15845	RKKKRKV	7	Sequence 4 from Patent US 20090258815	Synthetic construct	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15846	YGRKKRRQRRR	11	Sequence 5 from Patent US 20090258815	Human immunodeficiency vi	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15847	LPPLERLTLD	10	Sequence 6 from Patent US 20090258815	Human immunodeficiency vi	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15848	LALKLAGLDI	10	Sequence 7 from Patent US 20090258815	Mus musculus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15849	LPPDLRLTLD	10	Sequence 8 from Patent US 20090258815	Human immunodeficiency vi	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15850	LSAQLYSSLSLD	12	Sequence 9 from Patent US 20090258815	Human T-cell lymphotropic	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15851	RQARRNRRRRWRLPPLERLTLD	22	Sequence 10 from Patent US 20090258815	Synthetic construct	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15852	LPPLERLTLDRQARRNRRRRWR	22	Sequence 11 from Patent US 20090258815	Synthetic construct	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15853	YGRKKRRQRRRLPPLERLTLD	21	Sequence 12 from Patent US 20090258815	Synthetic construct	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15854	RKKKRKVLALKAGLDI	16	Sequence 13 from Patent US 20090258815	Synthetic construct	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15855	RRMKWKK	7	Sequence 14 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15856	RVHPYQR	7	Sequence 15 from Patent US 20090258815	Mus musculus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15857	KRPACTLKPECVQQLLVCSQEAKK	24	Sequence 16 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15858	GKKRSKA	7	Sequence 18 from Patent US 20090258815	Saccharomyces cerevisiae	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15859	KAKRQR	6	Sequence 19 from Patent US 20090258815	avian reticuloendothelios	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15860	RGRRRRQR	8	Sequence 20 from Patent US 20090258815	Rattus sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15861	RKRRR	5	Sequence 21 from Patent US 20090258815	Rattus sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15862	PPVKRERTS	9	Sequence 22 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15863	PYLNKRKGKP	10	Sequence 23 from Patent US 20090258815	Saccharomyces cerevisiae	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15864	CYGSKNTGAKKRKIDDA	17	Sequence 24 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15865	KKKKRKREK	9	Sequence 25 from Patent US 20090258815	Drosophila sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15866	KKKRRSREK	9	Sequence 26 from Patent US 20090258815	Drosophila sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15867	KVTKRKHDNEGSGSKRPK	18	Sequence 27 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15868	KKKKKEEEGEGKKK	14	Sequence 28 from Patent US 20090258815	Rattus sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15869	PRPRKIPR	8	Sequence 29 from Patent US 20090258815	Borna disease virus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15870	PPRIYPQLPSAPT	13	Sequence 30 from Patent US 20090258815	Borna disease virus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15871	KDCVINKHHRNRCQYCRLQR	20	Sequence 31 from Patent US 20090258815	Mus musculus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15872	APKRKSGVSKC	11	Sequence 32 from Patent US 20090258815	Polyomavirus sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15873	MPKTRRRPRRSQRKRPPT	18	Sequence 35 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15874	KRPMNAFIVWSRDQRRK	17	Sequence 36 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15875	RPRRK	5	Sequence 37 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15876	KRPMNAFIVWAQAARRK	17	Sequence 38 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15877	PRRRK	5	Sequence 39 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15878	RKRR	4	Sequence 40 from Patent US 20090258815	Arabidopsis sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15879	PPRKKRTVV	9	Sequence 41 from Patent US 20090258815	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15880	YKRPCKRSFIRFI	13	Sequence 42 from Patent US 20090258815	epstein-barr virus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15881	LKDVRKRKLGPGH	13	Sequence 43 from Patent US 20090258815	epstein-barr virus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15882	KRPRP	5	Sequence 44 from Patent US 20090258815	adenovirus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15883	RKRKK	5	Sequence 45 from Patent US 20090258815	Saccharomyces cerevisiae	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15884	RRSMKRK	7	Sequence 46 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15885	PAKRARRGYK	10	Sequence 47 from Patent US 20090258815	canine parvovirus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15886	RKCLQAGMNLEARKTKK	17	Sequence 48 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15887	RRERNKMAAAKCRNRRR	17	Sequence 49 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15888	KRMRNRIAASKCRKRKL	17	Sequence 50 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15889	KKSKKGRQEALERLKKA	17	Sequence 51 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15890	RKEWLTNFMEDRRQRKL	17	Sequence 52 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15891	KKQTTLAFKPIKKGKKR	17	Sequence 53 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15892	RKRKKMPASQRSKRRKT	17	Sequence 54 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15893	RAIKRRPGLDFDDDGEGNSKFLR	23	Sequence 55 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15894	RIRKKLR	7	Sequence 56 from Patent US 20090258815	Mus musculus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15895	KRAAEDDEDDDVDTKKQK	18	Sequence 57 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15896	GRKRKKRT	8	Sequence 58 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15897	REKKEKEQKEKCA	13	Sequence 59 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15898	LEKKVKKKFDWCA	13	Sequence 60 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15899	RKRRTKK	7	Sequence 61 from Patent US 20090258815	Arabidopsis sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15900	SDKKVRSRLIECA	13	Sequence 62 from Patent US 20090258815	Thermoplasma acidophilum	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15901	LKRKLQR	7	Sequence 63 from Patent US 20090258815	avian neuroretina	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15902	RRKGKEK	7	Sequence 64 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15903	CKRKTTNADRRKA	13	Sequence 65 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15904	VNEAFETLKRC	11	Sequence 66 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15905	MPTEERVRKRKESNRESARRSRYRKAAHLK	30	Sequence 67 from Patent US 20090258815	Zea mays	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15906	KVNSRKRRKEVPGPNGATEED	21	Sequence 68 from Patent US 20090258815	Rattus sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15907	PRRGPR	6	Sequence 69 from Patent US 20090258815	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15908	PRGRRQPIPKARQP	14	Sequence 70 from Patent US 20090258815	Hepatitis C virus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15909	KRSAEGGNPPKPLKKLR	17	Sequence 71 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15910	EYLSRKGKLEL	11	Sequence 72 from Patent US 20090258815	Agrobacterium tumefaciens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15911	PKRPRDRHDGELGGRKRARG	20	Sequence 73 from Patent US 20090258815	Agrobacterium tumefaciens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15912	KRPAATKKAGQAKKKK	16	Sequence 74 from Patent US 20090258815	Xenopus sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15913	KRKKEMANKSAPEAKKKK	18	Sequence 75 from Patent US 20090258815	Gallus gallus	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15914	YNNQSSNFGPMKGGN	15	Sequence 76 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15915	PAAKRVKLD	9	Sequence 77 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15916	KRPAEDMEEEQAFKRSR	17	Sequence 78 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15917	MNKIPIKDLLNPG	13	Sequence 79 from Patent US 20090258815	Saccharomyces cerevisiae	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15918	PKKARED	7	Sequence 80 from Patent US 20090258815	Polyomavirus sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15919	VSRKRPR	7	Sequence 81 from Patent US 20090258815	Polyomavirus sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15920	APTKRKGS	8	Sequence 82 from Patent US 20090258815	Simian virus 40	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15921	PNKKKRK	7	Sequence 83 from Patent US 20090258815	Simian virus 40	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15922	EEDGPQKKKRRL	12	Sequence 84 from Patent US 20090258815	Polyomavirus sp.	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15923	PLLKKIKQ	8	Sequence 85 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15924	PPQKKIKS	8	Sequence 86 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15925	PQPKKKP	7	Sequence 87 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15926	SKRVAKRKL	9	Sequence 88 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15927	IKYFKKFPKD	10	Sequence 89 from Patent US 20090258815	Saccharomyces cerevisiae	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15928	KTRKHRG	7	Sequence 90 from Patent US 20090258815	Saccharomyces cerevisiae	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15929	KHRKHPG	7	Sequence 91 from Patent US 20090258815	Saccharomyces cerevisiae	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15930	PQSRKKLR	8	Sequence 92 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15931	KKEKKKSKK	9	Sequence 93 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15932	KRKKRRHR	8	Sequence 94 from Patent US 20090258815	Homo sapiens	Antimicrobial, Antiviral	US 2009/0258815 A1	Patent Application	2009##10##15	US8138146, WO2007099993A1	Antiviral peptide and antiviral agent.	Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES.
DRAMP15933	AQEVKNWMTETLLVA	15	Sequence 3 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15934	AQEVKXWMTXTLLVA	15	Sequence 4 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15935	AQAVKXWMTXTLLVA	15	Sequence 5 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15936	AQEVKXWMTXTLLVAKKK	18	Sequence 6 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15937	AQKVEXWMTXTLLVA	15	Sequence 7 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15938	AQAVKXWMTXTLLVENA	17	Sequence 8 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15939	AQAVKXWMTXTLLKANAE	18	Sequence 9 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15940	EQLVWXKMTXALAVT	15	Sequence 10 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15941	AQAVKNWMTXTLLXA	15	Sequence 12 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15942	AQAWKXWATXTLLVAE	16	Sequence 13 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15943	AQAVKXWMEXTLKVAE	16	Sequence 14 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15944	AQAVKXWMTETLXVA	15	Sequence 15 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15945	AQAWKXWATETLXVAN	16	Sequence 16 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15946	IAQAKVEXWMTXTLLVAN	18	Sequence 17 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15947	AQAVKNWMTETLLVA	15	Sequence 19 from Patent US 20090281041	Synthetic construct	Antimicrobial, Antiviral	US 2009/0281041 A1	Patent Application	2009##11##12	CA2725227A1, EP2283033A1, US8324153, US20130059776, WO2009137532A1	Antiviral cell-penetrating peptides.	Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.
DRAMP15948	SWETWEREIENYTRQIYRILEESQEQQDRNERDLLE	36	Sequence 1 from Patent US 20100021427	Homo sapiens	Antimicrobial, Antiviral	US 2010/0021427 A1	Patent Application	2010##1##28	Unknown	Use of Antiviral Peptides For Treatment of Infections Caused by Drug-Resistant HIV.	The present invention provides methods of treating drug-resistant HIV infections especially of HIV strains that are resistant to infusion inhibitors, such as T20.
DRAMP15949	RRKKAAVALLPAVLLALLA	19	Sequence 2 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15950	RRKKAAVALLPAVLLALL	18	Sequence 3 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15951	RRKKAAVALLPAVLLA	16	Sequence 5 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15952	RRKKAAVALLPAVLL	15	Sequence 6 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15953	RRKKAAVALLPAVL	14	Sequence 7 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15954	RRKKAAVALLPAV	13	Sequence 8 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15955	RRKKAAVALLPA	12	Sequence 9 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15956	RRKKAAVALL	10	Sequence 11 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15957	RRKKAAVAL	9	Sequence 12 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15958	RRKKAAV	7	Sequence 14 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15959	RRKKAA	6	Sequence 15 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15960	RRKKA	5	Sequence 16 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15961	RRKKAVALLPAVLLALLAP	19	Sequence 18 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15962	RRKKVALLPAVLLALLAP	18	Sequence 19 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15963	RRKKLLPAVLLALLAP	16	Sequence 21 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15964	RRKKLPAVLLALLAP	15	Sequence 22 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15965	RRKKVLLALLAP	12	Sequence 23 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15966	RRKKALLAP	9	Sequence 25 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15967	RRKKLAP	7	Sequence 27 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15968	RRKKAP	6	Sequence 28 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15969	RRKKP	5	Sequence 29 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15970	RRKKAALLVLAALAVLA	17	Sequence 30 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15971	RRKKAAVALLAVLLALLA	18	Sequence 43 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15972	RRKKLLAVLLALLA	14	Sequence 44 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15973	RRKKLAVLLALLA	13	Sequence 45 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15974	RRKKAAAAAAAAA	13	Sequence 49 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15975	RKKLAVLLALLA	12	Sequence 50 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15976	RKAVLLALLA	10	Sequence 51 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15977	KLAVLLALLA	10	Sequence 52 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15978	KKLAVLLALLA	11	Sequence 53 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15979	EEDDLAVLLALLA	13	Sequence 54 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15980	RRKKLAVAAALLA	13	Sequence 55 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15981	RRKKLAVLLAAAA	13	Sequence 56 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15982	EEDD	4	Sequence 61 from Patent US 20100041604	Synthetic construct	Antimicrobial, Antiviral	US 2010/0041604 A1	Patent Application	2010##2##18	CA2727898A1, EP2310030A2, US8129499, WO2009152519A2, WO2009152519A3	Antiviral peptides against influenza virus.	The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.
DRAMP15983	ITFEDLLDYYGP	12	Sequence 1 from Patent US 20100130430	Synthetic construct	Antimicrobial, Antiviral	US 2010/0130430 A1	Patent Application	2010##5##27	CA2665186A1, EP2073829A2, EP2073829A4, EP2073829B1, EP2517720A1, WO2008045238A2, WO2008045238A3	Stabilized therapeutic small helical antiviral peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus in a cell. Also provided are methods of treating a mammal infected with a capsid-containing virus. Further provided are methods of treating a mammal at risk for infection with a capsid-containing virus. Methods of making the above peptides are additionally provided, as are uses of the above peptides and pharmaceutical compositions.
DRAMP15984	ITFXDLLXYYGP	12	Sequence 6 from Patent US 20100130430	Synthetic construct	Antimicrobial, Antiviral	US 2010/0130430 A1	Patent Application	2010##5##27	CA2665186A1, EP2073829A2, EP2073829A4, EP2073829B1, EP2517720A1, WO2008045238A2, WO2008045238A3	Stabilized therapeutic small helical antiviral peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus in a cell. Also provided are methods of treating a mammal infected with a capsid-containing virus. Further provided are methods of treating a mammal at risk for infection with a capsid-containing virus. Methods of making the above peptides are additionally provided, as are uses of the above peptides and pharmaceutical compositions.
DRAMP15985	ITFXDLLXYYGPKKK	15	Sequence 7 from Patent US 20100130430	Synthetic construct	Antimicrobial, Antiviral	US 2010/0130430 A1	Patent Application	2010##5##27	CA2665186A1, EP2073829A2, EP2073829A4, EP2073829B1, EP2517720A1, WO2008045238A2, WO2008045238A3	Stabilized therapeutic small helical antiviral peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus in a cell. Also provided are methods of treating a mammal infected with a capsid-containing virus. Further provided are methods of treating a mammal at risk for infection with a capsid-containing virus. Methods of making the above peptides are additionally provided, as are uses of the above peptides and pharmaceutical compositions.
DRAMP15986	WNASWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF	64	Sequence 1 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15987	YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF	36	Sequence 2 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15988	MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL	36	Sequence 3 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15989	TTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAALREL	38	Sequence 5 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15990	TTWEAWDRAIAEYAARIEALIRALQEQQEKNEAALREL	38	Sequence 6 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15991	TTWEAWDRAIAEYAARIEALIRAAQEQQEKLEAALREL	38	Sequence 7 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15992	TTWEAWDRAIAEYAARIEALLRAAQEQQEKNEAALREL	38	Sequence 8 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15993	TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALREL	38	Sequence 9 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15994	TTWEAWDRAIAEYAARIEALLRAAQEQQEKLEAALREL	38	Sequence 10 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15995	TTWEAWDRAIAEYAARIEALIRALQEQQEKLEAALREL	38	Sequence 11 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15996	TTWEAWDRAIAEYAARIEALIRAIQEQQEKLEAALREL	38	Sequence 12 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15997	TTWEAWDRAIAEYAARIEALIRALQEQQEKIEAALREL	38	Sequence 13 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15998	TTWEAWDRAIAEYAARIEALLRAIQEQQEKNEAALREL	38	Sequence 14 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP15999	TTWEAWDRAIAEYAARIEALLRAAQEQQEKIEAALREL	38	Sequence 15 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16000	TTWEAWDRAIAE	12	Sequence 17 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16001	YAARIEALLRALQE	14	Sequence 18 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16002	QQEKNEAALRE	11	Sequence 19 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16003	QQEKNEAALREL	12	Sequence 20 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16004	TTWEAWDRAIA	11	Sequence 21 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16005	EYAARIEALLRALQE	15	Sequence 22 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16006	TTWEAWDRAI	10	Sequence 23 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16007	AEYAARIEALLRALQE	16	Sequence 24 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16008	TTWEAWDRA	9	Sequence 25 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16009	IAEYAARIEALLRALQE	17	Sequence 26 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16010	TTWEAWDR	8	Sequence 27 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16011	AIAEYAARIEALLRALQE	18	Sequence 28 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16012	TTWEAWDRAIAEYAARIEAL	20	Sequence 29 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16013	LRALQEQQEKNEAALRE	17	Sequence 30 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16014	LRALQEQQEKNEAALREL	18	Sequence 31 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16015	TTWEAWDRAIAEYAARIE	18	Sequence 32 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16016	ALLRALQEQQEKNEAALRE	19	Sequence 33 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16017	ALLRALQEQQEKNEAALREL	20	Sequence 34 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16018	YAARIEALLRALQEQQEKNEAALREL	26	Sequence 35 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16019	EYAARIEALLRALQEQQEKNEAALREL	27	Sequence 36 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16020	AEYAARIEALLRALQEQQEKNEAALREL	28	Sequence 37 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16021	IAEYAARIEALLRALQEQQEKNEAALREL	29	Sequence 38 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16022	AIAEYAARIEALLRALQEQQEKNEAALREL	30	Sequence 39 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16023	TTWEAWDRAIAEYAARIEALLRALQE	26	Sequence 40 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16024	YAARIEALLRAAQE	14	Sequence 41 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16025	QQEKLEAALRE	11	Sequence 42 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16026	QQEKLEAALREL	12	Sequence 43 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16027	EYAARIEALLRAAQE	15	Sequence 44 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16028	AEYAARIEALLRAAQE	16	Sequence 45 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16029	IAEYAARIEALLRAAQE	17	Sequence 46 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16030	AIAEYAARIEALLRAAQE	18	Sequence 47 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16031	LRAAQEQQEKLEAALRE	17	Sequence 48 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16032	LRAALQEQQEKLEAALREL	19	Sequence 49 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16033	ALLRAAQEQQEKLEAALRE	19	Sequence 50 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16034	ALLRAAQEQQEKLEAALREL	20	Sequence 51 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16035	YAARIEALLRAAQEQQEKLEAALREL	26	Sequence 52 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16036	EYAARIEALLRAAQEQQEKLEAALREL	27	Sequence 53 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16037	AEYAARIEALLRAAQEQQEKLEAALREL	28	Sequence 54 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16038	IAEYAARIEALLRAAQEQQEKLEAALREL	29	Sequence 55 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16039	AIAEYAARIEALLRAAQEQQEKLEAALREL	30	Sequence 56 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2009##3##12	CA2682848A1, CN101678125A, EP2139526A1, EP2139526A4, WO2008124013A1	Novel formulations for delivery of antiviral peptide therapeutics.	Unknown
DRAMP16040	TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALRE	37	Sequence 57 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16041	AARIEALLRALQEQQEKNEAALRE	24	Sequence 58 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16042	RIEALLRALQEQQEKNEAALRE	22	Sequence 59 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16043	QEQQEKNEAALREL	14	Sequence 60 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16044	LQEQQEKNEAALREL	15	Sequence 61 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16045	EQQEKNEAALREL	13	Sequence 62 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16046	TTWEAWDRAIAEYAARIEALLRALQ	25	Sequence 63 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16047	TTWEAWDRAIAEYAARIEALLRAL	24	Sequence 64 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16048	TTWEAWDRAIAEYAARIEALLR	22	Sequence 65 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16049	TTWEAWDRAIAEYAARIEALL	21	Sequence 66 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16050	TTWEAWDRAIAEYAARIEA	19	Sequence 67 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16051	TTWEAWDRAIAEYAARI	17	Sequence 68 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16052	TTWEAWDRAIAEYAAR	16	Sequence 69 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16053	TTWEAWDRAIAEYAA	15	Sequence 70 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16054	TTWEAWDRAIAEYA	14	Sequence 71 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16055	TTWEAWDRAIAEY	13	Sequence 72 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16056	EL	2	Sequence 73 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16057	AARIEALLRALQE	13	Sequence 74 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16058	ARIEALLRALQE	12	Sequence 75 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16059	RIEALLRALQE	11	Sequence 76 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16060	EALLRALQE	9	Sequence 77 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16061	WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF	39	Sequence 78 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16062	YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNIT	39	Sequence 79 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16063	YQEWERKVDFLEENITALLEEAQIQQEKNMYELQKL	36	Sequence 80 from Patent US 20100261876	Synthetic construct	Antimicrobial, Antiviral	US 2010/0261876 A1	Patent Application	2010##10##14	CA2700354A1, CN101874038A, EP2201028A2, WO2009042194A2, WO2009042194A3	Novel methods of synthesis for therapeutic antiviral peptides.	Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
DRAMP16064	CNDFRSKTC	9	Sequence 1 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16065	NDFRSKT	7	Sequence 2 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16066	QHSTKWF	7	Sequence 3 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16067	LPYAAKH	7	Sequence 4 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16068	ILGDKVG	7	Sequence 5 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16069	LPYGSKH	7	Sequence 6 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16070	ILGYKVG	7	Sequence 7 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16071	HPQFLSL	7	Sequence 8 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16072	GLYNHPQ	7	Sequence 9 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16073	CSWGEYDMC	9	Sequence 10 from Patent US 20110135676	Synthetic construct	Antimicrobial, Antiviral	US 2011/0135676 A1	Patent Application	2011##6##9	EP2300492A1, EP2300492A4, WO2009151313A1	Novel antiviral peptide against avian influenza virus h9n2.	The present invention relates to recombinant phages carrying fusion peptides that bind to avian influenza virus (AIV). Such phages are useful as diagnostic reagents to replace anti-AIV antibodies because the phages are capable of competing with the latter antibodies for binding sites on the virus. Synthetic peptides with the sequence CNDFRSKTC, either in linear or cyclic conformations, or fusion phages bearing the above said peptides inhibited AIV propagation in embryonated egg as well as in MDCK cell lines. Therefore they may be used as'therapeutic agents to control, to treat and to eradicate bird flu caused by avian influenza virus.
DRAMP16074	ITEXDLLXYYGKKK	14	Sequence 7 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16075	ISFXELLDYYXESGS	15	Sequence 8 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16076	ITFEDLLXYYGXKK	14	Sequence 9 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16077	AQAVKXWMTXTLLVAKKK	18	Sequence 10 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16078	ISFXELLXYYGR	12	Sequence 11 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16079	ITFXDILXYYGEK	13	Sequence 12 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16080	ISFXELLXYYGEK	13	Sequence 13 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16081	ITFXDWLXYYGR	12	Sequence 14 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16082	ISFXEWLQYYXR	12	Sequence 15 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16083	ISFXELLXYYGRSGS	15	Sequence 16 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16084	ISFXELLXYYGESGS	15	Sequence 17 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16085	ISFXEILXYYGESGS	15	Sequence 18 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16086	ISFDELLDYYGESGS	15	Sequence 19 from Patent US 20120165249	Synthetic construct	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16087	IXFEXXLXYY	10	Sequence 21 from Patent US 20120165249	Human immunodeficiency vi	Antimicrobial, Antiviral	US 2012/0165249 A1	Patent Application	2012##6##28	Unknown	Stabilized Therapeutic Small Helical Antiviral Peptides.	Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.
DRAMP16088	XPXEXXXTVTTQNXAXQTMS	20	Sequence 1 from Patent US 20120289459	Synthetic construct	Antimicrobial, Antiviral	US 2012/0289459 A1	Patent Application	2012##11##15	CA2703368A1, CN101835795A, EP2203468A1, EP2203468B1, EP2203468B8, WO2009053340A1	Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8.	New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
DRAMP16089	PAEPYTTVTTQNTASQTMS	19	Sequence 2 from Patent US 20120289459	Synthetic construct	Antimicrobial, Antiviral	US 2012/0289459 A1	Patent Application	2012##11##15	CA2703368A1, CN101835795A, EP2203468A1, EP2203468B1, EP2203468B8, WO2009053340A1	Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8.	New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
DRAMP16090	RRRRRRRRPAEPYTTVTTQNTASQTMS	27	Sequence 3 from Patent US 20120289459	Synthetic construct	Antimicrobial, Antiviral	US 2012/0289459 A1	Patent Application	2012##11##15	CA2703368A1, CN101835795A, EP2203468A1, EP2203468B1, EP2203468B8, WO2009053340A1	Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8.	New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
DRAMP16091	SLVSSDESSSGSSHSSGEHS	20	Sequence 4 from Patent US 20120289459	Synthetic construct	Antimicrobial, Antiviral	US 2012/0289459 A1	Patent Application	2012##11##15	CA2703368A1, CN101835795A, EP2203468A1, EP2203468B1, EP2203468B8, WO2009053340A1	Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8.	New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
DRAMP16092	RRRRRRRRSLVSSDESSSGSSHSSGEHS	28	Sequence 5 from Patent US 20120289459	Synthetic construct	Antimicrobial, Antiviral	US 2012/0289459 A1	Patent Application	2012##11##15	CA2703368A1, CN101835795A, EP2203468A1, EP2203468B1, EP2203468B8, WO2009053340A1	Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8.	New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
DRAMP16093	RRRRRRRRHPAEPGSTVTTQNTASQTMS	28	Sequence 6 from Patent US 20120289459	Synthetic construct	Antimicrobial, Antiviral	US 2012/0289459 A1	Patent Application	2012##11##15	CA2703368A1, CN101835795A, EP2203468A1, EP2203468B1, EP2203468B8, WO2009053340A1	Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8.	New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
DRAMP16094	RRRRRRRRHPTESGSTVTTQNSAAQTMS	28	Sequence 8 from Patent US 20120289459	Synthetic construct	Antimicrobial, Antiviral	US 2012/0289459 A1	Patent Application	2012##11##15	CA2703368A1, CN101835795A, EP2203468A1, EP2203468B1, EP2203468B8, WO2009053340A1	Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8.	New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
DRAMP16095	YTTTVTTQNTASQT	14	Sequence 13 from Patent US 20120289459	African swine fever virus	Antimicrobial, Antiviral	US 2012/0289459 A1	Patent Application	2012##11##15	CA2703368A1, CN101835795A, EP2203468A1, EP2203468B1, EP2203468B8, WO2009053340A1	Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8.	New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
DRAMP16096	XAXQT	5	Sequence 14 from Patent US 20120289459	Synthetic construct	Antimicrobial, Antiviral	US 2012/0289459 A1	Patent Application	2012##11##15	CA2703368A1, CN101835795A, EP2203468A1, EP2203468B1, EP2203468B8, WO2009053340A1	Antiviral peptides from african swine fever virus which prevent the binding of the virus to dlc8.	New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
DRAMP16097	FAGIAIGIAALGVATAAQVT	20	Sequence 1 from Patent US 4626524	Synthetic construct	Antimicrobial, Antiviral	US 4626524 A	Granted Patent	1986##12##2	EP0191854A1, EP0191854A4, WO1986001408A1	Antiviral peptides.	The present invention provides peptides of a sequence which is similar or identical to the amino terminal sequence of the F.sub.1 chain of mumps virus. A variety of peptides are disclosed ranging from oligopeptides to dodecapeptides.
DRAMP16098	FAGIAIGIAALGVATAAQVTAAV	23	Sequence 2 from Patent US 4626524	Synthetic construct	Antimicrobial, Antiviral	US 4626524 A	Granted Patent	1986##12##2	EP0191854A1, EP0191854A4, WO1986001408A1	Antiviral peptides.	The present invention provides peptides of a sequence which is similar or identical to the amino terminal sequence of the F.sub.1 chain of mumps virus. A variety of peptides are disclosed ranging from oligopeptides to dodecapeptides.
DRAMP16099	VNINILQQIGYIKQQVRQLSYYS	23	Sequence 3 from Patent US 4626524	Synthetic construct	Antimicrobial, Antiviral	US 4626524 A	Granted Patent	1986##12##2	EP0191854A1, EP0191854A4, WO1986001408A1	Antiviral peptides.	The present invention provides peptides of a sequence which is similar or identical to the amino terminal sequence of the F.sub.1 chain of mumps virus. A variety of peptides are disclosed ranging from oligopeptides to dodecapeptides.
DRAMP16100	ECRSTSYAGAVVNDL	15	Sequence 1 from Patent US 4795740	Synthetic construct	Antimicrobial, Antiviral	US 4795740 A	Granted Patent	1989##1##3	Unknown	Antiviral peptides and means for treating herpes infections.	Disclosed herein are antiviral peptides of the formula A-R.sup.8 -R.sup.9 -R.sup.10 -R.sup.11 -R.sup.12 -R.sup.13 -R.sup.14 -R.sup.15 -B wherein A is from zero up to seven amino acid residues and includes a terminal hydrogen or a terminal N-acyl, or A is a phenylacetyl with optional substitution of the para position of the phenyl, R.sup.8, R.sup.9, R.sup.10, R.sup.13, R.sup.14 and R.sup.15 are various amino acid residues with the stipulation that one or more of the four amino acid residues immediately preceding R.sup.11 may optionally be deleted, R.sup.11 and R.sup.12 are independently Val, D-Val, Nva, D-Nva, Leu, D-Leu, Nle, D-Nle, Ile or D-Ile, and B is hydroxy, amino or lower alkylamino. The antiviral activity of the peptides can be enhanced by combining them with a protease inhibitor. The peptides and the combination are useful for the treatment of herpes viral infections in mammals.
DRAMP16101	STSYAGAVVNDL	12	Sequence 2 from Patent US 4795740	Synthetic construct	Antimicrobial, Antiviral	US 4795740 A	Granted Patent	1989##1##3	Unknown	Antiviral peptides and means for treating herpes infections.	Disclosed herein are antiviral peptides of the formula A-R.sup.8 -R.sup.9 -R.sup.10 -R.sup.11 -R.sup.12 -R.sup.13 -R.sup.14 -R.sup.15 -B wherein A is from zero up to seven amino acid residues and includes a terminal hydrogen or a terminal N-acyl, or A is a phenylacetyl with optional substitution of the para position of the phenyl, R.sup.8, R.sup.9, R.sup.10, R.sup.13, R.sup.14 and R.sup.15 are various amino acid residues with the stipulation that one or more of the four amino acid residues immediately preceding R.sup.11 may optionally be deleted, R.sup.11 and R.sup.12 are independently Val, D-Val, Nva, D-Nva, Leu, D-Leu, Nle, D-Nle, Ile or D-Ile, and B is hydroxy, amino or lower alkylamino. The antiviral activity of the peptides can be enhanced by combining them with a protease inhibitor. The peptides and the combination are useful for the treatment of herpes viral infections in mammals.
DRAMP16102	RRWWCRX	7	Sequence 1 from Patent US 5441936	Synthetic construct	Antimicrobial, Antiviral	US 5441936 A	Granted Patent	1995##8##15	WO1995015766A1	Antiviral peptides.	The present invention provides antiviral peptides having the general structure, Arg-Arg-Trp-Trp-Cys-Arg-X, where X is an amino acid or an amino acid analog, the stereochemistry of the amino acids or amino acid analogs can be (D)- or (L)-amino acids and the amino and carboxy termini of the peptide can be modified. The invention also provides a pharmaceutical composition comprising an antiviral peptide and methods of using an antiviral peptide in vitro or in vivo to reduce or inhibit a herpes simplex virus infection.
DRAMP16103	TKPKTKPK	8	Sequence 1 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16104	TKPKTKPR	8	Sequence 2 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16105	AKTKPRQQ	8	Sequence 3 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16106	ASTTTNYT	8	Sequence 4 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16108	DWLKAFYDKVAEKLKEAF	18	Sequence 6 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16109	KWLDAFYKDVAKELEKAF	18	Sequence 7 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16110	IKILGNQGSTLTKGPYSK	18	Sequence 8 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16111	LKIEDSDTYICEVEDQKEE	19	Sequence 9 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16112	TYICEVEDQKEE	12	Sequence 10 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16113	XPXLX	5	Sequence 11 from Patent US 5447915	Synthetic construct	Antimicrobial, Antiviral	US 5447915 A	Granted Patent	1995##9##5	CA2077088A1, EP0517792A1, US5115098, WO1991013088A1	Terminally blocked antiviral peptides.	This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
DRAMP16114	CATCEQIADSQHRSHRQMV	19	Sequence 1 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16115	CATCEQIADSQHRSHRQM	18	Sequence 3 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16116	CATCEQIADSQHRSHRQ	17	Sequence 4 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16117	CATCEQIADSQHRSHR	16	Sequence 5 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16118	CATCEQIADSQHRSH	15	Sequence 6 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16119	CATCQIADSQHRSHRQMV	18	Sequence 7 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16120	CATCIADSQHRSHRQMV	17	Sequence 8 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16121	CATCADSQHRSHRQMV	16	Sequence 9 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16122	CTCEQIADSQHRSHRQMV	18	Sequence 10 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16123	CACEQIADSQHRSHRQMV	18	Sequence 11 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16124	CATCEQIADSQHRHRQMV	18	Sequence 12 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16125	CAACEQIADSQHRSHRQMV	19	Sequence 16 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16126	CATCAQIADSQHRSHRQMV	19	Sequence 17 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16127	CATCEAIADSQHRSHRQMV	19	Sequence 18 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16128	CATCEQAADSQHRSHRQMV	19	Sequence 19 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16129	CATCEQIAASQHRSHRQMV	19	Sequence 20 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16130	CATCEQIADAQHRSHRQMV	19	Sequence 21 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16131	CATCEQIADSAHRSHRQMV	19	Sequence 22 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16132	CATCEQIADSQHASHRQMV	19	Sequence 23 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16133	CATCEQIADSQHRAHRQMV	19	Sequence 24 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16134	CATCEQIADSQHRSHAQMV	19	Sequence 25 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16135	CATCEQIADSQHRSHRAMV	19	Sequence 26 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16136	CATCEQIADSQHRSHRQAV	19	Sequence 27 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16137	CATCEQIADSQHRSHRQMA	19	Sequence 28 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16138	CATCEQIADSQHKSHRQMV	19	Sequence 29 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16139	CATCEQIADSQHRSHKQMV	19	Sequence 30 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16140	CATCEQIADSQHKSHKQMV	19	Sequence 31 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16141	CASCEQIADSQHRSHRQMV	19	Sequence 32 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16142	CATCDQIADSQHRSHRQMV	19	Sequence 33 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16143	CATCENIADSQHRSHRQMV	19	Sequence 34 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16144	CATCEQLADSQHRSHRQMV	19	Sequence 35 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16145	CATCEQVADSQHRSHRQMV	19	Sequence 36 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16146	CATCEQIAESQHRSHRQMV	19	Sequence 37 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16147	CATCEQIADTQHRSHRQMV	19	Sequence 38 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16148	CATCEQIADSNHRSHRQMV	19	Sequence 39 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16149	CATCEQIADSQHRTHRQMV	19	Sequence 40 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16150	CATCEQIADSQHRSHRNMV	19	Sequence 41 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16151	CATCEQIADSQHRSHRQML	19	Sequence 42 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16152	CATCEQIADSQHRSHRQMI	19	Sequence 43 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16153	CXTCEQIADSQHRSHRQMV	19	Sequence 44 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16154	CATCEQIADSQHXSHRQMV	19	Sequence 45 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16155	CATCEQIADSQHRSHXQMV	19	Sequence 46 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16156	CXTCEQIADSQHXSHRQMV	19	Sequence 47 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16157	CXTCEQIADSQHXSHXQMV	19	Sequence 48 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16158	LTVPSERGLQRRR	13	Sequence 54 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16159	ALNGNGDPNNMDKAVKLY	18	Sequence 55 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16160	KREITFHGAKEISLS	15	Sequence 56 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16161	EQIADSQHRSHRQMV	15	Sequence 57 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16162	GTHPSSSAGLKNDLLEN	17	Sequence 58 from Patent US 5616327	Synthetic construct	Antimicrobial, Antiviral	US 5616327 A	Granted Patent	1997##4##1	CA2108263A1, DE69223406D1, DE69223406T2, EP0590055A1, EP0590055B1, WO1992022575A1	M-protein peptides of influenza virus as antiviral agents.	Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
DRAMP16163	APGDEPAPPY	10	Sequence 3 from Patent US 5859187	Synthetic construct	Antimicrobial, Antiviral	US 5859187 A	Granted Patent	1999##1##12	CA2011884A1, DE4010593A1, US5120639	Antiviral peptides.	Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents.
DRAMP16164	APGDEPAPP	9	Sequence 4 from Patent US 5859187	Synthetic construct	Antimicrobial, Antiviral	US 5859187 A	Granted Patent	1999##1##12	CA2011884A1, DE4010593A1, US5120639	Antiviral peptides.	Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents.
DRAMP16165	AAPGDEPAPP	10	Sequence 5 from Patent US 5859187	Synthetic construct	Antimicrobial, Antiviral	US 5859187 A	Granted Patent	1999##1##12	CA2011884A1, DE4010593A1, US5120639	Antiviral peptides.	Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents.
DRAMP16166	AAAPGDEPAPP	11	Sequence 6 from Patent US 5859187	Synthetic construct	Antimicrobial, Antiviral	US 5859187 A	Granted Patent	1999##1##12	CA2011884A1, DE4010593A1, US5120639	Antiviral peptides.	Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents.
DRAMP16167	AGATAEETAY	10	Sequence 7 from Patent US 5859187	Synthetic construct	Antimicrobial, Antiviral	US 5859187 A	Granted Patent	1999##1##12	CA2011884A1, DE4010593A1, US5120639	Antiviral peptides.	Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents.
DRAMP16168	AGATAEETAA	10	Sequence 8 from Patent US 5859187	Synthetic construct	Antimicrobial, Antiviral	US 5859187 A	Granted Patent	1999##1##12	CA2011884A1, DE4010593A1, US5120639	Antiviral peptides.	Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents.
DRAMP16169	GATAEETA	8	Sequence 9 from Patent US 5859187	Synthetic construct	Antimicrobial, Antiviral	US 5859187 A	Granted Patent	1999##1##12	CA2011884A1, DE4010593A1, US5120639	Antiviral peptides.	Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents.
DRAMP16170	AGATAEETA	9	Sequence 10 from Patent US 5859187	Synthetic construct	Antimicrobial, Antiviral	US 5859187 A	Granted Patent	1999##1##12	CA2011884A1, DE4010593A1, US5120639	Antiviral peptides.	Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents.
DRAMP16171	EETRRMLHRAFDTLA	15	Sequence 11 from Patent US 5859187	Synthetic construct	Antimicrobial, Antiviral	US 5859187 A	Granted Patent	1999##1##12	CA2011884A1, DE4010593A1, US5120639	Antiviral peptides.	Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas EQU W'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1! and EQU Y'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2! that are useful as antiviral agents.
DRAMP16172	SSESFTLLEQWNNWKLQLAEQWLEQINEKHYLEDIS	36	Sequence 2 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16173	YTNTIYTLLEESQNQQEKNEQELLELDKWASLWNWF	36	Sequence 3 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16174	YTGIIYNLLEESQNQQEKNEQELLELDKWANLWNWF	36	Sequence 4 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16175	YTSLIYSLLEKSQTQQEKNEQELLELDKWASLWNWF	36	Sequence 5 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16176	LEANISKSLEQAQIQQEKNMYELQKLNSWDIFGNWF	36	Sequence 6 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16177	LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL	36	Sequence 7 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16178	CGGNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ	41	Sequence 8 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16179	LQARILAVERYLKDQQQ	17	Sequence 9 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16180	QQLLDVVKRQQEMLRLTVWGTKNLQARVTAIEKYLKDQ	38	Sequence 10 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16181	YTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST	48	Sequence 16 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16182	FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL	37	Sequence 17 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16183	ITLNNSVALDPIDISIELNKAKSDLEESKEWIRRS	35	Sequence 18 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16184	ALGVATSAQITAAVALVEAKQARSDIEKLKEAIR	34	Sequence 19 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16185	VAVSKVLHLEGEVNKIALLSTNKAVVSLSNGVS	33	Sequence 20 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16186	AVSKVLHLEGEVNKIALLSTNKAVVSLSNGVSV	33	Sequence 21 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16187	VSKVLHLEGEVNKIALLSTNKAVVSLSNGVSVL	33	Sequence 22 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16188	SKVLHLEGEVNKIALLSTNKAVVSLSNGVSVLT	33	Sequence 23 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16189	KVLHLEGEVNKIALLSTNKAVVSLSNGVSVLTS	33	Sequence 24 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16190	LEGEVNKIALLSTNKAVVSLSNGVSVLTSKVLD	33	Sequence 25 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16191	GEVNKIALLSTNKAVVSLSNGVSVLTSKVLDLK	33	Sequence 26 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16192	EVNKIALLSTNKAVVSLSNGVSVLTSKVLDLKN	33	Sequence 27 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16193	VNKIALLSTNKAVVSLSNGVSVLTSKVLDLKNY	33	Sequence 28 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16194	NKIALLSTNKAVVSLSNGVSVLTSKVLDLKNYI	33	Sequence 29 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16195	KIALLSTNKAVVSLSNGVSVLTSKVLDLKNYID	33	Sequence 30 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16196	IALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDK	33	Sequence 31 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16197	ALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQ	33	Sequence 32 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16198	TLNNSVALDPIDISIELNKAKSDLEESKEWIRRSN	35	Sequence 33 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16199	LNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQ	35	Sequence 34 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16200	NNSVALDPIDISIELNKAKSDLEESKEWIRRSNQK	35	Sequence 35 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16201	NSVALDPIDISIELNKAKSDLEESKEWIRRSNQKL	35	Sequence 36 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16202	SVALDPIDISIELNKAKSDLEESKEWIRRSNQKLD	35	Sequence 37 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16203	VALDPIDISIELNKAKSDLEESKEWIRRSNQKLDS	35	Sequence 38 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16204	ALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSI	35	Sequence 39 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16205	LDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIG	35	Sequence 40 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16206	DPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGN	35	Sequence 41 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16207	PIDISIELNKAKSDLEESKEWIRRSNQKLDSIGNW	35	Sequence 42 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16208	IDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWH	35	Sequence 43 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16209	DISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQ	35	Sequence 44 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16210	ISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQS	35	Sequence 45 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16211	SIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSS	35	Sequence 46 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16212	IELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSST	35	Sequence 47 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16213	ELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT	35	Sequence 48 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16214	TAAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQS	35	Sequence 49 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16215	AVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSI	35	Sequence 50 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16216	LVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNL	35	Sequence 51 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16217	VEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLI	35	Sequence 52 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16218	EAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIV	35	Sequence 53 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16219	AKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVA	35	Sequence 54 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16220	KQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAI	35	Sequence 55 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16221	QARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIK	35	Sequence 56 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16222	ARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKS	35	Sequence 57 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16223	RSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSV	35	Sequence 58 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16224	SDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQ	35	Sequence 59 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16225	KLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVN	35	Sequence 60 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16226	LKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNK	35	Sequence 61 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16227	AIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEIV	35	Sequence 62 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16228	WQEWERKVDFLEENITALLEEAQIQQEKNMYELQK	35	Sequence 63 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16229	QEWERKVDFLEENITALLEEAQIQQEKNMYELQKL	35	Sequence 64 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16230	EWERKVDFLEENITALLEEAQIQQEKNMYELQKLN	35	Sequence 65 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16231	WERKVDFLEENITALLEEAQIQQEKNMYELQKLNS	35	Sequence 66 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16232	ERKVDFLEENITALLEEAQIQQEKNMYELQKLNSW	35	Sequence 67 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16233	RKVDFLEENITALLEEAQIQQEKNMYELQKLNSWD	35	Sequence 68 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16234	KVDFLEENITALLEEAQIQQEKNMYELQKLNSWDV	35	Sequence 69 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16235	VDFLEENITALLEEAQIQQEKNMYELQKLNSWDVF	35	Sequence 70 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16236	DFLEENITALLEEAQIQQEKNMYELQKLNSWDVFG	35	Sequence 71 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16237	FLEENITALLEEAQIQQEKNMYELQKLNSWDVFGN	35	Sequence 72 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16238	LHRIDLGPPISLERLDVGTNLGNAIAKLEAKELL	34	Sequence 73 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16239	HRIDLGPPISLERLDVGTNLGNAIAKLEAKELLE	34	Sequence 74 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16240	RIDLGPPISLERLDVGTNLGNAIAKLEAKELLES	34	Sequence 75 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16241	IDLGPPISLERLDVGTNLGNAIAKLEAKELLESS	34	Sequence 76 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16242	DLGPPISLERLDVGTNLGNAIAKLEAKELLESSD	34	Sequence 77 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16243	LGPPISLERLDVGTNLGNAIAKLEAKELLESSDQ	34	Sequence 78 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16244	GPPISLERLDVGTNLGNAIAKLEAKELLESSDQI	34	Sequence 79 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16245	PPISLERLDVGTNLGNAIAKLEAKELLESSDQIL	34	Sequence 80 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16246	PISLERLDVGTNLGNAIAKLEAKELLESSDQILR	34	Sequence 81 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16247	SLERLDVGTNLGNAIAKLEAKELLESSDQILRSM	34	Sequence 82 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16248	LERLDVGTNLGNAIAKLEAKELLESSDQILRSMK	34	Sequence 83 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16249	MKQLEDKVEELLSKNYHLENEVARLKKL	28	Sequence 84 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16250	TDTLQAETDQLEDEKSALQTEIANLLKE	28	Sequence 85 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16251	IARLEEKVKTLKAQNSELASTANMLREQ	28	Sequence 86 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16252	EQKLISEEDLLEKRREQLKHKLEQLRNS	28	Sequence 87 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16253	IEKTNEKFHQIEKEFSEVEGRIQDLEKY	28	Sequence 88 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16254	YTSVITIELSNIKENKCNGAKVKLIKQELDKYKNAVTELQLLMQST	46	Sequence 97 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16255	ASGVAVSKVLHLEGEVNKIALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLL	54	Sequence 98 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16256	GEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTT	53	Sequence 99 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16257	GTIALGVATSAQITAAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEIVP	70	Sequence 100 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16258	YTPNDITLNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT	56	Sequence 101 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16259	PDAVYLHRIDLGPPISLERLDVGTNLGNAIAKLED	35	Sequence 118 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16260	TWQEWERKVDFLEENITALLEEAQIQQEKNMYELQKLNSWDVFGNWF	47	Sequence 120 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16261	IELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQST	42	Sequence 121 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16262	VSKGYSALRTGWYTSVITIELSNIKEN	27	Sequence 122 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16263	AFIRKSDELLHNV	13	Sequence 123 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16264	YTSVITIELSNIKENKXNGTDAKVKLIKQELDKYK	35	Sequence 124 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16265	TSVITIELSNIKENKXNGTDAKVKLIKQELDKYKN	35	Sequence 125 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16266	SVITIELSNIKENKXNGTDAKVKLIKQELDKYKNA	35	Sequence 126 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16267	SNIKENKXNGTDAKVKLIKQELDKYKNAVTELQLL	35	Sequence 127 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16268	KENKXNGTDAKVKLIKQELDKYKNAVTELQLLMQS	35	Sequence 128 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16269	AVSKGYLSALRTGWYTSVITIELSNIKENKXNGTDA	36	Sequence 129 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16270	VVSLSNGVSVLTSKVLDLKNYIDKQLL	27	Sequence 130 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16271	LLSTNKAVVSLSNGVSVLTSKVLDLKNY	28	Sequence 131 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16272	VLHLEGEVNKIKSALLSTNKAVVSLSNG	28	Sequence 132 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16273	ASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGV	37	Sequence 134 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16274	VLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSK	35	Sequence 135 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16275	NDQKKLMSNNVQIVRQQSYSIMSIIKEE	28	Sequence 136 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16276	SISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVS	36	Sequence 137 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16277	PIINFYDPLVFPSDEFDASISQVNEKINQSLAFIR	35	Sequence 138 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16278	RMKQLEDKVEELLSKLAFIRKSDELLHNV	29	Sequence 139 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16279	AFIRKSDELLHNVNAGKST	19	Sequence 140 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16280	FDASISQVNEKINQSLAFI	19	Sequence 141 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16281	SLAFIRKSDELLHNVNAGKST	21	Sequence 142 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16282	FDASISQVNEKINQSLAFIRKSDELLHNVNAGK	33	Sequence 143 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16283	ASISQVNEKINQSLAFIRKSDELLHNVNAGKST	33	Sequence 144 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16284	FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST	35	Sequence 145 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16285	ATSAQITAAVALVEAKQARSDIEKLKEA	28	Sequence 146 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16286	AAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSS	35	Sequence 147 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16287	IRDTNKAVQSVQSSIGNLIVAIKSVQDY	28	Sequence 149 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16288	AVQSVQSSIGNLIVAIKSVQDYVNKEIV	28	Sequence 150 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16289	LKEAIRDTNKAVQSVQSSIGNLIVAIKS	28	Sequence 151 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16290	EWIRRSNQKLDSI	13	Sequence 152 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16291	IDISIELNKAKSDLEESKEWIKKSNQKLDSIGNWH	35	Sequence 153 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16292	RMKQLEDKVEELLSKLEWIRRSNQKLDSI	29	Sequence 154 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16293	DQQIKQYKRLLDRLIIPLYDGLRQKDVIVSNQESN	35	Sequence 155 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16294	YSELTNIFGDNIGSLQEKGIKLQGIASLYRTNITEI	36	Sequence 156 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16295	TSITLQVRLPLLTRLLNTQIYRVDSISYNIQNREWY	36	Sequence 157 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16296	NKSLEQIWNNMTWMEWDREINNYTSLIHSLIEEQNQQEKNEQELLELDKWASLWNWF	57	Sequence 158 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16297	WMEWDREINNYTSLIGSLIEESQNQQEKNEQELLE	35	Sequence 159 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16298	YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWLIKIFI	49	Sequence 160 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16299	EAAAREAAAREAAARLELDKWASLWNWF	28	Sequence 161 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16300	RMKQLEDKVEELLSKLELDKWASLWNWF	28	Sequence 162 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16301	FWNWLSAWKDLELKSLLEEVKDELQKMR	28	Sequence 163 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16302	RMKQLEDKVEELLSKNYHLENELELDKWASLWNWF	35	Sequence 164 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16303	FWNWLSAWKDLELYPGSLELDKWASLWNWF	30	Sequence 165 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16304	CLELDKWASLWNWFC	15	Sequence 166 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16305	CLELDKWASLANWFC	15	Sequence 167 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16306	CLELDKWASLWNFFC	15	Sequence 168 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16307	LELDKWASLANAF	13	Sequence 169 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16308	LELDKWASLFNFF	13	Sequence 170 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16309	LELDKWASLWNAF	13	Sequence 171 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16310	LELDKWASLWNWA	13	Sequence 172 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16311	LELDKWASAWNWF	13	Sequence 173 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16312	LELDKAASLWNWF	13	Sequence 174 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16313	LKLDKWASLWNWF	13	Sequence 175 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16314	LELKKWASLWNWF	13	Sequence 176 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16315	CGGYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF	39	Sequence 177 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16316	YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNAF	36	Sequence 178 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16317	YTSLIHSLIEESQNQQEKNEQELLELDKWASLANWF	36	Sequence 179 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16318	YTSLIHSLIEESQNQQEKNEQQLLELDKWASLWNWF	36	Sequence 180 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16319	YTSLIHSLIEESQNQQEKNEQELLQLDKWASLWNWF	36	Sequence 181 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16320	YTSLIHSLIEESQNQQEKNQQELLQLDKWASLWNWF	36	Sequence 182 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16321	YTSLIQSLIEESQNQQEKNEQELLELDKWASLWNWF	36	Sequence 183 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16322	YTSLIHSLIEESQQQQEKNEQELLELDKWASLWNWF	36	Sequence 184 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16323	YTSLIHSLIEESQNQQEKNEQELLELNKWASLWNWF	36	Sequence 185 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16324	YTSLIHSLIEQSQNQQEKNEQELLELDKWASLWNWF	36	Sequence 186 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16325	YTSLIHSLIQESQNQQEKNEQELLELDKWASLWNWF	36	Sequence 187 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16326	YTSLIHSLIQQSQNQQQKNQQQLLQLDKWASLWNWF	36	Sequence 188 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16327	YTSLIHSLIEESQNQQEKNEQELLELDKWASLANAA	36	Sequence 189 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16328	YTSLIQSLIEESQNQQEKNEQQLLELDKWASLWNWF	36	Sequence 191 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16329	YTSLIHSLIEESQNQQEKNEQELLELDKWASLFNFF	36	Sequence 192 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16330	YTSLIHSLIEESQNLQEKNEQELLELDKWASLWNWF	36	Sequence 193 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16331	YTSLIHSLIEESQNQQEKLEQELLELDKWASLWNWF	36	Sequence 194 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16332	YTSLIHSLIEESQNQQEKNEQELLEFDKWASLWNWF	36	Sequence 195 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16333	YTSLIHSLIEESQNQQEKNEQELLELDKPASLWNWF	36	Sequence 196 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16334	YTSLIHSLIEESQNQQEKNEQELLELDKWASPWNWF	36	Sequence 197 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16335	YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNSF	36	Sequence 198 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16336	LLDNFESTWEQSKELWEQQEISIQNLHKSALQEYWN	36	Sequence 199 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16337	LSNLLQISNNSDEWLEALEIEHEKWKLTQWQSYEQF	36	Sequence 200 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16338	MTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWG	63	Sequence 201 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16339	SELEIKRYKNRVASRKCRAKFQLLQHYREVAAAKSSENDRLRLLL	45	Sequence 202 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16340	ASRKCRAKFKQLLQHYREVAAAKSSENDRLRLLLKQMCPSLDVDS	45	Sequence 203 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16341	LLQHYREVAAAKSSENDRLRLLLKQMCPSLDVDSI	35	Sequence 204 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16342	LQHYREVAAAKSSENDRLRLLLKQMCPSLDVDSIIPRTPDVLHED	45	Sequence 205 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16343	SSENDRLRLLLKQMCPSLDVDSIIPRTPDVLHEDL	35	Sequence 206 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16344	SENDRLRLLLKQMCPSLDVDSIIPRTPDVLHEDLLNF	37	Sequence 207 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16345	PLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGTTVCLGQNSQSP	46	Sequence 208 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16346	PGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTSTGPCRTCMTT	57	Sequence 209 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16347	VITIELSNIKENKCNGTDAKVKLIKQELDKYKNAV	35	Sequence 210 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16348	DEFDASISQVNEKINQSLAFIRKSDELL	28	Sequence 211 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16349	IINFYDPLVFPSDEFDASISQVNEKINQSLAFIRK	35	Sequence 212 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16350	INFYDPLVFPSDEFDASISQVNEKINQSLAFIRKS	35	Sequence 213 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16351	FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDE	35	Sequence 214 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16352	YDPLVFPSDEFDASISQVNEKINQSLAFIRKSDEL	35	Sequence 215 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16353	DPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL	35	Sequence 216 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16354	PLVFPSDEFDASISQVNEKINQSLAFIRKSDELLH	35	Sequence 217 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16355	LVFPSDEFDASISQVNEKINQSLAFIRKSDELLHN	35	Sequence 218 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16356	VFPSDEFDASISQVNEKINQSLAFIRKSDELLHNV	35	Sequence 219 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16357	FPSDEFDASISQVNEKINQSLAFIRKSDELLHNVN	35	Sequence 220 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16358	PSDEFDASISQVNEKINQSLAFIRKSDELLHNVNA	35	Sequence 221 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16359	SDEFDASISQVNEKINQSLAFIRKSDELLHNVNAG	35	Sequence 222 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16360	DEFDASISQVNEKINQSLAFIRKSDELLHNVNAGK	35	Sequence 223 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16361	EFDASISQVNEKINQSLAFIRKSDELLHNVNAGKS	35	Sequence 224 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16362	DASISQVNEKINQSLAFIRKSDELLHNVNAGKSTT	35	Sequence 226 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16363	FDASISQVNEKINQSLAFIRKSDELLHNVNA	31	Sequence 227 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16364	FDASISQVNEKINQSLAFIRKSDELLHNV	29	Sequence 228 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16365	FDASISQVNEKINQSLAFIRKSDELLH	27	Sequence 229 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16366	FDASISQVNEKINQSLAFIRKSDEL	25	Sequence 230 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16367	ISQVNEKINQSLAFIRKSDELLHNVNAGKST	31	Sequence 231 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16368	QVNEKINQSLAFIRKSDELLHNVNAGKST	29	Sequence 232 from Patent US 6228983	Synthetic construct	Antimicrobial, Antiviral	US 6228983 B1	Granted Patent	2001##5##8	CA2208420A1, CA2208420C, DE69534569D1, DE69534569T2, EP0793675A1, EP0793675A4, EP0793675B1, EP0793675B9, EP1714974A2, EP1714974A3, US6013263, US605426	Human respiratory syncytial virus peptides with antifusogenic and antiviral activities.	The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
DRAMP16369	GRKKRRQRRRPLAALPLVLAAPLAVLA	27	Sequence 30 from Patent US 7432045	Synthetic construct	Antimicrobial, Antiviral	US 7432045 B2	Granted Patent	2008##10##7	US20050203024, WO2005060541A2, WO2005060541A3	Method of inhibiting influenza infection with antiviral peptides.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP16370	YGRKKRRQRRRPLAALPLVLAAPLAVLA	28	Sequence 31 from Patent US 7432045	Synthetic construct	Antimicrobial, Antiviral	US 7432045 B2	Granted Patent	2008##10##7	US20050203024, WO2005060541A2, WO2005060541A3	Method of inhibiting influenza infection with antiviral peptides.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP16371	LAALPLVLAAPLAVLAPGRKKRRQRRRC	28	Sequence 32 from Patent US 7432045	Synthetic construct	Antimicrobial, Antiviral	US 7432045 B2	Granted Patent	2008##10##7	US20050203024, WO2005060541A2, WO2005060541A3	Method of inhibiting influenza infection with antiviral peptides.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP16372	LVLAAPLAVLAPGRKKRRQRRRC	23	Sequence 33 from Patent US 7432045	Synthetic construct	Antimicrobial, Antiviral	US 7432045 B2	Granted Patent	2008##10##7	US20050203024, WO2005060541A2, WO2005060541A3	Method of inhibiting influenza infection with antiviral peptides.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP16373	LAVLAPGRKKRRQRRRC	17	Sequence 34 from Patent US 7432045	Synthetic construct	Antimicrobial, Antiviral	US 7432045 B2	Granted Patent	2008##10##7	US20050203024, WO2005060541A2, WO2005060541A3	Method of inhibiting influenza infection with antiviral peptides.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP16374	GRKKRRQRRRC	11	Sequence 35 from Patent US 7432045	Synthetic construct	Antimicrobial, Antiviral	US 7432045 B2	Granted Patent	2008##10##7	US20050203024, WO2005060541A2, WO2005060541A3	Method of inhibiting influenza infection with antiviral peptides.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP16375	GRKKRRQRRR	10	Sequence 36 from Patent US 7432045	Synthetic construct	Antimicrobial, Antiviral	US 7432045 B2	Granted Patent	2008##10##7	US20050203024, WO2005060541A2, WO2005060541A3	Method of inhibiting influenza infection with antiviral peptides.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP16376	GRXXRRQRRRC	11	Sequence 40 from Patent US 7432045	Synthetic construct	Antimicrobial, Antiviral	US 7432045 B2	Granted Patent	2008##10##7	US20050203024, WO2005060541A2, WO2005060541A3	Method of inhibiting influenza infection with antiviral peptides.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP16377	GRKKRRQXXRC	11	Sequence 41 from Patent US 7432045	Synthetic construct	Antimicrobial, Antiviral	US 7432045 B2	Granted Patent	2008##10##7	US20050203024, WO2005060541A2, WO2005060541A3	Method of inhibiting influenza infection with antiviral peptides.	This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections.
DRAMP16378	TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGI	60	Sequence 1 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16379	NNLLRAIEAQQHLLQLTVWGIKQLQARILAV	31	Sequence 34 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16380	NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQGGC	41	Sequence 35 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16381	CGGNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQGGC	44	Sequence 36 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16382	LSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAV	39	Sequence 37 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16383	YTSLIYSLLEKSQIQQEKNEQELLELDKWASLWNWF	36	Sequence 40 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16384	WQEWEQKVRYLEANITALLEQAQIQQEKNEYELQKL	36	Sequence 42 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16385	DREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF	42	Sequence 43 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16386	MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF	48	Sequence 44 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16387	NNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDK	42	Sequence 45 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16388	WQEWEQKVRYLEANITALLEQAQIQQEKNEYELQKLDKWASLWNWF	46	Sequence 46 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16389	NNMTWQEWEQKVRYLEANITALLEQAQIQQEKNEYELQKLDKWASLWNWF	50	Sequence 47 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16390	WNWFITALLEQAQIQQEKNEYELQKLDKWASLWNWF	36	Sequence 48 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16391	WQEWDREISNYTSLITALLEQAQIQQEKNEYELQKLDEWASLWEWF	46	Sequence 49 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16392	WQEWEREISAYTSLITALLEQAQIQQEKIEYELQKLEWEW	40	Sequence 50 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16393	WQEWDREITALLEQAQIQQEKNEYELQKLDKWASLWNWF	39	Sequence 51 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16394	WQEWDREITALLEQAQIQQEKNEYELQKLDEWASLWEWF	39	Sequence 52 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16395	WQEWDREITALLEQAQIQQEKNEYELQKLDEWEWF	35	Sequence 53 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16396	WQEWEREITALLEQAQIQQEKIEYELQKLIEWEWF	35	Sequence 54 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16397	WQEWEREITALLEQAQIQQEKNEYELQKLIEWEWF	35	Sequence 55 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16398	WQEWEREITALLEQAQIQQEKIEYELQKLDEWEWF	35	Sequence 56 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16399	WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWNWF	39	Sequence 57 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16400	WQEWEQKITALLEQAQIQQEKNEYELQKLDKWAGLWEWF	39	Sequence 58 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16401	WQEWEQKITALLEQAQIQQEKNEYELQKLAEWAGLWAWF	39	Sequence 59 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16402	WQEWEQKITALLEQAQIQQEKIEYELQKLIEWEWF	35	Sequence 60 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16403	NASWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLI	36	Sequence 75 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16404	NKSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQN	36	Sequence 76 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16405	KSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQ	36	Sequence 77 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16406	SLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQ	36	Sequence 78 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16407	LEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQE	36	Sequence 79 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16408	EQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEK	36	Sequence 80 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16409	QIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKN	36	Sequence 81 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16410	IWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNE	36	Sequence 82 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16411	WNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQ	36	Sequence 83 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16412	NNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQE	36	Sequence 84 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16413	NMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQEL	36	Sequence 85 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16414	TWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLE	36	Sequence 87 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16415	MEWDREINNYTSLIHSLIEESQNQQEKNEQELLED	35	Sequence 89 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16416	EWDREINNYTSLIHSLIEESQNQQEKNEQELLELDK	36	Sequence 90 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16417	WDREINNYTSLIHSLIEESQNQQEKNEQELLELDKW	36	Sequence 91 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16418	NYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNW	36	Sequence 92 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16419	TSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFN	36	Sequence 93 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16420	SLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNI	36	Sequence 94 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16421	LIHSLIEESQNQQEKNEQELLELDKWASLWNWFNIT	36	Sequence 95 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16422	KSLEQIWNNMTWMEWEREIDNYTSLIYSLIEESQNQQEKNEQE	43	Sequence 96 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16423	NNMTWMEWEREIDNYTSLIYSLIEESQNQQEKNEQE	36	Sequence 97 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16424	EWEREIDNYTSLIYSLIEESQNQQEKNEQE	30	Sequence 98 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16425	SLEQIWNNMTWMEWEREIDNYTSLIYSLI	29	Sequence 99 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16426	LTWQEWDREINNYTSLIYSLIEESQNQQEENEQELL	36	Sequence 114 from Patent US 7556813	Synthetic construct	Antimicrobial, Antiviral	US 7556813 B2	Granted Patent	2009##7##7	CA2497767A1, CN1684972A, EP1554306A2, EP1554306A4, US20040122214, US20100016225, WO2004029073A2, WO2004029073A3	Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides.	Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
DRAMP16427	SLEQIWNNMTWEEWDREINNYTELIHELIEESQNQQEKNEQELL	44	Sequence 1 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16428	WEEWDREINNYTKLIHELIEESQNQQEKNEQELL	34	Sequence 2 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16429	WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL	34	Sequence 5 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16430	WQEWERKVDFLEENITALLEEAQIQQEKNMYELQ	34	Sequence 6 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16431	WEEWDREINNYTKLIHELIEESQNQQEENEQELL	34	Sequence 7 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16432	SLEQIWNNMTWEEWDREINNYTXLIHELIEESQNQQEKNEQELL	44	Sequence 8 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16433	SLEQIWNNMTWEEWDREINNYTELIHELIEESQNQQEKNEQELLX	45	Sequence 9 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16434	WEEWDREINNYTXLIHELIEESQNQQEKNEWELL	34	Sequence 10 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16435	WEEWDREINNYTELIHELIEESQNQQEKNEQELLX	35	Sequence 11 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16436	WQEWEQKITALLXQAQIQQEKNEYELQKLDKWASLWEWF	39	Sequence 12 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16437	WQEWEQKITALIEQAQIQQEKNEYELQKLDKWASLWEWFX	40	Sequence 13 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16438	WEEWDREINNYTXLIHELIEESQNQQEENEQELL	34	Sequence 14 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16439	WEEWDREINNYTKLIHELIEESQNQQEENEQELLX	35	Sequence 15 from Patent US 7575750	Synthetic construct	Antimicrobial, Antiviral	US 7575750 B2	Granted Patent	2009##8##18	CA2500248A1, CA2500248C, CN1327897C, CN1668330A, EP1542718A2, EP1542718A4, WO2004029201A2, WO2004029201A3	Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity.	This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
DRAMP16440	NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ	38	Sequence 2 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16441	YTSVITIELSNIKENKCNGDAKVKLIKQELDKYK	34	Sequence 14 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16442	TSVITIELSNIKENKCNGDAKVKLIKQELDKYKN	34	Sequence 15 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16443	VITIELSNIKENKCNGDAKVKLIKQELDKYKNAV	34	Sequence 16 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16444	VITIELSNIKENKMNGDAKVKLIKQELDKYKNAV	34	Sequence 17 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16445	YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNW	35	Sequence 87 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16446	YTSLIHSLIEESQNQQEKNEQELLELDKWASLWN	34	Sequence 88 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16447	YTSLIHSLIEESQNQQEKNEQELLELDKWASLW	33	Sequence 89 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16448	YTSLIHSLIEESQNQQEKNEQELLELDKWASL	32	Sequence 90 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16449	YTSLIHSLIEESQNQQEKNEQELLELDKWAS	31	Sequence 91 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16450	YTSLIHSLIEESQNQQEKNEQELLELDKWA	30	Sequence 92 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16451	YTSLIHSLIEESQNQQEKNEQELLELDKW	29	Sequence 93 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16452	YTSLIHSLIEESQNQQEKNEQELLELDK	28	Sequence 94 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16453	YTSLIHSLIEESQNQQEKNEQELLELD	27	Sequence 95 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16454	YTSLIHSLIEESQNQQEKNEQELLEL	26	Sequence 96 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16455	YTSLIHSLIEESQNQQEKNEQELLE	25	Sequence 97 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16456	YTSLIHSLIEESQNQQEKNEQELL	24	Sequence 98 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16457	YTSLIHSLIEESQNQQEKNEQEL	23	Sequence 99 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16458	YTSLIHSLIEESQNQQEKNEQE	22	Sequence 100 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16459	YTSLIHSLIEESQNQQEKNEQ	21	Sequence 101 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16460	YTSLIHSLIEESQNQQEKNE	20	Sequence 102 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16461	YTSLIHSLIEESQNQQEKN	19	Sequence 103 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16462	YTSLIHSLIEESQNQQEK	18	Sequence 104 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16463	YTSLIHSLIEESQNQQE	17	Sequence 105 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16464	YTSLIHSLIEESQNQQ	16	Sequence 106 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16465	YTSLIHSLIEESQNQ	15	Sequence 107 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16466	YTSLIHSLIEESQN	14	Sequence 108 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16467	YTSLIHSLIEESQ	13	Sequence 109 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16468	YTSLIHSLIEES	12	Sequence 110 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16469	YTSLIHSLIEE	11	Sequence 111 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16470	YTSLIHSLIE	10	Sequence 112 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16471	YTSLIHSLI	9	Sequence 113 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16472	YTSLIHSL	8	Sequence 114 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16473	YTSLIHS	7	Sequence 115 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16474	YTSLIH	6	Sequence 116 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16475	TSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF	35	Sequence 117 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16476	SLIHSLIEESQNQQEKNEQELLELDKWASLWNWF	34	Sequence 118 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16477	LIHSLIEESQNQQEKNEQELLELDKWASLWNWF	33	Sequence 119 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16478	IHSLIEESQNQQEKNEQELLELDKWASLWNWF	32	Sequence 120 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16479	HSLIEESQNQQEKNEQELLELDKWASLWNWF	31	Sequence 121 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16480	SLIEESQNQQEKNEQELLELDKWASLWNWF	30	Sequence 122 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16481	LIEESQNQQEKNEQELLELDKWASLWNWF	29	Sequence 123 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16482	IEESQNQQEKNEQELLELDKWASLWNWF	28	Sequence 124 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16483	EESQNQQEKNEQELLELDKWASLWNWF	27	Sequence 125 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16484	ESQNQQEKNEQELLELDKWASLWNWF	26	Sequence 126 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16485	SQNQQEKNEQELLELDKWASLWNWF	25	Sequence 127 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16486	QNQQEKNEQELLELDKWASLWNWF	24	Sequence 128 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16487	NQQEKNEQELLELDKWASLWNWF	23	Sequence 129 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16488	QQEKNEQELLELDKWASLWNWF	22	Sequence 130 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16489	QEKNEQELLELDKWASLWNWF	21	Sequence 131 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16490	EKNEQELLELDKWASLWNWF	20	Sequence 132 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16491	KNEQELLELDKWASLWNWF	19	Sequence 133 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16492	NEQELLELDKWASLWNWF	18	Sequence 134 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16493	EQELLELDKWASLWNWF	17	Sequence 135 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16494	QELLELDKWASLWNWF	16	Sequence 136 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16495	ELLELDKWASLWNWF	15	Sequence 137 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16496	LLELDKWASLWNWF	14	Sequence 138 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16497	LELDKWASLWNWF	13	Sequence 139 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16498	ELDKWASLWNWF	12	Sequence 140 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16499	LDKWASLWNWF	11	Sequence 141 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16500	DKWASLWNWF	10	Sequence 142 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16501	KWASLWNWF	9	Sequence 143 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16502	WASLWNWF	8	Sequence 144 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16503	ASLWNWF	7	Sequence 145 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16504	SLWNWF	6	Sequence 146 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16505	NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKD	37	Sequence 147 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16506	NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLK	36	Sequence 148 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16507	NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYL	35	Sequence 149 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16508	NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERY	34	Sequence 150 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16509	NNLLRAIEAQQHLLQLTVWQIKQLQARILAVER	33	Sequence 151 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16510	NNLLRAIEAQQHLLQLTVWQIKQLQARILAVE	32	Sequence 152 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16511	NNLLRAIEAQQHLLQLTVWQIKQLQARILAV	31	Sequence 153 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16512	NNLLRAIEAQQHLLQLTVWQIKQLQARILA	30	Sequence 154 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16513	NNLLRAIEAQQHLLQLTVWQIKQLQARIL	29	Sequence 155 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16514	NNLLRAIEAQQHLLQLTVWQIKQLQARI	28	Sequence 156 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16515	NNLLRAIEAQQHLLQLTVWQIKQLQAR	27	Sequence 157 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16516	NNLLRAIEAQQHLLQLTVWQIKQLQA	26	Sequence 158 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16517	NNLLRAIEAQQHLLQLTVWQIKQLQ	25	Sequence 159 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16518	NNLLRAIEAQQHLLQLTVWQIKQL	24	Sequence 160 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16519	NNLLRAIEAQQHLLQLTVWQIKQ	23	Sequence 161 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16520	NNLLRAIEAQQHLLQLTVWQIK	22	Sequence 162 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16521	NNLLRAIEAQQHLLQLTVWQI	21	Sequence 163 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16522	NNLLRAIEAQQHLLQLTVWQ	20	Sequence 164 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16523	NNLLRAIEAQQHLLQLTVW	19	Sequence 165 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16524	NNLLRAIEAQQHLLQLTV	18	Sequence 166 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16525	NNLLRAIEAQQHLLQLT	17	Sequence 167 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16526	NNLLRAIEAQQHLLQL	16	Sequence 168 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16527	NNLLRAIEAQQHLLQ	15	Sequence 169 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16528	NNLLRAIEAQQHLL	14	Sequence 170 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16529	NNLLRAIEAQQHL	13	Sequence 171 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16530	NNLLRAIEAQQH	12	Sequence 172 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16531	NNLLRAIEAQQ	11	Sequence 173 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16532	NNLLRAIEAQ	10	Sequence 174 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16533	NNLLRAIEA	9	Sequence 175 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16534	NNLLRAIE	8	Sequence 176 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16535	NNLLRAI	7	Sequence 177 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16536	NNLLRA	6	Sequence 178 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16537	NLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ	37	Sequence 179 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16538	LLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ	36	Sequence 180 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16539	LRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ	35	Sequence 181 from Patent US 7582301	Synthetic construct	Antimicrobial, Antiviral	US 7582301 B1	Granted Patent	2009##9##1	CA2372338A1, CN1351611A, DE60000665D1, DE60000665T2, DE60000665T3, DE60043021D1, EP1179012A1, EP1179012B1, EP1179012B2, EP1179012B9, EP1264840A1, EP12	Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides.	Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
DRAMP16540	RAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ	34	Sequence 182 from Patent US 7582301	Synthetic construct	Antimicro